NZ717223B2 - Aminoheteroaryl benzamides as kinase inhibitors - Google Patents

Aminoheteroaryl benzamides as kinase inhibitors Download PDF

Info

Publication number
NZ717223B2
NZ717223B2 NZ717223A NZ71722314A NZ717223B2 NZ 717223 B2 NZ717223 B2 NZ 717223B2 NZ 717223 A NZ717223 A NZ 717223A NZ 71722314 A NZ71722314 A NZ 71722314A NZ 717223 B2 NZ717223 B2 NZ 717223B2
Authority
NZ
New Zealand
Prior art keywords
mmol
alkyl
amino
lcms
compound
Prior art date
Application number
NZ717223A
Other versions
NZ717223A (en
Inventor
Jeffrey T Bagdanoff
Yu Ding
Wooseok Han
Zilin Huang
Qun Jiang
Jeff Xianming Jin
Xiang Kou
Patrick Lee
Mika Lindvall
Zhongcheng Min
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority claimed from PCT/US2014/062913 external-priority patent/WO2015066188A1/en
Publication of NZ717223A publication Critical patent/NZ717223A/en
Publication of NZ717223B2 publication Critical patent/NZ717223B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

Description

AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS BACKGROUND Protein s are involved in very x signaling cascades that regulate most cellular ons, including survival and proliferation. These signaling pathways have been heavily studied, particularly in the context of disorders caused by dysregulated cellular function, such as cancer. The extracellular signal-regulated kinases (ERKs) are one class of signaling kinases that are involved in ing extracellular signals into cells and subcellular organelles. ERK1 and 2 (ERK1/2) are kinases in the mitogen activated protein kinase (MAPK) pathway, and are also referred to as p42 and p44, respectively. ERK1 and ERK2 are present in relatively large quantities in cells (~107 molecules per cell), and are involved in regulating a wide range of activities. lndeed, dysregulation of the ERK1/2 e is known to cause a variety of pathologies including neurodegenerative diseases, developmental es, diabetes and . Wortzel and Seger, Genes & Cancer, 2:195-209 (2011), published online 9 May 2011.
The role of ERK1/2 in cancer is of special interest because activating mutations upstream of ERK1/2 in its signaling cascade are believed to be responsible for more than half of all s. Moreover, excessive ERK1/2 ty was also found in s where the upstream components were not mutated, suggesting that ERK1/2 signaling plays a role in carcinogenesis even in cancers without onal activations. The ERK pathway has also been shown to control tumor cell migration and invasion, and thus may be associated with metastasis. See A. von Thun, et al., ERK2 drives tumour cell migration in 3D microenvironments by suppressing expression of Rab17 and Liprin-,82, J. Cell Sciences, online ation date 10 Feb. 2012. In addition, it has been reported that silencing either ERK1 or ERK2 using shRNA killed melanoma cells in culture, and also made ma cells more sensitive to inhibitors of BRAF. J. Qin, et al., J. Translational m10:15 (2012). It is also reported that inhibitors of ERK1 and 2 are effective on tumor cells resistant to MEK inhibitors, and that inhibition of MEK and ERK simultaneously provides synergistic activity. Molec. Cancer eutics, vol. 11, 1143 (May 2012). lndazole derivatives acting as ERK inhibitors have been reported as therapeutics for treating cancers. WO2012/030685; WO2007/070398; WO2008/153858. Certain 2-amino pyridine/pyrimidine compounds with a biaryl linkage to a pyridone or similar ring have also been reported as inhibitors of ERK useful for treating cancer and hyperproliferative disorders: W02013/130976. Other inhibitors of ERK have also been disclosed as therapeutic agents, see e.g., /016597. Because of their therapeutic value, new inhibitors of ERK1 and / or ERK2 are needed to treat disorders associated with undesired levels of ERK1/2 activity. The current invention es novel compounds that inhibit ERK1 or ERK2 or both, for use to treat diseases such as cancer that are associated with excessive ty of ERK1 and/or ERK2.
SUMMARY OF THE INVENTION In one aspect, the invention provides a compound of the formula (I): Y L\ \\ R NI \ X or a pharmaceutically acceptable salt thereof, wherein: R1 is an optionally substituted group selected from C3_8 cycloalkyl, 5-8 ed heterocyclyl containing 1-2 heteroatoms selected from N, O and S as ring members, , -SOg-phenyl, -C(O)—phenyl, -C(R8)2-phenyl, and 5-6 membered heteroaryl ring, wherein said heterocyclyl and heteroaryl contain 1-2 heteroatoms ed from N, O and S as ring members, and n the optional substituents for R1 are 1-3 groups independently selected from D, halo, hydroxy, amino, -N(R8)2, CN, C1_4 alkyl, C1_4 alkoxy, -S(C1_4 alkyl), CM haloalkyl, CM haloalkoxy, C3_6 cycloalkyl, 3-6 membered heterocyclyl containing 1-2 atoms selected from N, O and S, oxo t on aromatic rings), CN, COORB, CON(R8)2, -NR8-C(O)R8, -NR8-C(O)OR8 -sozR8, -NR8802R8, and 802N(R8)2, where each R8 is independently H or C1_4 alkyl; L is a bond, or L can be a CM alkylene, C2_4 alkenylene, CM alkynylene, C3_6 cycloalkyl or a 4-7 membered heterocycloyl containing 1-2 heteroatoms selected from N, O and S as ring members, wherein L is optionally substituted with 1-3 groups ndently selected from R“, D, OH, NH2, -NHR“, -NHC(=O)R“, -NHC(=O)—OR“, - NchoyNHz-NHcFoyNHR“,¢«R“h,CN,hadr%,CONG¥h,aijOOREnmem each R11 is independently CM alkyl, which may be substituted with up to three groups independently selected from D, halo, OH, NH2,-NHMe, -NMe2, -OP(O)(OH)2 and O-C1_4 alkyl; X and Y are independently selected from H, D, halo, CN, amino, y, C1_4 alkyl, C1_4 haloalkyl, C1_4 alkoxy, and C1_4 haloalkoxy; R2 is H, C1_4 alkyl, or aryl-C1_2-alkyl-, wherein the aryl and C1_4 alkyl are optionally substituted with halo, CN, C1_4 alkyl, C1_4 haloalkyl, C3_6 cycloalkyl, C1_4 alkoxy, C1_4 koxy, or C1_4 alkylsulfonyl; or R2 can cyclize with X to form a 5-7 membered heterocyclic ring containing 1-2 heteroatoms selected from N, O and S fused to the phenyl ring to which X is attached, or R2 can cyclize with L to form a 5-7 ed cyclic ring containing 1-2 heteroatoms selected from N, O and 8, wherein the al heterocyclic ring formed by R2 cyclizing with X, or by R2 cyclizing with L, can be optionally substituted with one or two groups independently selected from CN, halo, CM alkyl, CM alkoxy, CM haloalkyl, CM haloalkoxy, oxo, CN, COOR7, CON(R7)2, and -SOZR7; each R7 is independently H or CH alkyl; ZSNMCW; R4 is H, D, halo, C1_4 alkyl, C1_4 haloalkyl, or C1_4 alkoxy; R5 is selected from —C(O)—R55’1 and R58; wherein R581 is an optionally tuted C3_8 cycloalkyl, C3_8 cycloalkenyl, saturated or unsaturated 3-8 membered heterocyclic ring containing 1-2 atoms selected from N, O and S, phenyl, or 5-6 membered heteroaryl ring containing 1-3 heteroatoms selected from N, O and 8, wherein the al substituents for R5 are 1-4 groups independently selected from D, halo, hydroxy, amino, CN, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 haloalkoxy, C3-6 cycloalkyl, 3-6 membered heterocyclyl containing 1-2 heteroatoms selected from N, O and S, oxo (except on aromatic rings), CN, -COOR9, -C(O)R9, CON(R9)2, -NR9C(O)R9, - R9, -SO2R9, -NR9SO2R9, and -SO2N(R9)2, where each R9 is independently H or C1-4 alkyl optionally substituted with 1-3 groups independently selected from D, halo, OH, NH2, NHMe and NMe2; and two tuents on the same or adjacent carbon atoms of R5 can optionally be taken together to form a 5-6 membered ring that can be saturated or aromatic and contains 1-2 atoms selected from N, O and S and can optionally be substituted with 1-2 groups ndently selected from D, Me, halo, OH, oxo, O(C1-4 alkyl), NH2, C1-4 alkylamino, di(C1-4 alkyl)amino; and R6 is H, D, halo, C1-4 alkyl, or C1-4 haloalkyl; including the ceutically acceptable salts of these compounds, for e a HCl salt form, and isotopically enriched versions of the compounds and salts, especially deuterated versions of the compounds, and salts thereof. These nds are inhibitors of ERK1 and/or ERK2, and are accordingly useful to treat conditions associated with excessive or undesired levels of activity of ERK1 and/or ERK2, particularly cancers that respond to inhibitors of ERK1 and/or ERK2.
In a particular aspect, the present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein: [FOLLOWED BY PAGE 4a] R1 is an optionally substituted group selected from C3-8 cycloalkyl, 5-8 ed heterocyclyl containing 1-2 heteroatoms selected from N, O and S as ring s, phenyl, -SO2-phenyl, -C(O)-phenyl, -C(R8)2-phenyl, and 5-6 membered heteroaryl ring, wherein said heterocyclyl and heteroaryl contain 1-2 heteroatoms selected from N, O and S as ring members, and wherein the optional tuents for R1 are 1-3 groups independently selected from D, halo, hydroxy, amino, 2, CN, C1-4 alkyl, C1-4 alkoxy, -S(C1-4 alkyl), C1-4 haloalkyl, C1-4 haloalkoxy, C3-6 cycloalkyl, 3-6 membered heterocyclyl containing 1-2 heteroatoms selected from N, O and S, oxo (except on aromatic rings), COOR8, CON(R8)2, -NR8-C(O)R8, -NR8-C(O)OR8 -SO2R8, -NR8SO2R8, and SO2N(R8)2, where each R8 is independently H or C1-4 alkyl; L is wherein R” is methyl or ethyl, and is optionally substituted with fluoro, amino, hydroxy, methylamino, ethylamino, ylamino, -OP(O)(OH)2, methoxy or ethoxy; X and Y are independently selected from H, D, halo, CN, amino, hydroxy, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 koxy; R2 is H, C1-4 alkyl, or 1alkyl-, wherein the aryl and C1-4 alkyl are optionally substituted with halo, CN, C1-4 alkyl, C1-4 haloalkyl, C3-6 cycloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, or C1-4 alkylsulfonyl; or R2 and L are linked together to form a heterocyclic group selected from morpholine, piperidine, thiomorpholine, piperazine, and pyrrolidine that is attached to R1 and is also optionally substituted with one or two groups independently selected from C1-4 alkyl, C1-4 alkoxy, oxo, CN, COOR7, CON(R7)2, and -SO2R7, where each R7 is independently H or C1-4 alkyl; Z is N or CR4; R4 is H, D, halo, C1-4 alkyl, C1-4 haloalkyl, or C1-4 alkoxy; [FOLLOWED BY PAGE 4b] R5 is selected from –C(O)-R5a and R5a ; wherein R5a is an optionally substituted C3-8 cycloalkyl, C3-8 cycloalkenyl, saturated or unsaturated 3-8 membered heterocyclic ring containing 1-2 heteroatoms selected from N, O and S, phenyl, or 5-6 membered heteroaryl ring containing 1-3 heteroatoms selected from N, O and S, wherein the al substituents for R5 are 1-4 groups independently selected from D, halo, hydroxy, amino, CN, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 yalkyl, C1-4 haloalkoxy, C3-6 cycloalkyl, 3-6 membered heterocyclyl containing 1-2 heteroatoms selected from N, O and S, oxo (except on aromatic rings), -COOR9, -C(O)R9, CON(R9)2, -NR9C(O)R 9, - NR 9CO 9, 2R -SO2R9, -NR9SO 9, 2R and -SO2N(R 9) 2, where each R9 is independently H or C1-4 alkyl optionally substituted with 1-3 groups independently selected from D, halo, OH, NH 5 2, NHMe and NMe2; and two tuents on the same or adjacent carbon atoms of R can optionally be taken together to form a 5-6 membered ring that can be saturated or aromatic and contains 1-2 heteroatoms selected from N, O and S and can optionally be substituted with 1-2 groups independently selected from D, Me, halo, OH, oxo, O(C1-4 alkyl), NH2, C1-4 mino, di(C1-4 alkyl)amino; and R6 is H, D, halo, C1-4 alkyl, or C1-4 haloalkyl.
In another , the invention es pharmaceutical compositions comprising a compound of Formula (I), or any of the sub-classes thereof that are described herein, d with at least one pharmaceutically acceptable r or excipient, ally admixed with two or more pharmaceutically acceptable carriers or excipients. These compositions are also useful to treat conditions associated with ive or undesired levels of activity of ERK1 and/or ERK2, particularly cancers that respond to inhibitors of ERK1 and/or ERK2. The compositions may also comprise one or more co-therapeutic agents, such as those bed herein, to enhance treatment of the treated condition or of associated symptoms of the condition.
In another aspect, the invention provides a method to treat a condition characterized by excessive or undesired levels of activity of one or both of ERK1 and ERK2, wherein the method comprises administering to a subject in need of such ent an effective amount of a compound of Formula (I) or any subgenus thereof as described herein, or a pharmaceutical composition comprising such compound. The subject can be a mammal, [FOLLOWED BY PAGE 5] and is preferably a human, and is typically a subject sed with a condition associated with excessive activity of ERK1 and/or ERK2. Conditions treatable by the compounds and s described herein include various forms of cancer that are responsive to ERK1/2 tors, such as solid tumors, adenoma, bladder cancer, brain cancer, breast cancer, al cancer, colorectal , colon cancer, epidermal carcinoma, follicular carcinoma, genitourinary cancers, glioblastoma, head and neck cancers, Hodgkin’s disease, dgkin’s lymphoma, hepatoma, kidney cancer , lung cancers such as small cell or all cell lung , leukemias such as AML or CML, multiple myeloma, lymphoid disorders, skin cancers including melanoma, neuroblastoma, ovarian cancer, pancreatic , prostate cancer, rectal cancer, sarcoma, testicular cancer, and thyroid cancer. The compounds are especially indicated for use to treat melanoma, ovarian cancer, d , colon cancer, lung cancer, pancreatic cancer, cervical cancer, head and neck cancer, and leukemias including chronic onocytic leukemia (CMML), AML and CML. Indications of special interest for use of the compounds of the invention include cancers where BRAF mutations like V600E are present, e.g., melanoma, ovarian cancer, thyroid cancer, colorectal cancer and lung cancer; breast cancer where the MAPK and/or P|3K pathway is dysregulated; cancers associated with KRAS mutations such as lung cancer, pancreatic cancer, and colorectal ; cancers having ERK2 mutations such as cervical or head and neck cancers; leukemia, especially when exhibiting NF-1 mutations; and non-small cell lung cancer wherein EGFR is mutated.
In one aspect, the invention provides nds of Formula (I) and the subgenera of Formula (I) described herein, as well as pharmaceutically acceptable salts of these compounds, and all stereoisomers (including diastereoisomers and enantiomers), tautomers and isotopically enriched versions thereof (including deuterium substitutions).
Compounds of the present ion also comprise polymorphs of compounds of Formula | (or subformulae thereof) and salts thereof. These compounds can be for use to treat conditions responsive to an ERK1/2 inhibitor, such as those described herein, and for use in the preparation of a medicament for treating these ers, and can be used in ation with co-therapeutic agents for treating these disorders. The pharmaceutical compositions and methods described herein can also be used with orformulated with a co-therapeutic agent; for example, compounds of Formula | and sub-formulae thereof can be used with or formulated with inhibitors of B-RAF and other therapeutic agents as further described herein.
In r aspect, the invention provides methods of making the nds of Formula I as well as key intermediate compounds useful for making the compounds of the invention.
BRIEF DESCRIPTION OF THE FIGURES Figure 1 shows the X—ray powder diffraction pattern of the free base of 4-(3-amino ((1S,38,48)f|uorohydroxycyclohexyl)pyrazinyl)-N-((S)—1-(3-bromo fluorophenyl)(methylamino)ethyl)fluorobenzamide.
Figure 2 is a DSC/TGA thermograph of the free base of 4-(3-amino((1S,38,4S)—3- fluorohydroxycyclohexyl)pyrazinyl)-N-((S)(3-bromofluorophenyl) (methylamino)ethyl)fluorobenzamide.
Figure 3 shows the X—ray powder ction pattern of the HCI salt form of 4-(3-amino ((1S,38,48)f|uorohydroxycyclohexyl)pyrazinyl)-N-((S)—1-(3-bromo fluorophenyl)(methylamino)ethyl)fluorobenzamide.
Figure 4 is a DSC/TGA thermograph of the HCI salt form of 4-(3-amino((1S,38,4S)—3- fluorohydroxycyclohexyl)pyrazinyl)-N-((S)(3-bromofluorophenyl) (methylamino)ethyl)fluorobenzamide.
DETAILED DESCRIPTION The following definitions apply unless otherwise provided or apparent from t: As used herein, the term “halogen” (or halo) refers to fluorine, bromine, chlorine or iodine.
Halogen-substituted groups and moieties, such as alkyI substituted by halogen (haloaIkyI) can be mono-, pon- or per-halogenated. Chloro and quoro are preferred halo substituents on alkyl or IkyI groups, unless ise specified; quoro, chIoro, and bromo are often preferred on aryl or heteroaryl , unless otherwise specified.
As used , the term “hetero atoms” refers to nitrogen (N), oxygen (0) or sulfur (S) atoms, in particular nitrogen or oxygen, unless otherwise provided.
WO 66188 2014/062913 As used herein the term “optionally substituted” indicates that a group being described can be unsubstituted or it can be tuted. Substituted groups are not intended to encompass numbers, ent or selections of substituent groups that would result in a nd that is not expected to be stable in water at room temperature for at least long enough to be administered as a pharmaceutical agent. When multiple substituents are present, the substituents are selected independently unless otherwise indicated, so where 2 or 3 substituents are present, for example, those tuents may be the same or different.
As used herein, the term “alkyl” refers to a fully saturated branched or unbranched hydrocarbon moiety having up to 10 carbon atoms. Unless otherwise provided, alkyl refers to hydrocarbon moieties having 1 to 6 carbon atoms, or 1 to 4 carbon atoms.
Representative examples of alkyl include, but are not limited to, , ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, tyl, n-hexyl, 3-methylhexyl, 2,2— dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, n-decyl and the like.
A substituted alkyl is an alkyl group containing one or more substituents in place of hydrogen atoms of the unsubstituted alkyl, such as one, two or three substituents, or 1-4 tuents, up to the number of hydrogens present on the unsubstituted alkyl group.
Suitable substituents for alkyl groups, if not otherwise specified, may be selected from halogen, D, CN, oxo, hydroxy, substituted or unsubstituted C1_4alkoxy, substituted or unsubstituted C3_6 cycloalkyl, tuted or unsubstituted 3-7 membered heterocycloalkyl containing 1 or 2 heteroatoms selected from N, O and S as ring members, substituted or unsubstituted phenyl, amino, lkyl)amino, di(C1_4 alkyl)amino, C1_4 alkylthio, C1_4 alkylsulfonyl, -C(=O)— CM alkyl, COOH, COO(C1_4 , -O(C=O)— CM alkyl, — NHC(=O)C1_4 alkyl and —NHC(=O)OC1_4 alkyl groups; wherein the substituents for substituted C1_4alkoxy, substituted C3_6 cycloalkyl, 3-7 membered heterocycloalkyl, and substituted phenyl are up to three groups independently selected from halo, C1_4alkyl, CM kyl, D, C1_4 alkoxy, amino, C1_4 alkylamino, di(C1_4 alkyl)amino, hydroxy, and ON.
Preferred substituents for alkyl groups, unless otherwise specified, include halogen, CN, oxo, hydroxy, C1_4 alkoxy, C3_6 cycloalkyl, phenyl, amino, (CM alkyl)amino, 4 alkyl)amino, C1_4 alkylthio, C1_4 alkylsulfonyl, — C1.4 alkyl, COOH, -COO(C1.4 alkyl), - O(C=O)—C1_4 alkyl, —NHC(=O)C1_4 alkyl and —NHC(=O)O CM alkyl groups.
As used herein, the term ene” refers to a divalent alkyl group having 1 to 10 carbon atoms, and two open valences to attach to other molecular components. The two molecular components attached to an alkylene can be on the same carbon atom or on different carbon atoms; thus for example propylene is a 3-carbon ne that can be 1,1-disubstituted, substituted or 1,3-disubstituted. Unless otherwise provided, alkylene refers to moieties having 1 to 6 carbon atoms, or 1 to 4 carbon atoms.
Representative examples of alkylene include, but are not limited to, methylene, ne, ylene, iso-propylene, n-butylene, sec-butylene, iso-butylene, tert-butylene, n- pentylene, isopentylene, tylene, n-hexylene, 3-methylhexylene, 2,2- dimethylpentylene, 2,3-dimethylpentylene, n-heptylene, n-octylene, n-nonylene, ndecylene and the like. A tuted ne is an ne group containing one or more, such as one, two or three tuents; unless otherwise specified, suitable and preferred substituents are selected from the substituents described as suitable and preferred for alkyl groups.
Similarly, “alkenylene” and “alkynylene” refer to alkylene groups having a double bond or a triple bond, respectively; they are typically 2-6 and often 2-4 carbon atoms in length, and can be substituted as explained for alkylene groups generally.
As used herein, the term “haloalkyl” refers to an alkyl as defined herein, which is substituted by one or more halo groups as defined herein. Unless otherwise specified, the alkyl portion of the haloalkyl has 1-4 carbon atoms. The kyl can be monohaloalkyl, dihaloalkyl, trihaloalkyl, or polyhaloalkyl including perhaloalkyl. A monohaloalkyl can have one iodo, bromo, chloro or fluoro within the alkyl group.
Dihaloalkyl and polyhaloalkyl groups can have two or more of the same halo atoms or a combination of different halo groups within the alkyl. Typically the polyhaloalkyl contains up to 6, or 4, or 3, or 2 halo groups. miting examples of haloalkyl include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, romethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl. A perhalo—alkyl refers to an alkyl having all hydrogen atoms replaced with halo atoms, e.g., trifluoromethyl. Preferred haloalkyl groups, unless specified otherwise, include monofluoro-, difluoro- and trifluoro- substituted methyl and ethyl groups, e.g. CF3, CF2H, CFH2, and CH2CF3.
WO 66188 As used herein, the term “alkoxy” refers to alkyl-O-, wherein alkyl is as defined above.
Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2—propoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy, and the like. lly, alkoxy groups have 1-6 carbons, more commonly 1-4 carbon atoms.
A “substituted alkoxy” is an alkoxy group containing one or more, such as one, two or three substituents on the alkyl portion of the alkoxy. Unless otherwise specified, suitable and red substituents are selected from the substituents listed above for alkyl groups, except that hydroxyl and amino are not normally present on the carbon that is directly attached to the oxygen of the substituted ‘alkyl-O’ group.
As used herein, the term “haloalkoxy” refers to haloalkyl-O-, n haloalkyl is defined above. Representative es of haloalkoxy include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, trichloromethoxy, 2—chloroethoxy, 2,2,2- oroethoxy, 1,1,1,3,3,3-hexafluoro-2—propoxy, and the like. Typically, haloalkyloxy groups have 1-4 carbon atoms, and up to three halogens, e.g., monofluoro, difluoro and trifluoro substituted methoxy groups and ethoxy groups.
Similarly, each alkyl part of other groups like “alkylaminocarbony , alkoxyalkyl”, “alkoxycarbonyl”, “alkoxy-carbonylalkyl”, “alkylsulfonyl”, “alkylsulfoxyl”, “alkylamino”, “haloalkyl” shall have the same meaning as described in the above-mentioned definition of “alkyl”. When used in this way, unless otherwise indicated, the alkyl group is often a 1- 4 carbon alkyl and is not further substituted by groups other than the component named.
When such alkyl groups are substituted, suitable substituents are selected from the le or preferred substituents named above for alkyl groups unless otherwise specified.
As used herein, the term "cycloalkyl" refers to saturated or rated non-aromatic monocyclic, bicyclic, tricyclic or spirocyclic hydrocarbon groups of 3-12 carbon atoms: the lkyl group may be unsaturated, and may be fused to another ring that can be saturated, unsaturated or aromatic, provided the ring atom of the lkyl group that is connected to the molecular a of interest is not an ic ring atom. Unless otherwise provided, cycloalkyl refers to cyclic hydrocarbon groups having between 3 and 9 ring carbon atoms or between 3 and 7 ring carbon atoms. ably, cycloalkyl groups, unless otherwise specified, are saturated monocyclic rings having 3-7 ring atoms, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
A tuted cycloalkyl is a lkyl group substituted by 1-3 (one, two, three), or more than three substituents, up to the number of hydrogens on the tituted group. lly, a substituted lkyl will have 1-4 or 1-2 substituents. le substituents, unless otherwise specified, are independently selected from the group consisting of halogen, hydroxyl, thiol, cyano, nitro, oxo, C1_4 -alkylimino, C1_4 -alkoximino, hydroxyimino, C1_4 -alkyl, C2_4-alkenyl, C2_4-alkynyl, C1_4 -alkoxy, C1_4 -thioalkyl, C2_4-alkenyloxy, C24- alkynyloxy, C1_4 -alkylcarbonyl, y, C1_4 -alkoxycarbonyl, amino, C1_4 -alkylamino, di- C1_4 -alkylamino, C1_4 -alkylaminocarbonyl, C1_4 -alkylaminocarbonyl, C1_4 - alkylcarbonylamino, C1_4 -alkylcarbonyl(C1_4 -alkyl)amino, C1_4 -alkylsulfonyl, C1_4 - alkylsulfamoyl, and C1_4 -alkylaminosulfonyl, where each of the aforementioned hydrocarbon groups (e.g., alkyl, alkenyl, alkynyl, alkoxy residues) may be further substituted by one or more groups independently selected at each occurrence from the list of substituents for ‘alkyl’ groups herein. Preferred substituents for a cycloalkyl, unless otherwise specified, include CM alkyl and the tuent groups listed above as red substituents for alkyl groups.
Exemplary monocyclic hydrocarbon groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, exyl and cyclohexenyl and the like.
Similarly, each cycloalkyl part of other groups like “cycloalkyloxy , cycloalkoxyalkyl”, “cycloalkoxycarbonyl”, alkoxy-carbonylalkyl”, “cycloalkylsulfonyl”, “halocycloalkyl” shall have the same meaning as bed in the above definition of “cycloalkyl”. When used in these terms, the lkyl is typically a monocyclic 3-7 carbon ring that is unsubstituted or is substituted with 1-4 groups, commonly 1-2 groups. When (optionally) substituted, the substituents are typically selected from CM alkyl and those groups set forth above as suitable or preferred substituents for alkyl groups, unless otherwise specified.
As used herein, the term "aryl" refers to an aromatic hydrocarbon group having 6-14 carbon atoms in the ring portion. Typically, aryl is monocyclic, bicyclic or tricyclic aryl having 6-14 carbon atoms, often 6-10 carbon atoms, e.g., phenyl or naphthyl. Phenyl is sometimes preferred. Furthermore, the term "aryl” as used herein, refers to an aromatic substituent which can be a single aromatic ring, or multiple ic rings that are fused together. Non-limiting examples e phenyl, naphthyl and 1,2,3,4-tetrahydronaphthyl, provided the tetrahydronaphthyl is connected to the formula being described h a carbon of the aromatic ring of the tetrahydronaphthyl group.
A substituted aryl is an aryl group substituted by 1-5 (such as one, or two, or three) substituents independently selected from the group consisting of hydroxyl, thiol, cyano, nitro, C1_4 -alkyl, C2_4-alkenyl, C2_4-alkynyl, C1_4 -a|koxy, C1_4 |kyl, C2_4-alkenyloxy, C24- alkynyloxy, halogen, C1_4-alkylcarbonyl, carboxy, C1_4-alkoxycarbonyl, amino, CM- alkylamino, di- C1_4 -a|kylamino, C1_4 -a|kylaminocarbonyl, di- C1_4 -alkylaminocarbonyl, C1_4 -a|kylcarbonylamino, C1_4 -alkylcarbonyl(C1_4 )amino, C1_4 -a|kylsulfonyl, sulfamoyl, C1. lsulfamoyl, and C1_4 -alkylaminosulfonyl where each of the afore-mentioned arbon groups (e.g., alkyl, alkenyl, alkynyl, alkoxy es) may be further substituted by one or more groups independently selected at each occurrence from the groups listed above as le substituents for alkyl groups. Preferred tuents for a substituted aryl group, unless otherwise specified, are C1_4alkyl, halogen, CN, y, substituted or unsubstituted CM alkyl, substituted or unsubstituted CM alkoxy, tuted or unsubstituted C3_6 cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl containing 1-2 heteroatoms selected from N, O and S as ring members, amino, (C1_4alkyl)amino, di(C1_4 alkyl)amino, C1_4 alkylthio, C1_4 alkylsulfonyl, -C(=O)— C1_4 alkyl, COOH, COO(C1_4 alkyl), -O(C=O)— CM alkyl,—NHC(=O)C1_4 alkyl and —NHC(=O)O CM alkyl groups; wherein the substituents for substituted C1-4 alkoxy, substituted C3_6 cycloalkyl, 3-6 membered heterocycloalkyl, and substituted alkyl are up to three groups independently selected from halo, oxo, C1_4alkyl, CM haloalkyl, CM alkoxy, amino, hydroxy, and ON.
Similarly, each aryl part of other groups like “aryloxy , aryloxyalky , aryloxycarbonyl”, “aryloxy-carbonylalkyl” shall have the same meaning as described in the above- mentioned definition of “aryl”.
As used herein, the term “heterocyclyl” or “heterocycloalkyl” refers to a heterocyclic radi- cal that is saturated or partially unsaturated but not aromatic, and can be a monocyclic or a polycyclic ring, ing a fused or bridged bicyclic, lic or spirocyclic ring system.
A heterocycle or heterocyclyl contains at least one non-carbon atom as a ring member, typically N, O or 8 unless otherwise ied. Unless otherwise specified, a heterocyclyl group has 3 to 10, and preferably 4 to 7 ring atoms; wherein one or more, preferably one to four, especially one or two ring atoms are heteroatoms independently selected from O, S and N (the remaining ring atoms ore being carbon). An unsaturated heterocyclyl can have one or two double bonds, but is not aromatic. ably, unless described as unsaturated, the heterocyclyl groups in the compounds of the invention are saturated single rings. Even though described at times as, e.g., a C54; atom group, a cycle contains at least one heteroatom as a ring atom and has the total number of ring atoms stated, e.g. 5 or 6 in this example; so a C54; heterocyclyl group refers to a 5-6 membered heterocyclic ring wherein at least one ring member is a heteroatom. Preferably, a heterocyclyl group has one or two atoms as ring atoms, and preferably the heteroatoms are not directly connected to each other. The bonding ring (i.e. the ring connecting to the Formula of interest) preferably has 4 to 7 ring atoms. The heterocyclic group can be fused to an ic ring, provided the atom of the heterocyclic group attached to the Formula of interest is not aromatic. The heterocyclic group can be attached to the Formula of interest via a heteroatom ally nitrogen) or a carbon atom of the heterocyclic group. The cyclyl can comprise fused or bridged rings as well as spirocyclic ring systems (e.g., 2-oxaazaspiro[3.3]heptane), and only one ring of a polycyclic heterocyclic group needs to contain a atom as a ring atom. Examples of heterocycles include tetrahydrofuran (THF), dihydrofuran, 1,4-dioxane, morpholine, 1,4- dithiane, piperazine, piperidine, 1,3-dioxolane, imidazolidine, imidazoline, pyrroline, pyrrolidine, tetrahydropyran, dihydropyran, oxathiolane, dithiolane, 1,3-dioxane, 1,3- dithiane, ane, thiomorpholine, and the like.
A substituted heterocyclyl is a heterocyclyl group independently substituted by 1-5 (such as one, or two, or three) substituents selected from the substituents described above as suitable or preferred for a lkyl group, unless otherwise specified.
Similarly, each heterocyclyl part of other groups like “heterocyclyloxy”, ocyclyloxyalkyl”, “heterocyclyloxycarbonyl” shall have the same meaning as described in the above-mentioned definition of “heterocyclyl”.
A “cyclic ether” as used herein refers to a heterocyclic ring containing 0 as a ring atom, typically a 4-8 membered ring, e.g., oxetane, tetrahydrofuran or tetrahydropyran. A cyclic ether of 5-8 members can contain two non-adjacent oxygen atoms as ring members, e.g., dioxane and dioxolane. These rings can be substituted as for heterocyclic rings; 2014/062913 preferred substituents if not otherwise ied include CM alkyl (e.g., methyl, ethyl), CN, OH, NH2, NHR, NR2, COOH, COOR, CONRZ, and OR, where each R is independently C1. 4alkyl. Typically, for stability reasons, OH, NH2, NHR, and NR2 substituents are not attached at a ring carbon directly bonded to an oxygen atom in the ring.
As used herein, the term "heteroaryl" refers to a 5-14 membered monocyclic- or bicyclic- or tricyclic-aromatic ring system, having 1 to 8 heteroatoms as ring members; the atoms are selected from N, O and 8. Typically, the heteroaryl is a 5-10 membered ring system, e.g., a 5-6 membered monocyclic or an 8-10 membered bicyclic group.
Typical heteroaryl groups include 2- or 3-thienyl, 2- or 3-furyl, 2- or 3-pyrrolyl, 2-, 4-, or 5- imidazolyl, 1-, 3-, 4-, or 5- pyrazolyl, 2-, 4-, or 5-thiazolyl, 3-, 4-, or 5-isothiazolyl, 2-, 4-, or olyl, 3-, 4-, or azolyl, 3- or 5-(1,2,4-triazolyl), 4- or 5-(1,2, 3-triazolyl), 1- or 2- or 3-tetrazolyl, 2-, 3-, or 4-pyridyl, 3- or 4-pyridazinyl, 2-pyrazinyl, and 2-, 4-, or 5- pyrimidinyl.
The term oaryl” also refers to a group in which a heteroaromatic ring is fused to one or more aryl, cycloalkyl, or heterocyclyl rings, where the radical or point of attachment to the Formula of interest is on a heteroaromatic ring. Nonlimiting examples include 1-, 2-, 3-, 5-, 6-, 7-, or 8- indolizinyl, 1-, 3-, 4-, 5-, 6-, or 7-isoindolyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, and 2-, 3-, 4-, 5-, 6-, or 7-indazolyl.
A substituted heteroaryl is a heteroaryl group having one or more substituents on the heteroaryl ring replacing a hydrogen atom that would be on the unsubstituted heteroaryl, typically 1, 2 or 3 substituents, selected from the tuents described above as suitable or preferred for an aryl group, unless otherwise ied.
Similarly, each heteroaryl part of other groups like “heteroaryloxy”, “heteroaryloxyalkyl”, “heteroaryloxycarbonyl” shall have the same meaning as described in the above- ned definition of “heteroaryl”.
Various embodiments of the invention are described herein. It will be recognized that es specified in each embodiment may be combined with other specified features to e further ments of the present invention. The following enumerated embodiments are representative of the invention.
Embodiment 1. A compound of formula (I): Y L\ \\ R Nl \ X R6J\(Z or a pharmaceutically acceptable salt thereof, wherein: R1 is an optionally substituted group selected from C3_8 cycloalkyl, 5-8 ed heterocyclyl containing 1-2 heteroatoms selected from N, O and S as ring members, phenyl, -SOg-phenyl, phenyl, 2-phenyl, and 5-6 membered heteroaryl ring, wherein said heterocyclyl and heteroaryl contain 1-2 heteroatoms selected from N, O and S as ring members, and wherein the al substituents for R1 are 1-3 groups independently selected from D, halo, hydroxy, amino, -N(R8)2, CN, C1_4 alkyl, C1_4 alkoxy, -S(C1_4 alkyl), CM haloalkyl, CM haloalkoxy, C3_6 cycloalkyl, 3-6 ed heterocyclyl containing 1-2 heteroatoms selected from N, O and S, oxo (except on aromatic rings), CN, COORB, CON(R8)2, -NR8-C(O)R8, (O)OR8 -802R8, -NR8802R8, and 802N(R8)2, where each R8 is independently H or C1_4 alkyl; L is a bond, or L can be a CM alkylene, C2.4 alkenylene, CM alkynylene, C34; cycloalkyl or a 4-7 membered heterocycloyl containing 1-2 heteroatoms selected from N, O and S as ring members, n L is optionally substituted with 1-3 groups independently selected from R“, D, OH, NH2, -NHR“, O)R“, O)—OR“, - NHC(=O)—NH2, -NHC(=O)—NHR“, -N(R“)2, CN, halo, N3, CON(R7)2, and COOR7; where each R11 is independently CM alkyl, which may be substituted with up to three groups independently selected from D, halo, OH, NH2,-NHMe, -NMe2, -OP(O)(OH)2 and O-C1_4 alkyl; X and Y are independently selected from H, D, halo, CN, amino, hydroxy, C1_4 alkyl, C1_4 haloalkyl, C1_4 alkoxy, and C1_4 haloalkoxy; R2 is H, C1_4 alkyl, or 1_2-alkyl-, wherein the aryl and C1_4 alkyl are ally substituted with halo, CN, C1_4 alkyl, C1_4 kyl, C3_6 cycloalkyl, C1_4 alkoxy, C1_4 haloalkoxy, or C1_4 alkylsulfonyl; or R2 can cyclize with X to form a 5-7 membered heterocyclic ring containing 1-2 heteroatoms selected from N, O and S fused to the phenyl ring to which X is ed, or R2 can cyclize with L to form a 5-7 membered heterocyclic ring containing 1-2 heteroatoms selected from N, O and 8, wherein the optional heterocyclic ring formed by R2 cyclizing with X, or by R2 cyclizing with L, can be optionally substituted with one or two groups independently selected from CN, halo, C1.4 alkyl, CM , CM haloalkyl, CM haloalkoxy, oxo, CN, COOR7, CON(R7)2, and -802R7; each R7 is independently H or CH alkyl; ZSNMCW; R4 is H, D, halo, C1_4 alkyl, C1_4 haloalkyl, or C1_4 alkoxy; R5 is selected from —C(O)—R55’1 and R58; wherein R581 is an ally substituted C3_8 cycloalkyl, C3_8 cycloalkenyl, saturated or unsaturated 3-8 ed heterocyclic ring containing 1-2 heteroatoms selected from N, O and S, phenyl, or 5-6 membered heteroaryl ring containing 1-3 heteroatoms selected from N, O and 8, wherein the optional substituents for R5 are 1-4 groups independently selected from D, halo, hydroxy, amino, CN, C1_4 alkyl, C1_4 alkoxy, C1_4 haloalkyl, C1_4 hydroxyalkyl, C1_4 haloalkoxy, C3_6 cycloalkyl, 3-6 ed heterocyclyl containing 1-2 heteroatoms selected from N, O and s, oxo (except on aromatic rings), CN, -COOR9, -C(O)R9, CON(R9)2, -NR9C(O)R9, - NR9cozR9, -802R9, -NR9802R9, and -SOZN(R9)2, where each R9 is independently H or C1_4 alkyl optionally substituted with 1-3 groups independently selected from D, halo, OH, NH2, NHMe and NMe2; and two tuents on the same or adjacent carbon atoms of R5 can optionally be taken together to form a 5-6 membered ring that can be saturated or aromatic and contains 1-2 heteroatoms selected from N, O and S and can ally be substituted with 1-2 groups independently selected from D, Me, halo, OH, oxo, O(C1_4 alkyl), NH2, C1_4 alkylamino, di(C1_4 alkyl)amino; and R6 is H, D, halo, C1_4 alkyl, or C1_4 haloalkyl.
Embodiment 2. The compound ing to embodiment 1 or a pharmaceutically acceptable salt thereof, wherein Z is N.
Embodiment 3. The compound of embodiment 1 or a pharmaceutically acceptable salt thereof, wherein Z is CH.
Embodiment 4. The compound according to any of embodiments 1-3 or a ceutically acceptable salt thereof, wherein R2 is H or Me.
Embodiment 5. The compound according to any one of embodiments 1 to 4 or a pharmaceutically acceptable salt thereof, wherein R6 is H.
Embodiment 6. The nd according to any one of embodiments 1 to 5 or a pharmaceutically acceptable salt thereof, wherein R5 is selected from —C(O)—R55’1 and R58; wherein R581 is selected from C3_8 cycloalkyl, 5-8 membered cyc|y| containing 1-2 heteroatoms selected from N, O and S, phenyl, and 5-6 membered heteroaryl, and is optionally substituted with 1-3 groups independently selected from D, halo, CN, hydroxy, C1_4 , C1_4 alkyl, C1_4 haloalkyl, C1_4 hydroxyalkyl, C1_4 haloalkoxy, -802R’, -N(R’)2, - O)—R’, and —SOZNR’2, where each R’ is independently H or C1_4 alkyl.
Embodiment 7. The compound according to any of embodiments 1-6, wherein R5 is selected from R52’1 and R58; wherein R581 is selected from , pyridine, pyridone, pyrazine, pyridazine, pyrazole, triazole, tetrazole, thiazole, oxazole, imidazole, azole, isoxazole, furan, and thiophene, each of which is optionally substituted with one or two groups independently selected from halo, D, CN, CM alkyl, C1_4alkoxy, CM haloalkyl, CM hydroxyalkyl, c1.4 haloalkoxy, CN, COORQ, CON(R9)2, and -802R9, where each R9 is independently H or CH alkyl.
Embodiment 8. The compound of embodiment 3 or a ceutically able salt thereof, wherein R5 is selected from —C(O)—R5a and R521; wherein R581 is C5_6 heteroaryl containing at least one N as a ring member, which is optionally substituted with 1-2 groups independently selected from halo, CN, CM alkyl, CM haloalkyl, CM hydroxyalkyl, CM alkoxy, and CM haloalkoxy.
WO 66188 Embodiment 9. The compound of embodiment 8 or a pharmaceutically acceptable salt thereof, wherein R5 is selected from R55’1 and R5a; n R581 is le or triazole and is optionally substituted with 1-2 groups independently selected from halo, CN, C1_4 alkyl, C1_4 haloalkyl, C1_4 hydroxyalkyl, C1_4 alkoxy, and C1_4 haloalkoxy.
Embodiment 10. The compound according to any of embodiments 1-6, wherein R5 is selected from —C(O)—R55’1 and R58; wherein R581 is selected from cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, tetrahydropyran, dihydropyran, tetrahydrofuran, oxetane, azetidine, pyrrolidine, piperidine, piperazine, morpholine, tetrahydrothiopyran (thiacyclohexane), and tetrahydrothiofuran (thiacyclopentane), each of which is optionally substituted with 1-3 groups independently selected from halo, D, CN, N(R9)2, hydroxy, C1. 4alkyl, C1_4 alkoxy, C1_4 haloalkyl, C1_4 hydroxyalkyl, C1_4 haloalkoxy, oxo, CN, COORQ, CON(R9)2, )R9, R9, -NH802R9, and -802R9, where each R9 is independently H or CH alkyl.
Embodiment 11. The compound of any of embodiments 1-10, n R1 is phenyl and is optionally substituted with up to three groups independently selected from halo, D, CN, 01.4 alkoxy, 01.4 alkyl, 01.4 haloalkyl, 01.4 haloalkoxy, SR’, -SOZR’, -N(R’)2, -NR’-C(O)— R’, and —SOZNR’2, where each R’ is independently H, C1_4 alkyl or C1_4 haloalkyl.
Embodiment 12. The compound of any of embodiments 1-10, wherein R1 is thiophene, thiazole, pyridine, pyrimidine, pyrazine or pyridazine, and is optionally tuted with up to three groups independently ed from halo, CN, C1_4alkoxy, CM alkyl, CM haloalkyl, C1_4 haloalkoxy, , -N(R’)2, -NR’-C(O)—R’, and —802NR’2, where each R’ is independently H or C1-4 alkyl.
Embodiment 13. The compound according to any of embodiments 1 to 12 or a pharmaceutically acceptable salt thereof, wherein L is selected from the group consisting of: cyclopropane-1,1-diyl; ropane-1,2-diyl; and , wherein R” is H, D, or C1-2 alkyl optionally substituted with up to three groups independently selected from D, hydroxy, halo, amino, C12 alkylamino, 2 alkyl)amino, and C12 alkoxy.
Embodiment 14. The compound of embodiment 13, wherein L is: WO 66188 wherein R” is methyl or ethyl, and is optionally substituted with fluoro, amino, hydroxy, methylamino, ethylamino, dimethylamino, -OP(O)(OH)2, methoxy or ethoxy.
Embodiment 15. The compound according to any of ments 1 to 14 or a pharmaceutically acceptable salt thereof, wherein R2 and L are linked together to form a heterocyclic group selected from morpholine, piperidine, thiomorpholine, piperazine, and pyrrolidine that is attached to R1 and is also optionally substituted with one or two groups independently selected from C1_4 alkyl, C1_4alkoxy, oxo, CN, COOR7, CON(R7)2, and -SOZR7, where each R7 is independently H or CM alkyl.
Embodiment 16. The compound of any of ments 1-15, wherein Y is H, methyl, or halo.
Embodiment 17. The compound of any of embodiments 1-16, n X is H, or R2 cyclizes with X to form a 5-7 ed cyclic ring fused to the phenyl ring to which X is attached, wherein the 5-7 membered ring is optionally substituted as described in Embodiment 1.
Embodiment 18. The compound of ment 1, which is of the Formula IA: Y 0 § NH2 N\/\ (IA) wherein R5 is pyrazole, imidazole, isoxazole, isothiazole, oxazole, triazole, or thiazole, which can be substituted with up to two groups independently selected from D, F, Cl, CN, Me, OMe, Et, iPr, OEt, and CF3; Y is H, F, Cl, or Me; R10 is H or—CHz-R*, where R* is H, -OH, F, -NH2, -NHMe, -NMe2, -OP(O)(OH)2 or —OMe; and R1 is phenyl or thienyl, optionally substituted with 1-2 groups independently selected from halo, CN, C1_4alkyl, C1_4alkoxy, CM haloalkyl, CM haloalkoxy, CN, COORB, )2, -SMe, and , where each R8 is ndently H or CH alkyl; or a pharmaceutically acceptable salt thereof.
Embodiment 19. The compound of embodiment 1, which is of the Formula IB: Y 0 E10 NH2 N\/\ ('3) n R5 is a 4-7 membered cyclic ether or C54; cycloalkyl, and R5 can be substituted with up to four groups independently selected from D, F, Cl, CN, amino, NHMe, NMe2, - CHZOH, -NHC(O)Me, -NHCOOMe, -NHSOzMe, Me, OMe, OH, oxo, Et, iPr, OEt, CN, and CF3; Y is H, F, Cl, or Me; R10 is H or—CHz-R*, where R* is H, -OH, F, -NH2, -NHMe, -NMe2, -OP(O)(OH)2 or —OMe; and R1 is phenyl, optionally substituted with 1-2 groups independently selected from halo, CN, C1_4alkyl, C1_4alkoxy, c1.4 haloalkyl, 01.4 haloalkoxy, CN, COORB, CON(R8)2, and -802R8, where each R8 is independently H or C1.4 alkyl; or a pharmaceutically acceptable salt thereof.
Embodiment 20. The compound of any one of embodiments 1-6 or 19, wherein R5 is cyclohexyl substituted with 1-3 groups groups independently selected from D, F, Cl, CN, amino, NHMe, NMe2, Me, NHSOZMe, NHCOMe, OMe, OH, Et, CN, , and CF3.
In an alternative to embodiment 20, the compound of any one of embodiments 1-6 or 19 wherein R5 is tetrahydropyranyl, especially 4-tetryahdropyranyl.
In another ative, the compound of any of embodiments 1-6 or 19, wherein R5 is selected from: QHIF © QF OH OH ment 21. The compound of any one of ments 1-20, wherein R1 is phenyl substituted with 0, 1 or 2 groups ndently selected from F, Cl, Br, I, SMe, SOzMe, and CH3.
Embodiment 22. The compound of embodiment 1, which is selected from the group consisting of the compounds of Examples 1-452 and pharmaceutically acceptable salts thereof. ment 23. A pharmaceutical composition comprising a compound according to any one of embodiments 1-22 admixed with at least one pharmaceutically acceptable excipient.
Embodiment 24. The pharmaceutical composition of embodiment 23, further comprising a therapeutic co-agent.
Embodiment 25. The pharmaceutical composition of embodiment 24, wherein the therapeutic co-agent is selected from anticancer compounds, analgesics, and antiinflammatory compounds.
Embodiment 26. A method to treat , sing administering to a subject in need of such treatment a eutically effective amount of a nd according to any of ments 1-20 or a pharmaceutical composition of any of embodiments 23-25.
Embodiment 27. The method of embodiment 26, wherein the cancer is selected from adenoma, bladder cancer, brain cancer, breast cancer, cervical cancer, colorectal , colon cancer, epidermal carcinoma, follicular carcinoma, genitourinary cancers, glioblastoma, head and neck cancers, Hodgkin’s disease, non-Hodgkin’s lymphoma, hepatoma, head and neck cancers, kidney cancer, lung s such as small cell or non-small cell lung cancer, leukemias such as AML or CML, multiple myeloma, id disorders, skin cancers including melanoma, neuroblastoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, sarcoma, testicular cancer, and thyroid cancer.
Embodiment 28. A compound according to any one of embodiments 1-22 for use as a medicament.
Embodiment 29. Use of a compound according to any one of embodiments 1 to 22 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of ; or use of a compound according to any one of embodiments 1 to 22 or a pharmaceutically acceptable salt thereof in medicine, ally for treatment of a cancer such as those named in embodiment 27.
Embodiment 30. A method of sythesizing a compound of the invention. For example, a method for synthesizing 4-(3-amino((1S,38,4S)—3-fluoro hydroxycyclohexyl)pyrazinyl)-N-((S)—1-(3-bromofluorophenyl)(methylamino)ethyl)- 2-fluorobenzamide comprising: (a). reacting 5-((1S,3S,4S)—4-((tert-butyldimethylsilyl)oxy)—3-fluorocyclohexyl)pyrazin amine with utyl 2-fluoro(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)benzoate in the presence of Pd(dppf)C|2, DCM, Na2C03 and DME to form tert-butyl 4-(3-amino ((18,38,48)((tert-butyldimethylsilyl)oxy)fluorocyclohexyl)pyrazinyl)—2- fluorobenzoate; (b). reacting tert-butyl 4-(3-amino((1S,38,48)((tert-butyldimethylsilyl)oxy) fluorocyclohexyl)pyrazinyl)fluorobenzoate in the presence of HCI, ETOH and NaOH to form 4-(3-amino((1S,38,4S)—3-fluorohydroxycyclohexyl)pyrazinyl) fluorobenzoic acid; (c). reacting 4-(3-amino((18,38,4S)fluorohydroxycyclohexyl)pyrazinyl) fluorobenzoic acid with (S)—N-(2—amino(3-bromofluorophenyl)ethyl)-N-methyl nitrobenzenesulfonamide hydrochloride in the presence of EDCI and HOAT to give 4-(3- amino((1S,3S,4S)fluorohydroxycyclohexyl)pyrazinyl)-N-((S)(3-bromo fluorophenyl)(N-methylnitrophenylsulfonamido)ethyl)—2—fluorobenzamide; and (d). reacting 4-(3-amino((18,38,4S)fluorohydroxycyclohexyl)pyrazinyl)-N-((S)- 1-(3-bromofluorophenyl)(N-methylnitrophenylsulfonamido)ethyl) fluorobenzamide in the presence of LiOH, DMF and 4-mercaptobenzoic acid to give 4- (3-amino((18,38,4S)fluorohydroxycyclohexyl)pyrazinyl)-N-((S)(3-bromo fluorophenyl)(methylamino)ethyl)fluorobenzamide.
Embodiment 31. The invention provides a high crystallinity HCI salt of mino ((1S,38,48)fluorohydroxycyclohexyl)pyrazinyl)-N-((S)—1-(3-bromo fluorophenyl)(methylamino)ethyl)fluorobenzamide in that said form has at least one of the following characteristics: a) A X-ray powder ction pattern with two or more peaks (preferably three peaks, able all peaks) at s 2—theta (wherein the angle variation is +/- 0.3, 0.2 or 0.1 degrees) as shown in Example 184; b) A X-ray powder diffraction pattern with peaks substantially the same as depicted in the Figure 3; or c) A thermal gravimetric analysis curve substantially in ance with that shown in Figure 4.
In some embodiments of Formula | or lA or IB, Y is H or halo, particularly F or Cl. Halo, especially F, is preferred. Y may be positioned ‘ortho’ to the yl depicted in these Formulas.
In many ments of the compounds described above, X is H. In other embodiments, X is a group ortho to the carbonyl shown in Formula I, such as F, Me or Cl, and in some such embodiments, X is a group that, taken together with R2 as described herein, forms a ring fused to the phenyl ring shown in Formula |. This fused ring is typically a 5, 6 or 7 atom ring, and may contain, in addition to the N to which R2 is attached, an additional N, O or S as a ring . The fused ring can be substituted or unsubstituted; when substituted, it can have one or two substituents as described for Formula (I), with halo, C1. 4 alkyl, 0x0, and hydroxy as preferred tuents unless otherwise specified.
In some embodiments of the compounds of Formula I and other ments described above, R2 is H or Me, and is preferably H. In alternative embodiments, R2 and X taken togetherform a 5-7 membered heterocyclic ring as described for Formula I above, in which case X is attached to the phenyl ring at a position ortho to the carbonyl group depicted in Formula I.
In certain of the foregoing embodiments, L is a C1_4 alkylene, which may be straight chain or branched, and can be unsubstituted or substituted with 1-3 groups as described for Formula I. In some embodiments, L is a group of the formula -CH(RL)- where RL is a C1. 3 alkyl or a C12 alkyl and is optionally substituted with 1-3 groups as described for Formula I. Preferably, L is C12 alkyl and is substituted by 1 or 2 groups independently selected from hydroxy, halo, amino, OMe, -NHMe, (OH)2 and —NMe2. In some ments, particularly where R1 is an aryl or heteroaryl group, L is -CH2- or a substituted alkylene of the formula —CH(CH2R*)- where R* is H, Me, OH, F, NH2, NHMe, - OP(O)(OH)2 or OMe. In other embodiments, L is -CH2CH2—. When L is substituted, it is often substituted with methyl, hydroxymethyl, aminomethyl, methylamino, methylaminomethyl, fluoromethyl, or ymethyl.
In embodiments where L is substituted ne (e.g., a group of formula —CHR”- as described herein), L contains a chiral center; in certain of these embodiments, L has this stereochemistry: >-u|:u [N1 [R11 where [N] and [R1] indicate the ons where -CH(R”)— is connected to NR2 and R1, respectively. ably, R” is -CH3, -CH20H, -CH2NH2, -CH2NHMe, -CH2NMe2, - CH2F, -CH20Me, -CH(OH)Me, (O)(OH)2 or -CH(OH)CH20H. In some ments, the compound of Formula (I) comprises L having the chiral configuration shown in excess over its enantiomer, so the compound is optically active. Preferably, such compounds of the invention are substantially free of the opposite enantiomer, i.e., at least 95% of the compound has the chirality shown above.
In some embodiments of the foregoing compounds, R1 is aryl or heteroaryl, optionally substituted as described below, and commonly R1 is an optionally substituted group ed from phenyl, thienyl, thiazolyl, nyl, pyridazinyl, pyrazinyl, and pyrimidinyl.
Substituted phenyl is preferred for R1.
R1 is often substituted with at least one group selected from those described for the embodiments described above. In some ments, R1 is phenyl, 3-thienyl, 2- thiazolyl, 2-pyridinyl, or 3-pyridinyl that is unsubstituted or is substituted with 1-2 groups independently selected from halo (F, Cl, Br or I), , methoxy, -SMe, methylsulfonyl, cyano, and cyclopropyl. In some ments, R1 is phenyl and is substituted in at least one position ‘meta’ to [L] (the position of R1 that is attached to L) with F, Cl, Br, I, SMe, CH2F, CHF2, or methylsulfonyl.
In some ments, the -C(=O)—NR2-L-R1 portion of the structure in Formula (I) has the following formula, where W1 and W2 are selected independently: o gHzR" R* = H, OH, NH2, NHMe, i NMeg, OMe, F, (OH)2 EL NH \ I 22 = CH w1,w2 = H, F, Cl, CN, w2 -SOZMe, Me, OMe, Br, I, CH2F, CF2H, SMe In these embodiments, at least one of W1 and W2 is typically other than H, and preferably at least one of W1 and W2 is halo, particularly Cl, Br or I.
In some embodiments of the compounds of the invention, R6 is H or Me; often R6 is H.
In some embodiments of any of the compounds bed above, Z is N. In alternative embodiments of any of the compounds described above, Z is CR4, preferably CH.
WO 66188 In some embodiments, R5 is a 5-6 membered heteroaryl ring or phenyl, and may be substituted as described for a | above. In such embodiments, R5 can be phenyl, pyridyl, pyridazinyl, or pyrimidinyl, optionally substituted as bed above. In other such embodiments, R5 is a nitrogen-containing 5-membered heteroaryl ring, such as pyrazole, ole, isoxazole, oxazole, thiazole, triazole, tetrazole, isothiazole, e, and the like, optionally substituted as described above; in these embodiments, Z is preferably CH. Pyrazoles, triazoles, and oles are sometimes preferred options for In the embodiments wherein R5 is heteroaryl, R5 may be unsubstituted or it may be substituted with 1-3 groups independently selected from Me, Et, isopropyl, propyl, butyl, t- butyl, sec-butyl, isobutyl, CF3, CN, Cl and F.
Some preferred embodiments of these R5 groups include: JV'V M M 5A 5A 5A 5A 5A / \ \ / N—N N_ N RSA/ R5A RSA/ R5A I I I JVV Mn. WV R5A R5A\ R5A A R5A N)E/ N)E/ N N/ >\ N )_N >_( R5A \R5A R5A RSA R5A where each R5A is independently selected from H, Me, Et, propyl, and isopropyl.
Preferably, no more than one or two of the R581 groups on R5 are other than H, and in most embodiments, R5A on N in these groups is methyl, ethyl, or isopropyl. Specific suitable groups include 1-methylpyrazole, 1-ethylpyrazole, 1-isopropylpyrazole, and 3- pyrazole and its tautomer; ylimidazolyl, 1-methylimidazolyl, 1-methylimidazol- -yl; and methyl-substituted versions of these. 2014/062913 In other embodiments, R5 is a non-aromatic cycloalkyl or heterocyclic group such as cyclohexyl, cyclopentyl, tetrahydropyranyl (e.g., 4-tetrahydropyranyl), 3-oxetanyl, 3- or 4- piperidinyl, 4- or 3- piperidinonyl, 3- or 4-thiacyclopentane, 3-thiacyclohexane, 3- tetrahydrofuran, and the like. In these embodiments, a ring sulfur can be oxidized to sulfoxide or sulfone oxidation state, and each of these rings may be substituted with 1-3 groups, typically 1-2 groups, selected from oxo, Me, Et, isopropyl, CF3, CN, Cl and F.
Some preferred examples of these ments include: NH2 NHMe NM62 NH2 The 1,4-disubstituted cyclohexyl embodiments can have either a cis or trans relative stereochemistry n the groups attached at positions 1 and 4; in some embodiments, a trans relative ation between these groups is preferred. Suitable cycloalkyl and heterocyclyl embodiments of R5 include: 0 (1, Q, Q, 0, 0H 6H OH OH OH OMe CHZF CHF2 CHZOH Preferred embodiments of R5 include these: Where R5 is heterocyclic or cycloalkyl and is substituted, it frequently will contain at least one chiral center. In these chiral compounds, both R and S isomers can be used dually, as well as mixtures of R and 8, including a racemic mixture. The compounds of the invention can also include somers where rotation about an heteroaryl- aryl(heteroaryl) bond is hindered by the presence of substituent groups; in these situations, each atropisomer is ed. Where one isomer (enantiomer, diastereomer, atropisomer, or geometric isomer) has higher intrinsic activity as an inhibitor of ERK1 or ERK2 than its opposite isomer, the more active isomer is lly preferred.
As used herein, the term “optical isomer” or “stereoisomer” refers to any of the various stereo isomeric configurations which may exist for a given nd of the present invention and includes geometric isomers. It is understood that a substituent may be attached at a chiral center of a carbon atom. The term "chiral" refers to molecules which have the property of non-superimposability on their mirror image partner, while the term "achiral" refers to les which are superimposable on their mirror image partner. The invention includes enantiomers, diastereomers or racemates of the compounds.
“Enantiomers” are a pair of stereoisomers that are non- superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a "racemic” e. The term is used to designate a racemic e where appropriate. "Diastereoisomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other. The absolute stereochemistry is specified according to the Cahn-lngold- Prelog ‘R-S’ . When a compound is a pure enantiomer, the chemistry at each chiral carbon may be specified by either R or 8. Resolved compounds whose absolute uration is unknown can be designated (+) or (-) depending on the direction o- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line. Certain compounds described herein contain one or more asymmetric centers or axes and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute chemistry, as (R)— or (S)-- Depending on the choice of the ng materials and synthesis procedures, the compounds can be present in the form of one of the possible isomers or as mixtures thereof, for example as pure optical isomers, or as isomer mixtures, such as racemates and diastereoisomer mixtures, depending on the number of tric carbon atoms.
The t invention is meant to include all such possible isomers, including racemic mixtures, riomeric mixtures and optically pure forms. Optically active (R)— and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be E or Z configuration unless specified. If the compound contains a di-substituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration, unless otherwise specified. All eric forms are also intended to be ed.
In many cases, the compounds of the present invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar o. As used herein, the terms “salt” or “salts” refers to an acid addition or base addition salt of a compound of the invention. “Salts” include in particular aceutical acceptable salts”. The term “pharmaceutically acceptable salts” refers to salts that retain the biological effectiveness and ties of the nds of this invention and, which typically are not biologically or otherwise undesirable.
Pharmaceutically acceptable acid addition salts can be formed with nic acids and organic acids, e.g., acetate, adipate, aluminum, ascorbate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate, caproate, chloride/hydrochloride, chloroprocaine, chlortheophyllonate, citrate, edetate, calcium edetate, ethandisulfonate, ethylsulfonate, ethylene e, fumarate, galactarate (mucate), gluceptate, gluconate, glucuronate, glutamate, glycolate, hexyl resorcinate, hippurate, hydroiodide/iodide, hydroxynapthoate (xinafoate), isethionate, e, lactobionate, laurylsulfate, lithium, malate, maleate, malonate, mandelate, mesylate, methylsulphate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, pantothenate, phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate, procaine, propionate, salicylate, sebacate, stearate, subacetate, ate, sulfate, sulfosalicylate, e, te, bitartrate, tosylate, triphenylacetate, and trifluoroacetate salts. Lists of additional suitable salts can be found, e.g., in REMINGTON'S PHARMACEUTICAL SCIENCES, 20th ed., Mack hing Company, , Pa., (1985); and in HANDBOOK OF PHARMACEUTICAL SALTS: PROPERTIES, SELECTION, AND USE, by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).
In one embodiment, the present invention provides 4-(3-amino((1S,3S,4S)—3-fluoro hydroxycyclohexyl)pyrazinyl)-N-((S)—1-(3-bromofluorophenyl)(methylamino)ethyl)- 2—fluorobenzamide in acetate, ascorbate, adipate, aspartate, benzoate, besylate, bromide/hydrobromide, onate/carbonate, bisulfate/sulfate, camphorsulfonate, e, chloride/hydrochloride, heophyllonate, citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate, glutamate, glutarate, glycolate, hippurate, hydroiodide/iodide, isethionate, e, lactobionate, laurylsulfate, malate, maleate, malonate, ate, mesylate, methylsulphate, mucate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate, propionate, sebacate, stearate, succinate, alicylate, sulfate, tartrate, te trifenatate,trifluoroacetate or xinafoate salt form.
In another embodiment, the present invention provides 4-(3-amino((1S,38,4S)—3- fluorohydroxycyclohexyl)pyrazinyl)-N-((S)(3-bromofluorophenyl) (methylamino)ethyl)fluorobenzamide in hydrochloride salt form.
Inorganic acids from which salts can be derived include, for e, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, ic acid, methanesulfonic acid, ethanesulfonic acid, esulfonic acid, trifluoroacetic, sulfosalicylic acid, and the like.
Pharmaceutically acceptable base addition salts can be formed with inorganic or organic bases and can have inorganic or organic counterions.
Inorganic counterions for such base salts include, for example, ammonium salts and metals from columns | to XII of the periodic table. In certain embodiments, the counterion is selected from sodium, ium, ammonium, alkylammonium having one to four C1- C4 alkyl groups, calcium, magnesium, iron, silver, zinc, and ; particularly suitable salts e ammonium, potassium, sodium, calcium and ium salts.
Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally ing substituted amines, cyclic amines, basic ion exchange , and the like. Suitable organic amines e isopropylamine, benzathine, ate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.
The pharmaceutically acceptable salts of the present invention can be synthesized from a basic or acidic moiety, by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K ide, carbonate, bicarbonate or the like), or by ng free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically d out in water or in an organic solvent, or in a mixture of the two. Generally, use of non-aqueous media like ether, ethyl e, tetrahydrofuran, toluene, chloroform, dichloromethane, methanol, ethanol, isopropanol, or acetonitrile is desirable, where practicable.
Any formula given herein is intended to represent unlabeled forms (i.e., compounds n all atoms are present at natural isotopic abundances, and not isotopically enriched) as well as isotopically enriched or labeled forms of the compounds. lsotopically enriched or labeled compounds have structures depicted by the formulas given herein except that at least one atom of the compound is replaced by an atom of the same element but having an atomic mass or mass number different from the atomic mass or the atomic mass distribution that occurs naturally. Examples of isotopes that can be incorporated into enriched or labeled compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2H, 3H, 11C, 13C, 14C, 15N, 18F 31P, 32P, 358, 36Cl, 125| respectively. The ion includes various isotopically labeled compounds as defined herein, for example those in which radioactive isotopes, such as 3H and 14C, or those in which non-radioactive isotopes, such as 2H and 13C, are present at levels icantly above the natural abundance for these isotopes.
These isotopically labeled compounds are useful in lic studies (with 14C), reaction kinetic studies (with, for example 2H or 3H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue bution assays, or in radioactive treatment of patients. In particular, an 18F or labeled compound may be particularly desirable for PET or SPECT studies. lsotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled ts in place of the non-labeled t previously employed.
Further, tution with heavier isotopes, particularly deuterium (i.e., 2H or D) may afford certain therapeutic advantages resulting from greater lic stability, for example increased in vivo ife or reduced dosage requirements or an improvement in therapeutic index. It is tood that deuterium in this context is regarded as a substituent of a compound of the formula (I) if it is incorporated at substantially above the level of natural isotopic abundance. The invention includes isotopically enriched versions of the compounds, e.g., deuterated versions as well as non-deuterated versions.
Deuterated versions may be deuterated at a single site, or at multiple sites.
The degree of incorporation of such an isotope in an isotopically-enriched compound, particularly deuterium, may be defined by the isotopic enrichment . The term "isotopic enrichment factor" as used herein means the ratio n the isotopic abundance of a specified isotope in a sample, and the natural abundance of the isotope in a non-enriched sample. If a substituent in a compound of this invention is d deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% ium oration), at least 6333.3 (95% deuterium oration), at least 6466.7 (97% deuterium oration), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
Pharmaceutically acceptable solvates in accordance with the invention include those wherein the t of crystallization may be isotopically substituted, e.g. D20, d6- acetone, d6-DMSO, as well as solvates with non-enriched solvents.
Compounds of the invention, e.g., compounds of a (I) that contain groups capable of acting as donors and/or acceptors for hydrogen bonds, may be capable of forming co- crystals with suitable co-crystal formers. These co-crystals may be prepared from compounds of formula (I) by known co-crystal g procedures. Such procedures include ng, heating, co-subliming, co-melting, or contacting in solution compounds of formula (I) with the co-crystal former under crystallization conditions and isolating co- crystals thereby formed. Suitable co-crystal formers include those described in WO 2004/078163. Hence the invention further provides stals comprising a compound of formula (I).
As used herein, the term "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal ), isotonic agents, absorption delaying agents, salts, preservatives, drug stabilizers, s, excipients, disintegration , lubricants, sweetening agents, flavoring agents, dyes, and the like and combinations thereof, as would be known to those skilled in the art (see, for example, REMINGTON'S PHARMACEUTICAL SCIENCES, 18th Ed. Mack Printing y, 1990, pp. 1289-1329).
Except r as any conventional r is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
The term "a therapeutically effective amount" of a nd of the present ion refers to an amount of the compound of the present invention that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc. In one non-limiting embodiment, the term “a therapeutically effective amount” refers to the amount of the nd of the present invention that, when administered to a subject, is ive to (1) at least partially alleviate, inhibit, prevent and/or ameliorate a condition, or a disorder or a disease (i) mediated by a kinase such as ERK1/2 or (ii) associated with activity of a kinase such as ERK1/2, or (iii) characterized by activity (normal or abnormal) of ERK1/2; or (2) reduce or inhibit the activity of ERK1/2 or (3) reduce or inhibit the expression of ERK1/2.
In another non-limiting embodiment, the term “a therapeutically effective ” refers to the amount of the compound of the present invention that, when administered to a cell, or a , or a non-cellular biological material, or a medium, is effective to at least partially reduce or inhibit the activity of ERK1/2, or at least partially reduce or inhibit the expression of ERK1/2.
As used herein, the term “subject” refers to an animal. Typically the animal is a mammal.
A t also refers to for e, primates (e.g., humans, male or female), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In certain embodiments, the subject is a e. In specific embodiments, the subject is a human.
As used herein, the term “inhibit”, "inhibition" or iting” refers to the reduction or suppression of a given condition, activity, effect, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
As used herein, the term “treat , treating" or "treatment" of any disease or er refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof).
In another embodiment “treat”, ing" or "treatment" refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient. In yet r embodiment, “treat”, "treating" or "treatment" refers to ting the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., ization of a physical parameter), or both. In yet another embodiment, “treat”, "treating" or "treatment" refers to delaying the development or progression of the disease or disorder.
As used herein, a subject is “in need of” a treatment if such subject would be expected to benefit biologically, medically or in quality of life from such treatment.
As used , the term "a,” "an,” "the” and similar terms used in the context of the present invention (especially in the context of the claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the t.
All methods described herein can be performed in any suitable order unless otherwise indicated herein or ise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g. "such as”) provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed.
Any asymmetric atom (e.g., carbon or the like) of the compound(s) of the present invention can be present in racemic or enantiomerically enriched, for example the (R)—, (S)— or (R,S)— configuration. In certain embodiments, each asymmetric atom has at least 50 % enantiomeric excess, at least 60 % enantiomeric excess, at least 70 % enantiomeric excess, at least 80 % omeric excess, at least 90 % enantiomeric excess, at least 95 % enantiomeric excess, or at least 99 % enantiomeric excess of either the (R)— or (8)- configuration; i.e., for optically active compounds, it is often preferred to use one enantiomer to the substantial exclusion of the other omer. Substituents at atoms with carbon-carbon double bonds may, where possible, be present in cis- (Z)- or trans- (E)— form, and both are included in the invention unless otherwise indicated.
Accordingly, as used herein a compound of the present invention can be in the form of one of the possible isomers, rotamers, atropisomers, or tautomers or as a mixture thereof, for example, as substantially pure geometric (cis or trans) isomers, diastereomers, optical isomers (antipodes), racemates or mixtures thereof. ‘Substantially pure’ or ‘substantially free of other isomers’ as used herein means the product contains less than 5%, and preferably less than 2%, of other s relative to the amount of the preferred isomer, by weight.
Any resulting es of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, reomers, racemates, for e, by chromatography and/or fractional crystallization.
Any resulting racemates of final products or intermediates can be resolved into the optical des by known methods, e.g., by separation of the diastereomeric salts f, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound. In particular, a basic moiety may thus be employed to resolve the compounds of the present ion into their optical antipodes, e.g., by fractional llization of a salt formed with an lly active acid, e.g., tartaric acid, dibenzoyl ic acid, diacetyl tartaric acid, di-0,0'-p-toluoyl tartaric acid, mandelic acid, malic acid or camphorsulfonic acid. Racemic products can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.
Furthermore, the compounds of the present invention, including their salts, can also be obtained in the form of their hydrates, or e other ts used for their crystallization. The compounds of the present invention may inherently or by design form solvates with pharmaceutically acceptable solvents (including water); therefore, it is intended that the invention embrace both solvated and unsolvated forms. The term te" refers to a molecular complex of a nd of the present invention (including pharmaceutically acceptable salts thereof) with one or more t molecules. Such solvent molecules are those ly used in the pharmaceutical art, which are known to be innocuous to the recipient, e.g., water, ethanol, and the like. The term "hydrate" refers to the complex where the solvent molecule is water.
The compounds of the present invention, including salts, hydrates and solvates thereof, may inherently or by design form polymorphs.
The compounds of a (I) can be ed according to the Schemes and examples provided herein. The Schemes in some instances illustrate preparation of compounds wherein L is methylene or a substituted alkylene group, but methods for preparing suitable benzamides where L is a bond or other options encompassed by Formula (I) are readily nt to the skilled person in view of the many known methods for making the ite benzamide intermediates, so these methods are equally applicable to preparation of compounds with other embodiments of L.
Scheme A. 0 R10 Y 0 R10 Y A \ A PyBrop, HOBt \\ N R1 L: OH + HZN R1 L} H /\XI DIEA, THF / Br x A B C NH2 NH2 NH2 NH2 oR N)\ N/S NJ\/Br | —’ N)\(B\OR R6 Reyz| —> RekfzI —> R6J\¢ZI Br R5 R5 R5 F G B\ NH2 06H\ N R1 BrNummfi/x R Precursors A and B can be coupled using known peptide bond formation conditions to provide intermediate C. Intermediate C can be coupled with a heteroaryl boronic acid such as intermediate G under well-known palladium-assisted conditions to form products of formula H, which are compounds of Formula (I). The requisite yridine/pyrazine compounds (G) for coupling with Compound C can be prepared from yridine/pyrazines by introducing a desired R5 group using palladium chemistry (see intermediate E above), then brominating adjacent to the amino group and converting to the boronic acid or ester (G). Scheme C illustrates application of this sequence, including hydrogenation of an olefin to arrive at a compound of formula G, where R5 is a ydropyran.
Alternatively, as shown in Scheme B, compound C can be converted to an ronic acid or ester, and can be coupled to heteroaryl bromide F, again using known palladium zed coupling conditions, to provide compounds of the invention.
Scheme B.
Intermediate F can be prepared by methods known in the art and s disclosed herein. Numerous compounds of Formula F can be synthesized from known amino- bromo-pyridines and -pyrazines as illustrated in Scheme C. Various aryl, heteroaryl, and vinyl boronic acid esters can be coupled to the bromopyridine or bromopyrazine using ium sts as is known in the art, to introduce a desired R5 group. This method WO 66188 is especially useful to introduce aryl or heteroaryl groups as R5 in Formula (I). Where the initial coupling product introduces a partially unsaturated group at the R5 position, as illustrated in Scheme C, the unsaturation can be reduced by conventional methods to provide compounds having a ted group (e.g., heterocyclyl or cycloalkyl) as R5. This option is illustrated in Scheme C, where preparation of a compound having 4- tetrahydropyranyl as R5 is shown.
Scheme C.
N)\ N \ 0‘ /0 Pdd(MD)fCl-DCM B 2 | RfikfzI + #R6 NH2 NH2 N \ NJYBF H2, Pd/C I NBS I / Z / Z flR6 —> R6 MeOH O 0 Scheme D rates another synthesis route, where the group ponding to R5 in a (I) is attached after the ne or pyrimidine is coupled to the benzamide portion. The method allows incorporation of a wide array of aryl, heteroaryl or vinylic (unsaturated) R5 groups, and as illustrated herein, a vinylic R5 group can be reduced after the coupling reaction to provide a saturated R5 group. Again, the route is depicted with a benzylic group on the amide nitrogen, corresponding to L = optionally substituted alkylene, and R1 = optionally substituted , but due to the wide availability of starting materials and methods for making the amide intermediates, it is equally applicable for synthesis of compounds with other L and R1 groups. Once the heteroaryl group is coupled to the benzamide phenyl ring, R5 can be attached by palladium coupling, where the c acid / ester can be on R5 or on the aminopyridine / aminopyrazine ring. R“ in this scheme represents optional substituents on the phenyl group, selected to correspond to substituents on R1 in Formula (I).
WO 66188 Scheme D. 0 R10 NJ\(Br Pd<dppn)Clz + kagY Rekz jig; ’\X, R2 / Na2003DME R5-B(OR)2 Pd catalyst hi5: R1* O R10 Y\ RR R5-Br NHz \ l u X Pd<dppf)CI2 32(PIN)2 “(ka l , R2 / KOAC dioxane R6)\( f)CI2 NI \ \X B ReJYZ O, ‘o Na2003,DME Scheme E illustrates a method to make compounds of Formula (I) starting from a 3- bromoaminopyridine or a corresponding pyrazine, and a benzoate ester substituted with a boronic acid or ester. After coupling to form a biaryl group, the aminopyridine can be ated readily under mild conditions, and the desired amide group can be prepared. R5 can be introduced by palladium-catalyzed replacement of Br from the pyridine ring. Here again, the boronic acid ester can be on either the aminopyridine ring, or on the aryl, heteroaryl or vinylic R5 group.
Scheme E.
Y O Pd(dppf)Cl2- Y O NQYBr + / o DCM NH2 0/ NBS —’ —’ K/zI Hos E? Na2003, DME N/ CH3CN OH \/2I Y O Y O H2N NH2 0/ LiOH (1 M) NH2 OH R“ N / —> I _ Krz N / THF, MeOH KrI EDC HOAt \ Z ' V Y 0 R10 NH2 Sb 0‘ NHz N B’ H N/ + Pd(dppf)C|2—DCM N/ RV \/$ | NI \ _. R1 * \ Z N , DME Br \ Pd (B(OR)2)2 Y 0 R10 Y 0 R10 R5-Br NH2 N NH2 N H —> N / Pd | $2 1* R“ Krz R B(OR)2 The invention further includes any variant of the present processes in which an intermediate obtainable at any stage thereof is used as starting material and the ing steps are carried out, or in which the starting materials are formed in situ under the reaction conditions, or in which the reaction components are used in the form of their salts or lly pure material. Compounds of the invention and intermediates can be interconverted ing to methods generally known to those skilled in the art.
In another aspect, the invention provides intermediates useful for the synthesis of the compounds of Formula (I), including compounds of Formula (II): wherein Z2 is CH or N; G is Br or—B(OR21)2; where each R21 is H or C1_4 alkyl, or two R21 taken er with the linkage —O-B-O- to which they are attached form a cyclic borate ester; J is H, F, Cl or Me; and R20 is H or C1_6alkyl.
In some embodiments, J is advantageously fluoro (F), and in other embodiments J is Cl.
In some embodiments G is a cyclic borate ester group such as 4,4,5,5-tetramethyl-1,3,2— dioxaborolanyl or 1,3,2—dioxaborolan-2—yl.
In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the t invention, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient. The pharmaceutical composition can be formulated for particular routes of administration such as oral administration, eral administration, and rectal administration, and the like.
In addition, the pharmaceutical compositions of the present invention can be made up in a solid form (including without limitation capsules, s, pills, es, powders or suppositories), or in a liquid form (including without limitation solutions, suspensions or emulsions). Pills or tablets may be either film coated or c coated according to methods known in the art. The pharmaceutical compositions can be subjected to conventional pharmaceutical operations such as sterilization and/or can contain conventional inert diluents, lubricating agents, or buffering agents, as well as nts, such as preservatives, stabilizers, g agents, emulsifiers and buffers, etc.
Typically, the pharmaceutical compositions comprising compounds of the invention are tablets or gelatin es comprising a compound of Formula (I) as an active ingredient together with one or more of the following excipients: a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for s also c) binders, e.g., magnesium aluminum te, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone; if desired d) disintegrants, e.g., starches, agar, c acid or its sodium salt, or effervescent mixtures; and/or e) absorbents, colorants, flavors and sweeteners.
Selection of suitable capsules for encapsulation and of suitable excipients for formulating the compound of Formula | to make oral dosage forms is within the ordinary level of skill.
Tablets may be either film coated or enteric coated using s known in the art.
Suitable compositions for oral administration include an effective amount of a compound of the invention in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs. itions intended for oral use are prepared according to any method known in the art for the cture of ceutical compositions and such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets may contain the active ingredient in admixture with nontoxic ceutically acceptable excipients which are suitable for the manufacture of tablets, ing the ones listed above. These excipients are, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, m phosphate or sodium phosphate; granulating and disintegrating agents, for e, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc. The s are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be ed.
Formulations for oral use can be presented as hard gelatin es wherein the active ingredient is mixed with an inert solid diluent, for e, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil, to form a solution, emulsion or dispersion inside the soft capsule.
Certain injectable compositions are s ic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions. Said itions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and n about 0.1-75%, or contain about 1-50%, of the active ingredient.
Suitable compositions for transdermal ation include an effective amount of a nd of the invention with a suitable r. Carriers suitable for transdermal delivery include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. For example, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with rs, optionally a rate controlling r to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
Suitable compositions for topical application, e.g., to the skin and eyes, include aqueous solutions, suspensions, ointments, creams, gels or sprayable formulations, e.g., for delivery by aerosol or the like. Such topical delivery s will in particular be appropriate for dermal application, e.g., for the treatment of skin cancer, e.g., for prophylactic use in sun creams, lotions, sprays and the like. They are thus particularly suited for use in topical, ing cosmetic, ations well-known in the art. Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
As used herein a topical application may also pertain to an inhalation or to an intranasal ation. They may be conveniently delivered in the form of a dry powder (either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids) from a dry powder inhaler or an aerosol spray presentation from a pressurized container, pump, spray, atomizer or nebulizer, with or without the use of a le propellant.
The t invention further provides anhydrous pharmaceutical compositions and dosage forms comprising the compounds of the present invention as active ingredients, where it is desirable to minimize exposure of the compound to water prior to administration. Anhydrous ceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity ions. An anhydrous pharmaceutical ition may be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions are packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e. g., vials), blister packs, and strip packs.
The invention further provides pharmaceutical itions and dosage forms that comprise one or more agents that reduce the rate by which the compound of the present invention as an active ingredient will ose. Such agents, which are referred to herein as "stabilizers,” e, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers, etc.
The compounds of formula I in free form or in salt form, exhibit valuable pharmacological properties, e.g. they modulate or inhibit activity of ERK1 and/or ERK2, as indicated by test data provided in the following sections, and are ore indicated for therapy as described herein, or for use as research chemicals, e.g. as tool compounds to further the understanding of the effects of EKR1/2 inhibition or inhibition of a mical pathway (MAPK).
Thus, as a r embodiment, the present invention provides the use of a compound of a (I) or any of the embodiments within the scope of Formula (I) as described herein, in therapy, or for the manufacture of a medicament. In a further embodiment, the therapy or medicament is for a disease which may be treated by tion of ERK1 and/or ERK2.
In another embodiment, the compounds of the invention are useful to treat cancers, including but not d to those mentioned herein.
In another embodiment, the invention provides a method of ng a disease which is ble by inhibition of ERK1 and/or ERK2, comprising administration of a therapeutically effective amount of a compound of formula (I) or (IA) or any of the embodiments of the invention as described . In a further embodiment, the disease is selected from the afore-mentioned lists of suitable conditions. The method typically comprises administering an effective amount of a compound as described herein or a pharmaceutical composition comprising such compound to a subject in need of such treatment. The compound may be administered by any suitable method such as those described herein, and the administration may be repeated at intervals ed by a treating physician. The ion thus provides a compound of Formula | and IA or any subgenus thereof as described herein for use to treat a condition ed by or associated with excessive or undesired levels of ERK1/2 activity, ing those mentioned above.
Thus, as a further embodiment, the present invention provides the use of a compound of formula (I), or any of the embodiments of such compounds described herein, for the manufacture of a medicament. In a further embodiment, the medicament is for treatment of a disease which may be treated by inhibition of ERK1 and/or ERK2. In another embodiment, the disease is a cancer, e.g., a cancer selected from the aforementioned list, suitably.
In some embodiments, the compounds are used in combination with one or more co- therapeutic agents. Suitable co-therapeutic agents include anticancer agents, analgesics, nflammatory agents, and the like. In some embodiments, the compositions include a co-therapeutic agent that acts on the RAF pathway, such as a B-RAF inhibitor or a C-Raf inhibitor.
In one embodiment, the invention provides a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound of formula (I). In one ment, the kit comprises means for tely retaining said compositions, such as a container, divided bottle, or divided foil . An example of such a kit is a blister pack, as lly used for the packaging of tablets, capsules and the like.
The kit of the invention may be used for administering ent dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist compliance, the kit of the invention typically comprises directions for administration.
In the ation therapies of the invention, the compound of the invention and the other eutic co-agent may be manufactured and/or formulated by the same or different manufacturers. Moreover, the compound of the invention and the other therapeutic may be brought together into a combination therapy: (i) prior to release of the combination product to physicians (e.g. in the case of a kit sing the compound of the invention and the other eutic agent); (ii) by the physician themselves (or under the guidance of the ian) shortly before administration; (iii) in the patient themselves, e.g. during sequential administration of the compound of the invention and the other therapeutic agent Accordingly, the invention provides the use of a compound of formula (I) for treating a disease or condition mediated by ERK1 and/or ERK2, n the medicament is prepared for administration with another therapeutic agent. The invention also provides the use of another co-therapeutic agent for ng a disease or condition, wherein the co-agent is administered with a compound of formula (I).
The invention also es a compound of formula (I) for use in a method of treating a disease or ion mediated by ERK1 and/or ERK2, wherein the compound of formula (I) is ed for stration with another therapeutic agent. The invention also provides another therapeutic co-agent for use in a method of treating a disease or condition mediated by ERK1 and/or ERK2, wherein the other therapeutic co-agent is prepared for administration with a compound of formula (I). The invention also provides a compound of a (I) for use in a method of ng a e or condition mediated by ERK1 and/or ERK2, wherein the compound of formula (I) is administered with another therapeutic co-agent. The invention also provides another co-therapeutic agent for use in a method of treating a disease or condition mediated by ERK1 and/or ERK2, n the other therapeutic co-agent is administered with a compound of formula (I).
The invention also provides the use of a compound of formula (I) for treating a disease or condition mediated by ERK1 and/or ERK2, wherein the patient is one treated previously or subsequently (e.g. within 24 hours) with another therapeutic agent. The invention also provides the use of a co-therapeutic agent for treating a disease or condition mediated by ERK1 and/or ERK2, wherein the patient has previously (e.g. within 24 hours) been treated with a compound of formula (I).
In one embodiment, the other therapeutic agent (co-therapeutic agent orjust co-agent) is a compound useful for treating a cancer, and is typically an FDA approved drug approved for ng at least one type of cancer. le co-therapeutic agents include erlotinib, bortezomib, trant, sunitib imatinib mesylate, letrozole, finasunate, platins such as oxaliplatin, carboplatin, and cisplatin, finasunate, fluorouracil, rapamycin, leucovorin, lapatinib, lonafamib, sorafenib, gefitinib,capmtothecin, topotecan, bryostatin, adezelesin, anthracyclin, esin, bizelesin, dolastatin, auristatins, duocarmycin, eleutherobin, taxols such as paclitaxel or docetaxel, cyclophasphamide, doxorubicin, vincristine, prednisone or prednisolone, other ting agents such as mechlorethamine, chlorambucil, and ifosfamide, antimetabolites such as oprine or mercaptopurine, other ubule inhibitors (vinca alkaloids like vincristine, vinblastine, vinorelbine and vindesine, as well as taxanes), podophyllotoxins (etoposide, teniposide, etoposide phosphate, and epipodophyllotoxins), topoisomerase inhibitors, other cytotoxins such as mycin, ubicin, icin, idarubicin, edrecolomab, epirubicin, cin, plicamycin, mitomycin, as well as other ncer antibodies (cetuximab, bevacizumab, ibritumomab, abagovomab, adecatumumab, afutuzumab, alacizumab, alemtuzumab, anatumomab, apolizumab, bavituximab, belimumab, bivatuzumab mertansine, blinatumomab, brentuximab vedotin, cantuzumab mertansine, catumazomab, cetuximab, citatuzumab bogatox, cixutumumab, clivatuzumab tetraxetan, conatumumab, dacetuzumab, daclizumab, detumomab, ecromeximab, edrecolomab, umab, epratuzumab, ertumaxomab, etaracizumab, uzumab, figitumumab, fresolimumab, galiximab, gembatumumab vedotin, gemtuzumab, ibritumomab tiuxetan, inotuzumab ozogamicin, intetumumab, umab, iratumumab, labetuzumab, lexatumumab, lintuzumab, lucatumumab, lumilisimab, mapatumumab, matuzumab, milatuzumab, mitumomab, nacolomab tafenatox, naptumomab estafenatox, necitumumab, nimotuzumab, ofatumumab, olaratumab, oportuzumab monatox, oregovomab, panitumumab, pemtumomab, pertuzumab, pintumomab, pritumumab, ramucirumab, rilotumumab, robatumumab, mab, sibrotuzumab, tacatuzumab etan, taplitumomab paptox, tenatumomab, ticilimumab, tigatuzumab, tositumomab or 131I- tositumomab, trastuzumab, imumab, tuocotuzumab celmoleukin, veltuzumab, visilizumab, volocixumab, votumumab, zalutumumab, zanolimumab, lGN-101, MDX- 010,ABX-EGR, EMD72000, , MDX—220, MRA, H-11 scFv, huJ591, TriGem, TriAb, R3, MT-201, G-250, ACA—125, Onyvax-105, CD:—960,Cea-Vac, BrevaRex AR54, IMC- 1C11, GlioMab-H, lNG-1, anti-LCG MAbs, MT-103, KSB-303, Therex, KW2871, anti- , Anti-PTHrP, 2C4 antibody, SGN-30, TRAIL-RI MAb, Prostate Cancer dy, H22xKi-r, ABX-Mai, lmuteran, Monopharm-C), and antibody-drug ates comprising any of the above agents (especially auristatins MMAE and MMAF, maytansinoids like DM-1, calicheamycins, or various cytotoxins). Preferred rapeutics, unless otherwise specified, include finib, debrafinib, LGX818, trametinib, MEK162, LEE011, PD- 0332991, panobinostat, stat, romidepsin, cetuximab, gefitinib, erlotinib, lapatinib, panitumumab, vandetanib, |NC280, everolimus, simolimus, , BYL719, and CLR457.
The pharmaceutical composition or combination of the present invention can be in unit dosage of about 1-2000 mg of active ingredient(s) for a subject of about 50-70 kg, or about 1-500 mg or about 1-250 mg or about 1-150 mg or about 05-100 mg, or about 1-50 mg of active ingredients. The therapeutically effective dosage of a compound, the pharmaceutical composition, or the combinations thereof, is dependent on the species of the subject, the body weight, age and individual condition, the er or disease being treated and the severity thereof. A physician, clinician or veterinarian of ordinary skill can readily determine the ive amount of each of the active ingredients necessary to prevent, treat or inhibit the ss of the disorder or disease.
The above-cited dosage properties are demonstrable in vitro and in vivo tests using advantageously s, e.g., mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof. The compounds of the present invention can be applied in vitro in the form of solutions, e.g., aqueous solutions, and in vivo either enterally, parenterally, advantageously intravenously, e.g., as a sion or in aqueous solution. The dosage in vitro may range between about 10-3 molar and 10-9 molar concentrations. A therapeutically effective amount in vivo may range depending on the route of administration, between about 0.1-500 mg/kg, or between about 1-100 mg/kg.
The compound of the present invention may be administered either simultaneously with, or before or after, one or more co-therapeutic agents, also referred to herein as co- agent(s). The compound of the present invention may be administered separately, by the same or different route of administration, or together in the same ceutical composition as the co-agent(s).
In one ment, the invention es a product comprising a compound of formula (I) and at least one other therapeutic co-agent as a combined preparation for simultaneous, separate or sequential use in therapy. In one embodiment, the therapy is the treatment of a disease or condition mediated by ERK1 and/or ERK2, such as cancer.
Products provided as a combined preparation include a composition comprising the compound of formula (I) and the other therapeutic co-agent(s) together in the same pharmaceutical ition, or the compound of formula (I) and the other eutic coagent (s) in separate form, e.g. in the form of a kit.
In one embodiment, the invention provides a pharmaceutical composition comprising a compound of formula (I) and another therapeutic co-agent(s). ally, the pharmaceutical composition may comprise a pharmaceutically acceptable carrier, as described above.
In one embodiment, the ion provides a kit comprising two or more separate ceutical compositions, at least one of which ns a compound of formula (I). In one embodiment, the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is a r pack, as typically used for the packaging of tablets, capsules and the like.
The kit of the invention may be used for administering ent dosage forms, for example, oral and parenteral, for administering the te compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist compliance, the kit of the invention typically comprises directions for administration.
In the combination therapies of the invention, the compound of the invention and the other eutic nt may be ctured and/or formulated by the same or different manufacturers. Moreover, the compound of the invention and the other therapeutic may be brought together into a combination therapy: (i) prior to release of the combination product to physicians (e.g. in the case of a kit comprising the compound of the invention and the other therapeutic agent); (ii) by the physician themselves (or under the guidance of the physician) shortly before administration; (iii) in the patient themselves, e.g. during sequential administration of the compound of the invention and the other therapeutic agent Accordingly, the invention provides the use of a nd of formula (I) for treating a disease or condition mediated by ERK1 and/or ERK2, wherein the medicament is ed for administration with another therapeutic agent. The invention also provides the use of another therapeutic co-agent for ng a disease or condition, wherein the medicament is administered with a compound of formula (I). Suitable co-therapeutic agents for use with the nds of the invention are typically selected based on the condition for treatment. For example, in the ent of ma, the co-therapeutic agent may be selected from Aldesleukin, Dabrafenib, Dacarbazine, DTIC-Dome (Dacarbazine), lntron A (Recombinant Interferon Alfa-2b), lpilimumab, Mekinist (Trametinib), Peginterferon Alfa-2b, PEG-lntron (Peginterferon Alfa-2b) Proleukin (Aldesleukin), inant Interferon Alfa-2b, Sylatron (Peginterferon Alfa-2b), Tafinlar (Dabrafenib), Trametinib, Vemurafenib, Yervoy (lpilimumab), and Zelboraf (Vemurafenib).
For the treatment of ovarian cancer, the co-therapeutic agent may be selected from Adriamycin PFS (Doxorubicin Hydrochloride), Adriamycin RDF (Doxorubicin Hydrochloride), Carboplatin, Clafen (Cyclophosphamide), Cisplatin, Cyclophosphamide, Cytoxan phosphamide), bicin Hydrochloride, Dox-SL (Doxorubicin Hydrochloride Liposome), DOXIL (Doxorubicin Hydrochloride Liposome), Doxorubicin Hydrochloride Liposome, Evacet (Doxorubicin Hydrochloride Liposome), abine Hydrochloride, Gemzar (Gemcitabine Hydrochloride), Hycamtin (Topotecan hloride), LipoDox ubicin Hydrochloride Liposome), Neosar (Cyclophosphamide), Paclitaxel, Paraplat (Carboplatin), Paraplatin (Carboplatin), Platinol (Cisplatin), Platinol-AQ (Cisplatin), Taxol (Paclitaxel), and Topotecan Hydrochloride. For the treatment of thyroid cancer, the co-therapeutic agent may be selected from Adriamycin PFS (Doxorubicin Hydrochloride), Adriamycin RDF (Doxorubicin Hydrochloride), Cabozantinib-S-Malate, Caprelsa (Vandetanib), Cometriq (Cabozantinib- S-Malate), Doxorubicin Hydrochloride, and anib. For the treatment of colon cancer, the co-therapeutic may be selected from Adrucil (Fluorouracil), Avastin (Bevacizumab), Bevacizumab ,Camptosar (Irinotecan Hydrochloride), Capecitabine, Cetuximab, Efudex ouracil), Eloxatin (Oxaliplatin), Erbitux (Cetuximab) ,Fluoroplex (Fluorouracil), Fluorouracil ecan hloride, Leucovorin Calcium, Oxaliplatin, Panitumumab, Regorafenib, Stivarga (Regorafenib), ix (Panitumumab), Wellcovorin (Leucovorin Calcium), Xeloda (Capecitabine), Zaltrap (Ziv-Aflibercept), and Ziv- Aflibercept. For the treatment of lung cancer, the rapeutic may be selected from Abitrexate trexate), Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation), Afatinib Dimaleate, Alimta (Pemetrexed Disodium), Avastin (Bevacizumab), Bevacizumab, Carboplatin, Cisplatin, Crizotinib, Erlotinib Hydrochloride, Folex (Methotrexate), Folex PFS (Methotrexate), Gefitinib, Gilotrif (Afatinib Dimaleate), Gemcitabine Hydrochloride, Gemzar (Gemcitabine Hydrochlorde), lressa (Gefitinib), Methotrexate, Methotrexate LPF (Methotrexate), Mexate (Methotrexate), Mexate-AQ (Methotrexate), Paclitaxel, Paclitaxel Albumin-stabilized Nanoparticle Formulation, at (Carboplatin), Paraplatin (Carboplatin), Pemetrexed Disodium, Platinol (Cisplatin), Platinol-AQ (Cisplatin), Tarceva (Erlotinib Hydrochloride), Taxol (Paclitaxel), and ,Xalkori (Crizotinib). For the treatment of pancreatic cancer, the co-therapeutic agent can be selected from Adrucil (Fluorouracil), Efudex (Fluorouracil), Erlotinib Hydrochloride, Fluoroplex (Fluorouracil), Fluorouracil, Gemcitabine Hydrochloride, Gemzar (Gemcitabine Hydrochloride), Mitomycin C, Mitozytrex (Mitomycin C), Mutamycin (Mitomycin) and Tarceva (Erlotinib Hydrochloride. For the treatment of al cancer, the co-therapeutic agent may be selected from Blenoxane (Bleomycin), Bleomycin, Cisplatin, Hycamtin (Topotecan Hydrochloride), ol (Cisplatin), Platinol-AQ atin), and Topotecan Hydrochloride. For the ent of head and neck cancer, the rapeutic agent may be ed from Abitrexate (Methotrexate), Adrucil (Fluorouracil), Blenoxane ycin), Bleomycin, Cetuximab, Cisplatin, Docetaxel, Efudex ouracil), Erbitux (Cetuximab), Fluoroplex (Fluorouracil), Fluorouracil, Folex (Methotrexate), Folex PFS (Methotrexate), Methotrexate, Methotrexate LPF (Methotrexate), Mexate (Methotrexate), -AQ (Methotrexate), Platinol atin), Platinol-AQ (Cisplatin), and Taxotere (Docetaxel). For the treatment of leukemia, including CMML, the co-therapeutic agent can be selected from Bosulif inib), Bosutinib ,Clafen (Cyclophosphamide), hosphamide, Cytarabine, Cytosar—U (Cytarabine), Cytoxan (Cyclophosphamide), Dasatinib, Gleevec (lmatinib Mesylate), lclusig (Ponatinib Hydrochloride) ,lmatinib Mesylate, Neosar (Cyclophosphamide), Nilotinib, Omacetaxine Mepesuccinate, Ponatinib Hydrochloride, Sprycel inib), Synribo taxine Mepesuccinate), Tarabine PFS (Cytarabine), and Tasigna (Nilotinib).
The invention also provides a compound of formula (I) for use in a method of ng a e or condition mediated by ERK1 and/or ERK2, wherein the compound of formula (I) is prepared for administration with another therapeutic agent. The invention also provides another therapeutic co-agent for use in a method of treating a disease or condition mediated by ERK1 and/or ERK2, wherein the other therapeutic co-agent is prepared for administration with a compound of formula (I). The invention also provides a nd of formula (I) for use in a method of treating a e or condition ed by ERK1 and/or ERK2, wherein the compound of formula (I) is administered with another therapeutic co-agent. The invention also provides another therapeutic co-agent for use in a method of treating a disease or condition mediated by ERK1 and/or ERK2, wherein the other eutic co-agent is administered with a compound of formula (I).
The invention also provides the use of a compound of formula (I) for treating a disease or condition ed by ERK1 and/or ERK2, wherein the patient has previously (e.g. within 24 hours) been treated with another therapeutic agent. The invention also provides the use of another therapeutic agent for treating a disease or condition mediated by ERK1 and/or ERK2, wherein the patient has previously (e.g. within 24 hours) been d with a compound of formula (I).
Specific individual ations which may e particular treatment benefits e a compound of the invention with at least one compound selected from inhibitors of BRAF, MEK, CDK4/6, SHP-2, HDAC, EGFR, MET, mTOR, Pl3K, and AKT. Examples of thes inhibitors include vemurafinib, debrafinib, LGX818, trametinib, MEK162, , PD- 0332991, panobinostat, stat, romidepsin, cetuximab, gefitinib, erlotinib, lapatinib, panitumumab, vandetanib, INC280, everolimus, simolimus, BMK120, BYL719, and CLR457.
The following examples are intended to illustrate the invention and are not to be construed as being limitations thereon. Temperatures are given in degrees Celsius. If not mentioned otherwise, all evaporations are performed under reduced pressure, lly between about 15 mm Hg and 100 mm Hg (= 20-133 mbar). The structure of final products, intermediates and starting materials is confirmed by standard analytical methods, e.g., microanalysis and spectroscopic characteristics, e.g., MS, IR, NMR.
All starting materials, building blocks, reagents, acids, bases, dehydrating , solvents, and sts ed to synthesize the compounds of the present invention are either commercially available or can be produced by organic synthesis methods known to one of ordinary skill in the art (Houben-Weyl 4th Ed. 1952, METHODS OF ORGANIC SYNTHESIS, THIEME, Volume 21). Further, the compounds of the present invention can be produced by organic synthesis s known to one of ry skill in the art in view of the following examples.
The compounds and/or intermediates were characterized by high performance liquid chromatography (HPLC) using a Waters Millennium tography system with a 2695 Separation Module rd, MA). The analytical columns were reversed phase Phenomenex Luna C18 -5 u, 4.6 x 50 mm, from Alltech (Deerfield, IL). A gradient elution was used (flow 2.5 mL/min), starting with 5% acetonitrile/95% water and progressing to 100% acetonitrile over a period of 10 minutes. All solvents contained 0.1% trifluoroacetic acid (TFA). nds were ed by ultraviolet light (UV) absorption at either 220 or 254 nm. HPLC solvents were from Burdick and Jackson (Muskegan, Ml), or Fisher Scientific (Pittsburgh, PA).
Mass spectrometric analysis was performed on a Waters System (Waters Acquity UPLC and a Waters SQD mass spectrometer detector; Column: Phenomenex Kinetex 2.6 um C18, column size 4.6 x 50 mm; column temperature 50°C. gradient: 2-98% acetonitrile in water with 0.1% TFA over a 1.5min period; flow rate 1.2 mL/min (or Polar gradient 1-30% over 1.3 min, NonPolar gradient 55-98% over 1.3min); Mass Spectrometer molecular weight scan range 0; or 150-1900. cone Voltage 20 V. All masses were reported as those of the protonated parent ions, unless ise ted. Nuclear magnetic resonance (NMR) analysis was performed on selected compounds, using a Varian 400 MHz NMR (Palo Alto, CA). The spectral reference was either TMS or the known chemical shift of the solvent.
X-ray Powder Diffraction (XRPD) was performed as follows: X-ray powder diffraction patterns were determined under the following conditions: ment: Bruker D8 Discovery Irradiation: CuK1oc (40 kV, 40 mA) CuK1 = 1.540598 A Scan range 3° — 40O (2—theta value) Scan type: 2—theta scan / detector scan (HI-STAR detector) Step time 60 seconds per frame Step size 0.02 s As will be iated by the skilled , the relative intensities of the various peaks within the “Table for figure 3” may vary due to a number of factors such as orientation effects of ls in the X-ray beam or the purity of the material being analysed or the degree of crystallinity of the sample. The peak positions may also shift for variations in sample height but the peak positions will remain substntially as defined in the “table for figure 3”. The skilled person will aslo appreciate that measurements using a different wavelength will result in different shifts according to the Bragg equation — nk = 2d sin 6.
Such alternative XRPD patterns generated by use of alternative wavelengths are heless representations of the same material.
Differential Scanning Calorimetry/Thermogravimetric Analysis (DSC/TGA) was performed as follows: Instrument: TA DSC QZOOO/TGA Q5000 ature Range: room temperature to 300°C Scan Rate: 10°/min Nitrogen Flow: 50 ml/min As will be tood by persons skilled in the art, slight variantions in observed peaks are expected based on the specific spectrometer employed and the anlyst’s sample preparation technique. Some margin of error is present in each of the peak assignments (+/- cm'1).
Abbreviations used herein have their ordinary meaning in the art unless otherwise indicated or defined in the following list: ATP adenosine phosphate BINAP racemic 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl BOC tertiary butoxycarbonyl br broad BSA bovine serum albumin d doublet dd doublet of doublets DCM dichloromethane DIEA diethylisopropylamine DME 1,4-dimethoxyethane DMF N,N-dimethylformamide DMSO dimethylsulfoxide DTT dithiothreitol EDTA ethylenediamine tetraacetic acid ESI electrospray ionization EtOAc ethyl acetate FCC flash column tography h ) HBTU 1-[bis(dimethylamino)methylene]-1H-benzotriazoliumhexafluorophosphate(1-) 3- oxide HOBt 1-hydroxyazabenzotriazole HPLC high pressure liquid chromatography IR infrared spectroscopy LCMS liquid chromatography and mass spectrometry MeOH methanol MS mass spectrometry MW microwave m multiplet min s mL milliliter(s) m/z mass to charge ratio NMR nuclear ic resonance ppm parts per million PyBOP riazolyloxytripyrro|idinophosphonium hexafluorophosphate rac racemic rt room temperature s singlet t triplet TFA trifluoroacetic acid THF tetrahydrofuran Tris-HCI aminotris(hydroxymethyl)methane hydrochloride EXAMPLES The following examples illustrate certain embodiments of the invention and how to make and use them, they are not intended to limit the scope of the invention.
Method 1 Example 1 S s of S 3-amino tetrah dro-2H- ran l razin l-N- 2-h drox phenylethyl )benzamide Scheme 1 $211112 $2; NH2 mg NHZ W \ N)\ N\ NJ\ Pd(dppf)C|2-DCM I H2,Pd/C I I NHzB /N /N N_BS. /N I o/GJLN/\© /N god Na2C03 DMEE MeOH Br quantitative fig crude crude mg V szdba3, PCy3, KOAc BZ(P|N)2, dioxane 0 (OH Step 6 5—2— H O Pd(dppf)C|2-DCM N \ N/\© {OH I : PyBrop HOBt N OH + 1:”N:o Ste 1. 5- 3 6-dih dro-2H- ran l razinamine To a solution of boronic ester (6.64 g, 31.6 mmol), 5-bromopyrazinamine (5 g, 28.7 mmol), and PdCl2(dppf) (2.1 g, 2.87 mmol) was added DME (71.8 mL) and 2 M Na2C03 solution (24 mL). The reaction e was heated at 90 °C for 15 h. The on mixture was worked up with EtOAc. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, filtered off, and concentrated in vacuo. The crude t was purified by flash chromatography (gradient EtOAc in heptanes) yielding 5-(3,6- dihydro-2H-pyran-4—yl)pyrazin-2—amine in 57% yield. LCMS (m/z): 178.1 (MH+), 0.34 min; 1H NMR (400MHz, CDCI3) 6 ppm 8.17 - 8.03 (m, 1 H), 8.04 - 7.88 (m, 1 H), 6.57 - 6.41 (m, 1 H), 4.68 - 4.42 (m, 2 H), 4.42 - 4.29 (m, 2 H), 4.06 - 3.84 (m, 2 H), 2.68 - 2.47 (m, 2 Ste 2. 5- tetrah dro-2H- ran l razinamine A solution of 5-(3,6-dihydro-2H-pyranyl)pyrazinamine (2.7 g, 15.24 mmol) and Pd-C (10%, a type) (1.6 g, 1.5 mmol) in MeOH (50 mL) was degassed by N2 stream for min. After equipped with hydrogen gas balloon, the reaction mixture was stirred for 15 h at room temperature. The crude t was filtered off through celite pad and washed with EtOAc. The volatile material was concentrated in vacuo yielding 5-(tetrahydro-2H- 4-yl)pyrazinamine and was used for the next step. LCMS (m/z): 180.3 (MH+), 0.28 min.
Ste 3. 3-bromo tetrah dro-2H- ran l razinamine To an ice cold solution of 5-(tetrahydro-2H-pyrany|)pyrazinamine (2.8 g, 15.6 mmol) in CH3CN (52 mL) was added NBS (2.78 g, 15.62 mmol) in two portions at 0 °C. The reaction mixture was stirred at 0 °C for 1 h. The reaction mixture was diluted with ethyl acetate and was washed with saturated sodium carbonate solution, water, brine, dried and concentrated. The crude 3-bromo(tetrahydro-2H-pyranyl)pyrazinamine (3.9 g, 97%) was used for the next step without r purification. LCMS (m/z): 258/260 (MH+), 0.52 min; 1H NMR (400MHz, CDCI3) 6 ppm 7.83 (s, 1H), 4.90 (br. s., 2H), 4.14 - 4.02 (m, 2H), 3.59 - 3.43 (m, 2H), 2.83 (d, J=5.5 Hz, 1H), 1.91 — 1.77 (m, 4H).
Step 4. (S)—4-bromo-N-(2-hydroxy-1phenylethyl)benzamide To a solution of 4-bromobenzoic acid (892 mg, 4.44 mmol) in THF (9.9 mL) was added (S)aminophenylethanol (609 mg, 4.44 mmol), DIEA (1.9 mL, 11.1 mmol), PyBroP (2.5 g, 5.32 mmol), and HOBT (815 mg, 5.32 mmol). The reaction mixture was stirred at room temperature for 20 h. The reaction mixture was extracted with EtOAc. The organic layer was washed with water and brine. After dried over anhydrous sodium sulfate, ed and concentrated in vacuo, the crude product was purified by flash chromatography (gradient EtOAc in DCM) yielding (S)—4-bromo-N-(2-hydroxy phenylethyl)benzamide (850 mg, 60%). LCMS (m/z): 338.1 (MH+), 0.61 min.
Ste 5. S -N- 2-h drox hen leth l 4 4 5 5-tetrameth H 3 2-dioxaborolan y|)benzamide To a solution of (S)bromo-N-(2-hydroxyphenylethyl)benzamide, 4,4,4',4',5,5,5',5'- thyl-2,2'-bi(1,3,2-dioxaborolane (B2(P|N)2) (238 mg, 0.937 mmol), Pd2(dba)3 (21.45 mg, 0.023 mmol), tricyclohexylphosphine (19.71 mg, 0.070 mmol) in dioxane (1.562 mL) was added potassium acetate (138 mg, 1.405 mmol). The reaction mixture was degassed by N2 stream for 15 min. The on mixture was heated at 100 OC overnight. After diluted with EtOAc, the reaction mixture was filtered through Celite. After concentrated, (S)—N-(2-hydroxyphenylethyl)(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)benzamide was used for the next step without further purification. LCMS (m/z): 368.3 (MH+), 0.88 min (for c ester) and 286.1 (MH+), 0.49 min (for the corresponding boronic acid).
Ste 6. S 3-amino tetrah dro-2H- ran l razin l-N- 2-h drox ethyl)benzamide To a solution of 3-bromo(tetrahydro-2H-pyranyl)pyrazinamine (154 mg, 0.418 mmol), (S)—N-(2-hydroxyphenylethyl)(4,4,5,5-tetramethyl-1,3,2-dioxaborolan y|)benzamide (90 mg, 0.349 mmol), and PdC|2(dppf) (25.5 mg, 0.035 mmol) was added dioxane (2.3 mL) and 2 M Na2C03 solution (1.163 mL). The reaction mixture was heated at the microwave synthesizer (120 °C, 10 min). The reaction mixture was worked up with EtOAc. The c layer was washed with water and brine, dried over anhydrous sodium sulfate, filtered off, and concentrated in vacuo. The crude product was purified by prep HPLC. The pure fractions were combined, free-based with sodium carbonate solution, and extracted with EtOAc. The organic layer was dried over anhydrous sodium sulfate, filtered off, and dried in vacuo. The pure solid was ved in MeCN/water (1:1, 6 mL) and lized yielding (S)—4-(3-amino(tetrahydro-2H-pyranyl)pyrazinyl)-N-(2- hydroxyphenylethyl)benzamide as free base (46%). LCMS (m/z): 419.2 (MH+), 0.58 min; 1H NMR (400MHz, DMSO-d6) 8 ppm 8.74 (d, J =12 Hz, 1 H), 7.99 (d, J = 8 Hz, 2 H), 7.88 (s, 1 H), 7.79 (d, J =12 Hz, 2 H), 7.37 (d, J = 8 Hz, 2 H), 7.29 (m, 2 H), 7.22 (m, 1 H), 5.99 (bs, 1 H), 5.07 (m, 1 H), 3.91 (m, 2 H), 3.67 (m, 2 H), 3.41 (m, 2 H), 2.82 (m, 1 H), 1.72 (m, 4 H).
S nthesis of 3-fluoro 3- meth lsulfon lbenz lcarbamo l hen lboronic acid Scheme 2 O O o\ ,o O\\ 00 \S’ + H2N Ho~ H i|3 F US\ —> HO‘EI; F N/\©/ \ OH OH A mixture of nofluorobenzoic acid (218 mg, 1.2 mmol), (3- (methylsulfonyl)phenyl)-methanamine (200 mg, 1.08 mmol), DIEA (0.754 mL, 4.32 mmol) and TBTU (381 mg, 1.2 mmol) in DMF (2 mL) was stirred at room temperature for 2 days, then the reaction mixture was diluted with water (10 mL), and t precipitated out as gum, and the supernatant was separated via centrifugation, and the gummy residue was sonicated with water (3 mL), and the gummy residue was further dried under high vacuum yielding 3-fluoro(3-(methylsulfonyl)benzylcarbamoyl)-phenylboronic acid (335 mg, 88%) as white foam. LCMS (m/z): 352.1 (MH+), 0.51 min. 8 s of +/- - 3-fluoro 222-trifluoro hen |eth lcarbamo | hen Iboronic acid Scheme 3 COOH —.TEA + + jl: N NHz \N Cl H HO\B | HO (5H OH (”9 (+/-) A mixture of 4-boronofluorobenzoic acid (54 mg, 0.294 mmol) in DCM (1468 uL) was cooled to 0 °C. Then ghosez reagent N,N,3-trimethylbut—2-enamine (65.8 uL, 0.587 mmol) was added and the whole mixture was stirred at rt for 20 min. The e was added into a mixture of TEA (246 uL, 1.762 mmol), 2,2,2-trifluorophenylethanamine (59.1 mg, 0.338 mmol) and DCM (1468 uL). The reaction was stirred at room temperature for 2 h. To the reaction mixture was added EtOAc, and washed with sat. sodium bicarbonate, water, and dried over Na2804. Filtered and concentrated to provide the crude product which was taken to the next step without further purification. LCMS (m/z): 342.2 (MH+), 0.84 min.
S nthesis of R 2-fluoro hen n l i amine HZN,“ (R)—3-Boc—aminopiperidine (1.05 g, 5.25 mmol) was dissolved in DCM (10 mL) and then triethylamine (1.10 mL, 7.89 mmol) was added. To this solution at room temperature was added 2-f|uorobenzenesu|fony|ch|oride (1.127 g, 5.79 mmol). After 2h, reaction was deemed complete by LCMS and d with water and extracted with DCM (30 mL), and the organic layer was separated and dried over magnesium sulfate, filtered and concentrated and taken to the next step as such. The crude product from above was dissolved in DCM (25 mL) and TFA (10 mL) added in one portion. Reaction mixture followed by LCMS. After 1 h, TFA was stripped in vacuo and then the e suspended in 3N HCI and washed with ether. The aq. layer was basified and extracted with DCM and the DCM |ayer separated and dried over magnesium sulfate, filtered and concentrated in vacuo to give 873 mg of (R)—1-((2-f|uoropheny|)su|fony|)piperidinamine as the desired product as free base. LCMS (m/z): 255.5 (MH+), 0.49 min. 8 s of R hen lsulfon l i eridinamine HZN,“ cm:0 (R)—3-Boc—aminopiperidine g, 4.21 mmol) was dissolved in DCM (10 mL) and then triethylamine (0.88 mL, 6.31 mmol) was added. To this solution at room temperature was added benzenesulfonylchloride (0.818g, 4.63 mmol). After 2 h, reaction was deemed complete by LCMS and diluted with water and extracted with DCM (30 mL), and the organic layer was separated and dried over magnesium sulfate, filtered and concentrated and taken to the next step as such. The crude product from above was dissolved in DCM (25 mL) and TFA (10 mL) added in one portion. on mixture followed by LCMS.
After 3 h, complete Boc—deprotection was observed. At this stage, TFA was stripped in vacuo and then the residue suspended in 3N HCI and washed with ether. The aq. layer was basified and extracted with DCM and the DCM layer separated and dried over magnesium sulfate, filtered and trated in vacuo to give 850 mg of (R)—1- (phenylsulfonyl)piperidinamine as the desired product as free base. LCMS (m/z): 241.4 (MH+), 0.43 min. 8 s of R fluoro1- 2-fluoro hen lsulfon l i eridin lcarbamo l hen lboronic acid Scheme 4 HN,2 F O " F 0 ..(R) N OH N N‘ ‘302 HO so HO H F ‘B ‘B To a solution of 4-boronofluorobenzoic acid (160 mg, 0.870 mmol), (R)—1-(2- fluorophenylsulfonyl)piperidinamine (225 mg, 0.870 mmol), and DIEA (456 uL, 2.61 mmol) in THF (1450 uL) and DMF (1450 uL) was added HOAt (237 mg, 1.740 mmol) and EDC (417 mg, 2.175 mmol). After 3 h stirring at room temperature, the on mixture was extracted with EtOAc. The organic layer was washed with NaHC03, water and brine, dried over anhydrous sodium sulfate, filtered off, and trated in vacuo yielding (R)- 3-fluoro(1-(2-f|uorophenylsulfonyl)piperidinylcarbamoyl)phenylboronic acid, which was used in next step reaction without purification. LCMS (m/z): 425.2 (MH+), 0.72 min.
S nthesis of 4- 22-difluoro hen leth Icarbamo lfluoro hen ic acid Scheme 5 m_1 Sfig_2 F F F o (>)‘\(F_>LiHMDS ©2YI= HOBdOH EDCI, HOAt Ho. db]H F BH3-DMS DIEA El; % 90% (+/_) (44.) Ste 1. 22-difluoro hen lethanamine To a solution of 2,2-difluorophenylethanone (1 g, 6.4 mmol) in toluene (32 mL) at room temperature was added LiHMDS (1M in THF) (7.05 mL, 7.05 mmol). The reaction mixture was stirred for 30 min, followed by addition of BH3-DMS (1.216 mL, 12.81 mmol). The reaction mixture was stirred for 1 h. After g at 0 °C, s 2 N NaOH solution was lly added over 5 min (Caution! gas ion). The reaction was d for 1 h.
The layer was separated and washed with water and brine. After dried over sodium sulfate, HCI in MeOH (7.17 mL, 8.97 mmol) was added to form a white precipitate. The precipitate was filtered off, washed with ether, and dried in vacuo yielding 2,2-difluoro phenylethanamine (21%). 1H NMR (400MHz, CDCI3) 6 ppm 7.49 (s, 5 H), 6.52 - 6.07 (m 1 H), 4.78 - 4.69 (m, 2 H).
Ste 2. 4difluoro hen leth Icarbamo lfluoro hen Iboronic acid To a solution of 4-boronofluorobenzoic acid (200 mg, 1.087 mmol), 2,2-difluoro phenylethanamine (232 mg, 1.196 mmol), and DIEA (0.570 mL, 3.26 mmol) in THF (3.866 mL) and DMF (0.483 mL) was added HOAt (296 mg, 2.175 mmol) and EDC (521 mg, 2.72 mmol). After 3 h stirring at room temperature, 10% citric acid solution was added (pH ~3) and extracted with 2-methyl THF and EtOAc (1:1). The organic layers were dried over anhydrous Na2804, filtered, and concentrated. The crude 4-(2,2-difluoro phenylethylcarbamoyl)fluorophenylboronic acid was obtained (90%) and used for the next step without purification. LCMS (m/z): 375.3 (MH+), 0.48 min.
Synthesis of 4-benzyl(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2—yl )—3,4- dih drobenzo 1 4 oxaze in-5 2H -one Scheme 6 0 m1 Step; dCI “MWQ —> —> + H Br F 0 Step g cm 9 N N / O\ ,B\OJ? _. + r 0 0312 Br 0 O (I) Ste 1. N-benz lbromofluoro-N- 2-h drox eth | benzamide To a solution of 4-bromofluorobenzoyl chloride (1 g, 4.21 mmol) in THF (14.04 mL) was added DIEA (1.103 mL, 6.32 mmol) and 2-(benzylamino)ethanol (0.764 g, 5.05 mmol) at room temperature. The reaction mixture was stirred for overnight. The reaction mixture was ted with EtOAc. The organic layer was washed with water and brine.
After dried over anhydrous sodium sulfate, filtered and concentrated in vacuo, the crude N-benzyl-4—bromofluoro-N-(2-hydroxyethyl)benzamide was used for the next step (83%). LCMS (m/z): 352/354 (MH+), 0.83 min.
Ste 2. 4-benz lbromo-3 4-dih drobenzo 1 4 oxaze in-5 2H -one To a solution of N-benzylbromofluoro-N-(2-hydroxyethyl)benzamide (494 mg, 1.403 mmol) in DMF (14.00 mL) was added NaH (60% in oil) (61.7 mg, 1.543 mmol) .
After H2 gas evolved, the reaction mixture was heated at 90 °C for 24 h. After quenched with water, the reaction e was extracted with EtOAc. The organic layer was washed with water and brine. After drying over anhydrous sodium sulfate and filtration, the organic layer was ated in vacuo. The oily crude 4-benzylbromo-3,4- dihydrobenzo[f][1,4]oxazepin-5(2H)—one was purified by flash chromatography (gradient EtOAc in heptane) in 84% yield. LCMS (m/z): 332.1/334.1 (MH+), 0.94 min.
Step 3. 4-benzyl(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)—3,4- dih drobenzo 1 4 oxaze in-5 2H -one 2014/062913 To a on of 4-benzylbromo-3,4-dihydrobenzo[f][1 ,4]oxazepin-5(2H)—one (111.3 mg, 0.335 mmol), B2(P|N)2 (170 mg, 0.670 mmol), Pd2(dba)3 (15.34 mg, 0.017 mmol), tricyclohexylphosphine (14.09 mg, 0.050 mmol) in dioxane (3.35 mL) was added ium acetate (99 mg, 1.005 mmol)just right after degassing. The reaction mixture was heated at 100 °C overnight. After diluted with EtOAc, the reaction mixture was filtered through Celite. After concentrated, the crude 4-benzyl(4,4,5,5-tetramethyl-1,3,2- dioxaborolany|)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)—one was obtained (>99%) and used for the next step without r purification. LCMS (m/z): 298.1 (MH+for boronic acid), 0.63 min and 380.2 (MH+), 1.05 min. 8 nthesis of S meth lamino hen lethanol Scheme 7 To a suspension of LiAlH4 (0.689 g, 18.16 mmol) in THF (20.18 mL) was added (S)—2- (methylamino)pheny|acetic acid (1 g, 6.05 mmol) in THF (20mL) slowly over 10 min at 0 °C. The reaction mixture was stirred at room temperature for overnight. After quenched with water (0.7 mL), NaOH (2.1 mL), water (0.7 mL). The reaction mixture was filtered off. The filtrate was extracted with EtOAc 3 times. The combined organic layer was washed with water and brine, dried over anhydrous sodium sulfate, filtered off, and concentrated in vacuo. The crude product was purified by flash tography (10% methanol in DCM) yielding (S)(methy|amino)pheny|ethanol as a colorless oil in 55% yield. LCMS (m/z): 152.1 (MH+), 0.31 min; 1H NMR z ,CDCI3) 87.40 - 7.33 (m, 2 H), 7.32 - 7.27 (m, 3 H), 3.77 - 3.69 (m, 1 H), 3.69 - 3.63 (m, 1 H), 3.58 (d, J= 9.8 Hz, 1 H), 2.36 (s, 3 H). sis of (S)—4-phenyloxazolidine Scheme 8 ©Y\OH + HYO —> HN NH2 H MeOH L To a solution of aminophenylethanol (1.5 g, 10.93 mmol) in methanol (36.4 mL) was added dehyde (1.065 g, 13.12 mmol) at room temperature. The reaction mixture was stirred at room temperature for 2 days . The reaction mixture was concentrated to dryness. The crude material was purified by flash chromatography (0- 50% EtOAc/heptanes) to give (S)—4-phenyloxazolidine in 40% yield. LCMS (m/z): 150.1 (MH+), 0.31 min. 8 nthesis of S -tert-but l 2—amino 3-chloro hen leth lcarbamate Scheme 9 Step 1 Step 2 Step 3 OH OH O o NaHMDS 1 Boczo ! NHBOc ©:: DTBAD —> —> + NH —> I 0 CI CI CI Ste fl NHBoc oR o N g/ HZNNHZ Q/K/NHBOC —> H2N/\© Ste 1. R amino 3-chloro hen lethanol To a solution of (R)—2-(3-chlorophenyl)oxirane (13 g, 84 mmol) in THF (84 mL) was added NaHMDS (1 M in THF) (252 mL, 252 mmol) slowly at 0 °C. The reaction mixture was warmed up to room temperature and stirred for overnight. To the reaction e, water (33 mL, 2.5 mL/g) added. After ng for 5 h at room temperature, solvent was removed in vacuo to about 1/4 and partitioned by DCM. The bottom layer is a little cloudy and the top layer was a brown solution. Both layers were concentrated, which contained the desired (R)—2-amino(3-chlorophenyl)ethanol (14 g, 97%). The combined ts were used in next step without further cation. LCMS (m/z): 172.1 (MH+), 0.37 min.
Step 2. (R)—tert—butyl (2—(3-chlorophenyl)—2-hydroxyethyl)carbamate To a solution of (R)—2-amino(3-chlorophenyl)ethanol (14 g, 82 mmol) in THF (272 mL) was added di-tert-butyl dicarbonate (24.92 g, 114 mmol). The mixture was stirred at room temperature for overnight. The reaction mixture was diluted with DCM and then washed with saturated sodium bicarbonate solution. The separated organic layer was then dried over anhydrous sodium sulfate, filtered off, and concentrated in vacuo. The crude product was purified by flash chromatography (0 to 50% ethyl e in heptane) yielding (R)- tert-butyl (2-(3-chlorophenyl)hydroxyethyl)carbamate (49.2%). LCMS (m/z): 216 (MH- tBu), 0.85 min; 1H NMR (400 MHz, CD3OD) 6 ppm 1.40 (s, 9 H) 3.18 (s, 1 H) 3.26 (d, J=4.70 Hz, 1 H) 4.69 (br. s., 1 H) 7.20 - 7.34 (m, 3 H) 7.35 - 7.41 (m, 1 H).
Ste 3. S -tert-but l 2- 3-chloro hen l 1 oisoindolin leth lcarbamate To a solution of (R)—tert-butyl (2-(3-chlorophenyl)hydroxyethyl)carbamate (8.12 g, 29.9 mmol) in THF (100 mL) was added phthalimide (6.16 g, 41.8 mmol) and polymer-bound triphenylphosphine (3 mmol of PPh3/1 g of resin, 9.8 g). DTBAD (7.09 g, 30.8 mmol) in THF (20 mL) was added slowly at room ature to the reaction mixture, which was then stirred at room temperature overnight. The reaction mixture was filtered through Celite and washed with EtOAc. The resulting filtrate was washed with Na2C03 solution, water and brine, dried over anhydrous sodium sulfate, filtered off, and concentrated in vacuo. The crude material was purified by flash chromatography (0-30% EtOAc/heptane) ng (S)—tert-butyl chlorophenyl)(1,3-dioxoisoindolinyl)ethyl)carbamate (58.4%). LCMS (m/z): 301.1 (MH+-Boc), 1.06 min.
Step 4. (S)—tert—butyl no(3-chlorophenyl)ethyl)carbamate To a solution of (S)—tert-butyl (2-(3-chlorophenyl)(1,3-dioxoisoindolin y|)ethyl)carbamate (5.0 g, 12.47 mmol) in ethanol (41.6 mL) was added hydrazine hydrate (6.06 mL, 125 mmol). The reaction mixture was heated at 60 °C for 2 h. The reaction mixture was filtered through Celite pad. The filtrate was concentrated and the residue was diluted with DCM and filtered off through Celite. The same process was repeated until no white precipitate was shown. To remove the white side product tely, the product was dissolved in 1N HCI (30 mL), washed with EtOAc, and the s phase was neutralized to pH 7 then xtracted by EtOAc. The organic was dried over anhydrous sodium sulfate, filtered off, and concentrated in vacuo ng (S)—tert-buty| (2-amino (3-chlorophenyl)ethyl)carbamate (89%). LCMS (m/z): 271.1 (MH+), 0.58 min.
Table 1. Aryl halides or the corresponding boronic esters/acids obtained from amide bond formation and/or boronic ester formation Structure Name MH+ F O _/OH (S)—4-bromof|uoro- flaw' ydroxy—1 - 338 0'76 phenylethyl)benzamid Br e OH (S)—2-f|uoro-N-(2— F O =/ fiflfihydroxy phenylethylH' 32%;: 051 (LB (4,4,5,5-tetramethy|— ' >§Vé acid) 1,3,2-dioxaborolan-2— y|)benzamide 1H NMR (400 MHz, CDCI3) 6 ppm 7.70 (d, J=8.2 Hz, 2 H) 0” (S)'4'br°m°'N'(2' 7.56 — 7.62 (m, 2 H) 7.30 — 7.44 fim/fi hyd roxy-1 - 321.9 0.75 (m, 5 H) 6.82 (d, J=5.9 Hz,1 . H, :henylethyl)benzamld NH?) 5.27 (dt, J=7_0, 4.7Hz, 1 Br H) 4.03 (t, J=5.1 Hz, 2 H) 2.38 (t, J=5.9 Hz, 1 H) Structure Name MH+ ("ii”) NMR 0 N-(3- QXN (methylsulfonyl)benzy 0‘? : ')4(4’4’5’5_ _ _ 416.2 0.86 o 802Me tetramethyI-1,3,2- N/A dioxaborolan-Z- y|)benzamide F 0 ;/ (S)—4-bromo-N-(1-(3- N chlorophenyl)—2— 4 0 89 ' H hydroxyethyl)—2— N/A fluorobenzamide (S)-(4-((1-(3- F O =/ chlorophenyl)—2— N hydroxyethyl)carbamo 420/422 HO‘B W3— 1 fluorophenyl)boronic OH CI acnd.
O {OH (S)—4-bromo-N-(2— ‘ hydroxy'1' N 334 0.76 ethyl)—2— H N/A Br methylbenzamide 0 {OH (S)—N-(2-hydroxy ' phenylethyl)—2— o methyl(4,4,5,5- ‘3 H/\©N 382.2 ethyI-1,3,2- N/A dioxaborolan-Z- y|)benzamide 1H NMR (400 MHz, DMSO-d6) NH2 0 (S)—2—amino-4—bromo- . ppm 8.51 (d, J=7.8 Hz,1 H) N-(2-hydroxy 7.60 (d, J=8.2, 2 H) 7.15 — 7.45 337.0 0.71 phenylethyl)benzamid (m, 5H) 6.90 (d, J=2.0 Hz, 1 H) e ..70 (dd, J=8.2, 2.0 Hz, 1 H) ..56 (bs, 2 H, NH2) 4.83 — 5.01 (m, 1 H)4.92 (m, 1H, OH) 3.53 Structure Name 3.76 (m, 2 H) (S)—3-f|uoro(1-(2— fluorobenzyl)piperidin- ylcarbamoyl)pheny|bo ronic acid (R)—3-f|uoro(1-(2— fluorobenzyl)piperidin- ylcarbamoyl)pheny|bo ronic acid (S)-(4-((2-((tert- 0 /NHBoc . ; butoxycarbonyl)amino - N/A N )—1-(3- HO pheny|)ethy|)car 437.1 0.86 ‘B F I bamoyl)—3- HO CI fluorophenyl)boronic acid Example 2 S s of S 2—amino i eridin | ridin Ifluoro-N- 2—h drox phenylethyl )benzamide Scheme 10 Step 1 NH2 Stag g NH2 mg NH2 NH2 W Br NI \ NI \ \ 0‘ ,o Pd(dppf)C|2-DCM H2, Pd/C NBS ”I N \ B . / / _, _. / ' + / / N22003,DME MeOH MeCN quantitative. . 0A0J< OAOJ<N Dick 010k F O Ste 4 :/ _r;_ NH2 9 Step; = B /OH NH2 Pd(dppf)Cl2-DCM H | ? / 1.Pd(dppf)CI2-DCM HA© N \ N/\© —> + N —> | B2(P|N)2, KOAc / N32003, DME dioxane 2. 30%TFA in DCM To a solution of 5-bromopyridinamine (0.84 g, 4.85 mmol) in DME (10 mL) was added N-Boc—5,6-dihydropyridine-1(2H)-carboxy|ate (1 g, 3.23 mmol), and sodium carbonate (4.85 mL, 9.70 mmol). The mixture was purged with nitrogen for 5 min, and followed by the addition of dppf)-CH2C|2 (0.26 g, 0.32 mmol). The resulting mixture was heated to 120 °C in an oil bath for 2 h. The reaction mixture was diluted with ethyl acetate, washed with water, brine, dried and was concentrated. The residue was purified by flash column chromatography on silica gel (ISCO) eluting with 0-90% ethyl acetate in heptane to give tert-butyl 6-amino-5',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxy|ate (560 mg, 63 %) as brown color solid. LCMS (m/z): 276 (MH+), 0.59 min.
Ste 2. tert-But l4- 6-amino ridin l i eridinecarbox late A suspension of tert-butyl 6-amino-5',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxy|ate (560 mg, 2.03 mmol), 5% Pd/C (1082 mg, 0.5 mmol) in methanol (30 mL) was purged with nitrogen for 2 min. The reaction e was stirred under hydrogen at ambient temperature for 16 h. The reaction mixture was diluted with romethane (50 mL) and was filtered h Celite pad. The te was concentrated and the e was purified by flash column chromatography on silica gel (ISCO) eluting with 0-90% ethyl acetate in heptane to give tert-butyl 4-(6-aminopyridinyl)piperidinecarboxylate (180 mg, 31.9 %) as yellow color solid. LCMS (m/z): 278 (MH+), 0.57 min.
Ste 3. tert-but l4- 6-aminobromo ridin l i eridinecarbox late To an ice cold on of tert-butyl 4-(6-aminobromopyridiny|)piperidine carboxylate(180 mg, 0.65 mmol) in DCM (18 mL) was added NBS (116 mg, 0.65 mmol) in two portions. The reaction mixture was stirred at 0 °C in an ice bath for 30 min. The reaction solution was diluted with ethyl acetate, washed with water, saturated aqueous sodium bicarbonate, brine, dried over sodium sulfate and trated. The resulting residue was purified by flash column chromatography on silica gel (ISCO) eluting with 0- 100% ethyl e in heptane to give tert-butyl 4-(6-aminobromopyridin yl)piperidinecarboxylate (180 mg, 78%) as yellow color 0“. LCMS (m/z): 300/302 (MH+), 0.67 min.
Ste 4. tert-but l 4- 6-amino 4 4 5 5-tetrameth H 3 2-dioxaborolan l ridin yl)piperidinecarboxy|ate To a suspension of tert-butyl 4-(6-aminobromopyridiny|)piperidinecarboxy|ate (180 mg, 0.50 mmol) in oxane (8 mL) was added bis(pinaco|ato)diboron (385 mg, 1.51 mmol) and potassium acetate (248 mg, 2.53 mmol). The mixture was purged with nitrogen for 3 min, then dppf)-CH2C|2Adduct (49.5 mg, 0.061 mmol) was added.
The reaction mixture was heated to 110 °C in an oil bath for 20 h and ed through neutral alumina (1 g). The filtrate was concentrated to give crude tert-butyl 4-(6-amino (4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)pyridinyl)piperidinecarboxylate, which was used directly in next step without any purification. LCMS (m/z): 322 (MH+ for c acid), 0.60 min.
Ste 5. S 2-Amino i eridin l ridin lfluoro-N- 2-h drox phenylethyl)benzamide To a suspension of (S)bromof|uoro-N-(2-hydroxypheny|ethy|)benzamide (67.1 mg, 0.20 mmol) in DME (5 mL) was added tert-butyl 4-(6-amino(4,4,5,5-tetramethyl- 1,3,2-dioxaborolanyl)pyridinyl)piperidinecarboxylate (40 mg, 0.099 mmol) and sodium carbonate (0.24 mL, 0.49 mmol). The mixture was purged with nitrogen for 10 min, then PdC|2(dppf)-CH2C|2Adduct (12.15 mg, 0.015 mmol) was added. The reaction mixture was heated to 120 °C in an oil bath for 3 h. The on mixture was diluted with ethyl acetate. The organic on was washed with water, brine, dried over sodium sulfate and concentrated. The resulting residue was treated with 30% TFA in DCM (20 mL) for 15 min. The reaction mixture was concentrated and the crude product was purified by HPLC to give (2-amino(piperidinyl)pyridinyl)—2-fluoro-N-(2- hydroxyphenylethyl)benzamide (9 mg, 20.8 %) as TFA salt. LCMS (m/z): 435 (MH+), 0.44 min; 1H NMR (300 MHz, CD3OD) 6 ppm 8.63 (br. s., 1 H) 7.90 (t, J=7.77 Hz, 1 H) 7.84 (s, 2 H) 7.47 -7.24 (m, 7 H), 5.27 -5.17 (m, 1 H) 3.93- 3.79 (m, 2 H) 3.52 (d, J=12.60 Hz, 2 H) 3.21- 3.05 (m, 2 H) 2.96 (t, J=12.31 Hz, 1 H) 2.15 (d, J=14.07 Hz, 2 H) 1.96 - 1.78 (m, 2 H).
S nthesis of 3-bromo 1- meth Isulfon l i eridin l razinamine and meth l4- 5- aminobromo razin l i eridinecarbox late Scheme 11 Stegz Ngfirm | \ N DIEA/DCM NAYBI‘ $21 46% \ IN TFA/DCM o”?“o Stegg N Bl’ Boc Nfi/ MeC02C| \ N DIEA/DCM 02‘0/ Following Step 1 to 3 in Scheme 10, using 5-bromopyrazinamine and N-Boc—5,6- dihydropyridine-1(2H)-carboxylate, tert-butyl 4-(5-aminobromopyrazinyl)piperidine carboxylate was ed. LCMS (m/z): 301 .0/303.0 (MH+-tBu), 0.875 min.
Ste 1.3-bromo ieridinl razinamine To a on of tert-butyl 4-(5-aminobromopyrazinyl)piperidinecarboxylate (70 mg, 0.196 mmol) in DCM (4 mL) was added TFA (1 mL, 12.98 mmol). The reaction mixture was stirred at room temperature for 45 min. After toluene was added, the volatile materials were evaporated yielding 3-bromo(piperidinyl)pyrazinamine. The crude product was used directly for the next reaction (99%). LCMS (m/z): 259.0 (MH+), 0.329 min.
Ste 2. 3-bromo 1- meth lsulfon | i eridin | razinamine To 3-bromo(piperidinyl)pyrazinamine (50 mg, 0.194 mmol) in DCM (2 mL) in ice bath was added DIEA (340 pl, 1.945 mmol) and methanesulfonyl chloride (16.67 ul, 0.214 mmol). The reaction mixture was stirred for 60 min. The reaction mixture was extracted with DCM. The c layer was washed with brine, dried over sodium sulfate, filtered and ated in vacuo. (30mg, 46%). LCMS (m/z): 335.2/3372 (MH+), 0.572 min.
Ste 3. meth l4- obromo razin | i eridinecarbox late To a solution of 3-bromo(piperidinyl)pyrazinamine (60 mg, 0.233 mmol) in DCM (2 mL) in ice bath was added DIEA (408 pl, 2.333 mmol) and methyl chloroformate (18.07 ul, 0.233 mmol). The reaction mixture was stirred under ice bath for 30 min. The reaction mixture was partitioned between DCM and water. The organic layer was separated and washed with brine, dried over sodium sulfate, filtered off, and evaporated in vacuo. The crude methyl 4-(5-aminobromopyrazinyl)piperidinecarboxy|ate was used for next step. LCMS (m/z): 315.0/317.0 (MH+), 0.647 min.
Example 3 S nthesis of 4- 2-amino tetrah - ran | ridin lfluoro-N-meth l-N- (pyrimidinylmethyl)benzamide Scheme 12 Stepl Br Step; NH2 0 NH2 N \ E's \ F o I O N \ QB/O / szdba3,PCy3,KOAc N + :: NI \ I —. / + N/\f \ / 6] B2(P|N)2,dioxane I N / o Stegfl F 0 I Mel, NaH Stepé NH2 ll“ NIJ F o —Qs‘e Q F o / N N \ H N / PyBOP N I 2W _. / | _.
N\ New \ Br DIEA N / Ste 1. 3-bromo tetrah dro-2H- ran | 2-amine Following Step 1 to 3 in Scheme 10, using 5-bromopyridinamine, 3-bromo (tetrahydro-2H-pyranyl)pyridinamine was obtained. LCMS (m/z): 257/259 (MH+), 0.38 min.
Ste 2. 5- tetrah dro-2H- ran | 4 4 5 5-tetrameth H 3 aborolan yl inamine Following Step 4 in Scheme 10, using 3-bromo(tetrahydro-2H-pyranyl)pyridin amine was ed, 5-(tetrahydro-2H-pyranyl)(4,4,5,5-tetramethyl-1,3,2- dioxaborolanyl)pyridinamine was obtained. LCMS (m/z): 233 (MH+), 0.36 min.
Ste 3. 4-bromofluoro-N- rimidin-2— lmeth lbenzamide To a flask was charged with 4-bromofluorobenzoic acid (180 mg, 0.821 mmol), pyrimidinylmethanamine (89.6 mg, 0.821 mmol), DIEA (0.358 mL, 2.05 mmol) in DMF (3 mL), and to the resulting solution was added PyBOP (513 mg, 0.915 mmol) and the resulting mixture was stirred at room temperature overnight, then was concentrated under reduced pressure and the residue was diluted with EtOAc (20 mL), washed with water (3 x 10 mL), brine (10 mL) and dried (NazSO4), concentrated and the residue was purified by flash chromatography on silica gel eluted with gradient EtOAc/heptane (0-100%) and 4- bromofluoro-N-(pyrimidinylmethyl)benzamide (74.5 mg, 29.3%) was obtained as light color solid. LCMS (m/z): 310.0/312.0 (MH+), 0.64 min.
Ste 4. 4-bromofluoro-N-meth l-N- n lmeth Ibenzamide To a flask was charged with ofluoro-N-(pyrimidinylmethyl)benzamide (74.5 mg, 0.24 mmol), NaH (60% dispersion in mineral oil, 11.5 mg, 0.288 mmol) in DMF(2 mL), to the slurry was added iodomethane (20 ul, mol) and to the resulting e was stirred at room temperature for 10min, then was quenched by water (20 ul), concentrated and the crude residue was dissolved in EtOAc, washed with water, and brine, dried (Na2804), trated and 4-bromofluoro-N-methyl-N-(pyrimidin y|methy|)benzamide was obtained as oil (55.3mg, 71% ). LCMS (m/z): 324.1/326.1 (MH+), 0.66 min.
Ste 5. 4- 2-amino tetrah dro-2H- ran | ridin |f|uoro-N-meth l-N- (pyrimidinylmethyl)benzamide To a microwave reactor vial was charged with 5-(tetrahydro-2H-pyrany|)(4,4,5,5- ethyl-1,3,2-dioxaborolanyl)pyridinamine (39.4 mg, 0.13 mmol), 4-bromo fluoro-N-methyl-N-(pyrimidinylmethyl)benzamide (28 mg, 0.086 mmol), aqueous Na2C03 (2 M, 0.26 mL) in DME (1.5 mL), and the mixture was purged with Argon followed by addition of tetrakis(triphenylphosphin) palladium (10 mg, 8.6 mmol), and final purge, then sealed and heated at 115 °C for 15 min in microwave synthesizer. The DME layer was collected, concentrated and the residue was subjected to prep HPLC purification and fractions containing final product were combined, frozen, lyophilized and TFA salt of 4-(2- amino(tetrahydro-2H-pyranyl)pyridinyl)f|uoro-N-methyl-N-(pyrimidin y|methy|)benzamid was obtained as white powder. LCMS (m/z): 422.2 (MH+), 0.49 min; 1H NMR (400 MHz, CD3OD) 6 8.81 (d, J = 4.9 Hz, 1H), 8.77 (d, J = 4.9 Hz, 1H), 7.95 (d, J = 2.2 Hz, 1H), 7.88 (d, J = 2.2 Hz, 1H), 7.80 (dd, J = 2.2, 0.6 Hz, 1H), 7.76 (dd, J = 2.2, 0.6 Hz, 1H), 7.62 - 7.70 (m, 1H), 7.51 - 7.58 (m, 1H), 7.45 (s, 1H), 7.38 - 7.43 (m, 1H), 7.35 (dd, J = 10.0, 1.5 Hz, 1H), 7.28 (dd, J = 7.8, 1.6 Hz, 1H), 4.99 (s, 1H), 4.74 (s, 1H), 3.98 - 4.10 (m, 2H), 3.54 (tdd, J = 11.5, 8.8, 2.7 Hz, 2H), 3.15 - 3.24 (m, 3H), 2.78 - 2.93 (m, 1H), 1.65 - 1.89 (m, 4H).
S nthesis of 4- 6-Aminobromo ridin Itetrah dro-2H-thio ran 1 1-dioxide and 4- o 4 4 5 5-tetrameth H 3 2-dioxaborolan l ridin l tetrah dro-2H- thiogyran 1,1-dioxide Scheme 13 Stegl NH2 m2 NH2 NH2 W N \ N \ 0‘ ,o Pd(dppf)C|2-DCM I H2, Pd/C I N \ B —, / / l + / / ,DME MeOH / . .
Br quantitative s s Stegg NH2 Stegfl NH2 St 95 NH2 (ID/g N \ N \ N \ B‘O mCPBA I NBs I Pd(dppf)Cl2-DCM I / / / _, _, —, DCM MeCN BZ(P|N)2, KOAc dioxane 0”“ d’s‘b d’s‘b Ste 1. 5- 3 6-Dih dro-2H-thio ran l ridinamine To a solution of 5-bromopyridin-2—amine (344 mg, 1.99 mmol) in DME (6mL) was added 2-(3,6-dihydro-2H-thiopyrany|)-4,4,5,5-tetramethy|-1,3,2—dioxaborolane (300 mg, 1.33 mmol), and sodium carbonate (1.99 mL, 3.98 mmol). The mixture was purged with nitrogen for 5 min, and followed by the addition of PdCI2(dppf)-CH2C|2 (108 mg, 0.13 mmol). The resulting mixture was heated to 115°C in an oil bath for 5 h. The reaction mixture was diluted with ethyl acetate, washed with water, brine, dried and was trated. The residue was purified by flash column chromatography on silica gel (ISCO) eluting with 0-90% ethyl acetate in heptane to give Fractions were combined and concentrated to give 5-(3,6-dihydro-2H-thiopyranyl)pyridinamine (120 mg, 47%) as brown color solid. LCMS (m/z): 193 (MW), 0.44 min.
Ste 2. 5- Tetrah dro-2H-thio ran l ridinamine A suspension of 5-(3,6-dihydro-2H-thiopyranyl)pyridinamine (260 mg, 1.35 mmol), Pd/C (36 mg, 0.33 mmol) in methanol (16 mL) was stirred under en at ambient temperature for 16 h. The reaction mixture was diluted with DCM (80 mL), and was filtered through Celite. The filtrate was trated to give 5-(tetrahydro-2H-thiopyran y|)pyridinamine (240 mg, 91% yield) as yellow color solid. LCMS (m/z): 195 (MW), 0.46 min.
Ste 3. 4- 6-Amino 3- ltetrah dro-2H-thio ran1 1-dioxide To an ice cooled solution of 5-(tetrahydro-2H-thiopyranyl)pyridinamine (290 mg, 1.49 mmol) in DCM (15 mL) was added 3-chlorobenzoperoxoic acid (592 mg, 3.43 mmol). The resulting solution was stirred at ambient temperature for 4 h. The reaction mixture was diluted with ethyl acetate. The resulting solution was washed with water, saturated aqueous sodium bicarbonate, dried over sodium sulfate and trated. The residue was purified by flash column chromatography on silica gel (ISCO) eluting with 0- 100% ethyl acetate in heptane to give minopyridinyl)tetrahydro-2H-thiopyran 1,1- dioxide (140 mg, 41.4 %) as white color solid. LCMS (m/z): 227 (MH+), 0.25 min.
Ste 4. 4- 6-Aminobromo ridin ltetrah dro-2H-thio ran1 ide To an ice cold solution of 4-(6-aminopyridinyl)tetrahydro-2H-thiopyran 1,1-dioxide (140 mg, 0.62 mmol) in DCM (15 mL) was added NBS (110 mg, 0.62 mmol) in two portions.
The reaction mixture was stirred at 0°C for 20 min. The reaction solution was diluted with ethyl acetate, washed with water, saturated aqueous sodium onate solution, brine, dried over sodium sulfate and concentrated to give 4-(6-aminobromopyridin y|)tetrahydro-2H-thiopyran 1,1-dioxide (190 mg, 0.62 mmol). LCMS (m/z): 305/307 (MH+), 0.33 min.
Ste 5. 4- o 4 4 5 5-tetrameth H 3 2-dioxaborolan l ridin l tetrah dro- 2H-thiopyran 1,1-dioxide To a suspension of 4-(6-aminobromopyridiny|)tetrahydro-2H-thiopyran 1,1-dioxide (190 mg, 0.62 mmol) in 1,4-dioxane (7 mL) was added naco|ato)diboron (474 mg, 1.86 mmol) and potassium acetate (305 mg, 3.11 mmol), and followed by the addition of dppf)-CH2C|2 (61.0 mg, 0.075 mmol) was added. The reaction mixture was heated to 100 °C in an oil bath for 16 h. The reaction mixture was diluted with ethyl acetate and was filtered through neutral a (5 g). The filtrate was refiltered again through Celite.
The filtrate was concentrated and the residue was triturated with heptane, and filtered to give 4-(6-amino(4,4,5,5-tetramethyl-1,3,2—dioxaborolanyl)pyridinyl)tetrahydro-2H- thiopyran oxide (140 mg, 64% . LCMS (m/z): 271 (MW), 0.15 min. 8 nthesis of meth l3- 6-aminobromo ridin l rrolidinecarbox late Scheme 14 Steal cr=3 ,9 Stag; Stegg 0 i0 N \ Cg CF3SOZ‘N ’302CF3 I Pd PPhs / co / arms #3 + w, ON)" )4 THF THF water / RT/ON o )4 71/00 Ste N / Ste if g \ I NBS / ACN TFA/ DCM MeOCOCI / DCM —> —> —> 83% N m1 NH2 MeSOZCI / DCM Ni Ste 1. tert-but l3- trifluorometh lsulfon lox -2 5-dih dro-1H- rrolecarbox late To an oven dried flask under N2 was added tert-butyl 3-oxopyrrolidinecarboxy|ate (2 g, .8 mmol) and THF (16 mL). The solution was cooled in acetone ice bath (-78 °C). To that was added lithium bis(trimethylsilyl)amide (12.96 mL, 12.96 mmol) (1 M solution in THF). The reaction e was stirred at -78 °C for 15min then added dropwise a solution of 1,1 ,1-trif|uoro-N-phenyl-N-((trifluoromethyl)sulfonyl) methanesulfonamide (4.05 g, 11.34 mmol) in THF (16 mL). The reaction mixture was stirred for 30 min then warmed to 0 °C and stirred for 1.5 h. The on mixture was quenched with satd. sodium bicarbonate solution and then extracted with ethyl acetate. The combined extracts were washed with brine, dried over sodium sulfate, filtered and evaporated. The crude t was purified by ISCO column (0-30%EtOAc/heptane) providing tert-butyl 3- (((trifluoromethyl)sulfonyl)oxy)-2,5-dihydro-1H-pyrrolecarboxylate (1.9 g, 55.5%).
Ste 2. tert-but l3- 6-amino ridin l-2 5-dih dro-1H- rrolecarbox late A solution of tert-butyl rifluoromethyl)sulfonyl)oxy)-2,5-dihydro-1H-pyrrole carboxylate (400 mg, 0.882 mmol) in THF (10 mL) was purged with N2 for 5 min and then was added potassium carbonate (610 mg, 4.41 mmol), ,5,5-tetramethyl-1,3,2- orolanyl)pyridinamine (233 mg, 1.059 mmol), Pd(PPh3)4 (10.20 mg, 8.82 umol) and water ( 0.1 mL). The reaction mixture was heated and stirred at 70 °C overnight. The reaction mixture was poured to saturated sodium bicarbonate solution and extracted with ethyl ether. The organic layer was separated, washed with brine, dried over sodium sulfate, filtered and evaporated. The crude product was ed by flash chromatography (0-10%MeOH / DCM) to yield the desired product (180 mg, 54.6%).
LCMS (m/z): 262.2 (MH+), 0.598 min.
Ste 3. tert-but l3- 6-amino ridin l rrolidinecarbox late To tert-butyl 3-(6-aminopyridinyl)—2,5-dihydro-1H-pyrrolecarboxylate (180 mg, 0.482 mmol) in MeOH (10 mL) under N2 here was added Pd-C (103 mg, 0.096 mmol).
The reaction mixture was stirred at room temperature under H2 balloon. After 2 h, the reaction mixture was filtered through Celite pad, washed with methanol and evaporated to provide desired product, which ded for next step without purification (150 mg, 71%). LCMS (m/z): 264.2 (MH+), 0.565 min.
Ste 4. tert-but l3- 6-aminobromo ridin l rrolidinecarbox late To tert-butyl 3-(6-aminopyridinyl)pyrrolidinecarboxy|ate(60 mg, 0.228 mmol) in Acetonitrile (4 mL) in ice bath was added NBS (36.5 mg, 0.205 mmol) and stirred. LCMS after 30 min showed ~1:1 mixture of starting material and desired product. To this added 12mg (0.3 equiv.) of NBS and stirred 30 min. LCMS shows complete reaction. To the reaction mixture was added aqueous saturated NaHC03 d 10 min and extracted with ethyl e. The combined extracts were dried over sodium sulfate, filtered off, and WO 66188 evaporated. The crude product was used for next step without purification (65 mg, 83%).
LCMS (m/z): 342.1/344.1 (MH+), 0.624 min.
Ste 5. 3-bromo rrolidinl ridinamine To tert-butyl 3-(6-aminobromopyridinyl)pyrrolidinecarboxylate (65 mg, 0.171 mmol) in DCM ( 2.4 mL) was added TFA (0.6 mL, 7.79 mmol). The reaction mixture was stirred at room temperature for 45 min. The on mixture was evaporated in vacuo after dilution with toluene. The crude product was used for next step without purification.
The crude yield was quantitative. LCMS (m/z): 242.1/244.1 (MH+), 0.214 min.
Ste 6. meth l3- 6-aminobromo ridin l rrolidinecarbox late To 3-bromo(pyrrolidinyl)pyridinamine,(20 mg, 0.083 mmol) in DCM in ice bath was added DIEA (43.3 ul, 0.248 mmol) and methyl chloroformate (6.40 ul, 0.083 mmol).
The on mixture was stirred in ice bath for 30 min. The reaction mixture was ioned between DCM and water. The DCM layer was separated and washed with brine, dried over sodium sulfate, filtered off, and evaporated. The crude product was used for next step without purification. LCMS (m/z): 300.0, 302.0 (MH+), 0.421 min.
Ste 7. 3-bromo 1- meth lsulfon l rrolidin l 2-amine To 3-bromo(pyrrolidinyl)pyridinamine (20 mg, 0.083 mmol) in DCM in ice bath was added DIEA (57.7 ul, 0.330 mmol) and methanesulfonyl chloride (7.08 ul, 0.091 mmol). The reaction mixture was d in ice bath 30 min. The reaction mixture was partitioned between DCM and water. The DCM layer was separated and washed with brine, dried over sodium sulfate, filtered and evaporated. The crude product was used for next step without purification. LCMS (m/z): 320.0/322.0 (MH+), 0.363 min.
Examples 4, 5, and 6 S nthesis of 4- 2-amino 1 idotetrah drothio hen l ridin l-N-benz l fluorobenzamide S 2-amino 1 1-dioxidotetrah drothio hen l ridin l-N- benz lfluorobenzamide and R 2-amino 1 1-dioxidotetrah drothio hen yl )pyridinyl)-N-benzylfluorobenzamide Scheme 15 St 1 F ””2 _e2_ Ste NH 0 F 2 2 m; 0 \\S)<F N \ N(8020Fs)2 N \ \ LDA o’ “o I ' / I C i _’ / fl 6 * —’ s /N \ CI ,B\ s O O \ /)—(\ 5 NH NH 2 2 NH2 mg m5 0 Stegfi NI \ N \ N \ I I N Pd(PPh3)4 / mCPBA / NBS / _, HO H —’ + —’ ‘ila F Na2C03 8 I§=o §=o o o O O s—w— N \ F mm N \ N \ F no I chiral separation | | / —. + _/ S: O , O H I: ‘0 0' O o Ste 1. 4 5-dih drothio hen ltrifluoromethanesulfonate To freshly prepared LDA (10.5 mmol in 40 mL THF) between -75 to -65 °C was dropwise added dihydrothiophene(2H)—one/THF solution (1.02 g/2 mL THF, 10 mmol) over 3 min, then the resulting reaction mixture was d at -75 °C for 3 h, followed by dropwise addition of N-(5-chloropyridinyl)-1,1,1-trifluoro-N- (trifluoromethylsulfonyl)methanesulfonamide/THF (4.12 g, 10.5 mmol in 5 mL THF) over min, then the reaction e was stirred at -75 °C for at least 1 h, then with temperature gradually warm up to room temperature overnight. The reaction mixture was concentrated, and the e was partitioned between EtZO/HZO (100 mL/50 mL); the ether layer was sequentially washed with water (2 x 50 mL), 3 M sodium e pH 4.8 buffer (2 x 50 mL), 3M NaOH (2 x 50 mL), and dried over magnesium sulfate, concentrated and a brown 0” was obtained as crude product (2.05 g) which was further purified by flash chromatography on silica gel eluted with gradient EtOAc/heptane (0- %) and desired product (0.9 g, 38.5% yield) was obtained as colorless oil. 2014/062913 Ste 2. 5- 4 5-dih drothio hen l ridinamine To a vial was charged with all reagents: 4,5-dihydrothiophenyl oromethanesulfonate (900 mg, 3.84 mmol), 5-(4,4,5,5-tetramethyl-1,3,2- orolanyl)pyridinamine(1.69 g, 7.69 mmol), K3PO4 (2.45 g, 11.5 mmol), and PdC|2(dppf)-CH2C|2 adduct (314 mg, 0.384 mmol) and DME(16 mL), and the mixture was purged with Argon, then sealed and heated at 90 °C via external oil bath overnight. The reaction mixture was cooled down to room temperature, and the precipitates in the on mixture was removed by filtration, and the filtrate was concentrated under reduced pressure and a black residue was obtained as crude product. The crude product was dissolved in EtOAc (30 mL), washed with water (20 mL), and the slug between the two layers was removed by filtration. The EtOAc layer was collected, stripped with 1N HCI (2 x 20 mL) and the s layers were combined, scrubbed with EtOAc (20 mL), basified with aqueous NaOH (3 g in 10 mL water), ted with EtOAc (2 x 30 mL), and the obtained EtOAc extracts were combined, washed with brine (30 mL), dried (Na2804), concentrated and desired t was obtained as light color solid. LCMS (m/z): 179.0 (MH+), 0.41, 0.43 min (for regioisomers).
Ste 3. 5-tetrah drothio hen l ridinamine -(4,5-dihydrothiophenyl)pyridinamine(0.78g, 4.38 mmol) was dissolved in ethanol(30 mL), to it was added Pd-C (Deggussa, 10%, 0.233 g) and the mixture was stirred under H2 balloon overnight. The on was not complete by LCMS. The Pd-C catalyst was removed by filtering through a Celite pad, and to the filtrate was added new Pd-C catalyst (0.24 g), and the mixture was stirred under H2 balloon under same condition for another 6 h. The reaction mixture was filtered off through Celite pad, and the filtrate was concentrated under reduced pressure yielding 5-(tetrahydrothiophenyl)pyridin amine (0.661 g, 84%) as colorless oil. LCMS (m/z): 181.2 (MH+), 0.39 min.
Ste 4. 3- 6-amino ridin ltetrah drothio hene1 1-dioxide -(tetrahydrothiophenyl)pyridinamine (0.33 g, 1.831 mmol) was dissolved in CH2C|2 (15 mL), to it was added mCPBA (70%, 0.903 g, 3.66 mmol) and the e was stirred at room temperature for 10 min and the reaction mixture was concentrated under reduced pressure and the residue was partitioned between EtOAc/sat. NaHC03 (30 mL/20 mL), the EtOAc layer was washed with sat. Na2C03 (20 mL), brine (20 mL), dried (Na2804), filtered off, and concentrated in vacuo yielding 3-(6-aminopyridinyl)tetrahydrothiophene 1,1-dioxide as light brown oil (96 mg, 25%). LCMS (m/z): 197.1 (MH+), 0.21 min.
Ste 5. 3- 6-aminobromo ridin h drothio hene1 1-dioxide 3-(6-aminopyridinyl)tetrahydrothiophene 1,1-dioxide (96 mg, 0.452 mmol) was dissolved in acetonitrile (5 mL) and the solution was cooled to 0 °C, to it was added NBS (80 mg, 0.452 mmol) and the mixture was stirred at 0 °C for 40 min. The on mixture was concentrated under reduced pressure and the residue was partitioned between sat. NaHC03 (30 mL/20 mL), the EtOAc layer was washed with sat. Na2C03 (20 mL), brine (20 mL), dried (Na2804), filtered off and concentrated in vacuo yielding 3-(6- aminobromopyridinyl)tetrahydrothiophene oxide as light brown oil (50 mg, 38% yield). LCMS (m/z): 291.0 (MH+), 0.29 min.
Ste 6. 4- 2-amino 1 1-dioxidotetrah drothio hen | ridin l-N-benz l fluorobenzamide To a microwave reactor was d with 3-(6-aminobromopyridin yl)tetrahydrothiophene 1,1-dioxide (50 mg, 0.172 mmol), 4-(benzylcarbamoyl)—3- phenylboronic acid (94 mg, 0.343 mmol), 2 M aqueous Na2C03 (0.34 mL) and PdC|2(dppf)-DCM adduct (14 mg) and DME (3 mL) were charged in a microwave vial and the mixture was purged with Argon, sealed and heated at 105 0C for 20 min. The DME layer of the reaction mixture was collected, concentrated under reduced pressure and the residue was redissolved in EtOAc (5 mL). The EtOAc solution was stripped with 1N HCI (4 x 1 mL) and the s layers were ed, scrubbed with EtOAc (2 x 1 mL), then concentrated under reduced pressure and the residue was partitioned between EtOAc/sat. Na2C03 (5 mL/1 mL), and the EtOAc extract was washed with sat. Na2C03 (2 x 1 mL), brine (1 mL), dried (Na2804), concentrated and the residue was redissolved in acetonitrile/water (6 mL/6 mL), frozen and lyophilized yielding racemic 4-(2-amino(1,1- dioxidotetrahydrothiophenyl)pyridinyl)-N-benzy|fluorobenzamidein as light yellow powder. LCMS (m/z): 440.2 (MH+), 0.60 min; 1H NMR (CDSOD) 8 ppm 7.97 (d, J = 2.0 Hz, 1H), 7.84 (t, J = 7.8 Hz, 1H), 7.50 (d, J = 2.3 Hz, 1H), 7.31 - 7.44 (m, 6H), 7.22 - 7.30 (m, 1H), 4.61 (s, 2H), 3.55 - 3.70 (m, 1H), 3.47 (dd, J = 13.3, 7.0 Hz, 1H), 3.33 - 3.39 (m, 1H), 3.08 - 3.25 (m, 2H), 2.53 (ddd, J = 13.1, 7.4, 5.7 Hz, 1H), 2.18 - 2.40 (m, 1H). The racemic product was further resolved by chiral SFC (ChiralPak 5mic OJ column, 4.6x100 (mm), 5mL/min, MeOH+0.1% DEA= 50%) to afford (S)—4-(2-amino(1,1- dioxidotetrahydrothiophenyl)pyridinyl)-N-benzylfluorobenzamide (Rt = 1.7 min) and (R)—4-(2-amino(1,1-dioxidotetrahydrothiophenyl)pyridinyl)—N-benzyl fluorobenzamide (Rt = 2.22 min). The absolute stereochemistry was arbitrarily assigned.
Example 7 S nthesis of 4- 2-amino BR 58 h drox meth l rrolidin l ridin l-N- S orophenyl )—2-hyd roxyethyl )—2-fluorobenzamide Scheme 16 NH2 NH2 NH2 N \ OH O N \ Steal Stepg OTf Stegé I | N \ / Stegfl / I g ’ ' @ + / —’ —’ N N / ‘ N 01~ Boc 0‘~ Boc ~ 0% Boc O’B\O N oN /O /O : /O fl 03‘ Boc O=~\‘ Boo 0 o / / F o / NH2 NH2 _ “ii Br {OH m1 NH2 M; Stegg NI \ F 0 3 _/ . | _/ N _, + E NI \ H / CI 0 0 H0 w: , Ni N, HO CI \ Boc i Boc 0NH OH OH N Ste 1. S tert-but l2-meth l4-oxo rrolidine-1 2-dicarbox late A solution of (2S,4R)—1-tert-butyl 2-methyl oxypyrrolidine-1,2-dicarboxylate (10 g, 40.8 mmol) in DCM (100 mL) was cooled to 0 °C, then treated portion wise with Dess- Martin inane (17.29 g, 40.8 mmol) over 20 min. The reaction was ined at 0 °C for 1 h, and then the cold bath was removed. After another 3 h at room temperature, the reaction was treated with 300 mL of 1:1 sat. aq. Na2803:sat. aq. NaHC03. The reaction was stirred vigorously overnight at room temperature, then the layers were separated. The organics were washed with water and brine, then dried over magnesium sulfate and concentrated. The ing mixture was slurried in DCM (20 mL) then filtered over Celite. The cs were concentrated. The crude oil was further purified by direct filtration from grained solids to provide (S)—1-tert-butyl yl 4-oxopyrrolidine-1,2- oxylate (8.53 g, 87% yield). LCMS (m/z): 244.3 (MH+), 0.42 min.
Ste 2. 1-tert-but |2-meth |4- trifluorometh lsulfon lox -1H- rrole-1 2 2H 5H - dicarboxylate A solution of (S)—1-tert-butyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxylate (2.9 g, 11.92 mmol) in THF (30 mL) was cooled to -78 °C, then treated with 1.0 M LiHMDS in THF (14.31 mL, 14.31 mmol). The reaction was maintained at -78 °C for 1h, then treated with a on of N-(5-chloropyridinyl)-1,1,1-trifluoro-N- luoromethyl)sulfonyl)methanesulfonamide (5.62 g, 14.31 mmol) in THF (15 mL). The reaction was maintained at -78 °C for 1 h, and then placed in a -30 °C refrigerator overnight. At completion, the reaction was quenched with water, and diluted with ether.
The organics were washed with 1N aqueous solution. NaOH (40 mL), then dried over magnesium sulfate and concentrated. The residue was dissolved in chloroform (40 mL) and cooled to 0 °C for 30 min. The resulting slurry was concentrated to ~8 mL total volume, then the viscous material was filtered and concentrated to provide (S)—1-tert— butyl 2-methyl 4-(((trifluoromethyl)sulfonyl)oxy)-1H-pyrrole-1,2(2H,5H)—dicarboxylate (4.4 g, 98% . LCMS (m/z): 376.4 (MH+), 0.64 min.
Ste 3. S tert-but |2-meth |4- 6-amino 3- l -1H- rrole-1 2 2H 5H - dicarboxylate A mixture of (S)—1-tert-butyl 2-methyl 4-(((trifluoromethyl)sulfonyl)oxy)-1H-pyrrole- ,5H)—dicarboxylate (1.55 g, 4.13 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl)pyridinamine (1.00 g, 4.54 mmol), Pd(PPh3)4 (0.239 g, 0.21 mmol) and Cs2C03 (3.36 g, 10.32 mmol) in THF (10 mL) and water (2 mL) was microwave heated to 100 °C for 10 min. The reaction was then diluted with ethyl acetate (50 mL) and water (25 mL).
The layers were separated and the cs were washed with water (25 mL) and brine (25 mL), dried over magnesium sulfate and concentrated, then purified by flash chromatography [0-8% methanol/DCM eluent] to provide (S)—1-tert-butyl 2-methyl 4-(6- aminopyridinyl)—1H-pyrrole-1,2(2H,5H)—dicarboxylate (0.955g, 72% yield). LCMS (m/z): 320.4 (MH+), 0.50 min.
WO 66188 Ste 4. 28 4R tert-but l2-meth l4- 6-amino ridin l rrolidine-1 2-dicarbox late A ed solution of (S)tert-butyl 2-methyl 4-(6-aminopyridinyl)—1H-pyrrole- 1,2(2H,5H)—dicarboxylate (0.955 g, 2.99 mmol) in methanol (30 mL) was treated with 10% Pd/C (0.183 g, 0.172 mmol), then maintained under an atmosphere of hydrogen for 3 h.
At completion, the reaction then filtered over a pad of Celite and concentrated to provide (2S,4R)tert-butyl yl 4-(6-aminopyridinyl)pyrrolidine-1,2-dicarboxylate (0.95 g. 99% yield). LCMS (m/z): 322.5 (MH+), 0.52 min.
Ste 5. 2S 4R -tert-but l4- 6-amino ridin l h drox meth l ine carboxylate To a solution of (2S,4R)tert-butyl 2-methyl 4-(6-aminopyridinyl)pyrrolidine-1,2- dicarboxylate (250 mg, 0.778 mmol) in 2-methyl THF (18 mL) was added LiAlH4 (59 mg, 1.56 mmol). After 15 min, the reaction was quenched by the sequential addition of water (60 uL), 1 N NaOH aqueous solution (60 uL) and water (60 uL). The mixture was stirred vigorously for 5 min, and then filtered over Celite, rinsing with 2-methyl THF. The organics were concentrated to provide (2S,4R)—tert-butyl 4-(6-aminopyridinyl)—2- (hydroxymethyl)pyrrolidinecarboxylate (230 mg, 100% yield). LCMS (m/z): 294.1 (MH+), 0.49 min.
Ste 6. 2S 4R but l4- 6-aminobromo ridin l h drox meth l rrolidine carboxylate A solution of )-tert-butyl 4-(6-aminopyridinyl)(hydroxymethyl)pyrrolidine carboxylate (230 mg, 0.784 mmol) in MeCN (10 mL) was treated with NBS (147 mg, 0.823 mmol). After 10 min, the reaction was complete. The reaction was treated with 10 mL 1:1 sat. aq. NaHC03:sat.aq. Na28203 and the mixture was d vigorously for 10 min. The mixture was d with ethyl acetate (30 mL) and the layers were ted.
The organics were washed with brine, dried over magnesium sulfate and concentrated to provide (2S,4R)-tert-butyl 4-(6-aminobromopyridinyl)—2-(hydroxymethyl)pyrrolidine- 1-carboxylate (290 mg, 100% yield). LCMS (m/z): 372.1/374.0 (MH+), 0.55 min.
Ste 7. 4- 2-amino 3R 58 h drox meth l rrolidin l 3- l-N- S 3- chlorophenyl)—2-hydroxyethyl)—2-fluorobenzamide Following Step 5 in Scheme 10, using (28, 4R)—tert—butyl 4-(6-aminobromopyridinyl)— 2-(hydroxymethyl)pyrrolidinecarboxylate and (S)—(4-((1-(3-chlorophenyl) hydroxyethyl)carbamoyl)fluorophenyl)boronic acid, (2S,4R)—tert—butyl 4-(6-amino(4- (((S)—1-(3-chlorophenyl)hydroxyethyl)carbamoyl)—3-fluorophenyl)pyridinyl)—2- (hydroxymethy|)pyrro|idinecarboxy|ate was obtained as TFA salt (30 mg, 35% yield.
LCMS (m/z): 585.3 587.3 (MH+), 0.74 min. Then, a on of (2S,4R)—tert—buty| 4-(6- amino(4-(((S)—1-(3-chlorophenyl)hydroxyethyl)carbamoyl)—3-fluorophenyl)pyridin y|)(hydroxymethyl)pyrrolidinecarboxylate-TFA was dissolved in DCM (2 mL) and treated with TFA (2.0 mL). After 30 min, the reaction was concentrated, and then purified by reverse phase prep HPLC yielding mino((3R,5S)(hydroxymethy|)pyrro|idin- 3-yl)pyridinyl)—N-((S)—1-(3-chlorophenyl)hydroxyethyl)fluorobenzamide as the bis- TFA salt (15.0 mg, 54% yield). LCMS (m/z): 485.2, 487.2 (MH+), 0.51 min; 1H NMR (400 MHz, CD3OD) 6 ppm 8.59 (dd, J = 4.50, 7.24 Hz, 1H), 7.87 - 7.77 (m, 4H), 7.39 - 7.31 (m, 3H), 7.29 - 7.24 (m, 2H), 7.24 -7.16 (m, 1H), 5.15 - 5.05 (m, 1H), 3.87 - 3.71 (m, 5H), 3.70 - 3.60 (m, 2H), 3.59 - 3.46 (m, 1H), 2.41 (td, J = 6.46, 12.91 Hz, 1H), 1.98 - 1.82 (m, 1H), 1.29 - 1.16 (m, 1H).
Example 8 Scheme 17 F 0 :/OH F o Z/OH ”I \ HQ 1. chloroacetic acid, HATU NI \ “Q / CI / CI G 2' NaH 0 . NH N A solution of 4-(2-amino((3R,5S)(hydroxymethyl)pyrrolidinyl)pyridinyl)-N-((S)- 1-(3-ch|oropheny|)hydroxyethy|)f|uorobenzamide (45 mg, 0.063 mmol) (see Example 7) and chloroacetic acid (7.2 mg, 0.076 mmol) in THF (2.5 mL) was treated with HATU (36 mg, 0.095 mmol) and DIEA (55 uL, 0.316 mmol). The reaction was maintained at room temperature for 1 h. The reaction mixture was then treated directly with NaH (15.2 mg, 0.631 mmol). After 15 min, the reaction was quenched with water (2 mL) and the reaction mixture was extracted with ethyl e (10 mL). The organics were washed with brine, then dried over Na2804, trated, then purified by reverse phase prep HPLC yielding 4-(2-amino((7R,8aS)—4-oxohexahydro-1H-pyrrolo[2,1-c][1,4]oxazin yl)pyridinyl)—N-((S)—1-(3-chlorophenyl)hydroxyethyl)fluorobenzamide (13.0 mg, 39% . LCMS (m/z): 525.2, 527.2 (MH+), 0.59 min; 1H NMR (400 MHz, CD3OD) 6 ppm 8.61 (dd, J = 4.30, 7.04 Hz, 1H), 7.91 (d, J = 1.96 Hz, 1H), 7.84 - 7.76 (m, 2H), 7.40 - 7.31 (m, 3H), 7.30 - 7.24 (m, 2H), 7.24 - 7.16 (m, 1H), 5.16 - 5.05 (m, 1H), 4.18 - 4.08 (m, 2H), 3.99 - 3.85 (m, 2H), 3.85 - 3.70 (m, 3H), 3.53 - 3.42 (m, 2H), 3.39 - 3.29 (m, 1H), 2.34 - 2.19 (m, 1H), 1.67 (q, J = 11.48 Hz, 1H).
Example 9 S nthesis of 4- 2-amino 6R 7aS oxohexah dro rrolo 1 2-c oxazol l ridin l-N- S 3-chloro hen lh drox eth lfluorobenzamide Scheme 18 F o {0 NH2 N NH2 N H H N \ N \ I CDI, DIEA I / c | _/ CI \Ofio5 A solution of 4-(2-amino((3R,5S)(hydroxymethyl)pyrrolidinyl)pyridinyl)-N-((S)- 1-(3-chlorophenyl)hydroxyethyl)fluorobenzamide (20 mg, 0.041 mmol) (Example 7) and DIEA (72 uL, 0.412 mmol) in itrile (0.5 mL) was treated with carbonyldiimidazole (8.0 mg, 0.049 mmol). After 1 h, the starting material was completely ed. The reaction mixture was quenched with 1.0 N aqueous NaOH solution (1.0 mL) and the mixture was stirred vigorously for 5 min, then, diluted with DCM (10 mL). The organics were washed with brine (2 mL) and dried over Na2804 and concentrated. The crude al was purified by reverse phase prep HPLC yielding 4-(2-amino ((6R,7aS)—3-oxohexahydropyrrolo[1,2-c]oxazolyl)pyridinyl)-N-((S)(3- chlorophenyl)hydroxyethyl)f|uorobenzamide (2.0 mg, 7% yield). LCMS (m/z): 511.3, 513.3 (MH+), 0.61 min; 1H NMR (400 MHz, CD3OD) 6 ppm 7.92 - 7.84 (m, 2H), 7.46 (s, 1H), 7.44 - 7.40 (m, 1H), 7.38 - 7.35 (m, 1H), 7.34 - 7.28 (m, 1H), 5.19 (t, J = 5.87 Hz, 1H), 4.61 - 4.56 (m, 1H), 4.34 (dd, J = 3.52, 9.00 Hz, 1H), 4.24 - 4.15 (m, 1H), 3.92 - 3.80 (m, 1H), 3.74 - 3.62 (m, 1H), 2.41 (td, J = 5.72,11.64 Hz, 1H), 1.84 - 1.71 (m, 1H).
Example 10 S nthesis of 4- 2-amino 6R 7aS iminohexah dro rrolo 1 2-c oxazol l 3- l-N- S 3—chloro hen lh drox eth lfluorobenzamide Scheme 19 F O {OH NH2 3 NH2 3 N \ N \ | B ON Cr v S2CO3 I / CI / CI :\O\A\NH A room temperature mixture of 4-(2-amino((3R,5S)—5-(hydroxymethyl)pyrrolidin yl)pyridinyl)—N-((S)(3-chlorophenyl)hydroxyethyl)f|uorobenzamide (12.5 mg, 0.026 mmol) le 7) and cesium carbonate (33.6 mg, 0.103 mmol) in ethanol (0.75 mL) was treated with cyanogen bromide (6.2 uL, 0.031 mmol). After 1 h, the reaction was diluted with water (1.0 mL) and extracted into ethyl acetate (10 mL). The organics were washed with brine (2 mL), then dried over Na2804 and concentrate and purified by reverse phase prep HPLC ng 4-(2-amino((6R,7aS)—3-iminohexahydropyrrolo[1,2- c]oxazolyl)pyridinyl)—N-((S)—1-(3-chlorophenyl)hydroxyethyl)fluorobenzamide.
LCMS (m/z): 510.1, 512.1 (MH+), 0.52 min. 1H NMR (400 MHz, CD3OD) 6 ppm 8.63 - 8.54 (m, 1H), 7.92 - 7.85 (m, 2H), 7.80 (t, J = 7.83 Hz, 1H), 7.40 - 7.31 (m, 3H), 7.29 - 7.24 (m, 2H), 7.24 - 7.16 (m, 1H), 5.14 - 5.06 (m, 1H), 4.97 - 4.88 (m, 1H), 4.61 - 4.49 (m, 2H), 3.88 - 3.70 (m, 4H), 3.32 (s, 1H), 2.41- 2.31 (m, 1H), 2.02 -1.89 (m, 1H).
Example 11 4- 2-amino 6R 7aS thioxohexah dro rrolo 1 2-c l ridin l -N- S ro hen lh drox eth lfluorobenzamide Scheme 20 F O :/OH NH2 N NH2 N H H N \ N \ | tIoCh' - DI DIEA / Cl / CI \Oks:.
To a solution of (2S,4R)—tert-butyl 4-(6-amino(4-(((S)—1-(3-chlorophenyl) hyd hyl)carbamoyl)fluorophenyl)pyridinyl)—2-(hyd roxymethyl)pyrro|idine-1 - carboxylate (45 mg, 0.063 mmol) (see e 7) in acetonitrile (0.75 mL) and DMF (0.5 mL) was added DIEA (42 ML, 0.240 mmol) and thiocarbonyl diimidazole (15.6 mg, 0.088 mmol). After 2 h, the reaction was quenched with 1 N aqueous solution. NaOH (1 mL) and stirred vigorously to effect decomposition of a mixed thiocarbamate byproduct. The reaction was then diluted with ethyl acetate (10 mL), washed with water (5 mL) and brine (5 mL), then dried over sodium sulfate and concentrated. The crude material was purified by reverse phase prep HPLC yielding 4-(2-amino((6R,7aS)—3- thioxohexahydropyrrolo[1,2-c]oxazolyl)pyridinyl)—N-((S)—1-(3-chlorophenyl) hydroxyethyl)fluorobenzamide (3.2 mg, 11% yield). LCMS (m/z): 527.3, 529.3 (MH+), 0.67 min; 1H NMR (400 MHz, CD30D) 6 ppm 8.64 (dd, J = 3.91, 7.04 Hz, 1H), 7.85 (d, J = 1.96 Hz, 2H), 7.83 - 7.77 (m, 3H), 7.39 - 7.32 (m, 5H), 7.30 - 7.26 (m, 3H), 7.25 - 7.19 (m, 2H), 5.15 - 5.07 (m, 2H), 4.73 - 4.69 (m, 2H), 4.45 - 4.35 (m, 3H), 3.85 - 3.65 (m, 8H), 2.38 (td, J = 5.58, 11.54 Hz, 2H), 1.80 - 1.70 (m, 1H). 8 nthesis of 5-mor holino 4 4 5 5-tetrameth H 3 2-dioxaborolan l ridinamine Scheme 21 m1 Br Step 2 Br Step g \ \ Br N N Br \N | | \N | / / | / —> —> N02 —> / 0 NH 0 NH NO V 2 NH2 ‘n’ V\n’ 0 0 m4. No2 m; No2 mg NH2 m1 NH2 0 NH2 Br Br 53 N \ N \ N \ N/ ‘o I I I / / / I a _. \ , _, EN] EN] [NJ ” o o 0 EO1 Ste 1. Eth | 5-bromo ridin lcarbamate -bromopyridinamine (20 g, 116 mmol) was dissolved in DCM (500 mL) and pyridine (28.0 mL, 347 mmol) was added, followed by ethyl chloroformate (11.44 mL, 119 mmol) dropwise. The reaction mixture was stirred for 1.5 h at room temperature. The reaction mixture was diluted with DCM. The two phases were separated and the organic phase was washed with 10% CuSO4 solution (2x) sat. NaHC03 solution (1x) Brine (1x) dried (Na2804) and evaporated. The residue was triturated with diethyl ether filtered and dried ing ethyl (5-bromopyridinyl)carbamate (21.58 g, 76 %) as a white solid. LCMS (m/z): 247.0 (MH+), 0.58 min; 1H NMR (400 MHz, CDCI3 )6 2 - 8.15 (m, 3 H) 7.00 (br. s., 1 H) 4.27 (q, J=7.0 Hz, 2 H) 1.34 (t, J=7.0 Hz, 3 H).
Ste 2. Eth l 5-bromonitro ridin lcarbamate To a mixture of concentrated H2804 (60 mL, 1126 mmol) and fuming HN03 (40 mL, 895 mmol), ethyl mopyridinyl)carbamate (21.5 g, 88 mmol) was added portionwise at 0 °C. After stirring at 0 °C for 5 min, the mixture was stirred at rt ght and poured onto ice water. A crash out formed and was filtered off and washed thoroughly with water and dried. Ethyl (5-bromonitropyridinyl)carbamate (21.26 g, 84%) was thus obtained as a white solid. LCMS (m/z): 290.1 (MH+), 0.76 min. 1H NMR (400 MHz, CDCI3) 6 ppm 9.63 (br. s., 1 H) 9.33 (d, J=2.0 Hz, 1 H) 8.28 (d, J=2.0 Hz, 1 H) 4.32 (q, J=7.3 Hz, 3 H) 1.68 (br. s., 2 H) 1.38 (t, J=7.0 Hz, 4 H).
Step 3. 5-Bromonitropyridinamine Ethyl (5-bromopyridinyl)carbamate (8 g, 27.6 mmol) was dissolved in EtOH (250 mL) and the solution was cooled down to 5 °C with an ice bath. Cold 1M KOH (130 mL, 130 mmol) was added dropwise, maintaining below 5 °C. The reaction mixture was stirred at room temperature ght, concentrated under d pressure. Upon concentration a crash out forms, which was filtered off washed with water and dried affording 5-bromo yridinamine (5.02 g, 83%). LCMS (m/z): 220.1 (MH+), 0.46 min; 1H NMR (400 MHz, CDCI3) 6 ppm7.97 (d, J=1.6 Hz, 1 H) 7.50 (d, J=2.0 Hz, 1 H) 6.03 (br. s., 2 H).
Step 4. 5-morpholinonitropyridinamine -Bromonitropyridinamine (2.32 g, 10.6 mmol) was suspended in morpholine (5 mL, 57.4 mmol) and the solution was heated at 140 °C for 1h. The reaction mixture was cooled to room ature and the solid crash out was triturated with water and filtered.
The solid this obtained was washed with water, EtOH, and dried, obtaining 5-morpholino- 2-nitropyridinamine (2.0 g, 8.92 mmol, 84%) as a bright yellow powder. Depending on the outcome of the previous step, this solid may still contain the ethoxy derivative from the previous step, and the two compounds can be separated by column chromatography on silica gel (analogix, 20% EtOAc in heptane for 2 min, to 100% EtOAc to 15 min, then 100% EtOAc to 20 min). LCMS (m/z): MH+), 0.43 min; 1H NMR (400 MHz, CDCI3) 6 ppm 10.54 (s, 1 H) 8.57 (d, J=2.7 Hz, 1 H) 7.85 (d, J=2.7 Hz, 1 H) 7.70 (d, J=2.3 Hz, 1 H) 6.32 (d, J=2.3 Hz, 1 H) 6.00 (br. s., 1 H) 3.93 - 3.83 (m, 7 H) 3.83 - 3.74 (m, 3 H) 3.63 - 3.55 (m, 3 H) 3.51 - 3.43 (m, 3 H) 3.41- 3.31 (m, 4 H).
Ste 5. 4- onitro ridin lmor holine A three neck round bottom flask equipped with a magnetic stir bar, a dropping funnel and a thermometer, was charged with CuBr (629 mg, 4.4 mmol) and HBr (25 mL). The solution was cooled to -5 °C (ice salt bath). Solid 5-morpholinonitropyridinamine (983 mg, 4.4 mmol) was slowly added, followed by the slow addition of a NaNOz (333 mg, 4.8 mmol) solution in H20 (25 mL) via the dropping funnel, ensuring that the temperature did not rise above 0 °C. The reaction mixture was stirred at -5 °C for 1 h, warmed to room temperature and stirred an additional 1.5 h. The reaction was deemed complete by LCMS and the mixture was cooled again to 0 °C, quenched with 6 N NaOH to pH 12, diluted with water and extracted with EtOAc. EtOAc was washed with water (x2), brine (x1) dried and concentrated. The residue was azeotroped with EtOH dried under high vacuum, obtaining 4-(5-bromonitropyridinyl)morpholine (1.21 g, 4.20 mmol, 96 % yield) as a light yellow solid. LCMS (m/z): 288.2 (MH+), 0.65 min. 1H NMR (400 MHz, CDCI3) 6 ppm 8.08 - 7.99 (d, J=2.3 Hz, 1 H) 7.41 (d, J=2.3 Hz, 1 H) 3.98 - 3.81 (m, 4 H) 3.45 - 3.30 (m, 4 H).
Step 6. omorpholinopyridinamine 4-(5-Bromonitropyridinyl)morpholine (95 mg, 0.33 mmol) was dissolved in EtOH (12 mL) and water (3.0 mL) was added, followed by SnCIz (313 mg, 1.65 mmol). The reaction mixture was heated to 80 °C for 2 h, cooled to room temperature and d with DCM.
The two phases were separated, the organic phase was washed with water. The water phase was back extracted with DCM. The pH was adjusted to 12 with 6N NaOH and the mixture was further extracted with DCM. The organic extracts were combined, dried (Na2804) and evaporated under reduced pressure ing the d 3-bromo linopyridinamine (71.5 mg, 84%). LCMS (m/z): 260.0 (MH+), 0.37 min.
Alternate Method To a solution of 4-(5-Bromonitropyridinyl)morpholine (2 g, 6.9 mmol) in MeOH (150 mL) in a round bottom flask was added Zn dust (4.54 g, 69.4 mmol). The reaction mixture was cooled to 0 °C. Solid NH4C| (3.71 g, 69.4 mmol) was added in portions, over 5 min.
The heterogeneous reaction e was stirred at room temperature for 2 h, filtered through a plug of Celite washing the filter cake with methanol and ethanol. The te was concentrated to a brownish solid which was purified by flash column chromatography on silica gel (ISCO, 80 g column, 0-70% EtOAc/heptane in 15 min and 70% EtOAc to 25 min), obtaining 3-bromomorpholinopyridinamine (936 mg, 52.2 %) as a slightly off white solid. LCMS (m/z): 258.2 (MH+), 0.35 min; 1H NMR (400 MHz, CDCI3) 6 ppm 7.75 (d, J=2.3 Hz, 1 H) 7.40 - 7.30 (m, 1 H) 4.66 (br. s., 2 H) 3.91- 3.74 (m, 4 H) 3.07 - 2.90 (m, 4 H).
Ste 7. 5-Mor holino 4 4 5 5-tetrameth H 3 aborolan l ridinamine 3-bromomorpholinopyridinamine (36 mg, 0.14 mmol), bis(pinacolato)diboron (70.8 mg, 0.28 mmol), potassium e (41.1 mg, 0.42 mmol) and tricyclohexylphosphine (5.9 mg, 0.021 mmol) were dissolved in 1,4-dioxane (1.5 mL) in a pressure vessel. The mixture was sparged with N2 for 5 min and palladium diacetate (3.1 mg, 0.014 mmol) was added. The reaction mixture was heated to 110 °C for 16 h, cooled to room ature and diluted with ethyl acetate. SyliaBondDMT was added, the mixture was stirred for 1h, filtered over a Celite pad and concentrated, obtaining 21.3 mg of a solid which contains the desired 5-morpholino(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)pyridinamine.
This solid was used in the next step without further purification. LCMS (m/z): 224.0 (MH+), 0.33 min (for boronic acid).
Scheme 22 CF so3 2 so CF 2N 2 3 Ste O/SOZCF3 \N LiHMDS THF 78 OC —ESte § 0 N \ f)Cl2_DCM I _9_Ste 2 Na co2 3, DME NH2 \ ”HEN N \ O O \ KCO lB—B: —>\ Pd(dPPf)C|2, 2 3 0 O Kg”| / O dioxane B NH2 NH2 NH2 NH2 $94 N)\ N)\ Br fieé N \ I I N)\(BrI 1.Pd/C,MeOH /N /N k/N /N 2. chiral separation N"O \\\"O O O O Step 1. 2-methyl-3,6-dihydro-2H-pyranyl trifluoromethanesulfonate To a solution of 2-methyldihydro-2H-pyran-4(3H)—one (2g, 17.52 mmol) in THF (8.76 mL) was added LiHMDS (18.40 mL, 18.40 mmol) dropwise at -78 °C. The reaction mixture was stirred at -78 °C for 1.5 h, then N-(5-chloropyridiny|)-1,1,1-trifluoro-N- ((trifluoromethyl)sulfonyl)methanesulfonamide (7.22 g, 18.40 mmol) in THF (17 mL) was added at -78 °C. The e was stirred at -78 °C for 1h, and then allowed to warm up to room temperature, and stirred overnight. The reaction was monitored by TLC. After quenched with sat NaHC03, The reaction mixture was ted with EtOAc 3 times. The combined c layers were washed with water, brine, and dried over anhydrous sodium sulfate. Filtered and concentrated in vacuo. The desire compound (4.2 g, 17.06 mmol) was obtained as a brown oil by flash column chromatography eluting with 30% EtOAc in heptane.
Ste 2. 5- 4 4 5 5-tetrameth H 3 2-dioxaborolan l razinamine To a solution of 5-bromopyrazinamine (1 g, 5.75 mmol), bis(pinacolato)diboron (2.92 g, 11.49 mmol), and PdC|2(dppf)CH2C|2 adduct (0.469 g, 0.575 mmol) in dioxane (16.42 mL) was added ium acetate (1.692 g, 17.24 mmol) just right after degassing. The reaction mixture was heated in microwave at 120 °C for 20 min. Diluted with EtOAc, and the reaction mixture was filtered through Celite. trated, and the crude product was used for next step without further purification. LCMS (m/z): 140 (MH+ for c acid), 0.12 min.
Ste 3. 5- 2-meth l-3 6-dih dro-2H- ran l razinamine To a on of 2-methyl-3,6-dihydro-2H-pyranyl trifluoromethanesulfonate (0.637 g, 2.88 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)pyrazinamine (0.914 g, 3.74 mmol), and dppf)-CH2C|2 adduct (0.235 g, 0.288 mmol) in DME (9.82 mL) was added 2M Na2C03 (3.27 mL). The reaction mixture was heated at microwave synthesizer (120 0C, 10 min). Ethyl acetated was added, and washed with sat NaHC03, and water.
Then the desired compound was extracted to 1N HCI aqueous layer, and washed with EtOAc. Basified with 2N NaOH, and the product was extracted to EtOAc layer. EtOAc organic layer was washed with water and dried over Na2804. Filtered and concentrated to provide 250 mg of desired compound. LCMS (m/z): 192.2 (MH+), 0.40 min.
Ste 4. 5- 2R 4R meth ltetrah dro-2H- ran l razinamine To a on of 5-(2-methyl-3,6-dihydro-2H-pyranyl)pyrazinamine (250 mg, 1.307 mmol) in MeOH (13.100 mL) was added Pd/C (278 mg, 0.261 mmol). The solution was degassed by N2 stream for 10 min. After flushed by H2 gas, hydrogen balloon was equipped. The reaction mixture was stirred for 25 h. After filtered through Celite, the volatile material was removed to give the crude product, which was purified with flash chromatography eluting with 0-10% of MeOH in DCM to provide 180 mg of diastereomers. Then chiral separation (ChiraIPak 5mic AD column, 4.6x100 (mm), 5mL/min, EtOH+0.1% DEA = 15%) provided 40 mg of 5-((2R,4R)—2—methyltetrahydro-2H- pyranyl)pyrazinamine (Rt = 1.32 min; LCMS (m/z): 194.2 (MH+), 0.44 min) in 22% yield and 30 mg of desired 5-((2S,4S)—2-methy|tetrahydro-2H-pyranyl)pyrazinamine (Rt = 1.83 min; LCMS (m/z): 194.2 (MH+), 0.44 min) in 16% yield.
Ste 5. 3-bromo 2R 4R meth h dro-2H- ran l razinamine and 3- bromo 28 4S meth ltetrah dro-2H- ran l razinamine To a solution of 5-((2R,4R)—2-methyltetrahydro-2H-pyranyl)pyrazinamine (40 mg, 0.207 mmol) in acetonitrile (3 mL) was added NBS (35.0 mg, 0.197 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 15 min. After ed with NaHC03, the reaction e was extracted with EtOAc three times. The c layers were combined and washed with water, and brine. Dried over Na2804, filtered and concentrated to afford 47 mg of 3-bromo—5-((2R,4R)—2-methy|tetrahydro-2H-pyran yl)pyrazinamine, which was used as it was. LCMS (m/z): 274 (MH+), 0.64 min. For 5- ((2S,4S)methyltetrahydro-2H-pyranyl)pyrazinamine, following the above method, 3-bromo((2S,4S)—2-methyltetrahydro-2H-pyranyl)pyrazinamine was obtained.
LCMS (m/z): 274 (MH+), 0.65 min. The absolute stereochemistry of the products were ed arbitrarily.
S nthesis of 3-bromoc clo ro | razinamine Scheme 23 NH2 NH2 NH2 N \ Y KOt—Bu, Pd(PPh)4 NBS Rf %| + / \ —> Nl)\ —> Nl)\(Br N O O / N / N dioxane/water, 160 °C Ste 1.5-c clo ro l razinamine To a microwave vial was charged with 5-bromopyrazinamine (400 mg. 2.3 mmol), 2- cyclopropyI-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.16 g, 6.9 mmol), KOt—Bu (1 M in t- BuOH, 9.2 mL), 1,4-dioxane (10 mL), and water (0.10 mL), and the mixture was purged with Argon, followed by addition of Palladium tetrakis (266 mg, 0.23 mmol) and final Argon purge, then the mixture was sealed and heated at 150 °C via microwave reactor for min. To the reaction mixture was added 2nd portion of PalladiumTetrakis (266 mg) and the reaction was heated at 160 °C via microwave reactorfor 20 min. The on mixture was ed through a thin layer of Celite, and the filtrate was concentrated. The residue was triturated with EtOAc (6 mL), and the itates were removed via centrifugation and filtration. The EtOAc supernatant was back extracted with aqueous TFA solution (3 x 3 mL, ter- 1 mL/10 mL). The TFA solutions were combined, diluted with acetonitrile (10 mL), frozen and lyophilized to afford 5-cyclopropylpyrazin amine in a yellow . The product after lyophilization was transferred to a vial, basified to pH > 12 with sat. Na2C03 (3mL), extracted with EtOAc(4 x 6 mL), and the EtOAc extracts were combined, and concentrated and further dried under high vacuum, and final 5-cyclopropylpyrazinamine free base was obtained (79 mg, 25.4% yield).
LCMS (m/z): 136.1 (MH+), 0.30 min. 1H NMR (CD3OD) 6 ppm 8.29 (d, J = 1.2 Hz, 1H), 7.70 (d, J = 1.6 Hz, 1H), 2.00 - 2.08 (m, 1H), 0.94 - 1.00 (m, 2H), 0.87 - 0.93 (m, 2H).
Step 2. 3-bromocyclopropylpyrazinamine A solution of 5-cyclopropylpyrazinamine (79 mg, 0.584 mmol) in acetonitrile (10 mL) was cooled down to 0 °C, and treated with l on of NBS (140 mg, 1.46 mmol) over the course of 1 hour while closely monitoring reaction progress by LCMS. The reaction e was concentrated and the residue was triturated with EtOAc (2 x 5 mL) and the EtOAc supernatants were separated via fugation, combined and washed with 1N NaOH (3 x 1 mL) and the EtOAc layer was dried (over Na2804), concentrated and a crude brown reside was obtained. The crude product was further purified by flash chromatography on silica gel eluted with gradient EtOAc/CHZCIZ (0-30%) to afford 3- bromocyclopropylpyrazinamine in colorless solid (38.2 mg, 38.5% yield). LCMS (m/z): 216.0 (MH+), 0.64 min. 8 nthesis of 3'-meth l 4 4 5 5-tetrameth H 3 2-dioxaborolan | - 3 4'-bi ridin amine Scheme 24 NH2 NH2 NH2 NH2 9J§< Ste 2 Br 43‘s 1 J- 4‘Ste 3 N \ N \ C. 1 \ N. \ I / / I / Pd(dPPf)C|2 NBS Pd(dPPf)CI2.Bz(P|N)2 / + \ —> —> —> ,B\ I NaZCO3, DME \ / KOAc, dioxane / o o / N | | / \ I +4 ~ N \N Ste 1. 3'-meth l-3 4'-bi ridinamine To a solution of (2 g, 9.09 mmol) in DME (45.4 mL) was added 4-chloromethylpyridine (1.739 g, 13.63 mmol), and PdCl2(dppf)-CH2Cl2Adduct (0.742 g, 0.909 mmol) and 2 M Na2C03 (15.15 mL), mixture was purged with nitrogen for 5min, The reaction mixture in sealed glass bomb was heated to 120 °C overnight. The reaction mixture was extracted by EtOAc, the organic layers and washed with brine water The organic was dried by Na2804 anhydrous, filtered and concentrated to yield crude t. The crude material was purified by flash chromatography (0-100% EtOAc/heptane) to yield 3'-methyl-3,4'- bipyridinamine (255 mg, 1.377 mmol, 15.15 % yield). LCMS (m/z): 406.3 (MH+), 0.47 Step 2. o-3'-methyl-3,4'-bipyridinamine To an ice cold solution of 3'-methyl-3,4'-bipyridinamine (250 mg, 1.350 mmol) in DCM (4499 uL) was added NBS (264 mg, 1.485 mmol) in two portions. The reaction mixture was stirred at 0 °C for 2 h. Reaction mixture was diluted with ethyl acetate, and was washed with water, brine, dried and trated. Residue was treated heptane, the solid filtered to give 5-bromo-3'-methyl-3,4'-bipyridinamine (350 mg, 1.325 mmol, 98 % yield) as brown color solid, used in next step reaction without purification. LCMS (m/z): 264.4/266.4 (MH+), 0.32 min; 1H NMR z, CDCI3) 6 ppm 8.51 (s, 1 H), 8.47 (d, J: .1 Hz, 1 H), 8.04 (d, J: 2.0 Hz, 1 H), 7.69 (d, J: 2.0 Hz, 1 H), 7.12 (d, J: 5.1 Hz, 1 H), .06 (br. s., 2 H), 2.32 (s, 3 H).
Ste 3. 3'-meth l 4 4 5 5-tetrameth H 3 2-dioxaborolan l -3 4'-bi ridinamine To a suspension of (5-bromo-3'-methyl-3,4'-bipyridinamine (100 mg, 0.379 mmol) in 1,4-dioxane (947 uL) was added bispinB (288 mg, 1.136 mmol) and potassium acetate, (186 mg, 1.893 mmol). Mixture was purged with nitrogen for 3min, then dppf)CH2C|2 adduct (30.9 mg, 0.038 mmol) was added. The reaction mixture was heated to 120 °C in microwave for 10 min, Formation of desired t was confirmed. still some starting material left, resubmitted for microwave 120 °C for 10 min. The reaction mixture was filtered h filter and rinsed with dioxane (0.7 mL), the filtrate solution was used in next step reaction without purification. LCMS (m/z): 230.1 (MH+for boronic acid), 0.22 min. 8 nthesis of 1- 4- 5-aminobromo 2- l i eridin lethanone Scheme 25 NH2 ““2 NAKBr| MeCOCl N&Brl \ N \ N DIEA/DCM To 3-bromo(piperidinyl)pyrazinamine (50 mg, 0.194 mmol) in DCM (4 mL) in ice bath was added DIEA (0.136 mL, 0.778 mmol) and acetyl chloride (0.017 mL, 0.233 mmol) . The reaction mixture was stirred at in ice bath 30min. The on mixture was partitioned between DCM and water. The DCM layer was separated and washed with brine. Dried over sodium sulfate, filtered and evaporated. Proceed for next step. LCMS (m/z): 299.1/301.1 (MH+), 0.508 min. 1H NMR (400 MHz, CD3OD) 6 ppm 7.81-7.69 (m, 2 H), 7.62-7.45 (m, 2 H), 7.37-7.09 (m, 6 H), 6.5 (dd, J=8.61, 2.35 Hz, 1 H), 6.50 (dd, J=13.50, 2.15 Hz, 1 H), 5.17—5.01 (m, 1 H), 4.55 (d, J=13.30 Hz, 1 H), 3.94 (d, J=13.69 Hz, 1 H), 3.63-3.63 (m, 2 H), 2.88 (tt, J=11.84, 3.62Hz, 1 H), 2.67 (td, J=12.91, 2.35 Hz, 1 H), 2.03 (s, 3 H), 1.96-1.79 (m, 2 H), 1.78-1.50 (m, 2 H).
S nthesis of 3-bromo 1-meth l-1H- razol l ridinamine Scheme 26 Ste e2 0 Pd(dDP)f)C| \ 2 Nl \ “1 + / NyiO /N NagCO3 DME Br Z\ Ste 1. 5- 1-meth l-1H- razol l ridinamine To a microwave vial was charged opyridinamine (500 mg, 2.89 mmol), 1- (4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)—1H-pyrazole (1.2 g, 5.78 mmol), aqueous Na2C03 (2 M, 5.78 mL), PdC|2(dppf) CH2C|2 (0.236 g) and DME (15 mL), and the reaction e was purged with Argon for 5min, sealed and heated with microwave reactor at 115 °C for 20min. The DME layer of reaction mixture was collected, trated and the residue was subjected to flash column chromatography on silica gel eluted with gradient Methanol/CH2CI2 and 5-(1-methyl-1H-pyrazolyl)pyridinamine was obtained as light brown solid (383 mg, 76% yield). LCMS (m/z): 175.2 (MH+), 0.34 min.
Ste 2. 3-bromo 1-meth l-1H- razol l ridinamine To 5-(1-methyl-1H-pyrazolyl)pyridinamine(380 mg, 2.18mmol) acetonitrile(30 mL) on at 0 °C was added NBS (388 mg, 2.18 mmol) and the reaction mixture was stirred at 0 °C for 30 min, then at room temperature for additional 40 min. The reaction mixture was then concentrated, redissolved in methanol, to it was added solid LiOH (80 mg), sonicated and concentrated, the residue was triturated with water (2 x 5 mL), and the supernatants were ded. the residue was dried under high vacuum, then triturated with EtOAc (2 x 8 mL), and the supernatants were collected, ed, and concentrated and the light brown residue was obtained as crude o(1-methyl-1H- pyrazolyl)pyridinamine. LCMS (m/z): 253.0/255.0 (MH+), 0.38 min. 8 nthesis of S 2-aminofluoro 1-meth l-1H- razol l ridin lfluoro-N- 2-h drox hen |eth Ibenzamide Scheme 27 “”2 ””2 St 91 St 92 _er g NH2 NHZ Br N / N / NBS f)C'2 | NBS | N/ N/ O\B,o \ \ l —> | —> + F —> F \ \ Na co DME Br NxN / / \ N—N N—N / / Ste 1.5-bromofluoro 2-amine To a solution of 4-fluoropyridinamine (400 mg, 3.57 mmol) in acetonitrile (35. 7 mL) was added NBS (648 mg, 3.64 mmol) in three portions at 0 °C . The reaction mixture was stirred at 0 °C for 20 min. LCMS showed the reaction complete. After quenched with sat Na28203 and NaHC03, stirred for 30 min. The reaction mixture was extracted with EtOAc 3 times. Washed by sat NaHC03, water and brine. Dried and concentrated. The crude material was ated with ether and taken to the next step without further purification. LCMS (m/z): 192.9 (MH+), 0.32 min.
Ste 2. 4-fluoro 1-meth l-1H- razol l ridinamine To the reaction mixture of 5-bromofluoropyridinamine (369 mg, 1.932 mmol), 1- methyl(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-1H-pyrazole (603 mg, 2.90 mmol), PdCl2(dppf)DCM (141 mg, 0.193 mmol) and DME (9.660 uL), 2M Na2C03 (3.220 mL) was added. The reaction mixture was heated at microwave synthesizer (120 °C 12 min). To the reaction e, anhydrous sodium sulfate was added, filtered, and concentrated.
The crude product was purified by flash chromatography eluting with 0-100% EtOAc ining 10% of MeOH/heptane to provide 280 mg of desired product in 75 % yield.
LCMS (m/z): 193.1 (MH+), 0.35 min.
Ste 3. 3-bromofluoro 1-meth l-1H- razol l ridinamine To a solution of 4-fluoro(1-methyl-1H-pyrazolyl)pyridinamine (150 mg, 0.780 mmol) in acetonitrile (7. 805 mL) was added NBS (142 mg, 0.796 mmol) in three ns at 0 °C . The reaction mixture was stirred at 0 °C for 20 min. LCMS showed the reaction complete. After quenched with sat Na2803 and NaHC03, stirred for 30 min. The reaction mixture was ted with EtOAc 3 times. Filtered out solid. The solid was not the desired product. The EtOAc layers were washed by sat NaHC03, water and brine. Dried and concentrated. The crude material was purified with flash chromatography g with 0-100% EtOAc (containing 10% MeOH/heptane to provide 30 mg of desired product.
LCMS (m/z): 273.1 (MH+), 0.46 min. 8 nthesis of +/- - 18 BR 5-aminobromo razin l c clo entanol +/- - 1R 3R -aminobromo 2- lc clo entanol and +/- bromo 1R 3R methox c clo ent l razinamine Scheme 28 SteL Steg g m; 0 NH2 Brz, PPh3 Pd(dppf)C|2, BZ(P|N)2 ['3 Pd(dppf)CI2 —. ‘0 + NI \ —.
TEA benzene KOAc, dioxane / N NaZCO3, dioxane 85 OC. 5 h 0 Br 100 ”C, o/n NH2 m-4 NBoq Steg g NBoc2 Step 6 NBocQ NBOCz N)\ 80020 N)\| H2 N)\ NJN | NaBH4 I NJNI I / N / N / N / N / N —> —> + DMAP Pd/C MeOH OH OH (+/_) Ste NH2 1 NHZ Br St 97e N \ NJ\(Br NJYBr _ NI \ 1. HCI, e I | I /N / N /N 1. HCI, dioxane /N —, + ‘— 2. NBS 2. NBS OH OH OMe OMe (+/_) (+/_) Ste 1. 3-bromoc c|o entenone To a solution of PPh3 (44.1 g, 168 mmol) in benzene (510 mL), Br2 (8.67 mL, 168 mmol) was added dropwise at 0 °C, the solution turned to yellow suspension, then TEA (23.44 mL, 168 mmol) was added . To the e was added cyclopentane-1,3-dione (15 g, 153 mmol) in benzene (100 mL). The reaction mixture was stirred at room temperature for overnight. Ether 200 mL was added, the reaction mixture was then filtered. The filtrate was concentrated, the residue was treated with EtZO, the solid was filtered one , repeated more time. The crude product was used in next step reaction. LCMS (m/z): 160.9 (MH+), 0.35 min.
Ste 2. 3- 4 4 5 5-tetrameth H 3 2-dioxaborolan l c clo entenone To a solution of 3-bromocyclopent—2-enone (13 g, 81 mmol) in dioxane ( 161 mL) was added B2(P|N)2 (41.0 g, 161 mmol) and PdC|2(dppf)CH2C|2 (2.95 g, 4.04 mmol). The reaction mixture was degassed for 15 min by N2 bubbling. Then KOAc (23.77 g, 242 mmol) was added. The reaction mixture was heated at 90 °C overnight. After cooling down, the reaction mixture was filtered off through a frit glass filter and rinsed with dioxane (160 mL), the filtrate was concentrated in vacuo ng crude 3-(4,4,5,5- tetramethyl-1,3,2-dioxaborolanyl)cyclopentenone, which was used for the next step without purification. LCMS (m/z): 126.9 (MH+), 0.17 min.
Ste 3. 3- 5-amino razin lc clo entenone To 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)cyclopent—2-enone (2.99 g, 14.37 mmol) (the te from last step) was added 2-amino-5 bromopyrazine (2.5 g, 14.37 mmol), PdCI2(dppf)-CH2C|2 (1.173 g, 1.437 mmol), Na2C03 (7.61 g, 71.8 mmol) and water (17.96 mL) the reaction mixture was stirred at 100 0C oil bath for overnight, filtered through . The reaction mixture was then extracted by EtOAc. The organic was then used 3N HCI (20mL) washed 2 times, and water 50mL once, the AQ was then neutralized by NaOH to pH= 8, the reaction mixture was then extracted by IPA (7:3) 3 times, the organic was dried and concentrated and used as it. LCMS (m/z): 176.1 (MH+), 0.32 min.
Ste 4. N N- di-tert-but l 5- 3-oxoc clo enten l razin |carbamate To a solution of 3-(5-aminopyrazinyl)cyclopentenone (500 mg, 2.85 mmol) in DCM (9.5mL) was added Boc20 (1988 ul, 8.56 mmol) and DMAP (523 mg, 4.28 mmol), the reaction mixture is dark solution, the reaction mixture was stirred at room temperature for h. The reaction mixture was concentrated and purified by flash chromatography (0-40% heptane) to give N,N- di-tert-butyl oxocyclopent—1-enyl)pyrazin y|)carbamate in 47% yield. LCMS (m/z): 376.2 (MH+) 0.96 min. 1H NMR (400MHz CDCI3) 6 ppm 8.77 (d, J = 1.2 Hz, 1 H), 8.72 (d, J :12 Hz, 1 H), 6.89 (s, 1 H), 3.15 (td, J = 2.3, 4.7 Hz, 2 H), 2.64 (td, J = 2450 Hz, 2 H), 1.45 - 1.37 (m, 18H).
Ste 5. +/- -N N-Di-tert-but l 5- 3-oxoc clo ent l razin |carbamate N,N- di-tert-butyl (5-(3-oxocyclopenteny|)pyraziny|)carbamate (600 mg, 1.598 mmol) in methanol was purged by N2 for 10 min, the Pd/C (170 mg, 0.160 mmol) was added, the reaction mixture was purged by N2 for another 5 min, the reaction mixture was then charged with en balloon and stirred at room temperature for 2 h. Filtered through Celite, the filtrated was concentrated, the crude material was used in next step reaction without purification. LCMS (m/z): 378.1 (MH+), 0.83 min.
Ste 6. +/- -N N-Di-tert-but l 5- 1R 3R h drox c clo ent l razin |carbamate and (+/—)—N,N-Di-tert—butyl R,3S)—3-hydroxycyclopentyl)pyrazinyl)carbamate (+/-)-N,N-Di-tert-butyl oxocyclopentyl)pyrazinyl)carbamate (600 mg, 1.590 mmol) was dissolved in methanol (5299 ul), then NaBH4 (90 mg, 2.385 mmol) was added, the reaction mixture was stirred at room temperature for 30 min, sat. NH4C| added, the on mixture was then concentrated to remove methanol. Extracted by EtOAc, the c was washed by sat.NaHC03 solution, water and brine, dried over anhydrous N32804, concentrated to yield the crude product. The crude product was purified by flash chromatography to give (+/-)-N,N-Di-tert-butyl (5-((1R,3R)—3-hydroxycyclopentyl)pyrazin- 2-y|)carbamate (24.9%). LCMS (m/z): 280.1 (MH+), 0.86 min. 1H NMR z ,CDCI3) 6 ppm 8.50 - 8.43 (m, 1 H), 8.43 - 8.33 (m, 1 H), 4.40 (br. s., 1 H), 3.58 - 3.45 (m, 1 H), 2.36 - 2.17 (m, 2 H), 2.02 - 1.75 (m, 5 H), 1.50 - 1.39 (m, 18 H). (+/-)-N,N-Di-tert-buty| (5- ((1R,3S)—3-hydroxycyclopentyl)pyrazinyl)carbamate (4%), LCMS (m/z): 380.1 (MH+), 0.85 min. 1H NMR (400MHz ,CDCI3) 6 ppm 8.43 (d, J = 1.2 Hz, 1 H), 8.36 - 8.32 (m, 1 H), 4.59 (d, J = 2.7 Hz, 1 H), 3.69 - 3.57 (m, 1 H), 2.37 - 2.13 (m, 2 H), 2.13 - 2.01 (m, 2 H), 1.93 - 1.68 (m, 2 H), 1.49 - 1.39 (m, 18 H).
Ste 7. +/- - 1S 3R 5-aminobromo razin l c clo entanol N,N-Di-tert-buty| (5-((1R,3S)—3-hydroxycyclopentyl)pyrazinyl)carbamate (35 mg, 0.092 mmol) in DCM (461 pl) was added HCI (922 pl, 3.69 mmol), the reaction e was stirred at room temperature overnight and concentrated to dryness yielding HCI salt. The crude product was used in next step reaction without purification. LCMS (m/z): 180.1 (MH+), 0.22 min. (+/-)-(1S,3R)—3-(5-aminopyrazinyl)cyclopentanol (15 mg, 0.084 mmol) was dissolved in acetonitrile (2 mL), then NBS (16.39 mg, 0.092 mmol) was added, the reaction mixture was stirred at room ature for 30 min, water was added, the reaction mixture was then extracted by EtOAc, the organic was dried and concentrated, the crude material was used in next step reaction. LCMS (m/z): 258.1/260.2 (MH+), 0.45 min. Following the above method, using N,N-Di-tert-buty| (5-((1R,3S)—3- hydroxycyclopentyl)pyrazinyl)carbamate, (1R,3R)—3-(5-aminobromopyrazin y|)cyc|opentano| was obtained. LCMS (m/z): 260.1 (MH+), 0.50 min.
Ste 8. N N-Di-tert—but l 5- 3-methox c clo ent l razin lcarbamate To a solution of diastereomeric mixture of -tert—butyl (5-(3- hydroxycyclopentyl)pyrazinyl)carbamate (50 mg, 0.132 mmol) in Mel (2.635 mL) was added silver oxide (305 mg, 1.318 mmol), the reaction mixture was capped in a reaction vial and stirred at room temperature overnight. 10 equiv. of silver oxide and 2 mL of Mel was added, the reaction mixture was stirred at room temperature for another day. The reaction mixture was filtered through Celite pad and washed with EtOAc and methanol.
After the filtrate was concentrated, the crude product was purified by flash chromatography (0-40% EtOAc/heptane) yielding N,N-Di-tert-butyl R,3R)—3- methoxycyclopentyl)pyrazinyl)carbamate (25 mg). LCMS (m/z): 394.1 (MH+), 1.06 min.
Example 12 S nthesis of +/- 3-amino 18 BR h drox c clohex | razin I-N-benz I fluorobenzamide Scheme 29 Step Step 1 0 PM fg)C| O O DP 2 NH2 ’BZ(P'N)2 NaZCO3 szo’ —’ —. + B NI \ KOAc, ’ \ /N O DCM OTf O 0 dioxane ?—$ Br Ste g J“: Step4_ NH2 f)C|2 | NaBH4, CeCI3 / N NI)\ é —. /N Na2003, DME EtOH Step Step; NH2 § NH2 Pd/C, _ _ N)\ H TBDMSCI, Imldazole 2 N/S | | —> /N —> 9N DMF : : "’OTBDMS(+/_) OTBDMS NJYBr| NBS /N HOB/©ij/\© Pd((dppf)C|2 —> 5 + HO\ O (+/-) N82C03, DME HQ 4%— 2 N \ GHQ 6N HCI, MeOH, THF 9N /N o"’OTBDMS <3"’OH Ste 1. 3-oxoc clohex—1-en |trifluoromethanesulfonate Cyclohexane-1,3-dione (8 g, 71.3 mmol) was weighed into a 500 mL round bottom flask and CH2C|2 (160 mL) was added resulting in clear colorless slurry at 0 °C under N2.
Sodium carbonate (8.32 g, 78 mmol) was added and the suspension was stirred for 15min. Trifluoromethanesulfonic anhydride (13.26 mL, 78 mmol) ved in DCM (16 mL) was added se over 1.2 h g internal temperature less than 1.9 °C to avoid bis-triflate ion. The mixture was left stirring at 0 °C for 45 min then allowed to p to 10 °C during 20 min. ed through fritted glass funnel to get rid of Na2C03 and sat NaHC03 was added. c layer was separated and washed with brine. Dried over NazSO4, filtered, concentrated and dried under reduced pressure to provide 9.18 g of desired product. LCMS (m/z): 245.1 (MH+), 0.81 min.
Step 2. 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)cyclohexenone To a mixture of 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1 ,3,2-dioxaborolane) (19.09 g, 75 mmol) and potassium acetate (11.07 g, 113 mmol) was added 3-oxocyclohexenyl trifluoromethanesulfonate (9.18 g, 37.6 mmol) as a solution in dioxane (44.6 mL). Argon was bubbled through for 15min, then Pd(dppf)C|2-DCM (0.824 g, 1.128 mmol) was added. The whole reaction mixture was heated at 100 °C overnight. Filtered the solution through Celite and all the solvent was evaporated. Dried under high vacuum to provide quantitative product which was used as it was. LCMS (m/z): 141 (MH+ for boronic acid), 0.43 min.
Ste 3. 3- 5-amino razin lc clohexenone Into a 500mL glass weighed 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)cyclohex enone (4.1 g, 18.46 mmol), 5-bromopyridinamine (4.15 g, 24.00 mmol) was added as a solution in dioxane (69.2 mL), followed by sat Na2C03 (23.08 mL) and Pd(dppf)C|2-DCM (1.350 g, 1.846 mmol). The whole mixture was then degassed by bubbling Ar through for 15min and refluxed overnight. EtOAc and water was added, and stirred for 30 min.
Organic was ted and the aqueous layer was ted with EtOAc three times.
Organic layers were combined and dried over NazSO4, filtered and concentrated. Purified with flash chromatography eluting with 0-100% EtOAc (containing 10% of MeOH)/heptane to provide 2 g of desired product. LCMS (m/z): 190 (MH+), 0.42 min.
Ste 4. 3- 5-amino razin lc clohexenol WO 66188 To a solution of 3-(5-aminopyrazinyl)cyclohexenone (150 mg, 0.793 mmol) in ethanol (2643 uL) was added cerium (lll) chloride (293 mg, 1.189 mmol) at room ature. The reaction mixture was stirred at room temperature for 1 h until all the materials were dissolved. The reaction mixture was then cooled to 0 °C and sodium borohydride (45.0 mg, 1.189 mmol) was added in ns. The reaction mixture was stirred upon warming up to room temperature for 2 h. The reaction mixture was cooled to 0 °C and 2 mL of water was slowly added until the bubbles clearly showed up and then disappeared, Continued to stir for 30 min. Then, sodium sulfate was added and stirred for min. Filtered and dried under high vacuum to provide 149 mg of desired product.
LCMS (m/z): 192.1 (MH+), 0.46 min.
Ste 5. 5- 3- ut ldimeth lsil lox c clohexen | razinamine To a solution of 3-(5-aminopyrazinyl)cyclohexenol (149 mg, 0.779 mmol) in DMF (5.5 mL) at 0 °C were added tert-butylchlorodimethylsilane (294 mg, 1.95 mmol) ) and 1H- imidazole (212 mg, 3.12 mmol).The reaction mixture was stirred at room temperature ght. After quenched with sat NaHC03, the reaction mixture was extracted with EtOAc 3 times. The ed organic layers were dried over anhydrous sodium sulfate.
Filtered and concentrated in vacuo. The crude product was purified with flash chromatography eluting with 0-100% of EtOAc/heptane to provide 238 mg of crude product which was used as it was. LCMS (m/z): 306.9 (MH+), 1.04 min.
Ste 6. 5- 1R 3S tert-but ldimeth lsil lox c clohex | razinamine A mixture of 5-(3-((tert-butyldimethylsi|y|)oxy)cyclohexeny|)pyrazinamine (238 mg, 0.779 mmol) and Pd/C (10%) (50 mg, 0.779 mmol) in MeOH (7.79 mL) was stirred under H2 atmosphere for 3 h . LCMS indicated about 60% conversion. More Pd/C (20 mg) was added, and stirred about r 4 h. LCMS indicated still little amount of starting material left. More Pd/C (20 mg) was added and stirred overnight. Catalyst was filtered out and solvent was evaporated. The residue was purified with flash chromatography g with 0-100% of EtOAc/heptane to provide 110 mg of desired cis racemate compound. LCMS (m/z): 308.4 (MH+), 1.01 min.
Ste 7. 3-bromo 3- tert-but ldimeth lsil lox c clohex | razinamine To a solution of 5-((1R,3S)—3-((tert—butyldimethylsi|y|)oxy)cyc|ohexy|)pyrazinamine (110 mg, 0.358 mmol) in acetonitrile (5.50 mL) was added NBS (66.9 mg, 0.376 mmol) at 0 °C.
The reaction mixture was stirred at 0 °C for 15 min. After quenched with sat sodium thiosulfate and sat NaHC03, extracted with EtOAc three times. The organic layers were combined and washed with brine, dried over , filtered and concentrated to afford 138 mg of desired cis racemate compound, which was used as it was. LCMS (m/z): 388 (MH+), 0.72 min.
Ste 8. 4- 3-amino 3- tert-but |dimeth lsil lox c c|ohex | razin nz l fluorobenzamide To 3-bromo(3-((tert-butyldimethylsilyl)oxy)cyc|ohexyl)pyrazinamine (68 mg, 0.176 mmol) in 2 mL MW vial was added (4-(benzylcarbamoyl)—3-fluorophenyl)boronic acid (72.1 mg, 0.264 mmol), PdC|2(dppf)-DCM (12.88 mg, 0.018 mmol), DME (1.32 mL) and 2M Na2C03 solution (0.44 mL). The reaction mixture was heated at microwave synthesizer (12 min, 120 °C). The reaction mixture was diluted with EtOAc and washed with water three times, dried over NaZSO4, filtered and concentrated. The crude product was purified by flash chromatography eluting with 0-100% of EtOAc (containing 10% of MeOH)/heptane to provide 60 mg of crude cis racemate compound which was taken to the next reaction without r purification. LCMS (m/z): 535.4 (MH+), 1.31 min.
Ste 9. 4- o 1R 3S h drox c c|ohex | razin l-N-benz l fluorobenzamide A mixture of 4-(3-amino(3-((tert-butyldimethylsilyl)oxy)cyc|ohexy|)pyrazinyl)—N- benzylfluorobenzamide (61 mg, 0.114 mmol) in 6N HCI (0.29 mL),THF (0. 57 mL) and MeOH (0.285 mL) was stirred for 2 h. Solid sodium bicarbonate was added to neutralize the reaction mixture. t was evaporated and 25 % of the residue was dissolved in DMSO, and purified with rep to provide 15 mg of desired cis racemate compound as a TFA salt. LCMS (m/z): 421.3 (MH+), 0.74 min. 1H NMR (400 MHz, MeOD-d4) 6 ppm 7.82 - 7.69 (m, 2 H) 7. 62 - 7. 45 (m, 2 H) 7.37 - 7.12 (m, 5 H) 4.52 (s, 2 H) 3.66 -3.52 (m, 1 H) 2.75 - 2.60 (m, 1 H) 2.11 - 2.01 (m, 1 H) 1.97 - 1.70 (m, 3 H) 1.52 - 1.29 (m, 3 H) 1.24 - 1.08 (m, 1 H).
S nthesis of +/- bromo 1R 3S methox c clohex l razinamine Scheme 30 NH2 Steg l N(Boc)2 Steg; N(Boc)2 m; N(Boc)2 N)\ N)\ I H2 N)\ /N 30620 I N)\ /N I NaBH4 I / N / N . —, DMAP Pd/C. MeOH o o OH Step 4 N(Boc)2 mi NHz N§ N)\(Br A92O MeI , | 1. HCI, dioxane. I /N /N (+/_) (+/—) 2. NBS o/ O/ Ste 1. +/- -N N-di-Boc o razin lc clohex—2-enone To 3-(5-aminopyrazinyl)cyclohex—2-enone (1.3 g, 6.87 mmol) in DCM (34.0 mL) was added di-tert-butyl dicarbonate (4.50 g, 20.61 mmol) and N,N-dimethylpyridinamine (0.084 g, 0.69 mmol) and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with DCM and then washed with sat sodium bicarbonate solution. The separated organic layer was then dried with sodium sulfate and concentrated. The crude product was purified by flash chromatography (0 to 50% ethyl e in heptane) yielding 1.3 g of (+/-)-N,N-di-Boc(5-aminopyrazinyl)cyclohex enone. LCMS (m/z): 390.3 (MH+), 1.02 min.
Ste 2. +/- -N N-di-Boc 5-amino razin lc clohexanone A mixture of N,N-di-Boc—3-(5-aminopyrazinyl)cyclohexenone (1.3 g, 3.34 mmol) and Pd/C (10%) (400 mg, 10.57 mmol) in MeOH (33.4 mL) was stirred under H2 atmosphere ght. The on mixture was filtered through Celite, and washed well with MeOH and EtOAc. The filtrate was evaporated yielding (+/-)-N,N-di-Boc(5- aminopyrazinyl)cyclohexanone which was used for the next step without r purification. LCMS (m/z): 392.9 (MH+), 0.97 min. 2014/062913 Ste 3. +/- -N N-di-Boc— 1S 3R 5-amino razin l c clohexanol (+/-)-N,N-di-Boc—3-(5-aminopyrazinyl)cyclohexanone (600 mg, 1.533 mmol) was ved in EtOH (17.2 mL), then NaBH4 (87 mg, 2.299 mmol) was added. The reaction mixture was stirred at room temperature for 30 min. After water added to quench the reaction, the reaction mixture was concentrated to remove ol and extracted by EtOAc, and the organic layer was washed by NaHC03 solution, water and brine, dried over anhydrous Na2804, and concentrated ng the crude (+/-)-N,N-di-Boc-(1S,3R)—3- (5-aminopyrazinyl)cyclohexanol (containing 5% trans isomer) which was taken to the next step without further purification. LCMS (m/z): 394.2 (MH+), 0.89 min.
Ste 4. +/- -N N-di-Boc 1R 3S methox c clohex l razinamine A mixture of (+/-)-N,N-di-Boc-(1S,3R)—3-(5-aminopyrazinyl)cyclohexanol (350 mg, 0.89 mmol), silver oxide (2.06 g, 8.9 mmol), acetonitrile (2. 224 mL) and methyl iodide (55.6 uL, 0.890 mmol) was stirred overnight. After EtOAc was added, the reaction e was filtered off. After volatile material was evaporated, the crude product was purified by flash chromatography (0-100% EtOAc in heptane) yielding 184 mg of (+/-)-N,N-di-Boc ((1R,3S)—3-methoxycyclohexyl)pyrazinamine (184 mg, 0.452 mmol). LCMS (m/z): 408.3 (MH+), 1.10 min.
Ste 5. +/- bromo 1R 3S methox c clohex l razinamine (+/-)-N,N-di-Boc((1R,3S)methoxycyclohexyl)pyrazinamine (184 mg, 0.452 mmol) in DCM (4. 515 mL) was added HCI (4M in dioxane) (4.515 mL, 18.06 mmol). The reaction mixture was stirred at room temperature overnight. After the volatile material was removed in vacuo, the residue was dissolved in EtOAc. The organic layer was washed by NaHC03 solution, water and brine, dried over ous Na2804, and concentrated affording (+/-)((1R,3S)methoxycyclohexyl)pyrazinamine in quantitative yield. LCMS (m/z): 208 (MW), 0.43 min. To a solution of (+/-)((1R,3S)—3- methoxycyclohexyl)pyrazinamine (54 mg, 0.261 mmol) in acetonitrile (4. 008 uL) was added NBS (48.7 mg, 0.274 mmol) at 0 °C. The on mixture was stirred at 0 °C for 15 min. After quenched with NaHC03, extracted with EtOAc three times. The organic layer was washed by water and brine, dried over ous Na2804, and concentrated to afford 75 mg of (+/-)bromo((1R,3S)methoxycyclohexyl)pyrazinamine in quantitative yield. LCMS (m/z): 286 (MW), 0.73 min.
Example 13 S nthesis of +/- 3-amino 3- meth n lc clohex l razin l-N-benz l benzamide Scheme 31 Ste Stegg o _28te é o NH NH N \Kr?” TEA D MC /N :1th TBAF N \ MsCI, TEA NJYBF I I /N —> I (+/-) (+/') (+/—) (+/.) OTBDMS OTBDMS OH OSOZMe o F o o F o OSOzMe o F o w AM no ._., H WooH Oxone NI \ K2003,MeOH NI \ —— /N —> /N (+1.) (+H "’s< . / Ste 1. +/- -N- 3-bromo 3- tert-but Idimeth lsil lox c clohex l razin yl)pivalamide Pivaloyl chloride (71.5 uL, 0.569 mmol) was added se to a stirred, cooled (0 °C) mixture of (+/-)bromo((1R,38)((tert-butyldimethylsilyl)oxy)cyclohexyl)pyrazin amine (110 mg, 0.285 mmol) and TEA (159 uL, 1.139 mmol) in CH2C|2 (949 uL). The red mixture was stirred at 0 °C for 1 h, then at room temperature for 2 h. EtOAc and Sat NaHC03 was added and stirred well. Organic layer was separated and the aqueous layer was extracted well with EtOAc. Combined EtOAc layers were washed with brine, dried over Na2804, filtered and concentrated. The residue was purified by flash chromatography on silica gel eluting with EtOAc/heptane to give (+/-)-N-(3-bromo(3- ((tert-butyldimethylsilyl)oxy)cyclohexyl)pyrazinyl)pivalamide 97 mg in 72.4% yield.
LCMS (m/z): 472.3 (MH+), 1.19 min.
Ste 2. +/- -N- 3-bromo 1R 3S tert-but ldimeth lsil lox c c|ohex l razin yl)pivalamide A mixture of (+/-)-N-(3-bromo(3-((tert—butyldimethylsilyl)oxy)cyclohexyl)pyrazin yl)pivalamide (97 mg, 0.206 mmol) in 6N HCI (687 uL), THF (687 uL) MeOH (687 uL) was stirred for 2h. LCMS indicated that the reaction was completed. Solid sodium onate was added to neutralize the HCI. Dissolved in EtOAc and water. Organic layer was separated and washed with brine, dried over , filtered and concentrated to provide 72 mg of crude (+/-)-N-(3-bromo((1R,3S)—3-((tert— butyldimethylsilyl)oxy)cyclohexyl)pyrazinyl)pivalamide in 98% yield. LCMS (m/z): 358.6 (MH+), 0.70 min.
Ste 3. +/- - 1S 3R 6-bromo ido 2- l c c|ohex l methanesulfonate To a mixture of (+/-)-N-(3-bromo((1R,3S)—3-((tert— butyldimethylsilyl)oxy)cyclohexyl)pyrazinyl)pivalamide (72 mg, 0.202 mmol) in CH2C|2 (2021 uL) at 0 °C was added TEA (56.3 uL, 0.404 mmol) and methanesulfonyl chloride (18.90 uL, 0.243 mmol). The resulting mixture was stirred at room temperature for 3h.
Another TEA (56.3 uL, 0.404 mmol) and Methanesulfonyl chloride (18.90 uL, 0.243 mmol) was added, and stirred for 6h. Worked up the reaction by adding water. The organic phase was washed with brine, dried over sodium sulfate, filtered and concentrated. The crude product was purified with flash chromatography eluting with 0-100% EtOAc/heptane to provide 54 mg of (+/-)-(1S,3R)—3-(6-bromopivalamidopyrazinyl)cyclohexyl methanesulfonate in 61.5% yield. LCMS (m/z): 436.1 (MH+), 0.75 min.
Ste 4. +/- - 1S 3R 6- 4- benz lcarbamo lfluoro hen l ivalamido razin lohexyl methanesulfonate To cis racemate (+/-)(6-bromopivalamidopyrazinyl)cyclohexyl methanesulfonate (54 mg, 0.124 mmol) in 2.0 mL MW vial was added (4-(benzylcarbamoyl)—3- fluorophenyl)boronic acid (50.9 mg, 0.186 mmol), dppf) (9.10 mg, 0.012 mmol), DME (1166 uL) and 2M Na2C03 solution (389 uL). The reaction mixture was heated at microwave synthesizer (12 min, 80 °C).The reaction mixture was diluted with EtOAc and washed with water three times, dried over NazSO4, filtered and trated. The crude product was purified by flash chromatography eluting with 0-100% of EtOAc (containing % of MeOH) to provide 73 mg of (1S,3R)—3-(6-(4-(benzylcarbamoyl)—3- fluorophenyl)pivalamidopyrazinyl)cyclohexyl methanesulfonate which was taken to the next reaction t further purification. LCMS (m/z): 583.4 (MH+), 0.87 min.
Ste 5. +/- -N-benz lfluoro 6- 1R 3R meth lthio c c|ohex l pivalamidopyrazinyl )benzamide A mixture of (+/-)-(1S,3R)—3-(6-(4-(benzylcarbamoyl)—3-fluorophenyl)pivalamidopyrazin- 2-yl)cyclohexy| methanesulfonate (25 mg, 0.043 mmol) and sodium methanethiolate (24.09 mg, 0.344 mmol) in MeOH (430 uL) was heated at 80 °C for 2 h. Solvent was d and the residue was purified with flash chromatography g with EtOAc (containing 10% of MeOH)/heptane to provide 25 mg of crude (+/-)-N-benzylfluoro (6-((1R,3R)—3-(methylthio)cyclohexy|)pivalamidopyrazinyl)benzamide which was taken to the next step without r purification. LCMS (m/z): 535.3 (MH+), 1.09 min.
Ste 6. +/- -N-benz lfluoro 6- 1R 3R meth lsulfon lc c|ohex l pivalamidopyrazinyl )benzamide To trans racemate N-benzylfluoro(6-((1R,3R)—3-(methylthio)cyclohexyl) pivalamidopyrazinyl)benzamide (35 mg, 0.065 mmol) in MeOH (327 uL) at 0 °C was added oxone (52.3 mg, 0.085 mmol) in water (327 uL). The reaction mixture was stirred at 0 °C and room temperature thereafter for 3 h. The reaction mixture was quenched by 2 equiv. of sodium thiosu|fate (20.70 mg, 0.131 mmol) in 2 mL water at 0 °C. Stirred for 30 min, and then basified by adding 6N NaOH at 0 °C. Diluted with EtOAc, and dried over sodium sulfate three times. Then filtered and concentrated to afford 25 mg of (+/-)-N- benzylfluoro(6-((1R,3R)—3-(methylsulfonyl)cyclohexyl)pivalamidopyrazin yl)benzamide in 67.4% yield which was taken to the next step without further purification.
LCMS (m/z): 567.4 (MH+), 0.90 min.
Ste 7. +/- 3-amino 1R 3R meth lsulfon lc c|ohex l razin l-N-benz l fluorobenzamide To (+/-)-N-benzylfluoro(6-((1R,3R)—3-(methylsulfony|)cyclohexyl) pivalamidopyrazinyl)benzamide (25 mg, 0.044 mmol) in MeOH (221 uL) was added potassium carbonate (61.0 mg, 0.441 mmol). The ing mixture was heated at 80 °C for 4 h. The reaction mixture was filtered and concentrated. Purified with auto-prep to provide 5.4 mg of (+/-)(3-amino((1R,3R)—3-(methylsulfonyl)cyclohexyl)pyrazinyl)— N-benzyIfluorobenzamide in 20.11% yield. LCMS (m/z): 483.1 (MH+), 0.78 min. 1H NMR (400MHz, 4) 6 ppm 8.00 — 7.81 (m, 2 H) 7.76 - 7.56 (m, 2 H) 7.43 - 7.16 (m, 5 H) 4.65 - 4.55 (m, 2 H) 3.61 - 3.51 (m, 1 H), 3.46 - 3.36 (m, 2 H) 2.87 - 2.97 (m, 3 H) 2.61 - 2.48 (m, 1 H) 2.19 — 1.95 (m, 3 H) 1.92 - 1.78 (m, 3 H).
Example 14 S nthesis of 4- 3—amino 1r4r h drox c clohex l razin l-N-benz l fluorobenzamide Scheme 32 NHz NH2 m1 m; m; NH2 0. [0 N/ N/ NJ} l B \ N Pd(dppf)CI2.CHzCl2 \ N NBSiACN + —. —2> —> DME/2 M NaZCO3 Pd—c MeOH 79% yield 0 0 56% yield 98% yield \ / o o o o F o NJYBr F 0 Step_ N/\© $25 N P)d(dppfC|20H20|2 HCI 3M aq + H H0\ —> —> )3 DME/2 M Na2CO3 ACN/water 47% yield O O \_/ O O F 0 F o NH2 N NH2 N H Stepfi H | N/ \ N NaBH4,MeOH \ N 32% (two steps) 0 SH Ste 1. 5- 1 4-dioxas iro 4.5 decen | 2-amine To 5-bromopyrazinamine (225 mg, 1.293 mmol) was added 4,4,5,5-tetramethyl(1,4- dioxaspiro[4.5]dec—7-enyl)—1,3,2-dioxaborolane (482 mg, 1.810 mmol), PdCl2(dppf)- CH2C|2 adduct (84 mg, 0.103 mmol), DME (3.5 mL) and then last sodium carbonate 2M (1.616 mL, 3.23 mmol). The reaction was microwaved at 120 °C for 15 min. To the reaction was added 80 mL of DCM, washed with water (1x), dried sodium sulfate, filtered and concentrated to residue. The crude was purified by silica gel tography using 12 gram column (solid load) eluting with 10-90% ethyl acetate and heptane. The desired fractions were trated to constant mass to give 173 mg of the d product as free base used as is (56% yield). LCMS (m/z): 234.2 (MH+), 0.43 min; 1H NMR (400 MHz, DMSO-d6) 6 ppm 8.01 (d, J=1.2 Hz, 1H), 7.80 (d, J=1.2 Hz, 1H), 6.33 (s, 2H), 6.27 (t, J=3.9 Hz, 1H), 3.89 (s, 4H), 2.52 (d, J=1.6 Hz, 2H), 2.33 (br. s., 2H), 1.76 (t, J=6.7 Hz, 2H).
Ste 2. 5- 1 4-dioxas iro 4.5 decan | razinamine To 5-(1,4-dioxaspiro[4.5]decenyl)pyrazinamine (645 mg, 2.77 mmol) in a round bottom flask that was flushed with argon was added Pd-C 10% degaussa (294 mg, 0.277 mmol). Then under argon with syringe was added MeOH ( 10 mL) and then last a hydrogen balloon was added. The flask was evacuated and refilled with hydrogen (6 X).
The reaction was stirred at room ature for total of 16 h, under the hydrogen balloon, ed by LCMS. The reaction was flushed with argon and 25 mL of DCM was added. The crude mixture was filtered through a Celite plug, and concentrated to constant mass to give 635 mg of the d product as free base, used as is (98% yield).
LCMS (m/z): 236.2 (MH+), 0.41 min; 1H NMR (400 MHz, DMSO-d6) 6 ppm 7.78 (d, J=1.2 Hz, 1H), 7.74 (d, J=1.2 Hz, 1H), 6.09 (s, 2H), 3.85 (s, 4H), 2.52-2.60 (m, 1H), 1.65-1.78 (m, 6H), 1.49-1.61 (m, 2H).
Ste 3. 3-bromo14-dioxas iro 4.5 decan l razinamine To 5-(1,4-dioxaspiro[4.5]decanyl)pyrazinamine (620 mg, 2.64 mmol) was added Acetonitrile (20 mL) and then was added NBS (469 mg, 2.64 mmol) in ns over 2 min. The reaction was stirred at room temperature for 20 min and quenched with saturated sodium bicarbonate solution, and 250 mL of ethyl acetate was added. The aqueous was extracted and the organic layer was washed with saturated sodium bicarbonate, water (2x), saturated salt solution, then dried with sodium sulfate, filtered and concentrated to residue to give 650 mg of the desired product, used as is, (79% yield). LCMS (m/z): 316.1 (MH+), 0.61 min.
Ste 4. 4- 3-amino 1 4-dioxas iro 4.5 decan l razin l-N-benz l fluorobenzamide To 3-bromo(1,4-dioxaspiro[4.5]decanyl)pyrazinamine (630 mg, 2.005 mmol) was added (4-(benzylcarbamoyl)fluorophenyl)boronic acid (767 mg, 2.81 mmol), PdC|2(dppf)CH2C|2 adduct (164 mg, 0.201 mmol), DME (9 mL) and then last sodium carbonate 2M (3.01 mL, 6.02 mmol) . The reaction was microwaved at 115 °C for 12 min .To the on was added 400 mL of ethyl acetate washed with water (2x), dried with sodium sulfate, filtered and concentrated to residue. The crude was purified by silica gel chromatography using 40 gram column g with 20-100% ethyl acetate and heptane.
The desired fractions were concentrated to constant mass to give 432 mg of the d t as free base used as is, (47% yield). LCMS (m/z): 463.2 (MH+), 0.82 min; 1H NMR (400 MHz, DMSO-d6) 6 ppm 8.94 - 8.81 (m, 1H), 7.89 (s, 1H), 7.80 - 7.69 (m, 1H), 7.67 - 7.52 (m, 2H), 7.33 (d, J=4.3 Hz, 4H), 7.27 -7.18 (m, 1H), 6.09 (s, 2H), 4.49 (d, J=5.9 Hz, 2H), 3.85 (s, 4H), 2.70 - 2.61 (m, 1H), 1.84 -1.67 (m, 6H), 1.65 -1.48 (m, 2H).
Ste 5. 4- 3-amino 4-oxoc clohex l razin l-N-benz lfluorobenzamide To 4-(3-amino(1,4-dioxaspiro[4.5]decan-8—yl)pyrazinyl)-N-benzylfluorobenzamide (170 mg, 0.368 mmol) was added acetonitrile (3 mL), water (2 mL) and then HCI 3M aqueous solution (0.613 mL, 1.838 mmol). The on was stirred at room temperature for 30 min followed by LCMS. To the reaction was added 200 mL of ethyl acetate, basified with excess 1M NaOH. The aqueous layer was ted and the organic layer was washed with water (3x), filtered and concentrated to residue to give the desired product as free base. Assume quantitative yield (0.368 mmol). LCMS (m/z): 419.3 (MH+), 0.75 min.
Ste 6. 4- 3-amino 1r4r h drox c clohex l razin l-N-benz l fluorobenzamide To 4-(3-amino(4-oxocyclohexyl)pyrazinyl)-N-benzylfluorobenzamide (77 mg, 0.184 mmol) was added MeOH (3 mL), cooled to 0 °C. Then sodium borohydride (6.96 mg, 0.184 mmol) was added. The reaction was stirred for 20 min while allowing it to warm to room temperature, followed by LCMS. Crude LCMS shows about a 9:1 \cis) isomers as expected. The reaction was quenched with excess saturated sodium de and stirred at room temperature for 1 hour. Then 150 mL of ethyl acetate was added and washed with saturated sodium bicarbonate, water (2x), saturated salt solution, dried with sodium sulfate, filtered and concentrated to residue to give 73 mg of crude product. To half (36.5 mg) of the crude product was dissolved in 2.0 mL of DMSO, filtered, purified by prep HPLC, and lyophilized to give 16.3 mg of the d t 4-(3-amino((1r,4r)- 4-hydroxycyclohexyl)pyrazinyl)-N-benzylfluorobenzamide as TFA salt, in (32 % . LCMS (m/z): 421.3 (MH+), 0.69 min; 1H NMR (400 MHz, DMSO-d6) 6 ppm 8.82 (br. s., 1H), 7.83 (s, 1H), 7.64-7.73 (m, 1H), 7.45-7.61 (m, 2H), 7.25-7.31 (m, 4H), 7.14- 7.23 (m, 1H), 4.43 (d, J=5.9 Hz, 2H), 1.66-1.91 (m, 3H), 1.38-1.57 (m, 2H), 1.11-1.31 (m, 2H). e 15 S nthesis of 4- 3-amino 1s 4s h drox c clohex l razin l-N-benz l fluorobenzamide Scheme 33 F o F O NH2 N/\© NH2 H N/\©H \ 'N L—Selectride,THF \ N 0 OH To 4-(3-amino(4-oxocyclohexyl)pyrazinyl)-N-benzylfluorobenzamide (77 mg, 0.184 mmol) was added THF (3 mL), cooled to 0 °C. Then ctride 1M THF (0.460 mL, 0.460 mmol) was added. The reaction was stirred for 20 min while allowing to warm to room temperature, followed by LCMS. The crude LCMS show about greater than 9:1 (cis/trans) isomers as expected. The reaction was basified with excess 5M NaOH and stirred at room temperature for 1 hour. Then 150 mL of ethyl acetate was added and washed with water (3x), saturated salt solution, dried with sodium sulfate, filtered and WO 66188 concentrated to residue to give 75 mg of product, used as is. To half (36.5 mg) of the crude product was dissolved in 2.0 mL of DMSO, filtered, ed by prep HPLC, and lyophilized to give 23 mg of the desired product 4-(3-amino((1s,4s)—4— hydroxycyclohexyl)pyrazinyl)—N-benzylfluorobenzamide as TFA salt, in (45% yield).
LCMS (m/z): 421.3 (MH+), 0.72 min; 1H NMR (400 MHz, DMSO-d6) 8 ppm 8.87 (br. s., 1H), 7.89 (s, 1H), 7.79 - 7.70 (m, 1H), 7.67 - 7.45 (m, 2H), 7.33 (d, J=4.3 Hz, 4H), 7.28 - 7.21 (m, 1H), 6.06 (s, 2H), 4.49 (d, J=5.9 Hz, 2H), 4.30 (br. s., 1H), 3.84 (br. s., 1H), 2.01 -1.84(m,2H), 1.75 - 1.64 (m, 2H), 1.60 - 1.43 (m, 4H).
Example 16 S nthesis of 4- 3-amino 1s 4s meth lsulfon lc clohex l razin l-N-benz l fluorobenzamide Scheme 34 F o o F 0 NH2 ”AK; NH N $21 A» H/\@ mg N/ N I \ IN \ O YKCI \ —s—CI —> g —> OH OH DCM, TEA DCM, TEA o F o *LNH o F o H NH | N/\©H \ N S_gte 2 N/ IN Stegfl sodium thiomethoxide, tert—butanol mCPBA, DCM —> —> 6‘ 0 48”\ S O \ o F o F o YLNH Stegg NH2 N’ ”AK; I I \ N HClconc., \ N ACN,Water 6% overall yield o=s=o | O=?=O Ste 1. N-benz lfluoro 6- 1r4r h drox c clohex l ivalamido 2- yl)benzamide To 4-(3-amino((1r,4r)hydroxycyclohexyl)pyrazinyl)-N-benzylfluorobenzamide (0.105 g, 0.25 mmol) was added DCM (2.5 mL), TEA (0.105 mL, 0.750 mmol) and then pivaloyl chloride (0.045 g, 0.375 mmol). The reaction was stirred at room temperature for 3 h ed by LCMS. To the reaction was added 150 mL of ethyl acetate, basified with excess saturated bicarbonate. The organic layer was washed with water (3x), saturated salt solution, dried sodium sulfate, filtered and concentrated to residue to give the t as free base, used as is. Assume quantitative yield (0.25 mmol). LCMS (m/z): 505.4 (MH+), 0.82 min.
Ste 2. 1r4r 6- 4- benz lcarbamo lfluoro hen l ivalamido razin yl)cyclohexyl methanesulfonate To N-benzylfluoro(6-((1r,4r)hydroxycyclohexyl)pivalamidopyrazin yl)benzamide (125 mg, 0.248 mmol) was added DCM (2.5 mL), TEA (0.104 mL, 0.743 mmol) and cooled to 0 °C then methanesulfonyl de (42.6 mg, 0.372 mmol) was added. The reaction was allowed to warm to room ature and stirred for 2 h, followed by LCMS. Then additional TEA (0.104 mL, 0.743 mmol) and methanesulfonyl chloride (42.6 mg, 0.372 mmol) was added and stirred at room temperature for 3 h more, for total of 5 h. To the reaction was added 150 mL of ethyl acetate, basified with excess saturated bicarbonate. The organic layer was washed water (3x), saturated salt solution, dried sodium sulfate, filtered and concentrated to residue to give product as free base, used as is. Assume quantitative yield (0.248 mmol). LCMS (m/z): 583.3 (MH+), 0.90 min.
Ste 3. N-benz lfluoro 6- 1s 4s meth lthio c clohex l ivalamido 2- yl)benzamide To (1 r,4r)(6-(4-(benzylcarbamoyl)fluorophenyl)pivalamidopyrazinyl)cyclohexyl methanesulfonate (130 mg, 0.223 mmol) was added t-butanol ( 3.5 mL), sodium thiomethoxide (235 mg, 3.35 mmol). The reaction was heated at 80 °C for 1 h followed by LCMS. The reaction was let cool. Then 75 mL of ethyl e was added, washed with saturated sodium bicarbonate, water (2x), saturated salt on, dried sodium sulfate, filtered and concentrated to residue to give product as free base, used as is. Assume quantitative yield (0.223 mmol). LCMS (m/z): 535.3 (MH+), 1.06 min.
Step 4. ylfluoro(6-((1s,4s)—4-(methylsulfonyl)cyclohexyl)—3- pivalamidopyrazinyl )benzamide To N-benzylfluoro(6-((1s,4s)(methylthio)cyclohexyl)pivalamidopyrazin y|)benzamide (118 mg, 0.221 mmol) was added DCM (4 mL). Then with stirring at room temperature a solution ofmCPBA (118 mg, 0.527 mmol) in DCM (1 mL) was slowly titrated in until on was done, followed by LCMS. Then 75 mL of ethyl e was added, washed with saturated sodium bicarbonate, water (2x), saturated salt on, dried sodium sulfate, filtered and concentrated to residue. The crude was dissolved in 5 mL of DMSO, filtered and purified by prep HPLC. The desired fractions were combined.
The product as a 100 mL solution in itrile/water with 0.1% TFA, was used as is in next step. Assume quantitative yield (0.221 mmol). LCMS (m/z): 567.4 (MH+), 0.85 min.
Ste 5. 4- 3-amino 1s 4s meth lsulfon lc clohex l 2- l-N-benz l fluorobenzamide To N-benzylfluoro(6-((1s,4s)(methylsulfonyl)cyclohexyl)—3-pivalamidopyrazin y|)benzamide (120 mg, 0.212 mmol) in a solution of water (60 mL) and Acetonitrile (40 mL) with 0.1% TFA was added HCI conc. (2 mL, 65.8 mmol). The reaction was stirred at 60 °C for 12 h, followed by LCMS. The crude was |yophi|ized to residue. The residue was dissolved in DMSO, purified by prep HPLC, and |yophi|ized to give 10.2 mg of the desired product 4-(3-amino((1s,4s)(methy|su|fony|)cyc|ohexy|)pyraziny|)-N- benzyIfluorobenzamide as TFA salt, in 6% overall yield. LCMS (m/z): 483.2 (MH+), 0.72 min; 1H NMR (CD3OD) 8 ppm 7.80 (s, 1H), 7.76 (t, J=7.6 Hz, 1H), 7.63 (dd, J=8.2, 1.6 Hz, 1H), 7.55 (dd, J=11.7, 1.2 Hz, 1H), 7.22-7.34 (m, 4H), 7.10-7.20 (m, 1H), 4.52 (s, 2H), 3.12 (dt, J=8.9, 4.4 Hz, 1H), 2.96 (t, J=4.9 Hz, 1H), 2.81 (s, 3H), 2.16-2.30 (m, 2H), 1.99-2.13 (m, 2H), .96 (m, 2H), 1.70-1.85 (m, 2H).
Example 17 S nthesis of 4- 3-amino 1r4r meth lsulfon lc clohex l razin l-N-benz l fluorobenzamide Scheme 35 F 0 F o NH2 N/\©H an/ 0|| _w| ||0 Following Scheme 35, using 4-(3-amino((1s,4s)hydroxycyclohexyl)pyrazinyl)—N- benzylfluorobenzamide (Example 15), 4.5 mg of the desired product 4-(3-amino—6- ((1r,4r)(methylsulfonyl)cyclohexyl)pyrazinyl)-N-benzylfluorobenzamide was obtained as TFA salt in 3% overall yield. LCMS (m/z): 483.2 (MH+), 0.71 min; 1H NMR ) 6 ppm .89 (m, 2H), 7.68 (dd, J=8.0, 1.4 Hz, 1H), 7.60 (dd, J=11.7, 1.6 Hz, 1H), 7.31-7.42 (m, 4H), 7.19-7.30 (m, 1H), 4.61 (s, 2H), 3.05-3.15 (m, 1H), 2.92 (s, 3H), 2.67-2.78 (m, 1H), 2.34 (br. s., 2H), 2.11 (br. s., 2H), 1.60-1.82 (m, 4H).
Example 18 S nthesis of N- S amino 3-chloro hen | eth | 3-amino 1r 4S methox c clohex | razin lfluorobenzamide Scheme 36 NH2 NH2 N(Boc)2 N(BOC)2 Stegfl N \ m1 NJ§ Steg; N)\ Stegg N)\ | l N | | / N / N B0020 NaBH4 f A920, Mel —> 3 —> MeCN/water DMAP EtOH Q O\ (O 0 OH N(Boc)2 ””2 NH2 NHB0C Stag; N \ “1&0 Stegfi NJ\(Br O _ St 91 NH2 N Step NH2 N H g H N \ N \ EDC,HOAt _, k?” TFA I CI _. 9N Cl DMF, DIEA ? : O\ 0\ Ste 1. 4- 5-amino razin lc clohexanone To -dioxaspiro[4.5]decanyl)pyrazinamine (8.68 g, 45.4 mmol) was added acetonitrile (368 mL), water (245 mL) and 3M HCI (76 mL). The reaction was stirred at room temperature for 30 min. The reaction was basified with excess 1M NaOH, and then diluted with of ethyl acetate. The organic layer was separated. The aqueous layer was ted well with EtOAc/2-methyl THF (1:1) three times. Organic layers were combined and dried over Na2804, filtered and concentrated to give 6.91 g of product as free base.
LCMS (m/z): 192.12 (MH+), 0.30 min.
Ste 2. lmidodicarbonic acid 2- 5- 4-oxoc clohex l razin l- 1 3-bis 1 1- dimethylethyl) ester To 4-(5-aminopyrazinyl)cyclohexanone (3.0 g, 15.69 mmol) in DCM ( 105 mL) was added di-tert-butyl dicarbonate (10.27 g, 47.1 mmol) and N,N-dimethylpyridinamine (0.192 g, 1.569 mmol). The mixture was stirred at room temperature ght. The reaction mixture was diluted with DCM and then washed with sat sodium bicarbonate solution. The separated organic layer was dried over sodium sulfate and trated.
Purified on the flash chromatography and eluting with 0 to 50% ethyl e in heptane to provide 2.2 g of desired product. LCMS (m/z): 392.7 (MH+), 0.91 min.
Ste 3. lmidodicarbonic acid 2- 5- 4-h drox c clohex l razin l- 1 3-bis 1 1- dimethylethyl) ester lmidodicarbonic acid, 2-(5-(4-oxocyclohexyl)pyrazinyl)-, s(1,1-dimethylethyl) ester (350 mg, 0.894 mmol) was dissolved in EtOH (10 mL), then NaBH4 (50.7 mg, 1.341 mmol) was added. The reaction mixture was d at room temperature for 30 min. The trans and cis ratio is around 85:15 from TLC. Saturated NaHC03 solution was added to quench the reaction. The reaction mixture was then extracted by EtOAc/2-methyl THF (1:1). The organic layers were combined and dried over anhydrous NazSO4, and concentrated to yield the crude product, which was taken to the next step without further cation. LCMS (m/z): 394.3 (MH+), 0.89 min.
Ste 4. lmidodicarbonic acid 2- 5- 4-methox c clohex l razin l- 1 3-bis 1 1- dimethylethyl) ester A mixture of imidodicarbonic acid, 2-(5-(4-hydroxycyclohexyl)pyrazinyl)-, 1,3-bis(1,1- dimethylethyl) ester (350 mg, 0.890 mmol), silver oxide (1.649 g, 7.12 mmol), acetonitrile (2.22 mL) and methyl iodide (1.112 mL, 17.79 mmol) was stirred overnight. EtOAc was added, and the solid was filtered out. Solvent was evaporated and the residue was purified via flash chromatography g with 0-100% EtOAc/heptane to provide 168 mg of desired trans compound in 46.3% yield. LCMS (m/z): 408.3 (MH+), 1.10 min.
Ste 5. 5- 1r4r hox c clohex l razinamine lmidodicarbonic acid, 2-( 5-(4-methoxycyclohexyl)pyrazinyl)-, 1,3-bis(1,1-dimethylethyl) ester (168 mg, 0.412 mmol) in DCM (4.123 mL) was added HCI (4M in e) (4.123 mL, 16.49 mmol), the reaction mixture was stirred at room temperature overnight.
Concentrated, and EtOAc was added. Washed with sat NaHC03, and water. The aqueous layer was extracted with EtOAc and 2-methyl THF (1:1) three times. Dried over NazSO4, filtered and trated to afford the desired trans product. LCMS (m/z): 208 (MH+), 0.42 min.
Ste 6. 3-bromo 1r4r methox c clohex l razinamine To a solution of ,4r)methoxycyclohexyl)pyrazinamine (92 mg, 0.444 mmol) in itrile (8.877 mL) was added NBS (83 mg, 0.466 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 15 min. After quenched with sat Na2803 and NaHC03, extracted with EtOAc and 2-methyl THF (1:1) three times. The organic layers were combined dried over NaZSO4, filtered and concentrated to afford 127 mg of desired trans compound in quantitative yield. LCMS (m/z): 288 (MW), 0.72 min.
Ste 7. tert-but | S 4- 3-amino 1r4S methox c clohex | razin l benzamido)—2-(3-chlorophenyl )ethyl )carbamate To 3-bromo((1r,4r)methoxycyclohexyl)pyrazinamine (35 mg, 0.122 mmol) in 2 mL MW vial was added (S)-(4-((2-((tert-butoxycarbonyl)amino)(3- phenyl)ethyl)carbamoyl)fluorophenyl)boronic acid (64.1 mg, 0.147 mmol), PdC|2(dppf) (8.95 mg, 0.012 mmol), DME (917 uL) and 2M Na2C03 solution (306 uL) .
The on mixture was heated at microwave synthesizer (12 min, 120 °C). The reaction mixture was diluted with EtOAc and washed with water three times, dried over Na2804, filtered and concentrated. The crude product was purified by flash chromatography to provide 28 mg of desired trans product in 38.3% yield.
Ste 8. N- S no 3-chloro hen | eth | 3-amino—6- 1r4S methoxycyclohexyl )pyrazinyl )—2-fluorobenzamide A mixture of tert-butyl ((S)—2-(4-(3-amino((1r,4S)methoxycyclohexyl)pyraziny|) fluorobenzamido)—2-(3-chlorophenyl)ethyl)carbamate (28 mg, 0.047 mmol), TFA (0.4 mL, 0.047 mmol) and CH2C|2 (1 mL) was stirred at room temperature for 30 min. Solvent was evaporated and the residue was dissolved in DMSO, purified with auto-prep to provide 15 mg of desired trans product as a TFA salt in 51.3% yield. LCMS (m/z): 498.2 (MH+), 0.76 min; 1H NMR (400 MHz, CD3OD) 6 ppm 7.94 - 7.85 (m, 2 H) 7.70 (dd, J=8.22, 1.56 Hz, 1 H) 7.62 (dd, J=11.93, 1.37 Hz, 1 H) 7.55 (s, 1 H) 7.49 - 7.34 (m, 3 H) 5.49 (dd, J=9.00, .87 Hz, 1 H) 3.53 - 3.41 (m, 2 H) 3.38 (s, 3 H) 2.70- 2.59 (m, 2 H) 2.20 (d, J=9.78 Hz, 2 H) 1.98 (d, J=12.91 Hz, 2 H) 1.65 (qd, J=13.04, 3.13 Hz, 2 H) 1.41 - 1.27 (m, 2 H).
S nthesis of 1s 4s obromo razin | meth lc clohexanol and 1r 4r - 4- 5-aminobromo razin lmeth lc clohexanol Scheme 37 NHBoc NHN NHN g Q:12 lb) _f W | Arm ZW0eN Z / 9(D IA ESQ/S ' I," O I ~‘ 0H s OH / N MeLi —> + + + NHBoc NH2 NH2 NJ\ Stegg Stegfi Br N \ N \ 0 I I I / N / N / N —> —> H6 ; HO: HO: Ste 1. tert-but l 5- 1s 4s h drox meth lc clohex l razin lcarbamate and tert-butyl (5-((1r,4r)—4-hydroxymethylcyclohexyl)pyrazinyl)carbamate N,N-di-Boc—4-(5-aminopyrazinyl)cyclohexanone (657 mg, 1.678 mmol) in THF (11.8 mL) was treated with methyllithium (1.469 mL, 2.350 mmol) at -78 °C. The reaction was stirred at -78 °C for 2 h. After methyllithium (1.469 mL, 2.350 mmol) was added more, the reaction mixture was stirred at -78 °C for another 2 h. This process repeated once more.
Then, the reaction e was ed with methanol and water. The resulting mixture was concentrated and the residue was suspended in ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous Na2804, filtered off, and concentrated. The crude diastereomeric mixture was purified by chromatography (0-100% ethyl acetate in ). For tert-butyl s,4s)hydroxymethylcyclohexyl)pyrazin- 2-yl)carbamate (26.7% yield). LCMS (m/z): 308.7 (MH+), 0.79 min. For tert-butyl (5- ((1r,4r)hydroxymethylcyclohexyl)pyrazinyl)carbamate (23.3% yield), LCMS (m/z): 308.7 (MH+), 0.75 min.
Ste 2. 1s 4s 5-amino razin lmeth lc clohexanol Tert-butyl (5-((1s,4s)hydroxymethylcyclohexyl)pyrazinyl)carbamate (138 mg, 0.449 mmol) in DCM was added HCI (4 M in dioxane) (4489 uL, 17.96 mmol). The on mixture was stirred at room temperature overnight. Diluted with EtOAc and washed with sat NaHC03. No separation, and dried with Na2804. Filtered and washed with EtOAc. Concentrated to provide 93 mg of desired product in quantitative yield. LCMS (m/z): 208 NH), 0.41 min.
Ste 3. 1s 4s 5-aminobromo razin lmeth lc clohexanol To a solution of (1s,4s)(5-aminopyrazinyl)—1-methylcyclohexanol (93 mg, 0.449 mmol) in acetonitrile (8974 uL) was added NBS (80 mg, 0.449 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 15 min. After ed with NaHC03. extracted with EtOAc three times. The organic layers were combined and washed with water, and brine. Dried over NaZSO4, filtered and concentrated to afford 100 mg of (1s,4s)—4-(5- 6-bromopyraziny|)methylcyclohexano| in 78 % yield. LCMS (m/z): 288 (MW), 0.60 min.
Ste 4. 1r 4r 5-amino razin l meth lc clohexanol and Ste 5. 1r 4r 5- aminobromo razin th lc clohexanol Following Steps 2 and 3, using )(5-aminopyrazinyl)—1-methylcyclohexanol, (1r,4r)(5-aminobromopyraziny|)methylcyclohexanol was obtained. LCMS (m/z): 288 NH), 0.57 min.
Examples 19 and 20 S nthesis of meth |3- 5-amino 4- benz lcarbamo lfluoro hen l razin | ro anoate and 4- 3-amino 3- meth lamino oxo ro | razin I-N-benz | fluorobenzamide Scheme 38 m1 NH2 mg NH2 m; NH2 NJW NJWI NJW o PdCI2(PPh3)2,Cu| NBS \ N pd/C \ N IN + %0/ —~ \ ¢ chog, THF l l MeOH 37% 81% \ \O O O F O Step4_ NA/Br F O NHz | f)C|2 HA© N N \ + mg —» I ”0‘3 / N DME, NaZCO3 o o \o o Stepfi l LIOH F o NHZ $9§ NHZ Stegz NHZ NArBr ArBr F O H N N/\© ' MeNH30| | Pd(dppf)C|2 NI \ \ N \ N N —> N —. / + H0 H TBTU, DIEA ‘ll3 DME, Na2003 74% 24% o N o H H Ste 1. meth l3- 5-amino razin l ro iolate To a 5 mL of microwave vial was added 5-iodopyrazinamine (100 mg, 0.452 mmol), methyl propiolate (161 uL, 1.810 mmol), potassium carbonate (125 mg, 0.905 mmol), copper (I) iodide (3.45 mg, 0.018 mmol), and THF (1508 uL). The on mixture was heated at 65 0C for 2 h. The reaction mixture was diluted with water and extracted with EtOAc. The organic layer was dried over anhydrous sodium sulfate, filtered, and evaporated in vacuo. The crude product was ed by flash chromatography OAc in DCM) yielding methyl 3-(5-aminopyrazinyl)propiolate (38%). LCMS (m/z): 178.4 (MH+), 0.48 min.
Ste 2. meth l3- 5-amino razin l ro anoate To a solution of methyl 3-(5-aminopyrazinyl)propiolate (30 mg, 0.169 mmol) in MeOH (847 uL) was added Pd-C (36.0 mg, 0.034 mmol). The solution was degassed by N2 stream for 15 min. After flushed with hydrogen gas and equipped with a hydrogen balloon, the reaction mixture was stirred for 16 h. The reaction mixture was ed through Celite. The volatile materials were removed in vacuo. The crude methyl 3-(5- aminopyrazinyl)propanoate was obtained (81%) and used for the next step without further purification. LCMS (m/z): 182.1 (MH+), 0.31 min.
Ste 3. meth l3- 5-aminobromo razin l ro anoate To a solution of methyl minopyrazinyl)propanoate (25 mg, 0.138 mmol) in CH3CN (690 uL) was added NBS (24.56 mg, 0.138 mmol). The reaction mixture was d for 1 h at room temperature. After quenched with Na28203 solution, the reaction mixture was d with NaHC03 solution for 20 min and extracted with EtOAc. The organic layer was washed with water and brine, dried over Na2SO4, filtered and concentrated in vacuo. The crude methyl 3-(5-aminobromopyrazinyl)propanoate was obtained (28%). LCMS (m/z): 260.2/262.2 (MH+), 0.54 min.
Ste 4. meth l3- 5-amino 4- benz lcarbamo lfluoro hen l razin l ro anoate To a solution of methyl 3-(5-aminobromopyrazinyl)propanoate (10 mg, 0.038 mmol), 4-(benzylcarbamoyl)f|uoropheny|boronic acid (13.65 mg, 0.050 mmol) and PdCI2(dppf) (2.81 mg, 3.84 umol) in DME (256 uL) was added 2M Na2C03 (3.87 mL). The reaction mixture was heated at microwave synthesizer (120 °C, 10 min). LCMS (m/z): 409.2 (MH+ for ester), 0.75 min; 395.2 (MH+ for very small amount of acid, but mixed with boronic ester), 0.66 min. To the on e, anhydrous sodium sulfate was added, filtered, and concentrated. The crude t was ed by prep HPLC, lyophilized yielding methyl 3-(5-amino(4-(benzylcarbamoyl)f|uoropheny|)pyraziny|)propanoate as a TFA salt (12%). LCMS (m/z): 409.1 (MH+), 0.73 min; 1H NMR (400MHz, MeOH-d4) 8 ppm 7.89 - 7.76 (m, 2 H), 7.69 - 7.61 (m, 1 H), 7.60 - 7.51 (m, 1 H), 7.42 - 7.28 (m, 5 H), 7.28 - 7.20 (m, 1 H), 4.64 - 4.55 (m, 2 H), 3.62 (s, 3 H), 3.06 - 2.93 (m, 2 H), 2.79 - 2.67 (m, 2 Ste 5. 3- 5-aminobromo razin | ro anoic acid To a solution of methyl 3-(5-aminobromopyrazinyl)propanoate (55 mg, 0.211 mmol) in MeOH (961 uL) and H20 (96 uL) was added potassium carbonate (170 mg, 1.230 mmol). The reaction mixture was stirred for overnight. To the reaction mixture, anhydrous NazSO4 was added. After diluted with EtOAc (3 mL) and filtered, the volatile materials were removed in vacuo. The crude 3-(5-aminobromopyrazinyl)propanoic acid was obtained and used for the next step without further purification. LCMS (m/z): 246.0/248.0 (MH+, major), 0.26 min.
Ste 6. 3- obromo razin l-N-meth l ro e To a solution of 3-(5-aminobromopyrazinyl)propanoic acid (32 mg, 0.130 mmol) in DMF (1300 uL) was added TBTU (62.6 mg, 0.195 mmol), DIEA (68.1 uL, 0.390 mmol), and methanamine hydrochloride (9.66 mg, 0.143 mmol). The reaction mixture was stirred for 3 h. The reaction mixture was extracted with EtOAc. The organic layer was washed with water and brine, dried over NaZSO4, filtered and concentrated in vacuo. The crude 3- (5-aminobromopyrazinyl)-N-methylpropanamide (74%) was obtained and was used for the next step without further purification. LCMS (m/z): 259/261 (MH+), 0.35 min.
Ste 7. 4- 3-amino 3- meth lamino oxo ro l razin l-N-benz l fluorobenzamide Following Step 4 in Scheme 38, using 3-(5-aminobromopyrazinyl)-N- methylpropanamide, 4-(3-amino(3-(methylamino)oxopropyl)pyrazinyl)-N-benzyl- 2-fluorobenzamide was obtained (24%). LCMS (m/z): 408.1 (MH+), 0.51 min; 1H NMR (400MHz, MeOH-d4) 6 ppm 7.89 - 7.78 (m, 2 H), 7.68 - 7.51 (m, 2 H), 7.41 - 7.29 (m, 4 H), 7.26 (d, J = 7.1 Hz, 1 H), 4.60 (s, 2 H), 2.98 (t, J = 7.3 Hz, 2 H), 2.66 (s, 3 H), 2.57 (t, J = 7.3 Hz, 2 H).
S s of 2- 5-aminobromo razin l ethanol Scheme 39 NH2 Step 1 NH2 Step 2 NH2 NH2 Steg g CsF, f)Cl2 N \ N \ o 03 I NBS NJYBrI KfI + I \B / N I _> / N N / N 0’ A NaBH4 I OH OH Ste 1.5-alll razinamine 2014/062913 To a solution of 5-bromopyrazinamine (1.3 g, 7.47 mmol) in was added 2-allyl-,4,5,5- tetramethyl-1,3,2-dioxaborolane (1.883 g, 11.21 mmol), PdC|2(dppf)CH2C|2 adduct (0.610 g, 0.747 mmol) and CsF (3.40 g, 22.41 mmol), the on mixture was purge though Nitrogen. The reaction mixture was then heated at 100 0C in oil bath for 3h.The on mixture was filtered through Celite, washed by EtOAc, the filtrated was ioned between EtOAc and water. The organic was dried over anhydrous sodium sulfate and concentrated in vacuo, The crude material was purified by flash chromatography column to yield 5-allylpyrazinamine in 37% yield. LCMS (m/z): 136.0 (MH+), 0.30 min.
Ste 2. 2- o razin l ethanol -allylpyrazinamine (180 mg, 1.332 mmol) in DCM (26.6 mL) was cooled down to -78 0C, then Ozone was bubbled through for 10 min until the solution turned to blue color.
Then Nitrogen was purged through for 5 min. NaBH4 (151 mg, 4.00 mmol) in ethanol (10 mL) was added slowly, The reaction e was allowed to return to room temperature.
After 1h, Sat. NH4C| was added slowly, the reaction mixture was then extracted by CHCI3/IPA(7:3) (3 times), the organic was dried and concentrated to yield the crude product. The crude product is used in next step reaction without purification. LCMS (m/z): 140.0 (MH+), 0.21 min.
Ste 3. 2- 5-aminobromo razin l ethanol To a solution of 2-(5-aminopyrazinyl)ethanol (30 mg, 0.216 mmol) in CH3CN (719 uL) was added NBS (38.4 mg, 0.216 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 30 min. The reaction mixture was quenched by sat. NaHC03, then extracted by EtOAc, The combined organic layer was washed with water and brine, dried over anhydrous sodium sulfate. Filtered and concentrated in vacuo yielding crude mino- 6-bromopyrazinyl)ethanol which was used in next step reaction without purification.
LCMS (m/z): 218.0/220.0 (MH+), 0.33 min.
S nthesis of 3-bromo 2-methox eth l razinamine Scheme 40 m1 m2 $2 § NH2 NBocz NBocZ NBocZ N)\ BOCZO \ N \ ozone A920 I ' I ng / N / / N DMAP NaBH4 Mel I 40% 95% N 80% I OH 0\ Step 5 NHZ N \ NJ\/Br Ste 1. N N-di-tert-but l 5-all l razin lcarbamate To a on of 5-allylpyrazinamine (1.2 g, 8.88 mmol) in CH2C|2 (29.6 mL) was added Boc20 (4.07 g, 18.64 mmol) and DMAP (1.627 g, 13.32 mmol) at room temperature. The reaction mixture was stirred at room temperature for overnight. After quenched with sat NaHC03, the reaction mixture was extracted with CH2C|2 3 times. The combined organic layer was washed with water and brine, dried over anhydrous sodium sulfate. Filtered and concentrated in vacuo. The desire was ed as a white solid (1.1 g, 37% yield) by flash column chromatography. Rf (TLC) = 0.3 (20% EtOAc in hexanes). LCMS (m/z): 336.2 (MH+), 1.04 min.
Ste 2. N N-di-tert-but l 5- 2-h drox eth l razin lcarbamate A solution of -tert—butyl (5-allylpyrazinyl)carbamate (1.1 g, 3.28 mmol) in DCM (32.8 mL) was cooled down to -78 OC, ozone was bubbled through until blue color appears, then Nitrogen was purged through for 5 min. NaBH4 (0.74 g, 19.6 mmol) in methanol (20 mL) was added slowly, The reaction mixture was allowed to return to room temperature. After 2 h, saturated NH4CI solution was added, the reaction mixture was partitioned n EtOAc and water. The organic was washed with NaHC03,water and brine, dried over anhydrous , filtered and concentrated. The crude product was used in next step reaction without purification. LCMS (m/z): 340.3 (MH+), 0.77 min.
Ste 3. N N-di-tert-but l 5- 2-methox eth l razin lcarbamate To a solution of -tert-butyl (5-(2-hydroxyethyl)pyrazinyl)carbamate (240 mg, 0.707 mmol) in Mel (7.7 mL) was added silver oxide (983 mg, 4.24 mmol). The reaction mixture was stirred at room temperature for overnight. The on mixture was filtered through Celite and washed with EtOAc and methanol, the organic was washed by sat.
NaHC03, water and brine, dried and concentrated. The crude material was used in next step reaction without purification. LCMS (m/z): 354.2 (MH+), 0.92 min.
Ste 4. 5- 2-methox eth l razinamine N,N-Di-tert—butyl (5-(2-methoxyethyl)pyrazinyl)carbamate (200 mg, 0.566 mmol) in DCM (1.9 mL) was added TFA (872 uL, 11.32 mmol) the on mixture was stirred at room ature for 1h, the reaction e was added 5 mL toluene and concentrated to dryness. The crude material was used in next step reaction without purification. LCMS (m/z): 154.1 (MH+), 0.27 min.
Ste 5. 3-bromo 2-methox eth | razin-2—amine To a solution of 5-(2-methoxyethyl)pyrazinamine (80 mg, 0.522 mmol) in DCM (1.7 mL) was added NBS (93 mg, 0.522 mmol) at room temperature. The reaction e was stirred at room temperature for 1 h. After quenched with NaHC03, the reaction mixture was extracted with DCM 3 times. The combined c layer was washed with water and brine, dried over anhydrous sodium sulfate. The crude material was used in next step reaction without purification. LCMS (m/z): 232.1/234.1 (MH+), 0.49 min.
Example 21 S nthesis of 4- 3-amino 2- meth lsulfon l eth l razin l -N-benz l fluorobenzamide Scheme 41 Step 1 Step_2 Step_3 Step 1 NB002 NBoc2 NHBoc NHBoc NI \ MsCl NI \ NaSMe NI \ mCPBA “RN TFA py, DCM DCM 98% 84% 98% OH OMS o=,,3\ Step 5‘ Ste NH2 NH2 N| \ NBS N]JV Pd(dppf)C|2 CHZCIZ Ol\l/\© / N —. / N —> MeCN “QB DME/2 M Na2003 71% (2 SteP5 ) ° O=§\ o=,5\ 34A; KRF O O 0’" \ Ste 1. 2- 5- bis utox carbon l amino razin l eth Imethanesulfonate To N,N-di-tert-butyl (5-(2-hydroxyethyl)pyrazinyl)carbamate (450 mg, 1.326 mmol) in DCM (10 mL) was added ne (0.429 mL, 5.30 mmol) and cooled to 0 °C using ice bath. Then Mesyl-Cl (0.382 mL, 4.91 mmol) was added and the reaction was allowed to warm to room temperature and stirred for 16 h. To the reaction was added 150 mL of ethyl acetate and saturated sodium bicarbonate. The organic layer was extracted and washed again with saturated sodium bicarbonate, water (3x), filtered, dried with sodium sulfate and concentrated to constant mass to give 540 mg of desired product, used as is, (98% yield). LCMS (m/z): 418.3 (MH+), 0.89 min; 1H NMR (400 MHz, CDCI3) 5 ppm 8.50 (s, 1H), 8.38 (s, 1H), 4.67 (t, J=6.3 Hz, 2H), 3.28 (t, J=6.3 Hz, 2H), 2.94 (s, 3H), 1.45 (s, 18H).
Ste 2. tert-but l5- 2- meth lthio eth l razin lcarbamate To 2-(5-(bis(tert-butoxycarbonyl)amino)pyrazinyl)ethyl methanesulfonate (540 mg, 1.293 mmol) in DMF (7 mL) was added sodium thiomethoxide (408 mg, 5.82 mmol) and was stirred at 85 °C for 3 h, followed by LCMS. The on was let cool, 200 mL of ethyl e and saturated sodium bicarbonate was added. The organic layer was ted and washed water (3x), saturated salt solution, dried sodium sulfate, filtered through 2 cm silica gel plug and flushed with ethyl acetate. The solvent was concentrated off to constant mass to give 294 mg of the desired product as free base used as is, (84% yield).
LCMS (m/z): 270.4 (MH+), 0.84 min. 1H NMR (400 MHz, cocks) 6 ppm 9.19 (s, 1H), 8.08 WO 66188 (d, J=1.2 Hz, 1H), 7.20 (br. s., 1H), 2.99-3.08 (m, 2H), 2.79-2.94 (m, 2H), 2.12 (s, 3H), 1.54 (s, 9H).
Ste 3. tert-but l5- 2- meth Isulfon leth | razin mate To tert-butyl 5-(2-(methylthio)ethyl)pyrazinylcarbamate (292 mg, 1.084 mmol) in DCM (10 mL) was added 40% (3.5 mL) of a freshly made solution of mCPBA (972 mg, 4.34 mmol) in DCM (8.7 mL) with stirring at room ature, followed by LCMS. After 30 min another 15% (1.3 mL of the above mCPBA solution) was added and stirred for 30 min, followed by LCMS. Then another 5% (0.044 mL of the above mCPBA solution) was added and stirred for 30 min more. The reaction was followed by LCMS. To the reaction was added 200 mL of ethyl acetate and excess saturated sodium bicarbonate. The organic layer was extracted and washed again with saturate sodium onate, water (3x), filtered and concentrated to constant mass to give 320 mg of the desired product used as is, (98% yield). LCMS (m/z): 302.1 (MH+), 0.62 min; 1H NMR (400 MHz, CDCI3) 6 ppm 9.20 (s, 1H), 8.14 (s, 1H), 7.23 (br. s., 1H), 3.47-3.57 (m, 2H), 3.26-3.36 (m, 2H), 2.86-2.93 (m, 3H), 1.55 (s, 9H).
Ste 4. 5- 2- meth Isulfon leth | razinamine To tert-butyl 5-(2-(methylsulfonyl)ethyl)pyrazinylcarbamate (320 mg, 1.062 mmol) in DCM (6 mL) was added TFA (2.5 mL, 32.4 mmol) and stirred at room temperature for 1 hour. The solvent was trated off to constant mass. The product was free based by using solid supported carbonate 2.5 grams at 0.8 mmol/gram with 6 mL of acetonitrile and stirred for 5 min. The solid support was filtered off and flush with acetonitrile. The product was concentrated to constant mass to give the desired product used as is, assume quantitative yield (1.062 mmol). LCMS (m/z): 202.1 (MH+), 0.20 min.
Ste 5. o 2- meth Isulfon leth | razinamine To 5-(2-(methylsu|fony|)ethy|)pyrazinamine (213 mg, 1.06 mmol) in acetonitrile (6 mL) was added NBS (179 mg, 1.007 mmol) and was stirred at room temperature for 1 h. The t was concentrated off to residue. To the crude was added ethyl acetate, washed with saturated sodium carbonate, water (2x), dried sodium sulfate, filtered and concentrated to constant mass to give 210 mg of the desired product as free base used as is, (71% yield). LCMS (m/z): 280.0/282.0 (MH+), 0.38 min.
Ste 6. 4- 3-amino 2- meth lsulfon leth l razin l-N-benz lfluorobenzamide To 3-bromo(2-(methylsulfonyl)ethy|)pyrazinamine (126 mg, 0.405 mmol) was added N-benzylfluoro(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)benzamide (144 mg, 0.405 mmol), PdC|2(dppf)-CH2C|2adduct (33.1 mg, 0.040 mmol), DME (1.5 mL) and then sodium ate 2 M aqueous solution (0.607 mL, 1.214 mmol). The reaction was microwave at 125 °C for 12 min followed by LCMS. To the reaction was added 5 mL of DME and 5mL of MeOH, filtered and concentrated to residue. The crude was dissolved in 2.5 mL of DMSO, filtered, purified by prep HPLC and lyophilized to TFA salt. To the TFA salt was added 200 mL of ethyl acetate, washed with saturated sodium carbonate (3x), water (3x), dried sodium sulfate, filtered and concentrated to constant mass to give 59 mg of the desired product 4-(3-amino(2-(methylsulfonyl)ethyl)pyrazinyl)-N-benzyl benzamide as free base in 34% yield. LCMS (m/z): 429.2 (MH+), 0.65 min; 1H NMR (400 MHz, CD3OD) 6 ppm 7.95 (s, 1H), 7.83 (t, J=7.6 Hz, 1H), 7.67 (dd, J=8.0, 1.4 Hz, 1H), 7.59 (dd, J=11.7, 1.2 Hz, 1H), 7.29-7.42 (m, 4H), 7.20-7.28 (m, 1H), 4.59 (s, 2H), 3.48-3.57 (m, 2H), 3.18 (dd, J=9.0, 6.7 Hz, 2H), 2.96 (s, 3H). es 22, 23, and 24 fluorobenzamide WO 66188 Scheme 42 Steal _p_>Ste 2 NH2 NH2 Br\/K ,0 Mg 0 NJ\ Pd(dppf)C|2 NI \ + H8 —> [évg + | # / N ‘o / N THF 0 C5,: m§ N8002 8&2 é NB002 $2 § mg 80020 NJ\ 03 NJ\ TFA I NI NBS —> / N —> —> / N DMAP NaBH4 (+/-) (+l') OH OH NH2 F o NJ\( F o Stegz NH2 N | N Pd(dppf)C|2 /N H + HO\B H —> N \ (5H DME,NaZCOS (+/-) OH KENK —QSte § NH2 N NH2 N H H chiral separation N \ N \ —’ | + | OH OH Ste 1. 4 4 5 5-tetrameth I 2—meth |a|| | -1 3 2—dioxaborolane To a suspension of magnesium turning (1.139 g, 46.9 mmol) in THF (65.1 mL) was added 4,4,5,5-tetramethy|-1,3,2—dioxaborolane (5.67 mL, 39.1 mmol) at room ature under nitrogen. 3-bromomethylpropene (3.97 mL, 39.1 mmol) was added slowly, after 30 min, more 3-bromomethylpropene (3.97 mL, 39.1 mmol) was added, The reaction mixture was stirred at room temperature for 1 h. heptanes was added, followed by 1N HCI. The reaction mixture was then extracted by heptanes. The organic was washed by water and brine, dried and concentrated to yield 4,4,5,5-tetramethyl(2-methylallyl)- 1,3,2-dioxaborolane. The product was used in the next step without purification, 1H NMR (400MHz ,CDCI3) 6 ppm 4.67 (d, J = 6.7 Hz, 2 H), 1.77 (s, 3 H), 1.34 - 1.20 (m, 12 H).
Ste 2. 5- 2-meth |a|| | razinamine To a solution of 5-bromopyrazinamine (1 g, 5.75 mmol) in was added 4,4,5,5- tetramethyl(2-methylallyl)-1,3,2—dioxaborolane (1.360 g, 7.47 mmol), PdC|2(dppf)-DCM adduct (0.469 g, 0.575 mmol), CsF (2.62 g, 17.24 mmol), purge though nitrogen. The reaction e was stirred at 100 0C in oil bath for 3h. The reaction mixture was partitioned between EtOAc and water. The organic was washed with brine, dried and concentrated. The residue was dissolved in 1N HCI (10 mL) The aqueous layer was back ted with EtOAc, The aqueous was then neutralized to pH = 8, then extracted by EtOAc 3 times. The organic was then dried and concentrated. The crude product was used in next step reaction. LCMS (m/z): 150.5 (MH+), 0.28 min.
Ste 3. N N-di-tert-but | 5- 2-meth |a|| | razin lcarbamate To a solution of 5-(2-methylallyl)pyrazinamine (235 mg, 1.575 mmol) in DCM (5.2 mL), Boc20 (731 uL, 3.15 mmol) was added, ed by DMAP (385 mg, 3.15 mmol). The reaction was stirred at room temperature for overnight. To the reaction was added 30 mL of DCM and washed with saturated sodium bicarbonate (2x) water (1x), dried sodium sulfate, ed and concentrated to residue. The crude was purified by silica gel chromatography eluting with 0-30% ethyl acetate and heptane to yield 250 mg of product.
LCMS (m/z): 350.1 (MH+), 1.12 min; 1H NMR (400MHz ,CDCI3) 8 ppm 8.45 (d, J = 1.2 Hz, 1 H), 8.41 - 8.33 (m, 1 H), 4.92 (s, 1 H), 4.75 (s, 1 H), 3.57 (s, 2 H), 1.73 (s, 3 H), 1.43 (s, 18 H).
Ste 4. +/- -N ert—but | 5- 2-h drox ro | razin lcarbamate N,N-Di-tert—butyl methylal|y|)pyraziny|)carbamate (120 mg, 0.343 mmol) in methanol (6.8 mL) was cooled down to - 78 °C ,the ozone was d through for 6 min.
Then en was purged through for 5 min. NaBH4 (39.0 mg, 1.030 mmol) in methanol (5 mL) was added slowly. The reaction mixture was allowed to return to room temperature.
After 1h, Sat. NH4C| was added slowly. The reaction mixture was partitioned between EtOAc and water. The c was washed with saturated NaHC03, water and brine, dried and concentrated. The crude product was used in next step reaction t purification. LCMS (m/z): 354.1 (MH+), 0.84 min.
Ste 5. +/- 5-amino razin l ro anol (+/-)-N,N-Di-tert-butyl (5-(2-hydroxypropyl)pyrazinyl)carbamate (110 mg, 0.311 mmol) in DCM (3.11 mL) was added TFA (1 mL, 12.98 mmol), the reaction mixture was stirred at room temperature for 30 min, the reaction mixture was coevaporated with toluene. The crude product was used in next step reaction without purification. LCMS (m/z): 154.1 (MH+), 0.24 min.
Ste 6. +/- 5-aminobromo razin l ro anol To a solution of (+/-)(5-aminopyrazinyl)propanol (47 mg, 0.307 mmol) in DCM (3.0 mL) was added NBS (49.1 mg, 0.276 mmol) at 0 °C. The reaction e was stirred at 0 °C for 10 min. After quenched with sat NaHC03, the reaction mixture was extracted with EtOAc 3 times. The combined organic layer was washed with water and brine, dried over ous sodium sulfate. Filtered and concentrated in vacuo. The crude product was used in next step reaction without purification. LCMS (m/z): 234. 0 (MH+), 0.40 min.
Ste 7. +/- 3-amino 2-h drox ro l razin l-N-benz lfluorobenzamide To a solution of 1-(5-aminobromopyrazinyl)propanol (30 mg, 0.129 mmol) in DME (970 uL) was added 4-(benzylcarbamoyl)fluorophenylboronic acid (31.8 mg, 0.116 mmol), dppf)CH2C|2 adduct (10.56 mg, 0.013 mmol), 2M Na2C03 (323 uL).
The reaction mixture was stirred at 120 °C for 10 min in microwave. The reaction mixture was partitioned between EtOAc and water. the organic was dried and concentrated. the crude t was purified by Prep HPLC. The pure fraction was combined and desalt to yield (+/-)(3-amino(2-hydroxypropyl)pyrazinyl)-N-benzylfluorobenzamide.
LCMS (m/z): 381.2 (MH+), 0.67 min; 1H NMR (400MHz, CDSOD) 5 ppm 7.95 - 7.81 (m, 2 H), 7.66 (dd, J = 1.6, 8.2 Hz, 1 H), 7.58 (dd, J = 1.6, 11.7 Hz, 1 H), 7.43 - 7.31 (m, 4 H), 7.31- 7.19 (m, 1 H), 4.62 (s, 2 H), 4.16 - 4.04 (m, 1 H), 2.79 (d, J = 6.3 Hz, 2 H), 1.23 (d, J = 6.3 Hz, 3 H).
The racemic (+/-)(3-amino(2-hydroxypropyl)pyrazinyl)-N-benzyl fluorobenzamide was resolved by chiral SFC (ChiralPak 5mic AD column, 4.6x100 (mm), methanol+0.1%DEA=40%, 5 mL/min). The polar enantiomer, (R)—4-(3-amino(2- hydroxypropyl)pyrazinyl)-N-benzylfluorobenzamide, was obtained at Rt = 1.39 min.
LCMS (m/z): 381.2 (MH+), 0.67 min. The less polar enantiomer, (S)—4-(3-amino(2- hydroxypropyl)pyrazinyl)-N-benzylfluorobenzamide was obtained at Rt = 1.97 min.
LCMS (m/z): 381.2 (MH+), 0.67 min. The stereochemistry was assigned arbitrarily.
S nthesis of 3-bromo 2-ethox eth l razinamine Scheme 43 NH2 $9; NH2 NH2 #0 Steal NHz NJ\ O’Bv/\0Et N \ Pd/C, H2 I le NBS NIJYBr —> / N | —, / N —> / N Pd(dppf)Cl2 80 % OEt OEt OEt Ste 1. E x vin l razinamine To a solution of 5-bromopyrazinamine (200 mg, 1.149 mmol) in DME (2874 uL) was added (E)(2-ethoxyvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (341 mg, 1.724 mmol), PdCI2(dppf)-CH2C|2 adduct (94 mg, 0.115 mmol), and 2M Na2C03 (958 uL). The reaction mixture was stirred at 130 0C in ave reactor for 20 min. The on e was filtered through Celite and washed with EtOAc, the filtrate was partition between EtOAc and water. The aqueous was extracted by EtOAc three times, the combined organic was dried and concentrated. The crude material was purified by flash tography to give (E)(2-ethoxyvinyl)pyrazinamine. LCMS (m/z): 166.1(MH+), 0.41 min.
Ste 2. 5- 2-ethox eth l 2-amine To a solution of (E)(2-ethoxyvinyl)pyrazinamine (75 mg, 0.454 mmol) in ethanol (4.54 mL) was added Pd/C (48.3 mg, 0.454 mmol). The reaction mixture was purged by nitrogen for 10 min, and then stirred at room temperature for 2 h under hydrogen balloon.
The reaction mixture was then filtered through Celite and washed with methanol and EtOAc, then concentrated. The crude product was used in next step reaction without purification. LCMS (m/z): 168.1 (MH+), 0.33 min.
Ste 3. 3-bromo 2-ethox eth | razinamine To a solution of 5-(2-ethoxyethyl)pyrazinamine (45 mg, 0.269 mmol) in DCM (897 uL) was added NBS (43.1 mg, 0.242 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 10 min. After ed with sat. NaHC03, the reaction mixture was ted with EtOAc 3 times. The combined organic layer was washed with water and brine, dried over anhydrous sodium sulfate. Filtered and concentrated in vacuo. The crude product was used in next step reaction without purification. LCMS (m/z): 246.0 (MH+), 0.59 min. 8 nthesis of +/- 5-aminobromo razin l ro anol Scheme 44 Step_1 NH2 Step g ““2 NH2 Step 3 \ N \ N \ BF3K f)C|2 Nl | 2M HCI W“ * 2cm / N N —» / C32C03 TH F/HZO 100 OC n(+/-) NH2 Ste NH2 —9 fl ”HYBr NI \ \ OH (+/-) OH (+/) To a solution of 5-bromopyrazinamine (200mg, 1.149 mmol) in was added potassium (3-(benzyloxy)propenyl)trifluoroborate (350 mg, 1.379 mmol), PdC|2(dppf).CH2C|2 adduct (94 mg, 0.115 mmol), Cs2C03 (1124 mg, 3.45 mmol). Purged through Nitrogen.
The on mixture was stirred at 100 0C in oil bath for 6 h. The reaction mixture was then partitioned between EtOAc and water, combined the organic layers and washed with water and brine, dried over anhydrous sodium sulfate and trated. The crude product was purified by flash chromatography to give 5-(3-(benzyloxy)propen yl)pyrazinamine in 61 % yield. LCMS (m/z): 245.2 (MH+), 0.67 min; 1H NMR (400MHz, CD30D) 8 ppm 8.26 (d, J = 1.2 Hz, 1 H), 7.96 (d, J :12 Hz, 1 H), 7.34 (d, J = 4.3 Hz, 5 H), 5.91 (s, 1 H), 5.44 (d, J :12 Hz, 1 H), 4.59 (s, 2 H), 4.49 (s, 2 H).
Ste 2. +/- 1- benz lox ro an | razinamine To a solution of benzyloxy)propeny|)pyrazinamine (91 mg, 0.377 mmol) in methanol (3771 uL) was added Pd/C (40.1 mg, 0.377 mmol) at room temperature. The reaction mixture was stirred at room temperature under hydrogen balloon for overnight.
The on mixture was filtered through Celite, washed with methanol and EtOAc. The crude material was used in next step reaction without purification. LCMS (m/z): 244.2 (MH+), 0.62 min.
Ste 3. +/- o razin | ro anol A solution of 5-(1-(benzyloxy)propany|)pyrazinamine (80 mg, 0.329 mmol) in 1N HCI (1096 uL) was heat in oil bath for 7 h, cooling down, The reaction mixture was extracted by EtOAc, the aqueous was concentrated to dryness to yield the crude product as HCI salt and used in next step on. LCMS (m/z): 154.1 (MH+), 0.26 min.
Ste 4. +/- 5-aminobromo razin | ro anol To a solution of 2-(5-aminopyraziny|)propano| (30 mg, 0.196 mmol) in DCM (653 uL) was added NBS (31.4 mg, 0.176 mmol) at 0 °C. The on mixture was stirred at 0 °C for 10 min. After quenched with sat NaHC03, the reaction mixture was extracted with EtOAc 3 times. The combined organic layer was washed with water and brine, dried over anhydrous sodium sulfate. Filtered and concentrated in vacuo. The crude product was used in next step reaction without purification. LCMS (m/z): 234.0 (MH+), 0.40 min.
S nthesis of 3- obromo razin l ro rile Scheme 45 40% 35% me fl we 5 NHBoc NH2 NH2 NJ\ TFA N)\ NBS I —> NJVBV | —> I DCM / N / N ON ON ON Ste 1. N N-di-tert-but l 5-meth l razin lcarbamate To a solution of 5-methylpyrazinamine (1 g, 9.16 mmol) in CH2C|2 ( 30 mL), Boc20 (4.47 mL, 19.24 mmol) was added, followed by DMAP (1.679 g, 13.75 mmol) at room temperature. The reaction mixture was d at room temperature for overnight. After quenched with sat NaHC03, the reaction mixture was extracted with CH2C|2 3 times. The combined organic layer was washed with water and brine, dried over anhydrous sodium sulfate. Filtered and trated in vacuo. The desire product was obtained as a white solid by flash column chromatography (20 % EtOAc in heptane). LCMS (m/z): 310.0 (MH+), 0.93 min.
Ste 2. N N-di-tert-but l 5- bromometh l razin lcarbamate To a solution of N,N-di-tert—butyl (5-methylpyrazinyl)carbamate (1.37 g, 4.43 mmol) in CCI4 (14.76 mL) was added NBS (0.828 g, 4.65 mmol), benzoyl peroxide (0.107 g, 0.443 mmol), AIBN (0.073 g, 0.443 mmol). The reaction mixture was stirred at reflux for 8 h.
Work up, the solid was filtered, the organic was concentrated. The crude product was purified by flash chromatography to give the tile product in 36% yield. LCMS (m/z): 231.1 (MH+-Boc), 1.04 min.
Ste 3. tert-but l5- 2-c anoeth l razin mate n-Butyl m (2.5 M in hexanes 103 uL, 0.258 mmol) was added into diisopropylamine (39.3 uL, 0.276 mmol) in dry THF at 0 0C under argon, the mixture was then stirred at 0 0C for 1 h, then cooled down to -78 OC, itrile (14.12 uL, 0.270 mmol) was added slowly, the reaction mixture was allowed to return to room temperature and stirred at room temperature for 1 h, cooled down to -78 0C again, and N,N-di-tert-butyl (5- (bromomethyl)pyrazinyl)carbamate (100 mg, 0.258 mmol) in THF (0.5 mL) was added slowly, the reaction e was stirred at -78 0C for 10 min, then allowed to return to room temperature, after 2 h, the reaction was quenched by sat.NH4C| solution, then extracted by EtOAc. The organic was washed by brine, dried and concentrated. The crude material was purified by flash chromatography (40% EtOAc/heptane) to give tert- butyl 5-(2-cyanoethyl)pyrazinylcarbamate in 40% yield. LCMS (m/z): 193.1 (MH+-tBu), 0.70 min; 1H NMR (400MHz ,CDCI3) 6 ppm 9.22 (s, 1 H), 8.12 (s, 1 H), 3.09 (t, J = 7.2 Hz, 2 H), 2.83 (t, J = 7.2 Hz, 2 H), 1.52 - 1.36 (m, 8 H).
Ste 4. 3- 5-amino razin l ro anenitrile To a solution of utyl 5-(2-cyanoethyl)pyrazinylcarbamate (25 mg, 0.101 mmol) in DCM (0.336 mL) was added TFA (0.1 mL, 1.298 mmol) at room temperature . The reaction mixture was d at room temperature for 1 h. After quenched with sat.
NaHC03, the reaction e was extracted with DCM. The combined organic layer was washed with water and brine, dried over anhydrous sodium sulfate. Filtered and concentrated in vacuo. The crude product was used in next step reaction without purification. LCMS (m/z): 149.1 (MH+), 0.24 min.
Ste 5. 3- 5-aminobromo razin l ro rile To a solution of 3-(5-aminopyrazinyl)propanenitrile (45 mg, 0.304 mmol) in DCM (1519 uL) was added NBS (48.7 mg, 0.273 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 10 min. After quenched with NaHC03, the reaction mixture was extracted with EtOAc 3 times. The combined organic layer was washed with water and brine, dried over anhydrous sodium sulfate. ed and concentrated in vacuo. The crude product was used in next step reaction without purification. LCMS (m/z): 227/229.1 (MH+), 0.45 min. 8 nthesis of 5- 5-aminobromo razin l i eridinone Scheme 46 0 OH m1 —9Ste 2 Step; NHBoc NHBOC DPPA NBS N \ —~ W —. NIg NaCN ka N t—BuOH, Et3N KfN cat. AIBN Ki NHB°C Step 4 8&2 5 N \ O H IKB“ / N)\ 2 /N + /\Of NaOEt | \/ cat. Raney Ni \\N \/ NHBoc NH2 NH2 fiaé m1 Br N \ N \ N \ I I I /N HCI /N NBS /N HN HN HN o o o Ste 1. ut |5-meth l razin |carbamate To solution 5-methylpyrazinecarboxylic acid (2.5 g, 18.1 mmol), tert-butanol (6.92 mL, 72.4 mmol), Et3N (3.78 mL, 27.1 mmol) in 1,4-dioxane (12.5 mL) at 95 °C was dropwise added diphenylphosphoryl azide (DPPA, 3.23 mL, 18.1 mmol), and the reaction was heated at 95 °C for 1.5 h, followed by a 2nd portion of DPPA (1 mL, 5.6mmol) and heated for additional 1.5 h. The reaction mixture was cooled down, concnetrated and the residue was d with EtOAc (50 mL), washed with water (30 mL), 3 M NaOH( 30 mL), sat.
NaHC03 (30 mL) and brine (30 mL), dried over Na2804, and concnetrated. The residue was purified by flashed tography on silica gel eluting with gradient EtOAc/CH2C|2 (0-20%) to afford tert-butyl 5-methylpyrazinylcarbamate as white solid. LCMS (m/z): 210.1 (MH+), 0.69 min; 1H NMR (400 MHz, CDCI3) 6 ppm 9.17 (s, 1H), 8.09 (s, 1H), 7.75 (br. s., 1H), 2.51 (s, 3H), 1.56 (s, 9H).
Ste 2. tert-but |5- bromometh l razin lcarbamate A solution of tert-butyl 5-methylpyrazinylcarbamate (2.79 g, 13.33 mmol), NBS (2.61 g, 14.67 mmol) and AIBN (0.219 g, 1.33 mmol) in CCI4 (45 mL) was purged with Argon, then the solution was heated with 85 0C oil bath for 4 h. The reaction mixtue was cooled to room temperature, concentrated and the residue was olved in EtOAc (~50 mL), washed with dilute aqueous NaOH twice (10 mL 1 N NaOH diluted in 20 mL H20), brine (30 mL), dried (Na2804) and concentrated. The residue was further ed by flash chromatography on silica gel eluted with nt EtOAc/CH2C|2 ) and tert-butyl 5- (bromomethyl)pyrazinylcarbamate was obtained in off-white solid. LCMS (m/z): 288.1/290.1 (MH+), 0.82 min; 1H NMR (400 MHz, CDCI3) 6 ppm 9.26 (s, 1H), 8.32 (d, J = 1.2 Hz, 1H), 7.62 (br. s., 1H), 4.56 (s, 2H), 1.56 (s, 9H).
Ste 3. tert-but |5- c anometh l razin lcarbamate A mixture of tert-butyl 5-(bromomethyl)pyrazinylcarbamate (0.75 g, 2.60 mmol) and NaCN (0.255 g, 5.21 mmol) in DMF (5 mL) was stirred at room temperature for 50 min.
The reaction mixture was cooled down to room temperature, diluted with 0.5 N NaOH (10 mL) and extratced with EtOAc (2 x 20 mL), and EtOAc layers were combined, washed with 0.5 N NaOH (10 mL), dried (Na2804), concentrated and the crude residue was purified by flash chromatography on silica gel eluted with gradient EtOAc/CH2CI2 ) to afford tert-butyl 5-(cyanomethyl)pyrazinylcarbamate (0.40 g, 65.6% yield). LCMS (MH+- tBu): 179.0 (MH+), 0.68 min; 1H NMR (400 MHz, CDCI3) 6 ppm 9.28 (s, 1H), 8.32 (s, 1H), 7.59 (br. s., 1H), 3.91 (s, 2H), 1.57 (s, 9H).
Ste 4. eth l4- 5- tert-butox carbon lamino razin lc anobutanoate To utyl 5-(cyanomethyl)pyrazinylcarbamate (0.32 g, 1.37 mmol) in a mixture solvent of ethanol/2-methyltetrahydrofuran (5mL/5mL) was added freshly ed sodium ethoxide (1 M, 1.366 mL), and the mixture was stirred at 0 °C for 10 min, followed by on of ethyl acrylate (145 ul, 1.366 mmol) and the mixture was stirred at 0 °C for 2 h. The reaction was quenched at this point by adding sat. NaHC03 (5 mL), and the on mixture was stirred for another 10 min, diluted with EtOAc (20 mL), ed and the filtrate was concentrated. The residue was dissolved in EtOAc (20 mL), washed with pH 7.0 sodium phosphate buffer, and EtOAc layer was concentrated, and the light brown al oil was purified by flash column eluted with gradient EtOAc/heptane (0-50%) to afford ethyl 4-(5-(tert-butoxycarbonylamino)pyrazinyl)—4-cyanobutanoate (100 mg, 22% yield). LCMS (m/z): 279.2 (MH+-tBu), 0.86 min.
Ste 5. tert-but l5- 6-oxo i eridin l razin lcarbamate Under Argon, to ethyl 4-(5-(tert-butoxycarbonylamino)pyrazinyl)cyanobutanoate in ethanol solution (94 mg, 0.281 mmol/8 mL) was added Raney Nickel st ethanol suspension (Nickel in ~2 mL ethanol, the amount of Raney Nickel was not accurately measured), and the reaction mixture was stirred under H2 balloon after 3 times air atomasphere exchange heated with external oil bath at 56 °C for overnight with H2 balloon. The reaction mixture was cooled down to room temperature, and filtered through a pad of Celite, the filtrate was trated to afford tert-butyl 5-(6-oxopiperidin yl)pyrazinylcarbamate in a yellow solid.
Ste 6. 5- 5-amino razin l i eridinone A mixture of tert-butyl 5-(6-oxopiperidinyl)pyrazinylcarbamate (60 mg, 0.205 mmol) and conc HCI (1 mL) in ol (2 mL) was heated with 70 °C oil bath for 1 hour and the reaction e was cooled down, concentrated to dryness and the residue was redissolved in methanol (3 mL), and to it was added NaHC03 (200 mg), and the mixture was heated with 70 °C oil bath for 2 h. The solid suspension of reaction mixture was d by filtration, and the filtrate was concentrated and a light yellow solid was obtained as crude 5-(5-aminopyrazinyl)piperidinone which was used directly in next step without further purification. LCMS (m/z): 193.1 (MH+), 0.22 min.
Ste 7. 5- 5-aminobromo razin l i eridinone To 5-(5-aminopyrazinyl)piperidinone (25 mg, 0.13 mmol) acetonitrile (10 mL) solution at 0 °C was added NBS (23.2 mg, 0.13 mmol) and the reaction mixture was stirred at 0 °C for 30 min, then at room temperature for 4 h. The reaction mixture was concnetrated, and the e was basified by 1 N NaOH (140 ul), diluted with methanol (2 mL), concentrated. The residue was triturated with EtOAc (3 x 1 mL), and the EtOAc supernatants were ted, combined and concentrated and a light solid was obtained as crude 5-(5-aminobromopyrazinyl)piperidinone which was used in next step without further purification. LCMS (m/z): 241/243 (MH+), 0.41 min.
Example 25 S nthesis of 4- 2-amino 6-oxo i eridin l ridin l-N- S 3-chloro hen l hydroxyethyl )—2-fluorobenzamide Scheme 47 m1 _28te 2 Br Br N/ \ NaH | Pd(dppf)C|2 I /Si/\/O\/C| \ \ _, I —.
NH \ DMF NVO\/\Si/ ’B\ Na2C03, DME O o 31% |\ o o “w, 120 0c, 10 min F mi F Step 5 NH2 Step 5 N \ N \ N \ ' ' NHAOH ' / H2(250psi> / / NBS —> crude —> —> / Pd/C, MeOH 100 °c CH3CN o N 16h (250 p5” \ /\/o N HN 54%(3 stem) ,Si/V V\ ,Si V I l o o crude F o _/ St_eQ E NH2 N Pd(dppf)CI2 H Na2003 DME / CI pW 120 OC 10min o HN crude Ste 1. 5-bromo 2- trimeth lsil lethox meth l ridin-2 1H -one To a on of 5-bromopyridin-2(1H)—one (2.01 g, 11.55 mmol) in DMF (30 mL) at 0 °C was added sodium hydride (0.924 g, 23.10 mmol). The reaction mixture was stirred for 1 h at room temperature. To this, (2-(chloromethoxy)ethy|)trimethylsilane (2.89 g, 17.33 mmol) was added slowly. The on mixture was stirred overnight. LCMS - 0.26 min, MH+ 304.1 (non-polar method). The reaction was quenched with sat. aq. NH4CI, and then diluted with ethyl acetate. The reaction mixture was ted with EtOAc. The combined organics were washed with water and brine, then dried over sodium sulfate, filtered off WO 66188 and concentrated in vacuo. The crude product was purified by flash chromatography column using 0-50% EtOAc/ heptane. 5-bromo((2-(trimethylsilyl)ethoxy)methyl)pyridin- 2(1H)—one was obtained as a yellow viscous liquid. LCMS (m/z): 304/306 (MH+), 0.95 min.
Ste 2. 6'-f|uoro 2- trimeth lsil l ethox meth l - 3 3'-bi ridin -6 1H -one To a solution of 5-bromo((2-(trimethylsilyl)ethoxy)methyl)pyridin-2(1H)—one (568 mg, 1.868 mmol) in DME ( 6227 uL, Ratio: 2.000) was added PdC|2(dppf) (68.3 mg, 0.093 mmol), 2-fluoro(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)pyridine (500 mg, 2.242 mmol), 2M Na2C03 ( 3113 ul, Ratio: 1.000) at room temperature. The reaction mixture was heated at microwave synthesizerfor 10 min at 120 °C. To the reaction mixture, sodium sulfate and EtOAc were added. After filtered off, the volatile materials were removed in vacuo. The crude product was ed by flash chromatography (gradient EtOAc in heptane) yielding 6'-f|uoro((2-(trimethylsilyl)ethoxy)methyl)-[3,3'-bipyridin]- 6(1H)—one (52%). LCMS (m/z): 321.3 (MH+), 0.93 min.
Ste 3. 5- 6-fluoro ridin l 2- trimeth lsil lethox meth l i one To a steel bomb, a on of 6'-f|uoro((2-(trimethylsilyl)ethoxy)methyl)-[3,3'-bipyridin]- 6(1H)-one (311 mg, 0.971 mmol) in MeOH (remaining 60% head space) was added followed by addition of Pd-C (207 mg, 0.194 mmol). After degassing with nitrogen stream, the steel bomb was pressurized with hydrogen gas up to 250 psi. The reaction was stirred at room temperature for 20 h. LCMS - 0.9 min MH+ 325.1 (single major). The on e was filtered off h Celite (washed with EtOAc). The volatile materials were concentrated in vacuo to give crude 5-(6-fluoropyridinyl)((2- (trimethylsilyl)ethoxy)methyl)piperidinone (290 mg, 0.894 mmol, 92%), which was used for the next step without further purification.
Ste 4. 5- 6-amino ridin l i eridinone To -(6-f|uoropyridinyl)—1-((2-(trimethylsilyl)ethoxy)methyl)piperidinone (290 mg, 0.894 mmol) in a steel bomb, ammonium ide (34.8 ul, 0.894 mmol) solution was added (40% head volumn remained). The steel bomb reactor was heated at 150 °C for 44 h (250 psi on pressure guage). LCMS - 0.23 min, MH+ 192.1 (without SEM); 0.66 min, MH+ 322.1 (with SEM). After diluted with MeOH and toluene, volatile materials were completely removed in vacuo. 5-(6-aminopyridinyl)piperidinone was used for the next step.
Ste 5. 5aminobromo ridin l i eridinone To a solution of 5-(6-aminopyridinyl)piperidinone (132 mg, 0.690 mmol) in itrile ( 8.00 mL) was added NBS (98 mg, 0.552 mmol) at 0 °C. The reaction mixture was stirred for 30 min upon warming-up to room temperature. LCMS 0.28 min, MH+ 270/272; 0.7 min, MH+ 402.1 (SEM protected one). After quenched with Na28203 solution, the reaction mixture was extracted with EtOAc, which was washed with NaHC03 solution and brine. The organic layer was dried over anhydrous Na2804, filtered off, concentrated in vacuo. The crude 5-(6-aminobromopyridinyl)piperidinone was used for the next step.
Ste 6. 4- 2-amino 6-oxo i eridin l ridin l-N- S 3-chloro hen l hydroxyethyl)—2-fluorobenzamide To a microwave vial, 5-(6-aminobromopyridinyl)piperidinone (45 mg, 0.167 mmol), (S)—(4-((1-(3-chlorophenyl)hydroxyethyl)carbamoyl)fluorophenyl)boronic acid (56.2 mg, 0.167 mmol), PdCl2(dppf) (12.19 mg, 0.017 mmol), DME (1111 ul, Ratio: 2.000), and Na2C03 (2M solution) ( 555 uL, Ratio: 1.000) were added. The reaction mixture was heated at microwave reactor for 10 min at 120 °C. LCMS - 0.58 min, MH+ 483.2; 0.85 min, MH+ 613.3. After anhydrous sodium sulfate were added to remove water, the reaction mixture was filtered off and dried in vacuo. The small n was purified by prep HPLC ng 4-(2-amino(6-oxopiperidinyl)pyridinyl)—N-((S)—1-(3- chlorophenyl)hydroxyethy|)f|uorobenzamide as a reomeric mixture (12%).
LCMS (m/z): 483.3 (MH+), 0.56 min; 1H NMR (400MHz, CD30D) 6 ppm 7.89 (m, 1H), 7.80 (m, 2H), 7.42 - 7.30 (m, 3H), 7.30 - 7.24 (m, 2H), 7.25 - 7.15 (m, 1H), 5.18 - 5.03 (m, 1H), 3.87 - 3.64 (m, 2H), 3.47 - 3.35 (m, 2H), 3.11 - 2.97 (m, 1H), 2.46 - 2.30 (m, 2H), 2.08 - 1.91 (m, 2H).
S nthesis of +/- 6-aminobromo ridin lmeth l i eridinone Scheme 48 Steg1 Ste F Step; B?“ Pd(dppf)CI2 H2 (250 psi) I NH4OH NaZCO3 DME Pd/C MeOH 150°C 0w 120°C 10min 16h (1:380 90% 98% [ll crude (’4') NH2 NH2 N \ N \ I | / NBS / CH3CN o N o N | (+1) I (+/) crude crude To a solution of ro(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolanyl)pyridine (500 mg, 2.242 mmol) was added PdC|2(dppf) (68.3 mg, 0.093 mmol), 4-bromomethylpyridin- 2(1H)—one (351 mg, 1.868 mmol), 2M Na2C03 (4.1 mL) and DME (8.3 mL) at room ature. The reaction mixture was heated at ave synthesizer for 10 min at 120 °C. The reaction mixture was extracted with EtOAc. The organic layers were washed with water and brine, dried over anhydrous Na2804, filtered off, and concnetrated in vacuo.
The crude 6-fluoro-1'-methyl-[3,4'-bipyridin]-2'(1'H)—one was purified by flash tography (gradient EtOAc in DCM). LCMS (m/z): 205.2 (MH+), 0.47 min.
Ste 2. +/- 6-fluoro ridin th l i eridinone To a steel bomb, a solution of 6-f|uoro-1'-methy|-[3,4'-bipyridin]-2'(1'H)-one (340 mg, 1.665 mmol) in MeOH (remaining 60% head space) was added followed by addition of Pd-C (Degussa) (354 mg, 0.333 mmol). After degassing with nitrogen stream, the steel bomb was filled with hydrogen (250 psi). The reaction mixture was stirred overnight. The reaction mixture was filtered off through Celite d with EtOAc/MeOH). The volatile materials were concentrated in vacuo to give crude (+/-)(6-f|uoropyridiny|) methylpiperidinone (341 mg, 1.638 mmol, 98 % yield) which was used for the next step without further purification. LCMS (m/z): 209.1 (MH+), 0.47 min.
Ste 3. +/- 6-amino ridin lmeth | i eridinone To a steel bomb, (+/-)(6-fluoropyridiny|)methy|piperidinone (341 mg, 1.638 mmol) was added followed by addition of ammonium hydroxide solution (0.00 mmol) - remaining 40% head space. The reactor was heat at 150 °C for 20 hr nal pressure built up to 100 psi upon g). After cooling down, the on was completed. The whole solvent (transferred to a flask) was removed in vacuo. Toluene was added and co- ated to remove water. The crude product, (+/-)(6-aminopyridinyl)—1- methylpiperidinone, was used for the next step without further cation (87%).
LCMS (m/z): 206.1 (MH+), 0.24 min.
Ste 4. +/- 6-aminobromo ridin lmeth | i eridinone To a solution of (+/-)(6-aminopyridinyl)—1-methy|piperidinone (291 mg, 1.418 mmol) in acetonitrile (14.200 mL) was added NBS (202 mg, 1.134 mmol) at 0 °C. The reaction mixture was stirred for 30 min upon warming-up to room temperature. After quenched with Na28203 solution, the reaction mixture was extracted with EtOAc, which was washed with NaHC03 solution and brine. The organic layer was dried over anhydrous Na2804, filtered off, concentrated in vacuo. The crude product 4-(6- aminobromopyridinyl)—1-methylpiperidinone (98%) was used for the next step.
LCMS (m/z): 284/286 (MH+), 0.34 min.
Examples 26, 27, and 28 4- 2-amino 1-meth loxo i eridin | ridin l-N- S 3-chloro hen l h drox eth lfluorobenzamide 4- 2-amino Rmeth loxo i eridin | ridin- 3- l-N- S 3-chloro hen lh drox eth lfluorobenzamide and 4- 2-amino S h loxo i | ridin l-N- S 3-chloro hen lh drox eth |- 2-fluorobenzamide F o Z/OH F o Z/OH F 0 {OH NH2 N NH2 N NH2 N H H H N \ N \ N \ I I I / CI / CI / CI N 0 T O N O Following Step 6 in Scheme 47, using (+/-)(6-aminobromopyridinyl)—1- methylpiperidinone and -((1-(3-ch|orophenyl)hydroxyethyl)carbamoy|)—3- fluorophenyl)boronic acid, 4-(2-amino(1-methyloxopiperidinyl)pyridinyl)—N-((S)— 1-(3-chlorophenyl)hydroxyethyl)—2-fluorobenzamide was obtained as a diastereomeric mixture (inseparable) (35%). LCMS (m/z): 497.3 (MH+), 0.59 min; 1H NMR (400MHz, CD3OD) 6 ppm 7.97 (m, 1H), 7.9 (m, 1H), 7.82 (m, 1H), 7.52 - 7.39 (m, 3H), 7.39 - 7.32 (m, 2H), 7.3 (m, 1H), 5.19 (m, 1H), 3.88 (m, 2H), 3.60 - 3.38 (m, 3H), 3.21 - 3.08 (m, 1H), 2.72 - 2.58 (m, 1H), 2.57 - 2.41 (m, 1H), 2.21 - 1.95 (m, 2H). The diastereomeric mixture was separated by chiral SFC (ChiralPak 5mic AD column, 4.6x100 (mm), 5mL/min, EtOH+0.1%, DEA= 45% in 5 min). The polar reomer, 4-(2-amino((R)—1-methyl oxopiperidinyl)pyridinyl)—N-((S)—1-(3-ch|orophenyl)hydroxyethy|) fluorobenzamide was obtained at Rt = 1.82 min. The less polar diastereomer, 4-(2-amino- —1-methyloxopiperidinyl)pyridinyl)—N-((S)(3-ch|orophenyl) hydroxyethyl)fluorobenzamide was obtained at Rt = 2.35 min. The absolute stereochemistry for both diastereomers was assigned arbitrarily.
Examples 29, 30, and 31 fluoro-N- R hen leth Ibenzamide and 4- 2-amino S meth loxo i eridin l 3- lfluoro-N- R hen leth mide F o 2 F o g F o 3 NH2 H/IjN NH2 NH/\© NH2 H/IjN N \ N \ N \ 0 (N10 Following Step 6 in Scheme 47, using (+/-)(6-aminobromopyridinyl)—1- methylpiperidinone and (R)-(3-fluoro((1-phenylethyl)carbamoy|)pheny|)boronic acid, 4-(2-amino(1-methyloxopiperidinyl)pyridinyl)fluoro-N-((R) phenylethyl)benzamide was obtained as a diastereomeric e (inseparable) (34%).
LCMS (m/z): 447.3 (MH+), 0.58 min;1H NMR (400MHz, CD3OD) 6 ppm 7.85 (m, 1H), 7.72 (m, 2H), 7.41 - 7.20 (m, 6H), 7.18 (m, 1H), 5.17 (m, 1H), 3.51 - 3.29 (m, 3H), 3.13 - 2.98 (m, 1H), 2.88 (s, 3H), 2.60 - 2.48 (m, 1H), 2.48 - 2.30 (m, 1H), 2.10 - 1.85 (m, 2H), 1.58 - 1.38 (m, 3H). The diastereomeric mixture was separated by chiral SFC (ChiralPak 5mic AD column, 4.6x100 (mm), 100mL/min, IPA+0.1%, DEA = 40%, 5m|/min). The polar reomer, 4-(2-amino((R)methyloxopiperidinyl)pyridinyl)fluoro-N-((R)- 1-phenylethyl)benzamide was obtained at Rt = 1.67 min. LCMS (m/z): 447.3 (MH+), 0.64 min. The less polar diastereomer, 4-(2-amino((S)methyloxopiperidinyl)pyridin- 3-yl)—2-fluoro-N-((R)phenylethyl)benzamide was obtained at Rt = 2.37 min. LCMS (m/z): 447.2 (MH+), 0.64 min. The absolute stereochemistry for both diastereomers was assigned arbitrarily.
Examples 32, 33, and 34 4- 2-amino 1-meth loxo i eridin l ridin l-N- R 3-chloro hen leth l fluorobenzamide 4- 2-amino Rmeth loxo i eridin l ridin l-N- R 3- chloro hen leth lfluorobenzamide and 4- o S meth loxo i eridin yl)pyridinyl)—N-((R)—1-(3-chlorophenyl)ethyl)—2-fluorobenzamide F o 5 F o g F o 3 NH2 N NH2 N NH2 N H H H N \ N \ N \ I I I / Cl / Cl / Cl T o T 0 (kilo Following Step 6 in Scheme 47, using (R)—(4-((1-(3-chlorophenyl)ethyl)carbamoyl)—3- fluorophenyl)boronic acid, mino(1-methyloxopiperidinyl)pyridinyl)—N-((R)- 1-(3-chlorophenyl)ethyl)fluorobenzamide was obtained as a reomeric mixture (inseparable) (33%). LCMS (m/z): 481.3 (MH+), 0.70 min; 1H NMR (400MHz, CD3OD) 6 ppm 7.86 (m, 1H), 7.73 (m, 2H), 7.39 - 7.20 (m, 5H), 7.19 (m, 1H), 5.14 (m, 1H), 3.52 - 3.28 (m, 3H), 3.14 - 2.98 (m, 1H), 2.88 (s, 3H), 2.62 - 2.48 (m, 1H), 2.46 - 2.30 (m, 1H), 2.12 - 1.84 (m, 2H), 1.48 (m, 3H). The reomeric mixture was separated by chiral SFC (ChiralPak 5mic AD column, 4.6x100 (mm), 5ml/min, EtOH+0.1% DEA=35%). The polar diastereomer, 4-(2-amino((R)methyloxopiperidinyl)pyridinyl)—N-((R)—1- (3-chlorophenyl)ethyl)—2-fluorobenzamide was obtained at Rt = 2.83 min. LCMS (m/z): 481.2 (MH+), 0.71 min. The less polar diastereomer, 4-(2-amino—5-((S)—1-methyl oxopiperidinyl)pyridinyl)—N-((R)—1-(3-chlorophenyl)ethyl)—2-fluorobenzamide was ed at Rt = 3.53 min. LCMS (m/z): 481.2 (MH+), 0.72. The absolute stereochemistry for both diastereomers was assigned arbitrarily.
S nthesis of 5- 6-aminobromo ridin lmeth l i eridinone Scheme 49 Br N \ | ' / \ I + _> o’B‘o 0 %—§ /N Following Scheme 48, using 5-bromomethylpyridin-2(1H)—one, 5-(6-amino bromopyridinyl)methylpiperidinone was obtained. LCMS (m/z): 284/286 (MH+), 0.34 min.
Examples 35, 36, and 37 4- 2-amino 1-meth loxo i l ridin l-N- S 3-chloro hen l h drox eth uorobenzamide 4- 2-amino Rmeth loxo i eridin l ridin- 3- l-N- S 3-chloro hen lh drox eth lfluorobenzamide and 4- 2-amino S meth loxo i eridin l ridin l-N- S 3-chloro hen lh drox eth l- 2-fluorobenzamide F o :/OH F 0 :/OH F o :/OH NH2 N NH2 N NH2 N H H H N \ N \ N \ I I I / CI / CI / CI /N /N /l\© O O 0 Following Step 6 in Scheme 47, using 5-(6-aminobromopyridinyl)—1-methy|piperidin- 2-one and (S)—(4—((1-(3-chlorophenyl)hydroxyethyl)carbamoyl)fluorophenyl)boronic acid, 4-(2-amino(1-methyloxopiperidinyl)pyridinyl)—N-((S)(3-chlorophenyl) hydroxyethyl)fluorobenzamide was obtained (33%). LCMS (m/z): 497.2 (MH+), 0.61 min; 1H NMR (400MHz, CD3OD) 8 ppm 8.70 (m, 1H), 7.98 (m, 1H), 7.88 (m, 2H), 7.44 (m, 3H), 7.36 (m, 2H), 7.30 (m, 1H), 5.19 (m, 1H), 3.88 (m, 2H), 3.51 (m, 2H), 3.21 (m, 1H), 2.97 (s, 3H), 2.50 (m, 2H), 2.07 (m, 2H). The diastereomeric mixture was separated by chiral SFC (ChiralPak 5mic AD column, 4.6x100 (mm), EtOH+0.1%DEA=40% , 5m|/min).
The polar diastereomer, 4-(2-amino((R)—1-methyloxopiperidinyl)pyridinyl)—N- ((S)—1-(3-chlorophenyl)—2-hydroxyethyl)fluorobenzamide was obtained at Rt = 2.22 min.
LCMS (m/z): 497.2 (MH+), 0.61 min. The less polar diastereomer, 4-(2-amino—5-((S) methyloxopiperidinyl)pyridinyl)—N-((S)(3-chlorophenyl)hydroxyethyl) fluorobenzamide was obtained at Rt = 3.09 min. LCMS (m/z): 497.3 (MH+), 0.59 min.
Examples 38, 39, and 40 4- 2-amino 1-meth o i eridin l ridin l-N- R 3-chloro hen leth l fluorobenzamide 4- 2-amino Rmeth loxo i eridin l ridin l-N- R 3- chloro hen leth uorobenzamide and 4- 2-amino S h loxo i eridin yl)pyridinyl)—N-((R)—1-(3-chlorophenyl)ethyl)—2-fluorobenzamide F O 3 F O E F O 3 NH2 N NH2 N NH2 N H H H N \ N \ N \ I I I / CI / CI / CI /N /N /l\© O O 0 Following Step 6 in Scheme 47, using (R)—(4-((1-(3-chlorophenyl)ethyl)carbamoy|) fluoropheny|)boronic acid and 5-(6-aminobromopyridiny|)methy|piperidinone, 4-(2-amino(1-methyloxopiperidinyl)pyridinyl)—N-((S)—1-(3-chlorophenyl) hydroxyethy|)f|uorobenzamide was obtained as a diastereomeric mixture (4%). LCMS (m/z): 481.3 (MH+), 0.69 min. 1H NMR (400MHz, CD3OD) 8 ppm 8.79 - 8.65 (m, 1H), 7.93 - 7.83 (m, 1H), 7.83 - 7.76 (m, 1H), 7.75 - 7.65 (m, 1H), 7.40 - 7.29 (m, 3H), 7.29 - 7.21 (m, 2H), 7.21 - 7.13 (m, 1H), 5.22 - 5.07 (m, 1H), 3.52 - 3.32 (m, 3H), 3.16 - 3.01 (m, 1H), 2.88 (s, 3H), 2.48 - 2.34 (m, 2H), 2.07 - 1.92 (m, 2H), 1.55 - 1.40 (m, 3H). The diastereomeric mixture was separated by chiral SFC IPak 5mic AD column, 4.6x100 (mm), 5m|/min, MeOH+0.1% DEA = 35%). The polar diastereomer, mino- -((R)—1-methyloxopiperidinyl)pyridinyl)—N-((R)—1-(3-chlorophenyl)ethyl)—2- fluorobenzamide was obtained at Rt = 2.98 min. LCMS (m/z): 481.2 (MH+), 0.71 min. The less polar diastereomer, 4-(2-amino((S)—1-methyloxopiperidinyl)pyridinyl)—N- ((R)—1-(3-chlorophenyl)ethyl)—2-fluorobenzamide was obtained at Rt = 3.93min. LCMS (m/z): 481.1 (MH+), 0.71 min.
Example 41 4- 2-amino 5-oxo rrolidin l 3- lfluoro-N- S h drox phenylethyl )benzamide Scheme 50 WO 66188 F Oyo Step 1 F Step 2 F Step g F N / O N’ N / / | N K + N Pd(dPPf)C|2-DCM | TFA/DCM | Pd-C | \ —> \ —. —> \ \ o Na2C03, DME MeOH ,B\ o‘ ’I 0 HO OH S\\\©\ 547% / / 80A, N y' NH NH o 2’0 o o F NH2 OH Step 4 Step § Step § F o _/ N/ N/ _ NaH, CH3I | NH4+ OH' | NBS / ACN N —> —> \ —> + DMF 80% 73% >§VO0‘3I 58% N N o \ o \ F o :/ H/\©N —93te 1 NHZ PdCl2(dppf)-CH2C|2 N/ 2M Na2C03/ DME / o Ste 1. tert-but l4- 6-fluoro ridin loxo-2 5-dih - rrolecarbox late To tert-butyl 2-oxo(tosyloxy)-2,5-dihydro-1H-pyrrolecarboxylate (0.8g, 2.037 mmol) (See Example24 for synthesis) in DME (27 mL) and sodium carbonate (7 mL, 14.00 mmol) (2M) was added (6-fluoropyridinyl)boronic acid (0.431 g, 3.06 mmol) and PdC|2(dppf).CH2C|2 adduct (0.333 g, 0.407 mmol). Purge with N2 for 5min.The reaction mixture was heated in oil bath at 90°C fo 2 h. The reaction mixture was partitioned between ethylacetate and water. The organic layer was separated, washed with brine, dried over sodium sulfate, filtered and evaporated. Purified by flash chromatography column using 0-50%EtOAc/ heptane. Fractions contains product were combined and evaporated to provide tert-butyl 4-(6-fluoropyridinyl)—2-oxo-2,5-dihydro-1 H-pyrrole carboxylate as an off white solid (54.7%). LCMS (m/z): 223.2 (MH+-‘Bu), 0.743 min.
Ste 2. 4- ro 3- l -1H- rrol-2 5H -one To utyl 4-(6-fluoropyridinyl)—2-oxo-2,5-dihydro-1H-pyrrolecarboxylate (315 mg, 1.132 mmol) in DCM (4 mL) was added TFA (1 mL, 12.98 mmol). The reaction mixture was stirred at room temperature for 1h. Reaction mixture was ated. Azeotrope with toluene (x=3) yielding 4-(6-fluoropyridinyl)-1H-pyrrol-2(5H)—one. Proceed for next step.
LCMS (m/z): 179.2 (MH+), 0.373 min. The crude yield was quantitative.
Ste 3. 4- 6-fluoro ridinl rrolidinone To 4-(6-fluoropyridinyl)—1H-pyrrol-2(5H)-one(190 mg, 1.066 mmol) in MeOH ( 10 mL) under N2 atmosphere was added Pd-C (227 mg, 0.213 mmol). The reaction mixture was stirred under H2 balloon at room temperature for overnight. Reaction mixture was filtered h , washed with MeOH. te was evaporated. Azeotrope with toluene (x=3). Yield was 80%. Proceed for next step. LCMS (m/z): 181.0 (MH+), 0.341 min.
Ste 4. 4- 6-fluoro ridin lmeth l rrolidinone To 4-(6-fluoropyridinyl)pyrrolidinone (200 mg, 0.888 mmol) in DMF (4 mL) in ice bath was added NaH (42.6 mg, 1.066 mmol) and iodomethane (0.067 mL, 1.066 mmol).
The reaction mixture was d in ice bath for 30 min and room temperature for 1 hour.
LC-MS shows mixture of SM and product (1:1). Added again NaH (42.6 mg, 1.066 mmol) and thane (0.067 mL, 1.066 mmol), stirred for 1h at room temperature. Complete reaction by LC-MS. Reaction mixture was diluted with EtOAc and washed with water and bine. The organic layer was dried over sodium sulfate, filtered and evaporated. The crude was purified by flash chromatography [080%EtOAc ins 10%MeOH) / heptane].
LCMS (m/z): 195.2 (MH+), 0.492 min. Yield 58% Ste 5. 4- 6-amino ridin lmeth l rrolidinone To 4-(6-fluoropyridinyl)—1-methy|pyrrolidinone(100 mg, 0.515 mmol) was added ammonium hydroxide (2 mL, 15.41 mmol). The reaction mixture was heated in heating block at 140°C for 48h. LC-MS shows 80% product. Reaction mixture was evaporated.
Azeotrope with e (x=3) and proceed for next step. LCMS (m/z): 192.2 (MH+), 0.256 min.
Ste 6. 4- 6-aminobromo ridin lmeth l rrolidinone To 4-(6-aminopyridinyl)—1-methylpyrrolidinone (90 mg, 0.377 mmol) in Acetonitrile ( 3 mL) in ice bath was added NBS (60.3 mg, 0.339 mmol). The reaction mixture was stirred in ice bath for 15 min and room temperature for 30min. LC-MS shows mixture of SM and t. Addded 0.1 equiv. more of NBS and stirred another 1h at room temperature. Reaction mixture was diluted with EtOAc and added 2mL of Satd sodium onate. Stirred 10min. The organic layer was separated, dried over sodium sulfate, filtered and evaporated. Proceed for next step (73%). LCMS (m/z): 270.2/272.2(MH+), 0.302 min.
Ste 7. 4- 2-amino 1-meth loxo rrolidin l ridin lfluoro-N- S h drox - 1-phenylethyl mide To 4-(6-aminobromopyridinyl)—1-methy|pyrrolidinone (18 mg, 0.067 mmol) in DME ( 1.6 mL) and sodium carbonate (0.167 mL, 0.333 mmol) was added (S)—2-fluoro-N-(2- hydroxyphenylethyl)(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)benzamide(30.8 mg, 0.080 mmol) and PdC|2(dppf).CH2C|2 adduct (5.44 mg, 6.66 umol). The reaction mixture was heated in microwave at 120°C for 15 min. The reaction mixture was diluted with Ethylacetate. The organic layer was separated and evaporated. The crude was ed by prep HPLC to provide desired product as a TFA salt (29.3%). LCMS (m/z): 449.3 (MH+), 0.52 min; 1H NMR (400 MHz, CD30D) 6 ppm 8.65 (dd, J=7.24, 4.11 Hz, 1 H) 7.97 (d, J=2.35 Hz, 1 H) 7.94-7.83 (m, 2 H) 7.49-7.39 (m, 4 H) 7.36 (t, J=7.63 Hz, 2 H) 7.32-7.24 (m, 1 H) 5.30-5.13 (m, 1 H) 3.94-3.76 (m, 3 H) 3.69 (quin, J=8.31 Hz, 1 H) 3.50 (dd, J=9.59, 7.24 Hz, 1 H) 2.89 (s, 3 H) 2.79 (dd, J=16.82, 9.00 Hz, 1 H) 2.56 (dd, J=16.82, 8.22 Hz, 1 H). e 42, 43, and 44 4- 2-amino 1-meth o rrolidin l ridin l-N- S 3—chloro hen l Following Step 6 in Scheme 50, using 4-(6-aminobromopyridinyl)—1-methy|pyrrolidin- 2-one and (S)—N-(1-(3-chlorophenyl)hydroxyethyl)fluoro(4,4,5,5-tetramethyl-1,3,2- dioxaborolanyl)benzamide, 4-(2-amino(1-methyloxopyrrolidinyl)pyridinyl)—N- ((S)—1-(3-chlorophenyl)hydroxyethyl)fluorobenzamide was obtained as a diastereomeric mixture (33.3%). LCMS (m/z): 483.3 (MH+), 0.59 min; 1H NMR (400 MHz, CD3OD) 6 ppm 8.79-8.61 (m, 1 H) 7.97 (d, J=1.96 Hz, 1 H) 7.93-7.82 (m, 2 H) 7.48-7.39 (m, 3 H) 7.39-7.25 (m, 3 H) 5.25-5.14 (m, 1 H) 3.95-3.76 (m, 3 H) 3.69 (quin, J=8.22 Hz, 1 H) 3.50 (dd, J=9.78, 7.43 Hz, 1 H) 2.89 (s, 3 H) 2.80 (dd, J=16.82, 9.00 Hz, 1 H) 2.56 (dd, J=16.82, 8.22 Hz, 1 H). The diastereomeric mixture was ted by chiral SFC (ChiralPak 5mic AD column, 4.6x100 (mm), IPA+0.1% DEA=40%, 5mL/min). The polar reomer, 4-(2-amino((R)methyloxopyrrolidinyl)pyridinyl)—N-((S)—1-(3- chlorophenyl)hydroxyethyl)fluorobenzamide, was obtained at Rt = 1.41 min. LCMS (m/z): 483.3 (MH+), 0.586 min; 1H NMR (400 MHz, CD3OD) 6 ppm 7.82 (d, J=1.56 Hz, 1 H) 7.74 (t, J=7.83 Hz, 1 H) 7.35 (d, J=2.35 Hz, 2 H) 7.33-7.15 (m, 5 H) 5.09 (t, J=5.87 Hz, 1 H) 4.48 (s, 1 H) ) 3.83-3.63 (m, 3 H) 3.50 (quint, J=8.22 Hz, 1 H) 3.36 (dd, J=9.39, 7.43 Hz, 1H) 2.78 (s, 3 H) 2.67 (dd, 2, 9.00 Hz, 1 H) 2.42 (dd, J=16.63, 8.41 Hz, 1 H).
The less polar diastereomer, 4-(2-amino((S)methy|oxopyrro|idinyl)pyridiny|)- N-((S)(3-chlorophenyl)hydroxyethyl)fluorobenzamide, was obtained at Rt = 2.16 min. LCMS (m/z): 483.3 (MH+), 0.585 min; 1H NMR (400 MHz, CD30D) 6 ppm 7.92 (d, J=2.35 Hz, 1 H) 7.84 (t, J=8.02 Hz, 1 H) 7.51-7.21 (m, 7 H) 5.18 (t, J=5.87 Hz, 1 H) 3.94- 3.72 (m, 3 H) 3.59 (quin, J=8.22 Hz, 1 H) 3.50-3.42 (m, 1 H) 2.88 (s, 3 H) 2.82-2.70 (m, 1 H) 2.51 (dd, 2, 8.61 Hz, 1 H).
Example 45 S nthesis of S 2-Amino 4-meth ltetrah dro-2H- ran | ridin lfluoro-N- (2-hydroxy—1-phenylethyl)benzamide Scheme 51 WO 66188 Ste F SteQ ; F m3 F stag g Pd(dppf)C|2—DCM N\ NI \ / H NI \ NI \ . / _. / _.
NaZCO3 DME 0 OH I o o o 8—25 $0 mg $21 NH2 NH2 Br F O _/ NH N \ N \ | I / / N N \ —> —> + I H03 H / E.‘ O o —25te § F 0 {OH Pd(dppf)C|2—DCM N \ N/\©H —> | NaZCO3, DME Ste 1. 4- ro ridin Itetrah dro-2H- rancarbaldeh de To a solution of 5-bromofluoropyridine (2.0 g, 11.36 mmol) in dioxaane (35 mL) was added tetrahydro-2H-pyrancarbaldehyde (2.59 g, 22.73 mmol), Pd(OAc)2 (0.25 g, 1.14 mmol), cesium carbonate (7.41 g, 22.73 mmol), and water (10.24 uL, 0.57 mmol), xantphos (0.98 g, 1.70 mmol). The mixture was purged with nitrogen for 5 min, the resulting mixture was heated to 110 °C in an oil bath for 15 h. The e was diluted with ethyl acetate, and was washed with water, brine, dried over sodium sulfate and concentrated. The e was purified by flash column chromatography on silicagel (ISCO) eluting with 0-80% ethyl acetate in heptane to give 4-(6-fluoropyridin y|)tetrahydro-2H-pyrancarbaldehyde (560 mg, 2.68 mmol, 23.5 % yield) as red color oil. LCMS (m/z): 210 (MW), 0.45 min.
Ste 2. 4- 6-Fluoro ridin ltetrah dro-2H- ran lmethanol To an ice cooled solution of 4-(6-f|uoropyridiny|)tetrahydro-2H-pyrancarbaldehyde (560 mg, 2.68 mmol) in methanol (18 mL) was added sodium borohydride (91 mg, 2.41 mmol). The reaction solution was stirred at ambient temperature for 30 min. The solvent was removed under vacuum. The residue was diluted with ethyl acetate, and was washed with water, brine, dried over sodium sulfate, filtered and concentrated to give (4- (6-fluoropyridinyl)tetrahydro-2H-pyranyl)methanol (550 mg, 2.60 mmol, 97 %) as brown color oil. LCMS (m/z): 212 (MW), 0.42 min.
Ste 3. 2-F|uoro 4- iodometh h dro-2H- ran l ridine To an ice cooled solution of triphenylphosphine (983 mg, 3.75 mmol), iodine (952 mg, 3.75 mmol) in dichloromethane (20 mL) was added imidazole (278 mg, 4.09 mmol). The solution was stirred at ambient temperature for 1 h, followed by the addition of (4-(6- fluoropyridinyl)tetrahydro-2H-pyranyl)methanol (360 mg, 1.70 mmol) in 10 mL dichloromethane. The reaction mixture was heated to 60°C in an oil bath for 48 h. Solid was ed off, the filtrate was purified by flash column chromatography on silicagel (ISCO) eluting with 0-80% ethyl e in heptane to give to give 2-fluoro(4- (iodomethyl)tetrahydro-2H-pyranyl)pyridine (330 mg, 1.03 mmol, 60.3 % yield) as light yellow color oil. LCMS (m/z): 322 (MW), 0.77 min.
Ste 4. ro 4-meth ltetrah dro-2H- ran l ridine To a solution of (2-fluoro(4-(iodomethyl)tetrahydro-2H-pyranyl)pyridine (330 mg, 1.03 mmol) in THF (5mL) at -15 °C, was added N-selectride (2.26 mL, 2.26 mmol) dropwise. The solution was stirred at ambient temperature for 16 h. The solution was recooled in an ice bath, and 0.3 mL of water was added. The resulting solution was stirred for 10 min. The solvent was removed under vacuum, and the residue was dissolved in DCM. lnsoluble solid was ed, and the te was purified by flash column chromatography on silica gel (ISCO) g with 0-80% ethyl acetate in heptane to give to 2-fluoro(4-methyltetrahydro-2H-pyranyl)pyridine (110 mg, 0.56 mmol, 54.8 % yield) as colorless oil with >90% purity. LCMS (m/z): 196 (MH+), 0.64 min.
Ste 5. N- 24-Dimethox benz l 4-meth h dro-2H- ran l ridinamine To a solution of 2-fluoro(4-methyltetrahydro-2H-pyranyl)pyridine (110 mg, 0.56 mmol) in (2,4-dimethoxyphenyl)methanamine (1016 uL, 6.76 mmol) and DIEA (246 uL, 1.41 mmol) was added potassium carbonate (156 mg, 1.12 mmol). The resulting e was heated to 160 °C in an oil bath for 16 h, The reaction mixture was diluted with ethyl e, washed with water, brine, dried over sodium e and concentrated. The residue was purified by flash column chromatography on silicagel (ISCO) eluting with 0- 100% ethyl acetate in heptane to give N-(2,4-dimethoxybenzyl)(4-methyltetrahydro-2H- pyranyl)pyridinamine (100 mg, 0.29 mmol, 51.8 % yield) as light yellow color solid.
LCMS (m/z): 343 (MW), 0.63 min.
Ste 6. 5- 4-Meth ltetrah - ran l ridinamine To an ice cold solution of N-(2,4-dimethoxybenzyl)(4-methyltetrahydro-2H-pyran yl)pyridinamine (100 mg, 0.29 mmol) in DCM (6 mL) was added 10mL 30% TFA in DCM solution. The resulting solution was stirred at 0°C for 15min. The solvent was removed via vacuum. The resulting residue was redissolved in ethyl acetate, and the organic solution was washed with 1M NaOH, brine, dried over sodium sulfate and concentrated. The residue was purified by flash column chromatography on silicagel (ISCO) eluting with 0-100% ethyl acetate in heptane to give ethyltetrahydro-2H- pyranyl)pyridinamine (50 mg, 0.26 mmol, 89 % yield) as white color solid. LCMS (m/z): 193 (MH+), 0.35 min.
Ste 7. 3-Bromo 4-meth h dro-2H- ran l ridinamine To an ice cold solution of 5-(4-methyltetrahydro-2H-pyranyl)pyridinamine (50 mg, 0.26 mmol) in DCM (5 mL) was added NBS (50.9 mg, 0.28 mmol) in two portions. The reaction mixture was d at ambient temperature for 40 min. The reaction solution was diluted with ethyl acetate, washed with water, aqueous sodium bicarbonate, brine, dried over sodium sulfate, filtered off, and concentrated to give 3-bromo(4-methyltetrahydro- 2H-pyranyl)pyridinamine (70 mg, 0.26 mmol, 99 % yield) as yellow color residue.
LCMS (m/z): 271/273 (MH+), 0.41 min.
Ste 8. S 2-Amino 4-meth ltetrah dro-2H- ran l 3- lfluoro-N- 2- hydroxy—1-phenylethyl)benzamide To a solution of 3-bromo(4-methyltetrahydro-2H-pyranyl)pyridinamine (70 mg, 0.26 mmol) in DME (4 mL) was added (S)f|uoro-N-(2-hydroxyphenylethyl) (4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)benzamide (298 mg, 0.77 mmol) and sodium carbonate (0.64 mL, 1.29 mmol). The mixture was purged with nitrogen for 10 min, then PdC|2(dppf)-CH2C|2 (31.6 mg, 0.039 mmol) was added. The reaction mixture was heated to 120 °C in an oil bath for 2 h. The reaction mixture was diluted with ethyl acetate, washed with water, brine, dried over sodium sulfate and concentrated. The resulting residue was purified by flash column tography on silicagel (ISCO) eluting with 0- 100% ethyl e in heptane to give 70mg crude product, which was purified by HPLC to give (S)(2-amino(4-methyltetrahydro-2H-pyranyl)pyridinyl)—2-fluoro-N-(2- yphenylethyl)benzamide (40.8 mg, 0.089 mmol, 34.5 % yield) as TFA sa|t.
LCMS (m/z): 450 (MH+), 0.61 min; 1H NMR (400 MHz, CDCI3) 6 ppm 8.22 (t, J=7.83 Hz, 1 H) 7.77 - 7.65 (m, 2 H) 7.50 (dd, J=11.74, 7.43 Hz, 1 H) 7.42 - 7.36 (m, 4 H) 7.33 (d, J=7.43 Hz, 2 H) 7.21 (d, J=11.74 Hz, 1 H) 5.33 (d, J=4.70 Hz, 1 H) 4.08 - 3.94 (m, 2 H) 3.83 - 3.65 (m, 4 H) 1.97 (ddd, J=13.40, 8.12, 5.09 Hz, 2 H) 1.72 (d, 9 Hz, 2 H) 1.35 (s, 3 H) Example 46 S nthesis of 4- 3-amino razin l -N-benz lbenzamide Scheme 52 ““2 NH N N 2 CI Pd(dppf)C|2_DCM H O + N \ —> éé‘B 9N| N32003, DME b,“ To a solution of N-benzyl(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)benzamide (150 mg, 0.445 mmol), 3-chloropyrazinamine (74.9 mg, 0.578 mmol), and PdCl2(dppf)- CH2C|2 adduct (36.3 mg, 0.044 mmol) in DME (3.3 mL) was added 2 M Na2C03 (1.11 mL). The reaction mixture was heated at microwave synthesizer (120 °C, 10 min). Diluted with EtOAc and washed with water twice. Then extracted with 1N HCI (3 X15 mL). The acidic solution was washed with ether twice (2 X15 mL), and then basified with Na2C03. ed by extracting with EtOAc (20 mL, 3 times) and then washed by sat NaHC03, water and brine, dried over Na2804 and filtered off, concentrated. The crude product was purified with flash chromatography eluting with 0-100% of EtOAc(containing 10% MeOH) in heptane, then trated on rotavap. The residue was triturated with ether to provide 80.2 mg of desired product. LCMS (m/z): 305.2 (MH+), 0.59 min. 1H NMR (400 MHz, DMSO-de) 8 ppm 8.74 (d, J=8.22 Hz, 1 H) 8.41 (s, 1 H) 8.06 (dd, J=9.39, 2.74 Hz, 1 H) WO 66188 8.01 (d, J=8.61 Hz, 2 H) 7.94 (br. s., 1 H) 7.83 (d, J=8.22 Hz, 2 H) 7.40 - 7.34 (m, 2 H) 7.30 (t, J=7.63 Hz, 2 H) 7.22 (d, J=7.43 Hz, 1 H) 6.40 (d, J=9.39 Hz, 1 H) 5.12 - 5.03 (m, 1 H) 3.75 - 3.60 (m, 2 H).
Table 2. Compounds prepared from Method 1 described above Exampl NMR Structure Name MH+ Rf e (mm) H NMR (400MHz ,CD30D) 6 ppm 7.83 (s, 1 H), 7.78 (t, J = NH2 (R)_4_(3_amino_ 1 7.6 Hz, H), 7.66 (d, J = 7.8 Hz, N \ F ”AK: rahydro- H), 7.60 (d, J: 11.3 Hz, 1 H), /N 7.46 - 7.39 (m, 2 H), 7.35 (t, J = 2H_Wran_4_ 47 7.6 Hz, 2 H), 7.27 (d, J: 7.0 Hz, , 4213 03 y|)pyraz'“'2'y')' 1 H), 5.26 (d, J = 7.0 Hz, 1 H), Z-flUOVO'N'U' .05 (d, J = 10.6 Hz, 2 H), 3.57 O (t, phenylethyl)benz J = 10.4 Hz, 2 H), 2.95 (d, J = 4.7 amide Hz, 1 H), 1.96 - 1.78 (m, 4 H), 1.58 (d, J: 7.0 Hz, 3 H) 1H NMR (400MHz , CD30D) (R)'4'(3'am'“°', 6 ppm 8.21 (br. s., 1 H), 7.91 - '(tetrahydr0' 7.80 (m, 2 H), 7.75 - 7.65 (m, 2 2H-pyran H), 7.60 (d, J: 11.7 Hz, 1 H), F O y|)pyrazmyl)— 7.42 - 7.29 (m, 2 H), 4.15 (d, J = 48 558.3 0.8 NHZ N\ @‘SOQ 2—fluoro-N-(1-((2- .3 Hz, 1 H), 4.10 -4.00 (m, 2 H), fluorophenyl)sulf 3.68 (d, J = 8.6 Hz, 1 H), 3.57 (dt, onyl)piperidin J = 23,115 Hz, 2 H), 3.50 - 3.40 (m, 1 zamide H), 3.03 - 2.88 (m, 2 H), 1.99 - 1.78 (m, 5 H), 1.76-1.65 (m, 1 H), 1.65- 1.54 (m, 1 H) (R)—4—(3-amino- H NMR (400MHz , CD30D) 6 6-(tetrahydro- ppm 7.89 - 7.75 (m, 4 H), 7.74 - 2H-pyran 7.65 (m, 2 H), 7.65 - 7.56 (m, 3 H), 4.16 (br. s.,1 H), 4.11 -4.00 y|)pyraziny|)- 49 (m, 2 H), 3.57 (dt, J = 25,114 2—fluoro-N-(1 - Hz, 3 H), 3.00 - 2.89 (m, 1 H), (phenylsulfony|)p 2.84 - 2.65 (m, 2 H), 1.95 -1.78 iperidin (m, 6 H), 1.69 (dd, J = 3.5, 9.8 y|)benzamide Hz, 1 H), 1.58- 1.43 (m,1 H) PCT/USZOl4/062913 Exaempl NMR Structure (+/-)(3_amino_ 1H NMR (400MHz, CD30D) 6-(tetrahydro- 5PPm 7-77 (S. 1 H). 7-71 (m. 1 2H_pyran_4_ H), 7.64 - 7.48 (m, 2 H), 7.45 - 7.37 (m, 2 H), 7.38 - 7.23 (m, 3 yl)pyrazin_2_yl)_ H), 6.29 - 5.93 (m, 1 H), 5.54 - 50 N_(2 oro_’ .42 (m, 1 H), 4.06 - 3.88 (m, 2 1'phehy'ethy'1'2' H), 3.54 - 3.42 (m, 2 H), 2.92 - f'UOVObenzam'de 2.76 (m, 1 H), 1.90- 1.67 (m, 4 H NMR (400 MHz, 6) 5 (+l')'4'(3'am'“°', ppm 9.67 (d, J=9.39 Hz, 1 H) '(tetrahydr°' 7.88 (s, 1 H) 7.70 - 7.48 (m, 6 H) 2H-pyran 7.47 - 7.22 (m, 4 H) 5.96 (t, y|)pyraziny|)— J=9.00 Hz, 1 H) 3.87 (d, J=10.96 2-fluoro-N- Hz, 2 H) 3.5 (m, 2 H) 2.92 - 2.70 (2,2,2-trifluoro (m, 1 H) 1-32 - 1-52 (m. 4 H) phenylethyl)benz amide 1H NMR (400MHz ,DSMO-D6) 8 4_(3_amino_5_ (tetrahydro-ZH- ppm 7.92 (d, J = 7.0 HZ, 1 H), 7.68 - 7.51 (m, 3 H), 7.43 - 7.26 pyran_4_ . (m, 5 H), 7.21 (d, J = 7.0 Hz, 1 y')pyraz'n'2'y')' 52 H), 4.73 (s, 1 H), 4.49 (s, 1 H), N'benzyl'z' 3.97 - 3.88 (m, 2 4( m, 2H ‘fluorO-N- hide inside of water peak) 2.90 methylbenzamid (s, 1 H), 2.88 - 2.80 (m, 3 H), e 1.78-1.69(m,4H) H NMR (400MHz ,DMSO-d6) 8 (S)'4'(3'am'n°'. ppm 7.89 (d, J = 3.1 Hz, 1 H), 6'(tetrahydr°' F O _/OH 7.63 - 7.52 (m, 2 H), 7.45 (t, J = 2 2H-pyran 7.6 Hz, 1 H), 7.38 - 7.31 (m, 3 H), ““2 Tm y|)pyraziny|)- 7.31 - 7.21 (m, 2 H), 5.75 (dd, J = 53 N \ 2-fluoro-N-(2- 451.2 0.66 6.3, 8.6 Hz,1 H), 4.76 (br. s., 1 /N hydroxy H), 4.03- 3.93 (m,1 H), 3.90 (dd, phenylethyl)—N- J = 2.9, 11.2 Hz, 2 H), 3.40 - 3.35 methylbenzamid (m, 6 H), 2.81 (td, J = 3.2, 6.6 Hz, 0 H), 2.76 (s,1 H), 2.70 (s, 2 H), 1.74 - 1.67 (m, 4 H) l NMR Structure H NMR (400MHz, DMSO-d6) ppm 7.78 (br. s.,1 H), 7.70 (br.
(S)-(4-(3-amin0- s., 1 H), 7.40 (br. s., 1 H), 7.34 rahydro- (br. s., 1 H), 7.26 (br. s., 1 H), 2H-pyran 6.02 (br. s., 1 H), 5.31 (d, J = 4.3 54 y))pyrazin_2_ Hz, 1 H), 5.04 (br. s., 1 H), 3.91 yl)phenyl)(4_ (d, J = 11.0 Hz, 1 H), 2.82 (br. s., phenyloxazolidin H), 2.04 (s,1 H), 1.71 (br. s., 2 H)’ 1'20 (S’ 2 H) y|)methanone H NMR (400MHz, CD30D) F 0 {OH (S)(3-amin0- 8 ppm 7.90 - 7.83 (m, 2H), 7.69 = 6-(tetrahydro- NHZ N (d, J=8.2 Hz, 1H), 7.64 (d, J=11.7 H 2H-pyran—4— N \ F l Hz,)1H), 7.56 (dag, J=2.0, 7.0 Hz, _ 1H,7.45-7.35 m,1H,7.32- 55 /N 0' £2F122Thi24 489__ 0-75 7.18 (m, 1H), 5.18 (t, J=5.9 Hz, fluorophenyl)_2_ 1H), 4.10 - 4.01 (m, 2H), 3.91 - 3.80 (m, 2H), 3.65-3.53 (m, 2H), h drox eth 0 y y yI)_2_ 3.03 -2.88 (m, 1H), 1.99 - 1.78 fluorobenzamlde. (m, 4H) . H NMR (400 MHz, CD30D) (S)'4'(3'am'n°' F o {OH 8 ppm 8.56 (br. s., 1 H) 7.89-7.70 = 6'“ NH N (m, 2 H) 7.66-7.46 (m, 2 H) 7.41- H (methY'SU'f°“Y')p 7.07 (m, 5 H) 5.23-5.01 (m, 1 H) N/ iperidin 3.90-3.60 (m, 4 H) 2.91-2.62 (m, \ N y|)pyraziny|)- 514.2 0.6436 H) .61 (m, 4 H) 2-fluoro-N-(2- y 04%0 ph9nylethyl)benz amide H NMR (400 MHz, CD30D) F O = (R)_4_(3_amino_ 8 ppm 8.73 (d, J=6.26 Hz, 1 H) 6_(1_ NH2 N 7.78 (s, 1 H) 7.63 - 7.71-7.63 (m, mthYISUIfony')“, H 1 H) 7.60-7.47 (m, 2 H) 7.35 (s, 1 \ 'N perldln CI 532/5 H)7.29-7.13(m, 3 H) 5.07-5.19- 57 |)pyraziny|)-N- 0.85 5.07 (m,1 H) 3.75 (d, 3 (1-(3- Hz, 2 H) ) 2.86-2.65 (m, 6 H) 1.99-1.70 (m, 4 H) 1.53-1.40 (m, N chloropheny|)eth 0,520 y|) 3 H) I fluorobenzamide Exampl 2° NMR Structure (min) Synthesis of (8)- H NMR (400 MHz, CD30D) methyl 4-(5- 6 ppm 7.65-7.66 (m, 1 H), 7.42 - .42 (m, 2 H), 7.41-7.05 (m, amino(3- H), 5.22-5.00 (m, 1 H) 4.14 (d, fluoro((2- J=13.3 Hz, 2 H), 3.63-3.69 (m, 2 hydroxy 58 494.2 0709 H) 3.60 (s, 3 H) 2.99-2.63 (m, 3 phenylethyl)carb H), 1.60 (d, J=12.52 Hz, 2 H), amoyl)phenyl)py 1.70-1.55 (m, 2 H) razin y|)piperidine carboxylate thy| 4-(5- amino(4-((1- 1H NMR (400 MHz, CD30D) (3-chlorophenyl)- 6 ppm 7.90-7.61 (m, 2 H)7.72- 2- 7.56 (m, 2 H) 7.46 (s, 1 H)7.41- 528.2 7.24 (m, 3 H) 5.19 (t, J=5.67 Hz, hydroxyethy|)car 59 /530. 0.7771 H)4.23 (d, J=12.91 Hz, 2 H) bamoyI) 2 3.92-3.76(m,2H) 3.70 (s, 3 H) fluorophenyl)pyr 3.06-2.62 (m, 3 H) 1.90 (d, azin J=12.52 Hz, 2 H) 1.72 (qd, y|)piperidine J=12.52, 4.30 Hz, 2 H) carboxylate H NMR (400 MHz, CD30D) 6 ppm 7.61-7.69 (m, 2 H), 7.62- (S)(6-(1- 7.45 (m, 2 H), 7.09 - 7.37-7.09 acetylpiperidin- (m, 6 H), 6.5(dd,J=8.61, 2.35 Hz, 4-y|) 1 H), 6.50 (dd, J=13.50, 2.15 Hz, aminopyrazin-Z- 1 H), 5.17-5.01 (m,1 H),4.55 (d, 60 478.2 y|)f|uoro-N-(2- =13.30 Hz, 1 H) 3.94 (d, hydroxy J=13.69 Hz, 1 H) 3.63-3.63 (m, 2 phenylethyl)benz H) 2.66 (tt, J=11.84, 3.62Hz, 1 H) 2.67 (td, J=12.91, 2.35 Hz, 1 H) amide 2.03 (s, 3 H)1.96-1.79 (m, 2 H) .50 (m, 2 H) H NMR (400 MHz, CD30D) (S)(6-(1- 6 ppm 7.63-7.70 (m, 2H)7.64- acetylpiperidin- 7.46 (m, 2 H) 7.37 (s, 1 H) 7.14 - 3- 7.31-7.14 (m, 3 H) 5.15-5.02 (m, 512-2 aminopyrazin-Z- 1 H)4.55 (d, J=13.69 Hz,1 H) 61 \N CI /514- 0-58 01-366 (m, 1 H)3.64-3.67(m,2 y|)-N-(1-(3- 2 H) 2.95-2.60 (m, 1 H) 2.74-2.60 chlorophenyI) (m, 1 H) 2.03 (s, 3 H)1.93-1.79 hydroxyethy|) (m, 2 H) 1.76-1.53 (m, 2 H) fluorobenzamide Exaempl NMR Structure methyl 3-(6- H NMR (400 MHz, CDgOD) 5_(3_ 8 ppm 8.66-8.41 (m, 1 H) 7.98- fluoro(((S) 7.61 (m, 3 H) 7.51-7.00 (m, 7 H) .02 (m, 1 H) 3.87-3.67 (m, hydroxy_1_ 3H) 3.61 (s, 3 H) 3.59-3.49 (m, 1 62 phenylethyl)carb 479.2 0.599 H) 3.44-3.28 (m, 3 H) 2.22 (br. S” amoy'whenyopy 1 H) 2.08-1.86 (m, 1 H) rIdIn yI)pyrroIidine carboxylate H NMR (400 MHz, CD30D) 4'(2'am'“0'5'(1'. 8 ppm 8.56 (dd, J=7.24, 4.11 Hz, (methylsulfonylw 1 H) 7.87 (d, J=1.96 Hz, 1 H) yrrolidin 7.84-7.74 (m, 2 H) 7.42-7.10 (m, yI)pyridinyI) 8 H) 5.19-5.04 (m, 1 H) 3.84-3.71 f|uoro_N_((S)_2_ 499'20'565(m, 2 H) 3.66 (dd, J=9.78, 7.43 hydroxy_1_ Hz, 1 H) 3.54-3.28 (m, 3 H) 2.84 phenylethymenz (s, 3 H) 2.37-2.22 (m, 1 H) 2.11- 1.93 (m,1 H) amide H NMR (400 MHz, DMSO-de) 6 ppm 8.70 (d, J=7.83 Hz, 1H), (S)_4_(2_amino_ 7.97 (d, J=8.61 Hz, 2H), 7.86 (d, rahydro- J=1.96 Hz, 1H), 7.53 (d, J=8.22 Hz, 2H), .42 (m, 2H), 7.29 2H_pyran_4_ (t, J=7.63 Hz, 2H), 7.15-7.25 (m, 64 yI)pyridin_3_yl)_ 2H), 5.38-5.51 (m, 2H), 5.00-5.14 N'(2'hydr°Xy'1' (m, 1H), 4.91 (t, J=5.87 Hz, 1H), ethyl)benz 3.85-3.97 (m, 2H), 3.57-3.78 (m, amide 2H), 3.38 (dt, J=3.72, 10.86 Hz, 2H), 2.56-2.72 (m, 1H), 1.49-1.71 (m, 4H) 1H NMR (400 MHz, METHANOL- (S)'4'(2'am'“°', d4) 6 ppm 7.76 (d, J=1.96 Hz, '(tetrahydr0' 1H), 7.66 (d, J=1.96 Hz, 1H), 2H-pyran 7.47 (d, J=7.83 Hz, 1H), 7.31- yI)pyridinyl)- 7.36 (m, 2H), 7.23-7.31 , N-(2-hydroxy 7.15-7.22 (m, 1H), 5.04-5.20 (m, phenylethyI) 1H), 3.95 (dd, J=2.93, 11.54 Hz, methylbenzamid 2H), 3.59-3.81 (m, 2H), 3.37-3.52 (m, 2H), 2.67-2.85 (m, 1H), 2.33 (s, 3H), 1.46-1.85 (m, 4H) Exaempl NMR Structure 1H NMR (400 MHz, DMSO-de) 5 4'(2'am'“°'5'I ppm 9.12 (t, J=5.87 Hz, 1H), 8.00 (tetrahdeO-ZH- (d, J=8.61 Hz, 2H), 7.81 (s, 2H), pyran 7.54 (d, J=8.22 Hz, 2H), 7.08- 66 yI)pyridinyl)- 7.44 (m, 6H), 4.46 (d, J=5.87 Hz, N- 2H), 3.88 (dd, J=2.35, 11.35 Hz, benzylbenzamid 2H), 2.66-2.80 (m, 1H), 1.46-1.77 e (m, 4H) (two CH2 proton next to oxygen were under water) H NMR (400 MHz, e) 5 4_(2_amino_5_ ppm 9.06 (t, J=5.87 Hz, 1H), 8.00 (tetrahydro-2H- (d, J=8.61 Hz, 2H), 7.85 (d, J=1.96 Hz, 1H), 7.81 4_ (d, J=1.57 . . Hz, 1H), 7.54 (d, J=8.22 Hz, 3H), yI)pyr'd'n's'yl)' 67 7.09 (t, J=7.83 Hz, 1H), 6.71 (br.
N'I(3' s., 1H), 6.60 (d, J=5.87 Hz, 2H), (d'methylam'no)I .40 (d, J=5.87 Hz, 2H), 3.84- benzyl)benzamid 3.97 (m, 4H), 3.33 (dt, J=2.35, e 11.35 Hz, 2H), 2.83 (s, 6H), 2.74 (br.s.,1H), 1.50-1.75 (m, 4H) 1H NMR (400 MHz, DMSO-de) 5 ppm 8.92 (d, J=7.83 Hz, 1 H), (S)'4'(2'am'“°'I 8.17 (d, J=8.61 Hz, 1 H), 7.99 (d, '(tetrahydr0' J=7.83 Hz, 1 H), 7.87 (d, J=1.96 2H-pyran Hz, 1 H), 7.80 (br. s., 1 H), 7.52 yI)pyridinyI) (d, J=7.83 Hz, 1 H), 7.34 - 7.39 ch|oro-N-(2- (m, 2 H), 7.30 (t, J=7.43 Hz, 2 H), hydroxy_1_ 7.22 (d, J=7.04 Hz, 1 H), 4.96 - etWDbenz 5.18 (m, 1 H), 3.91 (dd, 6, 3.13 Hz, 2 H), 3.58 - 3.79 (m, 2 amide H), 3.43 (2 H),2.68 - 2.91 (m, 1 H), 1.55 - 1.82 (m, 4 H) 1H NMR (400 MHz, DMSO-de) 5 (R)_4_(2_amino_ ppm 8.85 (d, J=8.22 Hz, 1 H), -(tetrahydro- 8.00 (d, J=8.61Hz, 2 H), 7.69 - 7.87 (m, 2 H), 7.52 (d, J=8.22 Hz, 2H_pyran_4_ 2 H), 7.31 - 7.36 (m, 2 H), 7.27 (t, 69 yI)pyridin_3_yl)_ J=7.63 Hz, 2 H), 7.13 - 7.20 (m, 1 N'(1' H), 5.15 (t, J=7.43 Hz, 1 H), 3.75 Phenylethyl)benz - 3.99 (m, 2 H), 3.36 (br. s., 2 H), amide 2.66 - 2.84 (m, 1 H), 1.53 - 1.75 (m, 4 H), 1.44 (d, J=7.04 Hz, 3 H) Exaempl NMR Structure 1H NMR (400 MHz, DMSO-de) 5 (s)_4_(2_amino_ ppm 8.67 (d, J=7.83 Hz, 1 H), -(tetrahydro- 7.88 (br. s., 1 H), 7.76 - 7.85 (m, . . 3:239:12;92::-3 yI)pyr'd'n's'yl)' . m, , . . m, 70 H), 7.14 - 7.20 (m, 1 H), 4.97 - N'(2'hydroxy'1' 5.10 (m, 1 H), 3.87 (dd, 6, phenylethy')'3' 3.33 Hz, 2 H), 3.53 - 3.74 (m, 2 methylbenzamid H), 3.33 (d, J=1.96 Hz, 2 H), 2.66 e -2.82 (m, 1 H), 2.11 (s, 3 H), 1.50 - 1.74 (m, 4 H) 1H NMR (400 MHz, DMSO-de) 5 . ppm 8.83 (d, J=8.22 Hz, 1 H), (S)'4'(2'am'“°' 7.78 - 7.93 (m, 4 H), 7.52 (t, -(tetrahydr0- J=7.63 Hz, 1 H), 7.30 - 7.35 (m, 2 2H-pyran H), 7.26 (t, J=7.43 Hz, 2 H), 7.14 yI)pyridinyl)—3- — 7.22 (m, 1 H), 4.99 - 5.08 (m, 1 fluoro-N-(2- H), 3.88 (dd, J=10.96, 3.13 Hz, 2 hydroxy_1_ H), 3.57 - 3.72 (m, 2 H), 3.30 (2 mobem H), 2.67-2.79 (m, 1 H), 1.53- 1.71 (m, 4 H), amide H NMR (400MHz ,CD30D) 8 (S)—4-(3-amino- ppm 7.79 (s, 1 H), 7.78 - 7.74 (m, .9. 1 H), 7.56 (dd, J: 1.4, 8.0 Hz, 1 ethoxyethyl)pyra H), 7.51 (dd, J = 1.2, 11.7 Hz, 1 H), 7.36 - 7.31 (m, 2 H), 7.27 (t, J zin_2_yl)_2_ 72 = 7.6 Hz, 2 H), 7.19 (d, J = 7.0 fluorO_N_(2_ Hz,1 H), 5.12 (t, J=6.1 Hz,1 H), hydroxy'1' 3.83 - 3.71 (m, 2 H), 3.67 (t, J = Phenylethyl)benz .7 Hz, 2 H), 3.42 (q, J = 7.0 Hz, amide H), 2.86 (t, J = 6.5 Hz, 2 H), 1.06 (t, J = 7.0 Hz, 3 H) 1H NMR (400 MHz, DMSO-de) 5 . ppm 8.77 (d, J=8.22 Hz, 1 H), (S)'4'(2'am'“°' 7.82 (d, J=1.96 Hz, 1 H), 7.76 (s, '(tetrahydr0' 1 H), 7.59 (d, J=1.57 Hz, 1 H), CI 0 : 2H-pyran 7.52 - 7.56 (m, 1 H), 7.46 (dd, NH2 N J=8.02, 1.37 Hz, 1 H), 7.32 - 7.37 73 4525 0'59 yI)pyridin-3—yl)—2- N \ H/\© -N-(2- (m, 2 H), 7.28 (t, J=7.43 Hz, 2 H), / y_1_ 7.16 - 7.23 (m, 1 H), 4.93 - 5.02 phewlemobem (m, 1 H), 3.84 - 3.93 (m, 2 H), 3.58 (d, J=7.04 Hz, 2 H), 3.30 (2 amide 0 H), 2.68-2.79 (m,1 H), 1.55- 1.70 (m, 4 H) WO 66188 Exampl NMR Structure 1H NMR (400 MHz, CD30D) 5 (S)—4-(2-amino- ppm 8.87 (d, J=8.22 Hz, 1 H), -(tetrahydro- 7.75 - 7.85 (m, 2 H),7.68 - 7.73 2H-pyran (m, 2 H), 7.63 - 7.68 (m, H),7.31 - 7.36 (m, 2 H), 7.28 (t, y|)pyridiny|)— 74 J=7.43 Hz, 2 H), 7.17 - 7.24 (m, 1 N-(2-hydroxy H), 5.02 - 5.20 (m, 1 H), 3.95 (dd, phenylethyl)—2- J=11.15, 3.33 Hz, 2 H), 3.65 - (trifluoromethyl)b 3.86 (m, 2 H), 3.45 (td, J=11.44, enzamide 2.54 Hz, 2 H), 2.68 - 2.90 (m, 1 H), 1.53 - 1.87 (m, 4 H) 4—(2-amino (tetrahydro-ZH- 1H NMR (400MHz, DMSO-d6) 5 pyran ppm 8.92 (m, H), 8.69 - 8.49 (m, 2 H), 7.87 (m, 1 H), 7.75 (m, y|)pyridiny|)—2- 75 1 H), 7.44 - 7.32 (m, 2 H), 7.28 fluoro-N- (m, 1 H), 5.58 (m, 1 H), 4.63 (m, (pyrazin 2 H), 3.89 (m, 2 H), 3.38 (m, 2 y|)benzam H), 2.64 (s, 1 H), 1.64 (m, 4 H). 1H NMR (400MHz, CD30D) 5 amino-4— ppm 7.89 (d, J=2.0 Hz, 1 H) 7.76 (2-amino (dd, J=5.1, 3.1 Hz, 2 H) 7.18- (tetrahydro-ZH- 7.49 (m, 5 H) 6.84 (d, J=1.6 Hz, 1 pyran H) 6.74 (dd, J=8.0, 1.8 Hz, 1 H) y|)pyridiny|)— 5.15 - 5.26 (m, 1 H) 4.06 (dd, N-(2-hydroxy J=11.0, 3.5 Hz, 2 H) 3.78 - 3.95 phenylethyl)benz (m, 2 H) 3.57 (td, J=11.5, 2.3 Hz, 2 H) 2.77 - 2.97 (m, 1 H) 1.68- amide 1.91 (m, 4 H) 1H NMR (400 MHz, CD30D) 5 ppm 8.81 (d, J=7.83 Hz, 1 H), (S)—4-(2-amino- 8.05 (d, J=8.61 Hz, 2 H), 7.92 (d, -(1,1- J=1.96 Hz, 1 H), 7.84 (d, J=1.57 dioxidotetrahydr Hz, 1 H), 7.61 (d, J=8.22 Hz, 2 o-2H-thiopyran- H), 7.39 -7.45 (m, 2 H), 7.35 (t, yridiny|)— J=7.43 Hz, 2 H), 7.24 - 7.31 (m, 1 N-(2-hydroxy H), 5.24 (q, J=7.04 Hz, 1 H), phenylethyl)benz 3.89 (d, J=6.65 Hz, 2 H), 3.30 (2 amide H), 3.07 - 3.22 (m, 2 H), 2.99 (tt, J=10.27, 5.38 Hz, 1 H), 2.17 - 2.40 (m, 4 H) Exampl NMR Structure 4—(2—amino 1H NMR (400MHz, DMSO-d6) 5 (1 1 - , ppm 8.89 - 8.74 (m, 1 H), 7.94 - dioxidotetrahydr 7.79 (m, 1 H), 7.72 (s,1 H), 7.47 78 o-2H-thiopyran- - 7.28 (m, 8 H), 7.25 - 7.14 (m, 1 4—yl)pyridiny|)— H), 4.47 (d, J = 8.1 Hz, 2 H), 3.14 N-benzyI - 2.98 (m, 2 H), 2.91 - 2.74 (m, 1 fluorobenzamide H), 2.15 - 2.01 (m, 4 H) (S)—4-(2-amino- -( 1 ,1 - otetrahydr 1H NMR (400MHz, CD30D) 5 o-2H-thiopyran- ppm 8.00 - 7.78 (m, 2 H), 7.42 (m, 1 H), 7.41 - 7.21 (m, 7 H), 5.2 79 4—yl)pyridiny|)— (m, 1 H), 3.91 - 3.78 (m, 2 H), 2—fluoro-N-(2- 3.32 (m, 2 H), 3.09 (m, 2 H), 2.82 hydroxy (m, 1 H), 2.29-2.15 (m, 4 H) phenylethyl)benz amide 1H NMR (400 MHz, CD30D) 5 ppm 8.70 (d, J=7.83 Hz, 1 H), (S)—4-(6-amino- 8.81 (d, J=6.65 Hz, 2 H), 8.58 (d, J=2.35 Hz, 1 [3,4'-bipyridin]—5- H), 8.11 (d, J=6.65 Hz, 2 H), 8.08 (d, J=2.35 Hz, 1 y|)-N-(2-hydroxy- H), 7.98 (d, J=8.22 Hz, 2 H), 7.57 (d, J=8.22 Hz, 2 H), 7.30 - 7.38 phenylethyl)benz (m, 2 H), 7.28 (t, J=7.43 Hz, 2 amide H), 7.14 - 7.22 (m, 1 H), 5.10 - .19 (m, 1 H), 3.80 (d, J=6.65 Hz, 2 H) 1H NMR (400 MHz, CD30D) 5 (S)—4-(6-amino- ppm 8.55 - 8.87 (m, 3 H), 8.47 - 8.55 (m, 1 bipyridin]—5- H), 8.15 (d, J=6.65 Hz, 2 H), 8.07 (d, J=2.35 Hz, 1 H), y|)f|uoro-N-(2- 81 | 429.3 0.45 (t, J=7.43 Hz, 1 H), 7.31 - hydroxy 7.42 (m, 4H), 7.27 (t, J=7.63 Hz, phenylethyl)benz 2 H), 7.15 - 7.22 (m, 1 H), 5.13 (t, amide J=5.87 Hz, 1 H), 3.70 - 3.85 (m, 2 Exampl NMR Structure H NMR (400MHz ,DMSO-D6) 5 ppm 8.78 (d, J = 7.8 Hz, 1 H), (S)—4-(6-amino- 8.70 (s, 1 H), 8.84 (d, J = 5.5 Hz, 1 1 hy|—3,4'- H), 8.24 (d, J = 2.0 Hz, H), 8.07 (d, J = 8.2 Hz, 2 H), 7.75 (br. bipyridinyl)—N- 82 s., 2 H), 7.84 (d, J = 8.2 Hz, 2 H), roxy 7.40 (d, J = 7.4 Hz, 2 H), 7.33 (t, phenylethyl)benz J = 7.8 Hz, 2 H), 7.25 (d, J = 7.0 amide Hz, 1 H), 5.11 (d, J = 5.5 Hz, 1 H), 3.78 - 3.83 (m, 2 H), 2.48 (s, 3 H) (S)—4-(6-amino- 1H NMR (300MHz, DMSO-d6) 5 3'-methy|—3,4'- bipyridinyl)—2- ppm 8.68 (s,1 H),8.62 (s, 2 H), 8.23 (s, 1 H), 7.83 - 7.66 (m, 2 83 fluoro-N-(2- H), 7.55 - 7.21 (m, 7 H), 5.06 (d, hydroxy J = 7.3 Hz, 1 H), 3.66 (d, J = 6.4 phenylethyl)benz Hz, 2 H), 2.44 (s, 3 H) amide 1H NMR (400 MHz, CD30D) 5 4—(2-amino ppm 7.79 - 7.88 (m, 1 H), 7.75 (d, ((R) J=2.35 Hz, 1 H), 7.31 - 7.44 (m, 8 methylmorpholin H), 7.30 (d, J=2.74 Hz, 1 H), 7.27 o)pyridiny|)—2- (d, J=7.43 Hz, 1 H), 5.19 (t, fluoro-N-((S) J=8.08 Hz, 1 H), 3.72 - 3.90 (m, 4 hydroxy H), 3.41 - 3.50 (m, 1 H), 3.32 - phenylethyl)benz 3.38 (m, 1 H), 3.11 (t, J=1.57 Hz, amide H), 2.98 - 3.02 (m, 2 H), 0.91 (d, J=8.85 Hz, 3 H) (S)—4-(2-amino- - 1H NMR (400MHz, CD30D) 8 morpholinopyridi ppm 8.08 (d, J=8.2 Hz, 2 H) 7.87 (d, J=2.7 Hz, 1 H) 7.83 (d, J=8.2 85 ny|)f|uoro- Hz, 2 H) 7.24 - 7.48 (m, 8 H) 5.19 N-(2-hydroxy 5.30 (m, 1H) 3.90 (m, 2H) - 3.85 phenylethyl)benz (m, 4 H) 3.12 (m, 4 H) amide WO 66188 Exampl NMR Structure 1H NMR (300 MHz, CD30D) 5 4—(2-amino ppm 8.04 (d, J=8.20 Hz, 2 H), (tetrahydro-ZH- 7.91 (d, J=2.05 Hz,1 H) 7.78 (d, pyran J=1.76 Hz, 1 H), 7.81 (d, J=8.20 86 y|)pyridiny|)— Hz, 2 H), 7.22 - 7.43 (m, 4 H), N-(3- .59 (s, 2 H), 3.93 - 4.13 (m, 2 chlorobenzyl)be H), 3.54 (td, J=11.43, 2.93 Hz, 2 nzamide H), 2.77 - 2.98 (m, 1 H), 1.85 - 1.91 (m, 4 H) 1H NMR (300 MHz, CD30D) 5 4—(2-amino ppm 7.95 (d, J=8.20 Hz, 2 H), (tetrahydro-ZH- 7.80 (d, J=2.05 Hz, 1 H), 7.89 (d, J=1.76 Hz, 1 H), 7.51 (d, J=8.20 pyran Hz, 2 H), 7.28 - 7.38 (m, 2 H), 87 y|)pyridiny|)— 7.13 - 7.28 (m, 2 H), 4.81 (s, 2 N-(2- H), 3.88 - 4.02 (m, 2 H), 3.45 (td, chlorobenzyl)be J=11.43, 2.93 Hz, 2 H), 2.88 - nzamide 2.85 (m, 1 H), 1.81 - 1.78 (m, 4 1H NMR (300 MHz, CD30D) 5 4—(2-amino ppm 7.93 (d, J=8.20 Hz, 2 H), (tetrahydro-ZH- 7.81 (d, J=2.05 Hz, 1 H), 7.88 (d, pyran J=1.76 Hz, 1 H), 7.51 (d, J=8.50 idiny|)— Hz, 2 H), 7.28 (d, J=1.17 Hz, 4 N-(4- H), 4.49 (s, 2 H), 3.87 - 4.02 (m, chlorobenzyl)be 2 H), 3.45 (td, J=11.36, 2.78 Hz, 2 H), 2.88 - 2.85 (m, 1 nzamide H), 1.82 - 1.79 (m, 4 H) 4—(2-amino 1H NMR (300 MHz, CD30D) 5 (tetrahydro-ZH- ppm 7.95 (d, J=8.50 Hz, 2 H), 7.82 (d, J=2.05 Hz, 1 H), 7.88 (d, pyran J=1.76 Hz, 1 H), 7.40 - 7.81 (m, 8 89 y|)pyridiny|)— H), 4.58 (s, 2 H), 3.89 - 4.01 (m, N-(3- 2 H), 3.45 (td, J=11.43, 2.93 Hz, (trifluoromethyl)b 2 H), 2.89 - 2.85 (m, 1 H), 1.82 - enzyl)benzamide 1.77 (m, 4 H) Exaempl NMR Structure (S)'2'(2'am'“°' 1H NMR (300 MHz, CD30D) 6 '(tetrahydr0' ppm 9.29 - 9.42 (m, 3 H), 8.00 (d, 2H-pyran J=2.05 Hz, 1 H), 7.21 - 7.52 (m, 5 yI)pyridinyl)- H), 5.25 (t, J=6.74 Hz, 1 H), 3.98 N-(2-hydroxy - 4.16 (m, 2 H), 3.81 - 3.96 (m, 2 midine_5_ H), 2.85 - 3.05 (m, 1 H), 1.76 - 1'91 (m’ 4 H) carboxamide 1H NMR (400 MHz, CD30D) 6 . ppm 7.90 (d, J=8.61 Hz, 2 H), 4'(2'am'“°'5' 7.82 (d, J=1.96 Hz, 1 H), 7.68 (d, (tetrahdeO-ZH- J=1.96 Hz, 1 H), 7.50 (d, J=8.22 pyran Hz, 2 H), 3.95 (dd, J=10.96, 3.52 91 yI)pyridinyl)- Hz, 2 H), 3.45 (td, J=11.64, 2.54 N- Hz, 2 H), 3.18 (d, J=7.43 Hz, 2 (cyclopropylmeth H), 2.71 -2.84 (m, 1 H), 1.58- yDbenzamide 1.78 (m, 4 H), 0.96 - 1.10 (m, 1 H), 0.38 - 0.52 (m, 2 H), 0.11 - 0.28 (m, 2 H) 1H NMR (400 MHz, CD30D) 6 ppm 8.02 (d, J=8.22 Hz, 2 H), N_(3_ 7.89 (d, J=1.96 Hz, 1 H), 7.76 (d, acetamidobenzyl =1-57 HZ! 1 H)! 7'66 (S! 1 -ami“° H???iréd’1fif'3222 21%“ 92 (tetrahydro'ZH' Hz, 1 H), 7.06 -7.13 (m,1 H), pyran'4' A .53 - 4.63 (m, 2 H), 4.02 (dd, y|)pyridin , 3.52 Hz, 2 H), 3.53 (td, y|)benzamide =11.54, 2.35 Hz, 2 H), 2.78 - .93 (m, 1 H), 2.09 (s, 3 H), 1.64 1.88 (m, 4 H) 1H NMR (400 MHz, CD30D) 6 m'“°'5'. ppm 8.71 (s,1 H), 8.59 (d, J=5.09 Hz, 1 H), 8.31 (d, J=8.22 (tetrahdeO-ZH- Hz, 1 H), 7.95 (d, J=8.22 Hz, 2 pyran H), 7.74 - 7.86 (m, 2 H), 7.69 (d, 93 yI)pyridinyl)- J=1.96 Hz, 1 H), 7.53 (d, J=8.22 N_(pyridin_3_ Hz, 2 H), 4.59 -4.68 (m, 2 H), ylmetWDbenzam 3.94 (dd, J=10.96, 3.52 Hz, 2 H), 3.45 (td, J=11.44, 2.54 Hz, 2 H),2.70 -2.84 (m, 1 H), 1.58 - 1.80 (m, 4 H) Exampl NMR 1H NMR (400 MHz, CD30D) 5 (2-amino- ppm 1.60 - 1.77 (m, 4 H) 2.71 - —(tetrahydro- 2.83 (m, 1 H) 3.45 (td, J=11.44, 2H-pyran 2.54 Hz, 2 H) 3.70 - 3.83 (m, 2 H) y|)pyridiny|)—2- 3.95 (dd, J=11.35, 3.13 Hz, 2 H) fluoro-N-(2- 5.09-5.17 (m, 1 H) 7.15 -7.22 hydroxy (m, 1 H) 7.27 (t, J=7.43 Hz, 2 H) phenylethyl)benz 7.29 - 7.36 (m, 4 H) 7.70 (d, J=1.96 Hz, 1 H) 7.80 amide (t, J=8.02 Hz, 1 H) 7.84 (d, J=2.35 Hz,1 H). 1H NMR (400MHz, DMSO-d6) 6 (S)—4-(3-amino- ppm 8.59 (d, J = 8 Hz, 1 H), 7.85 6-(tetrahydro- (s, 1 H), 7.58-7.49 (m, 2 H), 7.44 an (d, J = 8 Hz, 1 H), 7.39 - 7.27 (m, 95 aziny|)— A H), 7.25-7.18 (m, 1 H), 5.02 (m, N-(2-hydroxy 1 H), 3.93 - 3.87 (m, 2 H), 3.64 - phenylethyl)—2- 3.57 (m, 2 H), 3.43 (m, 2 H, methylbenzamid hidden behind DMSO), 2.81 (m, 1 H), 2.33 (s, 3 H), 1.74 - 1.66 (m, 4 H). 4—(2-amino ((28,6R)—2,6— 1H NMR (300 MHz, CD30D) 5 dimethylmorpholi ppm 7.83 - 7.95 (m, 2 H), 7.24 - 7.51 (m, 8 H), 5.22 (t, J=6.01 Hz, no)pyridiny|)— 96 1 H), 3.71 - 3.94 (m, 4 H), 3.44 2—fluoro-N-((S)— (d, J=10.84 Hz, 2 H), 2.34 (t, 2-hyd roxy-1 - J=10.99 Hz, 2 H), 1.22 (d, J=6.15 phenylethyl)benz Hz, 6 H) amide 4—(2-amino 1H NMR (300 MHz, CD30D) 5 ((28,6R)—2,6— ppm 8.23 (d, J=7.33 Hz, 2 H), dimethylmorpholi 8.06 (br. s., 1 H), 7.79 (d, J=7.62 no)pyridiny|)— Hz, 2 H), 7.41 - 7.68 (m, 6 H), N-((S) 5.41 (br. s., 1 H), 3.87-4.18 (m, hydroxy A H), 3.62 (d, J=12.31 Hz, 2 H), phenylethyl)benz 2.52 (t, J=10.70 Hz, 2 H), 1.31 - 1.52 (m, 6 H) amide Exaempl NMR Structure 1H NMR (300 MHz, CD30D) 5 (S)fmethy' 4'(5' ppm 7.98 - 8.12 (m, 2 H), 7.91 '(4'((2' (d, J=1.78 Hz, 1 H), 7.53 - 7.88 hydroxy (m, 2 H) 7.78 (s, 1 H), 7.21 - 7.48 phenylethyl)carb (m, 5 H), 5.24 (d, J=6.74 Hz, 1 amoyl)phenyl)py H),4.26 (d, J=12.89 Hz, 2 H), 3_ 3.89 (d, J=8.74 Hz, 2 H), 3.89 (d, y|)piperidine—1- J=1.76 Hz, 314), 2.73 - 3.03 (m, 3 H), 1.90 (d, J—12.80 Hz, 2 H), carboxylate 1.51 - 1.72 (m, 2 H) 4_(3_amino_5_ 1H NMR (400 MHz, CD30D) 5 Cin¥2-yF|))-2Fj1¥|upgro-Clo r0 | raz ppm 8.00 (s, 1H), 7.82 - 7.91 (m, 3H), 7.78 (d, J = 7.8 Hz, 1H), 99 7.83 - 7.89 (m, 2H), 7.59 (dd, J = N'(3' 11.5,1.4 Hz, 1H), 4.72 (s, 2H), (methY'SU'f°“¥')b 3.12 (s, 3H), 2.08 (tt, J = 7.9, 5.0 enzyl)benzamlde Hz, 1H), 0.84 - 1.02 (m, 4H) 4_(3_amino_5_ 1H NMR (400 MHz, CD30D) 5 R)—2- ppm 7.94 - 8.01 (m, 3 H) 7.81 - 7.89 (m, 4 H) 7.73 (d, J=7.83 Hz, methyltetrahydro 1 H) 7.58- 7.85 (m, 1 H)4.89 (s, _2H_pyran_4_ 100 2 H)4.00-4.09 (m, 1 H) 3.53 - y )pyraz'“'I 2'y )'I 3.85 (m, 2 H) 3.10 (s, 3 H) 2.87 - N'(3' 2.98 (m, 1 H) 1.74 - 1.92 (m, 3 H) (methylsulfonyl)b 1.44 - 1.58 (m, 1 H) 1.24 - 1.39 enzyl)benzamide (m, 1 H) 1.19 (d, J=6.26 Hz, 3 H) 4_(3_amino_5_ 1H NMR (400 MHz, DMso-d8) 5 ((28.4S) 9.23 (t, J=5.87 Hz, 1 H) 7.99 (d, J=8.22 Hz, 2 H) 7.78 methyltetrahydro - 7.90 (m, 5 H) 7.57 - 7.89 (m, 2 H) 4.59 (d, _2H_pyran_4_ 101 J=5.87 Hz, 2 H) 3.39 - 3.50 (m, 2 V)pyraz'n'I . 2'y)'I H) 3.18 (s, 3 H) 2.79-2.91 (m, 1 N'(3' H) 1.58 - 1.84 (m, 3 H) 1.29 - (methylsuh‘Onyll)b 1.43 (m, 1 H) 1.09 (d, J=8.28 Hz, enzyl)benzamide 3 H) 1H NMR (400 MHz, CD30D) 8 ppm 7.91 (s, 1 H), 7.87 (t, J = 7.8 (+/')'4'(3'am'“°'. Hz, 1 H), 7.88 (dd, J = 1.8, 8.2 -((1R.3S) Hz, 1 H), 7.84 -7.58 (m,1 H), hydroxycyclopen 7.44 - 7.31 (m, 4 H), 7.28 (d, J = tyl)pyraziny|)— 7.0 Hz, 1 H), 4.62 (s, 2 H), 4.39 - N_benzy|_2_ .31 (m, 1 H), 2.34 (ddd, J = 5.9, fluorobenzamide 88,137 Hz, 1 H), 2.10 (dd, J = .A5, 8.0 Hz, 1 H), 1.99 - 1.75 (m, A H) Exaempl NMR Structure H NMR (400MHz ,CD30D) ppm 7.91 (s, 1 H), 7.87 (t, J = (+/')'4'(3'am'“°'. 7.6 Hz, 1 H), 7.68 (dd, J = 1.6, -((1R13R) 8.2 Hz, 1 H), 7.64 - 7.56 (m, 1 H), hydroxycyclopen 7.44 - 7.31 (m, 4 H), 7.28 (d, J = tyl)pyraziny|)— 7.0 Hz, 1 H), 4.62 (s, 2 H), 4.39 - N_benzy|_2_ .31 (m, 1 H), 2.34 (ddd, J = 5.9, fluorobenzamide 8.6, 13.7 Hz, 1 H), 2.10 (dd, J = .5, 8.0 Hz, 1 H), 1.99 - 1.75 (m, A H) 1H NMR z, CDCIg) 5 ppm 8.25 (t, J = 8.2 Hz, 1 H), 7.98 (s, 1 H), 7.92 (s, 1 H), 7.77 -7.71 (m, 2 H), 7.57 (d, J = 7.8 Hz, 1 H), 7.60 (d, J = 8.2 Hz, 1 H), 7.38 (br. s., 2 H), 7.37 (br. s., 3 H), 4-(3-amin0(3- 7.34 - 7.28 (m, 2 H), 7.13 - 7.04 ycyCIOpe (m, 2 H), 4.72 (d, J = 5.5 Hz, 3 104 ntyI)pyrazin H), 4.63 (br. s., 3 H), 4.02 - 3.97 y|)_N_benzy|_2_ (m, 1 H), 3.97- 3.91 (m, 1 H), fluorobenzamide 3.37 (d, J = 8.2 Hz, 1 H), 3.33 (s, 3 H), 3.32 (s, 2 H), 3.16 (t, J = 8.8 Hz, 1 H), 2.47 -2.36 (m,1 H), 2.20 - 2.10 (m, 2 H), 2.10 - 2.01 (+/-) Gig/trans mixture (m, 1 H), 2.01 - 1.94 (m, 1 H), 1.94 - 1.85 (m, 3 H), 1.81 - 1.73 (m, 1 H) 4-(3-amino 1H NMR (500 MHz, METHANOL- ((13,4R)_4_ d4) ) 5 ppm 7.91 - 7.84 (m, 2 H) hydroxy_4_ 7.71 (dd, J=8.04, 0.79 Hz, 1 H) 7.66 (d, J=11.35 Hz, 1 H) 7.49 (s, methylcyclohexyl 1 H) 7.42-7.35 (m, 2 H) 7.34- 105 )pyrazin_2_yl)_N_ 7.28 (m, 1 H) 5.26-5.18 (m, 1 H) '(3' 3.88 (dd, J=8.67, 6.15 Hz, 2 H) ChloropheWD'Z' 2.71 -2.61 (m, 1 H) 2.06— 1.95 hydrOXyethy|) (m, 2 H) 1.85 - 1.73 (m, 4 H) 1.63 fluorobenzamide - 1.52 (m, 2 H) 1.26 (s, 3 H).
WO 66188 Exampl Structure Rf NMR e (mm) 4-(3-amino 1H NMR (500 MHz, METHANOL- ((1r,4S)—4- d4) ) 6 ppm 7.93 - 7.85 (m, 2 H) hydroxy_4_ 7.70 (dd, J=8.04, 1.42 Hz, 1 H) methy'CYC'OheXY' 3'3? ‘3’4J2=1;'§§(Hr:’2 33 iii ‘3’ 106 )pyraz'n'z'yl)'N' 0'71 7.29 (m,1 H) 5.26-5.18 (m, 1 H) '(3' 3.95 — 3.81 (m, 2 H) 2.78 - 2.69 ChloropheWD'Z' (m, 1 H) 2.00— 1.90 (m, 2 H) 1.85 hydrOXyethy|) - 1.72 (m, 4 H) 1.70 - 1.61 (m, 2 fluorobenzamide H) 1.31 (s, 3 H) (S)'4'(2'ami“°' 1H NMR (400 MHz, CD30D) '(1'methyl'1H' 8 ppm 8.18 (d, J = 2.3 Hz, 1H), pyrazol 7.98 (s, 1H), 7.85 - 7.93 (m, 2H), yI)pyridinyI) 7.83 (s, 1H), 7.40 - 7.48 (m, 4H), 107 0 58 fluoro-N-(Z- ' 7.37 (t, J = 7.4 Hz, 2H), 7.24 - hydroxy_1_ 7.32 (m, 1H), 5.22 (t, J = 6.1 Hz, phenYletWDbenz 1H), 3.92 (s, 3H), 3.81 - 3.91 (m, amide 2H) (S)—4-(2-amino- 4'f'U0r0'5'U' 1H NMR (400 MHz, MeOD-d4) methyl-1H- 8 ppm 8.22 (d, J=7.83 Hz, 1 H) pyrazol 7.91 (d, J=1.96 Hz, 1 H) 7.86- 108 yI)pyridinyI) 0.60 7.72 (m, 2 H) 7.38 - 7.26 (m, 6 H) fluoro_N_(2_ 7.20 (d, J=7.43 Hz, 1 H) 5.13 (t, y_1_ J=6.06 Hz, 1 H) 3.85 (s, 3 H) phenylethyl)benz 3'82 ' 3'69 (m’ 2 H) amide 4—benzyI (4,4,55- ethyl- 132. 1H NMR (400MHz, DMSO-d6) dioxaborolan-Z- 5PPm 7-91 (S. 1 H). 7-31 (d, J = ”'34" 2'1 32’ 1 33’ iii “’72:? 1'24 - . Z, , . . m, , 109 $'2¥§i§2§3§3m[- 431.3 0.73 .79 (s, 2 H). 4.27 (t, J = 5.1 Hz, ’ 2H), 3.94 (td,J=3.1,11.0 Hz,2 (2H)'°“e’ 8'(3' H), 3.57 (t, J = 5.1 Hz, 2 H), 3.50 ammo-5' - 3.35 (m, 2 H), 2.86 (s, 1 H), (tetrahdeO-ZH- 1.82 - 1.67 (m, 4 H) pyran y|)pyraziny|)— 4—benzyl-3,4— dihydrobenzo[f][ l NMR Structure 1,4]oxazepin- (2H)—one 8'(2'am'“°'5' 1H NMR (400MHz, DMSO-d6) 5 (111' ppm 7.91 (d, J = 2.0 Hz, 1 H), otetrahydr 7.88 (d, J = 7.9 Hz, 2 H), 7.43 - o-2H-thiopyran- 7.28 (m, 6 H), 7.18 (d, J = 1.7 Hz, 110 4-yI)pyridinyl)- 1 H), 4.80 (s, 2 H), 4.27 (t, J = 5.0 4_benzyl_3,4_ Hz, 2 H), 3.58 (t, J = 5.0 Hz, 2 H), dihydrobenzo[f][ 3.34 - 3.22 (m, 2 H), 3.19 - 3.07 azepin_ (m, 2 H), 2.94 (s, 1 H), 2.21 - 2.07 (m, 4 H) (2H)_One (S)'4'(3'am'“°' 1H NMR (400MHz ,CD30D) 6 F O {OH 2 5-(2- ppm 7.89 (s, 1 H), 7.84 (t, J = 7.8 NH2 3A© hydrOX)/ethy|)loyr Hz, 1 H), 7.84 (dd, J = 1.8, 7.8 NI \ azinyI) Hz, 1 H), 7.58 (dd, J = 1.2, 11.7 111 3972 0'53 /N -N-(2- Hz, 1 H), 7.44 -7.31 (m,4 H), hydroxy_1_ 7.27 (d, J = 7.0 Hz, 1 H), 5.20 (s, phenylethymenz 1 H), 3.90 - 3.79 (m, 4 H), 2.87 (t, OH J=8.5 Hz,2H). amide 1H NMR 400MHz ,CD30D 5 (S)'4'(3'am'“°', OH ppm 7.89((s, 1 H), 7.84 (t, J): 7.8 F 0 g/ 6-(2- Hz, 1 H), 7.84 (dd, J = 1.8, 7.8 NH2 3 methoxyethy|)py Hz, 1 H), 7.81 -7.55 (m, 1 H), razin-2—yl)—2- 7.44 - 7.39 (m, 2 H), 7.34 (t, J = “2 NI :N 411'3 0'62 K fluoro_N_(2_ 7.8 Hz, 2 H), 7.27 (d, J = 7.4 Hz, hydroxy_1_ 1 H), 5.19 (d, J = 8.3 Hz, 1 H), phenylethyl)benz 3.87 - 3.82 (m, 2 H), 3.70 (t, J = OMe 8.5 Hz, 2 H), 3.32 (s, 3 H), 2.92 amide (t, J = 8.5 Hz, 2 H).
(R)_4_(2_amino_ 1H NMR (400MHz, CD30D) 5 -(tetrahydro- ppm 7.92 - 7.87 (m, 1 H), 7.88 - F O HOWQ 113 F \ mgflrfiéflmr?’ 0'52 7.23 (m,2 H), 4.54-4.40 (m, 3 H), 4.09 - 3.95 (m, 2 H), 3.59 - flUIOIVObenzylw'p. 3.44 (m, 2 H), 2.92 - 2.78 (m, 1 erIdIn H), 2.84 (s, 1 H), 2.20- 1.98 (m, y|)benzamide 3 H), 1.99 - 1.52 (m, 8 H).
Exampl NMR Structure 1H NMR (400MHz ,CD30D) 8 (S)—4-(3-amino- ppm 7.94 (s, 1 H), 7.84 (t, J = 7.8 6-(2- Hz, 1 H), 7.69 (d, J = 8.2 Hz, 1 cyanoethyl)pyraz H), 7.63 (d,J = 12.1 Hz,1 H), iny|)f|uoro- 7.43 - 7.38 (m, 2 H), 7.34 (t, J = N-(2-hydroxy 7.6 Hz, 2 H), 7.27 (d, J = 7.4 Hz, phenylethyl)benz 1 H), 5.22 - 5.16 (m, 1 H), 3.89 - amide 3.79 (m, 2 H), 3.01 (t, J = 7.0 Hz, H), 2.84 (t, J = 7.2 Hz, 2 H) 1H NMR (400MHz ,CD30D) 8 4-(3-amino- ppm 7.90 - 7.77 (m, 2 H), 7.67 6-(1- (dd, J = 1.6, 8.2 Hz, 1 H), 7.59 (dd, J =1.4,11.9 Hz, 1 H), 7.40 - 115 hydroxypropan- 7.29 (m, 4 H), 7.28 - 7.21 (m, 1 2—yl)pyrazin H), 4.60 (s, 2 H), 3.76 (dd, J = y|)-N-benzy|—2- 7.4, 10.6 Hz, 1 H), 3.67 (dd, J = fluorobenzamide 59,106 Hz, 1 H), 3.02 - 2.93 (m, 1 H), 1.25 (d, J = 7.0 Hz, 3 H) 1H NMR (400 MHz, CD30D) 5 ppm 7.92 - 7.79 (m, 2 H) 7.66 4—(3-amino (dd, J=8.02, 1.37 Hz, 1 H) 7.59 ((1 r,4r)—4— (dd, J=11.54, 1.37 Hz, 1 H) 7.43 - 7.30 (m, 4 H) 7.30 - 7.22 (m, 1 H) methoxycyclohe 116 .61 (s, 2 H) 3.40 - 3.35 (m, 3 H) xyl)pyraziny|)— 3.26 (t, J=3.91 Hz, 1 H) 2.74 - N-benzyI 2.61 (m, 1 H) 2.20 (d, J=9.39 Hz, fluorobenzamide 2 H) 1.99 (d, 1 Hz, 2 H) 1.65 (qd, J=13.04, 3.13 Hz, 2 H) 1.41 - 1.25 (m, 2 H) 1H NMR (00300) 8 ppm 7.95 (s, (+/-)(3-amino- 1H), 7.86 (t, J = 7.6 Hz, 1H), 7.69 6-(6- (dd, J = 8014 Hz, 1H), 7.61 oxopiperidin (dd, J 1.2 Hz, 1H), 7.31 - 117 y|)pyraziny|)— 7.45 (m, 4H), 7.22 - 7.30 (m, 1H), N-benzyI .A62 (s, 2H), 3.53 (d, J = 7.8 Hz, fluorobenzamide H), 3.47 (q, J = 7.4 Hz, 1H), 3.15 - 3.26 (m, 1H), 2.40 - 2.57 (m, 2H), 2.06 - 2.24 (m, 2H), 1.36 (t, J = 7.2 Hz, 1H) Exaempl NMR Structure 1H NMR (400MHz, CD30D) 6 4-(2-am|n0-. ppm 8.88 - 8.77 (m, 1H), 8.03 - -(5- 7.95 (m, 2H), 7.92 - 7.83 (m, 4H), 118 oxopiperidin 419.3 0.55 7.48-7.30 (m, 2H), 7.28 -7.21 yl)pyridin—3—yl)— (m, 1H), 4.69 - 4.54 (m, 2H), 3.56 N_benzy|_2_ - 3.42 (m, 1H), 3.20 - 3.05 (m, fluorobenzamide 1H), 2.55 - 2.39 (m, 2H), 2.16 - 1.99 (m, 2H) F O E ' 1H NMR(400MHz, CD30D) 6 NHZ N 4_(2_amino_5_(5_ °X°piperidi“'3' 5‘23 {'971‘HT’;215 77823? 123;) Kiwi:I IdII- . m, -. m, ,. , 119 0' '« )' an 3 Y) 467.3 0.66 7.29-7.16 (m, 1H), 5.31 -5.16 '( ' (m, 1H), 3.59-3.34 (m, 2H), 3.21 ChlorOpheny')eth - 3.05 (m, 1H), 2.59 - 2.38 (m, NH Y')'2' 2H), 2.19 - 2.01 (m, 2H), 1.57 (m, 0 diastereomeric mixture fluorobenzamide 3H)_ F O NHZ N 4—(2—amino(2- N \ HAQ oxopiperidin 1H NMR(400MHz,CD30D)5 | idiny|)- ppm 7.94 (m 7.87-7.74 (m 120 / CI 4672 0'66 3 1H) a .
N-((R)(3- 2H), 7.35 (s, 6H), 5.24 (m, 1H), chlorophenyl)eth 2.67 - 2.4 (m, 2H), 2.1 - 1.94 (m, N O y|)_2_ 2H), 1.57 (m, 3H), 1.26 (m, 2H). diastereomeric mixture fluorobenzamide 4—(2—amino(2- oxopiperidin 1H ogg'f’ 2330?)”: mg);I ' r'd'nV)|- ppm - - m, ’ - 3’ 121 483.2 0.56 7H), 5.17—5.01 (m, 1H), 3.87- ' ' ' (3' 3.64 (m, 2H), 3.44-3.31 (m, 3H), ChlorOpheny')'2' 2.62 - 2.24 (m, 2H), 2.12 - 1.74 hydroxyethy|)-'2- (m, 2H). fluorobenzamlde reomeric mixture Exampl Rt NMR Structu re e (min) (S)—4-(2-amino- - 1H NMR (400 MHz, CD30D) 5 morpholinopyridi ppm 8.06 (d, J=8.2 Hz, 2 H) 7.87 122 (d, J=2.7 Hz, 1 H) 7.63 (d, J=8.2 ny|)-N-(2- Hz, 2 H) 7.24 - 7.48 (m, 6 H) 5.19 hydroxy - 5.30 (m, 1H) 3.90 (m, 2H) - 3.85 phenylethy|)benz (m, 4 H) 3.12 (m, 4 H) amide 1H NMR (400 MHz, MeOD-d4) 5 (3-amino- ppm 7.99 - 7.78 (m, 2 H) 7.72 - 6-(3- 4992'7.52 (m, 2 H) 7.46 (s, 1 H) 7.41 - methoxycyclohe 7.17 (m, 3 H) 5.24 - 5.08 (m, 1 H) 123 xyl)pyraziny|)— 3.86 (t, J=6.06 Hz, 2 H) 3.43 (m, N-((S)(3- 1H) 3.38 (s, 3 H) 2.75 (ddd, chlorophenyl)—2- J=12.03, 8.71, 3.52 Hz, 1 H) 2.40 hydroxyethy|) -2.02 (m, 2 H) 1.99 - 1.74 (m, 2 diastereomeric mixture; cis on cyclohexane ring benzamide H) 1.59 - 1.37 (m, 3 H) 1.18 (dd, J=11.35, 3.13 Hz, 1 H) 1H NMR (400 MHz, MeOD-d4) 5 (+/-)-cis(3- ppm 8.00 - 7.79 (m, 2 H) 7.74 - 7.52 amino(3- (m, 2 H) 7.43- 7.31 (m, 4 H) 7.30 -7.22 (m, 1 H)4.61 (s, 124 methoxycyclohe 2 H) 3.37 (s, 3 H) 2.73 (t, J=3.33 xyl)pyraziny|)— Hz, 1 H) 2.27 (d, J=11.74 Hz, 1 yI H)2.14 (d, J=12.13 Hz, 1 H) 1.99 fluorobenzamide -1.82(m,2H)1.52 -1.39 (m,3 H) 1.24 - 1.10 (m, 1 H) (S)—4-(3-amino- 1H NMR (400MHz, CD30D) 6 6-(tetrahydro- ppm 7.80 (s,1 H), 7.71 (m, 1 H), 7.61 (dd, J = 1.5, 8.0 Hz, 1 2H-pyran H), 7.57 - 7.43 (m, 3 H), 7.32 - 7.15 125 y|)pyraziny|)- 508.3 (m, 2 H), 4.39 (s, 2 H), 3.95 (dd, J 2-fluoro-N-(1-(2- = 26,116 Hz, 2 H), 3.48 (dt, J = fluorobenzyl)pip 25,117 Hz, 3 H), 2.92 - 2.75 (m, eridin 1 H), 2.56 (s, 2 H), 1.89 - 1.65 y|)benzamide (m, 10 H).
Exaempl NMR Structure 1H NMR 400MHz ,CD30D) 5 (R)'4'(3'am'“°'. ppm 7.91 (s, 1 H), 7.80 (t, J = 7.8 '(tetrahydr°' Hz, 1 H), 7.71 (d, J = 9.4 Hz, 1 2H-pyran H), 7.67 - 7.55 (m, 3 H), 7.41 - F o ”0%in yl)pyraziny|)— 7.27 (m, 2 H), 4.49 (br. s., 2 H), 126 508'4 0'63 NH2 2-quoro-N-(1-(2- .34 (br. s., 1 H), 4.10 - 4.01 (m, I fluorobenzyl)pip 2 H). 3-75 (br. 8-. 1 H). 3-64 - eridin_3_ 3.51 (m, 4 H), 3.02 (d, J = 13.7 yDbenzamide Hz, 1 H), 3.00 - 2.88 (m, 2 H), 2.12 (br. s., 2 H), 1.97 - 1.78 (m, H), 1.68 (d, J = 10.2 Hz, 1 H) Method 2 Example 127 S nthesis of S 3-amino 1 3-dimeth I-1H- 4- | razin | -N- 1- 3- chloro hen Ih drox eth Ifluorobenzamide Scheme 53 F 0 {0H Steal F 0 {OH $22 NH = 2 2 C) N Pd<dpp0CI2 NH2 N NBS I + —> H H —> K/N HO N’ ‘13 Na2003, DME | 1 \ N CI OH CI F o :/ F 0 {OH _28t 3 NH2 N = oH H NH2 N ‘3/0 f)CI2 N/ + | H —> \ N CI NI \ I \ Na2003,DME Kr/N CI \ \ Br N—N Ste 1. S o razin l-N- 1- 3-chloro hen lh drox eth l benzamide To the reaction mixture of 3-chloropyrazinamine (288 mg, 2.22 mmol), (S)(1-(3- chlorophenyl)hydroxyethylcarbamoyl)fluorophenylboronic acid (500 mg, 1.48 mmol), PdC|2(dppf)-DCM (108 mg, 0.148 mmol), DME (1.1 mL), 2M Na2C03 (3.703 mL) was added. The reaction mixture was heated at microwave synthesizer (120 0C, 12 min). To the reaction mixture, anhydrous sodium sulfate was added, filtered, and concentrated.
The crude product was pre-purified by flash chromatography eluting with EtOAc ining 10% MeOH) in heptane. The pure fractions were combined and concentrated to provide 389 mg of the desired product in 68% yield. LCMS (m/z): 387 (MH+), 0.69 min.
Ste 2. S 3-aminobromo razin l-N- 1- 3-chloro hen lh drox eth l fluorobenzamide To a solution of (S)(3-aminopyrazinyl)-N-(1-(3-chlorophenyl)hydroxyethyl) fluorobenzamide (389 mg, 1.006 mmol) in acetonitrile (21 mL) was added NBS (171 mg, 0.961 mmol) at 0 °C. The on e was stirred at 0 °C for 20 min. After quenched with sat NaHC03, and stirr for 30 min. The reaction mixture was extracted with EtOAc 3 times, the organic was washed by sat NaHC03, water and brine, dried, filtered off, and trated. The crude material was taken to the next step without further purification.
LCMS (m/z): 367 (MH+), 0.88 min.
Ste 3. S 3-amino 1 3-dimeth l-1H- 4- l razin l-N- 1- 3- chlorophenyl)—2-hydroxyethyl)—2-fluorobenzamide To the reaction mixture of (3-aminobromopyrazinyl)-N-(1-(3-chlorophenyl) hydroxyethyl)f|uorobenzamide (40 mg, 0.086 mmol), 1,3-dimethyl(4,4,5,5- tetramethyl-1,3,2-dioxaborolanyl)-1H-pyrazole (38.2 mg, 0.172 mmol), PdC|2(dppf)- DCM (6.28 mg, 8.59 umol), and DME (644 uL), 2 M Na2C03 (215 uL) were added. The reaction mixture was heated at microwave synthesizer (120 °C, 12 min). To the reaction mixture, anhydrous sodium sulfate was added, filtered, and concentrated. The crude product was purified by auto-prep to provide 25 mg of desired product as a TFA salt.
LCMS (m/z): 481.3 (MH+), 0.73 min; 1H NMR (500 MHz, CD3OD) 6 ppm 8.66 (d, J=6.26 Hz, 1 H) 8.17 (s, 1 H) 8.02 (s, 1 H) 7.76 - 7.51 (m, 3 H) 7.45 - 7.16 (m, 3 H) 5.07 — 4.09 (m, 1 H) 3.72 (s, 3 H) 3.62 (m, 2 H) 2.33 (s, 3 H).
Example 128 S nthesis of S 2-amino 1-meth |-1H-1 2 3-triazoI | ridin | -N- 1- 3- chloro hen |h drox eth |f|uorobenzamide Scheme 54 Ste 1 $2; Pd(dppf)C|2DCM / NBS Br NH2 0 l + \ Hog/@LO/ Na2co3 DME N/ CH3CN Steg3 F O NH H LiOH (1 M) 2 ? N / + H2N THF MeOH F O Stepfl 3/ $12; NH N EDC: ”ON 2 H Pd(dppf)C|2, )2 —> N / —, DIEA, THF Cl KOAc, dioxane 0 :/ F 0 {OH : Steg§ ? NH2 N NH2 N Pd(dppf)CI2—DCM H N/ N, | # 0' | \ , DME \ Cl o’ o N“ \ Ste 1. meth |4- 2-amino ridin |f|uorobenzoate To 3-bromopyridinamine (5 g, 28.9 mmol) in 500 mL round bottom flask was added (3- fluoro(methoxycarbony|)pheny|)boronic acid (7.44 g, 37.6 mmol), PdC|2(dppf)-DCM (2.115 g, 2.89 mmol), DME (108 mL) and 2M Na2C03 solution (36.1 mL). The reaction mixture was heated in an oil bath at 110 °C for 4 h. The reaction mixture was diluted with 2014/062913 EtOAc and washed with water three times, dried over NazSO4, filtered and concentrated.
The crude product was purified by flash chromatography eluting with 0-100% of EtOAc ining 10% of MeOH)/heptane yielding 5.6 g of methyl 4-(2-aminopyridinyl) fluorobenzoate in 79 % yield. LCMS (m/z): 247.1 (MH+), 0.50 min.
Ste 2. meth l4- 2-aminobromo ridin lfluorobenzoate To a solution of methyl 4-(2-aminopyridinyl)fluorobenzoate (5.64 g, 22.90 mmol) in acetonitrile (229 mL) was added NBS (4.16 g, 23.36 mmol) in two portions at 0 °C . The reaction mixture was stirred at 0 °C for 20 min. After quenched with sat Na28203 and NaHC03, and stirr for 30 min. The on mixture was extracted with EtOAc 3 times, the organic washed by sat NaHCOs, water and brine. Dried and concentrated. The crude material was triturated with ether to provide 7.05 g of methyl minobromopyridin- 2-fluorobenzoate in 95 % yield. LCMS (m/z): 327.1 (MH+), 0.66 min.
Ste 3. 4- 2-aminobromo ridin l f|uorobenzoic acid To a solution of methyl 4-(2-aminobromopyridinyl)—2-fluorobenzoate (1.9 g, 5.84 mmol) in THF (19.48 mL) and MeOH ( 9.74 mL, Ratio: 1.000) was added LiOH (1 M aqueous onueous solution) (10.52 mL, 10.52 mmol). The reaction mixture was stirred for 5 h. After 1N HCI (1.9 mL) was added up to pH 5, the reaction mixture was worked up with EtOAc, the organic layer was dried over N32804, filtered off and concentrated in vacuo. The crude 4-(2-aminobromopyridinyl)—2-fluorobenzoic acid was used for the next step without further purification. LCMS (m/z): 311.1/313.1 (MH+), 0.5 min.
Ste 4. S 2-aminobromo ridin l-N- 1- 3-chloro hen lh drox eth l fluorobenzamide To a solution of 4-(2-aminobromopyridinyl)—2-fluorobenzoic acid (300 mg, 0.964 mmol) in THF (8.036 mL) was added (S)amino(3-chlorophenyl)ethanol (331 mg, 1.157 mmol). The reaction mixture was stirred for 15 h. After water was added, the on mixture was worked up with EtOAc, the organic layer was dried over anhydrous NaZSO4, filtered off and concentrated in vacuo. The crude (2-aminobromopyridin- 3-yl)-N-(1-(3-chlorophenyl)hydroxyethyl)fluorobenzamide was used for the next step without further purification. LCMS (m/z): 464.1/466.1 (MH+), 0.69 min.
Ste 5. S 2-amino 4 4 5 5-tetrameth H 3 2-dioxaborolan | ridin | -N- 1- (3-chlorophenyl )—2-hyd roxyethyl )—2-fluorobenzamide To a solution of (S)(2-aminobromopyridinyl)-N-(1-(3-chlorophenyl) hydroxyethyl)f|uorobenzamide (85 mg, 0.183 mmol), bis(pinacolato)diboron (93 mg, 0.366 mmol), and PdC|2(dppf) (26.8 mg, 0.037 mmol) in dioxane (610 uL) was added ium acetate (54 mg, 0.549 mmol). The reaction mixture was heated at microwave sizer (120 °C for 20 min). The reaction e was filtered h Celite pad.
After the filtrate was almost concentrated, the crude (S)(2-amino(4,4,5,5- tetramethyl-1,3,2-dioxaborolanyl)pyridinyl)—N-(1-(3-chlorophenyl)hydroxyethy|) fluorobenzamide was used for the next step without further purification. LCMS (m/z): 430.2 (MH+ for boronic acid), 0.57 min.
Ste 6. S 2-amino 1-meth l-1H-1 2 3-triazol | ridin | -N- 1- 3- chlorophenyl)—2-hydroxyethyl)—2-fluorobenzamide To a solution of the crude (S)—4-(2-amino(4,4,5,5-tetramethy|—1,3,2-dioxaboro|an yl)pyridinyl)—N-(1-(3-chlorophenyl)hydroxyethyl)f|uorobenzamide (30 mg, 0.059 mmol) in residual dioxane was added 4-bromomethyl-1H-1,2,3-triazo|e (14.24 mg, 0.088 mmol), PdC|2(dppf) (42.9 mg, 0.059 mmol), DME (195 pl) and 2 M Na2C03 (130 pl) at room temperature. The on mixture was stirred for 5 h. After water and EtOAc were added, the organic layer was extracted with EtOAc. The organic layer was washed with water and brine, dried over anhydrous Na2804, ed off, and concnetrated in vacuo. The crude product was purified by prep HPLC. The pure fractions were lyophilized yielding (S)—4-(2-amino(1-methyl-1H-1,2,3-triazolyl)pyridinyl)—N-(1-(3- chloropheny|)hydroxyethy|)f|uorobenzamide as a TFA salt (25% over 2 steps).
LCMS (m/z): 467.3 (MH+), 0.61 min; 1H NMR (400MHz, CD3OD) 8 ppm 8.64 (m, 1 H), 8.31 (m, 1 H), 8.25 (m, 2 H), 8.2 (m, 1 H), 7.82 (m, 1 H), 7.4 (m, 3 H), 7.28 (m, 2 H), 7.22 (m, 1 H), 5.11 (m, 1 H), 4.07 (s, 3 H), 3.78 (m, 2 H). e 129 S nthesis of S 3-amino—6- 1 6-dih dro ridin l razin l-N- 2-h drox phenylethyl mide Scheme 55 $2.1 NIJTKNH2 O/©)‘\H_/\© Pd(dppf)C|2 jig/3 N32003 DME O NI/Kfit‘l—/\© Step g OH/\© Br Pd(dppf)Cl2, 82(PIN)2 / —> I KOAC, dioxane o’E"o O F 0 {OH Stegg NHz N Pd(dppf)C|2 N \ —. l/N Na2003, DME Ste 1. S 3-aminobromo razin l-N- 2-h drox hen leth Ibenzamide To a solution of 3,5-dibromopyrazinamine (826 mg, 3.27 mmol), (S)—N-(2-hydroxy phenylethyl)(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)benzamide (600 mg, 1.634 mmol), and PdC|2(dppf).CH2C|2 adduct (133 mg, 0.163 mmol) in DME (12.3 mL) was added 2 M Na2C03 (4.08 mL). The reaction mixture was heated at microwave synthesizer (120 °C, 10 min). The reaction mixture was worked uup with EtOAc. The organic layer was washed with sat NaHC03, water and brine, dried over Na2804, filtered off, concentrated in vacuo. The crude product was purified with silica flash chromatography eluting with 0-100% of EtOAc (containing 10% of MeOH) in heptane, and triturated with ether to e 800 mg of (S)—4-(3-aminobromopyrazinyl)-N-(2-hydroxy phenylethyl)benzamide. LCMS (m/z): 415 (MH+), 0.73 min.
Ste 2. S 3-amino 4 4 5 5-tetrameth H 3 2-dioxaborolan l razin l -N- 2- hydroxy—1-phenylethyl)benzamide To a solution of (S)(3-amino(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)pyrazin yl)-N-(2-hydroxyphenylethyl)benzamide (50 mg, 0.121 mmol), nacolato)diboron (61.4 mg, 0.242 mmol), and PdC|2(dppf)-CH2C|2 adduct (9.88 mg, 0.012 mmol) in dioxane (302 uL) was added potassium acetate (35.6 mg, 0.363 mmol)just right after degassing.
The reaction mixture was heated at microwave synthesizer (120 °C for 20 min). After d with EtOAc, the reaction mixture was filtered through Celite pad. After concentrated, the crude (S)(3-amino(4,4,5,5-tetramethyl-1,3,2-dioxaborolan y|)pyrazinyl)-N-(2-hydroxyphenylethyl)benzamide was used for the next step without r purification. LCMS (m/z): 379 (MH+ for boronic acid), 0.47 min.
Ste 3. S 3-amino 6-oxo-1 6-dih dro ridin l razin l-N- 2-h drox phenylethyl)benzamide To a on of amino(4-(2-hydroxyphenylethylcarbamoyl)phenyl)pyrazin ylboronic acid (55 mg, 0.145 mmol), opyridin-2(1H)-one (38.0 mg, 0.218 mmol), and PdCl2(dppf)-CH2Cl2 (11.88 mg, 0.015 mmol) in DME (1091 uL) was added 2M Na2C03 (364 uL). The reaction mixture was heated at microwave synthesizer (120 °C, 10 min). The reaction mixture was worked up with EtOAc. The organic layer was washed with sat NaHC03, water and brine, dried over Na2804, filtered off, concentrated in vacuo.
The crude product was purifed by prep HPLC yielding 4.3 mg of (S)—4-(3-amino(6-oxo- 1,6-dihydropyridinyl)pyrazinyl)-N-(2-hydroxyphenylethyl)benzamide as a TFA salt. LCMS (m/z): 428.2 (MH+), 0.55 min; 1H NMR (400 MHz, DMSO-d6) 3.60 - 3.75 (m, 2 H) 5.03 - 5.12 (m, 1 H) 6.40 (d, J=9.39 Hz, 1 H) 7.22 (d, J=7.43 Hz, 1 H) 7.30 (t, J=7.63 Hz, 2 H) 7.34 - 7.40 (m, 2 H) 7.83 (d, J=8.22 Hz, 2 H) 7.94 (br. s., 1 H) 8.01 (d, J=8.61 Hz, 2 H) 8.06 (dd, J=9.39, 2.74 Hz, 1 H) 8.41 (s, 1 H) 8.74 (d, J=8.22 Hz, 1 H).
S nthesis of S 3-aminobromo razin l-N- 1- 3-chloro hen lh drox eth l- 2 6-difluorobenzamide Scheme 56 $21 $22 $22 F O O F o i 11 Pd(dppf)CI2-DCM TMSCHN2 0/ NBS OH ‘0/ 52/500 NH2 —> _.4E5: N \ Na2C03 DME N/ F Br F Br F “W 120°C l S_2te Step_5 LiOH NH2 N H2 H2 H \ F N/ H/N/ Cl Ste 1. meth l4-bromo-2 uorobenzoate To a solution of 4-bromo-2,6-difluorobenzoic acid (800 mg, 3.38 mmol) in MeOH (11 mL) at room temperature, trimethylsilyldiazomethane (5.63 mL, 3.38 mmol) was slowly added until yellow solution was turned on. The small amount of AcOH was added until yellow color disappered. All volatile materials were removed in vacuo yielding methyl o- 2,6-difluorobenzoate (47%). LCMS (m/z): 251.1 (MH+), 0.86 min.
Ste 2. meth l4- 2-amino ridin l -2 uorobenzoate Followed by Step 1 in Scheme 54, methyl 4-(2-aminopyridinyl)—2,6-difluorobenzoate was obtained (9%). LCMS (m/z): 485.2 (MH+), 0.64 min; 1H NMR (400 MHz, CD3OD) 8 ppm 8.11 (m, 1 H), 7.76 (m, 2 H), 7.37 (m, 1 H), 7.27 (m, 2 H), 7.20 (m, 3 H), 5.09 (m, 1 H), 4.03 (s, 3 H), 3.73 (m, 2 H).
Ste 3 4 and 5. S 3-aminobromo razin l-N 3-chloro hen l hydroxyethyl)—2,6-difluorobenzamide Following Step 2, 3, and 4 in Scheme 54, (S)(3-amino(4,4,5,5-tetramethyl-1,3,2- dioxaborolanyl)pyrazinyl)—N-(1-(3-chlorophenyl)hydroxyethyl)-2,6- difluorobenzamide was obtained. LCMS (m/z): 482/484 (MH+), 0.68 min.
Table 3. Bromide or the corresponding boronic ester intermediates for Suzuki coupling Structure ' ) 4-(3-amino bromopyrazin-Z- y|)-N-(3- (methylsulfony|)b enzyl)benzamide4611/463l 4-(3-amino yrazin-Z- y|)f|uoro-N-(3- 812 0.782 (methylsulfony|)b enzyl)benzamide (S)—4-(3-amino- 6-(4,4,5,5- tetramethyl- 1,3,2- 397.1 (for dioxaborolan-Z- boronic 0.49 y|)pyrazin-2—y|)- acid) 2-fluoro-N-(2— hydroxy phenylethyl)benz amide (S)—4-(3-amino- 6-bromopyrazin- 2-y|)f|uoro-N- (2-hydroxy ethyl)benz amide 4311/433l 2014/062913 Structure 1H NMR (400 MHz, CD30D) 6 ppm 8.05 (s, 1 (S)—4-(3-amino- H) 8.00 (d, J=8.22 Hz, 3 6-bromopyrazin- H) 7.83 (d, J=8.22 Hz, 3 2-y|)-N-(2- H) 7.40 - 7.46 (m, 3 H) 413/415 y 7.35 (t, J=7.63 Hz, 2 H) phenylethyl)benz 7.23 - 7.31 (m, 1 H) 5.23 amide (t, J=6.65 Hz, 1 H) 3.88 (d, J=6.65 Hz, 2 H) (S)—4-(2-amino- opyridin- 3-y|)-N-(1-(3- chlorophenyl)—2— hydroxyethyl)—2— methylbenzamid (S)—4-(2-amino- —(4,4,5,5- tetramethyl- 1,3,2- dioxaborolan-Z- y|)pyridin-3—y|)— N-(1-(3- chlorophenyl)—2— hydroxyethyl)—2— methylbenzamid (S)—4-(2-amino- —(4,4,5,5- tetramethyl- F o 1,3,2- N dioxaborolan-Z- NH2 448.2 (for H y|)pyridin-3—y|)— N/ boronic 0.65 N/A | N-(1-(3- \ acid) chlorophenyl)—2— ,B hydroxyethy|)- o ‘o 2,6- difluorobenzami Structure F O (+/-)(3-amino- 6-bromopyrazin- HNA© (223") 2 fluoro N_ _ _ _ _ 427.1/429.1 phenylcycloprop y|)benzamide AK) 4-(2-amino- 5—bromopyridin- 23")‘2'fluoro'N' 4262/4282 0.79 phenylcycloprop y|)benzamide Chiral resolution of +/- 2-aminobromo ridin l fluoro-N- 1S 2R phenylcyclopropyl )benzamide Scheme 57 F O F O F O A ”All; : NH2 N E: “HZ ””2 N H H H N / N / N / [D I | I \ \ \ (+/_) Br Br peak1 Br peak2 (+/-)(2-aminobromopyridinyl)—2-fluoro-N-((1S,2R)—2-phenylcyclopropyl)benzamide (121 mg) was resolved by chrial chromatography (AD-H column 0/40, 1mL/min).
The polar compound (Peak1), minobromopyridinyl)—2-fluoro-N-((1R,28)—2- phenylcyclopropyl)benzamide, was obtained at 7.41 min (50 mg, 41%) and the less polar compound ), 4-(2-aminobromopyridinyl)—2-fluoro—N-((1S,2R)—2— phenylcyclopropyl)benzamide, was obtained at 10.26 min (54 mg, 44%). The absolute stereochemistry was assigned based on biochemical data and docking model of the corresponding analogs.
Example 130 S nthesis of +/- o 1-meth l-1H- razol l ridin lfluoro-N- 1R28 hen Ic clo ro Ibenzamide Followed Scheme 59, using (+/-)(2-aminobromopyridiny|)f|uoro-N-((1S,2R)—2- phenylcyclopropyl)benzamide, (+/-)(2-amino(1-methyl-1H-pyrazolyl)pyridinyl)— 2-fluoro-N-((1R,2S)phenylcyclopropyl)benzamide was obtained (11%). LCMS (m/z): 428.2 (MH+), 0.72 min; 1H NMR (400MHz, CD3OD) 8 ppm 8.19 (m, 1 H), 7.91 (s, 1 H), 7.82 (m, 1 H), 7.77 (m, 1 H), 7.64 (m, 1 H), 7.48 - 7.33 (m, 2 H), 7.31 - 7.12 (m, 5 H), 3.91 (s, 3 H), 3.10 (m, 1 H), 2.20 (m, 1 H), 1.33 (m, 2 H).
Example 131 S s of 4- 2-amino 1-meth l-1H- razol l ridin lfluoro-N- 1R28 cyclopropyl )benzamide Followed by Scheme 59, using 4-(2-aminobromopyridiny|)f|uoro-N-((1R,2S)—2- phenylcyclopropyl)benzamide, 4-(2-amino(1-methyl-1H-pyrazolyl)pyridinyl)—2- fluoro-N-((1R,2S)—2-phenylcyclopropy|)benzamide was obtained (53%). LCMS (m/z): 428.3 (MH+), 0.69 min; 1H NMR (400MHz, CD3OD) 6 ppm 8.11 - 8.02 (m, 1 H), 7.94 (m, 1 H), 7.97 - 7.88 (m, 2 H), 7.85 - 7.71 (m, 2 H), 7.43 - 7.30 (m, 2 H), 7.26 - 7.14 (m, 2H), 7.14 - 7.02 (m, 2 H), 3.83 (s, 3 H), 3.06 - 2.92 (m, 1 H), 2.19 - 2.02 (m, 1 H), 1.35 - 1.17 (m, 2 H). The absolute stereochemistry was assigned based on biochemical data and docking model.
Example 132 4- 2-amino1-meth l-1H- razol l ridin lfluoro-N- 1S 2R hen lc clo ro mide Followed by Scheme 59, using 4-(2-aminobromopyridinyl)—2-fluoro-N-((1S,2R)—2- phenylcyclopropyl)benzamide, 4-(2-amino(1-methyl-1H-pyrazolyl)pyridinyl)—2- fluoro-N-((1S,2R)—2-phenylcyclopropyl)benzamide was obtained (42%). LCMS (m/z): 428.3 (MH+), 1H NMR z, CD3OD) 6 ppm 8.09 - 8.02 (m, 1 H), 8.01 - 7.95 (m, 1 H), 7.96 - 7.88 (m, 2 H), 7.84 - 7.70 (m, 2 H), 7.42 - 7.29 (m, 2 H), 7.25 - 7.02 (m, 4 H), 3.83 (s, 3 H), 3.10 - 2.87 (m, 1 H), 2.24 - 2.00 (m, 1 H), 1.33 - 1.15 (m, 2 H). The absolute stereochemistry was assigned based on biochemical data and g model.
Example 133 S nthesis of S 2-amino1-deuterido-meth l5-meth l-1H- razol l ridin l- N-g1-(3-chlorophenyl)—2-hydroxyethyl)—2-fluorobenzamide Scheme 58 Stepl Step; m; \ lfl CDI 3 <\:N| o o nBuLI- NBS \ D + “8/, \ '1‘ —’ D NH 7< —’ —’ \O’ ‘O/ NaH D Et20 XD MeCN D D 47% 59% 92% {OH OH F 0 _r_>Ste 4 F O =/ NH2 N NH2 W H PdCl2(dppf) 3 + N \ N/ —, | N_N><D I / Cl DME,Na2C03 \ C' D D B 9% or \O \ D D Ste 1.1-deuterido-meth l-1H- razole To a on of NaH (1.851 g, 46.3 mmol) in 2-methyl THF (80 mL) was added 1H- pyrazole (3 g, 44.1 mmol) in 2-methyl THF (30 mL) at 0 °C. The reaction mixture was warmed up to room temperature and stirred for 1 h. To this, CD3| (3.02 mL, 48.5 mmol) was slowly added. The reaction mixture was stirred for overnight. After quenched with NH4CI solution, the reaction mixture extracted with EtOAc. The organic layer was washed with water and brine, ed off, and concentrated in vacuo. The crude product was distlled off yielding 1-deuterido-methyl-1H-pyrazole (47%) (b.p. ~130 °C, bath temp was ~200 °C). LCMS (m/z): 86 (MH+), 0.24 min; 1H NMR (500MHz, CDCI3) 6 ppm 7.55 - 7.42 (m, 1H), 7.39 - 7.28 (m, 1H), 6.28 - 6.15 (m, 1H).
Step 2. 1-deuterido-methyl,5-methyl-1H-pyrazole To a solution of n-BuLi (2.5 M in hexanes) (4.14 mL, 10.34 mmol) in ether (20 mL) at -30 °C was slowly added a on of 1-deuterido-methyl-1H-pyrazole (880 mg, 10.34 mmol) in ether (2 mL). The reaction mixture was allowed to warm up to room temperature and stirred for 2 h. After being cooled to 0 °C, a solution of dimethyl sulfate (0.931 mL, 9.82 mmol) in ether (3 mL) was slowly added to the reaction mixture. The reaction e was stirred at room temperature for 3 h. After quenched with sat. NH4C| on, the reaction mixture was extracted with ether (x2), but s phase still contained product. Then, the aqueous phase was extracted with DCM (x2). The combined organic phase was dried over anhydrous NazSO4, filtered off, and concentrated in vacuo. The crude product was purified by distillation ng erido-methyl,5-methyl-1H-pyrazole (59%). LCMS (m/z): 100.0 (MH+), 0.24 min; 1H NMR (400MHz, CHLOROFORM-d) 6 ppm 7.36 (m, 1H), 6.00 (m, 1H), 2.27 (s, 3H).
Step 3. 4-bromodeuterido-methyl,5-methyl-1H-pyrazole To a solution of 1-deuterido-methyl,5-methyl-1H-pyrazole (100 mg, 1.009 mmol) in MeCN (3.362 mL) was added NBS (171 mg, 0.958 mmol) slowly at 0 °C. After the ice bath was removed, the reaction e was stirred for 30 min. After quenched with sodium sulfite solution, the reaction mixture was extracted with EtOAc. The organic layer was washed with sodium ate solution and brine, dried over sodium e, filtered off and concentrated in vacuo. The crude 4-bromodeuterido-methyl,5-methyl-1H-pyrazole was obtained and was used for the next step without further purification (92%). LCMS (m/z): 178, 180 (MH+), 0.61 min.
Ste 4. S 2-amino 1-deuterido-meth l5-meth l-1H- razol l ridin l-N- 1- (3-chlorophenyl d roxyethyl )—2-fluorobenzamide Following Step 6 in Scheme 54, using 4-bromodeuterido-methyl,5-methyl-1H-pyrazole, (S)(2-amino(1-deuterido-methyl,5-methyl-1H-pyrazolyl)pyridinyl)—N-(1-(3- chlorophenyl)hydroxyethyl)fluorobenzamide was obtained as a free base (9%).
LCMS (m/z): 483.2 (MH+), 0.67 min; 1H NMR (500MHz, CD3OD) 6 ppm 8.00 (d, J=1.9 Hz, 1H), 7.86 (t, J=7.9 Hz, 1H), 7.58 - 7.23 (m, 8H), 5.19 (t, J=5.8 Hz, 1H), 3.93 - 3.77 (m, 2H), 2.37 (s, 1H).
Example 134 S nthesis of S 2-amino c anometh l ridin lfluoro-N- 2-h drox phenylethyl )benzamide Scheme 59 0 _/ 0 {OH no L NH2 N + Ho, / F 0© —> N \ F g Nl \ l / / OH Bl‘ \ To a on of (S)(2-aminobromopyridinyl)f|uoro-N-(2-hydroxy phenylethyl)benzamide (40 mg, 0.093 mmol) and isoxazolylboronic acid (20.99 mg, 0.186 mmol) in DME (697 pl) was added PdC|2(dppf)-CH2C|2 (7.59 mg, 9.30 umol) and 2 M Na2C03 solution (232 pl). The reaction mixture was heated in microwave at 120 °C for min. The reaction mixture was oned n EtOAc and water, The organic layer was dried over anhydrous sodium sulfate, filtered off, and concentrated in vacuo. The crude product was purified by prep HPLC. The pure fractions were collected and lyophilized yielding (S)—4-(2-amino(cyanomethyl)pyridinyl)f|uoro-N-(2-hydroxy phenylethyl)benzamide as a TFA salt in 7% yield. LCMS (m/z): 391.2 (MH+), 0.51 min; 1H NMR (400MHz ,CD30D) 8 ppm 8.66 (br. s., 1 H), 7.99 - 7.95 (m, 1 H), 7.92 - 7.82 (m, 2 H), 7.44 - 7.39 (m, 4 H), 7.38 - 7.32 (m, 2 H), 7.31 - 7.25 (m, 1 H), 5.25 - 5.18 (m, 1 H), 3.92 - 3.90 (m, 2 H), 3.90 - 3.80 (m, 2 H).
Example 135 S nthesis of S o 2 2 6 6-tetradeuterido-tetrah dro-2H- ran | razin yl)—N-§2—hydroxyQhenylethy|)benzamide Scheme 60 Steal o o o TSOH O I \ O “W —> W AWAO O benzene /\O O/\ Stegg Stegg TSOH LiAID /—\ O O 4 D D _. DWD + o: benzene HO OH D D 92% o 74% D D SteQA Ste9§ F o Q~J< —> + I _, O 54% D D ’N o CI 21% \ D D D D a: 4+ m w o B’ PdC|2(dPPf) B \ é —» D D O O \ KOAc O D D W 0 /OH 0‘ ,o Step 1 B NH2 + N/\©H \ N \ .
D D /N 20% (over2steps) D D 0 _/OH O /OH NH2 N Stegfi NH2 N H H NI \ H2/Pd-C N \ /N —’ I D D D D D D O D D Ste 1. dieth | 2 2'- 1 3-dioxolane-2 2-di | diacetate A solution of diethyl 1,3-acetonedicarboxylate (12 g, 59.3 mmol), ethyleneglycol (9.93 mL, 178 mmol), and p-toluenesulfonic acid monohydrate (564 mg, 2.97 mmol) in benzene (80 mL) was refluxed under heating removing water for 10 h by Dean-Stark trap. The benzene layer was washed with a ted aqueous sodium bicarbonate solution and brine. The solvent was distilled away and the residue obtained was purified by flash tography (10 to 40% EtOAc in heptanes) yielding diethyl 2,2'-(1,3-dioxolane-2,2- diyl)diacetate (42%). LCMS (m/z): 247.2 (MH+), 0.65 min; 1H NMR (400 MHz, CDCI3) 6 ppm 4.17 (q, J=7.04 Hz, 4 H) 4.03 (s, 4 H) 2.95 (s, 4 H) 1.27 (t, J=7.24 Hz, 6 H).
Ste 2. 2 2'- 1 3-dioxolane-2 2-di | diethanol-d4 To a suspension of LiAlD4 in THF (2.46 g, 58.7 mmol in 40 mL) between -10 to 0 °C was added a solution of diethyl 2,2'-(1,3-dioxolane-2,2-diyl)diacetate (6.06 g) in THF (20 mL) over 10 min. The reaction mixture was stirred at 0 °C for 1 h and ed by sequential addition of water (2.5 mL), 15 wt% NaOH (2.5 mL), and water (7.5 mL). The precipitates of the ed mixture were removed by filtration and the filter cake was rinsed carefully with THF. The filtrate was trated and crude 2,2'-(1,3-dioxolane-2,2-diyl)diethanol- d4 was obtained (92%). 1H NMR (400 MHz, CDCI3) 6 ppm 4.06 (s, 4 H) 2.49 (s, 2 H) 1.98 (s, 4 H).
Step 3. 1,4,8—trioxaspiro|4.5|decane-d4 A mixture of 2,2'-(1,3-dioxolane-2,2-diyl)diethanol-d4 (3.57 g, 21.5 mmol) and 4- methylbenzenesulfonic acid hydrate (0.204 g, 1.07 mmol) and benzene (150 mL) were heated for 3 h at ing temperature with Dean-Stark apparatus to remove water. The reaction mixture was cooled down, washed with sat. NaHC03 (20 mL x 2), and the aqueous layers were combined, extracted wuth Et20(2 x 20 mL), the organic layers were combined, washed with brine (30 mL), dried (Na2804), filtered off, and trated under 20 mbar via rotavap, and a light yellow oil was obtained as crude 1,4,8- trioxaspiro[4.5]decane-d4 (2.34 g, 73.5% . 1H NMR (400 MHz, CDCI3) 6 ppm 3.98 (s, 4 H) 1.73 (s, 4 H).
Ste 4. dih dro-2H- ran-4 3H 4 The 1,4,8—trioxaspiro[4.5]decane-d4 (2.34 g, 15.8mmol), formaldehyde(37%, 4.6 mL, 63.2 mmol) and pyridine 4-methylbenzenesulfonate(0.198 g, 0.79mmol) were equally splitted into two microwave vials. Each vial was heated at 80 °C for 30 min and additional 15 min.
The reaction mixtures were combined saturated with NaCl, extracted with EtZO until no d product found in aqueous layer by 1H-NMR. The ether extracts were combined, concentrated and the e was purified by flash column chromatography on silica gel (gradient EtZO/n-pentane) twice yielding dihydro-2H-pyran-4(3H)-one-d4. 1H NMR (400 MHz, CDCI3) 6 ppm 2.50 (s, 4 H).
Step 5. 3,6-dihydro-2H-pyranyl trifluoromethanesulfonate-d4 To a freshly prepared LDA (10.6 mmol) in THF (10 mL) between -75 to -65 °C was dropwise added a solution of dihydro-2H-pyran-4(3H)—one-d4 (1.05 g) in THF (3.5 mL) over 10 min. The resulting reaction mixture was stirred at -75 °C for 3 h, followed by addition of N-(5-chloropyridinyl)-1,1,1-trifluoro-N- ((trifluoromethyl)sulfonyl)methanesulfonamide in THF (4.16 g/5 mL) over 10 min. The reaction mixture was stirred at -75 °C for 1 h, then with temperature gradually warming up to room temperature overnight. The reaction mixture was cooled to 0 °C, ed with D20(10mL), and the two layers were separated, the organic layer was washed sequentially with D20(10 mL), citric acid (3 x 10 mL, 3 g citric acid in 30 mL water), 1M NaOH (2 x 10 mL), brine (30 mL), dried (Na2804), trated and the crude oily product was purified by flash chromatography on silica gel eluted with nt EtZO/n- pentane (0-60%). The purified product was further purified by distillation purification by Kugelrohr at 105°C/3 mbar yielding 3,6-dihydro-2H-pyranyl trifluoromethanesulfonate- d4 (500 mg, 21% yield). 1H NMR (400 MHz, coc13)5 ppm 5.82 (s, 1 H) 2.45 (s, 2 H).
Ste 6. 2- 3 6-dih dro-2H- ran | -4 4 5 5-tetrameth H 3 2-dioxaborolane-d4 A mixture of 3,6-dihydro-2H-pyranyl trifluoromethanesulfonate-d4 (500 mg, 2.12 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (806 mg, 3.18 mmol), potassium acetate(644 mg, 6.56 mmol), PdC|2(dppf)-CH2C|2 (86 mg, 0.106 mmol) and p- dioxane (5 mL) was charged into a microwave reactor vial, purged with argon for 5min, sealed and heated at 80 °C overnight via oil bath. The reaction mixture was cooled down to room temperature, diluted with EtOAc(10mL), filtered through a neutral alumina plug (1 .25' H x 0.75' D), and the filter cake was washed thoroughly with EtOAc. The filtrate was concentrated yielding crude -dihydro-2H-pyranyl)-4,4,5,5-tetramethyl-1,3,2- dioxaborolane-d4 in light brown solid . LCMS (m/z): 215.2 (MH+), 0.78 min.
Ste 7. S 3-amino 3 6-dih dro-2H- ran | razin l-N- 2-h drox phenylethyl)benzamide-d4 A e of 2-(3,6-dihydro-2H-pyranyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane-d4 (300 mg, 1.4 mmol), (S)(3-aminobromopyrazinyl)-N-(2-hydroxy phenylethyl)benzamide (694mg, 1.68 mmol), aqueous Na2C03 (2 M, 2.8 mL), and PdCl2(dppf)-CH2Cl2 (57.2 mg, 0,07mmol) and p-dioxane (6 mL) were charged into a ave reactor vial, purged with argon for 5 min, sealed and heated at 115 °C for 30 min. The reaction mixture was diluted with EtOAc (15 mL), filtered and the filtrate was washed with 1M HCI (4 x 30 mL), and the aqueous layers were combined, basified by solid NaOH to pH 12, extracted with EtOAc (60 mL), dried (Na2804), concentrated and the first crop of product was ed with some impurities. The EtOAc layer after aqueous HCI washes was trated and the residue was diluted with DMSO, purified by C18 reverse phase prep HPLC, and the product fractions were combined, saturated with Na2C03, extracted with EtOAc (60 mL), and a second crop pure product was obtained in light yellow solid. The first crop product was purified by flash chromatography on silica gel eluted with nt e/CH2C|2 ). The two crops of product were combined and (S)(3-amino(3,6-dihydro-2H-pyranyl)pyrazinyl)-N-(2-hydroxy phenylethyl)benzamide-d4 (179 mg, 27.9% yield) was obtained. LCMS (m/z): 421.2 (MH+), 0.65 min.
Ste 8. S 3-amino 2 2 6 6-tetradeuterido-tetrah dro-2H- ran l razin l -N- (2-hydroxy—1phenylethyl)benzamide A mixture of (S)—4-(3-amino(3,6-dihydro-2H-pyranyl)pyrazinyl)-N-(2-hydroxy phenylethyl)benzamide-d4 (175 mg) and Pd/C (10%, 22mg) in methanol was stirred under hydrogen balloon at room temperature for 2 h. The reaction mixture was filtered through a thin layer of Celite pad, and the filtrate was concentrated to afford crude white solid. The crude product was ed by flash tography (0-60% acetone/CHZCIZ) and pure product was dissolved in acetonitrile/water (1:1, 10 mL), frozen and lyophilized to (S)—4-(3-amino(2,2,6,6-tetradeuterido-tetrahydro-2H-pyranyl)pyrazinyl)-N-(2- hydroxyphenylethyl)benzamide in a white powder (64%). LCMS (m/z): 423.2 (MH+), 0.60 min; 1H NMR (400 MHz, CDCI3) 6 ppm 7.93 - 8.01 (m, 2 H), 7.92 (s, 1 H), 7.82 - 7.89 (m, 2 H), 7.38 - 7.47 (m, 4 H), 7.31 - 7.37 (m, 1 H), 6.90 (d, J=7.04 Hz, 1 H), 5.32 (dt, J=6.95, 4.55 Hz, 1 H), 4.68 (br. s., 2 H), 4.06 (d, J=4.30 Hz, 2 H), 2.93 (tt, 4, 4.40 Hz, 1 H), 1.79 - 1.99 (m, 4 H).
Examples 136 and 137 hydroxy-1phenylethyl)benzamide Scheme 61 0 /OH NH2 N/\©H 1. Pd/C, H2 NI \ NI \ OH/\©+ ON/\© / N 2. chiral separation O O 0 To a solution of (S)(3-amino(furanyl)pyrazinyl)-N-(2-hydroxy phenylethyl)benzamide (75 mg, 0.187 mmol) in MeOH (1.873 mL) was added platinum (IV) oxide (12.76 mg, 0.056 mmol). The on was degassed by N2 stream for 15 min.
After flushed with hydrogen gas and equipped with a hydrogen balloon, the reaction mixture was stirred for 24 h. The reaction mixture was filtered h Celite. After volatile materials were d, the crude product was re-setup the reaction. The reaction mixture was stirred for another 24 h. LCMS (m/z): more side products were formed. The reaction mixture was ed through Celite. After volatile materials were removed, to a solution of the crude product in MeOH (1.873 mL) was added Pd-C (100 mg, 0.094 mmol). The solution was degassed by N2 stream for 15 min. After flushed with hydrogen gas and ed with a hydrogen balloon, the reaction mixture was stirred for 24 h.
LCMS (m/z): all s.m. disappeared. The reaction mixture was filtered through Celite. After volatile materials were removed, the crude t was purified by flash chromatography (EtOAc in DCM) ng 4-(3-amino(tetrahydrofuranyl)pyrazinyl)-N-((S) hydroxyphenylethyl)benzamide (9 mg, 12%). LCMS (m/z): 405.2 (MH+), 0.58 min; 1H NMR (400MHz, CD3OD) 6 ppm 7.96 - 7.86 (m, 2 H), 7.80 (s, 1 H), 7.77 - 7.70 (m, 2 H), 7.38 - 7.32 (m, 2 H), 7.30 - 7.21 (m, 2 H), 7.21 - 7.12 (m, 1 H), 5.14 (m, 1 H), 4.08 - 3.97 (m, 1 H), 3.99 - 3.89 (m, 1 H), 3.89 - 3.67 (m, 4 H), 3.56 - 3.38 (m, 1 H), 2.33 - 2.04 (m, 2 H), 1.24 - 1.13 (m, 2 H). The racemic product was resolved in chrial HPLC (AD column, 5mL/min, MeOH= 30%, SFC) yielding 4-(3-amino((S)—tetrahydrofuranyl)pyrazin yl)-N-((S)hydroxyphenylethyl)benzamide and 4-(3-amino((R)-tetrahydrofuran yl)pyrazinyl)-N-((S)hydroxyphenylethyl)benzamide — 3.4 mg of polar enantiomer (Rt = 2.12 min) and 3.5 mg of less-polar enantiomer (Rt = 2.66 min). The absolute stereochemistry was arbitrarily assigned.
Table 4. nds ed using Method 2 described above.
Example Structure Name MH+ Rf NMR (mm) o {OH (S)—4-(3-am|no- 138 N/:\© 6-(furan yl)pyraziny|)— N|\ 01.2 2.84 ydroxy_1_ / N phenylethyl)benz amide Examplem MH+ R-t NMR (mm) H NMR (400MHz ,CD30D) 0 8 ppm 8.43 (s, 1 “1va H), 8.40 (d, J = NH N 5.1 Hz,1 H), 8.24 (s, 1 H), .01 '(3'am'n9'§'(3'. (d, J = 8.2 Hz, 2 H), 7.96 (s, 1 1 H), 7.89 (d, J = 8.6 Hz, 2 H), [N SOZMe methy'pfl'd'wr' y|)pyraZIny|)- 7.84 (s, 1 139 4741 049 H), 7.72 (s, 1 H), / N-(3- 7.63 - 7.58 (m, 1 H), 7.55 (d, J l (methylsulfony|)b :51 Hz, 1 H),4.69 (s, 2 H), benzamide 3.10 (s. 3 H), 2.48 (s. 3 H) 1H NMR (400MHz ,CD30D) (2'am'“°'.
F 0 (OH 5 ppm 8.97 (s, 1 H), 8.65 — 8.53 F 5-(1-methyl-1H- (m, 1 H), 8.18 (d, J = 2.3 Hz, 1 “”2 E/\© imidazol H), 7.88 (t, J = 7.4 Hz, 1 H), 140 N\/ y|)pyridiny|)—2— 7.74 (d, J = 2.3 Hz, 1 H), 7.67 | 4322 0'46 luorO-N-(2- (d, J = 1.6 Hz,1 H), 7.47-7.39 hydroxy_1_ (m, 4 H), 7.36 (t, J = 7.6 Hz, 2 / N/ phewletWDbenz H), 7.31 - 7.25 (m, 1 H), 5.34 - N=/ 5.17 (m, 1 - 3.78 (m, 5 amide H), 3.98 Synthesis of (S)— 1H NMR (400 MHz, CD3OD) 6 A_(2_amino_5_(1_ 8.11 (m, 1 H), 7.76 (m, 2 H), methyl-1 H-1 23_ 7.37 (m, 1 H), 7.27 (m, 2 H), 7.20 (m, 3 H), 5.09 (m, 1 l_5_ H), F o ?/ 4.03 (s, 3 H), 3.73 (m, 2 H) yl)pyridin_3_yl)_ 141 NH2 485.2 0.64 N/ F I HAQ N-(1-(3- chlorophenyl)—2- \ Cl hydroxyethy|)- 2,6- \N\N=\N difluorobenzami WO 66188 Example (nfitn) NMR 1H NMR (400MHz, DMSO-d6) 8 8.89 (s, 1 H), 8.70 (m, 2 H), (S)—4-(3-amino- 8.65 (m, 1 H), 8.22 (m, 2 H), 6-(pyridin 7.80 - 7.62 (m, 3 H), 7.49 - 7.20 y|)pyraziny|)— (m, 5 H), 7.08 (m, 1 H), 5.03 142 2—fluoro-N-(2- 0.53 (m, 1 H), 3-65 (d, J = 4 H212 H) hydroxy phenylethyl)benz amide 1H NMR (400MHz, DMSO-d6) 8 8.72 - 8.51 (m, 4 H), 8.43 (s, 1 H), 7.78 - 7.53 (m, 3 H), 7.40 methylpyridin £3753? (m; 4H?)’570-:2( (ma 1H?) y|)pyraziny|)— ' m’ ’ ' m’ ’ 143 0.52 3.65 (d, J — 8 Hz, 2 H)_ 2—fluoro-N-(2- y phenylethyl)benz amide 1H NMR (400MHz ,CD30D) 8 9.86 (d, J = 1.2 Hz, 1 H), 9.20 (3-amino- (d, J = 5.9 Hz, 1 H), 8.82 (s, 1 6-(pyridazin_4_ H), 8.49 (dd, J = 2.3, 5.9 Hz, 1 y|)pyraziny|)— H), 7.87 - 7.78 (m, 1 H), 7.70 - 7.62 (m, 2 H), 7.40 144 2—fluoro-N-(2 7.32 (m, 2 H), 7.27 (t, J = 7.4 Hz, 2 H), hydroxy_1_ 7.20 (d, J = 7.4 Hz, 1 H), 5.14 pheny'ethy'wenz (t, J = 6.1 Hz, 1 H), 3.85 - 3.72 amide (m, 2 H) 1H NMR (400 MHz, CD30D) 6 -(3-amino ppm 8.17 (s, 1 H) 8.03-7.95 (m, (1,3-dimethyl- 2 H) 7.93-7.83(m, 2 H) 7.76 (d, 1H_pyrazol_4_ J=8.22 Hz, 2 H) 7.72-7.59 (m, 2 145 H) 4-72 (3’ 2 H) 3-86 (S! 4 H) y|)pyraziny|)— 0.65 3.12 (s, 3 H) 2.47 (s, 3 H) 2—fluoro-N-(3- (methylsulfony|)b enzyl)benzamide Example MH+ Rf NMR (mm) 1H NMR (400MHz, CD30D) 8 8.17 - 8.09 (m, 1 H), 8.03 - 7.90 (m, 3 H), 7.88 - 7.73 (m, 3 H), 7.38 - 7.30 (m, 2 H), 7.31 - 7.23 (m, 2 H), 7.21 - 7.14 (m, 1 H), .21 -5.10(m, 1 146 4153 059 H), 3.84 (s, 3 H), 3.82 - 3.75 (m, 2 H) N_(2_hydroxy_1_ ethyl)benz amide 1H NMR (400 MHz, CD30D) 5 ppm 8.30 (t, J=8.02 Hz, 1 H) "(3'amm0'5'(1', 8.05 (s, 1 H) 7.97-7.83 (m, 4H) methyl-1 H' 7.75-7.67(m, 2 H) 7.64-7.55 pyrazol (m, 2 H) 4.82 (d, J=5.87 Hz, 2 147 yI)pyrazinyl)- 481.3 0.633 H) 3.99 (s, 3 H) 3.07 (s, 3 H) 2—fluoro-N-(3- lsulfony|)b enzyl)benzamide H NMR z, CD30D) 8 {0H 8.25 (s, 1 H), 8.05 (s, 1 H), F (S)_4_(3_amino_ 7.92 (s,1 H), 7.89-7.79 (m, 1 NH2 6'(1'methy"1H' H), 7.77 - 7.59 (m, 2 H), 7.47 - N / Mmpyrazo'jA" 7.39 (m, 2 H), 7.39 - 7.31 (m, 2 148 \ 'N y|)pyraZ|ny|)- 4332 054 H), 7.31 -7.21 (m, 1 H), 3.91 2-1‘|Uor0-N-(2- (s, 3 H), 3.89 - 3.78 (m, 1 H), / hydroxy 1.42- 1.28 (m, 1 H) N—KJ phenylethyl)benz / amide 1H NMR (400 MHz, CD30D) 5 /OH (S)(2-am'“°- ppm 8.73 (d, J=7.83 Hz, 1 H) ? 5-(1-methyl-1H- 8.08 (d, J=2.35 Hz, 1 H) 7.93- NH2 MD1,2,3-triazol 7.73 (m, 1 H) 7.48 (d, J=7.83 N \ yI)pyridinyl)- Hz, 1 H) 7.41 - 7.07 (m, 6 H) 149 | 5.22 - 5.01 (m. 1 H) 4.04 (S. 3 / CI N-(1-(3- 463.3 0.61 chlorophenyl)—2- H) 3.86 - 3.57 (m, 2 H) 2.44 - / I‘l/ hydroxyethy|) 2'24 (m’ 3 H) N=N methylbenzamid Example (nfitn) NMR 1H NMR (400MHz, METHANOL-d4) 5 ppm 8.82 - 8.62 (m, 1H), 8.12 (d, J=2.0 Hz, 150 0'67 1H), 8.00 - 7.76 (m, 2H), 7.58 - 7.17 (m, 7H), 6.49 (d, J=2.0 Hz, 1H), 5.20 (d, J=5.9 Hz, 1H), 3.95 - 3.69 (m, 5H) 1H NMR z, METHANOL-d4) 5 ppm 7.90 (m, 1 H), 7.85 (m, 1 H), 7.81 1H-pyrazol (m, 1 H), 7.55 (s, 1 H), 7.42 - y|)pyridiny|)- 7.34 (m, 3 H), 7.30 - 7.24 (m, 2 151 069 N-(1-(3- H), 7.21 (m,1 H), 5.10 (m,1 chlorophenyl)—2— H), 3.82 - 3.71 (m, 2 H), 3.75 hydroxyethyl)—2— (S: 3 H): 2-31 (S. 3 H) 1H NMR (400MHz, (S)—4-(2-amino— METHANOL-d4) 5 ppm 7.92 - (m,1 H), 7.87 (m, 1 H), 7.81 1H_pyrazol_4_ (m, 1 H), 7.76 (s, 1 H), 7.41 - - - 7.34 (m, 3 H), 7.30 - 7.24 (m, 2 152 gm'3'yl)' 0.69 H), 7.21 (m,1 H), 5.10 (m,1 '( '( ' H), 3.85 - 3.67 (m, 2 H), 3.76 chlorophenyl)—2- (S, 3 H), 2.26 (S, 3 H) hydroxyethyl)—2— luorobenzamide 1H NMR (400MHz, (S)_N_(2_amino_ METHANOL-d4) 5 ppm 7.88 1_phen,ylethyI)_4_ (m, 2 H), 7.84 (m, 1 H), 7.74 (2-am'n0<1a3- (m, 1 H), 7.44 - 7.33 (m, 6 H), 153 0-55 7.33- 7.27 (m, 1 H), 5.40 (m, 1 H), 3.76 (s, 3 H), 3.38 (m, 2 H), 2.25 (s, 3 H) Rt NMR Example (min) 1H NMR (400MHz, CD30D) 5 7.77 (m, 3 H), 7.37 (m, 2 H), 7.27 (m, 1 H), 5.1 (m, 1 H), 3.76 (m, 2 H), 3.67 (s, 3 H), 2.18 (s, 3 H), 2.11 (s,3 H) 154 0.63 1H NMR (400MHz, CD30D) 8 8.18 (s, 1 H), 7.98 (s, 1 H), _(3_amino_6_(1_ 7.84 (s, 1 H), 7.74 (m, 1 H), methyl'1 H' 7.68 - 7.62 (m, 2 H), 7.31 - 7.12 pyraz°"4' (m, 5 H), 3.84 (s, 3 H), 3.01 (m, 155 y|)pyraziny|)- 0.81 1 H), 212 (m, 1 H), 124 (m, 2 2—fluoro-N-(2- H) phenylcycloprop y|)benzamide H NMR (400MHz, CD30D) 8 8.03 (s, 1 H), 7.77 (m, 1 H), 7.64 (m, 1 H), 7.41 (m, 1 H), 7.34 (m, 2 H), 7.27 (m, 2 H), 7.19 (m, 1 H), 5.13 (m, 1 H), 155 0-74 3.77 (m, 2 H), 2.46 (s, 3 H), 2.30 (s, 3 H) 1H NMR z, CD30D) 8 8.86 (m, 1 H), 8.19 (m, 1 H), 7.77 (m, 1 H), 7.68 - 7.56 (m, 2 methylisoxazol— H), 7.36 - 7.31 (m, 2 H), 7.30 - _y|)pyrazin_2_ 7.23 (m, 2 H), 7.18 (m, 1 H), 157 0-74 5.12 yl)_2_fluoro_N_(2_ (m, 1 H), 3.77 (m, 2 H), 2.62 (S, 3 H) hydroxy—1- phenylethyl)benz amide Example MH" R-t NMR (mm) 1H NMR z, CD30D) 8 8.19 (d, J = 2.3 Hz, 1 H), 7.91 (s, 1 H), 7.85 (m, 1 H), 7.77 (d, methylisoxazol— J = 0.7 Hz, 1 H), 7.65 (d, J = -y|)pyridiny|)— 2.3 Hz, 1 H), 7.51 - 7.23 (m, 6 158 433-3 0-51 2_fluorO_N_(2_ H), 5.29-5.11 (m,1 H), 3.99- 3.77 (m, 5 H) hydrOXy phenylethyl)benz amide (S)—4-(2-amino- '(3'Cya“°'1' 1H NMR z, CD30D) 8 methyl-1H- 8.3 (m, 1 H), 8.08 (s, 1 H), 7.88 (m,1 H), 7.73 (m, 1 H), 7.48 - 159 475.3 0.64 7.7.33 (m, 3 H), 7.28 (m, 1 H), luoro-N-(1-(3— 7.17 (m, 1 H), 7.01 (m, 1 H), |uoropheny|)—2- 5-21 (m. 1 H). 3-99 (S. 3 H). 3.88 (m, 2 H) '(3'Cya“°'1' 1H NMR (400MHz, CD30D) 8 methyl-1H- 8.82 (m1 H), 8.17 (m, 1 H), pyrazol 8.07 (s 1 H), 7. 95 (m, 1 H), 180 y|)pyridiny|)— 491.1 0.88 7.80 (m, 1 H), 7. 38 (m, 3 H), N-(1-(3- 7.27 (m, 3 H),7 .21 (m, 1 H), chlorophenyl)—2- 5-10 (m, 1 H).3-92 (S. 3 H). 3.78 (m, 2 H) 1H NMR (400MHz, CD30D) 8 8.59 (m, 1 H), 8.12 (m, 1 H), 1H-Imldazol. . 7.88 (m, 1 H), 7.88 (m, 1 H), y|)pyridiny|) 7.53 (s, 1 H), 7.48 - 7.38 (m, 5 161 4462 0'45 luoro-N-(2- H), 7.41 -7.31 (m,1 H), 7.31 — y 7.23 (m, 1 H), 5.23 (m, 1 H), phenylethyl)benz 3.95 - 3.77 (m, 2 H), 3.70 (s, 3 amide H), 2.88 (s, 3 H).
Example MH+ 1H NMR (400MHz, CD30D) 8 8.88 (m, 1 H), 8.12 (m, 1 H), 1H-imidazoI 7.88 (m, 1 H), 7.70 (m, 1 H), y|)pyridiny|)— 7.53 (s, 1 H), 7.50 - 7.39 (m, 3 162 0.56 N-(1-(3- H), 7.35 (m, 2 H), 7.32 (m, 2 chlorophenyl)—2- H), 5.28 - 5.11 (m, 1 H), 3.90 - yethy|) 3.78 (m, 2 H), 3.70 (s, 3 H), 2.88 (s, 3 H) (S)—4-(2-amino- 1H NMR (400MHz, CD30D) 8 8.84 (m, 1 H), 8.12 (m, 1 H), 1H-imidazoI 7.88 (m,1 H), 7.88 (s, 1 H), 7.52 (s,1 H), 7.45 (m, 1 H), 163 0.48 7.43 (m, 1 H), 7.38 (m, 1 H), luoro-N-(1-(3- 7.25 (m, 1 H), 7.18 (m, 1 H), |uoropheny|)—2- 7.01 (m, 1 H),4.91 (m, 1 H), 3.87 (m, 2 H), 3.7 (s, 3 H), 2.88 (s, 3 H) 1H NMR (400MHz ,CD30D) 8 9.17 (s, 1 H), 8.90 (s, 1 H), 8.85 (br. s.,1 H), 8.28 (d, J = 2.0 Hz,1 H), 8.18 (d, J = 2.0 164 luoro-N-(2- 0.57 Hz,1 H), 7.91 (t, J = 7.8 Hz,1 hydroxy- 1- H), 7.55 - 7.25 (m, 8 H), 5.23 phenylethyl)benz (d, J = 5.1 Hz,1 H), 3.96 - 3.75 (m, 2 H) 1H NMR (400MHz, CD30D) 8 8.58 (m 1 H) 8.53 (s, 1 H) methylisoxazol- 8.00 (m 1 H) 788 (m, 1 H ridiny|)— 7.81 (m, 1 H) 738 (m,2H 165 0.62 2-fluoro-N-(1-(3- 7.29 (m 1 H), .15(m, 1 H |uoropheny|)—2- 7.08 (m 1 H) 93 (m, 1 H .13(m,1 H) 78 (m,2H 2.49 (s,3 H) Rt NMR Example (min) 1H NMR (400MHz, CD30D) 8 ppm 8.32 (s, 1 H), 8.06 (m, 1 H), 8.02 (m, 1 H), 7.91 (m, 1 166 0'7 H), 7.57 - 7.4 (m, 4 H), 7.39 - 7.24 (m, 4 H), 5.19 (m, 1 H), 3.86 (m, 2 H), 2.41 (s, 3 H) 1H NMR z, CD30D) 8 1,2,4-triazoI 8.71 - 8.54 (m, 1 H), 8.29 (d, J = 2.2 Hz, . . 1 H), 7.94 (m, 2 H), 167 fiffirgln'3'y')‘ 0.59 7.81 (m, 1 H). 7.38 (m, 3 H). 7.28 (m, 2 H), 7.22 (m, 1 H), Ch'oroF’he“y')'2' 5.12 (m, 1 H), 3.95 (s, 3 H), hydrOXyethy|) 3.86 - 3.65 (m, 2 H) luorobenzamide (S)'4'(2'am'“°' 1H NMR (400MHz, CD30D) 8 '(1'methyl'3' ppm 8.54 (m, 1 H), 7.94 - 7.84 uoromethy|)- (m, 1 H), 7.83- 7.74 (m, 1 H), 1H-Pyrazol 7.75 - 7.68 (m, 1 H), 7.63 - 7.54 168 yI)pyridinyI) 0.66 (m, 1 H), 7.41 - 7.30 (m, 4 H), luoro-N-(2- 7.29 - 7.22 (m, 2 H), 7.21 - 7.11 hydroxy_1_ (m,1 H), 5.21 -5.06 (m, 1 H), phenylethymenz 4.02 - 3.93 (m, 3 H), 3.86 - 3.65 (m’ 2 H) amide 1H NMR (400MHz, CD30D) 8 7.87 (d, J = 2.0 Hz, 1 H), 7.91 1H_pyrazol_4_ (d, J = 2.3 Hz,1 H), 7.81 (t, J = . . 7.8 Hz,1 H), 7.75 (s, 1 H), 7.41 yl)pyr'd'n_3_yl)'2' 169 0.61 - 7.30 (m, 4 H), 7.27 (t, J = 7.6 luorO'N'Q' Hz, 2 H), 7.20 (d, J = 7.0 Hz, 1 hydroxy'1' H), 5.13 (t, J = 5.9 Hz, 1 H), phenylethyl)benz 3.84 - 3.69 (m, 5 H), 2.26 (s, 3 amide H) 2014/062913 Example MH+ Rf NMR (mm) 1H NMR (400MHz, CD30D) 8 7.97 (d, J = 2.0 Hz, 1 H),7.93 1H-pyrazol (d, J = 2.0 Hz, 1 H), 7.89 (t, J = yl)pyridiny|)—2— 7.8 Hz, 1 H), 7.63 (s, 1 H), 7.48 170 446's 0'62 luoro-N-(2- - 7.31 (m, 6 H), 7.27 (d, J = 7.0 y Hz, 1 H), 5.20 (t, J = 5.9 Hz, 1 H), 3.91 - 3.74 (m, 5 H), 2.41 - 2.36 (m, 3 H) 1H NMR (400MHz, CD30D) 8 8.16 (d, J = 2.0 Hz, 1 H), 8.13 (d, J = 2.3 Hz, 1 H), 8.09 (s,1 1H-pyrazoI H), 7.94 - 7.88 (m, 2 H), 7.51 - . . 7.40 (m, 4 H), 7.37 (t, J = 7.6 171 y|)pyrldln 3 yl) 2_ _ _ _ 476.3 0.6 Hz, 2 H), 7.29 (d, J = 7.0 Hz, 1 luorO'N'Q' H), 5.23 (d, J = 6.7 Hz, 1 H), hydroxy'1' 4.33 (t, J = 5.1 Hz, 2 H), 3.94 - 3.80 (m, 2 H), 3.75 (t, J = 5.1 Hz, 2 H) 1H NMR (400MHz, CD30D) 8 8.17 (d, J = 2.3 Hz, 1 H), 8.12 (d, J = 2.0 Hz, 1 H), 8.09 (s,1 1H-pyrazol H), 7.94 - 7.88 (m, 2 H), 7.52 - 172 yl)pyridiny|)— 510.3 0.67 7.44 (m, 3 H), 7.38 — 7.32 (m, 2 N-(1-(3- H), 7.31 (d, J = 2.3 Hz, 1 H), chlorophenyl)—2- 5-20 (S. 1 H). 4-33 (t. J = 5.1 hydroxyethyl)—2— HZ, 2 H), 3.93 - 3.80 (m, 2 H), 3'75 (t’ J = 5'1 HZ’ 2 H) luorobenzamide Method 3 Example 173 S nthesis of 4- 3-amino tetrah dro-2H- ran | razin | -N- 3-chlorobenz | fluorobenzamide 2014/062913 Scheme 62 —Qe ‘St 1 MHz F 0 m; NJ\(BV O NH2 0/ I / Pdd fCI-DCM /N 0 (pp) 2 HO N|\ LiOH(1M) ‘ila ’ F , DME / N OH THF,MeOH 670/0 F 0 Step; F O NH2 OH NI \ NH2 PyBrop,HOBt 3 /N + HZN —> N \ DIEA,DMF /N Cl C' 87% Ste 1. meth l4- 3-amino tetrah dro-2H- ran l razin uorobenzoate To a solution of methyl 2-fluoro(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)benzoate (259 mg, 1.308 mmol), 3-bromo(tetrahydro-2H-pyranyl)pyrazinamine (225 mg, 0.872 mmol), and PdC|2(dppf) (64 mg, 0.087 mmol) was added DME (6.5 mL) and 2 M Na2C03 solution (3.2 mL). The reaction mixture was heated at the microwave synthesizer (120 °C, 10 min). The reaction mixture was worked up with EtOAc. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, filtered off, and concentrated in vacuo. The crude product was purified by flash chromatography (gradient EtOAc in e) to yield the desired product (192 mg, 67%). LCMS (m/z): 332.2 (MH+), 0.63 min.
Ste 2. 4- 3-amino tetrah dro-2H- ran l razin lfluorobenzoic acid To a solution of methyl 4-(3-amino(tetrahydro-2H-pyranyl)pyrazinyl)—2- fluorobenzoate (104 mg, 0.314 mmol) in THF (698 uL) and MeOH (349 uL) was added LiOH (1 M solution) (565 uL, 0.565 mmol). The reaction mixture was stirred for 1 h at room temperature. The reaction mixture was quenched with 1N HCI on up to pH 5, and worked up with EtOAc. The organic layer was washed with water and brine, dried 2014/062913 over anhydrous sodium sulfate, filtered off, and concentrated in vacuo. The crude product was used forthe next step. LCMS (m/z): 318.3 (MH+), 0.5 min.
Ste 3. 4- 3-amino tetrah dro-2H- ran l 2- l-N- 3-chlorobenz l fluorobenzamide To a solution of mino(tetrahydro-2H-pyranyl)pyrazinyl)f|uorobenzoic acid (17 mg, 0.054 mmol) and (3-chlorophenyl)methanamine (8.34 mg, 0.059 mmol) in THF (268 uL) was added PyBroP (27.5 mg, 0.059 mmol), DIEA (28.1 uL, 0.161 mmol) and HOBT (9.02 mg, 0.059 mmol). The reaction mixture was stirred overnight at room temperature. All volatile al was removed in vacuo and dissolved in DCM. The crude product dissolved in DCM was loaded to flash chromatography column (gradient EtOAc in heptane) providing 4-(3-amino(tetrahydro-2H-pyranyl)pyrazinyl)—N-(3- chlorobenzyl)f|uorobenzamide in 87% yield. LCMS (m/z): 441.1 (MH+), 0.79 min. 1H NMR (400MHz, DMSO-dg) 8 ppm 7.92 (s, 1 H), 7.74 (m, 1 H), 7.63 (m, 2 H), 7.35 (m, 4 H), 6.14 (s, 1 H), 4.48 (m, 2 H), 3.92 (m, 2 H), 3.43 (m, 2 H), 1.73 (m, 4 H).
Example 174 S nthesis of S -N- 2-amino 3-chloro hen l eth l 3-amino tetrah dro-2H- ran- 4- l razin lfluorobenzamide Scheme 63 F O F o /NHBoc NH2 OH {NHBoc ME NH2 N / 3 N EDC,HOAt IN + HZN —. N|\ \ ’N Cl DIEA,THF 0 O F 0 {NH2 Step 6 NH2 H _. I DCM EN Ste 1. S -tert-but l 2- 4- 3-amino tetrah dro-2H- ran l razin l fluorobenzamido)—2-(3-chlorophenyl )ethyl )carbamate To a solution of mino(tetrahydro-2H-pyranyl)pyrazinyl)f|uorobenzoic acid (35 mg, 0.110 mmol) in DMF ( 368 uL) was add (S)—tert-butyl (2-amino(3- chlorophenyl)ethyl)carbamate (33.9 mg, 0.110 mmol), aza-HOBt (22.52 mg, 0.165 mmol), EDC (31.7 mg, 0.165 mmol), and DIEA (57.8 uL, 0.331 mmol). The reaction mixture was stirred at room ature for 3 h. The reaction mixture was partitioned n EtOAc and water. The organic layer was washed by NaHC03, water and brine, dried over anhydrous sodium e, filtered off, and concentrated in vacuo yielding crude (S)—tert— butyl (2-(4-(3-amino(tetrahydro-2H-pyranyl)pyrazinyl)f|uorobenzamido)(3- chlorophenyl)ethyl)carbamate (>99%).
Ste 2. S -N- 2-amino 3-chloro hen l eth l 3-amino—6- tetrah dro-2H- ran yl)pyrazinyl)—2-fluorobenzamide The crude rt-butyl (2-(4-(3-amino(tetrahydro-2H-pyranyl)pyrazinyl) fluorobenzamido)—2-(3-chlorophenyl)ethyl)carbamate was dissolved in DCM (1.0 mL).
After TFA (0.3 mL) was added, the reaction mixture was stirred at room temperature for min. The reaction mixture was diluted with toluene and trated to dryness. The crude product was purified by reverse phase prep HPLC. The pure fractions were combined and lyophilized yielding (S)—N-(2-amino(3-chlorophenyl)ethyl)(3-amino hydro-2H-pyranyl)pyrazinyl)f|uorobenzamide as TFA salt (50% yield over 2 steps). LCMS (m/z): 470.1 (MH+), 0.67 min; 1H NMR (400MHz, CD3OD) 6 ppm 7.95 - 7.85 (m, 2H), 7.72 (d, J=8.2 Hz, 1H), 7.64 (d, J=12.1 Hz, 1H), 7.55 (s, 1H), 7.49 - 7.38 (m, 3H), 5.49 (dd, J=5.7, 8.8 Hz, 1H), 4.04 (dd, J=3.1, 11.3 Hz, 2H), 3.57 (dt, J=2.0, 11.5 Hz, 2H), 3.51 - 3.41 (m, 2H), 2.98 - 2.88 (m, 1H), 1.97 - 1.76 (m, 4H).
Example 175 S nthesis of 4- 3-amino 1r4S h drox c clohex l razin l-N- S 3-bromo- -fluorophenyl )—2-hyd roxyethyl )—2-fluorobenzamide Scheme 64 2014/062913 Steg 1 Step 2 O Pd(dppf)CI2DCM OH 1—>)(COCI)2 :OJ< BISPIN KOAc 2)t—BuOH DMF 100°C 64hr Br F Steg g o OJ< —N Pd(dppf)C|2-DCM (/NfNH2 2M Na2003 NH2 0J< O + —> \B F I DME, 100°C, 4hr N \ F O CI Ste w Stegg NB NI/KKEj/KO Pd<dppf>CI2-DCM 2M Na2co3 DME CH3CN o 00 100°C, 2 h, Br 0 O F O F O J< F O 0J< NH2 NH2 0 NH2 OJ< N/ N/ I S—Qte Q I steal N/ \ N \ N H2, Pd—C \ 3 N HCI —> —> MeOH/DCM, 6 h MeCN/water O O O O F O J< F O J< NH2 0 NH2 0 N/ _l231€ § N/ _l231€ 2&1— | | \ N \ N NaBH4 1. TBSCI MGOH, THF 2. 4 M HCI in dioxane -78 °C, 2 h 0 crude (trans:cis ~8: 1) (3H F o F 0 {OH Step \ N —> /N Br + CIHH2N DIEA trans only Br Ste 1. tert-But | 4-bromofluorobenzoate To a stirred solution of 4-bromofluorobenzoic acid (60 g, 274 mmol) in anhydrous THF (700 mL) at 0 0C was added DMF (2 mL) followed by oxa|y| chloride (48 mL, 548 mmol) portionwise over 1 hour. The mixture was stirred at 0 °C for 30 min, and then at room temperature for 1 hour. The solvent was d under reduced pressure, and the residue dissolved in DCM (700 mL). tert-Butyl alcohol (97 g, 1315 mmol) and pyridine (150 mL) were added, and the on mixture was stirred at room temperature for 64 h.
The mixture was transferred to a separating funnel and washed with water (400 mL), 2 N NaOH s solution (400 mL) and brine (2 x 200 mL), dried over magnesium sulfate, ed and concentrated under vacuum. The residue was purified by flash chromatography on silica gel (0 to 5% ethyl acetate in heptane over 30 min) to give tert- butyl 4-bromofluorobenzoate (60 g, 80%) as an oil. LCMS (m/z): 218 / 220 (MH+ (- tBu)), 1.11 min; 1H NMR (500 MHz, CDCI3) 6 ppm 7.81 - 7.71 (m, 1 H) 7.39 - 7.30 (m, 2 H) 7.29 (s, 1 H) 1.68 - 1.55 (m, 9 H).
Step 2. tert—Butyl 2-f|uoro(4,4,5,5-tetramethyI-1,3,2-dioxaboro|any|)benzoate A 2 L bottomed flask was charged with tert—butyl 4-bromofluorobenzoate (30 g, 114 mmol), bis(pinoco|ato)diboron (41.5 g, 164 mmol), potassium acetate (32.1 g, 327 mmol), PdCI2(dppf)-CH2C|2 (2.67 g, 3.27 mmol) and 1,4-dioxane (500 mL). The reaction mixture was degassed with argon for 15 min, then heated to 95 OC and maintained at this temperature for 16 h. After cooling down, the reaction mixture was evaporated to dryness, dissolved in DCM (300 mL), and filtered over celite washing with DCM (3 x 100 mL). The filtrate was washed with water (200 mL) and brine (2 x 200 mL), dried over magnesium sulfate, filtered and concentrated. The e was ed using flash chromatography on silica gel (0 to 10% EtOAc in heptane over 30 min), giving tert—butyl 2- (4,4,5,5-tetramethyl-1,3,2-dioxaboro|anyl)benzoate (27 g, 90%) as a solid.
LCMS (m/z): 267 (MH+ ), 1.23 min; 1H NMR (500 MHz, DMSO-dg) 8 ppm 7.83 (t, 1 H) 7.57 (d, 1 H) 7.43 (d, 1 H) 1.62 -1.46 (m, 9 H) 1.34 - 1.25 (m, 12 H).
Ste 3. tert—But |4- 3-amino razin |f|uorobenzoate A 2 L bottomed flask was charged with tert—butyl 2-fluoro(4,4,5,5-tetramethyl- 1,3,2-dioxaborolanyl)benzoate (54 g, 151 mmol), 2-aminochloropyrazine (19.54 g, 151 mmol), 2 N sodium carbonate (158 mL, 317 mmol) and DME (600 mL). The on mixture was degassed for 10 min using argon, and then PdCl2(dppf)-CH2Cl2 (6.16 g, 7.54 mmol) was added. The reaction mixture was heated to 100 oC and maintained at this temperature for 4 h. After cooling down, the reaction mixture was poured into water (400 mL) and extracted with EtOAc (3 x 200 mL). The combined organics were washed with brine (3 x 200 mL), dried over magnesium sulfate, filtered and concentrated. The crude al was purified using flash tography on silica gel (0 to 70% EtOAc in heptane over 50 min), giving tert—butyl 4-(3-aminopyraziny|)f|uorobenzoate (37.7 g, 86%) as a solid. LCMS (m/z): 290 (MH+), 0.80 min; 1H NMR (400 MHz, DMSO-dg) 8 ppm 7.98 (d, 1 H) 7.91 -7.81 (m, 2 H) 7.65 -7.46 (m, 2 H) 6.35 (br. s., 2 H) 1.54 (s, 9 H).
Ste 4. terf-but |4- 3-aminobromo razin |f|uorobenzoate To a d solution of tert—butyl 4-(3-aminopyraziny|)f|uorobenzoate (37.7 g, 130 mmol) in acetonitrile (800 mL) at 0 0C was added N-bromosuccinimide (23.19 g, 130 mmol) in one portion. The reaction was stirred at 0 °C for 2 h, then quenched with saturated NaHC03 solution (200 mL) and stirred at 0 °C for 30 min. The mixture was diluted with water (300 mL) and extracted with EtOAc (3 x 250 mL). The combined organics were washed with water (200 mL) and brine (2 x 200 mL), dried over magnesium sulfate, filtered and concentrated. The crude material was purified using flash chromatography on silica gel (0 to 40% EtOAc in heptane over 40 min), giving tert- butyl 4-(3-aminobromopyrazinyl)f|uorobenzoate (30.9 g, 64%) as a solid. LCMS (m/z): 368/370 (MH+), 1.03 min; 1H NMR (400 MHz, DMSO-dg) 8 ppm 8.14 (s, 1 H) 7.97 -7.74 (m, 1 H) 7.62 - 7.39 (m, 2 H) 6.64 (s, 2 H) 1.54 (s, 9 H).
Ste 5. Tert-but |4- 3-amino 1 4-dioxas iro 4.5 decen | razin | fluorobenzoate To utyl minobromopyrazinyl)fluorobenzoate (5.17 g, 46.2 mmol) in DME (115 mL) were added 4,4,5,5-tetramethyl(1,4-dioxaspiro[4.5]decenyl)-1,3,2- dioxaborolane (15.36 g, 57.7 mmol), PdC|2(dppf).CH2C|2 adduct (1.885 g, 2.309 mmol), and then 2 M aqueous solution sodium carbonate (19.57 g, 185 mmol). The reaction mixture was heated at 100 °C overnight. LCMS indicated the reaction was ted.
The reaction was coolded down. To the mixture was added 1000 mL of EtOAc and 300 mL of water. The resulting mixture was d for 30 min, and the organic layer was separated. The aqueous layer was ted with EtOAc (3 X 200 mL). The organic layers were combined, washed with water three times and brine, dried over sodium sulfate, filtered off, and concentrated in vacuo. The crude product was triturated by ether to provide tert-butyl 4-(3-amino(1,4-dioxaspiro[4.5]decenyl)pyrazinyl) fluorobenzoate (19.5 g, 45.6 mmol, 99%) as a light yellow solid. LCMS (m/z): 428.1 (MH+), 1.02 min.
Ste 6. Tert-but |4- 3-amino 1 4-dioxas iro 4.5 8- | razin l fluorobenzoate To a solution of tert-butyl 4-(3-amino(1,4-dioxaspiro[4.5]decen yl)pyrazinyl)f|uorobenzoate (11 g, 25.7 mmol) in DCM (100 mL) and MeOH (100 mL) at room temperature was added Pd/C (5 g, 25.7 mmol) (10% in carbon, wet). The resulting mixture was vacuumed, and then refilled with hydrogen. The process was repeated three times. Then the on was stirred at room temperature under H2 atmosphere for 6 h. Catalyst was filtered out through Celite®, and washed with DCM. The filtrate was concentrated, and the residue was ved in DCM (60 mL), filtered and concentrated. The crude product was purified by flash chromatography eluting with 0- 100% of EtOAc/heptane to provide tert-butyl 4-(3-amino(1,4-dioxaspiro[4.5]decan yl)pyrazinyl)—2-fluorobenzoate (8.18 g, 19.04 mmol, 74%) as a light yellow solid. LCMS (m/z): 430.2 (MH+), 0.99 min; 1H NMR (400 MHz, DMSO-d6) 6 ppm 7.98 - 7.82 (m, 2 H), 7.71 - 7.49 (m, 2 H), 8.13 (s, 2 H), 3.85 (s, 4 H), 3.30 (s, 1 H), 2.77 - 2.55 (m, 1 H), 2.48 (dt, J = 362,191 Hz, 2 H), 1.88 - 1.85 (m, 6 H), 1.83 - 1.48 (m, 10 H).
Ste 7. Tert-but l4- 3-amino 4-oxoc clohex l razin lfluorobenzoate To tert-butyl 4-(3-amino(1,4-dioxaspiro[4.5]decanyl)pyrazinyl)fluorobenzoate (14.34 g, 33.4 mmol) were added acetonitrile (250 mL), water (160 mL) and then 3 M aqueous solutionueous HCI (55.6 mL, 167 mmol). The reaction mixture was stirred at 25 °C for 30 min which was monitored by LCMS. The mixture was basified with 2 M NaOH aqueous solution under stirring to pH 9. Light yellow solid was precipitated out.
Acetonitrile was removed under reduced pressure at room temperature. The solid was filtered and washed with water (2 X 30 mL), and dried under high vacuum overnight to afford tert-butyl 4-(3-amino(4-oxocyclohexyl)pyrazinyl)fluorobenzoate (12 g, 31.1 mmol, 93%) as a light yellow solid. LCMS (m/z): 386.1 (MH+), 0.89 min; 1H NMR (400 MHz, ACETONITRILE-d3) 6 ppm 8.05 - 7.89 (m, 2 H) 7.73 - 7.51 (m, 2 H), 5.14 (br. s., 2 H), 3.30 - 3.08 (m, 1 H), 2.64 - 2.48 (m, 2 H), 2.40 (br. s., 2 H), 2.30 - 2.17 (m, 2 H), 2.12 - 1.99 (m, 2 H), 1.96 (dt, J = 4.99, 2.40 Hz, 4 H), 1.61 (s, 9 H).
Ste 8. Tert-but l4- o 4-h drox c clohex l razin lfluorobenzoate A solution of tert-butyl 4-(3-amino(4-oxocyclohexyl)pyrazinyl)fluorobenzoate (9 g, 23.35 mmol) in methanol (125 mL) and THF (125 mL) was cooled down to -78 °C, and then NaBH4 (2.297 g, 60.7 mmol) was added n wise. The reaction mixture was then stirred at -78 0C for 40 min, and LCMS indicated the reaction was completed. Some over- reduction product was observed. The ratio of trans to cis was about 8:1. 100 mL of sat.
NH4C| was added slowly at -78 °C, and then the mixture was warmed up gradually to room temperature. The reaction mixture was quenched by sat. , and extracted by EtOAc (2 X 200 mL). The c layers were combined, dried over Na2804, filtered off, concentrated and dried under high vacumm to provide tert-butyl 4-(3-amino(4- ycyclohexyl)pyrazinyl)—2-fluorobenzoate (8.9 g, 22.97 mmol, 98%), which was used in next step t further purification. LCMS (m/z): 388.2 (MH+), 0.86 min.
Ste 9 &10. 4- o 1r4r h drox c clohex l razin lfluorobenzoic acid Tert-butyl 4-(3-amino(4-hydroxycyclohexyl)pyrazinyl)fluorobenzoate (8.8 g, 22.71 mmol) was dissolved in THF (100 mL), and then TBDMSCI (8.22 g, 54.5 mmol) and imidazole (5.57 g, 82 mmol) were added. The reaction e was stirred at room temperature for 3 h. The reaction mixture was diluted by EtOAc (150 mL), washed by water and brine, dried over Na2804, filtered off, and concentrated. The crude al was purified by flash chromatography eluting with 0-100% of acetone/DOM (10% acetone/DOM in DCM, 10 to 50 %, 40 min duration, 320 g silica gel column) to afford tert- butyl 4-(3—amino((1s,4s)((tert-butyldimethylsilyl)oxy)cyclohexyl)pyrazinyl) fluorobenzoate (7.7 g, 15.35 mmol, 67.6%). LCMS (m/z): 502.3 (MH+), 0.96 min. To a solution of tert-butyl 4-(3-amino((1s,4s)((tert- imethylsi|y|)oxy)cyclohexyl)pyraziny|)fluorobenzoate (7.789 g, 15.52 mmol) in 4 N HCI in dioxane was stirred at room temperature for 48 h. The reaction mixture was concentrated. To the light yellow e was added 50 mL of EtZO, sonicated for 15 min, filtered, washed with 15 mL of EtZO twice, and dried under vacumm suction for 2 h to provide 4-(3-amino((1r,4r)hydroxycyclohexyl)pyrazinyl)f|uorobenzoic acid (11, 6.0 g, 15.99 mmol, 100 % yield) as a light yellow solid. LCMS (m/z): 332.0 (MH+, acid), 0.48 min; 1H NMR (400 MHz, DMSO-d6) 6 ppm 8.06 - 7.79 (m, 2 H). 7.69 - 7.50 (m, 2 H), 3.63 -3.30 (m, 3 H) 2.62 - 2.50 (m, 1 H), 1.97 -1.71 (m, 4 H), 1.34 -1.11 (m, 2 H), 1.63 - 1.42 (m, 2 H), Ste 11. 4- 3-amino 1r4S h drox c clohex l razin l-N- S 3-bromo fluoro hen lh drox eth lfluorobenzamide 4-(3-amino((1r,4r)hydroxycyclohexyl)pyraziny|)fluorobenzoic acid (670 mg, 2.022 mmol) in DMF (16.80 mL) was added aza-HOBt (413 mg, 3.03 mmol), EDC (581 mg, 3.03 mmol), DIEA (1.059 mL, 6.07 mmol) and (S)amino(3-bromo phenyl)ethanol hydrochloride (547 mg, 2.022 mmol). The reaction mixture was stirred at room temperature for 3 h. LCMS indicated the product. The reaction mixture was diluted with EtOAc, washed with sat NaHC03, water and brine, dried over Na2804, filtered off, and concentrated. The residue was purified with flash chromatography eluting with 0-100% of EtOAc (containing 10% heptane to provide mino((1r,4S)— 4-hydroxycyclohexyl)pyrazinyl)-N-((S)(3-bromofluorophenyl)hydroxyethyl) fluorobenzamide (920 mg, 1.66 mmol, 82%). LCMS (m/z): 547/549 (MH+), 0.72 min; 1H NMR (500 MHz, DMSO-d6) 6 ppm 8.74 (dd, J = 1.9, 7.9 Hz, 1H), 7.92 (s, 1H), 7.81 - 7.70 (m, 1H), 7.68 - 7.55 (m, 2H), 7.52 - 7.39 (m, 2H), 7.30 (d, J = 9.5 Hz, 1H), 6.11 (s, 2H), .09 (t, J = 5.7 Hz, 2H), 4.58 (d, J = 4.4 Hz, 1H), 3.69 (dt, J = 2.4, 5.8 Hz, 2H), 3.49 - 3.40 (m, 1H), 2.55 (t, J = 3.5 Hz, 1H), 1.98 - 1.76 (m, 4H), 1.55 (dd, J = 2.8, 12.6 Hz, 2H), 1.29 (d, J = 13.6 Hz, 2H). 8 nthesis of S -N- 2-amino 3-chloro hen l eth l -N-meth l nitrobenzenesulfonamide Scheme 65 Stepl {OH _/OH 2N fl). BocHN THF Step 3 Cl Cl TMAD THF, (n—Bu)3P 0 CC to rt, 16 h N020 “:0 methylamine 00‘ Step 4_ "'_\N HCI \ 02 BocHN/\© 50—70% (2 steps) H2NA©OZ Ste 1. S -tert-but l 1- ro hen lh drox eth lcarbamate To a mixture of (s)amino(3-chlorophenyl)ethanol (4 g, 19.22 mmol) in THF (64.1 mL) was added NaHC03 (1.776 g, 21.15 mmol), ed by Boc20 (4.91 mL, 21.15 mmol) and DMAP (0.235 g, 1.922 mmol). The reaction mixture was then stirred at room temperature overnight. LCMS indicated the reaction was not completed. TEA (5.36 mL, 38.4 mmol) was added, and the reaction mixture was stirred at room temperature for 5 h.
Water was added, and the reaction mixture was extracted by EtOAc. The organic layer was washed with brine, dried over sodium e, filtered and concentrated. The crude material was purified by flash chromtography eluting with 0-100% of EtOAc/heptane to afford (S)—tert—buty| (1-(3-chlorophenyl)hydroxyethyl)carbamate (4.0 g, 14.72 mmol, 77%). LCMS (m/z): 216.1 (MH+-56), 0.75 min.
Step 2. yInitrobenzenesulfonamide A solution of 2-nitrobenzenesulfonyl chloride (4 g, 18.05 mmol) in DCM (60.2 mL) was cooled down to 0 °C with an ice water bath. TEA (7.55 mL, 54.1 mmol) and 2 M methylamine in tetrahydofuran (13.54 mL, 27.1 mmol) were added. The resulting solution was stirred at room temperature for 6 h. The reaction mixture was d with DCM, washed with sat. NaHC03 (2 x 100 mL), brine (100 mL) and then dried over magnesium sulphate. The solution was filtered before concentrating under d pressure, and triturated in ether to afford N-methylnitrobenzenesulfonamide (3.12 g, 14.44 mmol, 80 % yield). LCMS (m/z): 217.1 (MH+), 0.53 min.
Ste 3. S -tert-but l 1- 3-chloro hen l N-meth lnitro hen lsulfonamido eth l- carbamate N-methyInitrobenzenesulfonamide (3.50 g, 16.19 mmol) in THF (56.6 mL) was added (S)—tert-butyl (1-(3-chlorophenyl)hydroxyethyl)carbamate (4 g, 14.72 mmol) and tributylphosphine (3.87 g, 19.14 mmol). Then (E)-di-tert-butyl diazene-1,2-dicarboxylate (3.29 g, 19.14 mmol) in THF (56.6 mL) was added slowly at 0 °C. The on mixture was stirred at room temperature overnight. LCMS indicated there was slightly starting material left. The reaction was diluted with EtOAc, washed with sat. NaHC03, water and brine, dried over Na2804, filtered off, and trated.The crude product was purified by flash chromatography g with 0-100% of heptane to afford (S)—tert—buty| (1-(3- chlorophenyl)(N-methylitrophenylsulfonamido)ethyl)carbamate (7 g, 14.9 mmol, 100%). LCMS (m/z): 370.1 (MH+-100), 1.05 min.
Ste 4. S -N- 2-amino 3-chloro hen leth l-N-meth lnitrobenzenesulfonamide (S)—tert-butyl (1-(3-chlorophenyl)(N-methylitrophenylsulfonamido)ethyl)carbamate (7 g, 14.9 mmol) in DCM (149 mL) was added HCI (4 M in dioxane) (14.90 mL, 59.6 mmol).
The reaction mixtue was stirred at room temperature for 4 h. LCMS indicated that the reaction was completed. White precipitate was filtered out and washed well with DCM to provide 2.8 g of (S)—N-(2-amino(3-chlorophenyl)ethyl)-N-methyl nitrobenzenesulfonamide as a HCI salt. The residue was evaporated to dryness, and d in DCM (20 mL) for 30 min. Solid was filtered and washed well with DCM to provide another 400 mg of (S)-N-(2-amino(3-chlorophenyl)ethyl)-N-methyl nitrobenzenesulfonamide which t total yield to 52.9% with 95% purity. LCMS (m/z): 370.1 (MH+-100), 0.67 min; 1H NMR (500 MHz, METHANOL-d4) 6 ppm 8.09 - 7.99 (m 1H), 7.92 - 7.77 (m, 3H), 7.60 (s, 1H), 7.53 - 7.35 (m, 3H), 4.74 - 4.62 (m, 1H), 3.93 (dd, J=9.0, 14.7 Hz, 1H), 3.53 (dd, J: 5.4, 14.8 Hz, 1H), 2.98 (s, 3H).
Example 176 S nthesis of S 3-amino tetrah dro-2H- ran l razin l-N- 1- 3- chloro hen l meth lamino eth lfluorobenzamide Scheme 66 Step1F O J< OOJ< W NH2 0 NIN\ Pd(dppf)CI2DCM 2M Na2C03 | H2, Pd-C + —>\ N —> KKN \ DME, 110 0C, 16 MeOH/DCM, 5 h h \ Br 0 85% 80% F o J< Stegg F NH2 0 NH2 N/ N \ DEN/Q EDC HOAt IN TFA,DCM 02 I _/N\ \ ’ >99% H2N1é>\© o 0 CI 9 St a; H 8:0 /N\ mg ,(I F O — F O / \ E gfigog, NH2 ”(5) NH2 ”(3) N| \ DMF NI \ Hooc—O—SH /N Cl 82% /N Cl 40°C,16 h 85% Ste 1. ut l4- 3-amino 3 6-dih dro-2H- ran | razin lfluorobenzoate To a solution of tert-butyl 4-(3-aminobromopyrazinyl)f|uorobenzoate (21 g, 57.0 mmol) in DME (127 mL) was added PdC|2(dppf).CH2C|2 adduct (2.329 g, 2.85 mmol), 2- (cyclohex—1-eny|)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (13.18 g, 62.7 mmol), and 2 M Na2C03aqueous solution (63.4 mL). The reaction was heated at 110 °C for 16 h. To the on mixture was added 200 mL of ethyl acetate, washed with water (2 x 100 mL), brine, dried over sodium sulfate, filtered and concentrated. The e was purified by flash chromatography eluting with 0-100% of EtOAc/DCM to provide tert-butyl 4-(3-amino- 6-(3,6-dihydro-2H-pyranyl)pyrazinyl)f|uorobenzoate (18 g, 48.5 mmol, 85%).
LCMS (m/z): 372.3 (MH+), 0.95 min.
Ste 2. Tert-but l4- 3-amino tetrah dro-2H- ran | razin lfluorobenzoate To a suspension of tert-butyl 4-(3-amino(3,6-dihydro-2H-pyranyl)pyrazinyl) fluorobenzoate (15 g, 40.4 mmol) in MeOH (800 mL) was added DCM (100 mL) until the suspension turned to a homogeneous solution. After degassed by N2 stream for 15 min, Pd/C (10 g, 9.40 mmol) was added to the reaction e. To this mixture, hydrogen balloon was equipped afterflushed with hydrogen gas three times. The reaction mixture was d for 6 h. After the reaction mixture was ed through Celite® pad, the volatile als were removed in vacuo. The residue was dissolved in MeOH (200 mL) by heating and cooling down to room temperature and standing overnight. The brown precipitate was filtered off, which ed 4.5 g of tert-butyl 4-(3-amino(tetrahydro-2H- pyranyl)pyrazinyl)fluorobenzoate. The flitrate was concentrated and dissolved in EtOH (200 mL) by heating. The second brown precipitate was filtered off to afford 3.9 g of 2014/062913 tert-butyl mino(tetrahydro-2H-pyranyl)pyrazinyl)fluorobenzoate (55.7% combined yield). LCMS (m/z): 374.7 (MH+), 0.90 min.
Ste 3. 4- 3-Amino tetrah dro-2H- ran l razin lfluorobenzoic acid To a solution of tert-butyl 4-(3-amino(tetrahydro-2H-pyranyl)pyraziny|) fluorobenzoate (4.5 g, 12.05 mmol) in DCM (60.3 mL) was added TFA (60.3 mL). The reaction mixture was stirred for 2 h. After diluted with toluene (30 mL), the volatile materials were d in vauco twice to provide 4-(3-amino(tetrahydro-2H-pyran azinyl)fluorobenzoic acid (5.2 g, 12.06 mmol, 100%) as a TFA salt. The crude product was used for the next step without further purification. LCMS (m/z): 318.5 (MH+), 0.55 min.
Ste 4. S 3-amino tetrah dro-2H- ran l razin l-N- 1- 3-chloro hen l (N-methylnitrophenylsulfonamido)ethyl )—2-fluorobenzamide To a solution of 4-(3-amino(tetrahydro-2H-pyranyl)pyraziny|)fluorobenzoic acid (1.55 g, 4.88 mmol) in DMF (16.28 mL) was added HOAt (0.997g, 7.33 mmol), EDC (1.498 g, 7.82 mmol). DIEA (2.61 m l, 14.65 mmol) and (S)—N-(2-amino(3- phenyl)ethyl)-N-methylnitrobenzenesulfonamide (2.084 g, 5.13 mmol). The reaction mixture was stirred at room temperature for 3 h, and LCMS indicated the reaction was completed. The reaction mixture was diluted with EtOAc, and the organic was washed by sat.Na2C03, water and brine, dried over Na2804, filtered off, and concentrated. The crude material was purified by flash chromatography eluting with 50% DCM/EtOAc (10% methanol) to provide (3-amino(tetrahydro-2H-pyran yl)pyrazin-2—yl)—N-(1-(3-chlorophenyl)(N-methylnitrophenylsulfonamido)ethyl) fluorobenzamide (2.68 g, 4.01 mmol, 82%). LCMS: 669.1 (MH+), 0.95 min.
Ste 5. S 3-amino tetrah dro-2H- ran l razin l-N- 1- 3-chloro hen l (methylamino)ethyl )—2-fluorobenzamide To a solution of (S)(3-amino(tetrahydro-2H-pyranyl)pyrazinyl)—N-(1-(3- phenyl)(N-methylnitrophenylsulfonamido)ethyl)fluorobenzamide (2.68 g, 4.01 mmol) in DMF (20 mL) was added 4-mercaptobenzoic acid (1.235 g, 8.01 mmol) and K2C03 (2.214 g, 16.02 mmol). The reaction mixture was heated at 40 °C overnight under nitrogen. Water (50 mL) was added, and the mixture turned into homogenous. The reaction was stirred at room temperature for 30 min, and then water (150 mL) was added slowly. Light yellow solid was precipitated out. The mixture was stirred for another 30 min, and the suspension was filtered out. The solid was washed well with water, followed by heptane, and air dried for 1 h. The solid was ded in water and stirred at room temperature for 1 h, and then filtered. To the solid was added EtOAc, and slowly rotated on rotavap to remove excess ethyl acetate until about 20 mL of EtOAc left, the white solid was filtered, and redissolved in acetoniltrile and water, lyophilized. The solution was dried on lyophilizer to afford (3-amino(tetrahydro-2H-pyranyl)pyrazinyl)-N- (1-(3-chlorophenyl)(methylamino)ethyl)fluorobenzamide (1.31 g, 2.69 mmol, 67.2%).
LCMS (m/z): 484.3 (MH+), 0.66 min; 1H NMR (500 MHz, METHANOL-d4) 6 ppm 7.90 (s, 1H), 7.83 (t, J = 7.7 Hz, 1H), 7.70 (dd, J: 1.1, 8.0 Hz, 1H), 7.63 (d, J: 10.7 Hz, 1H), 7.48 (s, 1H), 7.38 (d, J: 5.4 Hz, 2H), 7.32 (dt, J: 1.9, 4.6 Hz, 1H), 5.33 (dd, J = 5.2, 9.0 Hz, 1H), 4.05 (dd, J: 3.5, 11.0 Hz, 2H), 3.57 (dt, J: 1.9, 11.8 Hz, 2H), 3.12 - 3.04 (m, 1H), 3.04 - 2.88 (m, 2H), 2.48 (s, 3H), 1.89 - 1.88 (m, 1H), 1.96 - 1.76 (m, 4H). 8 nthesis of S -tert-but l2-amino hen leth lcarbamate /NHBoc Following Scheme 9, using (R)—2-aminophenylethanol, rt-butyl 2-amino phenylethylcarbamate was obtained in 47% yield. LCMS (m/z): 237.5 (MH+), 0.54 min. 1H NMR z ,CDCI3) 6 ppm 7.42 - 7.32 (m, 5 H), 4.81 (br. s., 1 H), 4.11 - 4.00 (m, 1 H), 3.44 - 3.28 (m, 1 H), 3.28 - 3.13 (m, 1 H), 1.49 - 1.35 (m, 9 H).
S nthesis of S f|uoro hen lethanamine Scheme 67 Step_1 Step_2 Step 3 ©/\:OH perfluorobutane NH2 CszSu ©/\/OH'2 yl fluoride HZNNHZ ? 0 O N F Et3N 3HF DIEA GNP ©/\/ To a solution of (S)aminophenylethanol (3 g, 21.87 mmol) in water (26.5 mL), and itrile (46.4 mL) was added 2,5-dioxopyrrolidinyl methyl phthalate (5.76 g, 20.78 mmol) at room temperature. The on mixture was d at room ature for overnight. After acetonitrile was removed in vacuo, the reaction e was then extracted with EtOAc. The organic was washed by water and brine, dried over anhydrous sodium sulfate, filtered off, and concentrated in vacuo yielding (S)—2-(2-hydroxy phenylethyl)isoindoline-1,3-dione (2.2 g, 40%). LCMS (m/z): 268 (MW), 0.79 min.
Ste 2. S 2-fluoro hen leth lisoindoline-1 3-dione To a solution of (S)—2-(2-hydroxyphenylethyl)isoindoline-1,3-dione (1.5 g, 5.61 mmol) in PhCF3 (18.71 mL) was added triethylamine trihydrofluoride (5.48 mL, 33.7 mmol), perfluorobutanesulfonyl fluoride (1.019 mL, 5.67 mmol), DIEA (14.70 mL, 84 mmol) at room temperature. The reaction mixture was stirred at room temperature for 1 h, then more perfluorobutanesulfonyl fluoride (1.019 mL, 5.67 mmol) was added. After 5 h, the reaction mixture was quenched with NaHC03 and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous sodium sulfate, filtered off, and concentrated in vacuo. The crude product was purified by flash tography (0-10% EtOAC in heptane) yielding (S)—2-(2-fluoro phenylethyl)isoindoline-1,3-dione (30% yield). LCMS (m/z): 270.1 (MH+), 0.96 min.
Ste 3. S fluoro hen lethanamine To a solution of (S)—2-(2-fluorophenylethyl)isoindoline-1,3-dione (290 mg, 1.077 mmol) in MeOH (3.59 mL) was added hydrazine (0.507 mL, 16.15 mmol). The reaction mixture was stirred at 80 °C for 3 h. The white precipitate was filtered off. The filtrate was concentrated to yield the crude (S)—2-fluorophenylethanamine, which was used in next step t further purification. LCMS (m/z): 140.1 (MH+), 0.28 min; 1H NMR (400MHz, CDCI3) 8 ppm 7.43 - 7.34 (m, 4 H), 7.34 - 7.27 (m, 1 H), 4.57 (dd, J = 3.7, 8.8 Hz, 1 H), 4.49 - 4.38 (m, 1 H), 4.38 - 4.32 (m, 1H), 4.32 - 4.25 (m, 1 H).
S nthesis of S azido 3-bromofluoro hen l ethanamine Scheme 68 in 1 m2 (OH (OH (OMS F B0020 : MsCl : F F H2N —> BocHN —’ BocHN Br Br Br Step; Step 4 _/N3 {N3 NaN3 E HCI F F F —> BocHN —> H2N Br Br Ste 1. S but l 1- 3-bromofluoro hen lh drox eth mate To a solution of (S)amino(3-bromofluorophenyl)ethanol (4.4 g, 16.26 mmol) in DCM (80 mL) was added TEA (6.80 mL, 48.8 mmol) followed by Boc anhydride (5.32 g, 24.4 mmol) at room temperature. The reaction mixture was stirred at room temperature for 16 h. The reaction mixture was extracted with EtOAc. The organic layer was washed with sat NaHC03, water and brine, dried over anhydrous Na2804, filtered off, and concentrated. The crude t was purified by flash chromatography ent EtOAc in heptane) to provide (S)—tert-butyl (1-(3-bromofluorophenyl)hydroxyethyl)carbamate (4.8 g, 88%). LCMS (m/z): 280 (MH+-tBu), 0.79 min.
Ste 2. S tert-butox carbon lamino 3- bromofluoro hen leth l methanesulfonate To a stirred solution of (S)—tert—butyl (1-(3-bromofluorophenyl) hydroxyethyl)carbamate (4.8 g, 14.36 mmol) in anhydrous DCM (100 mL) at 0 °C was added triethylamine (4.00 mL, 28.7 mmol) followed by esulfonyl chloride (1.343 mL, 17.24 mmol). The reaction was stirred at 0 °C for 1 hr, by which time the LCMS indicated the reaction had gone to completion. The reaction mixture was poured into saturated NaHC03 solution (100 mL). The e was shaken, the layers separated and the aqueous layer was extracted with DCM (2 x 50 mL). The ed organics were washed with NaHC03 solution (50 mL) and brine (50 mL), dried ), filtered and trated, giving (S)((tert-butoxycarbonyl)amino)(3- bromofluorophenyl)ethyl methanesulfonate (5.92 g, 14.36 mmol, 100 % yield) as a very pale orange solid. 1H NMR (500 MHz, DMSO-d6) 8 ppm 7.75 (d, J=8.83 Hz, 1 H), 7.43 - 7.55 (m, 2 H), 7.31 (d, J=9.46 Hz, 1 H), 4.86 - 5.00 (m, 1 H), 4.30 (dd, 9, 5.04 Hz, 1 H), 4.24 (t, J=9.30 Hz, 1 H), 3.16 - 3.23 (m, 3 H), 1.36 - 1.44 (m, 9 H).
Step 3. (S)—tert—butyl (2-azido(3- bromofluorophenyl)ethyl)carbamate (S)((tert-butoxycarbonyl)amino)(3- bromofluorophenyl)ethyl methanesulfonate (5.92 g, 14.36 mmol) was dissolved in anhydrous DMF (60 mL). Sodium azide (2.80 g, 43.1 mmol) was added, and the reaction heated to 70 °C and maintained at this temperature for 2 h. After cooling, the reaction mixture was poured into water (100 mL) and extracted with EtOAc (3 x 80 mL). The combined organics were washed with water (50 mL) and brine (3 x 50 mL), dried (MgSO4), filtered and concentrated. Flash tography (AnaLogix, 80 g column, loaded in DCM, 0 to 40% EtOAc in heptane over 30 min) gave (S)-tert-butyl (2-azido(3- bromofluorophenyl)ethyl)carbamate (4.29 g, 11.94 mmol, 83 % yield) as a white solid. 1H NMR (500 MHz, DMSO-d6) 6 ppm 7.73 (d, J=8.83 Hz, 1 H), 7.48 (t, J=4.26 Hz, 2 H), 7.29 (d, J=9.77 Hz, 1 H), 4.80 (d, J=8.20 Hz, 1 H), 3.47 (d, J=7.88 Hz, 2 H), 1.44 - 1.38 (m, 9 H), 1.36 (br. s., 1 H).
Ste 4. S azido—1- 3- bromofluoro hen l ethanamine To a stirred solution of (S)-tert-butyl do(3- bromofluorophenyl)ethyl)carbamate (3.15 g, 8.77 mmol) in dioxane (40 mL) was added hydrochloric acid (10.96 mL, 43.8 mmol) (4N solution in dioxane). The reaction was heated to 40 °C and maintained at this temperature for 2 h. After cooling the reaction mixture was evaporated to dryness, giving (S)azido(3- bromofluorophenyl)ethanamine hydrochloride (2.59 g, 8.76 mmol, 100 % yield) as a white solid.
S nthesis of S azido rofluoro hen l ethanamine Following Scheme 68, using (S)amino(3-chlorofluorophenyl)ethanol, (S)azido- 1-(3-ch|orofluorophenyl)ethanamine was obtained. LCMS (m/z): 215.1 (MH+), 0.48 min.
S nthesis of S azido 3-chloro hen l ethanamine Following Scheme 68, using (S)amino(3-chlorophenyl)ethanol, azido(3- ch|orof|uorophenyl)ethanamine was obtained. LCMS (m/z): 197 (MH+), 0.5 min.
Synthesis of (S)—3-ghenylmorgholine Scheme 69 Step; 1 SteQ 2 Steg g CI\)J\CI o NaH LiAIH4 (3) CI\)J\N (3) —> —> —> (S) H2N OH HN HN DMAP, Et3N OH H 0&0 K/o Ste 1. S ch|oro-N- 2-h drox hen leth mide To a solution of (S)aminophenylethanol (0.852 g, 6.21 mmol), Et3N (0.952 mL, 6.83 mmol), DMAP (76 mg, 0.621 mmol) in CH2C|2 (10 mL) at 0 °C was added 2-ch|oroacety| chloride (0519 mL, 6.52 mmol), and the resulting mixture was stirred at 0 °C for 15 min.
The reaction mixture was washed with aqueous HCI (1 M, 20 mL), then sat. NaHC03 (20 mL), dried (Na2804), concentrated, further dried under high vacuum and (S)—2-chloro-N- (2-hydroxyphenylethyl)acetamide (0.60 g, 45.2% yield) was ed as white solid.
LCMS (m/z): 214 (MH+), 0.44 min.
Step 2. (S)—5-phenylmorpholinone To a on of (S)—2-chloro-N-(2-hydroxyphenylethyl)acetamide (600 mg, 2.8 mmol) in anhydrous THF solution at 0 °C was added NaH mineral oil suspension (247 mg, 6.18 mmol). The resulting mixture was stirred overnight at room temperature. The reaction mixture was concentrated to dryness, and the residue was partitioned between CH2C|2/brine/H20 (20mL/18mL/2mL). CH2C|2 layer was dried over anhydrous Na2804, filtered off, concentrated in vacuo. The crude product, (S)phenylmorpholinone, was obtained as a white solid (498 mg, 97%). The crude product was used directly in next step without r purification. LCMS (m/z): 178.2 (MH+), 0.47 min.
Step 3. (S)—3-phenylmorpholine To a LiAlH4/THF slurry (0.47g/2 mL) was added dropwise (S)—5-phenylmorpholinone in THF solution (481 mg in 6mL) at room temperature over 5min. The resulting mixture was stirred aat room temperature thereafter for 1 hour, then was heated with 72 °C oil bath ght, then was cooled down to 0 °C, quenched by sequential addition of H20 (0.47 mL), 3M s solutionueous NaOH (0.47 mL) and H20 (1.4 mL), and the quenched residue was diluted with EtZO (30 mL), stirred for 10 min and the etheral on was ted by filtration. The filtrate was concentrated, further dried under vacuum and (S)- 3-phenylmorpholine (424 mg, 96% yield) was obtained as colorless solid. LCMS (m/z): 164.2 (MH+), 0.33 min.
S nthesis of S -tert-but l 2-amino 3-chloro hen leth l meth lcarbamate Scheme 70 OH SteQZ ©/'\/ _ NHBoc Boczo (R) Q/K/N\Boc Step; NH2 BOO [21800 Hydrazine4E?/\/N\ DtBAD ©NN\ Ste 1. R ro hen l meth lamino ethanol (R)—tert-butyl (2-(3-chlorophenyl)hydroxyethyl)carbamate (2.489, 9.13 mmol), prepared in Scheme 9, was dissolved THF (30.4 mL), and LiAlH4 (1.039 g, 27.4 mmol) was added.
The on mixture was heated at reflux for 6 h and then cooled down. Water (1.06 mL) was added, followed by aqueous NaOH (15%, 3 mL), and water (1.06 mL). The reaction mixture was stirred at room temperature for 1 h. Solid precipitate was filtered through Celite® and rinsed well with EtOAc. The filtrate was concentrated. The crude product (R)- 1-(3-chlorophenyl)(methylamino)ethanol (1.75 g, 9.43 mmol, 100%) was used in next step reaction without further cation. LCMS (m/z): 186.1 (MH+), 0.43 min.
Step 2. (R)—tert—butyl (2—(3-chlorophenyl)—2-hydroxyethyl)(methyl)carbamate (R)—1-(3-chlorophenyl)—2-(methylamino)ethanol (1.75 g, 9.43 mmol) was dissolved in THF (31.4 mL), and then Boc ide (2.298 mL, 9.90 mmol) was added. The reaction mixture was stirred at room temperature for 2 h. LCMS indicated that the reaction was completed. The reaction mixture was concentrated, and purified by flash chromatography to afford (R)—tert—butyl (2-(3-chlorophenyl)hydroxyethyl)(methyl)carbamate (2.0 g, 7.00 mmol, . LCMS (m/z): 212.1 (MH+-56), 0.94 min.
Ste 3. S -tert-but | 2- 3-chloro hen l 1 3-dioxoisoindolin yl)ethyl )(methyl)carbamate To a mixture of (R)—tert-butyl (2-(3-chlorophenyl)hydroxyethyl)(methyl)carbamate (2.0 g, 7.00 mmol) in THF (23.33 mL) was added phthalimide (1.339 g, 9.10 mmol) and PPh3 (3 mmol of PPh3/1 g of resin, 2.34 g, 7.02 mmol). Then DTBAD (1.660 g, 7.21 mmol) in THF was slowly added at room temperature, and the reaction mixture was stirred at room temperature overnight. The reaction mixture was filtered through Celite® and washed with EtOAc. The filtrate was concentrated, redissolved in EtOAc, washed with sat. Na2C03, water and brine, dried over sodium sulfate, filtered off, and trated. The crude product was purified by flash chromatography to afford (S)—tert-butyl chlorophenyl)- 2-(1,3-dioxoisoindolinyl)ethyl)(methyl)carbamate (1.96 g, 4.72 mmol, 67.5%). LCMS (m/z): 315.1 (MH+-100), 1.19 min.
Step 4. (S)—tert—butyl (2-amino(3-chlorophenyl)ethyl)(methyl)carbamate To a solution of (S)—tert-butyl (2-(3-chlorophenyl)(1,3-dioxoisoindolin yl)ethyl)(methyl)carbamate (1.96 g, 4.72 mmol) in ethanol (15.75 mL) was added hydrazine hydrate (2.296 mL, 47.2 mmol). The reaction mixture was heated at 60 °C for 2 h. The reaction mixture was then filtered through Celite pad and the filtrate was concentrated. The residue was re-dissolved in ethanol and ed h Celite® pad to remove extra white solid. NMR showed there was impurity in crude material. The crude product was filtered through a plug of silica, washed by DCM/EtOAc (2:1 ratio) and flashed with DCM/EtOAc (20% ol, 0.5 % NH3 in methanol) (1 :1 ratio) to provide (s)-tert-buty| no(3-chlorophenyl)ethyl)(methyl)carbamate (1.2 g, 89% yield).
LCMS (m/z): 285.1 (MH+), 0.65 min; 1H NMR (400 MHz, CDCI3) 6 ppm 7.37 (s, 1H) 7.26 ( 3H), 4.20 (br. s., 1H), 2.85- 2.77 (m, 3H), 1.51 - 1.38 (m, 9H).
S nthesis of S aminoc clo ro lbut—3- nol Scheme 71 meth | ro anesulfinamide 3.0 M ethyl magnesium bromide in EtZO (0.360 mL, 1.081 mmol) was added to a solution of ethynylcyclopropane (71.5 mg, 1.081 mmol) in THF (4 mL). The solution was heated to 50 °C for 1 h, then the resulting Grignard was added to a -78 °C solution of (S,E)—N-(2- ((tert-butyldimethylsi|y|)oxy)ethy|idene)methy|propanesulfinamide (100 mg, 0.360 mmol) in DCM (4.00 mL), and the reaction was allowed to warm to room temperature.
After 3h, the reaction was quenched with sat. aq. NH4CI.The layers were separated and the organics were dried over magnesium sulfate and trated to provide (S)—N-((S)— 1-((tert-butyldimethylsilyl)oxy)cyclopropylbutynyl)methy|propanesulfinamide, which was used directly. LCMS (m/z): 344.1 (MH+), 1.23 min.
Ste 2. S aminoc clo ro lbut nol 4.0 N HCI in e (0.873 mL, 3.49 mmol) was added to a room temperature solution of (S)—N-((S)—1-((tert-butyldimethylsi|y|)oxy)cyclopropylbutynyl)methylpropane sulfinamide (120 mg, 0.349 mmol) in MeOH (4 mL). After 30 min, the on was concentrated, then azeotroped with benzene to e (S)aminocyclopropylbut ynol as the HCI salt. LCMS (m/z): 126.2 (MH+), 0.50 min.
S nthesis of S amino 3-fluoro meth lthio hen l ethanol Scheme 72 Steg_1 Steg_2 NaSMe, DIEA HCI Xanphos, Pd2(dba)3 Ste 1: S -tert-but l4- 3-fluoro meth lthio hen l-2 2-dimeth loxazolidine carboxylate A mixture of Xantphos (13.91 mg, 0.024 mmol), Pd2(dba)3 (22.02 mg, 0.024 mmol), (S)- tert-butyl 4-(3-bromofluoropheny|)-2,2-dimethyloxazolidinecarboxylate (300 mg, 0.802 mmol), DIEA (700 pl, 4.01 mmol)and sodium methanethiolate (112 mg, 1.603 mmol) in toluene (2.6 mL) was microwave heated at 110 °C for 18 min. EtOAc was added, and washed with sat NaHC03, water, and brine. The mixture was ed off, concentrated and purified with flash chromatography eluting with 0-60% of EtOAc/heptane to e (S)—tert-butyl 4-(3-fluoro(methylthio)phenyl)-2,2-dimethyloxazolidinecarboxylate (278 mg, 102%) as an oil. LCMS (m/z): 286.1 (MH+-56), 1.14 min.
Ste 2: S amino ro meth lthio hen lethanol A solution of (S)—tert—butyl 4-(3-fluoro(methylthio)phenyl)-2,2-dimethyloxazolidine carboxylate (278 mg, 0.814 mmol) in 4 M HCI in dioxane (2.4 mL) was heated to 80 °C overnight. There was still some starting material left. More 4 M HCI in dioxane (2.035 mL, 8.14 mmol) was added, and heated at 80 °C for r 10 h. Solvent was removed under reduced vacuum to e (S)amino(3-fluoro(methylthio)pheny|)ethano| (194 mg, 0.814 mmol, 100%). LCMS (m/z): 170.1 (MH+-56), 0.26 min.
S nthesis of S no 3- meth lthio hen l ethanol Following Scheme 72, using (S)—tert-butyl 4-(3-bromophenyl)-2,2-dimethyloxazolidine carboxylate, (S)—2-amino(3-(methylthio)phenyl)ethanol was obtained. LCMS (m/z): 184 NH), 0.41 min. 8 nthesis of S amino 3- chlorometh l fluoro hen l ethanol Scheme 73 o\_ Step 1 ><O\: Step 2 _/OH ><N CI ' F A F : N HCI F I N \ N I —> H2N B + 00 BOC )L A DMSO CI N OH CI Ste 1. S but l4- 3- chlorometh lfluoro hen l-2 2-dimeth loxazolidine carboxylate To a on of (S)—tert-butyl 4-(3-fluoro(hydroxymethyl)pheny|)-2,2- dimethyloxazolidinecarboxylate (330 mg, 1.014 mmol) in anhydrous DMSO (2. 028 mL) was added 2,4,6-trichloro-1,3,5-triazine (112 mg, 0.609 mmol) portionwise. The mixture was stirred at room temperature for 30 min. The mixture was diluted with EtOAc, and separated. The organic phase was washed with H20 (5 x 30 mL), dried over anhydrous Na2804, filtered off and concentrated under reduced pressure. The residue was purified with flash chromatography g with 0-100% heptane to provide (S)—tert-buty| 4- (3-(chloromethyl)—5-fluorophenyl)-2,2-dimethyloxazolidinecarboxylate (329 mg, 94%).
LCMS (m/z): 288.1 (MW-56), 1.12 min.
Ste 2: S amino 3- chlorometh uoro hen l ethanol To a solution of (S)-tert-butyl 4-(3-(chloromethyl)fluorophenyl)-2,2-dimethyloxazolidine- 3-carboxylate (140 mg, 0.407 mmol) in anhyd DCM (1.357 mL) was added 4 N HCI in Dioxane (1.018 mL, 4.07 mmol) portionwise. The mixture was refluxed at 80 °C overnight.
The reaction was not completed. More 4N HCI in dioxane (1. 018 mL, 4.07 mmol) was added, and refluxed for another 24 h. Solvent was d under reduced vaccum to provide (S)amino(3-(chloromethyl)fluorophenyl)ethanol (70 mg, 84%). LCMS (m/z): 204 (MH+), 0.41 min.
S nthesis of S no 3-fluoro fluorometh l hen l ethanol Scheme 74 9a) IN Step 6 Br Br nBuLI, DMF. DAST F BH3.THF - DCM THF -78°C THF 0 C0 33% F Crude Crude.
Step_4 O\S\k HY CuSO4,660°C O/\—>MgBr 0.15 eq. ZnMe2 2 step 60% -78 °C Ste96&z Stegsge NHBOC NHHCI 0,3/NaBH4 - )HCI/dioxane -78 C0 (s) 2) Boczo )HCI/Dioxane Ste 1. 3-bromofluoro hen Imethanol To a suspension of 3-bromofluorobenzoic acid (4.51 g, 20.59 mmol) in THF (41.2 mL) at 0 oC, BH3.THF (41.2 mL, 41.2 mmol) was added se over 30 min, the reaction mixture was then allowed to return to room temperature and stirred at room temperature ovenight. Methanol (40mL) was added slowly and stirred at room temperature for 1 h.
THF and Methanol was removed in vacuo. The residue was then extracted by EtOAc, and washed with sat.NaHC03, The c was dried and concentrated. The crude product was used in next step on without purification. LCMS (m/z): 187.2 (MH+'18), 0.66 min. 1H NMR (400MHz, CDCI3) 8 ppm 7.32 (s, 1H), 7.19 - 7.14 (m, 1H), 7.05 (tdd, J=0.7, 1.5, 9.1 Hz, 1H), 4.70 (br. s., 2H), 1.78 (br. s., 1H).
Ste 2. 1-bromofluoro meth | benzene To a solution of (3-bromo—5-fluorophenyl)methanol (4 g, 19.51 mmol) in DCM (39.0 mL) at 0 OC, DAST (3.35 mL, 25.4 mmol) was added. The reaction mixture was allowed to return to room temperature and stirred at room temperation overnight. Sat. NaHC03 was added, the on mixture was then extracted by DCM. The organic was dried and concentrated.
The crude material was purified by flash tography (0-10% EtOAc/heptanes) to yield the final product as colorless oil. LCMS (m/z): no mass (MH+), 0.86 min. 1H NMR (400MHz, CDCI3) 8 ppm 7.30 (s, 1H), 7.23 (d, J=8.2 Hz, 1H), 7.03 (d, J=8.6 Hz, 1H), 5.41 (s, 1H), 5.29 (s, 1H).
Step 3. 3-fluoro(fluoromethyl)benzaldehyde 1-bromofluoro(fluoromethyl)benzene (1.30 g, 6.28 mmol) was dissolved in THF (31.4 mL), then cooling down to -78 oC, butyllithium (2.5M in Hexanes) (2.76mL, 6.91 mmol) was added at -78 0C, the reaction mixture was then stirred at -78 °C for 30 min.
DMF (0.972 mL, 12.56 mmol) was added, after strirred at -78 °C for 1h, The reaction mixture was quenched by HCI and the reaction mixture was then ted by EtOAc, the organic was dried and concentrated to yield the crude product. The crude material was used in next step reaction without purification. LCMS (m/z): no mass (MH+), 0.60 min.1H NMR (400MHz, CDCI3) 6 ppm 10.08 - 9.93 (m, 1H), 7.68 (s, 1H), 7.56 (d, J=8.2 Hz, 1H), 7.37 (d, J=7.8 Hz, 1H), 5.53 (s, 1H), 5.42 (s, 1H) Ste 4. R E -N- 3-fluoro fluorometh lbenz lidene h | ro anesulfinamide To a solution of 3-fluoro(fluoromethyl)benzaldehyde (890 mg, 5.70 mmol) and (R)—2- methylpropanesulfinamide (760 mg, 6.27 mmol) in DCE (19.0 mL) was added copper(|l) sulfate (anhydrous) (1.820 g, 11.40 mmol), the suspension was stirred under nitrogen at 60 0C in an oil bath for overnight. The suspention turned to light blue color. Cooling down, the reaction mixture was filtered though a plug of Celite and rinsed with DCM, the filtrate was concentrated to yield the crude product. The crude product was purified by flash tograph (0-30% EtOAc in heptane) to yield the (R,E)—N-(3-fluoro (fluoromethyl)benzylidene)methylpropanesulfinamide (900 mg, 60.9 % yield) as light yellow color oil. LCMS (m/z): 260.1 (MH+), 0.88 min. 1H NMR (400MHz, CDCI3) 8 ppm 8.57 (s, 1H), 7.60 (s, 1H), 7.56 (d, J=8.8 Hz, 1H), 7.26 - 7.22 (m, 1H), 5.50 (s, 1H), 5.38 (s, 1H), 1.29 - 1.23 (m, 9H) Ste 5. R-N- R 3-fluoro fluorometh l hen lall lmeth l ro sulfinamide Dimethyl Zinc (2M in Tolune) (0.434 mL, 0.868 mmol) and vinylmagnesium bromide (1M in THF) (4.51 mL, 4.51 mmol) was mixed at room temperature for 20 min under argon before cooling down to -78 0C, then (R,E)-N-(3-fluoro(fluoromethyl)benzylidene)—2- methylpropanesulfinamide (0.900 g, 3.47 mmol) in dry THF (11.57 mL) as added dropwise, maintain the internal temperature between -74 0C to -72 0C, after addition the on mixture was d at -78 0C for 1h, the reaction was quenched by sat.NH4Cl, THF was removed in vacuo, then extracted by EtOAc. The organic was washed by water and brine, dried over anhydrous , filtered and concentrated. The crude product was purified by flash chromatography (0-30% EtOAc/heptaneatane) to yield product 660 mg, LCMS (m/z): 288.0 (MH+), 0.83 min. 1H NMR (400MHz, CDCI3) 8 ppm 7.14 (s, 1H), 7.03 (d, J=9.0 Hz, 1H), 7.07 (d, J=9.4 Hz, 1H), 5.90 (ddd, J=7.4, 10.1, 17.3 Hz, 1H), 5.45 - 5.35 (m, 2H), 5.35 - 5.25 (m, 2H), 5.01 - 4.94 (m, 1H), 3.45 (br. s., 1H), 1.30 - 1.22 (m, Ste 6. R 3-fluoro fluorometh l hen l ro enamine (R)—N-((R)—1-(3-fluoro(fluoromethyl)phenyl)al|y|)methylpropanesulfinamide (660 mg, 2.297 mmol) in MeOH (7.66 mL), was added HCI (4 M in dioxane) (5.742 mL, 22.97 mmol) at 0 0C, the reaction mixture was stirred at room temperature for 2 h, The reaction mixture was concentrated to dryness. Sat. Na2C03 was added, the reaction mixture was then extracted by EtOAc. The organic was was dried and concentrated to yield the crude product. The crude t was used in next step reaction without purification. LCMS (m/z): 184.1 (MH+), 0.40 min.
Ste 7. R -tert-but | 1- 3-fluoro fluorometh | hen lall |carbamate To a solution of (3-fluoro(fluoromethyl)phenyl)propenamine (421 mg, 2.30 mmol) in DCM (7.6 mL) was added Boc2O (640 pl, 2.76 mmol), the reaction mixture was stirred at room temperature overnight, concentrated. The crude product was purified by flash chromatography (0-20% EtOAc/heptane) to yield (R)—tert-butyl (1-(3-fluoro omethyl)phenyl)allyl)carbamate. LCMS (m/z): 228.1 (MH+-56)), 0.91 min. 1H NMR (400MHz, CDCI3) 6 ppm 7.08 (s, 1H), 6.99 (d, J=9.0 Hz, 2H), 5.95 (ddd, J=5.5, 10.6, 16.8 Hz, 1H), 5.42 (s, 1H), 5.30 (s, 1H), 5.30 - 5.13 (m, 3H), 4.86 (br. s., 1H), 1.44 (s, 9H).
Ste 8. S -tert-but | 1- ro fluorometh | hen lh drox eth |carbamate (R)—tert-butyl fluoro(fluoromethyl)phenyl)allyl)carbamate (410 mg, 1.447 mmol) in DCM (14.5 mL) was cooled down to -78 °C, The reaction mixture was bubbled by 03 (from ozone generator) for 5 min.The reaction e is light blue color, N2 was bubbled through to get rid of 03, then NaBH4 (547 mg, 14.47 mmol) in ethanol (10 mL) was added, the reaction e was stirred at -78 0C for 10 min, then d to return to room temperature. After 30 min, sat. NH4C| was added followed methanol, the reaction e was concentrated, then extracted by EtOAc. The organic was washed by sat. NaHC03, water and brine, dried and concentrated to yield crude product.The crude product was purified byflash chromato graphy to give the (S)—tert-butyl (1-(3-fluoro (fluoromethyl)phenyl)hydroxyethyl)carbamate (223 mg, 54% yield). LCMS (m/z): 232.2 (MH+-56), 0.73 min.1H NMR (400MHz, CDCI3) 6 ppm 7.10 (s, 1H), 7.02 (d, J=9.4 Hz, 2H), .43 (s, 1H), 5.35 - 5.28 (m, 1H), 4.78 (br. s., 1H), 3.95 - 3.78 (m, 2H), 1.44 (br. s., 9H).
Ste 9. S amino 3-fluoro fluorometh | hen lethanol To a solution of (S)—tert-butyl (1-(3-f|uoro(fluoromethyl)phenyl) hydroxyethyl)carbamate (220 mg, 0.766 mmol) in DCM (2.5 mL), HCI (4M in dioxane) (1.9 mL 7.66 mmol) was added at room temperature, the reaction mixture was stirred at room temperature for 1h.The reaction mixture was then concentrated to dryness. The residue was recrystalized from DCM and heptane. The solid was filtered and air dry to yield (S)—2- amino(3-fluoro(fluoromethyl)phenyl)ethanol (145 mg, 0.908 mmol, 100 % yield) HCI salt as white solid. LCMS (m/z): 188.2 (MH+), 0.32 min.
WO 66188 Examples 177 and 178 S nthesis of 4- 3-amino 1r4S h drox c clohex | razin-2— Ifluoro-N- S 3- fluoro fluorometh | hen | h drox eth | benzamide and 4- 3-amino 1s 4R h drox c clohex | 2— Ifluoro-N- S 3-fluoro fluorometh | hen I hydroxyethyl )benzamide Scheme 75 Steg l Steg g F o F ””2 PdCIzdpprHzCIZ “1&0 / NH 0 DME/NaZCO3 NH2 0 2 NBS | + —> —.
V“| N / HO\Bflows N / I 100 00,311 | quant. 90% K/N KVN F O F O St Q§ NH2 0/ St 11 NH2 0/ o ‘B’ N / PdCI2(dppf).CH20l2 adduct {(I (Z) DME, Sodium Carbonate 2M \ N H2, Pd-C + —> \ N i 100 0 E) C' 1'5 h MeOH/EtOAC O O 85% O O F O F O / St 96 NH — 2 O J‘Ste 5 NH2 0/ \ lN HCI 3M aq N/ NaBH4 ACN/water \ N —, MeOH/THF 60% over two step 0 0C O O 99% O (trans/cis 4:1) F 0 F o Stegz / NH OH NH2 0 2 N/ N/ I LiOH I = \ N \ N —. + C|H3N quant 6H 5” F 0 (OH F o {0 Stepfi ? = F F NH2 N NH2 N H H N / N / |EA IN + 'N _. \ \ F F 5H OH Ste 1. Meth l4- 3-amino razin lfluorobenzoate To 3-chloropyrazinamine (27 g, 208 mmol) in DME (391 mL) and sodium carbonate (66.3 g, 625 mmol) was added methyl 2-fluoro(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- enzoate (64.2 g, 229 mmol) and PdC|2(dppf).CH2C|2 adduct (8.51 g, 10.42 mmol).
The reaction mixture was purged with N2 and heated in oil bath at 100 °C for 3h. The reaction mixture was partitioned between EtOAc and water. The organic layer was separated, washed with brine, dried over sodium sulfate, filtered and evaporated. The crude product was recrystallized by EtOAc and heptane (2:3) to give methyl 4-(3- aminopyraziny|)fluorobenzoate in 84% yield. LCMS (m/z): 248.1 (MH+), 0.58 min.
Ste 2. Meth l4- 3-aminobromo razin lfluorobenzoate To a suspension of methyl 4-(3-aminopyrazinyl)fluorobenzoate (31.5 g, 127 mmol) in acetonitrile (430 mL) at 0 0C was added NBS (23.9 g, 134 mmol). The reaction mixture was stirred in ice bath for 1 h, sat. sodium bicarbonate was added, d 30 min and product was ted with ethylacetate. The organic extracts were combined, washed with brine, dried over sodium sulfate, filtered and ated.The crude product was recrystallized in EtOAc and heptane to give methyl 4-(3-aminobromopyrazinyl)—2- fluorobenzoate as brown color solid in 96% yield. LCMS (m/z): 326.0/328.0 (MH+), 0.87 min.
Ste 3. Meth l4- 3-amino 1 4-dioxas iro 4.5 decen l razin l fluorobenzoate To a solution of methyl 4-(3-aminobromopyrazinyl)fluorobenzoate ( 10 g, 30.7 mmol) in DME (77 mL) was added 4,4,5,5-tetramethyI(1,4-dioxaspiro[4.5]decen y|)-1,3,2-dioxaboro|ane (9.79 g, 36.8 mmol), PdCI2(dppf).CH2C|2 adduct (1.252 g, 1.533 mmol), H20 (25.6 mL) and then last sodium carbonate (9.75 g, 92 mmol). The reaction was heat at 100 °C in oil bath for 2 h. Cooled down. The reaction mixture was extracted by EtOAc 3 times, the organic was washed with water and brine, dried and concentrated.
The crude material was recrystallized in DCM and heptane (1:1) to give product methyl 4-(3-amino(1,4-dioxaspiro[4.5]decenyl)pyrazinyl)f|uorobenzoate in 75% yield. LCMS (m/z): 382.2 (MH+), 0.82 min.
Ste 4. Meth l4- 3-amino 1 as iro 4.5 decan l razin lfluorobenzoate Methyl 4-(3-amino(1,4-dioxaspiro[4.5]decenyl)pyrazinyl)fluorobenzoate (6.1 g, 15.83 mmol) was dissolved in MeOH (150 mL) and EtOAc (80 mL) the reaction mixture was flushed with N2 for 15 min, Then Pd-C (DEGASSA) (6 g, 5.64 mmol) was added, the reaction mixture was then charged with hydrogen balloon and stirred at room temperature overnight. The on mixture was filtered through Celite, which was washed with EtOAc and methanol. The filtrate was concentrated to yield the crude product, which was used in the next step reaction t purification. LCMS (m/z): 388.0 (MH+), 0.79 min.
Ste 5. Meth l4- 3-amino 4-oxoc clohex l razin uorobenzoate To a solution of methyl 4-(3-amino(1,4-dioxaspiro[4.5]decanyl)pyraziny|) benzoate (6.2 g, 16.00 mmol) in Acetonitrile (100 mL), Water (40 mL) was added 3M aqueous solution HCI (13.34 mL, 80 mmol). The reaction was stirred at room temperature for 30 min. The reaction mixture was basified with 6M NaOH (10 mL), then use sat. NaHC03 to adjust to pH 8. After acetonitrile was removed in vacuo, the solid suspension e was filtered and washed with water and e, air-dried to give methyl 4-(3-amino(4-oxocyclohexyl)pyrazinyl)fluorobenzoate as light yellow solid in 67 % yield. LCMS (m/z): 344.0 (MH+), 0.70 min.
Ste 6. Meth l4- 3-amino 1r4r h drox c clohex l razin lfluorobenzoate To a solution of methyl 4-(3-amino(4-oxocyclohexyl)pyrazinyl)f|uorobenzoate (3.25 g, 9.47 mmol) in Methanol (100 mL) and THF (20 mL) at 0 °C, NaBH4 was added (0.358 g, 9.47 mmol). After 30 min, saturated NH4C| was added slowly, then stirred at room ature for 1 h. ol and THF was removed in vacuo. The residue was extracted by EtOAc 3 times, the combined organic was washed with NaHC03 and water, dried and concentrated. The crude product was used in next step reaction without purification. LCMS (m/z): 346.4 (MH+), 0.63 min ) and 0.66 min (cis); trans/cis (~4 :1).
To a solution of methyl 4-(3-amino((1r,4r)hydroxycyclohexyl)pyraziny|) fluorobenzoate (3.25 g, 9.41 mmol) in MeOH (15.68 mL) and THF (15.68 mL) and then LiOH 1M aqueous solution (23.53 mL, 23.53 mmol). The on was stirred at room temperature for 2 h, 6 M HCI (3.9 mL )was added slowly. Methanol and THF was removed in vacuo, the residue (yellow solid suspension) was filtered. The solid was washed with water and heptane, air dry to yield the crude product. The crude product was used in next step reaction without purification. LCMS (m/z): 332.1 (MH+), 0.49 min (trans) and 0.53 min (cis).
Ste 8. 4- 3-amino 1r4S h drox c clohex l 2- lfluoro-N- S 3- fluoro fluorometh l hen l h drox eth l benzamide and 4- 3-amino 1s 4R h drox c clohex l razin lfluoro-N- S 3-fluoro fluorometh l hen l hydroxyethy|)benzamide To a mixture of 4-(3-amino((1r,4r)hydroxycyclohexyl)pyrazinyl)f|uorobenzoic acid and mino((1s,4s)hydroxycyclohexyl)pyrazinyl)f|uorobenzoic acid (19.45 mg, 0.053 mmol) was added NMP (0.5 mL), Hiinig’s base (0.042 mL, 0.240 mmol) and (S)amino(3-fluoro(fluoromethyl)phenyl)ethanol-HCI (9 mg, 0.048 mmol).
Then HATU (36.6 mg, 0.096 mmol) was added. The reaction was stirred for 1 h at room temperature, followed by LCMS. To the crude reaction was added 0.5 mL of NMP, filtered, purifed by prep HPLC with both s isolated 4-(3-amino((1r,4S)—4- hydroxycyclohexyl)pyrazinyl)fluoro-N-((S)(3-fluoro(fluoromethyl)phenyl) WO 66188 yethyl)benzamide as trans and minor 4-(3-amino((1s,4R)—4- hydroxycyclohexyl)pyrazinyl)—2-fluoro-N-((S)—1-(3-fluoro(fluoromethyl)phenyl)—2- hydroxyethyl)benzamide as cis. Both products were lyophilized to TFA salts. For trans diastereomer, 1H NMR (400 MHz, CD3OD) 6 ppm 7.84 - 7.70 (m, 2 H), 7.64 - 7.47 (m, 2 H), 7.19 (s, 1 H), 7.09 (d, J=9.78 Hz, 1 H), 6.98(d, J=9.00 Hz, 1 H), 5.36 (s, 1 H), 5.24 (s, 1 H), 5.13 (t, J=5.87 Hz, 1 H), 3.87 - 3.70 (m, 2 H), 3.59 -3.45 (m, 1 H), 2.62 - 2.49 (m, 1 H), 2.05 - 1.92 (m, 2 H), 1.91- 1.79 ( m, 2 H), 1.57 (qd, J=12.98 Hz, 2.93 Hz, 2 H), 1.39- 1.24 For cis diastereomer, 1H NMR (400 MHz, CD3OD) 6 ppm 7.93-7.81 (m, 2H) 7.75- 7.58 (m, 2H) 7.29 (d, J=9.78 Hz, 1 H), 7.19 (d, J=9.78 Hz, 1H), 7.07 (d, J=9.00 Hz, 1H), .45 (s, 1 H), 5.33 (s, 1 H), 5.22( t, J=5.67 Hz, 1H), 4.01 (br. s., 1 H), 3.94 -3.77 (m, 2 H), 2.80 — 2.68 ( m, 1 H), 2.12 — 1.96 (m, 2 H) 1.91- 1.80 (m, 2 H), 1.77-1.60 (m, 4 H).
S nthesis of S -N- 2-amino 3-fluoroiodo hen l eth l -N-meth l nitrobenzenesulfonamide Scheme 76 S_Q 2 S_62 é S_r2 A Step Q \1/ MQ : N9”,6 NHBoc /OH o‘S‘N —.F\E;/\/68t:>ZF\©/\/—eas—>SBocHN/KQ/F _. | H ;F I ma Step3 Step_11 {N3 BocHN NH2 ALQOZ Ste 1. Meth |3-aminofluorobenzoate 3-bromofluorobenzoic acid (6.12 g, 33.1 mmol) was dissolved in MeOH (10 mL) and cooled in ice-water bath and toluene (50 mL) and then TMS-diazomethane (19.84 mL, 39.7 mmol) was added se. Reaction miature was allowed to return to room temperature for 1 h and concentrated in vacuo and the residue dissolved in DCM/Ether and filtered through a short plug of silica and the filtrate evaporated in vacuo to afford the desired product which was then dissolved in MeOH (60 mL) and Pd/C 10wt% 3.3 g was added and the mixture evacuated and stirred under 1 atm of hydrogen overnight and LCMS indicated desired product next morning. The reaction mixture was filtered through Celite and the te was concnetrated in vacuo and the residue azeotroped with toluene twice and taken to the next step as such (99%). LCMS (m/z): 211.1 (MH+), 0.55 min.
Step 2. Methyl 3-fluoroiodobenzoate Methyl ofluorobenzoate was dissolved in 5.0 N HCI (68.5 mL, 343 mmol) and cooled to 0 °C. NaNOz (2.51 g, 36.4 mmol) dissolved in 3.0 mL water was added dropwise. Then Kl (6.59 g, 39.7 mmol) dissolved in 45 mL water was added over 30 min and the mixture stirred at room temperature for 1 h and the reaction mixture was extracted with EtZO twice (200 mL) and then dried sium sulfate), filtered and concentrated in vacuo to give the crude product which was purified by flash tography (0-20%EtOAc/heptane) to afford 5.49 g of the desired product as a yellow syrup (59 %). 1H NMR (400 MHz, CDCI3) 6 ppm 8.18 (s, 1H), 7.69 (d, J=9.0 Hz, 1H), 7.63 (dd, J=7.6, 1.4 Hz, 1H), 3.93 (s, 3H).
Ste 3. roiodo hen lmethanol Methyl 3-fluoroiodobenzoate (5.49 g, 19.60 mmol) was dissolved in DCM (100 mL) and cooled to -78 °C. DIBAL-H (49.0 mL, 49.0 mmol) was added dropwise over 30 min and then after 1 h r n of DIBAL-H (49.0 mL, 49.0 mmol) was added. Reaction mixture agitated at -78°C for 4 h and poured carefully onto ice-cold 1N HCI. The mixture was agitated for 10 min and the layers separated and the aq. layer extracted with DCM and the ed organic extract was dried (magnesium sulfate), filtered and concentrated in vacuo to afford the desired product in quantitative yield. LCMS not conclusive.
Step 4. 3-fluoroiodobenzaldehyde (3-fluoroiodophenyl)methanol (9.79 g, 35.0 mmol mmol) was dissolved in DCM (94 mL) and then silica gel (18.0 g) was added. To the mixture at room temperature was added PCC (18.3 g, 45.0 mmol) portion-wise and the mixture ed at room ature for 1 h and followed by TLC. After 1 h, TLC indicated complete conversion of the SM to a non- polar (presumably aldehyde). The reaction mixture was filtered over 1-inch plug of silica pad and eluted with 30% Ether in DCM (200 mL). The filtrate was concentrated in vacuo to afford the crude product, which was taken to the next step without further purification.
Ste 5. R E -N- 3-fluoroiodobenz lidene meth l ro anesulfinamide To a solution of 3-fluoroiodobenzaldehyde (8.75 g, 35 mmol) and (R)—(+)—t— Butylsulfinamide (4.67 g, 38.5 mmol) in DCE ( 117 mL) was added copper(|l) sulfate (anhydrous) (16.76 g, 105 mmol) and the resulting suspension was heated at 60 °C overnight. LCMS indicated d t formation. Reaction mixture was filtered through Celite and the filtrate concentrate in vacuo and then taken to the next step as such. LCMS (m/z): 354.1 (MH+), 1.08 min.
Ste 6. R-N- R 3-fluoroiodo hen lall th l ro anesulfinamide Dimethyl zinc (1.2M in toluene) (7.29 mL, 8.75 mmol) and agnesium bromide (45.5 mL, 45.5 mmol) was mixed at room temperature for 20 min under argon before cooling down to -78 °C, then (R,E)-N-(3-fluoroiodobenzylidene)methylpropanesulfinamide in dry THF ( 117 mL) as added dropwise about 30 min. The internal temperature between -74 C to -72 °C, after addition the on mixture was stirred at -78 °C for 1 h, sample was taken quenched by Water, LCMS showed the desired product along with unreacted starting material. More vinylmagnesium bromide (12 mL, 12.0 mmol)) was added and reaction monitored by LCMS and after 30 min, reaction was deemed complete. The reaction mixture was poured over ice-cold by sat.NH4Cl and water, THF was removed in vacuo and the product extracted by EtOAc. The organic layer was washed by water and Brine, dried over anhydrous Na2804, filtered and concentrated and the crude product was purified by flash chromatography (0-70% EtOAc/heptane) to provide 8.99 g of (R)—N-((R)—1-(3-fluoroiodophenyl)allyl)methy|propanesulfinamide as the desired product as a ess yellow syrup. Yield (67.4%). The yield is for the 4 step sequence. Note: The major side-product corresponds to inated d product. LCMS (m/z): 382.5 (MH+), 0.96 min; 1H NMR (400 MHz, CDCI3) )6 ppm 7.48 (s, 1H), 7.37 (dt, J=7.6, 1.9 Hz, 1H), 7.06 (d, J=9.0 Hz, 1H), 5.85 (ddd, J=17.0, 10.0, 7.4 Hz, 1H), 5.25-5.47 (m, 3H), 4.90 (d, J=7.0 Hz, 1H), 3.23-3.66 (m, 1H), 1.26 (s, 9H).
Step 7. (R)—tert-butyl (1-(3-fluoroiodophenyl)allyl)carbamate (R)—N-((R)—1-(3-fluoroiodophenyl)allyl)methy|propanesulfinamide (8.99 g, 23.58 mmol) was dissolved in MeOH (40 mL) and treated with 4 N HCI (11.79 mL, 47.2 mmol) and the mixture agitated at room temperature for 1 h and concentrated in vacuo. The residue was dissolved water and Sat'd Na2CO3 was added. The t was extracted with 3:1 CHCl3:lPA and the organic layer was dried (magnesium sulfate), filtered and concentrated in vacuo. The residue was dissolved in DCM (60 mL) and Boc—anhydride (6.79 mL, 29.2 mmol) was added. The mixture was agitated overnight at room temperature and the next morning, the reaction mixture was concentrated in vacuo and the crude product (R)—tert-butyl (1-(3-fluoroiodophenyl)allyl)carbamate taken to the next step without any r cation. LCMS (m/z): 322.1 (MH+-56), 1.11 min.
Step 8. (S)—tert—butyl (1-(3-fluoroiodophenyl)—2-hydroxyethyl)carbamate (R)—tert—butyl (1-(3-fluoroiodophenyl)allyl)carbamate (8.89 g, 23.58 mmol) was dissolved in DCM (236 mL) and cooled to -78 °C. Ozone was purged through the mixture until blue color persisted. Reaction mixture was then purged with en and NaBH4 (8.92 g, 236 mmol) was added in one portion followed by addition of MeOH (120 mL) and the mixture was agitated at same temperature for 2 h and then acetone 20 mL was added. Reaction mixture was ed for another 1 h and then poured over saturated NH4C| and then extracted with DCM (500 mL) and then with 3:1 CHCI3/IPA (200 mL) and the organic extracts were combined and dried (magnesium sulfate), and the solvent concentrated in vacuo and the residue purified by flash tography to afford 6.74 g (17.7 mmol) of (S)—tert-butyl (1-(3-fluoroiodophenyl)hydroxyethyl)carbamate (75%).
LCMS (m/z): 326.1 (MH+-56), 0.90 min.
Step 9. (S)—tert—butyl (2-azido(3-fluoroiodophenyl)ethyl)carbamate (S)—tert—butyl (1-(3-f|uoroiodophenyl)—2-hydroxyethyl)carbamate (4.8112 g, 12.62 mmol) was dissolved in DCM (100 mL) and cooled to 0 °C. Et3N (2.62 mL, 18.93 mmol) was added next and then MsCl (1.180 mL, 15.15 mmol) was added se. The reaction mixture was agitated at same temperature for 30 min after which RM quenched with Sat'd NaHC03 and water. The product was extracted with DCM and the combined organic layer was dried (magnesium sulfate), filtered and concentrated in vacuo to afford the crude product which was dissolved in DMF (25 mL, ca 0.5 M). NaN3 (2.462 g, 37.9 mmol) was added next and the mixture heated at 70 °C. After 6 h, the reaction mixture was cooled to room temperature and diluted with EtOAc and water and the product ted with EtOAc. The combined organic extract was washed with water thrice and dried (magnesium sulfate), filtered and concentrated in vacuo and the residue purified by flash chromatography (0-50%) EtOAc/heptane to afford 4.03 g of (S)—tert-butyl (2-azido(3- fluoroiodophenyl)ethyl)carbamate as desired product. LCMS (m/z): 351.0 6), 1.05 min.
Step 10. (S)—tert—butyl (1-(3-fluoroiodophenyl)(2- nitrophenylsulfonamido)ethyl)carbamate (S)—tert-butyl (2-azido(3-fluoroiodophenyl)ethyl)carbamate (288 mg, 0.709 mmol) was dissolved in MeOH (7.09 mL) and then polymer-bound PPh3 (7.09 mmol) was added. RM agitated at 70 °C overnight. The next morning, LCMS indicated ion of desired t. RM filtered through Celite and the filter-cake washed with DCM and MeOH and the filtrate concentrated in vacuo to afford the crude amine which was taken to the next step without any further cation. The crude amine was dissolved in DCM (7 mL) and cooled to 0 °C and then Triethylamine (0.198 mL, 1.418 mmol) was added.
Then 2-nitrobenzenesulfonyl de (189 mg, 0.851 mmol) was added in one portion.
The reaction mixture was agitated at room temperature for 1 h and quenched with water and the product extracted with DCM. The organic layer was washed with brine and dried (magnesium sulfate), filtered and concentrated in vacuo and the residue purified by flash chromatography (0-40% EtOAc/heptane) to afford 290 mg of (S)—tert-butyl (1-(3-fluoro iodophenyl)(2-nitrophenylsulfonamido)ethyl)carbamate as the desired product. LCMS (m/z): 524.0 (MH+-56), 1.10 min.
Ste 11. S -N- 2-amino 3-fluoroiodo hen leth l-N-meth l enzenesulfonamide (S)—tert-butyl fluoroiodophenyl)(2- nitrophenylsulfonamido)ethyl)carbamate (290 mg, 0.513 mmol) was dissolved in DMF (5.1 mL) and K2C03 (142 mg, 1.026 mmol) followed by iodomethane (48.1 ul, 0.769 mmol) were added. The mixture was agitated at room temperature for 1 h upon which complete reaction observed. RM diluted with water and EtOAc. The organic layer was washed with water twice and dried (magnesium sulfate), filtered and concentrated in vacuo to give relatively pure product which was dissolved in DCM (5 mL) and treated with 4N HCI in e (2 mL) and the mixture agitated at room temperature overnight and the mixture concentrated in vacuo to afford the desired product (S)—N-(2-amino(3- fluoroiodophenyl)ethyl)-N-methylnitrobenzenesulfonamide as the hydrochloride salt.
LCMS (m/z): 480.4 (MH+), 0.72 min. e 179 S nthesis of S -N- 2-amino 3-fluoroiodo hen l eth l o tetrah dro-2H- ran l razin uorobenzamide Scheme 77 NH2 OH {N3 3 EDC HOAt N \ F I + HZN NI \ /N polymer- DMF D'EA bound PPh3 O O O Ste 1. S 3-amino tetrah dro-2H- ran l razin l-N- 2-azido 3-fluoro iodo hen |eth lfluorobenzamide 4-(3-Amino(tetrahydro-2H-pyranyl)pyrazinyl)fluorobenzoic acid TFA adduct (126 mg, 0.292 mmol) and HOAt (0.060 g, 0.438 mmol) was dissolved in DMF(1 mL) and DIEA (0.156 mL, 0.876 mmol). (S)—2-azido(3-fluoroiodophenyl)ethanamine hydrochloride salt (100 mg, 292 mmol), ed from the reaction of (S)—tert-butyl (2- azido(3-fluoroiodophenyl)ethyl)carbamate with 4M HCI in dioxane (Step 9 in Scheme 76), was added, followed by EDC (0.090 g, 0.467 mmol). The reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with EtOAc and water, and the organic layer was washed with water twice and then with saturated Na2C03. The organic layer was dried over magnesium sulfate, filtered and concentrated in vacuo providing crude (S)(3-amino(tetrahydro-2H-pyranyl)pyrazinyl)-N-(2- azido(3-fluoroiodophenyl)ethyl)fluorobenzamide without further purification.
Ste 2. S -N- 2-amino 3-fluoroiodo hen l eth l o tetrah dro-2H- pyranyl inyl )—2-fluorobenzamide The crude (S)(3-amino(tetrahydro-2H-pyranyl)pyrazinyl)-N-(2-azido(3- fluoroiodophenyl)ethyl)fluorobenzamide was dissolved in THF (5 mL), and triphenylphosphine er bound, 3 mmol/g) (0.97 g, 3.70 mmol) was added dropwise.
The e was heated at 70 °C for 3 h. LCMS indicated absence of starting material (at this stage, the phosphorylimine intermediate is likely present in solid phase). Water (4.5 mL) and THF (5 mL) were added, and the mixture was heated at 80 °C for 3 h and then filtered. The filter cake was washed with DCM and then filtrate was concentrated in vacuo. The residue was dissolved in DCM and washed with water and the organic layer dried over magnesium sulfate, filtered and concentrated in vacuo to afford the residue which was purified by flash chromatography (0-60% DCM/10% MeOH in EtOAc containing 0.5% , and the product fractions were collected and trated.
The residue was dissolved in acetonitrile and water, and lyophillized to obtain 101.2 mg of (S)—N-(2-amino(3-f|uoroiodophenyl)ethyl)(3-amino(tetrahydro-2H-pyran azinyl)fluorobenzamide as the desired product. LCMS (m/z): 580.1 (MH+), 0.70 min. 1H NMR (CD30D) 6 (ppm): 7.92 (s, 1H), 7.85 - 7.79 (m, 1H), 7.73 (dd, J=8.0, 1.4 Hz, 1H), 7.68 - 7.61 (m, 2H), 7.50 - 7.43 (m, 1H), 7.23 (d, J=9.5 Hz, 1H), 5.12 (t, J=6.9 Hz, 1H), 4.07 (dd, J=11.2, 3.3 Hz, 2H), 3.60 (td, J=11.7, 2.0 Hz, 2H), 3.09 - 2.83 (m, 3H), 2.02 - 1.76 (m, 4H). 8 nthesis of S -tert-but l 2-amino 3-bromofluoro hen leth lcarbamate Scheme 78 O (S)8 Step_2 H5)S‘o Step_3 Br — (E) N|H - F Os)< B;H zéQ é HN 0 Step; A HN’ so Step 5 ”HZ Br ? Br NHBoc NH2 NHBoc F F Ste 1. S E -N- 3-bromo—5-fluorobenz lidene meth l ro sulfinamide To a solution of 3-bromofluorobenzaldehyde (5 g, 24.63 mmol) and (S)—2- methylpropanesulfinamide (3.28 g, 27.1 mmol) in DCE (82 mL) was added copper(|l) sulfate (anhydrous) (7.86 g, 49.3 mmol). The suspension was stirred under nitrogen at 60 °C ght. The reaction mixture was cooled down, filtered through a plug of celite, and rinsed with DCM. The filtrate was concentrated to yield the crude t. The crude product was purified by flash chromatograph eluting with 0-30% EtOAc in heptane to yield the product (S,E)—N-(3-bromofluorobenzylidene)methy|propanesulfinamide (7.5 g, 24.49 mmol, 99 % yield) as a light yellow color oil. LCMS (m/z): 306.1/308.1 (MH+), 1.04 min.
Ste 2. S -N- S ofluoro hen lnitroeth lmeth l ro ane sulfinamide Nitromethane (1.0 mL, 17.20 mmol) was dissolved in THF (34.4 mL), then BuLi (2.5 M in hexanes) (7.22 mL, 18.06 mmol) was added at -78 °C. The reaction mixture was stirred at -78 °C for 10 min, then warmed up to room temperature for 20 min. After cooling down to -78 °C, (S,E)-N-(3-bromofluorobenzylidene)methy|propanesulfinamide (4.74 g, .48 mmol) in THF (6 mL) was added dropwise. The reaction mixture was stirred at -78 °C for 20 min, warmed up to room temperature, and stirred at room temperature for 5 h.
The reaction mixture was quenched by sat NH4CI, and extracted by EtOAc. The organic was dried over Na2804, filtered and concentrated. The crude product was purified by flash chromatography (0-40%-100% EtOAC/ heptane). Pure fractions were combined to yield (S)—N-((S)—1-(3-bromofluorophenyl)nitroethyl)methylpropanesulfinamide (2.2 g, 5.99 mmol, 38.7 % yield). LCMS (m/z): 367.1/369.1 (MH+), 0.89 min; 1H NMR z, CDCI3) 6 ppm 7.31 (s, 1H), 7.03 (d, J=9.0 Hz, 1H), 5.03 (q, J=5.7 Hz, 1H), 4.87 - 4.78 (m, 2H), 4.48 (d, J=5.1 Hz, 1H), 1.33 - 1.25 (m, 9H).
Ste 3. S -N- S amino 3-bromofluoro hen leth th l ro ane sulfinamide (S)—N-((S)—1-(3-bromofluorophenyl)nitroethyl)methy|propanesulfinamide (2.2 g, .99 mmol) was dissolved in MeOH (19.97 mL), d with N2 for 10 min, and then Pt02 (0.408 g, 1.797 mmol) was added. The reaction mixture was charged with hydrogen balloon and stirred at room temperature overnight. The reaction mixture was filtered through celite and washed by methanol and EtOAc. The filtrate was dried over , filtered and concentrated. The crude material was used in next step reaction t further purification. LCMS (m/z): 337.1/339.1 (MH+), 0.64min.
Ste 4. tert-but | S 3-bromofluoro hen l S -1 1-dimeth leth lsulfinamido ethyl)carbamate (S)-N-((S)amino(3-bromof|uorophenyl)ethyl)methy|propanesulfinamide (1.75 g, 5.19 mmol) was dissolved in DCM (17.30 mL), and then Boc20 (1.325 mL, 5.71 mmol) was added. The reaction e was stirred at room temperature for 3 h, and then concentrated. The crude product was ed to yield the product tert-butyl -(3- bromofluorophenyl)((S)-1,1-dimethylethylsulfinamido)ethyl)carbamate (1.78 g, 78%).
LCMS (m/z): 439.1 (MH+), 0.99 min.
Step 5. (S)—tert—butyl (2-amino(3-bromofluorophenyl)ethyl)carbamate To a solution of tert-butyl ((S)(3-bromof|uorophenyl)((R)-1,1- ylethylsulfinamido)ethyl)carbamate (1 .78 g, 4.07 mmol) in DCM (13.57 mL) was added HCI (4M in dioxane ) (4.07 mL, 16.28 mmol) at room temperature. The reaction mixture was stirred at room temperature for 1 h. The reaction mixture was neutralized to pH = 7, then extracted by EtOAc to give the desired (S)-tert-butyl (2-amino(3-bromo fluorophenyl)ethyl)carbamate (300 mg) as a free base. LCMS (m/z): 317.1/319.1 (MH+), 0.66 min.
S nthesis of S -tert-but | 2-amino 3-bromo hen leth lcarbamate Br ' mHBoc Following Scheme 78, using 3-bromobenzaldehyde, (S)-tert-butyl (2-amino(3- bromophenyl)ethyl)carbamate was obtained as a HCI salt. LCMS (m/z): 315.1/317.1 (MH+), 0.66 min.
S nthesis of S -meth l 2-amino 3-bromofluoro hen leth lcarbamate Scheme 79 \l/ O O ,é\ /NH Hlj \O o : Br + —> F F Br To a solution of (S)—N-((S)—2-amino(3-bromofluorophenyl)ethyl)methylpropane amide (100 mg, 0.297 mmol) in DCM (988 pl) was added TEA (124 pl, 0.890 mmol) and methyl chloroformate (24.12 pl, 0.311 mmol). The reaction mixture was stirred at room temperature for 1 h. The reaction e was extracted by EtOAc and the organics were washed with water and brine, dried over sodium sulfate, filtered off, and concentrated in vacuo. The residue was dissolved in EtZO (1 mL), then HCI (4M in dioxane) (148 pl, 0.593 mmol) was added. The reaction mixture was stirred at room temperature for 30 min. After the solvent was decant out, the residue solid was used in next step without further purification. LCMS (m/z): 291 .2/293 (MH+), 0.49 min. 8 -meth | 2-amino o hen leth Icarbamate /OYO Following Scheme 79, using (S)—N-((S)—2-amino(3-bromophenyl)ethyl)—2— methylpropanesulfinamide, (S)—methyl (2-amino(3-bromophenyl)ethyl)carbamate was obtained. LCMS (m/z): 273.0/2750 (MH+), 0.46 min.
(S)—methyl (2-amino(3-chlorophenyl)ethyl)carbamate Following Scheme 79, using (S)—N-((S)—2-amino(3-chlorophenyl)ethyl) methylpropanesulfinamide, thyl (2-amino(3-chlorophenyl)ethyl)carbamate was obtained. LCMS (m/z): 229.2 (MH+), 0.42 min. 8 nthesis of S -N- 2-amino 3-bromofluoro hen | eth | acetamide Scheme 80 \l/ YO ngl’séo o o {NH Br - + AOJK F F Br (S)—N-((S)—2-amino(3-bromofluorophenyl)ethyl)methylpropanesulfinamide (100 mg, 0.297 mmol) was dissolved in DCM (988 pl), followed by pyridine (71.9 ul, 0.890 mmol) and acetic ide (28.0 ul, 0.297 mmol). The reaction e was stirred at room temperature for 1 h, extracted by EtOAc, washed by water and brine, dried over Na2804 and concentrated. The residue was dissolved in EtZO (1 mL), then HCI (4 M in dioxane) (148 pl, 0.593 mmol) was added. The reaction mixture was stirred at room temperature for 30 min. After the solvent was decant out, the residue solid was used in next step reaction without purification. LCMS (m/z): 275.1/277.1 (MH+), 0.41 min.
Synthesis of (S)—N-(2-amino(3-bromophenyl)ethyl)acetamide WO 66188 Following scheme 80, using (S)—N-((S)—2-amino(3-bromophenyl)ethyl) methylpropanesulfinamide, (S)-N-(2-amino(3-bromophenyl)ethyl)acetamide was obtained. LCMS (m/z): 257.1/259.1 (MH+), 0.40 min.
Example 180 S nthesis of S -N- 2-amino 3-bromofluoro hen | eth | o tetrah dro- 2H- ran | razin lfluorobenzamide Scheme 81 F O /NHBOC NH2 OH /NHBocF Ste Ste N \ EDC HOAt N \ N \ I + HzN DIEA DMF 0 o o Ste 1. S -tert-but | 2- 4- 3-amino tetrah dro-2H- ran | razin l fluorobenzamido 3-bromofluoro hen | eth | carbamate To a solution of 4-(3-amino(tetrahydro-2H-pyranyl)pyrazinyl)fluorobenzoic acid (35 mg, 0.110 mmol) in DMF (368 pl) was added rt—butyl (2-amino(3-bromo fluorophenyl)ethyl)carbamate (40.8 mg, 0.110 mmol), aza-HOBt (22.52 mg, 0.165 mmol), EDC (31.7 mg, 0.165 mmol), and DIEA (57.8 ul, 0.331 mmol). The reaction mixture was stirred at room temperature for 3 h, and then partitioned between EtOAc and water. The organic was washed by NaHC03, water and brine, dried over Na2804 and concentrated.
The crude rt-butyl (2-(4-(-3amino---6(tetrahydro-H-p-yran-yl)pyrazin--y-|) fluorobenzamido)(3-bromofluorophenyl)ethyl)carbamate was used in next step reaction without further purification. LCMS (m/z): 632.1/634.1 (MH+), 0.97 min.
Ste 2. S -N- 2-amino 3-bromofluoro hen | eth | 3-amino tetrah dro-2H- pyranyl )pyrazinyl )—2-fluorobenzamide To a solution of rt-butyl (2-(4-(3-amino(tetrahydro-2H-pyranyl)pyrazinyl) benzamido)(3-bromofluorophenyl)ethy|)carbamate (69 mg, 0.110 mmol) in DCM ( 1.0 mL) was added TFA (0.5 mL) and stirred at room temperature for 1 h. The on mixture was concentrated to dryness, then dissolved in DMSO and subject to prep HPLC. Pure fraction was combined and lyophilized to yield final product as a TFA salt. LCMS (m/z): 532.1/534.1 (MH+), 0.69 min; 1H NMR (400 MHz, Methanol-d4) 6 ppm 7.94 - 7.84 (m, 2H), 7.73 (dd, J=1.4, 8.0 Hz, 1H), 7.66 (dd, J=1.4, 11.9 Hz, 1H), 7.55 (s, 1H), 7.49 - 7.39 (m, 1H), 7.29 (d, J=9.4 Hz, 1H), 5.48 (t, J=7.2 Hz, 1H), 4.04 (dd, J=2.9, 11.5 Hz, 2H), 3.57 (dt, J=2.2, 11.6 Hz, 2H), 3.51 - 3.41 (m, 2H), 3.01 - 2.85 (m, 1H), 1.97 - 1.76 (m, 4H).
Example 181 S s of S -N- 2-amino 3-chlorofluoro hen | eth | 3-amino tetrah dro- 2H- ran | razin lfluorobenzamide Scheme 82 F 0 $21 F o {N3 m; F o ””2 : a F F NHg OH /N3 NH; N \P/ NHZ N g H H N/ F HzN EDC,HOAt N’ N/ E I I \ N + —. 4— \ N 0' \ N 0' DIEA,DMF pyridine, NHAOH Ste 1. S 3-amino tetrah dro-2H- ran | razin l-N- 2-azido 3-chloro fluoro hen leth lfluorobenzamide To a solution of mino(tetrahydro-2H-pyranyl)pyrazinyl)fluorobenzoic acid (126 mg, 0.398 mmol) in DMF (1328 ul) was added (S)azido(3-chloro fluorophenyl)ethanamine (100.0 mg, 0.398 mmol), DIEA (348 pl, 1.991 mmol), EDC (153 mg, 0.797 mmol), and aza-HOBt (81 mg, 0.597 mmol). The reaction mixture was stirred for 15 h. After water was added, the reaction mixture was worked up with EtOAc. The organic layer was dried over Na2804, filtered off, and concentrated in vacuo. The crude product was ed by flash chromatography (gradient EtOAc in heptane) to provide (8)- 4-(3-amino(tetrahydro-2H-pyran-4—yl)pyrazinyl)-N-(2-azido(3-chloro fluorophenyl)ethy|)fluorobenzamide (118 mg, 58%). LCMS (m/z): 514.2 (MH+), 0.91 min.
Ste 2. S -N- 2-amino 3-chloro—5-fluoro hen l eth l 3-amino tetrah dro-2H- pyranyl )pyrazinyl )—2-fluorobenzamide To a solution of (S)(3-amino(tetrahydro-2H-pyranyl)pyrazinyl)-N-(2-azido(3- chlorofluorophenyl)ethyl)fluorobenzamide (118 mg, 0.230 mmol) in pyridine (2 mL) was added NH4OH (200 pi) and hylphosphine (344 pl, 0.344 mmol) tially at room temperature. The reaction mixture was stirred for 2 h. After EtOH (1 mL) was added, the reaction mixture was concentrated in vacuo. The crude t was purified by flash tography (20% MeOH in DCM containing 0.5% NH3 / DCM) to provide 89.6 mg of (S)—N-(2-amino(3-chlorofluorophenyl)ethyl)(3-amino(tetrahydro-2H- pyranyl)pyrazinyl)f|uorobenzamide (79%). LCMS (m/z): 488.2 (MH+), 0.66 min. 1H NMR (500MHz, METHANOL-d4) 8 ppm 7.98 - 7.89 (m, 1H), 7.89 - 7.79 (m, 1H), 7.74 (td, J=1.4, 8.0 Hz, 1H), 7.69 - 7.61 (m, 1H), 7.41 - 7.28 (m, 1H), 7.27 - 7.08 (m, 2H), 5.27 - .12 (m, 1H), 4.07 (dd, J=3.8, 11.0 Hz, 2H), 3.69 - 3.52 (m, 2H), 3.14 - 3.03 (m, 2H), 2.96 (tt, J=3.9, 11.7 Hz, 1H), 2.02 - 1.77 (m, 4H). 8 nthesis of S -N- 2-amino 3-bromofluoro hen l eth l -N-meth l nitrobenzenesulfonamide Scheme 83 HN’S‘b c m2 1 Step_2 \ ,0 Br 023’ N02 + —> N02 2 mg Q‘HBOC 8&2 A 2“”3“ Step_5 Br Br . at: . it: enzenesulfonamide (S)—N-((S)—2-amino(3-bromofluorophenyl)ethyl)methylpropanesulfinamide (3.3 g, 9.78 mmol) was ved in DCM (32.6 mL) at 0 °C, then TEA (1.405 mL, 10.08 mmol), and 2-nitrobenzenesu|fony| chloride (2.169 g, 9.78 mmol) were added. The reaction e was stirred at room temperatur for 3 h. The reaction mixture was concentrated in vacuo and the crude product was purified to yield N-((S)—2-(3-bromo fluorophenyl)((S)-1,1-dimethylethylsulfinamido)ethyl)nitrobenzenesulfonamide.
LCMS (m/z): 522.1/524.1 (MH+), 0.94 min.
Ste 2. S -N- 2-amino ofluoro hen l eth l nitrobenzenesulfonamide N-((S)(3-bromofluorophenyl)((R)—1,1-dimethylethylsulfinamido)ethyl) nitrobenzenesulfonamide (3.55 g, 6.80 mmol) in EtZO (22.65 mL), and HCI (4 M in dioxane) (3.40 mL, 13.59 mmol) was added. The reaction mixture was stirred at room temperature for 1 h. The reaction mixture was neutrailized by Na2C03 solution and extracted by EtOAc. The organic layer was washed with water, dried, filtered off, and concentrated in vacuo providing the crude (S)-N-(2-amino(3-bromo fluorophenyl)ethyl)nitrobenzenesulfonamide, which was used in next step reaction without further purification. LCMS (m/z): 418.2/420.2 (MH+), 0.62 min.
Step 3. (S)—tert—buty| (1-(3-bromofluorophenyl)—2-(2- nitrophenylsulfonamido)ethyl)carbamate (S)—N-(2-amino(3-bromofluorophenyl)ethyl)nitrobenzenesulfonamide (1.55 g, 3.71 mmol) was dissolved in CH2C|2 (12.35 mL), and then TEA (0.517 mL, 3.71 mmol) and hydride (1.119 mL, 4.82 mmol) were added. The reaction mixture was stirred at room temperature for 1 h, and concentrated. The crude product was purified by flash chromatography to yield (S)—tert-buty| (1-(3-bromof|uoropheny|)(2- nitrophenylsulfonamido)ethyl)carbamate. LCMS (m/z): 462.0/464.0 6), 0.99 min.
Ste 4. S -tert-but l 1- 3-bromofluoro hen l N-meth lnitro hen lsulfonamido ethy|)carbamate (S)—tert-butyl (1-(3-bromofluorophenyl)(2-nitrophenylsulfonamido)ethyl)carbamate (2.3 g, 4.44 mmol) was dissolved in DMF (14.79 mL). K2C03 (1.226 g, 8.87 mmol) and Mel (0.416 mL, 6.66 mmol) were added. The on mxiture was stirred at room temperature for 2 h, and then water was added. The reaction mixture was ted by EtOAc. The organic was washed by water and brine, dried and concentrated. The crude product was purified by flash chromatagrapghy to yield (S)—tert-buty| (1-(3-bromo fluorophenyl)(N-methylnitrophenylsulfonamido)ethyl) carbamate (2.3 g, 4.32 mmol, 97% yield).
Ste 5. S -N- 2-amino 3-bromofluoro hen leth l-N-meth l nitrobenzenesulfonamide (S)—tert-butyl (1-(3-bromofluorophenyl)(N-methylnitrophenylsulfonamido)ethyl) carbamate (2.3 g, 4.32 mmol, 97 % yield) was dissolved in CH2C|2 and HCI (4 M in dioxane, 4.44 mL, 17.75 mmol) wad added. The reaction mixture was d at room temperature overnight. Heptane was added. The solid was filtered, and dried by air to yield (S)—N-(2-amino(3-bromofluorophenyl)ethyl)-N-methyl nitrobenzenesulfonamide (1.8 g, 3.84 mmol, 87% yield). LCMS (m/z): 432.2/434.1 (MH+), 0.69 min.
(S)—N-(2-amino(3-bromofluorophenyl)ethyl)-N-methyl nitrobenzenesulfonamide hydrochloride salt was ed as follows: OH OH O\ O\ / _/ ’ ' / : o=s = ' NalO4 / RuCl3.H20 3 07,5 F (Boc)20/TEAIDCM E SOCIZ/Py/CHECN F F F \N O \N H2” —’ —> BocHN —> / / B0° CHSCN Boo step 2 ste 1 step 3 p Br Br Br Br “S".N/ [11 IU CE H 3/ \ N HCI/Dioxane :/ \ N02 - F : —.BOCHN DCM, RT KOH. CHBCN. RT. 1 h 60% yield, 4 steps step 4 Br Br step 5 Step 1: (S)—tert—butyl (1-(3-bromofluorophenyl)hydroxyethyl)carbamate.
To an ice water cooled solution of (S)amino(3-bromofluorophenyl)ethanol (30 g, 111 mmol) (HCI salt) in DCM (390 mL) was added TEA (46.5 mL, 333 mmol) followed by Boc—anhydride (26.4 mL, 114 mmol in 50 ml of DCM). The addition was completed in 15 minutes. The ice water bath was removed and the reaction e was stirred at room ature for 16 hours. The reaction e was concentrated, (the water bath temperature was kept below 300C), the e was diluted with 500 ml of EtOAc, washed with 100 ml of 1N NaOH, 100 ml of water and 100 ml of brine, dried over Na2804, filtered and concentrated to afford the crude product as an viscous liquid, (in smaller , it was a semi-solid). To this viscous (or semi-solid) product was added 120 ml of EtZO and the resultant mixture was then sonicated for 5 minutes. The e was concentrated to about 60 ml of total volume. After 1 hour at room temperature, a white crytalline solid precipitated out. (if no crystal , ~ 2 mg of the seed was added). After 4 hours, the white solid was filtered, washed with a mininal amount of ether and dried (over house vacumm for at least 1 hour) to afford a total of 30.5 g of the white solid as the desired product. Recovery was improved if the filtrate was concentrated and the above procedure was repeated. (S)—tert-butyl (1-(3-bromofluorophenyl) hydroxyethyl)carbamate: 30.5 g, 82 % yield. LC-MS: ( MW—56): 279.8 m/z at 0.84 min. 1H NMR (400 MHz, DMSO) ppm 1.29 - 1.43 (m, 8 H) 3.38 - 3.55 (m, 2 H) 4.39 - 4.61 (m, 1 H) 4.84 (t, J=5.67 Hz, 1 H) 7.15 (d, J=9.39 Hz, 1 H) 7.24 - 7.44 (m, 3 H).
Step 2: (4S)—tert-butyl 4-(3-bromofluorophenyl)-1,2,3-oxathiazolidinecarboxylate 2- oxide. To a solution of SOCI2 (19.98 mL, 274 mmol) in acetonitrile (280 ml) at -40 -450C ( inner temperature, dry ice-acetone bath temperature around -55C) under nitrogen atmosphere was added (S)—tert-butyl (1-(3-bromofluorophenyl) hydroxyethyl)carbamate (30.5 g, 91 mmol) in CH3CN (175 ml). The addition was completed in about 30 s. After about 20 minutes stirring at 450C, pyridine (40.6 mL, 502 mmol) was added ( in about 10 minutes). After stirring for 10 minutes at -400C, the g bath was removed, the mixture was warmed to room temeperature and stirred for 2 hours. LC-MS shown two diastereomeric products, and some amount of dimer by- product. The mixture was diluted with 400 ml of EtOAc, washed with brine (200 ml) three times, dried over Na2804, filtered and concentrated (water bath around 400C, about 2 hours) to afford 35.7 grams of the crude product as a light yellow viscous liquid, which was used immediately in the next step or stored at 4°C. (4S)—tert-butyl 4-(3-bromo fluorophenyl)-1,2,3-oxathiazolidinecarboxylate 2-oxide: LC-MS: (MW-100): 281.8 at 1.02 min.
Step 3: (S)—tert-butyl 4-(3-bromo—5-fluorophenyl)-1,2,3-oxathiazolidinecarboxylate 2,2- dioxide. To an ice water cooled solution of ert—butyl 4-(3-bromofluorophenyl)- 1,2,3-oxathiazolidinecarboxylate 2-oxide (34.6 g, 91 mmol) in acetonitrile (420 mL) under stirrring was added NalO4 (29.2 g, 137 mmol), and ium trichloride hydrate (0.359 g, 1.729 mmol), ed by water (320 ml). The reaction mixture was stirred at 0°C for 2 hours. The mixture was diluted with EtOAc (500 ml), washed with brine (200 ml) twice, dried over Na2804, filtered and concentrated to afford the crude product, which was used directly at the next step. 40.3 grams of the crude product was obtained. LC- MS: (MW + Na): 419.9 m/z at 1.01 min.
S£p_4: (S)—tert—butyl (1-(3-bromofluorophenyl)(N-methyl nitrophenylsulfonamido)ethyl)carbamate. To a solution of N-methyl nitrobenzenesulfonamide (18.69 g, 86 mmol) in acetonitrile (400 ml) at room temperature was added KOH (10.21 g, 182 mmol, commercial, powder form). The resultant mixture was stirred at room temperature for about 15 minutes before (S)—tert—butyl 4-(3-bromo fluorophenyl)-1,2,3-oxathiazolidinecarboxylate 2,2-dioxide (36.1 g, 91 mmol) in 180 ml of CH3CN was added (addition was ed in 15- 20 minutes). The resultant mixture was stirred at room temperature for 1-2 hours. The reaction mixture was concentrated to about 200 ml of total volume. To the residue was added 600 ml of EtOAc, followed by g with 180 ml of 3N HCI, 200 ml of 1N NaOH, and brine (200 ml), twice. The solution was dried by Na2804, filtered through a filter funnel with celite ( ~30 g) and silica gel ( 20 g). The ed solution was concentrated to afford 40.3 grams of the product as a viscous liquid, which was used at the next step directly. (S)—tert-butyl (1-(3-bromo fluorophenyl)(N-methylnitrophenylsulfonamido)ethyl)carbamate: LC-MS: (MW + Na): 555.8 m/z at 1.07 min. (40.3 g, 76 mmol, 83 % yield).
S£p_5: (S)—N-(2-amino(3-bromofluorophenyl)ethyl)-N-methyl nitrobenzenesulfonamide hloride salt. To a solution of (S)—tert-butyl (1-(3-bromo fluorophenyl)(N-methylnitrophenylsulfonamido)ethyl)carbamate (40 g, 75 mmol) in DCM (420 ml) at room temperature was added HCI (4M in dioxane, 150 ml, 601 mmol).
The ant solution was stirred at room temperature for 4 hours during which time a white solid precipitated out. The reaction mixture was filtered, the white solid was washed with DCM ( 50ml x2), and vacumm dried to afford 23.8 grams of the desired product as a white solid. ( HCI salt). (S)—N-(2-amino(3-bromofluorophenyl)ethyl)-N-methyl enzenesulfonamide (23.8 g, 68 % yield over four steps). LC-MS: ( M+1): 433.9 m/z at 0.66 min. 1H NMR (400 MHz, <dmso>) ppm 2.86 (s, 3 H) 3.56 - 3.82 (m, 2 H) 4.61 (t, J=7.24 Hz, 1 H) 7.42 - 7.61 (m, 2 H) 7.68 (d, J=1.57 Hz, 1 H) 7.75 -8.05 (m, 4 H).
S nthesis of S -N- 2-amino 3-bromofluoro hen l eth l -N- 2-fluoroeth l nitrobenzenesulfonamide Brm\ [/0 N02 I ’8 F O/ ing steps 4 and 5 in scheme 83, using 1-bromofluoroethane, (S)—N-(2-amino (3-bromofluorophenyl)ethyl)-N-(2-fluoroethyl)nitrobenzenesulfonamide was obtained. LCMS (m/z): 464.1/466.1 (MH+), 0.71 min.
Example 182 S nthesis of 4- 3-amino 18 38 4S fluoroh drox c clohex l razin l-N- S - 1-( ofluorophenyl )—2-hyd roxyethyl )—2-fluorobenzamide Scheme 84 F o J< m1 F o J< m; F o F O Step g NH2 0 BoczN O OJ< BOCZN BocZN OJ< N/ 80620, MeCN N/ LiHMDS N’ Selectfluor N’ I I I I \ N —’ \ N —. —’ \ N \ N cat. DMAP TESCI MeCN 73—95% 84% (+/-) crude 0 0 OTES 0 F 0 J< mi F o J< Step e F 0 NH2 0 NH2 0 NaBHA chiral resolution NH2 0J< N / —> N / —.
\ IN 91% IN N ’ \= 830/ I = \ N = (+/-) : (+/.) g 40% 27% 44% Ste ; 4 "'F Q’F Rt: 1.84 min 4M HCI in dioxane MM_L_ OH polar M [g OH 60% (2 steps) p_0lar MMJ _HPLC + + + F O J< F o J< F O J< NH2 0 NH2 0 NH2 0 N / N / I I N / \ N K/N \ N (+/.) : +/_ ' ( ) 13% O 47% "’F Rt: 2.87 min _ "IF F 0 6H 5H F O J< F o F 0 {OH NH2 0 NH2 OH F $21 Stegg NH; NK/IN/ / /OH H g N/ ' ' In dioxane NK/IN 4M HCI \_ F EDC HOAt | , DIEA, DMF + HCI HZN \xN BI ' ' 33% (2 steps) ? CrLIde ”'F ”'F OH OH Q.'1F Ste 1. Imidodicarbonic acid 4- 3- tert-butox carbon | amino 4- oxoc clohex | razin lfluorobenzoate 1 3-bis 1 1-dimeth leth | ester To a solution of tert-butyl 4-(3-amino(4-oxocyclohexyl)pyrazinyl)-2—fluorobenzoate (3 g, 7.78 mmol) in acetonitrile (130 mL) was added Boc20 (6.33 mL, 27.2 mmol) and DMAP (0.048 g, 0.389 mmol). The on mixture was stirred overnight at room temperature.
After volatile materials were removed on rotavap under reduced pressure, the crude t was purified by flash chromatography eluting with 0-50% of heptane to provide imidodicarbonic acid, 4-(3-((tert-butoxycarbonyl)amino)(4- oxocyclohexyl)pyrazinyl)fluorobenzoate, 1,3-bis(1,1-dimethylethyl) ester (4.34 g, 7.41 mmol, 95%). LCMS (m/z): 586.5 (MH+), 1.24 min; 1H NMR (500 MHz, CHLOROFORM-d) 6 ppm 8.52 - 8.41 (m, 1H), 7.97 (t, J=7.7 Hz, 1H), 7.61 - 7.44 (m, 2H), 3.46 - 3.30 (m, 1H), 2.68 - 2.52 (m, 4H), 2.38 (dd, J=3.0, 13.7 Hz, 2H), 2.28 - 2.10 (m, 2H), 1.69 - 1.61 (m, 9H), 1.42 - 1.29 (m, 18H).
Step 2. lmidodicarbonic acid, 4-(3-((tert—butoxycarbonyl)amino)—6-(4- trieth lsil lox c clohexen l razin lfluorobenzoate 1 3-bis 1 1- dimethylethyl) ester To a solution of imidodicarbonic acid, 4-(3-((tert-butoxycarbonyl)amino)(4- oxocyclohexyl)pyrazinyl)fluorobenzoate, 1,3-bis(1,1-dimethylethyl) ester (12.1 g, .66 mmol) in THF (68.9 mL) was slowly added LiHMDS (1 M in THF) (22.73 mL, 22.73 mmol) at -78 °C. After stirring for 30 min, triethylchlorosilane (3.67 mL, 21.69 mmol) was added. The reaction mixture was warmed to room temperature and stirred for 1 h.
Saturated sodium bicarbonate solution was added, and the mixture was extracted with EtOAc. The c layer was washed well with water and brine, dried over ous NaHCOS, filtered off, and concentrated in vacuo. The crude product was purified by flash chromatography eluting with 5% of heptane to e imidodicarbonic acid, 4-(3- —butoxycarbonyl)amino)(4-((triethylsilyl)oxy)cyclohexenyl)pyrazinyl) fluorobenzoate, 1,3-bis(1,1-dimethylethyl) ester (12.1 g, 17.29 mmol). LCMS (m/z, neutral-nonpolar method): 701.8 (MH+), 1.14 min; 1H NMR (400 MHz, CDCI3) 6 ppm 8.41 (s, 1H), 8.00 - 7.88 (m, 1H), 7.57 - 7.46 (m, 2H), 4.97 (br. s., 1H), 3.16 - 3.00 (m, 1H), 2.49 - 2.38 (m, 2H), 2.38 - 2.23 (m, 1H), 2.19 - 1.94 (m, 3H), 1.61 (s, 9H), 1.33 (s, 18H), 1.06 - 0.94 (m, 8H), 0.77 - 0.64 (m, 6H).
Ste 3. lmidodicarbonic acid 4- 3- tert-butox carbon l amino 3-fluoro oxoc clohex l razin lfluorobenzoate 1 3-bis 1 1-dimeth leth l ester To a solution of imidodicarbonic acid, 4-(3-((tert-butoxycarbonyl)amino)(4- ((triethylsi|y|)oxy)cyclohexeny|)pyrazinyl)f|uorobenzoate, 1,3-bis(1,1- dimethylethyl) ester (12.1 g, 17.29 mmol) in acetonitrile (57.6 mL) was added Selectfluor® (7.96 g, 22.47 mmol) at 0 °C. The reaction mixture was warmed up to room temperature and stirred overnigt. After quenched with sat. NaHC03 solution, the reaction e was extracted with EtOAc. The organic layer was washed with water and brine, dried over Na2804, filtered and concentrated in vacuo to provide icarbonic acid, 4-(3-((tert- butoxycarbonyl)amino)(3-fluorooxocyclohexyl)pyrazinyl)fluorobenzoate, 1,3- bis(1,1-dimethylethyl) ester (10.44 g, 17.29, 100%), which was used for the next step without further purification. LCMS (m/z, neutral—nonpolar method): 604.3 (MH+), 1.12 min.
Ste 4. +/- -tert-but |4- 3-amino 1R 3R fluorooxoc clohex l razin l fluorobenzoate To a solution of lmidodicarbonic acid, 4-(3-((tert-butoxycarbonyl)amino)(3-fluoro oxocyclohexyl)pyrazinyl)fluorobenzoate, s(1,1-dimethylethyl) ester (10.44 g, 17.29 mmol) in THF (57.6 mL) was added 4 M HCI in dioxane (130 mL, 519 mmol) at room temperature. The reaction mixture was stirred for 3-4 h, which was monitored by LCMS to prevent more of the t-butyl ester from hydrolyzing to carboxylic acid. The reaction was cooled in water bath, and neutralized with saturated sodium carbonate. The resulting mixture was ted with EtOAc three times. The combined organic layers were washed with brine, dried over Na2804, filtered and concentrated. The residue was purified by flash tography eluting with 0-100% of EtOAc/heptane to provide (+/-)- utyl 4-(3-amino((1R,3R)—3-fluorooxocyclohexyl)pyrazinyl)f|uorobenzoate (1.9 g, 4.71 mmol, 27.2%) and tert-butyl 4-(3-amino((1S,3S)—3-fluoro lohexyl)pyrazinyl)—2-fluorobenzoate (926 mg, 2.295 mmol, 13.3%). LCMS (m/z): 404.3 (MH+), 0.84 min and 404.3 (MH+), 0.84 min respectively.
Ste 5. +/- -Tert-but |4- 3-amino 18 38 4S fluoroh drox c clohex l razin yl)—2-fluorobenzoate To a on of (+/-)-tert-butyl 4-(3-amino((1R,3R)—3-fluorooxocyclohexyl)pyrazin yl)f|uorobenzoate (1.9 g, 4.71 mmol) in MeOH (47.1 mL) was added NaBH4 (0.267 g, 7.06 mmol) at 0 °C. The reaction mixture was d for 2 h. After quenched with sat.
NaHC03 solution, the reaction mixture was extracted with EtOAc. The organic layer was washed with water and brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude product was purified by flash chromatography eluting with flat 35% of EtOAc in heptane to provide (+/-)-tert-buty| 4-(3-amino((1S,3S,4S)—3-fluoro hydroxycyclohexyl)pyraziny|)fluorobenzoate (839 mg, 2.07mmol, 43.9%) and (+/-)- tert-butyl 4-(3-amino((1R,3R,4R)—3-fluorohydroxycyclohexyl)pyraziny|) 2014/062913 fluorobenzoate (900 mg, 2.22 mmol, 47%). LCMS (m/z): 406.3 (MH+), 0.85 min and 406.3 (MH+), 0.85 min tively.
Ste 6. Tert-but |4- 3-amino 18 38 4S -3—fluoroh drox c clohex l razin l fluorobenzoate Tert-butyl 4-(3-amino((1S,3S,4S)fluorohydroxycyclohexyl)pyrazinyl)—2- fluorobenzoate (839 mg, 2.07mmol) was subjected to chiral tion (ChiralPak 5mic AD column, 4.6x100 (mm), OH+0.1% DEA=70/30, SFC=5m|/min) to provide single enantiomer tert-butyl 4-(3-amino((1S,3S,4S)fluorohydroxycyclohexyl)pyrazin-2— yl)fluorobenzoate (Rt = 1.61 min, 336 mg, 0.829 mmol, 40%) and the less polar enantiomer (Rt = 2.45 min, 43%).
Ste 7. 4- 3-amino 18 38 4S fluoroh drox c clohex l razin l fluorobenzoic acid To a solution of tert-butyl utyl 4-(3-amino((1S,3S,4S)—3-fluoro hydroxycyclohexyl)pyrazin-2—yl)—2-fluorobenzoate (90 mg, 0.22 mmol) in DCM (0.444 mL) was added 4 M HCI in dioxane (3.7 mL, 14.80 mmol). The reaction mixture was stirred overnight at room temperature. After the volatile materials were evaporated in vacuo, the reaction e was triturated with Et2O, and filtered off to provide 4-(3-amino ((1S,3S,4S)fluorohydroxycyclohexyl)pyrazinyl)f|uorobenzoic acid (86 mg, 0.22 mmol, 100%) as a HCI salt, which was used for the next step without any further purification. LCMS (m/z): 350.2 (MH+), 0.51 min.
Ste 8. 4- 3-amino 18 38 4S fluoroh drox c clohex l razin l-N- S 3- bromofluorophenyl)—2-hydroxyethyl )—2-fluorobenzamide To a solution of 4-(3-amino((1S,3S,4S)fluorohydroxycyclohexyl)pyrazinyl)—2- fluorobenzoic acid (20 mg, 0.057 mmol) in DMF (573 uL) was added (S)amino(3- bromofluorophenyl)ethanol HCI salt (18.59 mg, 0.069 mmol), aza-HOBt (11.69 mg, 0.086 mmol), EDC (21.95 mg, 0.115 mmol), and DIEA (30.0 ul, 0.172 mmol). The reaction mixture was d for 15 h. Water was added, and the reaction mixture was extracted with EtOAc three times. The organic layers were dried over NazSO4, filtered and concentrated in vacuo. The crude product was purified by HPLC. Pure fractions were lyophilized to provide 4-(3-amino((1S,3S,4S)fluorohydroxycyclohexyl)pyrazin 2014/062913 ((S)(3-bromofluorophenyl)hydroxyethyl)f|uorobenzamide (12.9 mg, 0.019 mmol, 32.8%) as a TFA salt. LCMS (m/z): 565.1/567.1 (MH+), 0.72 min; 1H NMR (400 MHz, CD3OD) 6 ppm 7.78 (s, 2H), 7.63 - 7.47 (m, 2H), 7.37 (s, 1H), 7.22 - 7.02 (m, 2H), .15 - 5.03 (m, 1H), 4.43 - 4.15 (m, 1H), 3.77 (t, J = 5.7 Hz, 2H), 3.62 - 3.47 (m, 1H), 2.76 (br. s., 1H), 2.19 (dd, J: 3.1, 6.3 Hz, 1H), 2.02 - 1.92 (m, 1H), 1.89 - 1.66 (m, 2H), 1.56 (dd, J = 3.3, 12.3 Hz, 1H), 1.42 (br. s., 1H). The absolute stereochemistry was determined based on the information of X—ray co-structure of 4-(3-amino((1S,3S,4S)—3-fluoro hydroxycyclohexyl)pyrazinyl)—N-((S)(3-bromofluorophenyl)hydroxyethyl) fluorobenzamide.
Example 183 S nthesis of 4- 3-amino 1R 3R 4R fluoroh drox c clohex | razin l-N- S - 1- 3-bromofluoro hen lh drox eth lfluorobenzamide Scheme 85 F o J< F o F o {oH NH2 0 NH2 OH F Step 1 NH2 OH Step g N N / N / _/ I I = N / \ N 4M HCI In dioxane_ . \ N F EDC, HOAt I DIEA, DMF HCI HZN + \ N Br 41% (2 steps) crude F F L L F 6H 6H fluorobenzoic acid To a solution of tert-butyl 4-(3-amino((1R,3R,4R)fluorohydroxycyclohexyl)pyrazin- 2-y|)fluorobenzoate (Scheme 84: 365 mg, 0.9 mmol) in DCM (2 mL) was added 4 M HCI in dioxane (8 mL, 32.0 mmol). The reaction mixture was stirred for 3 days at room temperature. After the volatile materials were ated in vacuo to yield 4-(3-amino ((1R,3R,4R)—3-fluorohydroxycyclohexyl)pyrazinyl)fluorobenzoic acid, which was used for the next step without further purification. LCMS (m/z): 350.3 (MH+), 0.48 min.
Ste 2. 4- 3-amino 1R 3R 4R oroh drox c clohex | razin l-N- S 3- bromofluorophenyl)—2-hydroxyethyl )—2-fluorobenzamide To a solution of 4-(3-amino((1R,3R,4R)—3-fluorohydroxycyclohexyl)pyrazinyl) fluorobenzoic acid (20 mg, 0.057 mmol) in DMF (573 uL) was added (S)—2-amino(3- bromofluorophenyl)ethanol HCI salt (18.59 mg, 0.069 mmol), aza-HOBt (11.69 mg, 0.086 mmol), EDC (21.95 mg, 0.115 mmol), and DIEA (30.0 pl, 0.172 mmol). The reaction mixture was stirred for 15 h. Water was added, and the reaction e was extracted with EtOAc three times. The organic layers were dried over Na2804, ed and concentrated in vacuo. The crude product was purified by HPLC. Pure fractions were lyophilized to provide 4-(3-amino((1R,3R,4R)—3-fluorohydroxycyclohexyl)pyrazin yl)-N-((S)(3-bromofluorophenyl)hydroxyethyl)f|uorobenzamide (16.1 mg, 0.023 mmol, 41%) as a TFA salt. LCMS (m/z): 565.1/567.1 (MH+), 0.72 min; 1H NMR (400 MHz, CD3OD) 6 ppm 7.86 - 7.69 (m, 2H), 7.65 - 7.47 (m, 2H), 7.40 - 7.30 (m, 1H), 7.22 - 7.06 (m, 2H), 5.08 (t, J=5.7 Hz, 1H), 4.41 - 4.14 (m, 1H), 3.85 - 3.67 (m, 2H), 3.63 - 3.48 (m 1H), 2.74 (t, J=11.5 Hz, 1H), 2.17 (td, J=3.1, 6.3 Hz, 1H), 2.04 - 1.89 (m, 1H), 1.84 - 1.66 (m, 2H), 1.65 - 1.30 (m, 2H). The absolute stereochemistry was determined based on the information of X—ray co-structure in ERK2 of 4-(3-amino((1R,3R,4R)—3-fluoro—4- hydroxycyclohexyl)pyrazinyl)—N-((S)(3-bromofluorophenyl)hydroxyethyl) fluorobenzamide.
Example 184 S nthesis of 4- 3-amino 18 38 4S f|uoroh drox c clohex | razin l-N- S - 1- 3-bromofluoro hen | meth lamino eth | f|uorobenzamide Scheme 86 E 5 DMF DIEA Br HOZCQ "'F Q Ste 1. 4- o 18 38 4S fluoroh drox c clohex | razin l-N- S 3- bromofluoro hen l N-meth lnitro hen namido eth lfluorobenzamide To a solution of 4-(3-amino((1S,3S,4S)fluorohydroxycyclohexyl)pyrazinyl) benzoic acid (156 mg, 0.403 mmol) in DMF (1.28 mL) was added (S)—N-(2-amino (3-bromofluorophenyl)ethyl)-N-methylnitrobenzenesulfonamide (180 mg, 0.384 mmol), HOAt (105 mg, 0.768 mmol), DIEA (402 pl, 2.8 mmol), and EDC.HC| (147 mg, 0.768 mmol). The reaction mixture was stirred at room temperature for 15 h, LCMS indicated the t. The mixture was diluted with EtOAc and washed with water and once with saturatedd Na2C03 and the organic layer was dried (magnesium sulfate), filtered and concentrated in vacuo providing 4-(3-amino((1S,3S,4S)—3-fluoro hydroxycyclohexyl)pyrazinyl)-N-((S)—1-(3-bromofluorophenyl)(methylamino)ethyl)- 2-fluorobenzamide. The crude t was purified by ISCO column chromatography (0- 100% EtOAc in heptane) leading to 4-(3-amino((1S,3S,4S)—3-fluoro-4— hydroxycyclohexyl)pyrazinyl)-N-((S)(3-bromofluorophenyl)(N-methyl nitrophenylsulfonamido)ethyl)fluorobenzamide (99%).
Ste 2. 4- o 18 38 4S fluoroh drox c clohex l razin l-N- S 3- bromofluorophenyl)—2-( methylamino)ethyl )—2-fluorobenzamide To a solution of 4-(3-amino((1S,3S,4S)fluorohydroxycyclohexyl)pyrazinyl)-N- ((S)—1-(3-bromofluorophenyl)(N-methylnitrophenylsulfonamido)ethyl) fluorobenzamide (293 mg, 0.38 mmol) in DMF (3.8 mL) was added K2C03 (371 mg, 2.69 mmol) and 4-mercaptobenzoic acid (207 mg, 1.34 mmol). The reaction mixture was heated in microwave synthesizer at 45 °C for 55 min. After the reaction, water was added, and the mixture was extracted with EtOAc three times. The organic layers were ed and washed with water three times. The combined organic layer was dried over sodium sulfate, filtered off, and concentrated in vacuo. The residue was purified with flash tography eluting with EtOAc (containing 20% MeOH and 0.5 % ammonia in water )/DCM to provide 150 mg of 4-(3-amino((1S,3S,4S)—3-fluoro hydroxycyclohexyl)pyrazinyl)-N-((S)—1-(3-bromofluorophenyl)(methylamino)ethyl)- 2-fluorobenzamide. LCMS (m/z): 578, 580 (MH+), 0.64 min. 1H NMR (400 MHz, CDSOD) 8 ppm 7.80 (s, 1H), 7.76 - 7.68 (m, 1H), 7.59 (dd, J=1.6, 7.8 Hz, 1H), 7.53 (dd, J=1.2, 11.7 Hz, 1H), 7.37 (s, 1H), 7.18 (d, J=8.2 Hz, 1H), 7.11 (d, J=9.4 Hz, 1H), 5.27 - 5.10 (m, 1H), 4.42 - 4.13 (m, 1H), 3.65 - 3.49 (m, 1H), 2.97 - 2.88 (m, 1H), 2.87 - 2.79 (m, 1H), 2.74 (t, J=11.7 Hz, 1H), 2.35 (s, 3H), 2.22 - 2.11 (m, 1H), 2.04 - 1.92 (m, 1H), 1.85 - 1.68 (m, 2H), 1.55 (dq, J=3.1, 12.9 Hz, 1H), 1.46 - 1.33 (m, 1H). 2014/062913 Alternatively, mino((18,38,4S)fluorohydroxycyclohexyl)pyrazin yl)-N-((S)(3-bromofluorophenyl)(methylamino)ethyl)fluorobenzamide can be synthesized as follows: ,4S)—ethyl 4-( (tert-butyldimethylsilyl )oxy)—3-fluorocyclohexanecarboxylate COOEt COOEt TBSCI "’F "’F OH OTBS To a 500 mL flask was added (1 S)—ethyl rohydroxycyclohexane- carboxylate (17 g, 89.3 mmol, 97.9% ee), TBSCI (17.5 g, 116.1 mmol) and DCM (200 mL). Imidazole ( 12.1 g, 178 mmol) was added to the resultant clear solution and the reaction mixture was d for 16 hours. Water (100 mL) was added and the mixture was stirred for a further 10 minutes. The phases were separated and the organic layer was washed with water (100 mL) and concentrated under reduced pressure (40:5 °C, 50 ~ 250 mbar). Purification by flash chromatography on silica eluting with a mixture of heptane and ethyl acetate (100:1) gave (1R,3S,4S)—ethyl 4-((tert-butyldimethylsilyl)oxy) fluorocyclohexanecarboxylate as a colorless oil (20.6 g, yield 75.7%). 1H NMR (400MHz, DMSO-ds): 4.38 ~ 4.52 (m, 1 H), 4.03 ~ 4.08 (dd, J: 1 2 Hz, J: 8 Hz, 2 H), 3.77 ~ 3.81( m, 1 H), 2.54 ~2.60 (m, 1 H), 1.93 ~2.06 (m, 1 H), 1.58 ~ 1.86 (m, 4 H), 1.46~1.50 (m, 1 H), 1.17 ~ 1.20 (t, J: 12 Hz, J: 6 Hz, 3 H), 0.85( s, 9 H), 0.03 ~ 0.04 (d, J: 4 Hz, 8 H), [M+H]+= 305.1 via GC-MS (Instrument: Agilent logies, GC 6890N, MS 5975C.
GC conditions: Column : HP — 5 MS, Capillary: 30.0 m x 250 um x 0.25 pm, Detecor parameters: Temperature: 350 °C, Flow H2 : 40 mL / min, Airflow: 400 mL / min, Makeup (He): 40 mL / min. Injector parameters: temperature : 200 °C. Split ratio: 100:1. Carrier gas: He, Flow: 2.0 mL/ min, Mode: Constant flow. Oven parameters: 0 min, 50 °C; 2.0 min, 50 °C; 5.33 min, 100 °C; 15.83 min, 270 °C. Injection volume: 1 uL, Syringe wash solvent: acetonitrile. MS conditions: Volt: 70 EV, Scan range: m/z = 50 ~ 550) 24- tert-but ldimeth lsil lox fluoroc clohex l 2 5-dimeth l-1H- rrol l razine A A A A A A A NH} NIJ; ”(j N|\ NJ}/ COzEt N)\ N /N /N N /N bN I N)\ + ? 002H + —’ —> =C02El + ”C02Et —> + .u002H F /N OTBSF u, u, OTBSF OTBSF F F w .,l ,F F 3' 0TBS 0TBS onss OTBS overall yield of 4 steps: 51.8% To a 1 L flask was added 2-bromo(2,5-dimethyl-1H-pyrrolyl)pyrazine (23 g, 67 mmol), ,4S)—ethyl 4-((tert-butyldimethylsilyl)oxy) fluorocyclohexanecarboxylate (28 g, 83 mmol), {[P(t—Bu)3]PdBr}2 (800 mg, 1 mmol) followed by toluene (250 mL). The reaction mixture was degased three times by purging with nitrogen and then cooled to -35i5°C. To the reaction mixture was added NaHMDS (47 mL, 2 M in THF, 94 mmol), dropwise. The temperature was raised to room temeperature over a one hour period and stirred for a further 30 minutes. The reaction mixture was quenched with 8% aqueous ammonium chloride (200 mL), the phases ted, and the aqueous layer extracted with heptane (300 mL). The combined organic layer was washed with 10% brine (400 mL), concentrated under reduced pressure(45i5 °C, 50 ~ 100 mbar) to give 48 g of (1RS,3S,4S)-ethyl 4-((tertbutyldimethylsilyl 1-(5-(2,5-dimethyl-1H-pyrrolyl)pyrazinyl) fluorocyclohexanecarboxylate as a mixture of 1R and 1S diastereomers. This material was used for next step without further purification. HPLC retention time = 8.274 min HPLC method d: Instrument : Agilent Technologies 1200 series. Column: Waters Xbridge C18, 150*3.0 mm, 3 um. Column temperature: 35 oC. Flow rate: 0.70 mL / min.
Detection: 210 nm/ DAD. Mobile phase composition: A: 0.1% H3PO4 in water; B: acetonitrile. Gradient: 0 min: 90% A, 10% B; 5 min: 100% B; 11 min 100% B. LC-MS method: [M+H]+= 476.2706, 1H NMR(400MHz, DMSO-ds): 8.47 (s. 1 H), 8.43 (s, 1 H), .85(s, 2 H), 4.39 ~ 4.52 (m, 1 H), 4.14 (dd, J =1 2 Hz, J = 8 Hz, 2 H), 3.59 ~ 3.66 (m, 1 H), 2.28 ~ 2.94 (m, 1H), 2.06 (s, 6 H), 1.84 ~ 1.97 (m, 3 H), 1.46 ~ 1.52 (m, 3 H), 1.14 ~ 1.17 (t, J: 1 2 Hz, J: 8 Hz, 2H), 0.81 (s, 9 H), 0.01( d, J: 4 Hz, 6 H).
To a 1 L flask was added ,4S)—ethyl rt-butyldimethylsilyl)oxy)(5- (2,5-dimethyl-1H-pyrrolyl)pyrazinyl)fluorocyclohexanecarboxylate (48g, 67 mmol), ethanol (250 mL) followed by 11% aqueous NaOH solution (112 g, 300 mmol). The on e was stirred at 30:5 °C for 16 hours, and then was quenched with 10% aqueous HCI (70 mL) to pH = 6~7. After distillation of ethanol under reduced pressure (50:5 °C, 50 ~ 100 mbar), the pH of the resulting mixture was adjusted to between 4 and with 10% HCI. The aqueous solution was extracted twice with lPAc (200 mL X2). The combined organic layers were washed with 10% brine (200 mL) and concentrated under reduced pressure (50:5 °C, 50 ~ 100 mbar) to give 46 g of (1RS,3S,4S)((tert- imethylsilyl)oxy)(5-(2,5-dimethyl-1H-pyrrolyl)pyrazinyl) cyclohexanecarboxylic acid which was used for next step without further purifications. HPLC retention time = 7.390 min (Instrument: Agilent logies 1200 series. Column: Waters Xbridge C18, 150*3.0 mm, 3 um. Column ature: 35 OC.
Flow rate: 0.70 mL / min. Detection: 210 nm/ DAD. Mobile phase composition: A: 0.1% H3PO4 in water; B: acetonitrile. Gradient: 0 min: 90% A, 10% B; 5 min: 100% B; 11 min 100% B), LC-MS: [M+H]+= 448.2415.
To a 500 mL flask was added (1 4S)—4-((tert-butyldimethylsilyl)oxy)(5- (2,5-dimethyl-1H-pyrrolyl)pyrazinyl)fluorocyclohexanecarboxylic acid (46 g), toluene (250 mL) and HOAc (0.8 g, 13.3mmol) under nitrogen. The reaction mixture was refluxed for 1 hour and then cooled to room ature before adding 6% aqueous NaHC03 (200 mL). The phases were separated and the aqueous layer was extracted with heptane (250 mL). The combined organic layer was washed with 10% brine (200 mL) and trated under reduced pressure (50:5 °C, 50 ~ 100 mbar) to give an oil.
After the addition of 80 mL methanol to the residue, the mixture was heated to 55:5 °C and stirred for 1 hour. The temperature was cooled to 25:5 °C over a 2 hour period and stirred for a further 2-3 hours. The ing suspension was filtered and the wet cake was dried under reduced re (50:5 °C, 50 ~ 100 mbar) for 3 hours to give 8.6 g of 2-((1S,3S,4S)—4-((tert-butyldimethylsilyl)oxy)fluorocyclohexyl)(2,5-dimethyl-1H- pyrrolyl)pyrazine as a crystalline solid (dr > 99:1 ). The mother liquor was concentertaed under reduced pressure (50:5 °C, 50 ~ 100 mbar) to give 34.5 g (71 mmol) dark oil. To this residue was added tBuOH (200 mL), followed by tBuOK (8.0 g, 71 mmol). The reaction e was heated to 90:5 °C and stirred for 3 hours. After the temperature was cooled to room temperature, 10% aqueous NaHC03 (150 mL) was added followed by heptane (200 mL) and the mixture was stirred for a further 10 minutes.
The phases were separated and the aqueous layer was washed with heptane (200 mL).
The combined organic layers were washed with 10% brine (150 mL) and concentrated under reduced pressure (50:5 °C, 50 ~ 100 mbar) to give an oil residue. To this residue WO 66188 was added methanol (60 mL), and the mxiture was heated to 55:5 °C. After stirring for 1 hour, the temperature was cooled to 25:5 °C over a 2 hour period followed by stirring for a further 2 hours. The suspension was filtered and the resulting wet cake was dried under reduced pressure (50:5 °C, 50 ~ 100 mbar) for 3 hours to give the second batch of 24- tert-but ldimeth lsil lox oroc clohex l 2 th l-1H- pyrrolyl)pyrazine as a crystalline solid (5.6 g, dr = 98:2). The overall yield of the 4 steps starting from 2-bromo(2,5-dimethyl-1H-pyrrolyl)pyrazine is 51.8%. mp = 100.6°C ~ 102.9 °C. LC/MS: [M+H]+= 404.2459, 1H NMR(400MHz, DMSO-de): 8.53 (s, 1 H), 8.50 (s, 1 H), 5.75 (s, 2 H), 4.25 ~ 4.43 (m, 1 H), 3.60 ~ 3.69 (m, 1 H), 3.25 (s, 6 H), 2.93 ~ 3.00 (m, 1 H), 2.19 ~ 2.27 (m, 1 H), 1.98 (s, 6 H), 1.72 ~ 1.90 (m, 3 H), 1.39 ~ 1.61 (m, 2 H), 0.80 (s, 9H), 0.01 (d, J: 4 Hz, 6 H)., HPLC (Instrument : t Technologies 1200 series. Column: Waters Xbridge C18, 150*3.0 mm, 3 um. Column temperature: 35 oC. Flow rate: 0.70 mL / min. Detection: 210 nm/ DAD. Mobile phase composition: A: 0.1% H3PO4 in water; B: acetonitrile. Gradient: 0 min: 90% A, 10% B; 5 min: 100% B; 11 min 100% B) retention time: 8.084 min for 2-((1S,3S,4S)—4-((tert—butyldimethylsilyl)oxy)—3- fluorocyclohexyl)(2,5-dimethyl-1H-pyrrolyl)pyrazine, 8.324 min for 2-((1R,3S,4S)—4- ((tert-butyldimethylsilyl)oxy)fluorocyclohexyl)(2,5-dimethyl-1H-pyrrolyl)pyrazine. 2-bromo 2 5-dimeth l-1H- rrol l razine NI \8N8o N /N —> I/N BI‘ Br To a 250 mL flaks was added 5-bromopyrazinamine (18 g, 10.35 mmol), hexane-2,5-dione (14.5g, 12.41 mmol) and PPTS (0.9 g, 0.36 mmol) in toluene (60 mL).
The reaction mixture was heated to reflux in a Dean-Stark trap for 16 hours. The reaction mixture was cooled to room rature and then concentrated under reduced pressure (55:5 °C, 50 ~ 100 mbar) to give 2-bromo 2 5-dimeth l-1H- rrol l razine as an oil (28 g, containing ~10% toluene : 95%). This material was used t , assay yield further purification. LC/MS: [M+H]+= 252.0139, 1H NMR(400MHz, DMSO-de): 8.87 (s, 1H), 8.63 (s, 1 H), 5.86 (s, 2 H), 2.10 (s, 6 H). HPLC retention time = 6.21 min, Instrument: Agilent Technologies 1200 . Column: Waters Xbridge C18, 150*3.0 2014/062913 mm, 3 um. Column temperature: 35°C. Flow rate: 0.70 mL / min. Detection: 210 nm/ DAD. Mobile phase composition: A: 0.1% H3PO4 in water; B: acetonitrile. Gradient: 0 min: 90% A, 10% B; 5 min: 100% B; 11 min 100% B. 54- tert-but Idimeth lsil lox fluoroc clohex l razinamine N H2N NJ}. NJ} K/N NHZOH.HC| \ N E —> ? "'F F OTBS OTBS To a stirred suspension of 2-((1S,3S,4S)—4-((tert-butyldimethylsilyl)oxy)—3- cyclohexyl)(2,5-dimethyl-1H-pyrrolyl)pyrazine (1250 g, 3097 mmol) in ethanol (7.5 kg) was added hydroxylamine hloride (860.9 g, 12388.2 mmol) followed by triethylamine (642.5 g, 6349.0 mmol). The on mixture was heated to reflux (77-78 °C) for 42 hours, and then cooled to about 40°C. After distillation of 6 kg of ethanol under vacuum (<100 mbar ) at 40°C, the mixture was cooled to room temperature, diluted with MTBE (7.0 kg) and water (8.0 kg). After stirring for 10 minutes, the organic layer was separated and the aqueous layer was extracted with MTBE (6.0 Kg). The combined organic layers were washed successively with 2X12 kg of water and 8 kg of 10% brine.
The MTBE layer was concentrated under vaccum (<100 mbar ) to give 1.2 kg yellow solid as crude product. The crude product was dissolved in 2 kg DCM and further purified via silica column chromatography g with EtOAc and e (1/6, v/v) to recover 2- ((1S,3S,4S)—4-((tert—butyldimethylsilyl)oxy)fluorocyclohexyl)(2,5-dimethyl-1H-pyrrol- 1-yl)pyrazine (310 g), then eluting with EtOAc and heptane (1/3, v/v) to give 54- tert-but Idimeth lsil lox fluoroc clohex l razinamine (650 g, 64.5 % yield) as light yellow solid, mp 113-116 °C. ESl-MS (m/z): 326.1940 ([M+H]+, 100). HPLC (method A), retention time 12.26 min. 1H NMR (400 MHz, CDCI3): 7.93 (s, 1H), 7.86 (s, 1H), 4.50 (br. s, 2H), 4.41-4.46, 4.27-4.31 (m, 1H), 3.65-3.74 (m, 1H), 2.68- 2.74 (m, 1H), 2.24-2.30 (m, 1H), 1.97-2.02 (m, 1H), 1.74-1.87 (m, 2H), 1.44-1.63 (m, 2H), 0.91 (s, 9H), 0.10 (d, J = 8Hz, 6H). ut |4- 3-amino 18 38 4S tert—but Idimeth Isil |0X fluoroc clohex l razin lfluorobenzoate o O F F O HZN HzN 0 N23 NJYBF o’B‘o N ’ /T : E ; QWF QWF Pd(dppf)C|2 DCM, , DME, reflux Q'UF OTBS 0TBS OTBS A solution of 5-((1S,3S,4S)—4-((tert-butyldimethylsilyl)oxy)—3- fluorocyclohexyl)pyrazinamine (620.0 g, 1904.8 mmol) in DMSO (5 L) and water (400 mL) was cooled to ~4 °C. NBS (389.8 g, 2190.5 mmol) was added in 10 ns within 1 hour and the reaction temperature was controlled under 5°C with continuous stirring for minutes. After addition of 0.3 M aqueous Na2C03 (8.5 kg) the reaction temperature was increased to 35°C. MTBE (4.5 kg) was added and the mixture was stirred for a further 10 minutes. After phase separation, the aqueous layer was extracted with MTBE (4 kg). The combined organic layers were washed successively with 0.3 M s Na2C03 (8.5 kg) and water (8 kg), and concentrated under vacuum at 30-40°C to give crude product 3-bromo((1S,3S,4S)—4-((tert-butyldimethylsilyl)oxy)—3- fluorocyclohexyl)pyrazinamine as a foam (770 g). This crude product was used in next step without further purification. ESl-MS (m/z): 404.1105, 406.1093 ([M+H]+, 100). HPLC (method A), retention time = 14.38 min. 1H NMR (400 MHz, CDCI3): 7.81 (s, 1H), 4.99 (br. s, 2H), .42, 4.25-4.30 (m, 1H), .72 (m, 1H), 2.67-2.73 (m, 1H), 2.26-2.29 (m, 1H), 1.97-2.02 (m, 1H), 1.74-1.87 (m, 2H), 1.44-1.63 (m, 2H), 0.91 (s, 9H), 0.10 (d, J = 8 Hz, 6H).
To a solution of 3-bromo((1S, 3S, 4S)—4-((tert-butyldimethylsilyl)oxy)—3- fluorocyclohexyl)pyrazinamine (760.0 g, 1879.4 mmol) and tert—butyl 2-fluoro ,5-tetramethyl-1,3,2-dioxaborolanyl)benzoate (605.5 g, 1879.4 mmol) in DME (3.0 kg) was added 2.0 M aqueous Na2C03 (1880 mL, 3760 mmol) and Pd(dppf)C|2-DCM (38.4 g, 47.0 mmol). After degassing with N2 three times, the reaction mixture was heated to reflux (79-80 °C) and stirred at this temperature for 3 hours. The reaction temperature was cooled to room temperature and MTBE (2.5 kg) was added followed by water (4.0 kg). The mixture was stirred for 10 minutes before phase separation, and the aqueous layer was extracted with MTBE (1.8 kg). The ed organic layers were washed with water (2X4 kg), and concentrated under vacuum at 30-40 °C to give crude product tert—butyl 4-(3-amino((1S, 3S, 4S)—4-((tert-butyldimethylsilyl)oxy) fluorocyclohexyl)pyrazinyl)f|uorobenzoate (ca. 1 kg). The mixture of this crude product and EtOH (95%, 3.2 kg) was heated to reflux (78-80°C) for 30 minutes to give a solution. The temperature was cooled to 40°C within 100 minutes followed by addtion of water (800 g) within 30 minutes. The temperature was cooled to ~5°C within 100 minutes and stirring at this temperature was continued for a further 60 s. The solid precipitation was filtered and the wet cake was washed with EtOH/water (1.2 L, 5/1, l). After drying under vaccum at 50°C for 5 hours, tert—butyl 4-(3-amino((1S, 38, 4S tert-but h lsil lox fluoroc clohex l razin uorobenzoate was obtained as a brown powder (755g, 76.4% yield over 2 steps, assay purity is 98.8%). mp 169-172 °C. ESl-MS (m/z): 520.2739 ([M+H]+, 100). HPLC (method A) retention time .76 min. 1H NMR (400 MHz, CDCI3): 7.98 (t, J = 8 Hz, 1H), 7.91 (s, 1H), 7.61 (d, J = 8 Hz, 1H), 7.55 (d, J = 8 Hz, 1H), 4.68 (br. s, 2H), 4.42-4.48, 4.30-4.36 (m, 1H), 3.67-3.76 (m, 1H), .83 (m, 1H), 2.28-2.36 (m, 1H), 1.98-2.05 (m, 1H), 1.83-1.92 (m, 2H), 1.46- 1.68 (m, 2H), 1.62 (s, 9H), 0.92 (s, 9H), 0.11 (d, J = 8 Hz, 6H). 4- 3-amino 183848 fluoroh drox c clohex l razin lfluorobenzoic acid \2 N i) HCI, EtOH \ N "’F ii) NaOH Q’F OTBS To a suspension of tert—butyl 4-(3-amino((1S, 3S, 4S)—4-((tert- butyldimethylsilyl)oxy)fluorocyclohexyl)pyraziny|)fluorobenzoate (685.0 g, 1318.0 mmol) in EtOH (3.6 kg) was added aqueous HCI (36%, 400.5 g, 3954.2 mmol). The reaction e was heated to 30°C and stirred for 4 hours. The reaction temperature was lowered to 5°C and a on of NaOH (342.7g, 8567.5 mmol) in water (1.6 kg) was added. The reaction mixture was heated to 30°C and stirred at this temperature for 18 hours. The pH of the reaction mixture was adjusted to 5 using 4 N aqueous HCI to form a solid itation. After distillation of EtOH under vacuum at 40-50 °C, water (2.5 kg) was added to the residue and the ature was cooled to 5°C within 1 hour. The suspension was filtere, the solid was collected and dried under vacuum (<100 mbar) at 50-60°C for 24 hours to give 4-(3-amino((1S,3S,4S)—3-fluoro hydroxycyclohexyl)pyrazin-2—yl)fluorobenzoic acid as a brown powder (460 g, HPLC purity at 230 nm was 98.2%, quantitative yield). Mp 226-228 °C. ESl-MS (m/z): 350.1282 +, 100). HPLC (method A), retention time 5.93 min. 1H NMR (400 MHz, DMSO-D6): 13.32 (br. s, 1H), 8.00 (t, J = 8 Hz, 1H), 7.99 (s, 1H), 7.70 (d, J = 8 Hz, 1H), 7.65 (d, J = 8 Hz, 1H), 6.24 (br. s, 2H), 5.16 (br. s, 1H), 4.44—4.49, 4.30-4.35 (m, 1H), 3.50-3.60 (m, 1H), 2.79-2.84 (m, 1H), 2.20-2.25 (m, 1H), 1.92—1.99 (m, 1H), 1.72-1.83 (m, 2H), 1.50-1.60 (m, 1H), 1.36-1.46 (m, 1H). 4- 3-amino 183848 fluoroh drox c clohex l razin l-N- S 3-bromo fluoro hen l meth lamino eth lfluorobenzamide I: ] : | SQ2 302 F O /NH N NO ' F O :/ \ 2 F O {N\ N02 F ' F : NHZ N OH H2N ' F H H N2 NH2 _ N NI \ N/ HCI N \ LiOH DMF {N Br K!“ Br bN , : —. = : o EDCI, HOAT "’F ”F "IF OH OH OH HS To a solution of 4-(3-amino((1S,3S,4S)—3-fluorohydroxycyclohexyl)pyrazin yl)fluorobenzoic acid (300 g, 95% assay, 815.8 mmol) and (S)—N-(2-amino(3- -fluorophenyl)ethyl)-N-methy|nitrobenzenesulfonamide hydrochloride (397.7 g, 848.5 mmol) in DMF (2.5 kg) was added DIPEA (421.8 g, 3263.4 mmol), followed by EDCI (312.8 g, 1631.7 mmol) and HOAt (222.1g, 1631.7 mmol). Afterthe on mixture was stirred at 25 °C for 18 hours, the reaction temperature was lowered to 10°C before IPAC (3.5 kg) and water (4.0 kg) was added. The mixture was stirred for 10 minutes and then the layers were separated. The aqueous layer was extracted with IPAC (2.5 kg). The combined organic layers were washed successively with 10% aqueous Na2C03 (4.5 kg) and water (2X4 kg), and then concentrated under vacuum (<100 mbar) at 40-45 °C to give 4-(3-amino((1S,3S,4S)—3-fluorohydroxycyclohexyl)pyraziny|)- N-((S)—1-(3-bromo—5-fluorophenyl)(N-methylnitrophenylsulfonamido)ethyl) fluorobenzamide as a foam (670 g, assay purity is 93%), which was used in next step without further purification. ESl-MS (m/z): 16, 765.1161 +, 100). Mp=115- 117 OC. HPLC (method A), retention time = 10.57 min. 1H NMR (400 MHz, CDCI3): 8.11 (t, J = 8 Hz, 1H), 7.99 (m, 1H), 7.91 (s, 1H), 7.59-7.72 (m, 5H), 7.35 (s, 1H), 7.19 (d, J = 8 Hz, 1H), 7.09 (d, J = 8 Hz, 1H), 5.46 (br. s,1H), 4.77 (br. s, 2H), 4.48-4.55, 4.35-4.42 (m, 1H), 3.93 (q, J1 = 12 Hz, J1 = 16 Hz, 1H), 3.73-3.82 (m, 1H), 3.33 (q, J1 = 4 Hz, J1= 12 Hz, 1H), 3.00 (s, 3H), 2.78-2.85 (m, 1H), 2.31-2.37 (m, 1H), 2.12-2.20 (m, 1H), 1.84- 1.96 (m, 2H), 1.60-1.71 (m, 1H), .56 (m, 1H).
To a suspension of 4-(3-amino((1S,3S,4S)—3-fluorohydroxycyclohexyl)-pyrazinyl)- N-((S)—1-(3-bromofluorophenyl)(N-methylnitrophenyl-sulfonamido)ethyl) fluorobenzamide (500 g crude product from previous step) in DMF (2.0 kg) was added 4- mercaptobenzoic acid (161.5 g, 1047.7 mmol). The on mixture became a solution after 5 minutes and then was cooled to 10°C. After addition of LiOH-H20 (137.3 g, 3274.0 mmol) in one portion, the mixture was stirred at 25°C for 3 hours before the ature was cooled to 10°C. The reaction mixture was diluted with water (3.0 kg) and extracted with IPAC (3*2.5 kg). The IPAC layers was first washed with 15% aqueous Na2C03 (2*3.0 kg) followed by water (2*3.0 kg), and then trated under vacuum (<100 mbar) at 40-45 °C. To the resulting residue was added MeCN (1.8 kg) to give a clear solution, which was heated to 50°C and stirred for 30 minutes. The mixture was further cooled to 10°C in 2 hours and d at this temperature for a further 1 hour. After filtration of the resulting suspension, the solid cake was washed with pre-cooled MeCN (400 g, 5 °C). The wet cake was dried under vacuum (<100 mbar) at 80°C for 18 hours to give 4- 3-amino 1S 3848 fluoroh drox c clohex l razin l -N- S 3- bromofluorophenyl)—2-(methylamino)ethyl)—2-fluorobenzamide as a crystalline solid (245 g, overall yield for 2 steps is 66%, HPLC purity = 98.3%, chiral purity = 99.0% ). Mp 115-117°C. ESl-MS (m/z): 578.1381, 580.1381 ([M+H]+, 100). HPLC (method A), retention time = 7.24 min. 1H NMR (400 MHz, 6): 8.82 (d, J = 8 Hz, 1H), 8.0 (s, 1H), 8.82 (t, J = 8 Hz, 1H), 7.70 (d, J = 8 Hz, 1H), 7.67 (d, J = 8 Hz, 1H), 7.53 (s, 1H), 7.48 (d, J = 8 Hz, 1H), 7.34 (d, J = 8 Hz, 1H), 6.21 (br. s, 2H), 5.18 (m, 2H), 4.46-4.52, WO 66188 4.32-4.37 (m, 1H), 3.52-3.60 (m, 1H), 2.80-2.94 (m, 3H), 2.36 (s, 3H), .25 (m, 1H), .98 (m, 1H), 1.76-1.86 (m, 3H), 1.51-1.62 (m, 1H), 1.39-1.48 (m, 1H).
The free base form of 4-(3-amino((1S,38,4S)—3-fluoro hydroxycyclohexyl)pyrazin-2—yl)—N-((S)—1-(3-bromofluorophenyl)(methylamino)ethyl)- 2-fluorobenzamide was prepared by suspending 4-(3-amino((1S,38,4S)—3-fluoro hydroxycyclohexyl)pyrazin-2—yl)—N-((S)—1-(3-bromofluorophenyl)(methylamino)ethyl)- 2-fluorobenzamide (200mg) was suspended in 4ml of nitromethane at room temperature.
The suspension was heated to 55°C until the solution was clear. Eight heat-cool cycles were conducted in the temperature range 55°C to 5°C. The solid was generated by filtration and dried under vacuum at 40°C overnight. An X-ray powder diffraction pattern of the free base form was determined in Figure 1. A A graph of the free base of 4-(3-amino((18,38,48)fluorohydroxycyclohexyl)pyrazinyl)—N-((S)—1-(3- bromofluorophenyl)(methylamino)ethyl)fluorobenzamide is provided in Figure 2.
The HCl salt form of 4-(3-amino((1S,38,4S)—3-fluoro ycyclohexyl)pyrazin-2—yl)—N-((S)—1-(3-bromofluorophenyl)(methylamino)ethyl)- 2-fluorobenzamide was prepared by dissolving amorphous mino((1S,38,4S)—3- fluorohydroxycyclohexyl)pyrazinyl)—N-((S)(3—bromofluorophenyl) (methylamino)ethyl)fluorobenzamide (120mg) in 0.5N HCl ethanol solution (414uL) with stirring at room temperature. A precipitate is observed after 5 minutes of stirring. A DSC/TGA thermograph of the highly crystalline HCl salt form of 4-(3-amino ((1S,38,48)fluorohydroxycyclohexyl)pyrazinyl)—N-((S)—1-(3-bromo fluorophenyl)(methylamino)ethyl)fluorobenzamide is provided in Figure 4. An X-ray powder diffraction pattern of the free base form was determined in Figure 3. The most significant peaks in the XRPD of Figure 3 are shown in the table: Angle 2-theta Intensity % 12.346 9.9 .57 10.8 16.195 15.3 16.652 59.3 18.245 4.5 WO 66188 19.118 47.7 19.26 100 19.642 39.3 .029 5.4 21.509 22.2 21.777 22.2 22.568 68.9 23.611 36.3 24.334 88 24.733 18.9 .748 10.9 26.826 16 27.421 13.6 28.46 15.5 28.837 13.6 29.177 17.3 29.382 10.1 29.88 19.1 .14 20.5 31.361 7.8 31.424 7.8 32.751 21.2 33.787 12.3 34.649 17 .391 26.9 37.057 11.4 38.005 6.1 40.657 6.2 40.954 5.1 41.658 5.1 42.926 5.8 44.201 17.7 Examples 185 and 186 S nthesis of 4- 3-amino 1R BR 48 f|uoroh drox c clohex | razin I-N- S - 1- 3-bromofluoro hen | h drox eth | f|uorobenzamide and 4- 3-amino 18 38 4R f|uoroh drox c clohex | razin I-N- S 3-bromo fluoro hen Ih drox eth Ifluorobenzamide Scheme 87 F o J< F 0 F 0 :/OH NH2 0 NH2 OH T Slag; m1 “”2 N/ N/ fl I I \ N \ N N/ /OH \ N Br 41% crude ? ' F F o OJ< _ HC1H2N 7 Rt—1.58 mm F F NH 2 U F S1eg1 0” 0H ' 5’ N, 0H K/NI chiral resomtlon 4M HC1 In dloxane EDC. HOAt DIEA. DMF » + —.
E (+/-) 86% F O J< F O F O /OH "'F NHZ O E ; NH2 OH F N/ NH2 N K/IN H \ $21 I Ste N’ _ | E 45% KKN \ N Br 0 : crude 5 -. Rt = 2 42 mm 0H 0%. O ; "F absulute stereochemistry ed arily Ste 1. ut |4- 3-amino 18 38 4S f|uoroh drox c clohex | razin I fluorobenzoate tert-butyl 4-(3-amino((1R,3R,4S)f|uorohydroxycyclohexy|)pyrazinyI) fluorobenzoate (154 mg, 0.38 mmol) was subjected to chiral separation (ChiraIPak 5mic AD column, 4.6x100 (mm), CO2/IPA+0.1% DEA=75/25, SFC=5mI/min) to provide polar enantiomer, tert-butyl 4-(3-amino((1R,3R,4S)—3-fluorohydroxycyclohexyl)pyrazin y|)f|uorobenzoate (Rt = 1.86 min, 63 mg, 0.155 mmol, 41%) and the less polar enantiomer, tert-butyl 4-(3-amino((1S,38,4R)fluorohydroxycyclohexyl)pyrazin y|)f|uorobenzoate (Rt = 2.91, 70 mg, 0.173 mmol, 46%). The absolute stereochemistry was assigned arbitrarily.
Ste 2 and 3. 4- 3-amino 1R 3R 4S fluoroh drox c clohex l razin l benzoic acid and 4- 3-amino 18 38 4S f|uoroh drox c clohex | razin | orobenzoic acid To a solution of each ester (1 mmol) in DCM (2 mL) was added 4 M HCI in dioxane (30 mL). The reaction mixture was stirred at room temperature for 2 days. After the volatile materials were evaporated in vacuo, the reaction mixture was triturated with EtZO and filtered off to e 4-(3-amino((1R,3R,4S)—3-fluorohydroxycyclohexyl)pyrazin y|)f|uorobenzoic acid (60 mg from 63 mg of the ester) and 4-(3-amino((1S,3S,4R)—3- hydroxycyclohexyl)pyrazinyl)—2-fluorobenzoic acid (59 mg from 70 mg of the ester) as a HCI salt respectively, which was used for the next step without any further purification. LCMS (m/z): 350.2 (MH+), 0.5 min (for each acid).
Ste 4 and 5. 4- o 1R 3R 4S fluoroh drox c clohex l razin l -N- S 3-bromofluoro hen l h drox eth l f|uorobenzamide and 4- 3-amino 18 3S 4R oroh drox c clohex l razin-2— l-N- S 3-bromo fluoro hen lh drox eth lfluorobenzamide To a solution of each acid (20 mg, 0.057 mmol) in DMF (573 uL) was added (S)—2-amino- 2-(3-bromof|uorophenyl)ethanol HCI salt (18.59 mg, 0.069 mmol), aza-HOBt (11.69 mg, 0.086 mmol), EDC (21.95 mg, 0.115 mmol), and DIEA (30.0 ul, 0.172 mmol). The reaction mixture was stirred for 15 h. Water was added, and the reaction mixture was extracted with EtOAc three times. The organic layers were dried over , filtered and concentrated in vacuo. The crude product was purified by HPLC. Pure fractions were lyophilized to provide the d product (11 mg, 0.016 mmol, 28%) as a TFA sa|t respectively. For 4-(3-amino((1R,3R,4S)—3-fluorohydroxycyclohexyl)pyrazinyl)-N- ((S)—1-(3-bromof|uorophenyl)hydroxyethyl)fluorobenzamide, LCMS (m/z): 565.1/567 (MH+), 0.74 min; 1H NMR (400 MHz, CD3OD) 6 ppm 7.95 - 7.79 (m, 1H), 7.76 - 7.59 (m, 1H), 7.46 (s, 1H), 7.33 - 7.14 (m, 2H), 5.24 - 5.10 (m, 1H), 4.75 - 4.49 (m, 1H), 4.16 (br. s., 2H), 3.96 - 3.77 (m, 4H), 2.80 (t, J=12.5 Hz, 2H), 2.25 (dq, J=7.6, 11.9 Hz, 2H), 2.08 - 1.78 (m, 7H), 1.76 - 1.55 (m, 4H). For 4-(3-amino((1S,3S,4R)—3-f|uoro hydroxycyclohexyl)pyrazinyl)—N-((S)(3-bromof|uoropheny|)hydroxyethy|) benzamide, LCMS (m/z): 565.1/567.1 (MH+), 0.74 min; 1H NMR (400 MHz, CD30D) 6 ppm 7.84 - 7.70 (m, 2H), 7.66 - 7.49 (m, 2H), 7.37 (s, 1H), 7.24 - 7.05 (m, 2H), 5.09 (d, J=5.5 Hz, 1H), 4.66 - 4.41 (m, 1H), 4.07 (br. s., 1H), 3.88 - 3.65 (m, 2H), 2.71 (t, J=12.9 Hz, 1H), 2.16 (dq, J=7.4, 12.0 Hz, 1H), 1.99 - 1.70 (m, 3H), 1.66 - 1.47 (m, 2H). The absolute stereochemistry was not determined yet.
Examples 187 and 188 S nthesis of 4- o 1R 3S 4R f|uoroh drox c clohex | razin I-N- S - 1- 3-bromofluoro hen | h drox eth | f|uorobenzamide and 4- 3-amino 1S 3R 4S f|uoroh drox c clohex | razin I-N- S 3-bromo fluoro hen |h drox eth |f|uorobenzamide Scheme 88 F o J< F O J< F o F 0 NH2 O NH O 0J< NH2 OH Steg l w $2 g NH2 N / N / N/ \ IN NaBH4 \ IN chiral resolution N / mg | | —> —. \ N \ N (+/-) 91 /oo (+/-) Qular M Mil HPLC- crude 36°/° . F "F EM _ "’F 0 relative stereochemistry C:)H OH confirmed by NMR 4M HCI in dioxane F O J< F o NH2 0 NH2 OH OH l N / F O _/ I $2 i a \_ N \,N NH2 N E 467% $2 4— ; crude (OH N / ? F \ N Br F HCI HZNAQ/ OH OH absolute chemistry assigned arbitrarily Br ,' . ’F EDC, HOAt 6” DIEA, DMF F 0 :/OH NH2 N K/NI Br ; F Ste 1. +/- -tert-but l4- 3-amino 1R 3S 4R fluoroh drox c clohex l razin yl)—2—fluorobenzoate To a solution of (+/-)-tert-buty| 4-(3-amino((1R,3S)fluorooxocyclohexyl)pyrazin yl)fluorobenzoate (208 mg, 0.516 mmol) in MeOH (3.017 mL) was added NaBH4 (29.3 mg, 0.773 mmol) at 0 °C. The reaction mixture was stirred for 2 h. LCMS showed ~4:1 ratio of two diastereomers. After ed with NaHC03 solution, the on mixture was extracted with EtOAc. The organic layer was washed with water and brine, dried over sodium sulfate, filtered off and concentrated in vacuo. The major reomer was separated by neutral prep HPLC. After lyophilzation, (+/-)-tert-butyl 4-(3-amino ((1R,3S,4R)—3-fluorohydroxycyclohexyl)pyrazinyl)fluorobenzoate was obtained in .8% yield. (74.9 mg). LCMS (m/z): 406.3 (MH+), 0.80 min. The relative stereochemistry of (+/-)-tert-butyl 4-(3-amino((1R,3S,4R)—3-fluorohydroxycyclohexyl)pyrazin-2—yl)—2— fluorobenzoate was confirmed by NMR.
Ste 2. tert-but |4- 3-amino 1R 3S 4R f|uoroh drox c clohex | razin | fluorobenzoate and utyl 4-(3-amino((1S,3R,4S)—3-fluoro hydroxycyclohexyl )pyrazin-2—yl )—2-fluorobenzoate (+/-)-Tert-buty| 4-(3-amino((1R,3S,4R)fluorohydroxycyclohexy|)pyraziny|) fluorobenzoate (74.9 mg, 0.185 mmol) was subjected to chiral SFC lPak 5mic AD , 4.6x100 (mm), C02/EtOH+0.1%, DEA=80/20, SFC=5mL/min) to provide polar enantiomer, tert-butyl 4-(3-amino((1R,3S,4R)f|uorohydroxycyclohexy|)pyrazin y|)f|uorobenzoate (Rt = 1.95 min, 33 mg, 44 %) and the less polar enantiomer, tert- butyl 4-(3-amino((1S,3R,4S)—3-fluorohydroxycyclohexyl)pyrazinyl)—2- fluorobenzoate (Rt = 3.17, 35 mg, 46%). The absolute stereochemistry was assigned arbitrarily.
Ste 3 and 4. 4- 3-amino 1R 3S 4R f|uoroh drox c clohex | razin | fluorobenzoic acid and 4- 3-amino 1S 3R 4S fluoroh drox c clohex l razin l fluorobenzoic acid To a solution of each ester (1 mmol) was added 4 M HCI in e (111 mL). The reaction mixture was stirred at room temperature for 2 days. After the volatile als were evaporated in vacuo, the reaction mixture was triturated with EtZO and filtered off to provide 4-(3-amino((1R,3S,4R)fluorohydroxycyclohexyl)pyraziny|) fluorobenzoic acid (31 mg from 33 mg of the ester), LCMS (m/z): 350.2 (MH+), 0.47 min, and 4-(3-amino((1S,3R,4S)f|uorohydroxycyclohexyl)pyrazinyl)f|uorobenzoic acid (33 mg from 35 mg of the ester), LCMS (m/z): 350.2 (MH+), 0.48 min, as a HCI salt respectively, which was used for the next step without any further purification.
Ste 5 and 6. 4- 3-amino 1R 3S 4R f|uoroh drox c clohex | razin | -N- S 3-bromofluoro hen | h drox eth | orobenzamide and 4- 3-amino 1S 3R 4S f|uoroh drox c clohex | razin-2— l-N- S 3-bromo fluoro hen |h drox eth uorobenzamide Following Step 8 in Scheme 85, using 4-(3-amino((1R,3S,4R)—3-fluoro hydroxycyclohexyl)pyrazin-2—yl)f|uorobenzoic acid, 4-(3-amino((1R,3S,4R)—3-f|uoro- 4-hydroxycyclohexyl)pyraziny|)-N-((S)(3-bromofluorophenyl)hydroxyethy|) fluorobenzamide was obtained. LCMS (m/z): 567.1 (MH+), 0.71 min; 1H NMR (400MHz, CD3OD) 6 ppm 7.93 - 7.78 (m, 2H), 7.73 - 7.55 (m, 2H), 7.46 (s, 1H), 7.33 - 7.13 (m, 2H), 5.17 (t, J=5.9 Hz, 1H), 3.95 - 3.78 (m, 2H), 3.75 - 3.42 (m, 1H), 3.09 - 2.93 (m, 1H), 2.32 - 2.14 (m, 1H), 2.05 - 1.79 (m, 5H), 1.80 - 1.59 (m, 1H). Using 4-(3-amino ((1S,3R,4S)—3-fluorohydroxycyclohexyl)pyrazinyl)fluorobenzoic acid, 4-(3-amino- 6-((1S,3R,4S)—3-fluorohydroxycyclohexyl)pyrazinyl)-N-((S)(3-bromo fluorophenyl)hydroxyethyl)f|uorobenzamide was obtained. LCMS (m/z): 565.0/567.1 (MH+), 0.71 min; 1H NMR (400MHz, CD3OD) 6 ppm 7.95 - 7.80 (m, 2H), 7.75 - 7.56 (m, 2H), 7.46 (s, 1H), 7.33 - 7.12 (m, 2H), 5.17 (t, J=5.9 Hz, 1H), 3.96 - 3.78 (m, 2H), 3.76 - 3.55 (m, 1H), 3.10 - 2.95 (m, 1H), 2.31 - 2.12 (m, 1H), 2.08 - 1.82 (m, 5H), 1.79 - 1.62 (m, 1H).
Example 189 S nthesis of 4- 3-amino 18 38 4S f|uoroh drox c clohex | 2- | f|uoro-N- S 3-fluoroiodo hen lh drox eth Ibenzamide Scheme 89 F o F o I/OH Steal Step2 = NH2 OH F 3 z N F 4M HCI F K/N| EDC HOAt , N BocHN —— HZN + —> in dioxane K/IN 3 DIEA, DMF _ ' crude E | crude | "’F "’F Ste 1. S amino 3-fluoroiodo hen lethanol h oride rt-buty| (1-(3-f|uoroiodophenyl)—2-hydroxyethyl)carbamate (2.507 g, 6.58 mmol) was dissolved in DCM (60 mL) and treated with 4 N HCI in dioxane (4.93 mL, 19.73 mmol). The mixture was stirred overnight at room temperature. After the majority of the solvent was evaporated carefully in vacuo, the slurry was titurated with EtZO to afford 1.525 g of a fine white HCI salt of (S)—2-amino(3-fluoroiodophenyl)ethanol (72%), which was isolated by suction filtration. LCMS (m/z): 282.4 (MH+), 0.46 min.
Ste 2. 4- 3-amino 18 38 4S fluoroh drox c clohex l razin lfluoro-N- ((8)4 -(3-f|uoroiodopheny| )—2-hydroxyethy|)benzamide To a solution of 4-(3-amino((1S,3S,4S)fluorohydroxycyclohexyl)pyrazinyl)—2- fluorobenzoic acid (16 mg, 0.046 mmol) in DMF (0.46 mL) was added (S)—2-amino(3- fluoroiodophenyl)ethanol hydrochloride (17.5 mg, 0.055 mmol), HOAt (9.35 mg, 0.069 mmol), EDC (17.6 mg, 0.092 mmol), and DIEA (24 pl, 0.137 mmol). The reaction e was stirred for 15 h. After water was added, the reaction mixture was extracted with EtOAc and the organic layer was washed with water twice. The organic layer was separated and dried over Na2804, filtered off and concentrated in vacuo. The crude product was purified by flash ography eluting with 0-100% EtOAc/heptane to provide crude product, which was triturated with 70% of DCM/ether to e 9.3 mg of 4-(3-amino((18,38,4S)fluorohydroxycyclohexyl)pyrazinyl)fluoro-N-((S)(3- fluoroiodophenyl)hydroxyethyl)benzamide as a TFA salt (28%). LCMS (m/z): 613.1 (MH+), 0.74 min; 1H NMR (400MHz, CD3OD) 6 ppm 7.93 - 7.78 (m, 2H), 7.76 - 7.57 (m, 3H), 7.73 - 7.56 (m, 3H), 7.43 (d, J=7.8 Hz, 1H), 7.21 (d, J=9.4 Hz, 1H), 5.15 (t, J=5.9 Hz, 1H), 4.37 (m, 1H), 3.83 (m, 2H), 3.63 (m, 1H), 2.84 (t, J=11.7 Hz, 1H), 2.27 (dd, J=2.9, 9.2 Hz, 1H), 2.14 - 1.98 (m, 1H), 1.96 - 1.75 (m, 2H), 1.65 (dq, J=3.3, 13.0 Hz, 1H), 1.56 - 1.34 (m, 1H). 8 s of S 4- 3-amino 18 38 4S fluoroh drox c clohex l razin l- 2-fluorobenzamido)—2-(3-fluoroiodophenyl)ethyl dihydrogen phosphate Step; i. >rO‘P’OK ' 0114’ St 1 >r .
OH _62_ OH N 7< _/ O : - F wr F HzN (s) Fmoc-Chloride. FmoCHN F ole HCI, FmocHN THE, Water, Imidazole, DMF Sodium bicarbonate 2. Hydrogen Peroxide 30% I —> I 73% yield 86% yield >(O‘5’OKI F o F O /o NH2 OH F o 9 o NHZ N Step; ‘p’ / H Cl) N Steg4_ I N/ / \ N I = \ N l % piperidine in DMF F ; _ H N HATU, DIEA, NMP 2 + —> —> 61% yield (two steps) [F W, | F 9 OH Ho—Fll—OH F o / —ES‘e é NH2 N 1. MeOH I 2. HC|4M in Dioxane \ N l 94% yield [ 1": Ste 1. S - 9H-fluoren Imeth | 1- 3-fluoroiodo hen lh drox eth lcarbamate: To (S)—2-amino(3-fluoroiodophenyl)ethanol (4500 mg, 14.17 mmol) was added THF (Volume: 40 mL, Ratio: 2.67) and water (Volume: 15 mL, Ratio: 1.000), followed by NaHC03 (4762 mg, 56.7 mmol). The e was d for 2 minutes then cooled to 0°C in an ice bath. To the reaction was added (9H-fluoren-9—yl)methyl carbonochloridate (5499 mg, 21.26 mmol) and the reaction was stirred at 0 °C for 30 minutes, allowed to warm to room temperature and stirred for a further 60 minutes, before conducting LCMS.
Ethyl acetate was added to the crude on mixture. The mixture was washed with water (2x), saturated salt solution, dried sodium e, ed and concentrated to residue. The crude product was purified by silica gel chromatography using a 300 g column (solid load) eluting from 0-60% ethyl acetate in heptane. The desired fractions were concentrated to constant mass to give as white solid 5375 mg of the desired product as free base used as is, (73% yield). LCMS (m/z): 504.1 (MH+), 1.05 min. 1H NMR (<cd3od>) d: 7.78 (d, J=7.4 Hz, 2H), 7.64 (d, J=7.2 Hz, 2H), 7.53 (s, 1H), 7.33-7.43 (m, 3H), 7.25-7.33 (m, 2H), 7.07 (d, J=9.2 Hz, 1H), 4.64 (t, J=5.9 Hz, 1H), 4.31-4.46 (m, 2H), 4.21 (t, J=6.3 Hz, 1H), 3.66 (d, J=3.1 Hz, 2H).
Ste 2. S - 9H-fluoren lmeth l 2- di-tert-butox hos ho lox 3-f|uoro iodopheny|)ethyl)carbamate: To (S)-(9H-f|uorenyl)methyl (1-(3-fluoroiodophenyl) hydroxyethy|)carbamate (5260 mg, 10.45 mmol) was added imidazole (818 mg, 12.02 mmol), imidazole HCI (1857 mg, 17.77 mmol), and DMF (Volume: 50 mL). The reaction was stirrred to dissolve under argon for 2-3 s. Then t-butyl diisopropylphosphoramidite (4928 mg, 17.77 mmol) was added drop wise over 2-3 minutes and stirred at room temperature for 2 hours. The reaction was ed by neutral LCMS and by TLC eluting with 1:1 ethyl e/heptane. The crude reaction was placed in a water bath, hydrogen peroxide 30% (5.34 mL, 52.3 mmol) was added slowly, and the mixture was stirred at room temperature for 30 minutes, followed by LCMS. The crude reaction was placed in an ice bath and excess saturated sodium thiosulphate was added (carefully) drop wise over 5-10 minutes. To the crude reaction mixture was added 800 ml of ethyl e washed with water (3x), ted salt solution, dried sodium sulfate, filtered and concentrated to residue. The crude was purified by silica gel chromatography using 300 g column eluting from 0-55% ethyl acetate in heptane. The desired peak was concentrated to constant mass to give 6560 mg of the desired product as free base used as is, (86% yield). LCMS (m/z): 696.3 (MH+) weak, 1.25 min. Note: - 112 fragment at 584.2 is major ion in LCMS as expected from loss of two t-buty| protecting . 1H NMR (<cd3od>) d: 7.79 (d, J=7.3 Hz, 2H), 7.64 (d, J=7.3 Hz, 2H), 7.58 (s, 1H), 7.45 (d, J=7.6 Hz, 1H), 7.34-7.42 (m, 2H), 7.22-7.32 (m, 2H), 7.12 (d, J=9.1 Hz, 1H), 4.90 (t, J=6.0 Hz, 1H), 4.41-4.48 (m, 1H), 4.31-4.40 (m, 1H), 4.21 (t, J=6.6 Hz, 1H), 4.08 (t, J=6.3 Hz, 2H), 1.42 (s, 9H), 1.40 (s, 9H).
Ste 3. S amino 3-fluoroiodo hen leth ldi-tert-but l hos hate: To (S)—(9H- nyl)methyl (2-((di-tert-butoxyphosphoryl)oxy)(3-f|uoro iodopheny|)ethy|)carbamate (6450 mg, 9.27 mmol) was added DMF (Volume: 90 mL) ed by piperidine (25 mL, 253 mmol) and stirred at room temperature for 30 minutes, followed by LCMS. To the crude reaction mixture was added 750 ml of ethyl acetate, washed with saturated sodium bicarbonate (2x), water (5x), saturated salt solution, dried sodium sulfate, and filtered. The solvent was concentrated off to constant mass under high vacuum to give the desire crude product which includes FMOC piperidine impurity, used as is. LCMS (m/z): 474.2 (MH+), 0.80 min.
Ste 4. S 4- 3-amino 18 38 4S fluoroh drox c clohex l razin l fluorobenzamido 3-fluoroiodo hen leth Idi-tert-but | hos hate: To a solution of WO 66188 4-(3-amino((18,38,4S)—3-fluorohydroxycyclohexy|)pyraziny|)f|uorobenzoic acid (3927 mg, 9.3 mmol) in NMP (Volume: 60 mL) was added (S)—2-amino(3-fluoro iodophenyl)ethyl di-tert-butyl phosphate (4740 mg, 9.30 mmol), DIEA (9.75 mL, 55.8 mmol), and then HATU (5304 mg, 13.95 mmol). The reaction mixture was stirred at room temperature for 2 hours followed by LCMS. To the crude reaction was added 850 ml of ethyl acetate washed with saturated bicarbonate (2x), water (3x), saturated salt on, dried sodium sulfate, filtered and dried to residue. The crude product was purified by silica gel chromatograph 330g column eluting with 0-70% (EtOAc with 10% MeOH)/ e . The desired peak was concentrated to constant mass to give 5.75 grams of crude product. The material was re-purified by silica gel chromatograph 330g column eluting with 0-60% (EtOAc with 10% MeOH) / heptane to give 5.03 grams of crude product. The material was further purified by adding 1200 ml of ethyl acetate to dissolve and 200 ml of heptane, washed with 200 ml of 0.5 N HCI (5x), water, saturated sodium bicarbonate, water (3x), saturated salt solution, dried sodium sulfate, filtered and concentrated to nt mass to give 4.70 grams of desired product, yield used as is. (61% yield over two steps). LCMS (m/z): 805.4 (MH+), 0.99 min. 1H NMR (<cd3od>) d: 7.90 (s, 1H), 7.77-7.86 (m, 1H), .73 (m, 2H), 7.63 (dd, , 1.2 Hz, 1H), 7.42- 7.52 (m, 1H), 7.26 (d, J=9.5 Hz, 1H), 5.43 (t, J=5.7 Hz, 1H), 4.30-4.49 (m, 1H), 4.28 (t, J=6.3 Hz, 2H), 3.58-3.72 (m, 1H), 2.83 (t, J=11.6 Hz, 1H), 2.27 (dt, J=6.2, 3.1 Hz, 1H), 2.02-2.13 (m, 1H), 1.77-1.94 (m, 2H), 1.58-1.74 (m, 1H), 1.48-1.55 (m, 1H), 1.45 (d, J=5.8 Hz, 18H).
Ste 5. S 4- 3-amino 18 38 4S fluoroh drox c clohex | razin l benzamido)—2-(3-fluoroiodophenyl)ethyl dihydrogen phosphate: (S)—2-(4-(3- amino((1S,38,4S)f|uorohydroxycyclohexyl)pyraziny|)f|uorobenzamido)(3- fluoroiodophenyl)ethy| di-tert-butyl phosphate (4600 mg, 5.72 mmol) was fully dissolved in MeOH (Volume: 70 mL). Then HCI 4M in Dioxane (14.29 mL, 57.2 mmol) was added and stirred at room temperature for 3 hours, followed by LCMS. The t was concentrated mostly off. Then MeOH e: 70 mL) was added and the solvent was concentrated off to residue, additional MeOH (Volume: 70 mL) was added and the residue concentrated to constant mass. The product was dissolved in 90 ml of 1:1 ACN/water and lyophilized to give 3.99 grams of the desired product as HCI salt. (94% yield). LCMS (m/z): 692.9 (MH+), 0.63 min. 1H NMR (<cd3od>) d: 7.84-7.93 (m, 1H), 7.75 (s, 1H), 7.60-7.71 (m, 3H), 7.45-7.51 (m, 1H), 7.26 (dt, J=9.7, 1.6 Hz, 1H), 5.40 (t, J=5.9 Hz, 1H), 4.31-4.50 (m, 1H), 4.22-4.30 (m, 2H), 3.64 (tdd, J=11.7, 8.6, 5.1 Hz, 1H), 2.82-2.98 (m, 1H), 2.32 (ddt, J=11.7, 5.8, 2.8 Hz, 1H), 2.01-2.15 (m, 1H), 1.89-1.97 (m, 1H), .89 (m, 1H), 1.58-1.72 (m, 1H), 1.42-1.55 (m, 1H). 31PNMR(<cd3od>) d: 0.00 (s, 1P).
Conversion of HCI salt to di-sodium salt: To the above desired product as HCI salt (24 mg, 0.035 mmol) was added water e: 17 mL) then titrated with 2M sodium carbonate to pH10-11 and then extracted with 15 ml of DCM (4x). The basic water was directly loaded on to a 12 gram Grace Reveleris C18 e phase column, eluted with 0-20% ACN/water over 18 minutes at flow rate of 15 ml/minute, with no buffers. The desired fractions were lyophilized to give 18 mg of the desire t (S)—2-(4-(3-amino- 6-((1S,3S,4S)fluorohydroxycyclohexyl)pyrazinyl)fluorobenzamido)(3-fluoro- -iodophenyl)ethyl dihydrogen phosphate as the di-sodium salt, determined by counterion is. (70% yield). LCMS (m/z): 692.9 (MH+), 0.64 min. 1H NMR (<cd3od>) d: 7.82- 7.92 (m, 2H), 7.64-7.72 (m, 2H), 7.58 (dd, J=11.4, 1.2 Hz, 1H), 7.39 (d, J=7.6 Hz, 1H), 7.28 (d, J=9.5 Hz, 1H), 5.17 (dd, J=6.9, 4.1 Hz, 1H), 4.25-4.49 (m, 1H), 4.02-4.20 (m, 2H), .73 (m, 1H), 2.83 (t, J=11.6 Hz, 1H), 2.27 (dd, J=6.1, 3.6 Hz, 1H), 1.98-2.14 (m, 1H), 1.78-1.94 (m, 2H), 1.59-1.73 (m, 1H), 1.40-1.55 (m, 1H).
Example 190 S nthesis of 4- o 1R 3R 4R fluoroh drox c clohex l razin l fluoro-N- S 3-fluoro—5-iodo hen lh drox eth lbenzamide F 0 :/OH NH2 N \ N | To a solution of 4-(3-amino((1R,3R,4R)fluorohydroxycyclohexyl)pyrazinyl) fluorobenzoic acid (18 mg, 0.052 mmol) in DMF (0.52 mL) was added (S)—2-amino(3- fluoroiodophenyl)ethanol hydrochloride (19.6 mg, 0.062 mmol), HOAt (10.52 mg, 0.077 mmol), EDC (19.76 mg, 0.103 mmol), and DIEA (27 ul, 0.155 mmol). The reaction mixture was stirred for 15 h. After water was added, the reaction mixture was extracted with WO 66188 EtOAc and the organic layer was washed with water twice. The organic layer was separated and dried over Na2804, filtered off and concentrated in vacuo. The crude product was purified by flash chromtography eluting with 0-100% heptane to provide 15.8 mg of 4-(3-amino((1 R)—3-fluorohydroxycyclohexyl)pyrazinyl)- 2-f|uoro-N-((S)(3-f|uoroiodopheny|)hydroxyethy|)benzamide as a free base (50%).
LCMS (m/z): 613.1 (MH+), 0.74 min; 1H NMR (400MHz, CD3OD) 6 ppm 7.89 - 7.69 (m, 2H), 7.66 - 7.47 (m, 3H), 7.39 - 7.26 (m, 1H), 7.12 (d, J=9.4 Hz, 1H), 5.05 (t, J=5.9 Hz, 1H), 4.43 - 4.14 (m, 1H), 3.84 - 3.66 (m, 2H), 3.64 - 3.45 (m, 1H), 2.74 (t, J=11.7 Hz, 1H), 2.17 (td, J=3.1, 6.0 Hz, 1H), 2.05 - 1.87 (m, 1H), 1.84 - 1.66 (m, 2H), 1.65 - 1.47 (m, 1H), 1.47 - 1.27 (m, 1H). 8 nthesis of S 4- 3-amino 1R 3R 4R fluoroh drox c clohex l razin l- 2-f|uorobenzamido 3-fluoroiodo hen |eth Idih dro en hos hate 03,0 NH OH F 2 NH2 N %/ I? N / Step 1 H O \|< | N / _/ \ N I \ N I HZN + HATU, DIEA, NMP 77% yield . F HO—F|’—OH F o {O Step 2 F NHz ” HCI 4M in Dioxane N / MeOH | \ N | 72% yield Ste 1. S 4- 3-amino 1R 3R 4R fluoroh drox c clohex l razin l fluorobenzamido 3-fluoroiodo hen Ieth Idi-tert-but | hos hate: To a solution of 4-(3-amino—6-((1R,3R,4R)fluorohydroxycyclohexyl)pyrazinyl)fluorobenzoic acid (215 mg, 0.509 mmol) in NMP (Volume: 4 mL) was added (S)—2-amino(3-fluoro iodophenyl)ethyl t-butyl phosphate (260 mg, 0.509 mmol), DIEA (0.534 mL, 3.06 mmol) and then HATU (290 mg, 0.764 mmol). The reaction mixture was stirred at room temperature for 1 hour, followed by LCMS. To the crude reaction was added 150 ml of ethyl acetate washed with saturated onate (2x), water (3x), saturated salt solution, dried sodium sulfate, filtered and dried to residue. The crude product was purified by silica gel chromatograph 24g column (DCM g) eluting with 0-80% (EtOAc with 10% MeOH) / heptane. The desired fractions were concentrated to constant mass to give 315 mg of desired product as free base. (77% . LCMS (m/z): 805.3 (MH+), 1.01 min.
Ste 2. S 4- 3-amino 1R 3R 4R fluoroh drox c clohex l razin l fluorobenzamido)—2-(3-fluoroiodophenyl)ethyl dihydrogen phosphate: To a solution of (S)—2-(4-(3-amino((1R,3R,4R)—3-fluorohydroxycyclohexyl)pyrazin-2—yl) fluorobenzamido)(3-fluoroiodophenyl)ethyl di-tert-butyl phosphate (315 mg, 0.392 mmol) was added HCI 4M in dioxane (5 mL, 20.00 mmol) and methanol (Volume: 0.5 mL). The reaction mixture was stirred at room ature for 1 hour followed by LCMS.
The solvent was concentrated off. The crude material was basified and dissolved with 3M NaOH on with minimal MeOH added. The material was purified by 12 gram Grace Reveleris C18 reverse phase column eluted with 0-15% ACN/water over 18 minutes at a flow rate of 15 ml/minute, without buffers. The desired fractions were ted, acidified with 1 M HCI to pH of 1 and extrated with ethyl acetate (5x). The combined organic layer (800 ml) was washed with minimal water (3x 25 ml) to remove salts. The solvent was concentrated off, dissolved in 1:1 ACN/water and lyophilized to give 207 mg of the desired product as HCL salt. (72% yield). LCMS (m/z): 693.2 (MH+), 0.64 min. 1H NMR (<cd3od>) d: 7.87 (s, 1H), 7.81-7.86 (m, 1H), .72 (m, 2H), 7.61 (dd, J=11.7, 1.6 Hz, 1H), 7.46 (ddd, J=8.0, 2.3, 1.4 Hz, 1H), 7.26 (dt, J=9.5, 1.9 Hz, 1H), .38 (t, J=5.7 Hz, 1H), 4.29-4.49 (m, 1H), 4.18-4.29 (m, 2H), 3.64 (tdd, J=11.6, 8.6, 4.9 Hz, 1H), 2.76-2.92 (m, 1H), 2.27 (ddd, J=8.8, 5.9, 2.5 Hz, 1H), 2.01-2.13 (m, 1H), 1.76- 1.94 (m, 2H), 1.58-1.71 (m, 1H), 1.39-1.55 (m, 1H). 31P NMR (<cd3od>) d: 0.16 (br. s., 1P). es 191 and 192 S nthesis of 4- 3-amino 1r4S aminoc clohex l 2- l -N- S 3- chlorophenyl)—2-hydroxyethyl)—2-fluorobenzamide and 4-(3-amino((1s,4R)—4- aminoc clohex l razin l-N- S 3-chloro hen lh drox eth l fluorobenzamide Scheme 90 Steal F O F O Stegg NH2 0/ NH2 0 1. H2N/\© N / N / I I pd—C, MeOH N/ N I \ N \ en 21 1 —> 2. NaBH4, MeOH trans/ois_ —> 83% yield 2:1 trans/cis 93% yield 0 HN. J: ] Step 5 F O Step 3 Step 4 NH2 OH (OH | H2N (S) hydride, 1M aq LiOH, \ N DCM, TEA THF, MeOH 2:1 trans/Cis —, —> CI 78% yield HATU, Huenig's base DMSO HN O —> E; \K 83% yield (two steps) 0 {OH F 0 (OH NHZ N NH2 N H H N / N/ DCM, TFA \ CI \ N Cl $in 17% yield 34% yield NH2 Ste 1. meth l4- 3-amino 4- benz lamino c clohex | razin l fluorobenzoate To methyl 4-(3-amino(4-oxocyclohexyl)pyrazinyl)—2-fluorobenzoate (300 mg, 0.874 mmol) was added MeOH (4 mL), phenylmethanamine (112 mg, 1.048 mmol) and last dry 4 A molecular sieves. The on was stirred at room temperature for 16 h. Then NaBH4 (165 mg, 4.37 mmol) was added and stirred at room temperature for 2 h followed by LCMS. To the reaction was added 150 mL of ethyl acetate, washed with saturated sodium bicarbonate, water (2x), saturated salt solution, dried over sodium sulfate, filtered and concentrated to resdiue to give 352 mg of the desired product in 2:1 trans to cis ratio, used as is (93 %). LCMS (m/z): 435.3 (MH+), 0.68 min and 0.72 min.
Ste 2. meth l4- 3-amino 4-aminoc clohex | razin | fluorobenzoate WO 66188 To methyl 4-(3-amino(4-(benzylamino)cyclohexyl)pyrazinyl)—2-f|uorobenzoate (350 mg, 0.806 mmol) in a round bottom flask that was flushed with argon was added Pd-C % degaussa, wet (171 mg, 0.161 mmol). Then under argon with syringe, was added MeOH (5 mL) and last a hydrogen balloon. The flask was evacuated and refilled with hydrogen six times. The reaction was stirred at room temperature for 14 h. The reaction was purged with argon, then Pd-C 10% degaussa, wet (171 mg, 0.161 mmol) was carefully added. Then a hydrogen balloon was added, and the flask was evacuated and refilled with hydrogen six times. The reaction was stirred for onal 10 h to give a total of 24 h, followed by LCMS. The on was flushed with argon and 35 mL of DCM was added. The crude mixture was filtered through a Celite plug, and concentrated to constant mass to give 230 mg of desired product (which is 2:1 trans to cis ratio), used as is (83%). LCMS (m/z): 345.2 (MH+), 0.48 min and 0.51 min.
Ste 3. meth l4- 3-amino 4- tert-butox carbon lamino c clohex l razin l f|uorobenzoate To methyl 4-(3-amino(4-aminocyclohexyl)pyrazinyl)f|uorobenzoate (230 mg, 0.668 mmol) was added DCM (5 mL), TEA (0.233 mL, 1.670 mmol), and Boc—anhydride (0.186 mL, 0.801 mmol). The reaction was stirred at room temperature for 1 h, followed by LCMS. To the reaction was added 150 mL of ethyl acetate, washed with saturated sodium bicarbonate, water twice, saturated salt solution, dried over sodium sulfate, filtered and concentrated to constant mass to give 233 mg of the desired product (which is 2:1 trans to cis ratio), used as is (78%). LCMS (m/z): 445.2 (MH+), 0.92 min for both.
Ste 4. 4- 3-amino 4- tert-butox carbon lamino c clohex l razin l benzoic acid To methyl 4-(3-amino(4-((tert-butoxycarbonyl)amino)cyclohexy|)pyrazinyl)—2- benzoate (230 mg, 0.517 mmol) was added MeOH (2 mL), THF (2 mL) and then lithium hydroxide 1M aqueous solution (1.552 mL, 1.552 mmol). The reaction was stirred at room ature for 1 h. he solvent was concentrated to residue, then THF (20 mL) was added and concentrated to residue. Then THF (20 mL) was added again and re- concentrated to residue to nt mass to give the desired product (which is 2:1 trans to cis ratio), used as is. Assume quanitative yield (0.517 mmol). LCMS (m/z): 431.2 (MH+), 0.78 min for both.
WO 66188 Ste 5. S -tert-but l 4- 5-amino 4- 1- 3-chloro hen lh drox eth lcarbamo l fluoro hen l razin lc clohex lcarbamate To 4-(3-amino(4-((tert-butoxycarbonyl)amino)cyclohexyl)pyrazinyl)fluorobenzoic acid (222 mg, 0.516 mmol) was added DMSO (4 mL), Hiinig’s base (0.450 mL, 2.58 mmol), (S)amino(3-chlorophenyl)ethanol (133 mg, 0.774 mmol) and then HATU (392 mg, 1.031 mmol). The reaction was stirred for 1 h at room temperature. To the reaction was added 50 mL of ethyl acetate, washed with water twice, saturated salt solution, dried over sodium sulfate, filtered and concentrated to residue. The crude was purified by flash tgraphy using 12 gram column (solid load) eluting with 10-95% ethyl acetate in heptane. The d fractions were concentrated to constant mass to give 252 mg of product (which is 2:1 trans to cis ratio), used as is (83% over two steps).
LCMS (m/z): 584.3 (MH+), 0.91 min for both.
Ste 6. 4- 3-amino 1r4S noc clohex l razin l-N- S 3-chloro hen l- oxyethyl)fluorobenzamide and 4-(3-amino((1s,4R)—4- aminoc clohex l razin l-N- S 3-chloro hen lh drox eth l fluorobenzamide To (S)—tert-butyl (4-(5-amino(4-((1-(3-chlorophenyl)hydroxyethyl)carbamoyl) fluorophenyl)pyrazinyl)cyclohexyl)carbamate (252 mg, 0.431 mmol) was added DCM (8 mL) and then TFA (2 mL, 26.0 mmol). The reaction was stirred for 1 h at room temperature. The solvent was concentrated, redissolved in DMSO, filtered, and purified by prep HPLC with both isomer collected. With major isomer, trans eluted out first and mior, cis s eluted out second. After lypholization, 87 mg of trans product 4-(3- amino((1r,4S)aminocyclohexyl)pyrazinyl)-N-((S)(3-chlorophenyl) hydroxyethyl)fluorobenzamide was obtained as TFA salt in 34% yield. LCMS (m/z): 484.2 (MH+), 0.58 min; 1H NMR (CD3OD) 6 ppm 7.79 (s, 1H), 7.76 (t, J=7.8 Hz, 1H), 7.58 (dd, J=7.8, 1.6 Hz, 1H), 7.52 (dd, J=11.9, 1.4 Hz, 1H), 7.36 (s, 1H), 7.30 - 7.23 (m, 2H), 7.22 - 7.16 (m, 1H), 5.10 (t, J=5.9 Hz, 1H), 3.83 - 3.70 (m, 2H), 3.08 (tt, J=11.7, 3.9 Hz, 1H), 2.69 - 2.49 (m, 1H), 2.06 (d, J=10.6 Hz, 2H), 1.97 (d, J=12.9 Hz, 2H), 1.75 - 1.57 (m, 2H), 1.55 - 1.31 (m, 2H).
In addition, after lypholization 43 mg of the cis product 4-(3-amino((1s,4R) aminocyclohexyl)pyrazinyl)-N-((S)(3-chlorophenyl)hydroxyethyl) fluorobenzamide was obtained as TFA salt, in 17% yield. LCMS (m/z): 484.2 (MH+), 0.61 min; 1H NMR (CD3OD) 8 ppm 7.87 (s, 1H), 7.81 - 7.72 (m, 1H), 7.60 (dd, J=8.0, 1.4 Hz, 1H), 7.55 (d, J=11.7 Hz, 1H), 7.36 (s, 1H), 7.26 (d, J=5.9 Hz, 2H), 7.22 - 7.16 (m, 1H), .10 (t, J=5.7 Hz, 1H), 3.87 - 3.67 (m, 2H), 2.91 - 2.80 (m, 1H), 1.98 (q, J=8.9 Hz, 2H), 1.90 - 1.71 (m, 6H).
Example 193 S nthesis of 4- 6- 1r 4S tamidoc clohex l amino razin l -N- S 3- F o Z/OH I N/\©H \ N CI To 4-(3-amino((1r,4S)—4-aminocyclohexyl)pyrazinyl)-N-((S)(3-chlorophenyl) hydroxyethyl)fluorobenzamide (15 mg, 0.025 mmol) were added DCM ( 0.25 mL), THF (0.75 mL) and TEA (10.49 pl, 0.075 mmol) at 0 °C. Then acetic anhydride (2.367 pl, 0.025 mmol) was added. The on was stirred for 30 min at 0 °C. The reaction was concentrated, dissolved in 1 mL of DMSO, filtered, purified by prep HPLC, and lyophilized to give 5.4 mg of the desired product 4-(6-((1r,4S)acetamidocyclohexy|) aminopyrazinyl)—N-((S)—1-(3-ch|oropheny|)hydroxyethy|)f|uorobenzamide as a TFA salt (33% yield). LCMS (m/z): 526.3 (MH+), 0.67 min; 1H NMR (CD30D) 8 ppm 7.71- 7.82 (m, 2H), 7.58 (dd, J=8.0, 1.4 Hz, 1H), 7.53 (d, J=11.7 Hz, 1H), 7.37 (s, 1H), 7.22- 7.29 (m, 2H), .22 (m, 1H), 5.10 (t, J=5.9 Hz, 1H), 3.71-3.84 (m, 2H), 3.52-3.66 (m, 1H), 2.51-2.65 (m, 1H), 1.86-2.02 (m, 4H), 1.83 (s, 3H), 1.53-1.69 (m, 2H), 1.22-1.39 (m, 2H).
Example 194 S s of 4- 3-amino 1r4S meth Isulfonamido c clohex | razin | -N- S - 1- ro hen |h drox eth |fluorobenzamide F o {0 I MAE:H \ N Cl To 4-(3-amino((1r,4S)—4-aminocyclohexy|)pyrazinyl)-N-((S)(3-chlorophenyl) hydroxyethyl)fluorobenzamide (15 mg, 0.025 mmol) was added DCM ( 0.25 mL, Ratio: 1.000), THF (0.250 mL), TEA (10.49 pl, 0.075 mmol) d to ve and cooled to 0 °C, and then methanesulfonyl chloride (1.955 pl, 0.025 mmol) was added. The reaction was stirred for 30 min at 0 °C, followed by LCMS. The reaction was concentrated dissolved in 1 mL of DMSO, filtered, purified by prep HPLC, and lyophilized to give 1.6 mg of the desired product 4-(3-amino((1r,4S)—4- (methylsulfonamido)cyc|ohexy|)pyrazinyl)-N-((S)(3-ch|oropheny|)hydroxyethyl) fluorobenzamide as TFA salt (9% yield). LCMS (m/z): 562.2 (MH+), 0.69 min. 1H NMR (CD30D) 8 ppm 7.70-7.82 (m, 2H), 7.59 (d, J=7.8 Hz, 1H), 7.53 (d, J=11.7 Hz, 1H), 7.37 (s, 1H), 7.22-7.30 (m, 2H), 7.13-7.21 (m, 1H), 5.09 (t, J=5.9 Hz, 1H), 3.68-3.89 (m, 2H), 2.87 (s, 3H), 2.48-2.60 (m, 1H), 2.05 (d, J=14.9 Hz, 2H), 1.84-1.95 (m, 2H), 1.54-1.74 (m, 2H), 1.38 (q, J=12.9 Hz, 2H).
Example 195 S nthesis of meth | 18 4r 5-amino 4- S 3-chloro hen | hyd roxyethyl )carbamoyl )—3-fluorophenyl )pyrazinyl )cyclohexyl )carbamate 2014/062913 F 0 :/OH I NDH \ N Cl HN\n/O\ To 4-(3-amino((1r,4S)—4-aminocyclohexyl)pyrazinyl)-N-((S)(3-ch|oropheny|) hydroxyethyl)fluorobenzamide (15 mg, 0.025 mmol) was added DCM (0.25 mL), THF (0.250 mL), TEA (10.49 pl, 0.075 mmol) stirred to dissolve and cooled to 0 °C, and then methyl chloroformate (1.943 pl, 0.025 mmol) was added. The reaction was d for 30 min at 0 °C, followed by LCMS. The reaction was concentrated dissolved in 1 mL of DMSO, filtered, purified by prep HPLC, and lyophilized to give 4.5 mg of the desired product methyl ((1S,4r)(5-amino(4-(((S)(3-chlorophenyl) hydroxyethyl)carbamoyl)fluorophenyl)pyrazinyl)cyclohexy|)carbamate as TFA salt (27% yield). LCMS (m/z): 542.3 (MH+), 0.75 min. 1H NMR (CD3OD) 8: 7.73-7.81 (m, 2H), 7.58 (dd, J=8.0, 1.4 Hz, 1H), 7.48-7.55 (m, 1H), 7.37 (s, 1H), 7.23-7.30 (m, 2H), 7.15-7.22 (m, 1H), 5.10 (t, J=5.9 Hz, 1H), 3.69-3.84 (m, 2H), 3.53 (s, 3H), 3.31-3.36 (m, 1H), 2.48- 2.62 (m, 1H), 1.84-2.00 (m, 4H), 1.51-1.68 (m, 2H), 1.21-1.44 (m, 2H) Example 196 S nthesis of 4- 3-amino 1r4S 2-h drox acetamido c clohex | 2- | -N- S 3-chloro hen |h drox eth |fluorobenzamide F o :/ N/IWWQH \N CI HN\n/\OH 2014/062913 To 4-(3-amino((1r,4S)—4-aminocyclohexy|)pyrazinyl)-N-((S)(3-ch|oropheny|) hydroxyethyl)fluorobenzamide (11 mg, 0.018 mmol) were added NMP (0.4 mL), 2- hydroxyacetic acid (2.80 mg, 0.037 mmol), Hiinig’s base (0.013 mL, 0.074 mmol) and then HATU (17.49 mg, 0.046 mmol). The reaction was stirred for 30 min at room temperature. The reaction was concentrated, dissolved in 0.75 mL of DMSO, filtered, purified by prep HPLC, and lyophilized to give 3.6 mg of the desired product 4-(3-amino- ,4S)(2-hydroxyacetamido)cyc|ohexy|)pyraziny|)-N-((S)(3-ch|oropheny|) hydroxyethyl)fluorobenzamide as TFA salt (29%). LCMS (m/z): 542.2 (MH+), 0.63 min. 1H NMR ) 6 ppm 7.83 - 7.72 (m, 2H), 7.59 (dd, J=8.0, 1.4 Hz, 1H), 7.53 (d, J=11.7 Hz, 1H), 7.37 (s, 1H), 7.32 - 7.23 (m, 2H), 7.22 - 7.16 (m, 1H), 5.10 (t, J=5.9 Hz, 1H), 3.86 (s, 2H), 3.82 - 3.63 (m, 3H), 2.65 - 2.50 (m, 1H), 2.02 - 1.86 (m, 4H), 1.72 - 1.56 (m, 2H), 1.48 - 1.33 (m, 2H).
Example 197 S nthesis of S -N- 2-amino 3-chloro hen | eth | 3-amino 4 4- difluoroc clohex | razin |f|uorobenzamide Scheme 91 F O F O m; m; NH2 0 StepL / O NH2 0 N/ F H2N _.\\\ A IN N/ o l m \ ' \ N /‘\ \O/\/N\/\O/ NaOH 1M aq THF, MeOH —> —> 31% yield.
HATU, Huenlgsbase. , O 100% yield F F DMSO 12% yield /NH :/ 2 ma F 0 F 0 NH N HCI 4M In dioxane N’ N/ | |N ’ \ N CI \ CI 33% yield F F F F Ste 1. meth |4- 3-amino 4 4-difluoroc clohex | razin |fluorobenzoate To methyl 4-(3-amino(4-oxocyclohexyl)pyrazinyl)f|uorobenzoate (250 mg, 0.728 mmol) was added DCM (10 mL) and the solution was cooled to 0 °C in ice bath. Then Deoxo-fluoro solution in toluene 50% (805 mg, 1.820 mmol) was added at 0 °C. The reaction was allowed to warm up to room temperature and stirred for 2 h. To quench the reaction, TEA (1.522 mL, 10.92 mmol) was added and stirred for 1 h at room temperature. The solvent was concentrated off to residue and the crude was purified by flash chromotgraphy (dry load) using 12 gram column eluting with 5-75% ethyl acetate in heptane. The desired fractions were concentrated to constant mass to give 83 mg of the d product as a free base, used as is (31% yield). LCMS (m/z): 366.2 (MH+), 0.87 min.
Ste 2. 4- o 4 4-difluoroc clohex l razin lfluorobenzoic acid To methyl 4-(3-amino(4,4-difluorocyclohexyl)pyrazinyl)f|uorobenzoate (83 mg, 0.227 mmol) was added MeOH (1.5 mL), THF (1.5 mL) and then 1 M aqueous solution NaOH (0.909 mL, 0.909 mmol). The reaction was stirred at room temperature for 6 h. The reaction was concentrated to residue. THF was added and concentrated to residue again.
Then the mixture was dissolved in 1:1 ACN/water, acidified with 6 M HCI and lized to give desired product as HCI sa|t used as is. Assume quanitative yeiId, (0.227 mmol).
LCMS (m/z): 352.1 (MH+), 0.71 min.
Ste 3. S -tert-but | 2- 4- 3-amino 4 4-difluoroc clohex l 2- l benzamido)—2-(3-chlorophenyl )ethyl )carbamate To 4-(3-amino(4,4-difluorocyclohexyl)pyraziny|)fluorobenzoic acid (48 mg, 0.124 mmol) werr added DMSO (1 mL), Hiinig’s base (0.108 mL, 0.619 mmol), (S)-tert-butyl (2- amino(3-chlorophenyl)ethyl)carbamate (50.3 mg, 0.186 mmol) and then HATU (94 mg, 0.248 mmol). The reaction was d for 1 h at room temperature. To the reaction was added 0.5 mL of DMSO, filtered, purified by prep HPLC, and lyophilized to give 11 mg of the d product used as is (12% yield). LCMS (m/z): 604.2 (MH+), 1.05 min.
Ste 4. S -N- o 3-chloro hen l eth l 3-amino 4 4- difluoroc clohex l razin lfluorobenzamide To (S)-tert-butyl (2-(4-(3-amino(4,4-difluorocyclohexyl)pyraziny|) f|uorobenzamido)(3-ch|oropheny|)ethy|)carbamate (11 mg, 0.018 mmol) was added HCI 4M in dioxane (1 mL, 4.00 mmol). The reaction was stirred for 1 h at room temperature. The solvent was removed and concentrated to residue, which was dissolved in 1:1 acetonitrile/ water, filtered and lyophilized to HCI salt. The crude salt residue was dissolved in 1 mL of DMSO, purified by prep HPLC and lyophilized to give 3.8 mg of the desired product (S)—N-(2-amino(3-chlorophenyl)ethyl)(3-amino(4,4- difluorocyclohexyl)pyraziny|)f|uorobenzamide as a TFA salt (33%). LCMS (m/z): 504.2 (MH+), 0.74 min; 1H NMR ) 6 ppm 7.85 - 7.73 (m, 2H), 7.62 (dd, J=8.0, 1.4 Hz, 1H), 7.54 (dd, J=12.1, 1.2 Hz, 1H), 7.46 (s, 1H), 7.38 - 7.28 (m, 3H), 5.39 (dd, J=9.0, .9 Hz, 1H), 3.40 - 3.33 (m, 2H), 2.72 (br. s., 1H), 2.12 - 1.98 (m, 2H), 1.96 - 1.73 (m, 6H).
Examples 198 and 199 S nthesis of omericall enriched reomers of cis 3-amino 3- h drox c clohex | razin l-N- S 3-chloro hen lh drox eth l fluorobenzamide Scheme 92 NHZ Ste NH2 9: Ste 2 NH2 N)\ le 0 \ Br chiral separation NI NB N \ I —> | o / N / N / N OTBDMS OTBDMS OTBDMS OTBDMS (+/-))cis diastereomer polar less polar polar or less polar F O MN?” F O F O {OH :‘ENJag NHZ +HH2N“© —~Ste NH2 N N a OTBDMS OTBDMS OTBDMS [30’6" or less [JO/af polar or less polar polar or less polar F O /OH Step g Q yum cis diastereomer cis diastereomer from polarprecursor from less polarprecursor WO 66188 Step 1. Polar and less polar enantiomerically enriched cis(3-((tert— but ldimeth lsil lox c c|ohex l razinamines -(3-((tert—butyldimethylsilyl)oxy)cyclohexyl)pyrazinamine (500 mg, 1.626 mmol), prepared from Scheme 29, was resolved by chiral SFC (ChiraIPak 5mic OD column, 0 (mm), Cog/IPA+0.1% DEA=90/10, SFC=5mL/min). For polar enantiomer (peak 1) (230 mg, 0.748 mmol, 46.0% yield), Rt = 1.58 min. For less polar enantiomer (peak 2) (230 mg, 0.748 mmol, 46.0% yield), Rt = 2.36 min.
Ste 2 3 4 5 and 6. cis 3-amino 3-h drox c c|ohex | razin I-N- S 3- chlorophenyl)—2-hydroxyethy|)—2-f|uorobenzamide diastereomers Following Steps 2, 3, and 7 in Scheme 75, each omeric enriched cis(3-((tert— butyldimethylsilyl)oxy)cyclohexyl)pyrazinamine underwent bromination ed by Suzuki coupling with 3-fluoro(methoxycarbonyl)phenyl)boronic acid. After hydrolysis, following Step 8 in Scheme 75, using (S)amino(3-ch|oropheny|)ethano| and each enantiomer, each diastereomer of cis(3-amino(3-hydroxycyclohexyl)pyraziny|)-N- ((S)(3-chlorophenyl)hydroxyethyl)f|uorobenzamide was obtained respectively. For cis diastereomerfrom polar precursor, LCMS (m/z): 485.0 (MH+), 0.70 min; 1H NMR (400 MHz, METHANOL-d4) 6 ppm 7.90 - 7.69 (m, 2 H) 7.64 - 7.48 (m, 2 H) 7.37 (s, 1 H) 7.30 - 7.09 (m, 3 H) 5.10 (t, J=6.06 Hz, 1 H) 3.89 - 3.69 (m, 2 H) 3.66 - 3.47 (m, 1 H) 2.79 - 2.60 (m, 1 H) 2.06 (d, 4 Hz, 1 H) 1.97 - 1.68 (m, 3 H) 1.52 - 1.26 (m, 3 H) 1.24 -0.99 (m, 1 H). For cis diastereomer from less polar precursor, LCMS (m/z): 485.0 (MH+), 0.70 min. 1H NMR (400 MHz, OL-d4) 6 ppm 7.88 - 7.70 (m, 2 H) 7.65 - 7.49 (m, 2 H) 7.37 (s, 1 H) 7.32 - 6.98 (m, 3 H) 5.10 (s, 1 H) 3.76 (t, J=6.06 Hz, 2 H) 3.58 (s, 1 H) 2.79- 2.59 (m, 1 H) 2.06 (d, J=12.13 Hz, 1 H) 1.97 - 1.61 (m, 3 H) 1.54 - 1.30 (m, 3 H) 1.25 - 0.96 (m, 1 H).
Absolute stereochemistry on cyc|ohexane ring for both diastereomers has not been determined.
Examples 200 and 201 S nthesis of 4- 3-amino tetrah dro-2H- ran l razin l f|uoro-N- 1S 2R hen |c c|o ro |benzamide and 4- 3-amino tetrah dro-2H- ran | razin | fluoro-N- 1R2S hen |c c|o ro |benzamide WO 66188 Scheme 93 O F O F O NH2 N' "'1 NH2 N' "’1 NH2 N“' H H H N \ N \ N \ /N resolution I I ,N /N (+/-) Peak1 Peak2 O O 0 Following Step 2 in Scheme 89, using (+/-)-transphenylcyclopropanamine, EDC (30.2 mg, 0.158 mmol), HOAt (17.2 mg, 0.126 mmol), and DIEA (0.033 mL, 0.189 mmol), (+/-)- trans(3-amino(tetrahydro-2H-pyranyl)pyraziny|)f|uoro-N-(2- phenylcyclopropyl)benzamide was obtained (19 mg, 70%). LCMS (m/z): 433.2 (MH+), 0.82 min; 1H NMR z, CDCI3) 8 ppm 8.29-8.22 (m, 1 H), 7.94 (s, 1 H), 7.76-7.71 (m, 1 H), 7.63-7.56 (m, 1 H), 7.35-7.18 (m, 4 H), 7.04-6.94 (m, 1 H), 4.67 (s, 2 H), 4.09 (m, 2 H), 3.35 (m, 2 H), 3.15 (m, 1 H), 2.93 (m, 1 H), 2.22 (m, 1 H), 2.90-1.8 (m, 4 H), 1.43-1.23 (m, 3 H).
The racemic product was resolved by chiral SFC (ChiralPak 5mic AD-H column, 4.6x100 (mm), heptane:EtOH= 50/50, 1mL/min). For polar mino(tetrahydro-2H-pyran yl)pyrazinyl)f|uoro-N-((1S,2R)—2-phenylcyclopropyl)benzamide (27%) at Rt = 11.0 min, LCMS (m/z): 433.2 (MH+), 0.81 min. For less polar 4-(3-amino(tetrahydro-2H- 4-yl)pyrazinyl)f|uoro-N-((1R,2S)pheny|cyclopropyl)benzamide (+/-)-trans (3-amino(tetrahydro-2H-pyranyl)pyrazinyl)f|uoro-N-(2- phenylcyclopropyl)benzamide (27%) at Rt = 15.8 min, LCMS (m/z): 433.2 (MH+), 0.81 min. The absolute stereochemistry was assigned based on biochemical data and docking model.
Examples 202 and 203 S nthesis of 4- 3-amino—6- 1r4S h drox c clohex | razin |f|uoro-N- 1S 2R - 2- hen lc clo ro lbenzamide and 4- 3-amino 1r4R h drox c clohex | razin- 2- |f|uoro-N- 1R2S hen lc clo ro lbenzamide Scheme 94 F o F o F o NH2 N' NH2 N' NH2 N H H H N’ N’ N’ \ N resolution \ N \ N : —> : : (+/—) peak1 peak2 OH OH OH Following Step 2 in Scheme 89, using (+/-)-transphenylcyclopropanamine (48.6 mg, 0.37 mmol), EDC (127 mg, 0.66 mmol), HOAt (67.8 mg, 0.498 mmol), and DIEA (0.174 mL, 0.996 mmol), (+/-)-trans(3-amino(tetrahydro-2H-pyranyl)pyrazinyl)—2- fluoro-N-(2-phenylcyclopropyl)benzamide was obtained (40 mg, 97%), which was separated by chiral SFC (ChiralPak 5mic OJ column, 4.6x100 (mm), C02/IPA+0.1% /40, SFC=5m|/min). The polar diasteremer was 4-(3-amino((1r,4S)—4- hydroxycyclohexyl)pyrazinyl)fluoro-N-((1S,2R)—2-phenylcyclopropyl)benzamide (Rt = 1.38 min)._LCMS (m/z): 447.3 (MH+), 0.76 min; 1H NMR (500MHz, CD30D) 6 ppm 7.89 - 7.78 (m, 2H), 7.72 - 7.53 (m, 2H), 7.33 - 7.23 (m, 2H), 7.24 - 7.10 (m, 3H), 3.68 -3.53 (m, 1H), 3.14 - 3.03 (m, 1H), 2.74 - 2.56 (m, 1H), 2.27 - 2.13 (m, 1H), 2.12 - 1.88 (m, 4H), 1.77 - 1.57 (m, 2H), 1.52 - 1.29 (m, 4H). The less polar diastereomer was 4-(3—amino ((1r,4R)—4—hydroxycyclohexyl)pyrazinyl)fluoro-N-((1R,2S)—2- phenylcyclopropyl)benzamide (Rt = 1.82 min). LCMS (m/z): 447.3 (MH+), 0.75 min; 1H NMR (500MHz, CD3OD) 6 ppm 7.89 - 7.78 (m, 2H), 7.72 - 7.53 (m, 2H), 7.33 - 7.23 (m, 2H), 7.24 - 7.10 (m, 3H), 3.68 - 3.53 (m, 1H), 3.14 - 3.03 (m, 1H), 2.74 - 2.56 (m, 1H), 2.27 - 2.13 (m, 1H), 2.12 - 1.88 (m, 4H), 1.77 - 1.57 (m, 2H), 1.52 - 1.29 (m, 4H). The absolute stereochemistry was ed based on biochemical data and docking model.
Example 204 S nthesis of 4- 2-amino tetrah dro-2H- ran | 3- l-N-benz lc ano fluorobenzamide Scheme 95 $2 1 $2 2 $9g F F F F DOOM Pd(OAc)2 COZH 052003 COZMe CuCN COzMe —> —> —> Mel DMF CI Ph|(OAC)2. I2 (31 I CI I CI CN NH20 _QSte 4&5 Ste NH2 H2 N \ 1. Pd(PPh3)4 N :NN/\© / Na2C03 T3P TEA I 2 LiOH Ste 1. 4-chlorofluoroiodobenzoic acid To a 250 mL flask were added rofluorobenzoic acid (4 g, 22.92 mmol), Pd(OAc)2 (0.257 g, 1.146 mmol), iodobenzene diacetate (8.12 g, 25.2 mmol), iodine (6.40 g, 25.2 mmol) and DMF (60 mL). The solution was heated under a nitrogen atmosphere at 100 °C for 20 h. LCMS showed about half of 4-chlorofluorobenzoic acid was converted to the product (LCMS retention time 0.98 min, no MH+ peak). After cooling to room temperature, the solution was diluted with EtOAc and washed three times with 1 N HCI.
The aqueous layers were combined and extracted once with EtOAc. The organic layers were combined, dried over Na2804 and concentrated to give a dark brown oil (16.4 g, 42% pure), which was taken to the next step t purification.
Step 2. Methyl 4-chlorofluoroiodobenzoate 4-Chlorofluoroiodobenzoic acid (16.4 g, 22.93 mmol, along with 4-chloro fluorobenzoic acid) were dissolved in DMF (30 mL). Cs2C03 (8.96 g, 27.5 mmol) was added, followed by Mel (1.577 mL, 25.2 mmol). After 90 min at room temperature. LCMS showed the reaction was completed (retention time 1.06 min, no MH+ peak). It was diluted with EtOAc and ed through a piece of filter paper. The te was washed three times with water. The aqueous layers were combined and extracted once with EtOAc. The organic layers were combined, dried over Na2804 and trated. The residue was purified on a silica gel column (heptane:EtOAc 1:0 to 9:1) to give a mixture of methyl 4-chlorofluoroiodobenzoate and methyl 4-chlorofluorobenzoate in approximately 1:1 ratio (1.99 g).
Step 3. Methyl 4-chlorocyanofluorobenzoate 2014/062913 Methyl 4-chlorofluoroiodobenzoate (1.99 g, 10.6 mmol) was dissolved in DMF ( 12 mL). CuCN (2.84 g, 31.7 mmol) was added and the sion was heated under microwave at 110 °C for 18 min. EtOAc was added and the suspension was filtered through a piece of filter paper. The filtrate was washed three times with water. The aqueous layers were combined and extracted once with EtOAc. The organic layers were combined, dried over NazSO4 and trated. The residue was purified on a silica gel column (heptane:EtOAc 1:0 to 9:1) to give the product as a colorless solid (505 mg). 1H NMR (400 MHz, CDCI3) 6 ppm 7.56 (s, 1H), 7.40 (d, 1H, J=8 Hz), 4.00 (s, 3H); 13C NMR (100 MHz, CDCI3) 6 ppm 161.78 (d, J=58 Hz), 159.44, 139.16 (d, J=11 Hz), 129.96, 121.99, 121.74, 115.48, 114.72, 53.04.
Ste 4. Meth l4- 2-amino tetrah dro-2H- ran l ridin lc ano fluorobenzoate To a 2 mL microwave vial were added 5-(tetrahydro-2H-pyranyl)(4,4,5,5- tetramethyl-1,3,2-dioxaborolanyl)pyridinamine (638 mg, 1.049 mmol), methyl 4- chlorocyanofluorobenzoate (140 mg, 0.655 mmol), Pd2(dba)3 (30.0 mg, 0.033 mmol), XPhos (31.2 mg, 0.066 mmol), NaHC03 (275 mg, 3.28 mmol), DME (3 mL) and H20 (1.5 mL). The solution was heated under microwave at 100 °C for 15 min. Water and EtOAc were added and the aqueous layer was extracted three times with EtOAc. The organic layers were combined, dried over NazSO4 and concentrated. The residue was purified on a silica gel column (heptane:EtOAc 1:0 to 1:4) to give the product as a yellow foam (85 mg). LCMS (m/z) 356.1 (MH+), 0.58 min.
Ste 5. 4- 2-amino tetrah - ran l ridin lc anofluorobenzoic acid To methyl 4-(2-amino(tetrahydro-2H-pyranyl)pyridinyl)cyanofluorobenzoate (85 mg, 0.239 mmol) and lithium hydroxide drate (11.04 mg, 0.263 mmol) were added THF (1 mL) and H20 (1.000 mL). The on was stirred at room temperature for 3 h. All solvents were evaporated to give the crude product's lithium salt as a yellow solid (92 mg) which was used in the next step without purification. LCMS (m/z) 342.0 (MH+), 0.42 min, Ste 6. 4- 2-amino tetrah dro-2H- ran l ridin l-N-benz lc ano fluorobenzamide To 4-(2-amino(tetrahydro-2H-pyranyl)pyridinyl)cyanofluorobenzoic acid were added DCM (1 mL), followed by amine (0.017 mL, 0.153 mmol), triethylamine (0.053 mL, 0.383 mmol) and T3P (50% in EtOAc, 0.084 mL, 0.141 mmol). After 1 h more amine (0.017 mL, 0.153 mmol) and T3P (50% in EtOAc, 0.084 mL, 0.141 mmol) were added and at 2 h the reaction was completed. Saturated NaHCO3 solution was added and extracted twice with EtOAc. The organic layers were combined, dried over Na2804 and concentrated. The residue was purified on a silica gel column (heptane:EtOAc 1:0 to 0:1) to give the product as a colorless solid (17 mg). LCMS (m/z) 431.1 (MH+), 0.65 min. 1H NMR (400 MHz, CDCI3) ) 6 ppm 8.03 (s, 1 H), 7.74 (s, 1 H), 7.54 (d, 1 H, J 12 Hz), 7.43-7.30 (m, 4 H) 7.26 (s, 1 H), 7.23 (s, 1 H) 6.57 (br s, 1 H), 4.74 (d, J 5.53 Hz, 2 H), 4.10 -4.06 (m, 2 H), 3.55 -3.46 (m, 2 H), 2.77 -2.67 (m, 1H), 1.80 -1.70 (m, 4 H).
Example 205 S nthesis of 4- 2-amino tetrah dro-2H- ran l ridin lfluoro—N- 6- methylpyridinyl)methyl)benzamide Scheme 96 _QSte l Stegz \ 0 DIEA, PdOAc2 | \JL (o—Tol)3P/DMF B0620 cat. DMAP \ + OEt N N/ OEt —> | o / 81% 934 BoczN N $2. $124 1. co Me M6020 cone . N H/Me0H 2 1. NaH MeOH 2. :%I/H:% M60 0\CoéngeMeZ Z Dimethylmalonate2. 3. cat. HCI/MeOH \ 002Me —. | 36% / co M2 e . N BocHN 94% (one pot) HZN HZN l/N COZMe m; $99 NHz SteQZ NH2 OH F o HZSO4/toluene N \ N \ L'A'H4/THF_ Dean-Stark I NBS I 0H / / ’ —’ + H0 quantitative \ OH I MeCN ‘B 790/0 I / OH H2N N o o F O F O 4—Ste 11 NH2 OH “”2 N \ Pd(PPh3)4 H N / NaZCO3 NI \ PyBrop, HOAt H2N /N NI \ —> / + I —> / DIEA, THF 0 O Stepg Stegfl fl NHz-OH HCI, K2003 \ Zn, ACOH \ —. I N —> I N/ /O / / / NH N \OH 2 Ste 1. E -eth l3- 6-amino ridin lacr late To a glass bomb were charged with 5-bromopyridinamine (10.0 g, 57.8 mmol), ethyl acrylate (8.14 mL, 75 mmol) and DIEA (25.2 mL, 144mmol) in DMF (40 mL). The mixture was purged with argon, followed by addition of Pd(OAc)2 (0.649 g, 2,89 mmol) and (o- Tol)3P (3.87 g, 12.72 mmol), and finally purged thoroughly with argon. The mixture was , and heated with 100 °C oil bath overnight. The reaction mixture was cooled down to room temperature, and the precipitates were removed by ing through a thin layer of Celite. The filtrate was concentrated as much as possible via p, and the residue was partitioned between EtOAc/water (150 mL/100 mL). EtOAc layer was washed with water (2 x 100 mL), dried over , and concentrated. A brown slid was obtained as crude product. The crude product was triturated with EtOAc (40 mL) and the yellow solid was collected via filtration. The filter cake was rinsed with small amount of EtOAc and dried under vaccum as the first crop of product (5.0 g). The mother liquor from trituration was stripped by dilute aqueous 1 N HCI (30 mL) and water (70 mL). Aqueous layer was transferred to a clean tive funnel, basicified with 20 mL sat. Na2C03, and extracted with EtOAc (60 mL). EtOAc layer was dried over , concentrated and provided the second portion of product (4.0 g). The two crops of product were combined to afford 81% yield. LCMS (m/z) 193.2 (MH+), 0.39 min.
Ste 2. E -eth l3- 6- bis tert-butox carbon lamino ridin lac late To solution of (E)-ethyl 3-(6-aminopyridinyl)acrylate (6.6 g, 34.3 mmol) and DMAP (0.21 g, 1.7 mmol) in THF(150 mL) was added di-tert-butyl dicarbonate (15.7 g, 71.9 mmol). The mixture was stirred ght at room temperature. The reaction was 2014/062913 concentrated and a brown solid was obtained as crude (E)-ethyl 3-(6-(bis(tert- butoxycarbonyl)amino)pyridinyl)acrylate (12.5 g, 93%). LCMS (m/z) 237.4 (MH+) 0.98 min.
Ste 3. trimeth l2- 6- tert-butox carbon lamino ridin l ro ane-1 1 3-tricarbox late and tetrameth l2- 6-amino ridin l ro ane-1 1 1 acarbox late To a flame flask was charged with ous MeOH (50mL), and the content was cooled down to 0 0C. To the flask was added sodium hydride (3.18 g, 60% in dispersion mineraloil, 80 mmol) with gas evolution under control. The reaction mixture was stirred at room temperature untill gas evolution ceased. To this freshly prepared NaOMe/MeOH solution was added dimethyl malonate (10.52 g, 80 mmol), and the mixture was stirred at room temperature for 20 min. The mixture turned into a milky slurry. The milky slurry was diluted with 25 mL ous MeOH, and decanted to a flask with sodium hydride (12.5 g, 31.9 mmol). The reaction mixture slurry was stirred at room temperature for 15 min, and then heated to reflux overnight. The reaction mixture was cooled down to room temperature, and concentrated. The residue was partitioned between EtOAc/H20 (100 mL/100 mL). The EtOAc layer was washed with 1 N NaOH (3 x 30 mL), brine (30 mL), dried over Na2804, and concentrated. A light brown oil was obtained as crude t.
The crude product was purified by flash chromatography eluting with nt EtOAc/CH2C|2_ Two major peaks were ed and ted as trimethyl 2-(6-(tert- butoxycarbonylamino)pyridinyl)propane-1,1,3-tricarboxylate (2.65 g, 20.3% yield) and tetramethyl 2-(6-aminopyridinyl)propane-1,1,1,3-tetracarboxylate (1.89 g, 16% yield).
The two products were characterized and confirmed by LCMS and 1H NMR. For trimethyl 2-(6-(tert-butoxycarbonylamino)pyridinyl)propane-1,1,3-tricarboxylate. LCMS (m/z) 411.5 (MH+), 0.64 min; 1H NMR (CDCI3) 6 ppm 8.15 (d, J = 2.0 Hz, 1H), 7.88 (d, J = 8.6 Hz, 1H), 7.60 - 7.52 (m, 2H), 3.90 (td, J = 9.8, 4.7 Hz, 1H), 3.76 (s, 3H), 3.56 (s, 3H), 3.55 (s, 3H), 2.92 - 2.81 (m, 1H), 2.80 - 2.69 (m, 1H), 1.53 (s, 9H). Fortetramethyl 2-(6- aminopyridinyl)propane-1,1,1,3-tetracarboxylate: LCMS (m/z) 369.5 (MH+) 0.47 min; 1H NMR (CDCI3) 6 ppm 8.31 (s, 1H), 8.19 (d, J = 2.3 Hz, 1H), 7.93 (d, J = 8.6 Hz, 1H), 7.60 (dd, J = 8.6, 2.3 Hz, 1H), 3.92 (td, J = 9.7, 4.9 Hz, 1H), 3.82 (s, 3H), 3.76 (s, 3H), 3.57 (s, 3H), 3.55 (s, 3H), 2.93 - 2.82 (m, 1H), 2.81- 2.70 (m, 1H).
Ste 4. dimeth l3- 6-amino ridinl entanedioate To a mixture of trimethyl 2-(6-(tert-butoxycarbonylamino)pyridinyl)propane-1,1,3- tricarboxylate (2.5 g, 6.1 mmol) and tetramethyl minopyridinyl)propane-1,1,1,3- tetracarboxylate (1.8 g, 4.9 mmol) in MeOH (30 mL) was added aqueous NaOH solution (2.44 g NaOH in 5 mL water, 60.9 mmol). The resulting mixture was heated to relux by oil bath for 1 hour. The reaction mixture was cooled down to room ature, and concentrated under reduced re via rotavap. To the concentrated residue were added water (15 mL) and conc. HCI (3 mL). The resulting mixture was heated to reflux overnight. The reaction e was cooled down, and concentrated under reduced pressure via rotavap, and a solid was obtained. The obtained solid residue was triturated with methanol (100 mL) and the precipitates was removed by filtration, and a light color filtrate was obtained. To the filtrate was added conc. HCI (200 uL) and the resulting mixture was heated to reflux via external oil bath for 1 h. The on mixture was cooled down, and tarted. The e was partitioned between EtOAc/sat. NaHC03 (50 mL/50 mL). Aqeous layer was extracted with EtOAc (50 mL). The EtOAc extracts were combined, washed with brine (50 mL), dried over Na2804, and concentrated. Awhite solid was obtained as desired dimethyl 3-(6-aminopyridinyl)pentanedioate (2.6 g, 10.31 mmol, 93.9% yield). LCMS (m/z) 253.2 (MH+) 0.38 min; 1H NMR (CDCI3) 6 ppm 7.95 (d, J = 2.3 Hz, 1H), 7.32 (dd, J = 8.2, 2.3 Hz, 1H), 6.46 (d, J = 8.6 Hz, 1H), 4.37 (br. s., 2H), 3.61 (s, 6H), 3.55 (quin, J = 7.5 Hz, 1H), 2.80 -2.66 (m, 2H), 2.65- 2.51 (m, 2H).
Ste 5. 3- 6-amino ridin-3— l entane-1 5-diol To aluminum (lll) lithium hydride/THF slurry (0.94g in 60 mL THF, 25 mmol) at 0 0C was added dimethyl 3-(6-aminopyridinyl)pentanedioate/THF solution (2.5 g, 9.9 mmol in 30 mL THF) over ~10 min. The slurry was stirred at 0 0C for 40 min, and then at room temperature for 45 min. The mixture was cooled down to 0 °C, and quenched by sequential addition of water (0.96 mL) with gas evolution under control, then 15% aqueous NaOH (0.96 mL), and water (2.9 mL). The quenched mixture was stirred at room temperature for 30 min. The precipitates were d via filtration. The filtrate was concentrated, and a light yellow solid (1.97 g, quantitative yield) was obtained as 3-(6- aminopyridinyl)pentane-1,5-diol. LCMS (m/z) 197.2 (MH+) 0.22 min.
Ste 6. 5- tetrah dro-2H- ran l ridinamine To 3-(6-aminopyridinyl)pentane-1,5-diol/toluene mixture (1.96 g, 10 mmol in 40 mL) were added 1 mL water to help ving, and then conc. H2804 (98%, 1.6 mL, 30 mmol). The resulting mixture was heated to reflux with Dean-Stark to remove water from reaction mixture for 1 h 20 min. The reaction e was cooled down to room temperature, and concentrated. The residue was d with ice cold water (15 mL), neutralized by solid Na2C03 (4 g), and extracted with EtOAc (3 x 30 mL). The EtOAc extracts were combined, washed with brine (30mL), dried over Na2804, and concentrated. A light yellow solid was obtained as crude 5-(tetrahydro-2H-pyran yl)pyridinamine. LCMS (m/z) 179.2 (MH+) 0.33 min; 1H NMR (CDCI3) 6 ppm 7.95 (d, J = 2.0 Hz, 1H), 7.32 (dd, J = 8.2, 2.3 Hz, 1H), 6.49 (d, J = 8.2 Hz, 1H), 4.34 (br. s., 2H), 4.11 - 3.99 (m, 2H), 3.51 (td, J = 11.2, 3.3 Hz, 2H), 2.73 -2.56 (m, 1H), 1.75 -1.69 (m, 4H).
Ste 7. o tetrah dro-2H- ran l ridinamine To 5-(tetrahydro-2H-pyranyl)pyridinamine /acetonitrile solution (1.4 g, 7.85 mmol/30 mL) at 0-5 0C was added portionwise NBS (1.4 g, 7.85 mmol) with internal temperature controlled below 5 oC. The resulting mixture was stirred at 0 0C for 1 hour 40 min. The reaction mixture was concentrated under reduced pressure, and the residue was triturated with dilute aqueous NaOH/H20(1 g/30 mL). The solid suspension was collected via filtration. The filtercake was washed with ice cold water (~10 mL), and the tes were combined, and extracted with EtOAc (20 mL). The EtOAc extract was washed with brine (20 mL), dried over Na2804, and concentrated. A light yellow solid was combined with the filter cake, and dried under high vacuum as crude 3-bromo(tetrahydro-2H- pyranyl)pyridinamine. LCMS (m/z) 257.1/259.1 (MH+) 0.39 min. 1H NMR (CDCI3) 6 ppm 7.90 (d, J :16 Hz, 1H), 7.54 (d, J = 2.0 Hz, 1H), 4.80 (br. s., 1H), 4.12 -4.02 (m, 2H), 3.54 -3.44 (m, 2H), 2.71 - 2.61 (m, 1H), 1.78 -1.68 (m, 4H).
Ste 8. 4- 2-amino tetrah dro-2H- ran l ridin lfluorobenzoic acid To a microwave vial were d with 3-bromo(tetrahydro-2H-pyranyl)pyridin amine (500 mg, 1.95 mmol), 4-boronofluorobenzoic acid (1.07 g, 5.83 mmol), aqueous Na2C03 (2 M, 4.86 mL) and DME (10 mL). The e was purged with argon, then followed by addition of Pd(PPh3)4 (225 mg, 0.194 mmol). The e was purged with argon, sealed and heated via microwave reactor at 125 0C for 20 min, and then at 130 0C for another 40 min. The DME layer of the reaction mixture was collected, and the solid precipitates were ated with methanol (2 x 10 mL). Methanol supernatants were combined with DME layer, and concentrated. The obtained residue was stirred with Et20 (2 x 60 mL), and the EtZO supernatants were discarded. The solid residue was ioned between EtOAc (20 mL) and aq. HCI (1N, 20 mL). The EtOAc layer was stripped with 1N HCI (2 x 5 mL), and the aqueous layers were combined. The aqueous layer was concentrated under reduced pressure, and the obtained light yellow solid was triturated with methanol (8 mL). The supernant was isolated via filtration and concentarted. 4-(2- Amino(tetrahydro-2H-pyranyl)pyridinyl)—2-fluorobenzoic acid (0.844 g, 2.67 mmol, 137% yield) was obtained as light yellow foam. LCMS (m/z) 317.2 (MH+) 0.46 min.
Ste 9. E meth | icolinaldeh de oxime To 6-methylpicolinaldehyde l solution (642 mg, 5.3 mmol/2.1 mL) was added hydroxyamine hydrochloride (368 mg, 5.3 mmol) and K2C03 aqueous solution (0.88 g/4.2 mL). The resulting solution was then heated to reflux via external oil bath for 30 min. The reaction mixture was cooled down to 0 OC, and stirred for 30 min. The white solid suspension was collected via filtration, and the filter cake was washed with some ld water. The filter cake was air dried, and further dried under high vacuum as the first crop t (0.565 g). The filtrates were combined, and concentrated to dryness. The residue was redissolved in water (2 mL), coolded to 0 °C and stirred for 20 min. The solid product was collected via filtration as the second crop of product (70 mg) as light yellow solid.
The two crops of product were combined to provide (E)methylpicolinaldehyde oxime (88%). LCMS (m/z) 136.9 (MH+) 0.21 min.
Ste 10. 6-meth | ridin lmethanamine To methylpicolinaldehyde oxime (0.635 g, 4.66 mmol)/acetic acid (267 uL, 4.66 mmol)/ethanol (10 mL) on was added portionwise zinc dust (5.19 g, 79 mmol) over min. The resulting mixture was stirred for additional 30 min. LCMS of reaction aliquot indicated reaction was ted. The zinc precipitates in reaction mixture was removed by filtration, and the filtrate was concentrated. The residue was ed to pH > 12 with excess sat. KOH (~ 7 mL), and stirred with EtZO (30 mL). The EtZO layer was collected, dried over , and concentrated. The residue was redissolved in EtOAc(15 mL), dried over Na2804, and concentrated. hylpyridinyl)methanamine was obtained as a colorless oil (385 mg, 3.15 mmol, 67.6%). LCMS (m/z) 123.2 (MH+) 0.15 min.
Ste 11. 4- 2-amino tetrah - ran l ridin lfluoro-N- 6-meth l ridin- 2-yl)methyl)benzamide To a vial were charged with 4-(2-amino(tetrahydro-2H-pyranyl)pyridinyl)—2- fluorobenzoic acid (20 mg, 0.063 mmol), (6-methylpyridinyl)methanamine (11.6 mg, 0.095 mmol), DIEA (28 uL, 0.158 mmol), PyBOP (65.8, 0.126 mmol) and DMF (0.5 mL).
The mixture was stirred at room temperature for 10 min. The reaction e was then ed by preparative HPLC, and product fractions were combined, frozen and lyophilized to afford 4-(2-amino(tetrahydro-2H-pyranyl)pyridinyl)—2-fluoro-N-((6- methylpyridinyl)methyl)benzamide as a white powder. LCMS (m/z) 421.3 (MH+) 0.41 min. 1H NMR (DMSO-d6) 6 ppm 8.99 (d, J = 3.1 Hz, 1H), 7.95 -7.83 (m, 3H), 7.79 (t, J = 7.6 Hz, 1H), 7.53 (d, J = 11.7 Hz, 2H), 7.44 (dd, J = 8.0, 1.4 Hz, 1H), 7.24 (d, J = 7.4 Hz, 2H), 4.60 (d, J = 5.5 Hz, 2H), 4.02 - 3.88 (m, 2H), 3.40 (td, J = 11.2, 2.7 Hz, 3H), 2.88 - 2.71 (m, 1H), 2.51 (br. s., 3H), 1.82 - 1.58 (m, 4H).
Example 206 S nthesis of S 2-amino1- difluorometh lmeth l-1H- razol l ridin l- 2-fluoro-N- 1- 3-fluoro fluorometh l hen lh drox eth l benzamide Scheme 97 F 0 Ste St 2 F 0 —eL NH2 0/ NH2 0 | / N d(d(Mpnon -DCM2_ Pd(dppf)Cl2-DCM + \NI/g \ N Na2003'DME B2(P|N)2, KOAc \ )‘F \ ,B\ F \ o o N—N H H m4 F o / Ste E NH2 N EDC, HOAt H “OH (1 M) DIEA, THF \ THF MeOH /\E?fl F \_\ \ >¢F >’F Ste 1. meth l4- 2-amino 4 4 5 5-tetrameth H 3 2-dioxaborolan l ridin l fluorobenzoate: A mixture of methyl 4-(2-aminobromopyridinyl)f|uorobenzoate (2 g, 6.15 mmol), B2(PIN)2 (3.12 g, 12.30 mmol), PdCl2(dppf) (0.225 g, 0.308 mmol), KOAc (1.811 g, 18.45 mmol) and dioxane (30.8 mL) was heated at oil bath overnight at 100 °C. The reaction mixture was extracted with EtOAc. The organic layer was washed with water and brine, dried over NazSO4, filtered off and trated in vacuo. To the crude product, ether was added. The ble material was filtered off to provide methyl 4-(2-amino (4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)pyridinyl)fluorobenzoate as a brown solid (79%). LCMS (m/z): 291.2 (MH+), 0.44 min (for boronic acid).
Ste 2. meth l4- 2-amino 1-meth l-1H- razol l ridin lfluorobenzoate A mixture of crude methyl 4-(2-amino(4,4,5,5-tetramethyl-1,3,2-dioxaborolan yl)pyridinyl)—2-fluorobenzoate (712 mg, 1.912 mmol), 1-(difluoromethyl)—4—iodo methyl-1H-pyrazole (740 mg, 2.87 mmol), PdC|2(dppf) (70.0 mg, 0.096 mmol), DME (7.899 mL), and 2M Na2C03 (3.95 mL) was heated at 100 °C overnight. After adding NazSO4 followed by dilution with EtOAc, the reaction mixture was ed off and the resulting volatile materials were concentrated in vacuo. The crude product was ed by flash chromatography eluting with 0-100% of EtOAc in DCM. LCMS (m/z): 491.1 (MH+), 0.64 min Ste 3. 4- 2-amino 1-meth l-1H- razol l ridin lfluorobenzoic acid To a solution of methyl 4-(2-amino(1-(difluoromethyl)methyl-1H-pyrazolyl)pyridin- 3-yl)—2-fluorobenzoate (352 mg, 0.935 mmol) in THF (6236 uL) and MeOH (3118 uL) was added LiOH (1 M solution) (1684 uL, 1.684 mmol). The reaction mixture was stirred at room temperature. To the reaction mixture, 1 N HCI was added up to pH 5. The reaction mixture was ted with EtOAc. The organic layer was dried over anhyrous sodium e, filtered off, and concentrated in vacuo to provide crude 4-(2-amino(1- (difluoromethyl)methyl-1H-pyrazolyl)pyridinyl)—2-fluorobenzoic acid (88%). LCMS (m/z): 363.3 (MH+), 0.51 min.
Ste 4. S 2-amino 1-meth l-1H- razol l ridin l-N- 1- 3-chloro hen l hydroxyethyl)—2-fluorobenzamide To a solution of 4-(2-amino(1-(dif|uoromethyl)methyl-1 H-pyrazolyl)pyridinyl)—2— fluorobenzoic acid (25 mg, 0.069 mmol) in DMF were added (S)—2-amino(3-fluoro (fluoromethyl)phenyl)ethanol (15.50 mg, 0.083 mmol), EDC, HOAt, and DIEA. The reaction mixture was stirred for 15 h. After water was added, the reaction mixture was worked up with EtOAc. The organic layer was dried over Na2804, filtered off and concentrated in vacuo. The crude product was ed by reverse phase prep HPLC. The pure fractions were lyophilized to provide (S)—4-(2-amino(1-(difluoromethyl)—3-methyl- 1 zolyl)pyridinyl)—2-fluoro-N-(1-(3-fluoro(fluoromethyl)phenyl) hydroxyethyl)benzamide as a TFA salt (50%). LCMS (m/z): 532.2 (MH+), 0.65 min; 1H NMR (400 MHz, CD30D) 6 ppm 8.23 (m, 1H), 7.97 (m, 1H), 7.93 (m, 1H), 7.82 (m, 1H), 7.51 - 7.30 (m, 3H), 7.2 (m, 1H), 7.09 (d, J = 8 Hz, 1H), 6.98 (d, J =12 Hz, 1H), 5.30 (d, J = 44 Hz, 2H), 5.14 (m, 1H), 3.8 (m, 2H), 2.32 (s, 3H). 8 nthesis of 4- 2-amino 1- rometh lmeth l-1H- razol | ridin l fluorobenzoic acid Following Steps 2 and 3 in Scheme 97, using 1,5-dimethyl(4,4,5,5-tetramethyl-1,3,2- dioxaborolanyl)-1H-pyrazole, 4-(2-amino(1-(difluoromethyl)methyl-1H-pyrazol yl)pyridinyl)—2-fluorobenzoic acid was obtained. LCMS (m/z): 363.1 (MH+), 0.53 min. 8 s of 4- 2-amino 1-meth l-1H-1 2 3-triazol | ridin lfluorobenzoic NH2 OH ing Steps 2 and 3 in Scheme 97, using 5-iodomethyl-1H-1,2,3-triazole, 4-(2— amino(1-methyl-1H-1,2,3-triazo|y|)pyridinyl)—2—fluorobenzoic acid was obtained.
LCMS (m/z): 314.3 (MH+), 0.38 min. 8 nthesis of 4- 2—amino—5- 1 5-dimeth l-1H- 4- | ridin | fluorobenzoic acid Following Steps 1 and 2 in Scheme 97, using methyl 4-(2—aminobromopyridinyl)—2— fluorobenzoate and 1,5-dimethyl(4,4,5,5-tetramethyl-1,3,2—dioxaborolan-2—yl)—1H- pyrazole, 4-(2—amino(1,5-dimethyl-1H-pyrazolyl)pyridinyl)—2—fluorobenzoic acid was obtained. LCMS (m/z): 327.1 (MH+), 0.45 min. 8 nthesis of 4- 2—amino 1 5-dimeth l-1H- razol | ridin | fluorobenzoic acid Following Steps 2 and 3 in Scheme 97, using methyl 4-(2-aminobromopyridinyl)—2- fluorobenzoate and 1,3-dimethyl(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)—1H- pyrazole, 4-(2—amino(1,3-dimethyl-1H-pyrazolyl)pyridinyl)—2-fluorobenzoic acid was obtained. LCMS (m/z): 327.2 (MH+), 0.47 min.
S nthesis of 4- 2-amino—5- 1 5-dimeth l-1H- razol l ridin l fluorobenzoic acid Following Steps 2 and 3 in Scheme 97, using methyl 4-(2-aminobromopyridinyl)—2- benzoate and 4-bromo—1-(difluoromethyl)methyl-1H-pyrazole, 4-(2-amino(1,3- yl-1H-pyrazolyl)pyridinyl)—2-fluorobenzoic acid was obtained. LCMS (m/z): 341.2 (MH+), 0.47 min.
S nthesis of 38 4R 4-chlorofluoro hen lmeth l rrolidinamine Scheme 97b 2014/062913 CI F CI F Steal F Stegg b Step; F \ ? SCI u/figOH —> + N02 3‘ ' HZN \ Z l 2 t 0 N N02 l (+/—) '1“ (+/—) Ste 1. E ch|orofluoro 2-nitrovin l benzene To a solution of 4-chlorofluorobenzaldehyde (8 g, 50.5 mmol) and ammonium e (9.72 g, 126 mmol) in acetic acid (168 mL) was added nitromethane (8.16 mL, 151 mmol).
The reaction mixture was heated at reflux for 5 h and cooled down. Water (100 mL) was added, and the mixture was stirred at room ature for 1 h. The solid was filtered, washed by water, and dried under vacuum. The solid was purified by flash chromatography (0-20% EtOAc/heptane) to yield clean t 4.2 g in 41 % yield. 1H NMR (400 MHz, CDCI3) 8 ppm 7.92 (d, J=13.7 Hz, 1H), 7.54 (d, J=13.8 Hz, 1H), 7.49 (d, J=7.5 Hz, 1H), 7.33 (dd, J=2.0, 9.3 Hz, 1H), 7.31 - 7.28 (m, 1H).
Ste 2. +/- - BR 48 4-chlorofluoro hen l meth lnitro rrolidine (E)chlorofluoro(2-nitrovinyl)benzene (4.2 g, 20.84 mmol), hylamino)acetic acid (4.64 g, 52.1 mmol), paraformaldehyde (3.75 g, 125 mmol) were mixed in dry e (104 mL). The reaction mixture was heated at reflux using Dean-stark overnight. The reaction mixture was partitioned between EtOAc and water. The organic was washed by sat. NaCl, dried over NaZSO4 and concentrated. The crude material was purified by flash chromatography to yield (+/-)-(3R,4S)(4-chlorofluorophenyl)methyl nitropyrrolidine in 45% yield. LCMS (m/z): 259.2 (MH+), 0.52 min; 1H NMR (400 MHz, CDCI3) 8 ppm 7.37 (t, J=8.0 Hz, 1H), 7.15 (dd, J=2.0, 10.2 Hz, 1H), 7.09 - 7.01 (m, 1H), 4.91 - 4.82 (m, 1H), 3.98 (d, J=5.1 Hz, 1H), 3.34 (dd, J=4.1, 10.8 Hz, 1H), 3.23 (t, J=8.6 Hz, 1H), 3.10 (dd, J=7.8, 10.6 Hz, 1H), 2.63 (dd, J=7.0, 9.4 Hz, 1H), 2.44 (s, 3H).
Ste 3. +/- - SS 4R 4-chlorofluoro hen lmeth l rrolidinamine Zinc dust (5.76 g, 88 mmol) was added into a mixture of (+/-)-(3R,4S)(4-chloro fluorophenyl)—1-methylnitropyrrolidine (2.28 g, 8.81 mmol) in MeOH (29.4 mL) and acetic acid (30 mL, 524 mmol). The reaction mixture was stirred at room temperature for h and filtered. Solvent was removed under vacuum. The residue was neutralized to pH 9, then extracted by Cl3 (3:7). The organic was dried over NazSO4, filtered and concentrated. The crude product was purified by flash tography ( DCM/Methanol/ NH3 90:9:1) to obtain (3S,4R)—4-(4-chlorofluorophenyl)methy|pyrrolidinamine in 40% yield. LCMS (m/z): 229.2 (MH+), 0.25 min.
S nthesis of +/- - 3S 4R 3-chlorofluoro hen l meth l rrolidinamine l (+/-) Following Scheme 97b, using 3-chlorofluorobenzaldehyde (3.92 g, 24.72 mmol), (+/-)- (3S,4R)—4-(3-chlorofluorophenyl)methylpyrrolidinamine was obtained. LCMS (m/z): 229.0 (MH+), 0.32 min.
Examples 207 and 208 S nthesis of trans 2-amino 1-meth l-1H- razol l ridin l-N- 3S 4R 3- chlorofluoro hen l meth l rrolidin l fluorobenzamide and trans 2-amino 1-meth l-1H- razol l ridin l-N- 3R 4S 3-chlorofluoro hen l meth l rrolidin lfluorobenzamide Scheme 98 ed Step 2 in Scheme 89, using (+/-)-(3S,4R)—4-(3-chlorofluorophenyl) methylpyrrolidinamine, 4-(2-amino(1-methyl-1H-pyrazolyl)pyridinyl)—N- ((38,4R)—4-(3-chlorofluorophenyl)methylpyrrolidinyl)—2-fluorobenzamide was obtained in 70% yield. LCMS (m/z): 523.3 (MH+), 0.56 min. The crude racemic mixture was resolved by chiral SFC (ChiraIPak 5mic OD column, 0 (mm), |PA+0.1% DEA=30%, 5mL/min). For polar diastereomer (Rt = 2.37 min), LCMS (m/z): 523.2 (MH+), 0.57 min; 1H NMR (400 MHz, CD3OD) 6 ppm 8.19 (d, J=2.0 Hz, 1H), 7.91 (s, 1H), 7.79 - 7.73 (m, 2H), 7.63 (d, J=2.3 Hz, 1H), 7.52 (dd, J=2.3, 7.0 Hz, 1H), 7.46 - 7.29 (m, 3H), 7.26 - 7.13 (m, 1H), 4.66 (d, J=6.3 Hz, 1H), 3.45 - 3.37 (m, 1H), 3.21 (t, J=9.0 Hz, 1H), 3.16 - 3.08 (m, 1H), 2.82 (dd, J=5.7, 10.0 Hz, 1H), 2.70 (t, J=9.2 Hz, 1H), 2.54 - 2.41 (m, 3H), 1.27 (d, J=17.6 Hz, 1H). For less polar diastereomer (Rt = 3.96 min), LCMS (m/z): 523.2 (MH+), 0.58 min; 1H NMR (400 MHz, CD3OD) 6 ppm 8.19 (d, J=2.0 Hz, 1H), 7.91 (s, 1H), 7.79 - 7.73 (m, 2H), 7.63 (d, J=2.3 Hz, 1H), 7.52 (dd, J=2.3, 7.0 Hz, 1H), 7.46 - 7.29 (m, 3H), 7.26 - 7.13 (m, 1H), 4.66 (d, J=6.3 Hz, 1H), 3.45 - 3.37 (m, 1H), 3.21 (t, J=9.0 Hz, 1H), 3.16 - 3.08 (m, 1H), 2.82 (dd, J=5.7, 10.0 Hz, 1H), 2.70 (t, J=9.2 Hz, 1H), 2.54 - 2.41 (m, 3H), 1.27 (d, J=17.6 Hz, 1H).
Examples 209 and 210 S nthesis of 4- 2-amino 1-meth l-1H- razol l ridin l-N- 3S 4R 4- chlorofluoro hen l meth l rrolidin l orobenzamide and trans 2-amino 1-meth l-1H- razol l ridin l-N- 3R 4S 4-chlorofluoro hen l meth | rrolidin |f|uorobenzamide Scheme 99 Following Step 2 in Scheme 86, using (3S,4R)—4-(4-chlorofluorophenyl) methylpyrrolidinamine, (+/-)(2-amino(1-methyl-1H-pyrazolyl)pyridinyl)—N- ((38,4R)—4-(4-chlorofluorophenyl)methylpyrrolidinyl)—2-fluorobenzamide was obtained in 79% yield. LCMS (m/z): 523.2 (MH+), 0.57 min. The crude racemic mixture was resolved by chiral SFC (ChiralPak 5mic OD , 4.6x100 (mm), 1% DEA=30%, 5mL/min). For polar diastereomer (Rt = 2.45 min), LCMS (m/z): 523.2 (MH+), 0.58 min; 1H NMR (400 MHz, CD3OD) 6 ppm 8.18 (d, J=2.2 Hz, 1H), 7.90 (s, 1H), 7.80 - 7.72 (m, 2H), 7.66 - 7.61 (m, 1H), 7.44 - 7.36 (m, 3H), 7.33 - 7.29 (m, 1H), 7.19 (dd, J=1.8, 8.3 Hz, 1H), 4.71 - 4.62 (m, 1H), 3.90 (s, 3H), 3.44 - 3.37 (m, 1H), 3.22 (d, J=9.6 Hz, 1H), 3.12 (dd, J=7.9, 10.0 Hz, 1H), 2.86 - 2.80 (m, 1H), 2.74 - 2.67 (m, 1H), 2.51 - 2.44 (m, 3H). For less polar diastereomer (Rt = 3.92 min), LCMS (m/z): 523.2 (MH+), 0.58 min; 1H NMR (400 MHz, CD30D) 6 ppm 8.19 (d, J=2.2 Hz, 1H), 7.90 (s, 1H), 7.80 - 7.70 (m, 2H), 7.63 (d, J=2.2 Hz, 1H), 7.46 - 7.36 (m, 3H), 7.30 (dd, J=2.0, 10.6 Hz, 1H), 7.19 (dd, J=1.8, 8.4 Hz, 1H), 4.66 (d, J=5.9 Hz, 1H), 3.91 (s, 3H), 3.44 - 3.36 (m, 1H), 3.19 (t, J=9.0 Hz, 1H), 3.11 (dd, J=7.8, 10.0 Hz, 1H), 2.83 - 2.78 (m, 1H), 2.69 (dd, J=8.4, 9.5 Hz, 1H), 2.45 (s, 3H). 8 nthesis of 4- 3-aminoc clo ro l razin lfluorobenzoic acid Scheme 100 F O Ste Ste NH2 o/ Y H2 )2 032003 LiOH | + ,B‘K” —> N/ —> N/ §N F I': F toluene \ MeOH/THF 90x)0 97% Br \N Ste 1. meth |4- 3-aminoc clo ro l razin lfluorobenzoate To methyl 4-(3-aminobromopyrazinyl)fluorobenzoate (for synthesis see Example 34, Step 2) (300 mg, 0.920 mmol) in toluene (10 mL) and water (1 mL) was added potassium cyclopropyl trifluoroborate (408 mg, 2.76 mmol), di(1-adamantyl)-n- butylphosphine (66.0 mg, 0.184 mmol), cesium carbonate (1499 mg, 4.60 mmol), and palladium(|l) e (20.65 mg, 0.092 mmol). The reaction mixture was heated in heating block at 100 °C overnight. The reaction e was quenched with sat. NH4C| and extracted with ethyl acetate. The organic extracts were combined, washed with brine, dried over sodium sulfate, filtered and evaporated. The crude was purified by flash chromatography (0 to 80% EtOAc in heptane) yielding methyl 4-(3-amino cyclopropylpyrazinyl)fluorobenzoate (250 mg, 90%). LCMS (m/z): 288.2 (MH+), 0.756 min.
Ste 2. 4- 3-aminoc clo ro l razin lfluorobenzoic acid To methyl 4-(3-aminocyclopropylpyrazinyl)fluorobenzoate (250 mg, 0.870 mmol) in THF (6 mL) and MeOH (3 mL) was added 1M LiOH (1.740 mL, 1.740 mmol). The reaction mixture was stirred at room temperature for 2 h. The pH of reaction es was adjusted to ~4 by aqueous. 2N HCI. The reaction mixture was ioned between EtOAc and water. The organic layer was separated, washed with brine, dried over sodium sulfate, filtered and evaporated to yield 4-(3-aminocyclopropylpyrazinyl) fluorobenzoic acid (230 mg, 97%) as a light yellow solid. LCMS (m/z): 274.2 (MH+), 0.621 min. 8 s of 4- 2-aminoc clo ro l ridin lfluorobenzoic acid Following Scheme 100, using methyl 4-(2-aminobromopyridinyl)—2-fluorobenzoate, 4-(2-aminocyclopropylpyridinyl)—2-fluorobenzoic acid was obtained (80%). LCMS (m/z): 273.0 (MH+), 0.515 min. 8 nthesis of 4- 3-aminoc clohex l razin l fluorobenzoic acid NH2 OH Following Steps 1, 2 and 3 in Scheme 66, using 2-(cyclohex—1-enyl)-4,4,5,5- tetramethyl-1,3,2—dioxaborolane, minocyclohexylpyrazinyl)fluorobenzoic acid was obtained. LCMS (m/z): 316.3 (MH+), 0.79 min.
Example 211 S nthesis of 4- 2-amino 1S 4r oxidotetrah dro-2H-thio ran l ridin l-N- S 3-chloro hen lh drox eth lfluorobenzamide Scheme 101 F o F o F 0 Step; 1 J< Ste ; J< NH2 ’0’? —9 NH2 0 NH2 0 N\B\O 0J< l/ Br O\ ,O N \ + B _, N \ NI \ I / Br 6] S TSte A / —fSte 5 S A F 0 {OH NH2 OH NH2 /OH 3 N \ 2 N \ —’ | I / + H2N/\© _. / CI s_._ a 0+ 8+ (3—0: Ste 1. ut l4- 2-amino ridin lfluorobenzoate A degassed mixture of 3-(4,4,5,5-tetramethy|—1,3,2-dioxaborolany|)pyridinamine (2.4 g, 10.91 mmol), tert-butyl 4-bromofluorobenzoate (3.30 g, 12.00 mmol), Pd(PPh3)4 (0.63 mg, 0.0.545 mmol), 2.0 M Na2C03 s solution (10.91 mL) in n-butanol (26 mL) was microwave heated to 130 0C for 10 min. The reaction was diluted with ethyl acetate (30 mL), and then washed with water (10 mL) and brine (10 mL). The organics were dried over sodium e, filtered, concentrated, and then purified by flash tography (10-60% ethyl acetate/heptane eluent) to provide tert-butyl 4-(2- aminopyridinyl)fluorobenzoate (1.35 g, 43% yield). LCMS (m/z): 289.4 (MH+), 0.67 min.
Ste 2. tert-but l4- 2-aminobromo ridin lfluorobenzoate A solution of tert-butyl 4-(2-aminopyridinyl)—2-fluorobenzoate (700 mg, 2.43 mmol) in acetonitrile (10 mL) was treated with NBS (453 mg, 2.55 mmol). After 10 min, the reaction was completed. The reaction was treated with 1:1 sat. aq. NaHC03: sat.aq. Na28203 (10 mL). The e was stirred vigorously for 10 min. The mixture was diluted with ethyl e (30 mL) and the layers were separated. The organics were washed with brine, dried over magnesium sulfate, filtered and concentrated to provide tert-butyl mino- -bromopyridinyl)—2-fluorobenzoate (803 mg, 90% yield). LCMS (m/z): 367.2, 369.2 (MH+), 0.75 min.
Ste 3. tert-but l4- 2-amino 3 6-dih -thio ran l ridin l fluorobenzoate A degassed mixture of tert-butyl 4-(2-aminobromopyridinyl)fluorobenzoate (400 mg, 1.09 mmol), -dihydro-2H-thiopyranyl)-4,4,5,5-tetramethyl-1,3,2- dioxaborolane (296 mg, 1.31 mmol), Pd(PPh3)4 (126 mg, 0.109 mmol) in 2.0 M Na2C03 aqueous solution (1.63 mL) and n-butanol (5 mL) was microwave heated to 130 0C for 15 min. The reaction was diluted with ethyl acetate (20 mL), and then washed with water (10 mL) and brine (10 mL). The organics were dried over sodium sulfate, filtered, concentrated, and then purified by flash chromatography (10-60% ethyl acetate/heptane eluent) to provide tert-butyl 4-(2-amino(3,6-dihydro-2H-thiopyranyl)pyridinyl)—2- fluorobenzoate (400 mg, 95% yield). LCMS (m/z): 387.1 (MH+), 0.87 min; 1H NMR (400 MHz, CD30D) 8 ppm 7.83 - 7.76 (m, 2H), 7.68 (d, J = 1.96 Hz, 1H), 7.37 - 7.34 (m, 1H), 7.33 - 7.29 (m, 2H), 7.28 - 7.24 (m, 2H), 7.24 - 7.18 (m, 1H), 5.10 (t, J = 5.87 Hz, 1H), 3.83 - 3.69 (m, 2H), 2.81 - 2.70 (m, 2H), 2.63 - 2.49 (m, 3H), 2.08 (dd, J = 2.74, 13.30 Hz, 2H), 1.72 (dq, J = 2.93, 12.59 Hz, 2H).
Ste 4. tert-but l4- o 1-oxido-3 6-dih dro-2H-thio ran l ridin l fluorobenzoate A 0 oC solution of 4-(2-amino(3,6-dihydro-2H-thiopyranyl)pyridinyl)—2- fluorobenzoate in e (20 mL) was treated with a on of oxone (227 mg, 0.369 mmol) in water (5 mL). After 20 min, the reaction was diluted with ethyl acetate (50 mL) and water (50 mL). The layers were separated and the aqueous layer was washed with ethyl acetate (50 mL). The combined organics were washed with water (30 mL) and brine (30 mL), dried over ium sulfate, filtered and concentrated to provide tert-butyl 4- (2-amino(1-oxido-3,6-dihydro-2H-thiopyranyl)pyridinyl)—2-fluorobenzoate (220 mg, 74% yield). LCMS (m/z): 403.5 (MH+), 0.66 min.
Ste 5. tert-but l4- 2-amino 1r4r oxidotetrah dro-2H-thio ran | ridin l fluorobenzoate A degassed slurry of tert-butyl 4-(2-amino(1-oxido-3,6-dihydro-2H-thiopyran yl)pyridinyl)—2-fluorobenzoate (220 mg, 0.547 mmol) in methanol (15 mL) was treated with 1.0 N HCI s solution (0.82 mL) and 10% Pd(OH)2. The vessel was charged with hydrogen to 250 PSI. After 2 h, the reaction was completed. The slurry was degassed, filtered over celite and concentrated to provide tert-butyl mino((1r,4r)— otetrahydro-2H-thiopyranyl)pyridinyl)—2-fluorobenzoate (150 mg, 68% yield).
LCMS (m/z): 405.6 (MH+), 0.63 min.
Ste 6. 4- 2-amino 1r4r oxidotetrah dro-2H-thio ran | ridin l fluorobenzoic FA A room temperature solution of tert-butyl 4-(2-amino((1r,4r)oxidotetrahydro-2H- thiopyranyl)pyridinyl)f|uorobenzoate (50 mg, 0.124 mmol) in DCM (2 mL) was treated with TFA (1 mL). After 1 h, the reaction was concentrated. The resulting material was slurried in benzene with sonication, and then concentrated again to provide 4-(2- amino((1r,4r)oxidotetrahydro-2H-thiopyranyl)pyridinyl)fluorobenzoic acid- TFA (57 mg, 100% yield). LCMS (m/z): 349.2 (MH+), 0.37 min.
Ste 7. 4- 2-amino 1S 4r oxidotetrah dro-2H-thio ran | ridin l-N- S (3-chlorophenyl )—2-hyd roxyethyl )—2-fluorobenzamide A solution of 4-(2-amino((1r,4r)oxidotetrahydro-2H-thiopyranyl)pyridinyl)—2- fluorobenzoic FA (57 mg, 0.123 mmol) and (S)amino(3-chlorophenyl)ethano| (25 mg, 0.148 mmol) in DMF (1 mL) was treated with HATU (61 mg, 0.160 mmol) and DIEA (129 uL, 0.738 mmol). After 1 h, the reaction was diluted with water (5 mL) and extracted into ethyl acetate (2 x 10 mL). The product was present in both layers.
Therefore both the s and organic layers were trated and ed by reverse phase prep HPLC to provide 4-(2-amino((1S,4r)—1-oxidotetrahydro-2H-thiopyran yl)pyridinyl)—N-((S)—1-(3-chlorophenyl)hydroxyethyl)fluorobenzamide as a TFA salt (20 mg, 26% yield). LCMS (m/z): 502.1, 504.1 (MH+), 0.57 min. 1H NMR (400 MHz, CD3OD) 8 ppm 8.63 (dd, J = 4.11, 7.24 Hz, 1H), 7.90 (d, J = 1.96 Hz, 1H), 7.80 (t, J = 7.83 Hz, 1H), 7.76 (d, J = 1.57 Hz, 1H), 7.38 - 7.31 (m, 3H), 7.29 -7.25 (m, 2H), 7.24 - 7.17 (m, 1H), 5.14 - 5.06 (m, 1H), 3.83 -3.70 (m, 2H), 3.06 (d, J = 12.91 Hz, 2H), 2.85 - 2.70 (m, 3H), 2.38 - 2.24 (m, 2H), 1.83 (d, J = 12.13 Hz, 2H).
Example 212 S nthesis of S 2-amino tetrah dro-2H-thio ran l ridin l-N- 1- 3- chloro hen lh drox eth lfluorobenzamide F 0 :/OH I NDH / CI The reaction sequence depicted in Scheme 101, steps 5, 6, and 7 was applied to tert- butyl 4-(2-amino(3,6-dihydro-2H-thiopyranyl)pyridinyl)—2-fluorobenzoate to obtain (S)(2-amino(tetrahydro-2H-thiopyranyl)pyridinyl)—N-(1-(3-chlorophenyl) hydroxyethyl)fluorobenzamide. LCMS (m/z): 486.0, 488.0 (MH+), 0.73 min; 1H NMR (400 MHz, CD30D) 8 ppm 7.83 -7.76 (m, 2H), 7.68 (d, J = 1.96 Hz, 1H), 7.37 -7.34 (m, 1H), 7.33 -7.29 (m, 2H), 7.28 - 7.24 (m, 2H), 7.24 - 7.18 (m, 1H), 5.10 (t, J = 5.87 Hz, 1H), 3.83 - 3.69 (m, 2H), 2.81 -2.70 (m, 2H), 2.63 - 2.49 (m, 3H), 2.08 (dd, J = 2.74, 13.30 Hz, 2H), 1.72 (dq, J = 2.93, 12.59 Hz, 2H).
S nthesis of 4- 2-amino 1-meth l-1H- razol-4— l ridin lmeth lbenzoic acid Scheme 102 O Stepl 0 Br —> Br OH K2003, Mel 0— Step; NH2 Stegg NH2 0 Br Q ,0 B NI \ lB—B\ —> N \ ‘O / o o l NH 0/ N/ Step4_ 2 NH2 0/ A | ,N o o —> N/ N | oxB N / | | | \ Br o NH2 0 Step g Step g ”“2 OH —> I —> N/ \ \ LiOH \\ / N—N N—N \ / Step 1. methyl 4-bromomethylbenzoate A stirred mixture of 4-bromomethylbenzoic acid (6 g, 27.9 mmol), iodomethane (5.21 mL, 84 mmol) and ium carbonate (11.57 g, 84 mmol) in DMF (60 mL) was stirred at room temperature overnight. The reaction mixture was partitioned n water (250 mL) and 4:1 s:ethyl acetate (650 mL). The organic layer was washed with water and dried over Na2804. The solvent was removed under vacuum to give 6.39 g of desired product as an oil in 100% yield. 1H NMR (400 MHz, CD3OD) 6 ppm 7.86 - 7.65 (m, 7 H) 7.50 (br. s., 2 H) 3.88 (s, 3 H) 2.56 (s, 3 H).
Ste 2. 3- 4 4 5 5-tetrameth H 3 2-dioxaborolan l ridinamine To a suspension of 3-bromopyridinamine (6 g, 34.7 mmol) in 1,4-dioxane (87 mL) was added Bispin (13.21 g, 52.0 mmol) and potassium acetate (10.21 g, 104 mmol). The e was purged with nitrogen for 10 min, and then PdCl2(dppf)-CH2C|2 adduct (2.83 g, 3.47 mmol) was added. The reaction mixture was heated to 108 °C in an oil bath for 2 - 3 h. The reaction mixture was diluted with ethyl acetate, filtered h ce|ite and trated. The residue was used in next step Suzuki coupling without further purification. LCMS (m/z): 139 (MH+) 0.22 min (for boronic acid).
Ste 3. meth l4- 2-amino ridin lmeth lbenzoate To 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)pyridinamine(7.37 g, 33.5 mmol) in 500 mL round bottom flask were added methyl 4-bromomethylbenzoate (6.390 g, 27.9 mmol), dppf)-DCM (2.041 g, 2.79 mmol), DME (209 mL) and 2 M Na2C03 solution (69.7 mL). The on mixture was bubbled through N2 for 20 min and heated in an oil bath at 108 °C for 1.5 h. The reaction mixture was diluted with EtOAc, washed with water three times, dried over NazSO4, filtered and concentrated. The crude product was purified by flash chromatography eluting with 0-100% of EtOAc (containing 10% of MeOH)/heptane to e crude product around 8 g which contained fair amount of B2(P|N)2 from previous experiment. Ether was added to dissolve the crude mixture, and then e was added to crush out the desired produt. Solid was filtered out to provide 4.2 g of desired product with high purity in 62.1 % yield. LCMS (m/z): 243.5 (MH+), 0.56 min.
Ste 4. meth l4- 2-aminobromo ridin lmeth lbenzoate To a solution of methyl 4-(2-aminopyridinyl)—2-methylbenzoate (4.2 g, 17.34 mmol) in acetonitrile (173 mL) was added NBS (3.15 g, 17.68 mmol) in two portions at 0 °C . The reaction mixture was stirred at 0 °C for 20 min. LCMS showed the on completed.
After quenched with sat. Na2803 and NaHC03, the reaction mixture was d for 30 min. The on mixture was extracted with EtOAc 3 times, washed by sat NaHC03, water and brine. The organics was dried over NazSO4, filtered and concentrated. The crude material was triturated with ether and taken to the next step without further purification. LCMS (m/z): 323.1 (MH+), 0.68 min.
Ste 5. meth l4- 2-amino 1-meth l-1H- razol l ridin lmeth lbenzoate To methyl 4-(2-aminobromopyridinyl)—2-methylbenzoate (500 mg, 1.557 mmol) in 20 mL MW vial was added 1-methyl(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-1H- pyrazole (421 mg, 2.024 mmol), PdC|2(dppf)DCM (114 mg, 0.156 mmol), DME (11.7 mL) and 2 M Na2C03 solution (3.892 mL). The reaction mixture was heated at microwave synthesizer (12 min, 120 °C). The reaction mixture was diluted with EtOAc and washed with water three times, dried over NaZSO4, filtered and concentrated. The crude product was purified by flash chromatography eluting with 0-100% of EtOAc (containing 10% of MeOH)/heptane to e crude product which was triturated with ether to provide 400 mg of pure product in 80 % yield. LCMS (m/z): 323.4 (MH+), 0.60 min.
Ste 6. 4- 2-amino 1-meth l-1H- razol l ridin lmeth lbenzoic acid To a solution of methyl 4-(2-amino(1-methyl-1H-pyrazolyl)pyridinyl)—2- methylbenzoate (1.20 g, 3.72 mmol) in THF/MeOH/HZO (1:1:1, 36 mL) was added LiOH- H20 (0.234 g, 5.58 mmol). The solution was stirred at room temperature overnight. The pH was adjusted to 3-5, optimally 4. All the organic ts were removed by reduced re. EtOAc was added to triturate out all the impurities. Water was added and the mixture was stirred for 30 min. Solid was ed and washed well with 50% of ether and water. The solid was then pied on rotovap with e to provide about 800 mg of desired acid in 69.7 % yield. LCMS (m/z): 309.2 (MH+), 0.50 min.
S nthesis of 4- 2-amino 1-eth l-1H- razol l ridin lfluorobenzoic acid Scheme 103 Step 1 Step 2 F O F O isoprene OJ< OH —. Br . 03 + N \ cat. st04 Br 33(6) / Step; 3,625 F o J< >1 : Pd(dPPf)CI2, NaZCO3 NBS NH2 0 \B’O —’ ' N \ + 00C,20min '/ N'(\g F o F o —23te é NH2 oJ< SteQ 5 NH2 OH Pd(dppf)CI2 N32C03 N/ I TFA \ —> | DME, 120°C, 20 min Step 1. tert-butyl 4-bromofluorobenzoate A slurry of 4-bromofluorobenzoic acid (20.16 g, 92 mmol) in dioxane (90 mL) and conc.
H2804 (5 mL) was cooled to 0 °C, and then bubbled through with isobutene for 2 h. The on was allowed to gradually warm up to room temperature overnight. Solid NaHC03 (40 g) was carfully added to the reaction and the mixture was stirred for 1 h. The e was concentrated, and then redissolved in water and ethyl e. The layers were seperated. The aqueous phase was washed with ethyl acetate. The combined organics were washed with sat aq NaHC03 and brine, then dried over Na2804, filtered and concnetrated. The resulting oily tert-butyl 4-bromofluorobenzoate was used without further purification. 1H NMR (400 MHz, MeOH-d4) 8 ppm 7.79 - 7.70 (m, 1H), 7.42 - 7.23 (m, 3H), 1.59 (s, 11H).
Step 2. tert-butyl ro(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)benzoate A slurry of tert-butyl 4-bromofluorobenzoate (5.55 g, 20.17 mmol), BISPIN (7.68 g, 30.3 mmol), PdCl2(dppf)-CH2Cl2adduct (1.153 g, 1.412 mmol) and potassium acetate (5.94 g, 60.5 mmol) in DMF (75 mL) was degassed, and then heated to 100 °C overnight. The reaction was concentrated, then dissolved in DCM, filtered over celite, and then washed with water and brine. The cs were filtered over celite, concentrated, and then purified by flash tography eluting with 0 - 20% ethyl acetate/heptane to e 5.2 g of tert-butyl 2-fluoro(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)benzoate in 80% yield.
Ste 3. tert-but |4- 2-amino ridin |f|uorobenzoate A slurry of tert-butyl 2-fluoro(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)benzoate (5.1 g, 15.83 mmol), 3-bromoaminopyridine (3.01 g, 17.41 mmol) and Pd(PPh3)4 (0.732 g, 0.633 mmol) in n-butanol (50 mL) and 2.0 M Na2C03aqueous solution (19.79 mL, 39.6 mmol) was ed, and then heated to 100 °C overnight. The reaction was cooled, and diluted with ethyl acetate. The layers were seperated, and the organics were washed with brine, filtered over celite and concentrated. The crude was purified by flash chromatography eluting with 10 - 50% ethyl acetae/heptane to provide 3.41 g of tert-butyl 4-(2-aminopyridiny|)fluorobenzoate in 75% yield.
Ste 4. ut l4- 2-aminobromo ridin lfluorobenzoate NBS (2.145 g, 12.05 mmol) was added to a room temperature solution of tert-butyl 4-(2- aminopyridinyl)f|uorobenzoate (3.31 g, 11.48 mmol) in MeCN (60 mL). The resulting mixture was stirred for 10 min. The reaction was quenched with 1:1 of sat. aq.
Na28203:sat. aq. NaHC03 solution, and then extracted into ethyl acetate. The combined organics were washed with brine, dried over sodium e and concentrated in vacuo yielding utyl minobromopyridinyl)—2-f|uorobenzoate. The material was used without further purification. LCMS (m/z): 369.0 (MH+), 0.85 min.
Ste 5. tert-but |4- 2-amino1-eth |-1H- razol | ridin |f|uorobenzoate To tert-butyl 4-(2-aminobromopyridinyl)f|uorobenzoate (200 mg, 0.544 mmol) (See Scheme 101, Step 2 for synthesis) in DME (3 mL) and 2 M sodium carbonate (1.5 mL, 3.0 mmol) was added 1-ethy|(4,4,5,5-tetramethyl-1,3,2-dioxaboro|anyl)-1H- le (182 mg, 0.816 mmol) followed by PdC|2(dppf)-CH2C|2 adduct (44.5 mg, 0.054 mmol). The reaction mixture was microwave heated at 120 °C for 20 min. The reaction mixture was partitioned between ethylacetate and water. The organic layer was separated, washed with brine, dried over sodium sulfate, filtered and evaporated. The crude was purified by flash chromatography eluting with 0 -50% of EtOAc WO 66188 (contains10%MeOH) / heptane ng tert-butyl 4-(2-amino(1-ethyl-1H-pyrazol yl)pyridinyl)—2-fluorobenzoate (160 mg, 77%). LCMS (m/z): 383.2 (MH+), 0.782 min.
Ste 6. 4- 2-amino 1-eth l-1H- razol l ridin lfluorobenzoic acid To tert-butyl 4-(2-amino(1-ethyl-1H-pyrazolyl)pyridinyl)—2-fluorobenzoate (160 mg, 0.418 mmol) in DCM (0.5 mL) was added TFA (2 mL, 26 mmol). The reaction mixture was stirred at room temperature for 1 h. The reaction mixture was co-evaporated with toluene in The crude 4-(2-amino(1-ethyl-1H-pyrazolyl)pyridinyl)—2-fluorobenzoic acid was used for next step. LCMS (m/z): 327.2 (MH+), 0.509 min.
Example 213 4- 2-amino 1- meth lsulfon l rrolidin l ridin lfluoro-N- S h drox phenylethyl )benzamide Scheme 104 Ste Ste 0‘ ,0 NHZ B H2 NQYCI NBS/ACN + Pd(dppf)C|2/N32003N N/ K/Nl DME/lOOUC/S—4h 94% 93% \N 3&24. m; CF34? CFs 9 O 0‘ O CF3802\N,SOZCF3 0:S\O — ‘0 O‘B/B: B’O ITI. O’ O \S_,N\sl/ + / \ + N )4 \ / '\ /'\ N Pd(dppf)C|2/KOAC N O 0 f0 )f0 98% >7,F): Dioxane o K 0 O K F o ste Stepfi StepZ “”2 O/ Pd(dppf)CI2 3 /TFA, DCM NH2 0 / ’ N / N / N l DME/11OOC/20min I \ N 60% \ \ NwO NH F o F o F o F o :/ NH2 0’ NH2 0/ NH2 OH NH2 N $28 mg mm H N/ N/ N/ N/ | | | | \ N MeSOZCI LIOH HATU/TEA \ N \ N \ N DIEA/ DCM DMF MeOH / THF NH N\ ,,o N\ ,,o N\ ,,0 fi\ fi\ §\ 0 o o Ste 1. meth |4- 3-amino razin |f|uorobenzoate To a mixture of 3-chloropyrazinamine (5 g, 38.6 mmol) in DME ( 160 mL) and aq. 2 M sodium carbonate (40 mL, 80 mmol) was added methyl 2-fluoro(4,4,5,5-tetramethyl- 1,3,2-dioxaboro|any|)benzoate (12.97 g, 46.3 mmol) ed by PdC|2(dppf)-CH2CI2 adduct (3.15 g, 3.86 mmol). The reaction mixture was purged with N2 and heated in an oil bath at 100 °C for 3 -4 h. The reaction mixture was partitioned between ethylacetate and water. The organic layer was separated, washed with brine, dried over sodium sulfate, filtered and evaporated. The crude was triturated with DCM. Solid observed was filtered, washed with ether and dried under reduced pressure to provide product as an off white solid. Filtrate was purified by flash chromatography eluting with 0% EtOAc/ heptane to provide 10.6 g of product in 93% yield. LCMS (m/z): 248.1 (MH+), 0.563 min.
Ste 2. meth |4- o razin |f|uorobenzoate To a mixture of methyl 4-(3-aminopyrazinyl)f|uorobenzoate (8.9 g, 36.0 mmol) in acetonitrile (300 mL) in an ice bath was added NBS (5.77 g, 32.4 mmol). The reaction mixture was stirred at 0 °C for 1 h. NBS (0.05 equiv.) was added and the resulting mixture was stirred for another 30 min. To the reaction mixture was added saturated sodium bicarbonate solution. The mixture was stirred for 30 min and t was extracted with EtOAc. The organic extracts were combined, washed with brine, dried over sodium e, filtered and evaporated. The residue was dried under high vaccum to provide a brown solid (12.2g, 94%). LCMS (m/z): 326.0/328.0 (MH+), 0.846 min.
Ste 3. tert-but |5- trifluorometh lsulfon lox -3 4-dih dro -1 2H -carbox late Tert-butyl 3-oxopiperidinecarboxy|ate (1.1 g, 5.52 mmol) was taken in THF (10 mL) and cooled to -78 °C. To that was added lithium bis(trimethylsilyl)amide (6.07 mL, 6.07 mmol) (1 M solution in THF). The reaction e was stirred at -78 °C for 20 min, and then a solution of 1,1 ,1-trif|uoro-N-phenyl-N-((trifluoromethyl)sulfonyl) methanesulfonamide (2.071 g, 5.80 mmol) in THF (10 mL) was added dropwise. The reaction mixture was stirred at -78 °C for 15min, then warmed to and stirred at 0 °C for 3 h. The reaction mixture was quenched with sat. sodium onate solution and then extracted with ethyl acetate. The combined extracts were washed with brine, dried over sodium sulfate, filtered and evaporated.The crude was purified through a plug of neutral alumina with 10% EtOAc in heptane. Solvent was evaporated and the residue was dried to provide the desired product as a yellow liquid (2 g, 98%).
Ste 4. tert-but l 5- 4 4 5 5-tetrameth H 3 2-dioxaborolan l -3 4-dih dro ridine- 1(2H )—carboxylate A mixture of 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (1.223 g, 4.81 mmol), potassium e (1.289 g, 13.13 mmol) and PdC|2(dppf)-CH2C|2 adduct (0.107 g, 0.131 mmol) in flask was flushed with N2, and then dioxane (12 mL) was added, followed by a solution of tert-butyl 5-(((trifluoromethyl)sulfonyl)oxy)-3,4-dihydropyridine- carboxylate (1.45 g, 4.38 mmol) in dioxane (12 mL). The reaction mixture was purged with N2 for 5 min, and then heated in oil bath at 80 °C overnight. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was separated, washed with brine, dried over sodium sulfate, filtered and evaporated. The residue was purified by flash chromatography g with 0 - 30% of EtOAc / heptane to yield the desired product as a highly viscous liquid (1.2 g, 89%). LCMS (m/z): 254.1 (MH+- tBu), 1.21 min.
Ste 5. ut l5- 5-amino 3-fluoro methox carbon l hen l razin l-3 4- dih dro ridine-1 2H -carbox late To a mixture of methyl 4-(3-aminobromopyrazinyl)fluorobenzoate (240 mg, 0.70 mmol) in DME (6 mL) and 2 M sodium ate (1.0 mL, 2.0 mmol) was added tert- butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-3,4-dihydropyridine-1(2H)- carboxylate(180 mg, 0.582 mmol) followed by PdCl2(dppf).CH2Cl2 adduct (14.4 mg, 17.5 umol). The reaction mixture was heated in microwave at 110 °C for 20 min. The reaction mixture was partitioned between cetate and water. The organic layer was separated, and washed with water and brine. The organic was dried over sodium sulfate, filtered and evaporated. The e was purified by flash chromatography eluting with 0- 50- 80% EtOAc in heptane to yield the desired product as a yellow solid (150 mg, 60%).
LCMS (m/z): 429.2 (MH+), 1.03 min.
Ste 6. meth l4- 3-amino 1 4 5 6-tetrah dro ridin l razin-2— l fluorobenzoate To tert-butyl 5-(5-amino(3-fluoro(methoxycarbonyl)phenyl)pyrazinyl)—3,4- dihydropyridine-1(2H)—carboxylate (150 mg, 0.350 mmol) arable mixture) in DCM (4 mL) was added TFA (1 mL, 12.98 mmol). The reaction mixture was stirred at room ature for 30 - 45 min. The on mixture was evaporated on rotovap, and azeotroped with toluene. The crude product was proceeded to next step without purification. LCMS (m/z): 329.2 (MH+), 0.502 min.
Ste 7. meth l4- 3-amino i eridin l razin lfluorobenzoate To methyl mino(1,4,5,6-tetrahydropyridinyl)pyrazinyl)fluorobenzoate (115 mg, 0.350 mmol) in MeOH (10 mL) was added Pd/C (93 mg, 0.088 mmol). The reaction mixture was stirred at room temperature for 24 h under H2 balloon. The reaction mixture was filtered through Celite and washed with DCM. The filtrate was evaporated and dried to yield the desired product. The crude product was proceeded for the next step (115 mg, 95%). LCMS (m/z): 331.2 (MH+), 0.492 min.
Ste 8. meth l4- 3-amino 1- meth lsulfon l i eridin l razin l fluorobenzoate To a mixture of crude methyl 4-(3-amino(piperidinyl)pyrazinyl)fluorobenzoate (38 mg, 0.114 mmol) in DCM (2 mL) in an ice bath was added DIEA (79 uL, 0.454 mmol) followed by methanesulfonyl chloride (9.73 uL, 0.125 mmol). The reaction mixture was stirred at 0 °C for 30 min. The reaction mixture was ioned n DCM and water.
The DCM layer was separated and washed with brine. The organic layer was dried over sodium sulfate, filtered and evaporated. The crude product (50% purity) was proceeded to next step. LCMS (m/z): 409.1 (MH+), 0.721 min.
Ste 9. 4- o 1- meth lsulfon l i eridin l razin lfluorobenzoic acid To methyl 4-(3-amino(1-(methylsulfonyl)piperidinyl)pyrazinyl)fluorobenzoate (60 mg, 0.147 mmol) in THF (4 mL) and MeOH (2 mL) was added 1 M LiOH (400 uL, 0.400 mmol). The on mixture was stirred at room temperature overnight. The pH of the reaction mixture was adjusted to ~3 to 4 with 2 N HCI, and the product was extracted with ethyl acetate. The c layer was separated from water and washed with brine, dried over sodium sulfate, filtered off, and evaporated to provide the crude product, which was taken to the next step t further purification. LCMS (m/z): 395.1 (MH+), 0.573 min.
Ste 10. 4- 3-amino 1- meth lsulfon l i eridin l razin lfluoro-N- S hydroxy—1-phenylethyl)benzamide To a mixture of 4-(3-amino(1-(methylsulfonyl)piperidinyl)pyraziny|) fluorobenzoic acid (40 mg, 0.101 mmol) in DMF (1 mL) was added (S)amino phenylethanol (13.91 mg, 0.101 mmol) followed by HATU (57.8 mg, 0.152 mmol) and DIEA (0.089 mL, 0.507 mmol). The reaction mixture was stirred at room ature overnight. The reaction mixture was diluted with DMF and filtered h syringe filter, which was then purified by prep HPLC to yield the desired product as a TFA sa|t (33.4%).
LCMS (m/z): 514.2 (MH+), 0.687 min; 1H NMR (400 MHz, CD3OD) 6 ppm7.95 (s, 1 H) 7.85 (t, J=7.83 Hz, 1 H) 7.73-7.57 (m, 2 H) 7.49-7.21 (m, 5 H) 5.22 (d, J=6.65 Hz, 1 H) 3.94-3.78 (m, 3 H) 3.71 (d, J=11.74 Hz, 1 H) 3.03-2.93 (m, 2 H) 2.87-2.74 (m, 4 H) 2.07- 1.97 (m, 1 H) 1.92 (d, J=12.13 Hz, 1 H) 1.85-1.68 (m, 1 -1.25 (m, 1 H). e 214 meth l3- 5-amino 3-fluoro S h drox hen leth lcarbamo l hen l razin- 2- | i eridinecarbox |ate Scheme 105 F o F o F o F 0 {OH NH2 0/ NH2 0/ NH2 OH NH2 N N/ Step1 N’ Step2 N/ Step3 N/ | | L'OH | HATU/TEA I N MeC020| I \ \ N \ N \ N DIEA/ DCM MeOH / THF DMF 77% 83% 29% NH NTO\ NTO\ NY0\ o o o Ste 1. meth l3- 5-amino 3-fluoro methox carbon l hen l razin l i e- 1-carboxylate To methyl 4-(3-amino(piperidinyl)pyrazinyl)f|uorobenzoate (55 mg, 0.166 mmol) (for synthesis, see Example 34, Step 7) in DCM (3 mL) in ice bath was added DIEA (0.116 mL, 0.666 mmol) and methyl chloroformate (0.013 mL, 0.166 mmol) . The reaction mixture was stirred at in ice bath for 30 min. The reaction mixture was partitioned between DCM and water. The DCM layer was ted, washed with brine, dried over sodium sulfate, filtered and evaporated. The residue (50 mg, 77%) was taken to the next step without further purification. LCMS (m/z): 389.2 (MH+), 0.785 min.
Ste 2. 4- 3-amino 1- methox carbon l i eridin l razin lfluorobenzoic To methyl 3-(5-amino(3-fluoro(methoxycarbonyl)phenyl)pyrazinyl)piperidine carboxylate (50 mg, 0.129 mmol) in THF (4 mL) and MeOH (2 mL) was added 1 M LiOH (0.500 mL, 0.500 mmol). The reaction mixture was d at room temperature for 4 h.
The reaction mixture pH was adjusted to ~ 3 with 2 N HCI, and product was extracted with ethyl acetate. The EtOAc layer was separated, washed with brine, dried over sodium sulfate, ed and evaporated. The e was proceeded to next step without purification (40 mg, 83%). LCMS (m/z): 375.2 (MH+), 0.637 min.
Ste 3. meth l3- 5-amino 3-fluoro S h drox hen leth lcarbamo l hen l razin l i eridinecarbox late To a mixture of 4-(3-amino(1-(methoxycarbonyl)piperidinyl)pyrazinyl)—2- fluorobenzoic acid (28 mg, 0.06 mmol) in DMF (1 mL) was added (S)amino phenylethanol (12.31 mg, 0.090 mmol) followed by HATU (34.1 mg, 0.090 mmol) and DIEA (0.052 mL, 0.299 mmol). The reaction mixture was stirred at room temperature ght. The reaction mixture was diluted with DMF, filtered h syringe filter and purified by prep HPLC to yield the desired product as a TFA salt (10.9 mg, 29.4%) LCMS (m/z): 494.2 (MH+), 0.733 min. 1H NMR (400 MHz, CD3OD) 6 ppm7.82-7.72 (m, 2 H) 7.63-7.48 (m, 2 H) 7.38-7.11 (m, 5 H) 5.12 (t, J=6.06 Hz, 1 H) 4.09 (d, 1 Hz, 1 H) 3.97 (d, J=12.13 Hz, 1 H) 3.87-3.68(m, 2 H) 3.59 (s, 3 H) 3.11-2.66 (m, 3 H) 2.00-1.88 (m, 1 H) ) 1.85-1.65 (m, 2 H) 1.58-1.40 (m, 1 H) Example 215 4- 6- 1-acet l i eridin lamino razin lfluoro-N- S h drox phenylethyl mide Scheme 106 F 0 :/OH H2 NH2 N Step1 OStep2 OHStep3 H N / N / N / IN MeCOCl LiOH HATU /TEA | \ N DIEA/ DCM MeOH /THF DMF 81% 71% 30% NH N\n/ N\n/ N\n/ O O O Ste 1. meth l4- 6acet l i eridin ino 2- lfluorobenzoate To a mixture of methyl 4-(3-amino(piperidinyl)pyrazinyl)—2-fluorobenzoate (55 mg, 0.166 mmol) (for sis, see example 34, Step 7) in DCM (3 mL) in ice bath was added DIEA (0.116 mL, 0.666 mmol) followed by acetyl chloride (0.012 mL, 0.166 mmol).
The reaction mixture was stirred at 0 °C for 30 min. The reaction mixture was partitioned between DCM and water. The DCM layer was separated, washed with brine, dried over sodium sulfate, filtered and evaporated. The e was proceeded to next step without purification (50 mg, 81%). LCMS (m/z): 373.3 (MH+), 0.666 min.
Ste 2. 4- 6- 1-acet l i eridin lamino razin lfluorobenzoic acid To a mixture of methyl 4-(6-(1-acety|piperidinyl)aminopyrazinyl)—2-fluorobenzoate (50 mg, 0.134 mmol) in THF (4 mL) and MeOH (2 mL) was added 1 M LiOH (0.500 mL, 0.500 mmol). The reaction mixture was stirred at room temperature for 4 h. The pH of on mixture was adjusted to ~3 with 2 N HCI, and the product was extracted with ethyl acetate. The organic layer was separated, washed with brine, dried over sodium sulfate, filtered and evaporated. The residue was proceeded for next step without purification (34 mg, 70.7%). LCMS (m/z): 359.1 (MH+), 0.534min.
Ste 3. 4- 6acet l i eridin lamino razin lfluoro-N- S h drox phenylethyl)benzamide To a mixture of 4-(6-(1-acety|piperidinyl)—3-aminopyrazinyl)fluorobenzoic acid (34 mg, 0.076 mmol) in DMF (1.5 mL) was added (S)aminophenylethanol (15.62 mg, 0.114 mmol), ed by HATU (43.3 mg, 0.114 mmol) and DIEA (0.066 mL, 0.379 mmol). The reaction e was stirred at room temperature overnight. The reaction mixture was diluted with DMF, ed through syringe filter and purified by prep HPLC to yield the desired product as a TFA salt (13.9 mg, 30%). LCMS (m/z): 478.2 (MH+), 0.641 min. 1H NMR (400 MHz, CD3OD) 6 ppm 7.98-7.97 (m, 2 H) 7.73-7.58 (m, 2 H) 7.47-7.23 (m, 5 H) 5.22 (t, J=6.06 Hz, 1 H) 4.62-4.37 (m, 1 H) 4.08-3.75 (m, 3 H) 3.27-3.08 (m, 1 H) 3.03-2.71 (m, 2 H) 2.11 (d, J=11.35 Hz, 3 H) 2.04 (d, J=8.22 Hz, 1 H) 2.00-1.75 (m, 2 H) 1.73-1.46 (m, 1 H) Example 216 meth l3- o 4- S 3-chloro hen lh drox eth l carbamo l fluoro hen l razin l i eridinecarbox late Scheme 107 NH2 OH /OH NH2 ; H N/ ' N/ I H2N HATU/TEA I N/\© \ N \ N CI CI 38% NTO\ \fl/ \ O 0 To mino(1-(methoxycarbonyl)piperidinyl)pyrazinyl)f|uorobenzoic acid (12 mg, 0.026 mmol) (for synthesis, see Example 35, Step 2) in DMF (1 mL) was added (8)- 2-amino(3-chlorophenyl)ethanol (6.60 mg, 0.038 mmol), followed by HATU (14.63 mg, 0.038 mmol) and DIEA (0.022 mL, 0.128 mmol). The reaction mixture was d at room temperature overnight. The reaction mixture was diluted with DMF, filtered through syringe filter and purified by prep HPLC to yield desired product as a TFA salt (6.5 mg, 38%). LCMS (m/z): 528.1/530.1 (MH+), 0.798 min. 1H NMR (400 MHz, CD30D) 6 ppm7.96-7.80 (m, 2 H) 7.75-7.58 (m, 2 H) 7.50-7.23 (m, 4 H) 5.19 (t, J=5.87 Hz, 1 H) 4.25-4.01 (m, 2 H) 3.92-3.79 (m, 2 H) 3.68 (s, 3 H) 3.20-2.74 (m, 3 H) 2.08-1.97 (m, 1 H) 1.91-1.73 (m, 2 H) 1.67-1.51 (m, 1 H) Example 217 F o 5/ \2 F o F 0 Step1 Step2 NH2 0 o o ~ , NH2 0 NH2 0 B I | CZH5BV’KZCOS Pd(dppf)C|2/Na2CO3 N/ + —>N/ N/ I / I —> + I N / DMF \ DME/120 C/15mln0 \ N \ N o=<N—N 74% 64% 0 f \ \ \ \ N—N N—NH >/"0 F o F o F 0 {OH NH2 ('3 NH2 OH /OH NH2 ; N/\©H N/ N/ I N/ | Step3 HzN Step4 | \ N LiOH \ N EDC-Cl/HOAt \ N —> —> \\ DMF MeOH ITHF \\ 17% // N—N N—N N-N \_. \,. < Ste 1. meth l4- 3-amino 1H- razol l razin l fluorobenzoate To methyl 4-(3-aminobromopyrazinyl)fluorobenzoate (For Synthesis see Example 34, Step 2) (100 mg, 0.307 mmol) in DME (3 mL) and 2 M sodium carbonate (0.75 mL, 1.5 mmol) was added tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-1H- pyrazolecarboxylate (90 mg, 0.307 mmol) followed by PdC|2(dppf)-CH2C|2 adduct (25.04 mg, 0.031 mmol). The on mixture was heated in microwave at 120 °C for 15min. The on mixture was partitioned n ethyl acetate and water. The organic layer was separated, washed with water and brine, dried over sodium sulfate, ed and evaporated. The residue was proceeded to next step without purification (90 mg, 74%, 80% purity). LCMS (m/z): 314.1 (MH+), 0.595 min.
Ste 2. meth l4- 3-amino1-eth l-1H- razol l razin lfluorobenzoate To methyl 4-(3-amino(1H-pyrazolyl) pyrazinyl)fluorobenzoate (45 mg, 0.115 mmol) in DMF (2 mL) was added ium carbonate (47.6 mg, 0.345 mmol), followed by bromoethane (0.017 mL, 0.230 mmol). The reaction mixture was stirred at room temperature for 48 h. The reaction mixtures was partitioned between ethylacetate and water. The organic layer was separated, washed with brine, dried over sodium e, filtered, evaporated and purified by flash chromatography eluting with 0 - 60% of EtOAc (contains 10% of MeOH) / heptane to yield the desired product (25mg, 64%, 80% ).
LCMS (m/z): 342.0 (MH+), 0.73 min.
Ste 3. 4- 3-amino 1-eth l-1H- razol l razin lfluorobenzoic acid To methyl 4-(3-amino(1-ethyl-1H-pyrazolyl)pyrazinyl)fluorobenzoate (25 mg, 0.073 mmol) in MeOH (1 mL) and THF (2 mL) was added 1 M LiOH (0.220 mL, 0.2 20 mmol). The reaction mixture was stirred at room temperature for 4 h. The pH of reaction mixture was adjusted to ~ 4 by 2 N HCI. The product was extracted with ethyl acetate twice. The combined organics extracts were washed with brine, dried over sodium sulfate, ed, and evaporated. The residue was proceeded to next step t further purification. LCMS (m/z): 328.1 (MH+), 0.607 min.
Ste 4. S 3-amino 1-eth l-1H- razol l razin lfluoro-N- 2-h drox phenylethyl) benzamide To 4-(3-amino(1-ethyl-1H-pyrazolyl)pyrazinyl)fluorobenzoic acid (25 mg, 0.076 mmol) in DMF (1 mL) was added EDC.HC| (21.96 mg, 0.115 mmol), followed by HOAt (15.60 mg, 0.115 mmol), (S)aminophenylethanol (15.92 mg, 0.092 mmol) and DIEA (0.040 mL, 0.229 mmol). The on mixture was stirred at room temperature for 6 h. The reaction mixture was diluted with DMF and filtered through syringe filter. The crude was purified by prep HPLC to yield the d product as a TFA salt (9.1 mg, 17%).
LCMS (m/z): 447.2 (MH+), 0.699 min. 1H NMR (400 MHz, CD3OD) 6 ppm 8.67-8.41 (m, 1 H), 8.17 (s, 1 H), 8.03 (s, 1 H), 7.86 (s, 1 H), 7.78 (t, J=7.63 Hz, 1 H), 7.67-7.53 (m, 2 H), 7.40-7.09 (m, 5 H), 5.21-5.03 (m, 1 H), 4.13 (q, J=7.30 Hz, 2 H), .65 (m, 2 H), 1.39 (t, J=7.24 Hz, 3 H).
Example 218 S nthesis of 4- 2—amino 5-oxo rrolidin l ridin lfluoro-N- S h drox phenylethyl )benzamide Scheme 109 fial $22 \ro o 0 O o o o s" >I\OJJ\N/\H,OH Ki \fl yo O TsCl N K + 0 O N —> H O DMAP/DCM \ DlEA :8 o o 0‘ I/ F o F o J< W Step; NH OJ< stem NH2 0 o t ,O B PdCI2(dppf)/ KOAc N / Pd(dppf)C|2-DCM N / + E; —> I I Nazcog, DME \ 66.5% B, o o F o F 0 NHZ OH Stegg NH2 0H l H2 N/ 3/ —> \ + HZN Pd/C NH NH F 0 {OH Step7 3 NH2 N EDC/HOAt H , N/l % \ Ste 1. Tert-but l4-h drox oxo-2 5-dih dro-1H- rrolecarbox late To Boc—Gly—OH (1 g, 5.71 mmol) in DCM (12 mL) under N2 atmosphere at 0 °C was added DMAP (1.743 g, 14.27 mmol) and Meldrum's acid (0.987 g, 6.85 mmol). A solution of isopropyl chloroformate (8.56 mL, 8.56 mmol) in toluene was added se. The reaction mixture was stirred at 0 °C for 3 h. The reaction mixture was washed with 15% KHSO4 twice, dried over sodium sulfate, filtered and ated. The crude t was taken in 50 mL of EtOAc and refluxed for 1 h. After le materials were evaporated, the crude product was triturated with EtOAC and the resulting solid was filtered and dried to provide a yellow solid (75%). LCMS (m/z): 200.1 (MH+), 0.504 min.
Ste 2. Tert-but l2-oxo tos lox -2 5-dih dro-1H- rrolecarbox late To tert-butyl 4-hydroxyoxo-2,5-dihydro-1H-pyrrolecarboxylate (680 mg, 3.41 mmol) in DCM (12 mL) was added DIEA (1.192 mL, 6.83 mmol) and tosyl chloride (651 mg, 3.41 mmol). The reaction e was stirred at room temperature for 6 h. The on mixture was diluted with DCM and washed with saturated sodium bicarbonate. The organic layer was separated, washed with brine, dried over sodium sulfate, filtered and evaporated.
The crude product was purified by flash chromatography (0 to 50% EtOAc / heptane).
Pure fractions were combined, evaporated and dried to give desired product as a white solid (0.98 g, 81%). LCMS (m/z): 354.1 (MH+), 0.97 min; 1H NMR (400 MHz, DMSO-d6) 6 ppm 7.99 (d, J=8.22 Hz, 2 H) 7.54 (d, J=7.83 Hz, 2 H) 5.77 (s, 1 H) 4.33 (s, 2 H) 2.43 (s, 3 H) 1.41 (s, 9 H).
Ste 3. Tert-but l 4- 2-amino 4 4 5 5-tetrameth H 3 2-dioxaborolan l 3- l - 2-fluorobenzoate To tert-butyl 4-(2-aminobromopyridinyl)f|uorobenzoate (400 mg, 1.089 mmol) in DME (12 mL) was added 4,4,4',4',5,5,5'-heptamethyl-2,2'-bi(1,3,2-dioxaborolane) (523 mg, 2.179 mmol), potassium acetate (321 mg, 3.27 mmol) and PdCI2(dppf)-CH2C|2 (89 mg, 0.109 mmol). The reaction mixture was purged with N2 and heated in microwave vial in g block at 110 °C for overnight. The reaction mixture was partitioned between ethyl e and water. The organic layer was separated, washed with brine, dried over sodium sulfate, filtered and ated. The crude was taken in ether and sonicated for min and black solid was filtered off. The filtrate was evaporated to provide product as a light yellow solid (300 mg, 66.5%). LCMS (m/z): 333.2 (MH+), 0.672 min (for boronic acid).
Ste 4. Tert-but l4- 6-amino 4- tert-butox carbon lfluoro hen l ridin l oxo-2,5-dihydro-1H-pyrrolecarboxylate To utyl 4-(2-amino(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)pyridinyl)—2- fluorobenzoate (158 mg, 0.382 mmol) in DME (3 mL) and sodium ate (0.509 mL, 1.019 mmol) was added tert-butyl 2-oxo(tosyloxy)-2,5-dihydro-1H-pyrrole carboxylate (90 mg, 0.255 mmol) and PdCl2(dppf)-CH2Cl2 (41.6 mg, 0.051 mmol). The reaction mixture was heated in microwave at 90 °C for 30 min. LCMS showed starting material remained. More catalysts were added and heated again at 90 °C for 20 min. The reaction mixture was partitioned between ethylacetate and water. The organic layer was separated, washed with brine, dried over sodium e, filtered and evaporated. The crude product was purified by flash torgraphy using 0-50% EtOAc (contains %MeOH) / heptane to provide product as a yellow solid (66%). LCMS (m/z): 470.2 (MH+), 0.846 min.
Ste 5. 4- 2-amino 5-oxo-2 5-dih dro-1H- rrol l ridin l f|uorobenzoic acid To tert-butyl 4-(6-amino(4-(tert-butoxycarbonyl)fluorophenyl)pyridinyl)—2-oxo-2,5- dihydro-1H-pyrrolecarboxylate (158 mg, 0.337 mmol) was added TFA (2 mL, 26.0 mmol). The on mixture was stirred at room temperature for 1 h. After toluene was added, the volatile solvents were evaporated. The crude product was used for the next step. LCMS(m/z): 314.2 (MH+), 0.382 min.
Ste 6. 4- o 5-oxo rrolidin l ridin l f|uorobenzoic acid To 4-(2-amino(5-oxo-2,5-dihydro-1H-pyrrolyl)pyridinyl)—2-fluorobenzoic acid (100 mg, 0.319 mmol) in MeOH (15 mL) under N2 atmosphere was added Pd-C (67.9 mg, 0.064 mmol). The reaction mixture was stirred at room temperature for 24 h under H2 balloon. The reaction mixture was filter through Celite and washed with methanol. The filtrate was ated. The crude was proceed for next step. LCMS(m/z): 316.2 (MH+), 0.338 min.
Ste 7. +/- 2-amino 5-oxo in l ridin lfluoro-N- S h drox phenylethyl)benzamide To 4-(2-amino(5-oxopyrrolidinyl)pyridinyl)—2-fluorobenzoic acid (30 mg, 0.076 mmol) in DMF (1 mL) was added (S)aminophenylethanol (12.53 mg, 0.091 mmol), EDC-HCI (21.89 mg, 0.114 mmol), HOAt (15.54 mg, 0.114 mmol) and DIEA (0.040 mL, 0.228 mmol). The on mixture was stirred at room temperature for 5 h. The reaction mixture was d with DMF and directly purified by prep HPLC to provide (+/-)(2- amino(5-oxopyrrolidinyl)pyridinyl)—2-f|uoro-N-((S)hydroxy phenylethyl)benzamide as a TFA salt (20.2%). LCMS (m/z): 435.2 (MH+), 0.476 min; 1H NMR (400 MHz, CD3OD) 6 ppm 7.88 (s, 1 H), 7.84-7.74 (m, 2 H), 7.38-7.30 (m, 4 H), 7.27 (t, J=7.43 Hz, 2 H), .13 (m, 1 H), 5.18-5.05 (m,1 H), 3.85-3.56 (m, 4 H), 3.39 - 3.26(m, 1 H), 2.62 (dd, J=16.82, 8.61 Hz, 1 H), .33 (m, 1 H).
Examples 219 and 220 S nthesis of 4- 2-amino R oxo rrolidin l ridin uoro-N- S h drox - fluoro-N- S h drox hen leth Ibenzamide Scheme 110 OH OH F O :/ F O :/ NH2 N NH2 N H H N/ N’ \ —- \ eak1 p NH QH O O (+/-)(2-amino(5-oxopyrrolidinyl)pyridinyl)—2-fluoro-N-((S)hyd roxy phenylethyl)benzamide was resolved by chiral SFC (Chiral Pak 5mic C10=AD-H , 4.6x100 (mm), 5mL/min, MeOH = 50%). The polar compound (peak 1)was obtained at Rt = 1.36 min (24.5%). LCMS (m/z): 435.2 (MH+), 0.485 min. The less polar compound (peak 2) was obtained at Rt = 2.20 min (22%).
LCMS (m/z): 435.2 (MH+), 0.482 min. The absolute stereochemistry on cyclic lactam was arbitrarily assigned.
Example 221 S nthesis of 2S 4R -meth l4- 6-amino 4- S 3-chloro hen l h drox eth lcarbamo lfluoro hen l ridin l rrolidinecarbox late WO 66188 Scheme 1 1 1 O=‘\ Oti 0 o / / fluoro hen l ridin l-1H- rrole-1 2 2H 5H -dicarbox late A mixture of tert-butyl 4-(2-amino(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)pyridin y|)f|uorobenzoate (400 mg, 0.966 mmol), (S)—1-tert-butyl 2-methyl 4- fluoromethyl)sulfonyl)oxy)-1H-pyrrole-1,2(2H,5H)-dicarboxylate (1.087 g, 2.90 mmol, Pd(PPh3)4 (112 mg, 0.097 mmol) and cesium carbonate (1.258 g, 3.86 mmol) in THF (10 mL) and water (2 mL) was degassed, then microwave heated to 90 °C for 10 min. At completion, the reaction was diluted with ethyl acetate. The organics were washed with brine, dried over magnesium sulfate and concentrated. The crude mixture was purified by flash chromatography over silica gel (20-90% ethyl e/heptane) to provide (S)—1-tert- butyl 2-methyl 4-(6-amino(4-(tert-butoxycarbonyl)fluorophenyl)pyridinyl)—1 H- pyrrole-1,2(2H,5H)-dicarboxylate (470 mg, 95%). LCMS (m/z): 514.3 (MH+), 0.92 min.
Ste 2. 2S 4R tert-but |2-meth |4- 6-amino 4- tert-butox carbon | fluoro hen l ridin l rrolidinedicarbox late A degassed on of tert-buty| 2-methyl 4-(6-amino(4-(tert-butoxycarbonyl) fluorophenyl)pyridinyl)—1H-pyrrole-1,2(2H,5H)-dicarboxylate (470 mg, 0.915 mmol) in methanol (40 mL) was treated with 10 wt.% Pd/C (3.214 g, 3.02 mmol). The system was degassed again, then charged with 1 atm hydrogen overnight. At completion, the reaction degassed, then treated ammonia gas then filtered over Celite. The cake was reslurried in methanol, treated with ammonia gas, and filtred to retrieve onal product. The process was repeated until no further product eluted from filter cake. The combined organics were concentrated to provide (2S,4R)—1-tert—butyl 2-methyl mino(4-(tert— butoxycarbonyl)fluorophenyl)pyridinyl)pyrrolidine-1,2-dicarboxylate (300 mg, 64%).
LCMS (m/z): 516.1 (MH+), 0.89 min.
Ste 3. 4- 2-amino 3R 58 methox carbon l rrolidin l ridin l fluorobenzoic acid-2TFA A solution of (2S,4R)—1-tert-butyl 2-methyl 4-(6-amino(4-(tert-butoxycarbonyl)—3- fluorophenyl)pyridinyl)pyrrolidine-1,2-dicarboxylate (300 mg, 0.58 mmol) in DCM (6 mL) was treated with TFA (3 mL). After 1h, the reaction was concentrated, then the residue was slurried in benzene, sonicated, then concentrated to e mino ((3R,5S)—5-(methoxycarbonyl)pyrrolidinyl)pyridinyl)fluorobenzoic acid-2TFA (345 mg, 100% yield). LCMS (m/z): 360.2 (MH+), 0.34 min.
Ste 4. 28 4R -meth l4- 6-amino 4- S 3-chloro hen l h drox eth lcarbamo lfluoro hen l ridin l rrolidinecarbox late A e of mino((3R,5S)—5-(methoxycarbonyl)pyrrolidinyl)pyridinyl)—2- fluorobenzoic acid-2TFA (35 mg, 0.060 mmol), HATU (34 mg, 0.089 mmol), and DIEA (0.104 mL, 0.596 mmol) in DMF (2 mL) was d with (S)—2-amino-2—(3- chlorophenyl)ethanol (51 mg, 0.348 mmol). At completion, the reaction was washed with water and brine, then dried over MgSO4 and concentrated. The crude material was purified by reverse phase prep HPLC to provide (2S,4R)—methyl mino(4-(((S)—1- (3-chlorophenyl)hydroxyethyl)carbamoyl)—3-fluorophenyl)pyridinyl)pyrrolidine carboxylate (4.2 mg, 9%). LCMS (m/z): 513.2, 515.2 (MH+), 0.58 min; 1H NMR (400 MHz, CD3OD) 6 ppm 7.97 - 7.86 (m, 3H), 7.49 - 7.40 (m, 3H), 7.39 - 7.34 (m, 2H), 7.33 - 7.26 (m, 1H), 5.19 (t, J = 5.87 Hz, 1H), 4.62 (dd, J = 7.63, 10.76 Hz, 1H), 3.93 - 3.77 (m, 6H), 3.74 - 3.61 (m, 1H), 2.87 (td, J = 6.90, 13.21 Hz, 1H), 2.33 - 2.21 (m, 1H).
Examples 222 and 223 S nthesis of 2S 4R 6-amino 4- S 3-chloro hen l h drox eth l carbamo l - 3-fluoro hen l ridin l rrolidinecarbox lic acid and 2S 4R -meth l4- 6-amino 4- S 3-chloro hen lh drox eth lcarbamo lfluoro hen l ridin l rrolidinecarbox late Scheme 112 IL?9 mIf E 12 12 _Z / i9E _2 g \ Q <\(jg/ENE l‘%[NI _2 0:5:\/M 0 HO ‘ HN / ‘fio ‘QO / W0 fluoro hen l ridin l rrolidinecarbox lic acid A solution of (2S,4R)—methyl 4-(6-amino(4-(((S)—1-(3-chlorophenyl) hydroxyethyl)carbamoyl)fluorophenyl)pyridinyl)pyrrolidinecarboxylate (120 mg, 0.234 mmol) in MeOH (4 mL) was treated with 1.0 M LiOH aqueous on (0.468 mL), then heated to 70 °C. After 1 h, the reaction was concentrated then dissolved in water (2 mL) and treated with 1.0 N aqueous HCI (0.468 mL). The reaction mixture was extracted with ethyl acetate (20 mL). The organic layer was washed with water and brine, then dried over MgSO4 and concentrated to provide the crude product (97 mg, 57%). A portion of this material was purified by reverse phase prep HPLC yielding (2S,4R)—4-(6-amino(4- (((S)—1-(3-chlorophenyl)hydroxyethyl)carbamoyl)fluorophenyl)pyridinyl)pyrrolidine- 2-carboxylic acid. LCMS (m/z): 501.1 (MH+), 0.49 min; 1H NMR (400 MHz, CD3OD) 8 ppm 8.56 - 8.64 (m, 1H), 7.75 - 7.87 (m, 4H), 7.31 - 7.38 (m, 4H), 7.24 - 7.29 (m, 3H), 7.17 - 7.24 (m, 1H), 5.07 - 5.14 (m, 1H), 4.36 (dd, J = 7.63, 9.98 Hz, 1H), 3.64 - 3.83 (m 4H), 3.52 - 3.62 (m, 1H), 3.27 - 3.34 (m, 1H), 2.72 - 2.81 (m, 1H), 2.56 (s, 1H), 2.15 (td, J = 10.42, 13.21 Hz, 1H).
Ste 2. 2S 4R -meth l4- o 4- S 3-chloro hen l h drox eth lcarbamo lfluoro hen l ridin l rrolidinecarbox late A on of (2S,4R)—4-(6-amino(4-(((S)(3-chlorophenyl)hydroxyethyl)carbamoyl)- 3-fluorophenyl)pyridinyl)pyrrolidinecarboxylic acid (25 mg, 0.050 mmol) in THF (2 mL) and DMF (2 mL) was treated sequentially treated with a 2.0 M solution of 2014/062913 methylamine in THF (1.25 mL, 2.5 mmol), and HATU (95 mg, 0.25 mmol). After 2 h, the reaction was d with ethyl acetate and washed with water and brine. The organics were dried over magnesium sulfate and concentrated to provide (2S,4R)—methy| 4-(6- amino(4-(((S)—1-(3-chlorophenyl)hydroxyethyl)carbamoyl)—3-fluorophenyl)pyridin y|)pyrro|idinecarboxylate after purification by reverse phase prep HPLC (1.8 mg, 5%).
LCMS (m/z): 512.2, 514.2 (MH+), 0.54 min; 1H NMR (400 MHz, CD3OD) 6 ppm 8.64 - 8.73 (m, 1H), 7.84 - 7.96 (m, 2H), 7.45 (s, 1H), 7.40 - 7.44 (m, 1H), 7.35 - 7.38 (m, 1H), 7.27 - 7.34 (m, 1H), 5.16 - 5.24 (m, 1H), 4.38 (dd, J = 7.83, 10.17 Hz, 1H), 3.75 - 3.92 (m, 2H), 3.60 - 3.72 (m, 1H), 2.78 - 2.89 (m, 3H). 8 nthesis of 4- 2-amino 1-meth l-1H-imidazol l ridin l fluorobenzoic acid Following Steps 4 and 5 in Scheme 109, using omethyl-1H-imidazole, 4-(2- amino(1-methyI-1H-imidazoIyl)pyridiny|)f|uorobenzoic acid was obtained.
LCMS (m/z): 313.1 (MH+), 0.3 min. 8 nthesis of 4- 2-amino 1-meth l-1H- razol l ridin l fluorobenzoic acid 2014/062913 ing Steps 4 and 5 in Scheme 109, using 1-methyl(4,4,5,5-tetramethyl-1,3,2— dioxaborolan-2—yl)—1H-pyrazole, 4-(2—amino(1-methyl-1H-pyrazolyl)pyridinyl)—2— fluorobenzoic acid was obtained. LCMS (m/z): 313.4 (MH+), 0.44 min. 8 nthesis of 4- 2—amino 1-iso ro l-1H- razol l ridin lfluorobenzoic acid Following Steps 4 and 5 in Scheme 109, using 1-isopropyl(4,4,5,5-tetramethyl-1,3,2— dioxaborolan-2—yl)—1H-pyrazole, 4-(2—amino(1-isopropyl-1H-pyrazolyl)pyridinyl)—2— fluorobenzoic acid was obtained. LCMS (m/z): 341 NH), 0.56 min.
Example 224 S nthesis of S 3-amino oxetan l razin l fluoro-N- 2—h drox ghenylethyl )benzamide Scheme 113 F o F o —ES‘e l NH2 0/ _I28te Z Pd(dppf)C|2-DCM NH2 o/ 0‘3’0 N/ Pd(dppf)Cl2-DCM —>KrNI + —> o’é‘o O N/ + KOAc,DME ,DME \ N %‘§ 55% ,B\ 11% 0 0 Br %—§ F o F 0 =/ NH2 0/ m; NH2 OH {OH $94— : H - - EDC/HOAt N/ LIOH N/ N/ N/\© I | + H2N I \ N N \ N THF,MeOH \ DIEA/DMF 11.4% 0 O O Ste 1. Meth l4- 3-amino 4 4 5 ameth H 3 2-dioxaborolan l razin l fluorobenzoate To methyl 4-(3-aminobromopyrazinyl)fluorobenzoate (400 mg, 1.227 mmol) in DME (12 mL) was added 4,4,4',4',5,5,5'-heptamethyl-2,2'-bi(1,3,2-dioxaborolane (589 mg, 2.453 mmol), potassium acetate (361 mg, 3.68 mmol) and PdC|2(dppf)-CH2Cl2 (100 mg, 0.123 mmol). The reaction mixture was purged with N2 and heated in microwave at 120°C for 15min. The reaction mixtures was partitioned between ethylacetate and water. The organic layer was separated, washed with brine, dried over sodium e, filtered and evaporated. The crude product was taken in ether and sonicate for 20 min. The black solid was filtered off. To the filtrate was added heptane. The itate was filtered and dried to provide a light yellow solid. (250mg, 54.6%). LCMS (m/z): 292.2 (MH+), 0.47 min (for boronic acid).
Ste 2. Meth l4- 3-amino oxetan l razin lfluorobenzoate To methyl 4-(3-amino(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)pyrazinyl) fluorobenzoate (150 mg, 0.402 mmol) in DME (6 mL) and sodium carbonate (1.5 mL, 3.0 mmol) was added 3-iodooxetane (370 mg, 2.01 mmol) and PdCl2(dppf)-CH2Cl2 (32.8 mg, 0.042 mmol). The reaction mixture was heated in microwave at 100 °C for 15 min. The on mixture was partitioned n ethylacetate and water. The organic layer was separated, washed with brine, dried over sodium sulfate, filtered and evaporated. The crude t was purified by prep HPLC to isolate the product (13.5 mg, 11.0%). LCMS (m/z): 304.2 (MH+), 0.61 min.
Ste 3. 4- 3-amino oxetan l razin l fluorobenzoic acid To methyl 4-(3-amino(oxetanyl)pyrazinyl)—2-fluorobenzoate (13 mg, 0.043 mmol) in MeOH (1 mL) and THF (2 mL) was added LiOH (0.128 mL, 0.128 mmol). The reaction mixture was stirred 2 h at room temperature. The reaction mixtures was adjusted to acidic (pH ~3) and solvent was evaporated on rotovap. The crude was azeotrope with toluene and proceed for next step. LCMS (m/z): 290.1 (MH+), 0.46 min.
Ste 4. S 3-amino oxetan l razin lfluoro-N- 2-h drox phenylethyl)benzamide To 4-(3-amino(oxetanyl)pyrazinyl)fluorobenzoic acid -crude (10 mg, 0.035 mmol) in DMF (1 mL) was added (S)—2-aminophenylethanol (14.22 mg, 0.104 mmol), DIEA (0.030 mL, 0.173 mmol), EDC (13.25 mg, 0.069 mmol) and Bt (7.06 mg, 0.052 mmol). The reaction mixture was stirred at room temperature for overnight. The crude was purified by prep HPLC to provide d product as a TFA salt (11.5%).
LCMS (m/z): 409.2 (MH+), 0.597 min; 1H NMR (400 MHz, CD3OD) 6 ppm 7.92-7.82 (m, 2H) 7.78-7.64 (m, 2 H) 7.48-7.32 (m, 5 H) 7.23 - 7.31-7.23 (m, 1 H) 5.28-5.17 (m, 1 H) .03-4.90 (m, 5 H) 4.47-4.34 (m, 1 H)3.96-3.76 (m, 3 H).
Examples 225, 226, and 227 S nthesis of +/- -N- o 3-chloro hen l eth l 2-amino 1 th l-1H- pyrazolyl)pyridinyl)—2-fluorobenzamide WO 66188 Scheme 114 Following Steps 1 and 2 in Scheme 82, Steps 5 and 6 in Scheme 102, using (+/-)-tertbutyl (2-amino(3-chlorophenyl)ethyl)carbamate, (+/-)-N-(2-amino(3- chlorophenyl)ethyl)(2-amino(1,3-dimethyl-1H-pyrazolyl)pyridinyl)—2- fluorobenzamide was obtained. LCMS (m/z): 479.3 (MH+), 0.54 min. 1H NMR (400MHz, CDCI3) 6 ppm 8.16 (m, 2H), 7.87 (m, 1H), 7.47 - 7.18 (m, 7H), 5.23 (m, 1H), 4.58 (bs, 2H), 3.88 (s, 3H), 3.19 (m, 2H), 2.36 (s, 3H). The racemic mixture was resolved by chiral SFC (ChiralPak 5mic AD column, 4.6x100 (mm), 5 mL/min, EtOH+0.1%, DEA = 30%).
The polar enantiomer, (S)—N-(2-amino(3-chlorophenyl)ethyl)(2-amino(1,3- yl-1H-pyrazolyl)pyridinyl)—2-fluorobenzamide, was obtained at Rt = 2.6 min.
LCMS (m/z): 479.1 (MH+), 0.57 min. The less polar enantiomer, (R)—N-(2-amino(3- phenyl)ethyl)(2-amino(1,3-dimethyl-1H-pyrazolyl)pyridinyl)—2- fluorobenzamide, was obtained at Rt = 3.22 min. LCMS (m/z): 479.1 (MH+), 0.57 min. The absolute stereomchemisty was assigned based on biochemical data and docking model.
S nthesis of 4- 3-amino 1r4r deuteridoh drox c clohex l 2- l fluorobenzoic acid Scheme 115 F O _r_:Ste 1 F o Stegg F o NH2 0/ NH2 0/ NH2 OH N/ N/ N/ I I I \ N NaBD4 LiOH \ N \ N 0 I5: ;OH :cis = ~4:1) D‘;OH Ste 1. meth l4- 3-amino 1r4r deuteridoh drox c clohex l razin l fluorobenzoate A solution of ethyl 4-(3-amino(4-oxocyclohexyl)pyraziny|)fluorobenzoate (98 mg, 0.285 mmol) in methanol (1.903 mL), THF (0.952 mL) was cooled down to -78 °C. To this, NaBD4 (32.4 mg, 0.856 mmol) was slowly added by a portion. The reaction mixture was allowed to warm up to room temperature for 1 h. The on e was quenched with NH4C| solution, then followed by Na2C03 solution and stirred for 1 h. The reaction mixture was extracted by EtOAc. The combined organic layer was washed with water and brine, dried over anhydrous Na2804, filtered off, and concentrated in vacuo to e crude methyl 4-(3-amino((1r,4r)deuteridohydroxycyclohexyl)pyrazinyl) fluorobenzoate (81.4 mg, trans:cis = ~4:1, 82%), which was used for the next step. LCMS (m/z): 347.1 (MH+), 0.61 min (major, trans) and 0.64 min (cis).
Ste 2. 4- 3-amino 1r4r deuteridoh drox c clohex l razin l fluorobenzoic acid To a solution of methyl 4-(3-amino((1r,4r)deuteridohydroxycyclohexyl)pyrazin y|)fluorobenzoate (81 mg, 0.234 mmol) in THF (1559 ul,) and MeOH (780 pl) was added LiOH (1M solution) (421 pl, 0.421 mmol). The reaction mixture was stirred at room ature for 1 h. After pH was adjusted to 5, the reaction mixture was extracted with EtOAc. The combined organic layer was washed with water and brine, filtered off, and concentrated in vacuo. The crude 4-(3-amino((1r,4r)deuterido 2014/062913 hydroxycyclohexyl)pyrazin-2—yl)fluorobenzoic acid (99%) was used for the next step without further purification. LCMS (m/z): 333.1 (MH+), 0.47 min (major, trans) and 0.51 min (cis).
S s of S aminodeuterido 3-bromofluoro hen l ethanol Scheme 116 Ste Ste Ste F\EB>)10|-l D NH2 LiAlD41F\E?)ELOH—>Dess—Martin[O]2F\©/io::3F\©)\/OH Ste 1. ofluoro hen l-1 euterido-methanol 3-Bromofluorobenzoic acid (5.3 g, 24.20 mmol) was dissolved in THF (81 mL). To this, LiAlD4 (1.102 g, 29.0 mmol) was added at 0 OC. The reaction mixture was stirred at room temperature overnight. After the reaction mixture was cooled down to 0 °C, 1.1 mL of water was added, followed by 1.1 mL of 15% NaOH and 3.2 mL of water. The suspension was stirred at room ature for 2 h, then filtered through Celite and rinsed with Et2O, the filtrate was concentrated to yield the crude product, which was purified by flash chromatography (0-30% EtOAc/heptane) to yield (3-bromofluorophenyl)-1,1-di- deuterido-methanol in 64% yield. LCMS (m/z): 232.0 (MNa+), 0.69 min.
Step 2. 3-bromofluorobenzaldehyde-d1 (3-Bromofluorophenyl)-1,1-di-deuterido-methanol (3.2 g, 15.4 mmol) was dissolved in DCM (51.5 mL) and cooled down to 0 °C. Dess—Martin periodinane (9.83 g, 23.18 mmol) was added to the reaction mixture, which was stirred at 00C for 3 h. Saturated Na28203/ NaHC03 (8:1) solution was added to the mixture, which was stirred at room temperature for 1 h. The reaction mixture was then extracted with DCM. The combined organic layer was washed with water and brine, filtered off, and concentrated in vacuo. The crude material was purified by flash chromatography to yield 3-bromofluorobenzaldehyde-d1 as white solid (2.6 g, 82%). 1H NMR (400MHz, CDCI3) 5 ppm 7.83 (s, 1H), 7.57 - 7.50 (m 2H).
Ste 3. S aminodeuterido ofluoro hen lethanol Following Steps 4 to 9 in Scheme 74, using 3-bromo—5-fluorobenzaldehyde-d1, (S)—2- aminodeuterido(3-bromofluorophenyl)ethanol was obtained as a HCI salt. LCMS (m/z): 235.0/237.0 (MH+), 0.40 min. 8 nthesis of R amino 3-bromofluoro hen | -2 2-di-deuterido-ethanol hydrochloride Scheme 1 1 7 Step 1 Step 2 NHBoc NHBoc Br / Br 0 RuCI3, NalO4 1. isobutyl chloroformation a —> 2. NaBD4 F F NHBoc m; NHZ HCI Br D Br D D HCI in dioxane D OH OH F F Ste 1. R 3-bromofluoro hen l tert-butox carbon lamino acetic acid A solution of (S)—tert—butyl (1-(3-bromofluorophenyl)a||y|)carbamate (1.235 g, 3.74 mmol) in CCI4 (4 mL), acetonitrile (4 mL) and water (6 mL) was treated with sodium periodate (1.680 g, 7.85 mmol) and RuCI3 (16 mg, 0.075 mmol). After 1 h, the on was complete. The reaction was partitioned between ethyl acetate and water. The organics were washed with brine, then filtered over celite and concentrated. The crude was redissolved in e, then ed and trated again to provide crude (R)—2- (3-bromofluorophenyl)((tert-butoxycarbonyl)amino)acetic acid (1.30 g, 99% yield) which was used directly. LCMS (m/z): 348.2 (MH+), 0.52 min.
Ste 2. R -tert-but | 1- 3-bromofluoro hen lh drox -2 2-deuterido- ethyl)carbamate A -10 °C solution of (R)(3-bromofluorophenyl)((tert-butoxycarbonyl)amino)acetic acid (1.30 g, 3.73 mmol) in DME (6 mL) was treated with N-methyl morpholine (0.431 mL, 3.92 mmol). After 5 min, the reaction was treated with isobutyl chloroformate (0.515 mL, 2014/062913 3.92 mmol). After an additional 5 min, the reaction was filtered and the cake was washed with DME (4 mL). The combined organics were treated with a solution of NaBD4 (0.251 g, .97 mmol) in water (1 mL). At completion, the reaction was partitioned between ethyl acetate and water. The cs were washed with brine, then dried over sodium sulfate and concentrated. The crude material was purified by prep HPLC to provide the title compound, (R)—tert—butyl (1-(3-bromofluorophenyl)hydroxy-2,2-deuteridoethyl mate (55 mg, 4.4% yield). LCMS (m/z): 337.3 (MH+), 1.03 min.
Ste 3. R amino 3-bromofluoro hen | -2 2-di-deuterido-ethanol h drochloride A solution of (R)—tert-butyl (1-(3-bromof|uoropheny|)hydroxy-2,2-deuterido- carbamate (46 mg, 0.137 mmol) in 4 M HCI in dioxane (1368 ul) was stirred for overnight. The volaitle materials were removed in vacuo. The crude product was used for the next step without further purification. LCMS (m/z): 236/238 (MH+), 0.4 min. 8 nthesis of 4- 3-amino 4- h drox meth lc clohex | razin lfluorobenzoic Scheme 118 $91 $2; Stegg O l \ / \ o / \ HO OH O 0 O 0 1. NaH, BnBr _ i? stOH.HZO S? L'A'H4 2. 3 N HCI —> —> —> O OEt OBn O OEt OH F o Stepfi F O —QSte Q NH2 OMe Bpin 1. LiHMDS,Tf2NPh NHz OMe NI \ 2. (Bpin)2,PdC|2dppf,KOAc —> /N + N \ —> | F 0 F 0 m5 Stepz NHz OMe NHZ OH N \ N \ ”Z I /N LiOH l Pd/C trans/cis mixture OH OH Ste 1. Eth l 1 4-dioxas iro 4.5 decanecarbox late Ethyl 4-oxocyclohexanecarboxylate (15.01 g, 88.16 mmol) was combined with ethylene glycol (21 mL, 4.27 equiv.) and enesulfonic acid monohydrate (0.2 g, 0.012 equiv.) in anhydrous toluene (50 mL), and the mixture was stirred 14 h at room temperature. The reaction was diluted with ether (200 mL) and was washed with H20 (2X200 mL), saturated sodium bicarbonate (100 mL) and brine (80 mL). The organic layer was dried (Na2804), filtered and trated under reduced pressure to yield 18.15 g ethyl 4- lohexanecarboxylate ethylene ketal (96% yield). LCMS (m/z): 214.8 (MH+), 0.74 min.
Ste 2. 1 4-dioxas iro 4.5 decan lmethanol LiAlH4 (2.51 g, 66.3 mmol) was ded in THF (60 mL) and then cooled in an ice- bath. To the suspension was added Ethyl 1,4-dioxaspiro[4.5]decanecarboxylate (11.357 9, 53.0 mmol) dissolved in THF (40 mL) dropwise and the reaction mixture was lly warmed to room temperature over 1 h upon which LCMS indicated complete reduction of SM. The reaction mixture was diluted with ether (200 mL) and quenched with 2.5 mL water and then 5 mL (10% NaOH) and then 7.5 mL water. To this, anhydrous MgSO4 was added, which was then agitated for 30 min and filtered over Celite. The filtrate was concentrated in vacuo to afford the desired product in quantitative yield.
LCMS (m/z): 173.1 (MH+), 0.41 min.
Ste 3. 4- benz lox meth lc clohexanone 1,4-dioxaspiro[4.5]decanylmethanol (1.33 g, 7.72 mmol) was ved in DMF (14 mL) and then cooled to 0 °C. To the solution was added NaH (0.402 g, 10.04 mmol) in portions and the mixture agitated at 10 °C for 1 h and then benzyl bromide (1.194 mL, .04 mmol) was added and the mixture agitated over 72 h. The on mixture was quenched with water and extracted with ether and the combined organic extracts dried ), filtered and concentrated in vacuo and the crude product 8-((benzy|oxy)methy|)- 1,4-dioxaspiro[4.5]decane dissolved in acetonitrile (35 mL) and water (25 mL) and treated with 3N HCI (13 mL) and agitated at room temperature for 20 min upon which LCMS indicated desired product. The reaction mixture was ed with 40 mmol aqueous NaOH and then extracted with EtOAc (200 mL) and the organic layer was washed with water and dried (MgSO4), filtered and concentrated in vacuo and the residue purified by flash chromatography (0-50% EtOAc/heptane) to afford 1.23 g of the desired product as a ess syrup (73%). LCMS (m/z): 329.2 (MH+), 1.33 min.
Ste 4. 2- 4- benz lox meth l c clohexen l -4 4 5 ameth H 3 2- dioxaborolane 1,4-dioxaspiro[4.5]decanylmethanol (1.23 g, 5.63 mmol) was dissolved in THF (22.5 mL) and cooled to -78 °C. Then LiHMDS (6.20 mL, 6.20 mmol) was added dropwise and the mixture strred at this temperature for 1 h upon which 1,1 ,1-trifluoro-N-phenyl-N- ((trifluoromethy|)su|fony|)methanesulfonamide (2.214 g, 6.20 mmol) was added in one portion and the reaction mixture was let to warm to room temperature and stirr overnight.
The next morning, the reaction mixture was ed with 1.0 M NaHSO4 and the solvent evaporated in vacuo. The e was partitioned between NaOH/ether and the organic layer was separated and washed with 1.0 M NaOH twice, and dried with brine and then MgSO4, filtered and concentrated in vacuo to afford the desired product 4- ((benzyloxy)methyl)cyclohexeny| trifluoromethanesulfonate in quantitative yield which was taken to the next step t any further purification. The intermdiate 4- ((benzyloxy)methyl)cyclohexenyl (1000 mg, 2.85 mmol), )2 (1087 mg, 4.28 mmol), PdCI2(dppf)-CH2C|2 (233 mg, 0.285 mmol) and KOAc (560 mg, 5.71 mmol) were charged in a microwave vial and then dioxane (9.5 mL) was added. The mixture was evacuated and purged with N2 and then heated to 100 °C for 22 min in microwave. The crude mixture was diluted with ether and water and the organic layer was separated and dried (MgSO4), filtered and concentrated in vacuo and the residue purified by flash chromatography (0-10% EtOAc/heptanes) to afford the desired product (51%). LCMS (m/z): 219.2 (MH+), 0.88 min.
Ste 5. Meth l4- 3-amino 4- benz lox meth lc clohexen l razin l benzoate Methyl 4-(3-aminobromopyrazinyl)fluorobenzoate (343 mg, 1.051 mmol), 2-(4- ((benzyloxy)methyl)cyclohexeny|)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (414 mg, 1.261 mmol) PdCl2(dppf)-CH2Cl2 adduct (86 mg, 0.105 mmol) were placed in a microwave vial and then DME (3.5 mL) was added. Then 2.0 M Na2C03 (1261 uL, 2.52 mmol) was added and the mixture was degassed and purged with nitrogen and then heated at 115 °C for 30 min upon which the reaction was complete. The reaction mixture was diluted with EtOAc and washed with water and the organic layer was separated and dried ), ed and concentrated and the residue purified by flash chromatography (0-100% EtOAc/heptane) to afford 381 mg the desired product as a yellow solid (81%). LCMS (m/z): 448.2 (MH+), 1.16 min.
Ste 6. Meth l4- 3-amino 4- h drox meth lc clohex l razin lfluorobenzoate Methyl 4-(3-amino(4-((benzyloxy)methyl)cyclohexeny|)pyrazinyl) fluorobenzoate (381 mg, 0.851 mmol) was dissolved in THF (5 mL) and then MeOH (15 mL) was added and then Pd-C (10% wet) (550 mg, 0.517 mmol) was added. The mixture was put under vacuum and purged with hydrogen and this cycle was repeated thrice and then finally under en overnight. After 14 h, LCMS indicated alkene saturation but only partial benzyl deprotection, and therefore r Pd-C (10% wet) (700 mg) was added and the mixture stirred at room temperature for another 5 h after which complete benzyl deprotection ed. The reaction mixture was filtered and concentrated in vacuo to afford 215.6 mg of the desired product as a mixture of romers (cis/trans unspecified) (70%). LCMS (m/z): 360.2 (MH+), 0.71, 0.72 min.
Ste 7. S 3-amino 4- h drox meth lc clohex l razin l-N 3- chlorophenyl)—2-hydroxyethyl)—2-fluorobenzamide Methyl 4-(3-amino(4-(hydroxymethyl)cyclohexyl)pyrazinyl)fluorobenzoate (215.6 mg, 0.600 mmol) was dissolved in THF (3 mL) and then MeOH (3 mL) was added and then 1.0 M LiOH (2400 uL, 2.400 mmol) was added. The reaction mixture was agitated overnight and the next morning, LCMS ted formation of desired t. The reaction mixture was concentrated in vacuo and then azeotroped with THF twice (10 mL each) and then ied with 1.5 mL of 4.0 N HCI in dioxane and concentrated in vacuo.
The residue was dissolved in DMSO (5 mL) and taken to the next step as such. LCMS (m/z): 346.2 (MH+), 0.57, 0.58 min.
S nthesis of 4- 3-amino 1s 4s oroc clohex l razin l fluorobenzoic acid Scheme 119 F 0 Steel F o Stag; F 0 mg F o NH2 OMe NH2 OMe NH2 0M9 NH2 OH N \ N \ N BH Nl \ N \ | a /N 4 K», Et3N.3HF,PBSF /N LIOH I ? Et3N O OH F i: Ste 1. meth l4- 3-amino 1r4r h drox c clohex l razin-2— lfluorobenzoate Methyl 4-(3-amino(4-oxocyclohexyl)pyrazinyl)—2-fluorobenzoate (401.4 mg, 1.169 mmol) was suspended in MeOH and cooled to 0 °C. To the mixture was added NaBH4 (133 mg, 3.51 mmol) dissolved in MeOH (5 mL) and the mixture was gradually warmed to room temperature and stirred for 30 min upon which reaction was complete. The reaction mixture was d with EtOAc and saturated NaHC03 and the organic layer washed with water twice and dried (MgSO4), filtered and concentrated in vacuo to afford 339.4 mg of the desired product (84%). LCMS (m/z): 346.2 (MH+), 0.63 min.
Ste 2. Meth l4- 3-amino 1s 4s fluoroc clohex l razin lfluorobenzoate A flask containing a solution of methyl 4-(3-amino((1r,4r)hydroxycyclohexyl)pyrazin- 2-y|)f|uorobenzoate (339.4 mg, 0.983 mmol) in itrile (3.2 mL) was cooled to 0 °C in a ice/brine bath and orobutanesulfonyl fluoride (530 pl, 2.95 mmol) followed by triethylamine trihydrofluoride (480 pl, 2.95 mmol) and triethylamine (1233 ul, 8.84 mmol) was added and the resulting reaction mixture was allowed to stir at 0 °C for 90 min. After the elapsed time, LCMS indicated a 25:1 ratio of elimination vs. desired product. The reaction mixture was ed with water and extracted with EtOAc and the organic extract washed with water twice and dried (MgSO4), filtered and concentrated in vacuo to afford the crude product mixture which was carefully chromatographed (0-60% EtOAc/heptane) to afford 67.5 mg of the desired product. (19.8%). LCMS (m/z): 348.2 (MH+), 0.86 min.
Ste 3. 4- 3-amino 1s 4s f|uoroc clohex l razin l f|uorobenzoic acid Methyl 4-(3-amino((1s,4s)f|uorocyclohexyl)pyrazinyl)fluorobenzoate (67.5 mg, 0.194 mmol) was dissolved in THF (1 mL) and MeOH (1 mL) and then 1.0 M LiOH (0.777 mL, 0.777 mmol) was added. The reaction mixture was ed at room temperature.
After 1 h, LCMS indicated formation of desired acid. LCMS (m/z): 334.2 (MH+), 0.70 min.
S nthesis of 3-bromo 1r4r f|uoroc clohex l razinamine Scheme 120 NH2 m1 NH2 Step g NH2 W SteE g NH2 I NS NNBF /N I I LiEt3BH /N Et3N.3HF, PBSF NBS /N /N —> —, Et3N o OH i 2 F F Ste 1. 1s 4s 5-amino razin lc clohexanol 4-(5-aminopyrazinyl)cyclohexanone (1.049 g, 5.48 mmol) was dissolved in THF (10 mL) and cooled to 0 °C. ctride (12.06 mL, 12.06 mmol) was added dropwise and the mixture d for 20 min upon which reaction complete. The reaction e was quenched with 5 N NaOH (40 mmol) and then MeOH (5mL). The reaction mixture was WO 66188 diluted with 2-methyl THF and the aqeous layer separated and the organic layer washed with brine and dried (MgSO4), filtered and concentrated in vacuo to afford the desired product in a 95:5 cis/trans ratio which was then titurated with ether to obtain 586.3 mg of a faint yellow itate as the d product (55%). LCMS (m/z): 194.1 (MH+), 0.32 min.
Ste 2 and 3. 3-bromo 1r4r fluoroc clohex l razinamine Following Step 2 and 3 in Scheme 119, 3-bromo((1r,4r)f|uorocyclohexyl)pyrazin amine was obtained. LCMS (m/z): 276.0 (MH+), 0.81 min.
S nthesis of 4- 3-amino 4-c anoc clohex l razin l f|uorobenzoic acid F O NH2 OH trans/cis mixture Following Steps 4 to 7 in Scheme 118, 4-(3-amino(4-cyanocyclohexyl)pyraziny|) fluorobenzoic acid was obtained. LCMS (m/z): 341.2 (MH+), 0.64, 0.66 min (trans, cis).
Table 5. Compounds prepared using Method 3 described above.
Structure 1H NMR (400MHz, CD30D) 5 7.88 (S)-N-(2-amino—1 - - 7.7 (m, 2 H), 7.62 (m, 1 H), 7.52 (3- (m, 1 H), 7.46 (s, 1 H), 7.36 (m, 3 chlorophenyl)ethy H), 5.4 (m, 1 H), 3.38 (m. 2 H), 2.56 |)(3-amino—6- (m, 1 H), 1.79 (m, 4 H), 1.64 (m, 1 cyclohexylpyrazin H), 1.48 - 1.33 (m, 4 H), 1.33 (m, 1 y|)-2— H). fluorobenzamide 1H NMR (400MHz ,CD30D) 5 8.13 (S)-4—(2-amino—5- (d, J = 2.0 Hz,1 H), 8.01 (d, J = 2.0 (1 -methyI-1 H- Hz,1 H), 7.91 (t, J = 7.6 Hz,1 H), pyrazoI 7.54 (d, J = 2.0 Hz,1 H), 7.53 - y|)pyridinyI) 7.43 (m, 2 H), 7.43 - 7.34 (m, 1 H), fluoro-N-(1-(3- 7.25 (d, J = 7.8 Hz,1 H), 7.17 (d, J fluorophenyl)—2- = 10.2 Hz,1 H), 7.02 (dt, J = 2.2, hydroxyethyl)ben 8.5 Hz,1 H), 6.51 (d, J = 2.0 Hz,1 H), 5.23 (d, J = 6.3 Hz,1 H), 3.96 - 3.89 (m, 3 H), 3.90 - 3.80 (m, 2 H) (S)-4—(2-amino—5- 1H NMR z ,CD30D) 5 8.13 (1 -methyI-1 H- (d, J = 2.0 Hz,1 H), 8.04 (s, 1 H), pyrazoI 7.98 (d, J = 2.0 Hz,1 H), 7.95 - idinyI) 7.87 (m, 2 H), 7.80 (d, J = 7.8 Hz,1 fluoro—N-(2— H), 7.65 (t, J = 7.8 Hz,1 H), 7.53 (d, hydroxy—1-(3- J = 2.0 Hz, 1 H), 7.52 - 7.44 (m, 2 (methylsulfonyl)p H), 6.50 (s, 1 H), 5.31 (d, J = 5.5 henyl)ethyl)benza Hz,1 H), 4.00 - 3.86 (m, 5 H), 3.12 mide (s, 3 H) 1H NMR (400MHz, CD30D) 5 ppm (S)-4—(2-amino—5- 8.13 (d, J = 2.0 Hz,1 H), 8.03 (d, J (1 I-1 H- = 2.3 Hz, 1 H), 7.91 (t, J = 7.8 Hz,1 pyrazoI H), 7.54 (d, J = 2.0 Hz,1 H), 7.52 - y|)pyridinyI) 7.40 (m, 2 H), 7.28 - 7.13 (m, 3 H), fluoro—N-(2— 7.10 (d, J = 6.7 Hz,1 H), 6.51 (d, J hydroxy—1-(m- = 2.0 Hz, 1 H), 5.24 - 5.15 (m, 1 H), to|y|)ethy|)benza 3.95 - 3.89 (m, 3 H), 3.89 - 3.74 (m, mide 2 H) Structure H NMR (400MHz, CD30D) 8 8.13 (S)—4—(2-amino—5- (d, J = 2.3 Hz, 1 H), 8.00 (d, J = 2.0 (1 -methyI-1 H- Hz, 1 H), 7.91 (t, J = 7.8 Hz, 1 H), pyrazoI 7.56 - 7.45 (m, 3 H), 7.30 (s, 1 H), y|)pyridinyI)-N- 7.18 - 7.10 (m, 2 H), 6.50 (d, J = 2.0 (1 -(3-ch|oro—5- Hz, 1 H), 5.18 (t, J = 5.7 Hz, 1 H), fluorophenyl)—2- 3.91 (s, 3 H), 3.90 - 3.81 (m, 2 H). hydroxyethyl)—2- fluorobenzamide 1H NMR (400MHz, CD30D) 5 8.10 - 7.98 (m, 1H), 7.90 - 7.75 (m, 2H), (S)—N-(2-amino—1 - 7.50 - 7.25 (m, 7H), 6.45 - 6.32 (m, 1H), 5.46 - 5.30 (m, 1H), 3.81 (s, chlorophenyl)ethy 3H), 3.48 - 3.28 (m, 2H) |)(2-amino—5- (1 I-1 H- pyrazoI y|)pyridinyI) fluorobenzamide 1H NMR (400MHz, CD30D) 8 8.87 (s, 1 H), 8.54 (d, J = 4.7 Hz, 1 H), (S)—4—(2-amino—5- F O {OH 8.08 (d, J = 2.0 Hz, 1 H), 7.79 (t, J (1_methyl_1H_ : = 7.6 Hz, 1 H), 7.64 (d, J = 2.3 Hz, imidazol_5_ ”“2 N 1H), 7.57 (d, J = 1.6 Hz, 1 H), 7.43 - 12102314114113I) r.d.n_3_ I)_2_ 234 N \ 450.3 049 7.32 (m, 3 H), 7.32 -7.23 (m,1 H), / F 7.19 - 7.12 (m, 2 H), 7.08 (d, J = 9.8 fluorophenyl)_2_ Hz, 1 H), 6.92 (dt, J = 2.0, 8.4 Hz, yethyl)ben / N/ . 1H), 5.15-5.09 (m,1 H), 3.83- zam'de N=/ 3.71 (m, 5 H) 1H NMR (400MHz, CD30D) 8 8.97 F O _/ 1 , (s, H), 8.66 (br. s.,1 H), 8.18 (d, J ? (2'am'"°'5' = 2.0 Hz, 1 H), 7.88 (t, J = 7.8 Hz, 1 ”“2 N .(1Tmethyl'1H' H), 7.72 (d, J = 2.0 Hz, 1 H), 7.67 N \ 'T'dafil': (d, J :16 Hz, H), 7.50 - 7.40 (m, m' 'y)'I N' 235 I / CI 2’1)?! 466.4 0 55 3 H), 7.40-7.25 (m, 3 H), 5.20 (d, J — 5.9 Hz, 1 H), 3.95 - 3.81 (m, 5 H) chlorophenyl)_2_ / N/ hydroxyethyl)—2- N:/ fluorobenzamide Structure 1H NMR (400MHz, CD30D) 8 8.21 4-(2-amino—5-(1 - - 8.12 (m, 2 H), 8.05 (s, 1 H), 7.99 methyl-1 H- (t, J = 7.8 Hz, 1 H), 7.88 (s, 1 H), pyrazoI 7.81 (t, J = 7.6 Hz, 1 H), 7.54 - 7.44 idinyI)-N- 437.2 0.62 (m, 2 H),7.41 (d, J = 7.8 Hz, 1 H), ((6-chloropyridin- 7.37 (d, J = 7.8 Hz, 1 H), 4.71 (s, 2 2-yl)methyI) H), 3.94 (s, 3 H). fluorobenzamide 4-(2-amino—5-(1 - 1H NMR (400MHz, CD30D) 8 = methyl-1 H- 8.15 (q, J = 2.2 Hz, 2 H), 8.05 (s, 1 pyrazoI H), 7.94 - 7.87 (m, 2 H), 7.62 (s, 1 y|)pyridinyI) H), 7.53 - 7.42 (m, 3 H), 4.46 (s, 2 fluoro-N-((1- H), 3.93 (s, 3 H), 3.87 (s, 3 H) methyl-1 H- pyrazoI y|)methy|)benzam H NMR (400MHz, CD30D) 8 = 8.15 (d, J = 2.0 Hz, 1 H), 8.17 (d, J = 2.3 Hz, 1 H), 8.05 (s, 1 H), 7.98 (t, J: 7.8 Hz, 1 H), 7.88 (s, 1 H), 7.75 238 4_(2_amino_5_(1_ (d, J = 3.5 Hz, 1 H), 7.56 (d, J = 3.5 methy|_1H_ Hz, 1 H), 7.52 - 7.43 (m, 2 H), 4.92 F O pyrazoI (S. 2 H). 3-93 (S. 3 H) NH N / idinyI) 2 H/YJ 409'2 0'49 S fluoro-N-(thiazol- I 2- \ ylmethyl)benzami 1H NMR (400MHz, CD30D) 8 8.15 F 0 4-(2-amino—5-(1- (d, J = 2.3 Hz, 1 H), 8.09 (s, 1 H), NH2 Nm methyl-1H- 8.03 (s, 1 H), 7.94 - 7.84 (m, 2 H), H pyrazoI 7.48 - 7.37 (m, 3 H), 7.31 (br. s., 1 N, s y|)pyrIdIny|) H), 7.13 (d, J: 3.9 Hz,1 H), 4.62 239 l \ 408.2 0.64 fluoro—N- (s, 2 H), 3.93 (s, 3 H) hen-S- / ylmethyl)benzami / de Structure H NMR (400MHz, CD30D) 8 8.16 (S)(2-amino—5- (1 -methyI-1 H- (q, J=2.1 Hz, 2H), 8.05 (s, 1H), 7.92 (t, J=7.8 Hz, 1H), 7.88 (s, 1H), 7.51 I y|)pyridinyI) - 7.44 (m, 2H), 7.29 (s, 1H), 7.18 (d, J=9.8 Hz, 1H), 7.07 (d, J=9.0 Hz, fluoro-N-(1-(3- fluoro 1H), 5.45 (s, 1H), 5.34 (s, 1H), 5.23 (fluoromethyl)phe (t, J=5.9 Hz, 1H), 3.93 (s, 3H), 3.92 - - 3.82 (m, 2H) yethyl)ben zamide H NMR (400MHz, CD30D) 8 8.16 (S)(2-amino—5- (s, 2H), 8.06 (s, 1H), 7.96 - 7.90 (m, (1 -methyI-1 H- 1H), 7.89 (s, 1H), 7.56 (dd, J=2.0, 7.0 Hz, 1H), 7.53 - 7.45 (m, 2H), I 7.44 - 7.37 (m, 1H), 7.25 y|)pyridinyI)-N- (t, J=8.8 Hz, 1H), 5.23 - 5.15 (m, 1H), 3.94 (1 -(3-ch|oro—4- fluorophenyl)—2- (s, 2H), 3.92 - 3.80 (m, 2H) hydroxyethyI) fluorobenzamide (S)(2-amino—5- 1H NMR (400MHz, CD30D) 8 8.01 (1 ,5-dimethyI-1 H- (d, J=2.2 Hz, 1H), 7.96 (d, J=2.1 pyrazoI Hz, 1H), 7.95 - 7.90 (m, 1H), 7.66 y|)pyridinyI) (s, 1H), 7.52 (d, J=1.5 Hz, 0.5H), fluoro-N-(1-(3- 7.49 (s, 1H), 7.47 (d, J=1.7 Hz, fluoro 0.5H), 7.30 (d, J=0.9 Hz, 1H), 7.19 (fluoromethyl)phe (d, J=9.8 Hz, 1H), 7.09 (d, J=8.5 ny|) Hz, 1H), 5.46 (s, 1H), 5.35 (s, 1H), hydroxyethyl)ben .24 (t, J=5.8 Hz, 1H), 3.95 - 3.86 zamide (m, 2H), 3.86 (s, 3H), 2.42 (s, 3H) (S)(2-amino—5- 1H NMR (400MHz, CD30D) 8 8.02 (1 ,3-dimethyI-1 H- (d, J=2.2 Hz, 1H), 7.97 (d, J=2.2 pyrazoI Hz, 1H), 7.94 - 7.88 (m, 1H), 7.85 y|)pyridinyI) (s, 1H), 7.51 - 7.44 (m, 2H), 7.29 (d, fluoro-N-(1-(3- J=0.9 Hz, 1H), 7.18 (d, J=9.8 Hz, fluoro 1H), 7.07 (d, J=8.5 Hz, 1H), 5.45 (s, (fluoromethyl)phe 1H), 5.33 (s, 1H), 5.23 (t, J=5.9 Hz, ny|) 1H), 3.93 - 3.86 (m, 2H), 3.86 - 3.84 hydroxyethyl)ben (m, 3H), 2.36 (s, 3H) zamide 2014/062913 Structure 1H NMR (400MHz, CD30D) 8 8.15 (s, 2H), 8.06 (s, 1H), 7.93 - 7.85 (m, (S)—4-(2-amino—5- 2H), 7.50 - 7.41 (m, 2H), 4.03 - 3.97 (1 -methyI-1 H- (m, 1H), 3.93 (s, 3H), 3.72 (d, J=5.1 pyrazoI Hz, 2H), 1.94 - 1.74 (m, 4H), 1.74 - 1.64 (m, 2H), 1.38 - 1.08 (m, 5H) y|)pyridinyI)-N- (1 -cyclohexyI hydroxyethyl)—2- fluorobenzamide 1H NMR (400MHz, CD30D) 8 8.19 4-(2-amino—5-(1 - (d, J = 2.35 Hz, 1H), 7.91 (s, 1H), methyl-1 H- 7.87 (t, J = 7.83 Hz, 1H), 7.77 (s, pyrazoI 1H), 7.66 (d, J = 2.35 Hz, 1H), 7.58 y|)pyridinyI)-N- (s, 1H), 7.55 (d, J = 7.04 Hz, 1H), (3- 7.38 - 7.51 (m, 4H), 6.59 - 6.92 (m, oromethyl)b 1H), 4.67 (s, 2H), 3.91 (s, 3H) fluorobenzamide 1H NMR (400MHz, CD30D) 8 8.92 4-(2-amino—5-(1 - (d, J = 3.52 Hz, 1H), 8.15 (s, 2H), methyl-1 H- 8.05 (s, 1H), 7.92 (t, J = 7.83 Hz, pyrazoI 1H), 7.88 (s, 1H), 7.57 (s, 1H), 7.41 y|)pyridinyI)-N- - 7.51 (m, 3H), 7.37 (d, J = 7.43 Hz, (3-bromobenzyl)- 1H), 7.21 - 7.31 (m, 1H), 4.60 (d, J 2- = 5.87 Hz, 2H), 3.93 (s, 3H) fluorobenzamide (S)—4-(3-amino—6- (1 ,5-dimethyI-1 H- pyrazoI y|)pyrazinyI) fluoro—N-(2- hydroxy-1 - phenylethyl)benz amide Structure (S)—N-(2-amino—1 - 1H NMR (400MHz, CD30D) d 7.93 phenyl)ethy - 7.77 (m, 3H), 7.60 - 7.43 (m, 2H), |)(2-amino—5- 7.43 - 7.28 (m, 5H), 5.47 - 5.33 (m, (1 ,5-dimethyI-1 H- 1H), 3.82 - 3.68 (m, 3H), 3.47 - 3.30 pyrazoI (m, 2H), 2.39 - 2.24 (m, 3H) y|)pyridinyI) fluorobenzamide (3-amino—6- (1 ,3,5-trimethyl- 1H NMR (400MHz, CD30D) d 8.01 1H-pyrazoI (s, 1 H), 7.85 (m, 1 H), 7.70 (m, 1 y|)pyrazinyI) H), 7.63 (m, 1 H), 7.41 (m, 2 H), fluoro—N-(2— 7.34 (m, 2 H), 7.27 (m, 1 H), 5.20 hydroxy-1 - (m, 1 H), 3.84 (m, 2 H), 3.79 (s, 3 phenylethyl)benz H), 2.39 (s, 3 H), 0.32 (s, 3 H) amide (S)—N-(2-amino—1 - (3- 1H NMR (400MHz, CD30D) 8 7.91 chlorophenyl)ethy - 7.80 (m, 1H), 7.79 - 7.67 (m, 2H), |)(2-amino—5- 7.49 - 7.43 (m, 1H), 7.42 - 7.25 (m, (1 ,3,5-trimethyl- 6H), 5.45 - 5.30 (m, 1H), 3.67 1H-pyrazoI (s,3H), 3.46 - 3.30 (m, 2H), 2.17 (s, y|)pyridinyI) 3H), 2.10 (s, 3H) fluorobenzamide (S)—4—(3-amino—6- 1H NMR (400MHz, CD30D) 8 7.80 cyclopropylpyrazi -7.71 (m, 2 H), 7.56 (m, 1 H), 7.49 nyl)—2-fluoro— (m, 1 H), 7.36 - 7.15 (m, 5 H), 5.11 N-(2-hydroxy (m, 1 H), 3.76 (m, 2 H), 1.94 (m, 1 phenylethyl)benz H), 0.82 (m, 4 H) amide Structure (S)—N-(2-amino—1 - 1H NMR (400MHz, CD30D) 5 7.82 ethyl)—4-(3- - 7.75 (m, 2 H), 7.58 (m, 1 H), 7.49 amino (m, 1 H), 7.43 - 7.26 (m, 5 H), 5.39 cyclopropylpyrazi (m, 1 H), 3.36 (m, 2 H), 1.94 (m, 1 nyl)—2- H), 0.81 (m, 4 H) fluorobenzamide (S)—4-(2-amino—5- (1 -methyI-1 H- 1H NMR (400MHz, CD30D) 5 ppm pyrazoI 8.06 (m, 1H), 7.99 (m, 1H), 7.90 (m, y|)pyridinyI)-N- 1H), 7.79 (m, 1H), 7.38 (m, 2H), (1 -(3- 7.26 (d, J=9.0 Hz, 1H), 7.13 (d, (difluoromethyl)— J=8.6 Hz, 1H), 6.88 - 6.49 (t, J-56 -fluorophenyI) Hz, 1H), 5.39 (s, 2H), 5.17 (t, J=5.7 hydroxyethyl)—2- Hz, 1H), 3.83 (s, 3H), 3.82 (m, 2H) fluorobenzamide (S)—4-(2-amino—5- 1H NMR (400MHz, CD30D) 5 ppm (1 -methyI-1 H- 8.77 - 8.61 (m, 1H), 8.17 - 8.08 (m, pyrazoI 1H), 8.03 - 7.95 (m, 1H), 7.95 - 7.83 y|)pyridinyI) (m, 1H), 7.57 - 7.35 (m, 6H), 7.35 - fluoro-N-(1-(3- 7.26 (m, 1H), 6.54 - 6.43 (m, 1H), (fluoromethyl)phe .43 (s, 1H), 5.32 (s, 1H), 5.28 - ny|) .19 (m, 1H), 3.91 (s, 1H), 3.91 - hydroxyethyl)ben 3.79 (m, 2 H) zamide ....\ (S)—4-(2-amino—5- (1 ,3-dimethyI-1 H- IZ 1H NMR z, CD30D) 5 ppm pyrazoI 8.69 (m, 1H), 8.02 (m, 7H), 7.97 (m, y|)pyridinyI) 7H), 7.56 - 7.38 (m, 6H), 7.33 (m, 255 fluoro-N-(1-(3- 1H), 5.44 (s, 1H), 5.32 (s, 1H), 5.25 methyl)phe (m, 1H), 3.96 - 3.82 (m, 2H), 3.86 ny|) (s, 3H), 2.36 (s, 3H) hydroxyethyl)ben zamide Structure (S)(2-amino—5- (1 ,5-dimethyI-1 H- 1H NMR (400MHz, CD30D) 5 ppm pyrazoI 6.60 (m, 1H), 7.9 (m, 1H), 7.66 (m, y|)pyridinyI) 1H), 7.62 (m, 1H), 7.56 (m, 1H), fluoro-N-(1-(3- 7.43 - 7.27 (m, 5H), 7.24 (m, 1H), (fluoromethyl)phe 5.35 (s, 1H), 5.23 (s, 1H), 5.16 (m, ny|) 1H), 3.65 - 3.72 (m, 2H), 3.76 (s, hydroxyethyl)ben 3H), 2.32 (s, 3H) zamide (S)(3-amino—6- (tetrahydro—ZH- 1H NMR (400MHz, CD30D) 5 ppm 4- 6.69 (m, 1H), 7.66 (m, 2H), 7.73 - y|)pyrazinyI) 7.56 (m, 2H), 7.56 - 7.36 (m, 3H), fluoro-N-(1-(3- 7.33 (m, 1H), 5.44 (s, 1H), 5.32 (s, (fluoromethyl)phe 1H), 5.24 (m, 1H), 4.04 (m, 2H), ny|) 3.94 - 3.76 (m, 2H), 3.57 (m, 2H), yethyl)ben 2.94 (m, 1H), 1.97 - 1.76 (m, 4H) zamide (S)(3-amino—6- 1H NMR (400MHz, CD30D) 5 ppm (tetrahydro—ZH- 7.66 (m, 2H), 7.72 - 7.56 (m, 2H), pyran 7.56 - 7.36 (m, 3H), 7.46 - 7.36 (m, y|)pyrazinyI)-N 2H), 7.29 (m, 1H), 5.44 (s, 1H), (1-(3- .32 (s, 1H), 5.16 (m, 1H), 4.05 (m, bromophenyI) 2H), 3.65 (m, 2H), 3.57 (m, 2H), hydroxyethyI) 2.95 (m, 1H), 1.97 - 1.76 (m, 4H) fluorobenzamide (S)(3-amino—6- 1H NMR (400MHz, CD30D) 5 ppm (tetrahydro—ZH- 7.66 (m, 2H), 7.73 - 7.60 (m, 2H), 7.56 - 7.36 (m, 3H), 7.46 (s, 1H), y|)pyrazinyI)-N- 7.30 - 7.17 (m, 2H), 5.17 (m, 1H), (1 -(3-bromo—5- 4.04 (m, 2H), 3.66 (m, 2H), 3.57 (m, fluorophenyl)—2- 2H), 2.95 (m, 1H), 1.97 - 1.79 (m, hydroxyethyI) fluorobenzamide Structure (S)—4—(2-amino—5- (difluoromethyl)— 1H NMR (400MHz, CD30D) 5 ppm yI-1H- 7.93 (m, 1H), 7.87 - 7.77 (m, 2H), pyrazoI 7.74 (s, 1H). 7.45 (t, J = 60 Hz, 1H), y|)pyridinyI) 514.3 0.63 7.41 - 7.28 (m, 5H), 7.23 (m, 1H), fluoro-N-(1-(3- .28 (d, J = 48 Hz, 1H), 5.15 (m, (fluoromethyl)phe 1H), 3.78 (m, 2H), 2.46 (s, 3H) ny|) hydroxyethyl)ben zamide (2-amino—5- (1 - (difluoromethyl)— 1H NMR (400MHz, CD30D) 5 ppm 3-methyI-1H- 8.2 (m, 1H), 7.97 (m, 1H), 7.87 - pyrazoI 7.77 (m, 2H), 7.4 - 7.28 (m, 5H), y|)pyridinyI) 7.32 (t, J = 60, 1H), 7.23 (m, 1H), -N-(1-(3- .28 (d, J = 48 Hz, 2H), 5.15 (m, (fluoromethyl)phe 1H), 3.78 (m, 2H), 2.31 (s, 3H) ny|) hydroxyethyl)ben zamide (S)—4—(2-amino—5- (1 - oromethyl)— 1H NMR (400MHz, CD30D) 5 ppm -methyI-1H- 7.93 (m, 1H), 7.87 (m, 1H), 7.81 pyrazoI (m, 1H), 7.75 (s, 1H), 7.46 (t, J = 56 y|)pyridinyI) Hz, m), 7.38 (m, 2H), 7.19 (m, 1H), fluoro-N-(1-(3- 7.9 (d, J =12 Hz, 1H), 6.98 (d, J = fluoro 8 Hz, 1H), 5.3 (d, J = 48 Hz, 2H), (fluoromethyl)phe .14 (m, 1H), 3.78 (m, 2H), 2.46 (s, ny|) hydroxyethyl)ben zamide (S)—4—(2-amino—5- 1H NMR (500 MHz, METHANOL- (1 -methyI-1 H- d4) 8 8.19 (d, J=2.35 Hz, 1 H) 7.91 pyrazoI (s, 1 H) 7.86 (t, J=7.83 Hz,1 H) y|)pyridinyI)-N- 7.77 (s,1 H) 7.67 (d, J=2.35 Hz, (1 -(3- 1H) 7.49 - 7.39 (m, 3 H) 7.39 - 7.25 chlorophenyl)—2- (m, 3 H) 5.19 (t, J=5.87 Hz, 1 H) hydroxyethyl)—2- 4.02- 3.78 (m, 5 H). fluorobenzamide Structure (S)—4-(2-amino—5- (1 - oromethy|)- 1H NMR (400MHz, CD30D) 5 ppm -methyI-1H- 8.2 (m, 1H), 8.1 (m, 1H), 7.6 (m, pyrazoI 1H), 7.55 (m, 1H), 7.48 - 7.20 (m, yI)pyridinyl)—N- 7H), 5.32 (m, 1H), 4.03 (m, 2H), (1 -(3- 2.54 (s, 3H) chlorophenyl)—2- hydroxyethyl)—2- fluorobenzamide (S)—4-(2-amino—5- (1-methyI-1H- 1H NMR (400MHz, CD30D) 6 ppm 1,2,3-triazoI 8.20 (d, J=2.0 Hz, 1H), 7.96 - 7.83 yI)pyridinyl)—N- (m, 3H), 7.53 - 7.39 (m, 3H), 7.27 (1-(3- ' (d, J=8.2 Hz, 1H), 7.19 (d, J=9.8 chlorophenyl)—2- Hz, 1H), 5.17 (s, 1H), 4.13 (s, 3H), hydroxyethyl)—2- 3.86 (dd, J=6.1, 8.0 Hz, 2H) fluorobenzamide (S)—4-(2-amino—5- (1-methyI-1H- 1H NMR (400MHz, CD30D) 6 ppm 1,2,3-triazoI 8.19 (m, 1H), 7.91 (m, 1H), 7.89 (m, yI)pyridinyl)—N- 2H), 7.61 (s, 1H), 7.53 - 7.36 (m, (1-(3- ' 4H), 7.36 - 7.21 (m, 1H), 5.48 (s, henyl)—2- 2H), 5.18 (t, J=5.9 Hz, 1H), 4.13 (s, hydroxyethyl)—2- 3H), 3.86 (dd, J=5.9, 8.6 Hz, 2H) fluorobenzamide 2014/062913 Structure (2-amino (1 -methyI-1 H- 1H NMR (400MHz, CD30D) 5 ppm 1,2,3-triazoI 8.20 (d, J=2.0 Hz, 1H), 7.98 - 7.83 y|)pyridinyI) (m, 3H), 7.53 - 7.39 (m, 3H), 7.27 fluoro-N-(1-(3- (d, J=8.2 Hz, 1H), 7.19 (d, J=9.8 fluoro Hz, 1H), 5.17 (s, 1H), 4.13 (s, 3H), iodophenyI) 3.88 (dd, J=6.1, 8.0 Hz, 2H). hydroxyethyl)ben zamide (S)(3-amino- 1H NMR (400MHz, CD30D) 5 ppm 6-(1H-pyrazoI 8.84 (br. s., 1 H) 8.35-8.27 (m, 1 H) y|)pyrazinyI) 8.09(s, 2 H) 7.92-7.82 (m, 1 H) fluoro-N-(2- 419.2 0.585 7.78-7.81 (m, 2 H) 7.50-7.21 (m, 5 hydroxy H) 5.29-5.14 (m, 1 H) 3.92-3.78 (m, phenylethyl)benz 2 H) amide (S)(2-amino 1H NMR (400MHz, CD30D) 5 ppm (1 -methyI-1 H- 8.23 -7.98 (m, 3 H), 7.88 (s, 1 H), pyrazoI 7.58 (d, J=7.83 Hz, 1 H), 7.51 - idinyI)-N- 428.2 0.57 7.01 (m, 7 H), 5.23 (dd, , (2-hydroxy .09 Hz, 1 H), 4.07 - 3.53 (m, 5 H), phenylethyI) 2.44 (s, 3 H) methylbenzamide (S)(2-amino (1 ,3-dimethyI-1 H- 1H NMR (400MHz, CD30D) 5 8.08 pyrazoI - 7.78 (m, 4H), 7.53 - 7.42 (m, 3H), y|)pyridinyI)-N- 7.35 (d, J=9.8 Hz, 1H), 7.23 (d, (1 -(3- 514.1 0.65 J=8.6 Hz, 1H), 8.97 - 8.58 (t, J=56 (difluoromethy|)- Hz, 1H), 5.48 (s, 2H), 5.28 (t, J=5.7 -fluorophenyI) Hz, 1H), 3.89 (m, 2H), 3.85 (s, 3H), hydroxyethyI) 2.38 (s, 3H) fluorobenzamide Structure (S)—4-(2-amino—5- (1 ,5-dimethyI-1 H- 1H NMR (400MHz, CD30D) 5 ppm pyrazoI 8.03 - 7.85 (m, 3H), 7.64 (s, 1H), y|)pyridinyI)-N- 7.55 - 7.41 (m, 3H), 7.35 (d, J=9.4 (1 -(3- Hz, 1H), 7.23 (d, J=8.6 Hz, 1H), (difluoromethyl)— 6.99 - 6.56 (t, J=56 Hz, 1H), 5.48 -fluorophenyI) (s, 2H), 5.26 (t, J=5.7 Hz, 1H), 3.91 hydroxyethyl)—2- (m, 2H), 3.84 (s, 3H), 2.40 (s, 3H) fluorobenzamide (S)—4-(2-amino—5- (1 -methyI-1 H- 1H NMR z, CD30D) 8 8.20 1,2,3-triazoI (d, J=2.0 Hz, 1H), 7.95 - 7.82 (m, y|)pyridinyI)-N- 3H), 7.54 - 7.42 (m, 3H), 7.34 (d, (1 -(3- J=9.4 Hz, 1H), 7.22 (d, J=8.6 Hz, (difluoromethyl)— 1H), 5.25 (t, J=5.9 Hz, 1H), 4.13 (s, -fluorophenyI) 3H), 3.97 - 3.80 (m, 2H) hydroxyethyl)—2- fluorobenzamide (S)—4-(2-amino—5- F 0 {OH = (1- F 1H NMR 400MHz,( C . D3OD 5ppm) ””2 N éflfigflefiy')‘ 7.94 (m, 1H), 7.85 - 7.76 (m, 2H), N/ 7.74 (s, 1H), 7.65 | - 7.25 (t, J=60 pyrazol_4_ \ _ 273 F F y1l)pélridinyI)-N- 550.1 0.73 :12ggfif,fiffifirg’fifli? \\ ( .'( ' Hz, 1H), 6.89-6.49 (t, J=56 Hz, N‘N>,F (d'fluoromethy')' 1H), 5.21 - 5.08 (m, 1H), 3.89 - 3.70 -fluorophenyI) F (m, 2H), 2.46 (s, 3H) yethyl)_2_ fluorobenzamide (S)—4-(2-amino—5- F o r (1- ' F NH2 N (difluoromethyl)— 1H NMR (400MHz, CD30D) 6 ppm H 3-methyI-1H- 8.28 (s, 1H), 8.07 (d, J=2.0 Hz, 1H), | pyrazoI 7.98- 7.81 (m, 2H), 7.61 -7.45 (m, 274 F F y|)pyridinyI)-N- 550.1 0.73 4H), 7.36 (m, 1H), 7.26 (m, 1H), \ (1-(3- 6.97 - 6.60 (t, J=56 Hz, 1H), 5.25 (t, N—N (difluoromethy|)- J=5.7 Hz, 1H), 4.01 - 3.77 (m, 2H), >’F rophenyI) 2.40 (s, 3H) hydroxyethyl)—2- fluorobenzamide 2014/062913 Structure (S)-4—(2-amino—5- (1 - (difluoromethyl)- 1H NMR (400MHz, CD30D) 5 ppm -methyI-1H- 8.86 - 8.73 (m, 1H), 8.10 - 7.98 (m, pyrazoI 2H), 7.96 - 7.83 (m, 2H), 7.73 - 7.55 y|)pyridinyI)-N- (m, 3H), 7.55 - 7.41 (m, 5H), 6.98 - (1 -(3- 6.61 (m, 1H), 5.36 -5.22 (m, 1H), (difluoromethyl)p 4.01 - 3.77 (m, 2H), 2.65 - 2.51 (m, henyI) 3H) hydroxyethyI) fluorobenzamide (S)-4—(2-amino—5- (1 ,5-dimethyI-1 H- pyrazoI 1H NMR (400MHz, CD30D) 5 ppm idinyI)-N- 8.85 - 8.74 (m, 1H), 8.06 - 7.87 (m, (1 -(3- 3H), 7.73 - 7.57 (m, 3H), 7.55 - 7.42 (difluoromethyl)p (m, 4H), 6.98 - 6.62 (m, 1H), 5.39 - henyI) 5.22 (m, 1H), 4.00 - 3.81 (m, 5H), hydroxyethyI) 2.48 - 2.36 (m, 3H) fluorobenzamide (S)-4—(2-amino—5- (1 ,3-dimethyI-1 H- 1H NMR (400MHz, CD30D) 5 ppm I 8.81 (d, J=4.1 Hz, 1H), 8.10 - 7.97 y|)pyridinyI)-N- (m, 2H), 7.97 - 7.83 (m, 2H), 7.70 - (1 -(3- 7.57 (m, 2H), 7.56 - 7.43 (m, 3H), (difluoromethyl)p 6.98 - 6.63 (m, 1H), 5.37 - 5.23 (m, henyI) 1H), 3.99 - 3.80 (m, 5H), 2.44 - 2.33 hydroxyethyI) (m, 3H) fluorobenzamide (R)(2-amino—5- (1 - (difluoromethyl)- 1H NMR (400MHz, CD30D) 5 ppm -methyI-1H- 9.03 (d, J=6.3 Hz, 1H), 8.11 - 7.94 pyrazoI (m, 2H), 7.93 - 7.77 (m, 3H), 7.74 - y|)pyridinyI) 562.1 0] 7.64 (m, 1H), 7.61 - 7.54 (m, 1H), fluoro-N-(1-(3- 7.53 - 7.42 (m, 2H), 5.36 (t, J=6.9 fluoro Hz, 1H), 3.19 (s, 3H), 2.65 - 2.51 lsulfonyl)p (m, 3H), 1.64 (d, J=6.9 Hz, 3H) henyl)ethyl)benza mide Structure (S)—4—(3-amino—6- 1H-NMR (400MHz, CD30D) 8 7.85 (tetrahydro—ZH- - 7.70 (m, 2 H), 7.66 - 7.50 (m, 2 pyran H), 7.34 - 7.22 (m, 1 H), 7.19 - 7.12 y|)pyrazinyI) (m, 1 H), 7.12- 7.04 (m,1 H), 6.98 fluoro-N-(1-(3- -6.83 (m, 1 H), 5.18 - 5.04 (m, 1 fluorophenyl)—2- H), 4.03 - 3.87 (m, 2 H), 3.83 - 3.67 hydroxyethyl)ben (m, 2 H), 3.54 - 3.40 (m, 2 H), 2.92 zamide -2.78 (m, 1 H), 1.89- 1.66 (m, 4 H) (S)—4—(3-amino—6- (1 -methyI-1 H- pyrazoI y|)pyrazinyI) 451.1 0.66 fluoro-N-(1-(3- fluorophenyl)—2- yethyl)ben zamide (S)—4—(3-amino—6- ropylpyrazi 1H NMR z, CD30D) 8 8.05 nyl)—2-fluoro— (m, 1 H), 7.91 - 7.87 (m, 2 H), 7.87 N-(2-hydroxy - 7.78 (m, 2 H), 7.68 - 7.64 (m, 2 471.2 0.63 (3- H), 7.64 - 7.57 (m, 1 H), 5.30 (m, 1 (methylsulfonyl)p H), 3.91 (m, 2 H), 3.12 (s, 3 H), henyl)ethyl)benza 2.05 (m, 1 H), 0.93 (m, 2 H). mide (S)—4—(2-amino—5- 1H NMR (400MHz, CD30D) 8 8.60 (1 ,3-dimethyI-1 H- (m, 1 H), 7.92 (m, 1 H), 7.87 (m, 1 pyrazoI H), 7.81 (m 1 H), 7.76 (m, 2 H), y|)pyridinyI) 464.1 0.60 7.37 (m, 2 H), 7.28 (m, 1 H), 7.15 fluoro-N-(1-(3- (m, 1 H), 7.08 (m, 1 H), 6.92 (m, 1 fluorophenyl)—2- H), 5.12 (m, 1 H), 3.84 - 3.69 (m, 2 hydroxyethyl)ben H), 3.76 (s, 3 H), 2.26 (s, 3 H) zamide Structure (S)(2-amino 1H NMR (400MHz, CD30D) 8 8.52 (1 ,3-dimethyI-1 H- (m, 1 H), 7.92 (m, 1 H), 7.87 (m 1 pyrazoI H), 7.81 (m, 1 H), 7.76 (m, 1 H), y|)pyridinyI) 7.36 (m, 2 H), 7.22 - 7.08 (m, 3 H), fluoro-N-(2- 7.01 (m, 1 H), 5.1 (m, 1 H), 3.82- hydroxy—1-(m- 3.68 (m, 2 H), 3.76 (s, 3 H), 2.26 (s, tolyl)ethy|)benza 3 H), 2.25 (s, 3 H). mide (S)(2-amino (1 ethyI-1 H- 1H NMR (400MHz, CD30D) 8 8.74 pyrazoI (m, 1 H), 7.95 (m, 1 H), 7.92 (m, 1 y|)pyridinyI) H), 7.87 (m 1 H), 7.81 (m, 2 H), fluoro-N-(2- 7.76 (m, 1 H), 7.71 (m,1 H), 7.56 hydroxy—1-(3- (m, 1 H), 7.38 (m, 2 H), 5.21 (m, 1 (methylsulfonyl)p H), 3.84 (m, 2 H), 3.76 (s, 3 H), henyl)ethyl)benza 3.03 (s, 3 H), 2.26 (s, 3 H). mide 4-(3-amino cyclopropylpyrazi 1H NMR (400MHz, CD30D) 8 7.93 nyI)-N-(3- - 7.84 (m, 3 H), 7.87 (m 1 H), 7.76 chloro 4 . . (m, 1 H), 7.67 (m, 1 H), 7.59 (m, 1 (methylsulfonyl)b H), 4.09 (m, 2 H), 3.15 (s, 3 H), enzyI) 2.05 (m, 1 H), 0.92 (s, 4 H). fluorobenzamide 4-(3-amino 1H NMR (400MHz, CD30D) 8 7.91 cyclopropylpyrazi - 7.84 (m, 2 H), 7.83 (m 1 H), 7.70 - nyI)fluoro- 459.2 0.75 7.57 (m, 3 H), 7.51 (m,1 H), 4.71 N-(3-fluoro (m, 2 H), 3.16 (s, 3 H), 2.04 (m, 1 (methylsulfonyl)b H), 0.91 (s, 4 H) enzyl)benzamide (R)(3-amino-6— 1H NMR (400MHz, CD30D) 8 7.90- ropylpyrazi 7.82 (m, 2 H) 7.80-7.72 (m, 1 H) nyI)fluoro- 7.68-7.51 (m, 4 H) 5.32 (q, J=7.04 N-(1-(3-fluoro 473.3 0.775 Hz,1 H) 3.16 (s, 3 H) .99 (m, (methylsulfonyl)p 1 H) 1.61 (d, J=7.04 Hz, 3 - henyl)ethyl)benza 0.87 (m, 4 H) mide WO 66188 Rt NMR (min) 1H NMR (400MHz CD30D))5ppm 8.97 (d, J:828Hz 1H 7.(87s 1 (R)(2-amino H), 7.80 (t, J:7.83 Hz,1 H), 7.72 cyclopropylpyridi (dd, J=11.93, 2.15 Hz, 2 H) 7.83 nyI)fluoro- (dt, J=7.83, 1.78 Hz, 1 H), 7.55 (d, N-(1-(3-fluoro 472.3 0.682 J:9.39 Hz, 1 H), 7.45-7.35 (m, 2 H), (methylsulfonyl)p .40-5.25 (m, 1 H), 3.18 (s, 3 H), henyl)ethyl)benza 2.03-1.88 (m, 1 H), 1.81 (d, J=7.04 mide Hz, 3 H), 1.07-0.97 (m, 2 H), 0.80- 0.89 (m, 2 H) (S)(2-amino (1 -methyI-1 H- 1H NMR (400MHz, CD30D) 8 8.18 pyrazoI (m, 2 H), 8.05 (s, 1 H), 7.88 (m 2 y|)pyridiny|)-N-4 H), 7.48 (m, 2 H), 7.31 (s, 1 H), (1 -(3-chloro fluorophenyI) I6: 7.14 (m, 2 H), 5.12 (m, 1 H), 3.93 (s, 3 H), 3.87 (m, 2 H). hydroxyethy|) fluorobenzamide (S)(2-amino (1 H-pyrazoI -N-(2-y|)pyridiny|)4 hydroxy-1 - phenylethyl)benz amide I53 1H NMR (400MHz, CD30D) 8 ppm8.24-8.15 (m, 2 H) 8.08 (s, 2 H)7.91 (t, J=7.83 Hz, 1 H) 7.54-7.22(m, 7 H) 5.22 (t, J=8.08 Hz, 1 H)3.98-3.77 (m, 2 H) Structure (S)(2-amino (1-isopropyI-1H- 1H NMR (400MHz, CD30D) 5 ppm I 8.17 (s, 3 H) 8.04 (s, 1 H) 7.98-7.88 y|)pyridinyI) (m, 3 H) 7.80 (d, J=7.83 Hz, 1 H) fluoro-N-(2- 7.70-7.81 (m, 1 H) .42 (m, 2 hydroxy(3- 538.3 0.601 H) 5.31 (t, J=5.67Hz, 1 H) 4.58 (dt, (methylsulfonyl)p J=13.30, 8.85 Hz, 1 H) 4.08-3.74 henyl)ethy|)benza (m, 2 H) 3.12 (s, 4 H) 1.52 (d, mide J=6.65 Hz, 8 H) 1H NMR (400MHz, CD30D) 5 ppm (S)(2-amino 8.08 (d, J=2.35 Hz, 1 H) 8.05 (s,1 (1-isopropyI-1H- H) 8.00 (br. s., 1 H) 7.87-7.72 (m, 2 pyrazoI H) 7.42-7.35 (m, 2 H) 7.33-7.23 (m, idinyI) 478.2 0.698 1 H) 7.18 (d, J=7.43 Hz, 1 H) 7.09 fluoro-N-(1-(3- (d, J=10.17 Hz, 1 H) 8.93 (t,J=8.41 fluorophenyI) Hz,1 H)4.48 (quin, J=6.65 Hz,1 H) hydroxyethyl)ben 5.13 (t, J=5.87 Hz, 1 H) .58 zamide (m, 2 H) 1.42 (d, J=6.65 Hz, 8 H) 1H NMR (400 MHz, CD30D) 8 ppm 7.88 - 7.82 (m, 2H), 7.71 - 7.85 (m, (S)(3-amino-6— 1H), 7.83 - 7.58 (m, 1H), 4.10 - 4.01 (tetrahydro-ZH- (m, 2H), 4.01 - 3.94 (m, 1H), 3.72 pyran (d, J=5.1 Hz, 2H), 3.58 (dt, J=2.5, azinyI)-N- 11.4 Hz, 2H), 3.01 - 2.90 (m, 1H), (1 -cyclohexyI 1.97 - 1.75 (m, 9H), 1.75 - 1.84 (m, hydroxyethyI) 2H), 1.38 - 1.09 (m, 5H) fluorobenzamide (S)(2-amino (1-isopropyI-1H- 1H NMR (400MHz, CD30D) 8 ppm pyrazoI 8.85-8.47 (m, 1 H) 8.13-8.02 (m, 3 y|)pyridinyI) H) 7.89-7.71 (m, 2 H) 7.47-7.10 (m, fluoro-N-(2- 7H) 5.23-5.05 (m, 1 H) 4.47 (spt, hydroxy J=6.65 Hz, 1 H) 3.92-3.88 (m, 2 H) phenylethyl)benz 1.43 (d, J=6.65 Hz, 8 H) amide Structure (S)(2-amino 1H NMR (400MHz, CD30D) 5 ppm (1 ,5-dimethyI-1 H- 8.00 (d, J=2.35 Hz, 1 H) 7.96 - 7.86 pyrazoI (m, 2 H) 7.65 (s, 1 H) 7.53 - 7.43 idinyI) (m, 2 H) 7.42 - 7.33 (m, 1 H) 7.25 fluoro-N-(1-(3- (d, J=7.83 Hz, 1 H) 7.17 (d, fluorophenyI) J=10.17 Hz, 1 H) 7.02 (td, , hydroxyethyl)ben 1.96 Hz, 1 H) 5.22 (t, J=5.87 Hz, 1 zamide H) 3.84 (s, 5 H) 2.40 (s, 3 H) (S)(2-amino- 1H NMR (400MHz, CD30D) 5 ppm -(1-ethyI-1H- 8.20-8.15 (m, 2 H) 8.12 (s, 1 H) pyrazoI 8.04 (s, 1 H) 7.96-7.87 (m, 3 H) y|)pyridinyI) 7.80 (d, J=7.83 Hz, 1 H) 7.70-7.60 fluoro-N-(2- (m, 1 H) 7.54-7.42 (m, 2 H) 5.31 (t, hydroxy—1-(3- J=5.48 Hz, 1 H) ) 4.22 (q, J=7.30 (methylsulfonyl)p Hz, 2 H) 4.05-3.77 (m, 2 H) 3.12 (s, henyl)ethy|)benza 3 H) 1.48 (t, J=7.24 Hz, 3 H) mide (S)(2-amino 1H NMR (400MHz, CD30D) 5 ppm (1 -ethyI-1 H- 8.08 (s, 2 H) 8.03 (s, 1 H) 7.89-7.76 pyrazoI 480.3 (m, 2 H) 7.47-7.33 (m, 3 H) 7.31- y|)pyridinyI)-N- /482. 0.687 7.13 (m,3 H) 5.11 (t, J=5.87 Hz, 1 (1 -(3- H) 4.14 (q, J=7.30 Hz, 2 H) 3.93- chlorophenyI) 3.58 (m, 2 H) 1.40 (t, J=7.43 Hz, 3 hydroxyethyl) fluorobenzamide 1H NMR (400MHz, CD30D) 5 ppm (2-amino 8.19-8.14 (m, 2 H) 8.12 (s, 1 H) (1 -ethyI-1 H- .87 (m, 2 H) 7.52-7.44 (m, 2 pyrazoI H) 7.38 (td, , 5.87 Hz, 1 H) y|)pyridinyI) 7.25 (d, J=7.83 Hz, 1 H) 7.18 (d, fluoro-N-(1-(3- J=10.17 Hz, 1 H) 7.02 (td,J=8.41, fluorophenyI) 1.96 Hz, 1 H) 5.22 (t, J=5.87 Hz, 1 hydroxyethyl) H) 4.22 (q, J=7.43 Hz, 2 H) 4.01- benzamide 3.67 (m, 2 H) 1.48 (t, J=7.43 Hz, 3 Structure (2-amino 1H NMR (400MHz, CD30D) 5 ppm (1-ethyI-1H- 8.06 (s, 2 H) 8.02 (s, 1 H) 7.94 (s, 1 pyrazoI H) .65 (m, 4 H) 7.60-7.50 yI)pyridinyI) 508.3 0.624 (m, 1 H) 7.42-7.32 (m, 2 H) 5.26 (q, -N-(1-(3- J=6.52 Hz, 1 H) 4.12 (q, J=7.04 Hz, (methylsulfonyl) 2 H) 3.03 (s, 3 H) .47 (m, 3 phenyl)ethyl) H) 1.43-1.32 (m, 3 H) benzamide (S)(2-amino (1 -methyI-1 H- 1H NMR (400MHz, CD30D) 8 ppm 1,2,3-triazoI 8.2 (m,1 H), 7.95-7.81 (m, 3 H), y|)pyridinyI)-N- 467.2 0.61 7.48 (m, 3 H), 7.35 - 7.25 (m, 3 H), (1 -(3- .19 (m, 1 H), 4.13 (s, 3 H), 3.86 chlorophenyI) (m, 2 H) hydroxyethyI) fluorobenzamide 4-(3-amino ((1r,4S) 1H NMR (400MHz, CD30D) 5 ppm hydroxycyclohexy 8.85 - 8.72 (m, 1H), 8.23 (d, J=1.6 |)pyrazinyI)-N- Hz, 1H), 7.99 (d, J=1.6 Hz, 1H), ((S)(3- 7.96 - 7.87 (m, 3H), 7.71 - 7.57 (m, (difluoromethy|)- 2H), 7.57 - 7.43 (m, 4H), 6.97 - 6.62 -fluorophenyI) (m, 1H), 5.35 - 5.22 (m, 1H), 4.22 - hydroxyethyI) 4.10 (m, 3H), 4.01 - 3.82 (m, 2H) fluorobenzamide (S)(2-amino (1 -methyI-1 H- 1,2,3-triazoI 1H NMR (400MHz, CD30D) 8 8.72 y|)pyridinyI)-N- (m, 1 H), 8.21 (m, 1 H), 7.80 (m, 3 (1 -(3-chloro H), 7.48 (m, 2 H), 7.3 (s, 1 H), 7.15 fluorophenyI) (m, 2 H), 5.19 (m,1 H), 7.41 (s, 3 hydroxyethyI) H), 3.87 (m, 2 H). fluorobenzamide Structure (R)—4-(2-amino—5- (1 -methyI-1 H- 1H NMR (400MHz, CD30D) 8 8.7 1,2,3-triazoI (m, 1 H), 8.11 (m, 1 H), 7.79 (m, 2 y|)pyridinyI)-N- 451.2 0.71 H), 7.71 (m, 1 H), 7.35 (m, 3 H), (1-(3- 7.29 - 7.12 (m, 3 H), 5.15 (m, 1 H), phenyl)ethy 4.03 (s, 3 H), 1.47 (m, 3 H). |) fluorobenzamide (S)—4-(2-amino—5- (1 -methyI-1 H- 1H NMR (400MHz, CD30D) 8 8.62 1,2,3-triazoI (m, 1 H), 8.2 (m, 1 H), 7.89 (m, 3 y|)pyridinyI) 433.3 1.642 H), 7.5 - 7.39 (m 4 H), 7.39 - 7.22 —N-(2— (m, 2 H), 5.23 (m, 1 H), 4.13 (s, 3 hydroxy-1 - H), 3.87 (m, 2 H) phenylethyl)benz amide (S)—4-(2-amino—5- (1 -methyI-1 H- 1H NMR (400MHz, CD30D) 5 8.67 1,2,3-triazoI (m, 1 H), 8.2 (m, 1 H), 7.87 (m, 3 y|)pyridinyI) 451.1 0.45 H), 7.45 (m, 2 H), 7.38 (m,1 H), fluoro-N-(1-(3- 7.30 - 7.20 (m, 2 H), 7.02 (m, 1 H), fluorophenyl)—2- 5.22 (m, 1 H), 4.12 (s, 3 H), 3.86 hydroxyethyl)ben (m, 2 H zamide (S)—4-(2-amino—5- (1 -methyI-1 H- 1H NMR (400MHz, CD30D) 8 8.58 1,2,3-triazoI (m, 1 H), 8.19 (m, 1 H), 7.85 (m, 3 y|)pyridinyI) 447.1 0.58 H), 7.46 (m, 2 H), 7.24 (m, 3 H), —N-(2— 7.21 (m, 1 H), 5.19 (m, 1 H), 4.12 hydroxy—1-(m- (s, 3 H), 3.84 (m, 2 H), 2.35 (s, 3 H) tolyl)ethy|)benza mide WO 66188 Structure N-(2-amino(3- phenyl)ethy 1H NMR (400MHz, CD30D) 5 8.07 |)(2-amino (m, 1 H), 8.02 (s, 1 H), 7.95 (s, 1 (1-methyI-1H- ' ' H), 7.85 (m, 1 H), 7.78 (s,1 H), pyrazoI 7.47 (m, 1 H), 7.35 (m, 5 H), 5.4 (m, y|)pyridiny|) 1 H), 3.84 (s, 3 H), 3.38 (m, 2 H) fluorobenzamide 8831;531:1331? 1H NMR (400MHz, CD30D) 5 ppm 8.05 (s, 1 H) 7.94-7.76 (m, 4 H) pyran_4_ 7.73-7.58 (m, 3 H) 5.35-5.25 (m, 1 yl)pyrazin_2_yl)_2_ 515.3 0.575 H) 4.05 (dd, J=11.54, 2.15 Hz, 2 H) fluoro-N-(2- 33-84 (m, 2 H) 3.64-3.49 (m, 2 h(r11ethdroxlysulfon(3- H) 3'13 (S! 3 H) -33 (m, 1 H) y yI) p 1.97-1.75 (m, 4 H) 1.15 (d, J=5.87 henyl)ethyl)benza - Hz, 1 H) mide (S)(3-amino-6— 1H NMR (400MHz, CD30D) ) 5 (tetrahydro-2H- ppm 7.83-7.68 (m, 2 H) .42 pyran (m, 2 H) 7.20-7.07 (m, 3 H) 7.00 (d, yI)pyrazinyI) 451 1 0.695 J=7.04 Hz, 1 H) 5.08 (t, J=6.06 Hz, fluoro-N-(2- 1 H) 4.07-3.88 (m, 2 H) 3.83-3.64 hydroxy(m- (m, 2 H) 3.48 (td, J=11.44, 2.54 Hz, tolyl)ethy|)benza 2 H) 2.96-2.74 (m, 1 H) 2.25 (s, 3 mide H) 1.89-1.63 (m, 4 H) mino 1H NMR (400MHz, CD30D) ) 5 (tetrahydro-2H- ppm 7.98-7.80 (m, 3 H) 7.71 (dd, pyran J=8.02, 1.37 Hz, 1 H) 7.67-7.59 (m, yI)pyrazinyI) 503 2 0.6822 H) 7.51 (d, J=9.00 Hz, 1 H) 4.71 fluoro-N-(3- (s, 2 H) 4.10-3.99 (m, 2 H) 3.57 (td, fluoro J=11.44, 2.54 Hz, 2 H) 3.15 (s, 3 H) (methylsulfonyl)b 3.01-2.87 (m, 1 H) 1.98-1.74 (m, 5 enzyl)benzamide H) Structure 4-(3-amino (tetrahydro-ZH- 1H NMR (400MHz, CD30D) 5 ppm pyran 7.95 - 7.84(m, 4 H) 7.79 — 7.57(m, y|)pyrazinyI)-N- 519.3 0.736 3 H) 4.70 (s, 2 H) 4.09 - 3.98 (m, 2 (3-chloro H) 3.57 (td, J=11.64, 2.54 Hz, 2 H) (methylsulfonyl)b 3.15 (s, 3 H) 3.00 — 2.87 (m, 1 H) enzyI) 1.97— 1.76 (m, 4 H) fluorobenzamide (S)(3-amino 1H NMR z, CD30D) 5 ppm (1-isopropyI-1H- 8.17 (s, 1 H) 8.07 (s, 1 H) 7.87 (s, 1 pyrazoI H) 7.83-7.75 (m, 1 H) 7.67-7.54 (m, y|)pyrazinyI) 461 .3 0.75 2 H) 7.38-7.31 (m, 2 H) 7.27 (t, fluoro-N-(2- J=7.63 Hz, 2 H) .14(m,1 H) hydroxy-1 - 5.13 (t, J=6.06 Hz, 1 H) 4.47 (spt, phenylethyl)benz J=6.72 Hz, 1 H) 3.85-3.69 (m, 2 H) amide 1.43 (d, J=6.65 Hz, 6 H) (R)(2-amino 1H NMR (400MHz, CD30D) 5 ppm (1 -ethyI-1 H- 8.99 (d, J=6.26 Hz, 1 H), 8.16 (s, 2 pyrazoI H) 8.12 (s, 1 H) 7.94-7.78 (m, 3 H) idinyI) 7.63 (dt, J=7.83, 1.76 Hz, 1 H) 7.56 526.30.653 fluoro-N-(1-(3- (d, J=9.39 Hz, 1 H) 7.51-7.42 (m, 2 fluoro H) 5.40-5.26 (m, 1 H) 4.22 (q, (methylsulfonyl)p J=7.17 Hz, 2 H) 3.16 (s, 3 H) 1.62 henyl)ethy|)benza (d, J=7.04 Hz, 3 H) .41 (m, 3 mide H) (S)(2-amino- -(1-ethyI-1H- 1H NMR (400MHz, CD30D) 5 ppm pyrazoI 8.10-8.05 (m, 2 H) 8.03 (s, 1 H) y|)pyridinyI) 446.3 0.616 7.87-7.73 (m, 2 H) 7.44-7.10 (m, fluoro-N-(2- 7H) 5.30-4.94 (m, 1 H) 4.13 (q, hydroxy-1 - J=7.17 Hz, 2 H) 3.89-3.54 (m, 2 H) phenylethyl)benz 1.39 (t, J=7.24 Hz, 3 H) amide Structure 1H NMR (400MHz, METHANOL- N-((S)amino d4) 6 ppm 7.61 (s, 1H), 7.77 - 7.65 (3-fluoro (m, 1H), 7.65 - 7.46 (m, 3H), 7.36 iodophenyl)ethyl) (d, J=7.6 Hz, 1H), 7.11 (d, J=9.6 (3-amino Hz, 1H), 5.02 (t, J=6.6 Hz, 1H), ((1R,3R,4R) 4.44 - 4.09 (m, 1H), 3.67 - 3.45 (m, fluoro 1H), 2.99 - 2.65 (m, 2H), 2.75 (t, ycyclohexy J=11.5 Hz, 1H), 2.26 - 2.06 (m, 1H), |)pyrazinyI) 2.06 - 1.66 (m, 1H), 1.67 - 1.64 (m, fluorobenzamide 2H), 1.56 (dq, J=3.3, 13.0 Hz, 1H), 1.46- 1.29 (m, 1H) 1H NMR (400MHz ,CD30D) 6 7.97 4-(2-amino(5- (d, J=2.35 Hz, 1 H), 7.93-7.63 (m, 2 oxopyrrolidin-S- H), 7.49-7.31 (m, 6 H), 22 y|)pyridinyI)-N- (m, 1 H),4.64-4.57 (m, 2 H), 3.62- benzyI-Z- 3.66 (m, 2 H),3.46-3.36 (m, 1 H), fluorobenzamide .65 (m, 1 H), 2.56-2.44 (m, 1 4-(2-amino 1H NMR (400MHz ,CD30D) 6 6.61 (tetrahydro-ZH- (d, J = 5.1 Hz, 1H), 6.06 (t, J = 7.6 pyran Hz, 1H), 7.96 (d, J = 2.0 Hz, 1H), y|)pyridinyI) 7.60 (d, J = 2.0 Hz, 1H), 7.41 - 7.50 fluoro-N-((4- (m, 2H), 7.30 (d, J = 5.1 Hz, 1H), methylpyrimidin- 4.76 - 4.62 (m, 2H), 4.05 (dd, J = 2- 11.2, 2.9 Hz, 2H), 3.55 (td, J = 11.4, y|)methy|)benzam 2.5 Hz, 2H), 2.61 - 2.95 (m, 1H), ide 2.55 (s, 3H), 1.69 - 1.69 (m, 4H) 4-(2-amino 1H NMR (400MHz, DMSO-d6) 6 (tetrahydro-ZH- 9.26 - 9.11 (m, 2 H), 9.06 - 6.96 (m, pyran 1 H), 7.96 - 7.76 (m, 3 H), 7.69 - y|)pyridinyI) 408.2 0.42 7.44 (m, 3 H), 7.40 (dd, J = 1.4, 6.0 fluoro-N- Hz, 1 H), 4.54 (d, J = 5.9 Hz, 2 H), azin 4.02 - 3.77 (m, 3 H), 3.37 (dt, J = ylmethyl)benzami 27,113 Hz, 2 H), 2.77 (s,1 H), de 1.76 - 1.54 (m, 4 H) Structure 1H NMR (400MHz ,CD30D) 8 7.95 4-(3-amino—6— (t, J = 7.8 Hz, 1H), 7.87 (s, 1H), (tetrahydro—ZH- 7.70 (dd, J = 78,16 Hz, 1H), 7.61 pyran (dd, J =11.9, 1.4 Hz, 1H), 4.05 (dd, y|)pyrazinyI) J =11.3,2.3 Hz, 3H), 3.57 (td, J = fluorobenzamide 11.5, 2.7 Hz, 3H), 2.89 - 3.01 (m, 1H), 1.77 - 1.97 (m, 6H) 4-(3-amino—6— 1H NMR (400MHz ,CD30D) 8 7.83 (tetrahydro—ZH- - 7.91 (m, 2H), 7.68 (dd, J = 8014 pyran Hz, 1H), 7.60 (dd, J =11.7, 1.6 Hz, azinyI) 1H), 4.05 (dd, J = 11.3, 2.3 Hz, 2H), fluoro—N- 3.57 (td, J =11.5,2.7 Hz, 2H), 2.88 methylbenzamide - 3.01 (m,4H), 1.74 - 1.96 (m, 4H) 1H NMR (400 MHz, d6—DMSO) ) 5 (S)—4-(3-amino—6— ppm 0.47 - 0.55 (m, 2 H) 0.64 - (tetrahydro—ZH- 0.73 (m, 2 H) 1.21 - 1.30 (m, 1 H) pyran 1.62 - 1.73 (m, 4 H) 2.72 - 2.86 (m, y|)pyrazinyI)-N-425.1 0.64 1 H) 3.30 - 3.41 (m, 2 H) 3.45 (d, (4-cyclopropyI J=6.26 Hz, 3 H) 3.87 (d, 6 ybutyn- Hz, 2 H) 4.66 (q, J=6.65 Hz, 1 H) 2-y|) 7.52 (d, J=11.74 Hz, 1 H) 7.55 - fluorobenzamide 7.59 (m, 1 H) 7.61 - 7.68 (m,1 H) 7.87 (s, 1 H) 8.35- 8.42 (m, 1 H) 1H NMR (400MHz ,CD30D) 5 7.77 - 7.88 (m, 3H), 7.59 (d, J = 8.2 Hz, (S)—(4-(3-amino— 2H), 7.54 (br. s., 1H), 7.41 (t, J = NH2 6-(tetrahydro—2H- 7.6 Hz, 2H), 7.28 - 7.36 (m, 1H), 322 N \ 4.54 (d, J = 11.3 Hz, 1H), 3.95 - | y|)pyrazin 4.11 (m, 3H), 3.88 (br. s., 1H), 3.68 y|)pheny|)(3- (t, J = 11.5 Hz, 1H), 3.56 (td, J = phenylmorpholino 11.4, 2.5 Hz, 2H), 3.34 - 3.41 (m, )methanone 1H), 2.85 - 3.01 (m, 1H), 1.73 - 1.99 (m, 4H) Structure 1H NMR (400MHz ) 8 8.03 4-(3-amino—6- (d, J = 8.2 Hz, 2H), 7.98 (s, 1H), (tetrahydro—ZH- 7.83 - 7.91 (m, 3H), 7.80 (s, 1H), pyran 7.75 (d, J = 7.8 Hz, 1H), 7.59 - 7.67 y|)pyrazinyI)-N- (m, 1H), 4.71 (s, 2H), 3.99 -4.10 (m, 2H), 3.57 (td, J = 11.3, 2.7 Hz, lsulfonyl)b 2H), 3.12 (s, 3H), 2.90 - 3.03 (m, enzyl)benzamide 1H), 1.78 - 1.99 (m, 4H) 1H NMR (400MHz, DMSO-d6) 4-(3-amino—6- 88.86 (s,1 H), 7.90 (s, 1 H), 7.76- (tetrahydro—ZH- 7.51 (m, 2 H), 7.32 (m, 4 H), 7.23 pyran (m, 1 H), 6.11 (s, 1 H), 4.47 (m, 1 y|)pyrazinyI)-NH ), 3.91 (m, 2 H), 3.40 (m, 2 H), benzyI-Z- 3.26 (m, 1H), 2.78 (m, 1 H), 1.71 fluorobenzamide (m, 4 H) (S)—4—(3-amino—6- (tetrahydro—ZH- 1H NMR (400MHz, DMSO-d6) pyran 88.61 (s,1 H), 7.92 (s, 1 H), 7.78- y|)pyrazinyI) 473.2 0.61 7.51 (m, 5 H), 6.12 (s, 1 H), 4.95 fluoro—N-(2— (m, 1 H), 3.92 (m, 2 H), 3.66 (m, 2 hydroxy-1 - H), 3.4 (m, 2 H), 1.73 (m, 4 H) phenylethyl)benz amide 1H NMR (400MHz ) 8 7.90 (s, 1 H), 7.82 (t, J = 7.6 Hz, 1 H), (S)—N-(2-amino—1 - 7.70 (dd, J = 1.4, 8.0 Hz, 1 H), 7.63 phenylethyl)—4—(3- (dd, J :12, 11.7 Hz, 1 H), 7.49 - amino 7.36 (m, 4 H), 7.32 (d, J = 7.4 Hz, 1 (tetrahydro—ZH- H), 5.20 (t, J = 6.8 Hz, 1 H), 4.05 pyran (dd, J = 2.9, 11.2 Hz, 2 H), 3.58 (dt, y|)pyrazinyI) J = 23,117 Hz, 2 H), 3.08 (d, J = fluorobenzamide 7.4 Hz, 2 H), 2.94 (s, 1 H), 2.00 - 1.77 (m, 4 H).
Structure 1H NMR z ,CD30D) 8 7.92 (S)—4-(3-amino—6— (d, J = 8.6 Hz, 2 H), 7.75 (d, J = 9.8 (tetrahydro—ZH- Hz, 3 H), 7.40 - 7.32 (m, 2 H), 7.29 pyran (t, J = 7.4 Hz, 2 H), 7.26 - 7.18 (m, y|)pyrazinyI)-N- 1 H), 5.41 (dd, J = 7.4, 15.7 Hz, 1 (2-fluoro—1 - H), 4.71 - 4.66 (m, 1 H), 4.62 -4.53 phenylethyl)benz (m, 1 H), 4.00 - 3.89 (m, 2 H), 3.48 amide (dt, J = 27,115 Hz, 2 H), 2.92 - 2.74 (m, 1 H), 1.88 - 1.68 (m, 4 H). 4-(3-amino—6— 1H NMR (400MHz, DMSO-d6) (tetrahydro—ZH- 88.35 (m, 1 H), 7.90 (s, 1 H), 7.70- pyran 4 0.77 7.51 (m, 3 H), 7.35 -7.12 (m, 4 H), y|)pyrazinyI) 6.10 (s, 1 H), 3.92 (m, 2 H), 3.53 - 3.35 (m, 4 H), 2.82 (m, 2 H), 1.72 phenethylbenzam (m, 4 H) (S)—4-(3-amino—6— 1H NMR (400MHz, CD30D) 8 7.91 (tetrahydro—ZH- - 7.84 (m, 2H), 7.70 (dd, J=1.6, 7.8 pyran Hz, 1H), 7.65 (dd, J=1.2, 11.7 Hz, y|)pyrazinyI) 1H), 7.30 (s, 1H), 7.20 (d, J=9.8 Hz, fluoro-N-(1-(3- 487 2 0.67 1H), 7.08 (d, J=9.0 Hz, 1H), 5.46 (s, fluoro 1H), 5.35 (s, 1H), 5.23 (t, J=5.7 Hz, (fluoromethyl)phe 1H), 4.06 (dd, J=2.3, 11.3 Hz, 2H), ny|) 3.93 - 3.82 (m, 2H), 3.58 (dt, J=2.5, hydroxyethyl)ben 11.4 Hz, 2H), 3.00 - 2.90 (m, 1H), zamide 1.98 - 1.79 (m, 4H).
(S)—4-(3-amino—6— hydro—ZH- 1H NMR (400MHz, CD30D) 8 8.21 pyran (m, 1H), 7.94 (m, 1H), 7.75 (m, 1H), y|)pyrazinyI)-N- 489.1 0.74 7.63 (m, 2H), 7.21 (m, 1H), 7.05 (m, (1 -(3-ch|oro—5- 2H), 5.20 (m, 1H), 4.09 (m, 4H), fluorophenyl)—2- 3.56 (m, 2H), 2.93 (m, 1H), 1.88 (m, hydroxyethyl)—2- 4H) fluorobenzamide Structure 1H NMR (400MHz, CD30D) 5 ppm 4-(3-amino—6- 8.72 (br. s., 1H), 7.94 - 7.77 (m, (tetrahydro—ZH- 2H), 7.74 - 7.59 (m, 2H), 7.48 (s, 1H), 7.42 - 7.23 (m, 3H), 5.06 - 4.95 y|)pyrazinyI)-N-485.1 0.76 (m, 1H), 4.14 (quin, J=6.2 Hz, 1H), ((18,2R)—1-(3- 4.05 (dd, J=3.6, 11.5 Hz, 2H), 3.66 chlorophenyl)—2- - 3.51 (m, 2H), 2.95 (ddd, J=3.5, hydroxypropyl)—2- 79,154 Hz, 1H), 2.02 - 1.75 (m, fluorobenzamide 4H),1.30 - 1.13 (m, 3H) mino—5-(1 - 1H NMR (400MHz, CD30D) 5 ppm methyl-1 H- 8.14 (d, J=1.6 Hz, 2H), 8.05 (s, 1H), pyrazoI 7.94 - 7.80 (m, 2H), 7.55 - 7.40 (m, y|)pyridinyI)-N- 480.1 0.66 3H), 7.39 - 7.23 (m, 3H), 5.48 (s, ((18,2R)—1-(3- 1H), 4.99 (d, J=5.9 Hz, 1H), 4.21 - chlorophenyl)—2- 4.07 (m, 1H), 3.93 (s, 3H), 1.29 - hydroxypropyl)—2- 1.11 (m, 3H) enzamide (S)—4-(3-amino—6- 1H NMR (400MHz, DMSO- (tetrahydro—ZH- 16 (m, 1 H), 7.90 (s, 1 H), pyran 7.76 - 7.53 (m, 3 H), 7.48 - 7.20 (m, y|)pyrazinyI) 437.2 0.61 6 H), 6.11 (s, 2 H), 5.54 (d, J = 4 fluoro—N-(2- Hz, 1 H), 4.75 (m, 1 H), 3.92 (m, 2 hydroxy—Z- H), 3.58 - 3.28 (m, 4 H), 2.82 (m, 1 phenylethyl)benz H), 1.71 (m, 4 H) amide 4-(3-amino—6- (tetrahydro—ZH- 1H NMR (400MHz, DMSO-d6) pyran 87.96 (m, 1 H), 7.91 (s, 1 H), 7.79 y|)pyrazinyI) 422.2 0.46 (m, 1 H), 7.70 - 7.57 (m, 2 H), 7.38 fluoro-N-((6- (m, 2 H), 4.62 (m, 2 H), 3.90 (m, 2 methylpyridin-Z- H), 3.4 (m, 2 H), 2.55 (s, 3 H), 1.72 y|)methy|)benzam (m, 4 H) Structure (S)—4—(3-amino—6- 1H NMR (400MHz, CD30D) 5 ppm (tetrahydro—ZH- 7.95 - 7.79 (m, 2H), 7.77 - 7.58 (m, 4- 2H), 7.47 (s, 1H), 7.35 (d, J=9.8 Hz, y|)pyrazinyI)-N 1H), 7.22 (d, J=8.6 Hz, 1H), 6.98 - (1 -(3- 6.58 (t, J=56 Hz, 1H), 5.48 (s, 2H), (difluoromethyl)— 5.25 (t, J=5.9 Hz, 1H), 4.12 - 3.97 -fluorophenyl)—2— (m, 2H), 3.95 - 3.76 (m, 2H), 3.57 yethyl)—2- (dt, J=2.3, 11.5 Hz, 2H), 2.94 (m, fluorobenzamide 1H), 2.00 - 1.75 (m, 4H) (S)—4—(3-amino—6- 1H NMR z, CD30D) 5 ppm (tetrahydro—ZH- 7.98 - 7.90 (m, 1H), 7.89 - 7.80 (m, pyran 1H), 7.73 (d, J=8.2 Hz, 1H), 7.66 (d, y|)pyrazinyI)-N- J=11.7 Hz, 1H), 7.39 - 7.31 (m, 1H), (1 -(3-ch|oro—5- 7.26 - 7.11 (m, 2H), 5.33 (dd, J=5.2, fluorophenyl)—2- 9.0 Hz, 1H), 4.15 - 4.01 (m, 2H), (methylamino)eth 3.60 (dt, J=2.2, 11.7 Hz, 2H), 3.14 - y|) 2.86 (m, 3H), 2.54 - 2.43 (m, 3H), fluorobenzamide 1.99 - 1.79 (m, 4H) 1H NMR (400MHz, CD30D) 5 ppm 4-(3-amino—6- 8.76 (br. s., 1H), 7.92 - 7.78 (m, ((1r,4S)—4— 2H), 7.74 - 7.56 (m, 2H), 7.47 (s, hydroxycyclohexy 1H), 7.35 (d, J=9.0 Hz, 1H), 7.22 (d, |)pyrazin-2—yI)-N- J=8.6 Hz, 1H), 6.99 - 6.59 (t, J=56 ((S)(3- Hz, 1H), 5.26 (m, 2H), 4.10 (q, (difluoromethyl)— J=7.0 Hz, 8H), 3.89 (m, 2H), 3.63 -fluorophenyl)—2— (m, 1H), 2.64 (t, J=12.1 Hz, 1H), hydroxyethyl)—2- 2.12 - 1.88 (m, 4H), 1.75 - 1.56 (m, fluorobenzamide 2H), 1.50 - 1.32 (m, 2H). 1H NMR (400MHz, CD30D) d = N-((S)—2-amino—1 - 7.96 - 7.82 (m, 2H), 7.76 - 7.59 (m, (3-bromo—5- 2H), 7.59 - 7.48 (m, 1H), 7.41 (d, fluorophenyl)ethy| J=8.2 Hz, 1H), 7.29 (d, J=9.4 Hz, )(3-amino—6- 1H), 5.48 (t, J=7.2 Hz, 1H), 4.51 - ((1R,3R,4R)—3- 4.24 (m, 1H), 3.74 - 3.55 (m, 1H), fluoro 3.53 - 3.38 (m, 2H), 2.84 (t, J=11.9 hydroxycyclohexy Hz, 1H), 2.27 (td, J=3.1, 6.0 Hz, |)pyrazinyI) 1H), 2.14 - 1.96 (m, 1H), 1.96 - 1.73 fluorobenzamide (m, 2H), 1.64 (dq, J=2.9, 13.0 Hz, 1H),1.56 - 1.39 (m, 1H) 4-(3-amino—6- 1H NMR (400MHz, CD30D) 5 ppm ((1r,4S)—4— 7.64 - 7.69 (m, 1H), 7.63 - 7.44 (m, hydroxycyclohexy 2H), 7.43 - 7.31 (m, 1H), 6.91 - 6.44 |)pyrazin-2—yI)-N- (t, J = 56 Hz, 1H), 5.25 - 5.10 (m, ((S)(3- 1H), 3.66 - 3.66 (m, 2H), 3.60 - 3.42 (difluoromethyl)p (m, 1H), 2.67 - 2.43 (m, 1H), 2.03 - henyl)—2- 1.76 (m, 4H), 1.66 - 1.44 (m, 2H), hydroxyethyl)—2- 1.42 - 1.25 (m, 2H) fluorobenzamide 1H NMR (400MHz, CD30D) 6 ppm mino—6- 6.66 (br. s., 1H), 7.93 - 7.63 (m, ((1r,4S)—4— 2H), 7.79 (s, 1H), 7.74 - 7.67 (m, ycyclohexy 2H), 7.66 - 7.54 (m, 3H), 5.30 (t, |)pyrazinyI) J=5.8 Hz, 1H), 4.01 - 3.62 (m, 2H), fluoro-N-((S)—2- 3.71 - 3.55 (m, 1H), 2.77 - 2.60 (m, hydroxy—1-(3- 1H), 2.16 - 2.05 (m, 2H), 2.02 - 1.69 (trifluoromethyl)p (m, 2H), 1.60 - 1.60 (m, 2H), 1.51 - ethy|)benza 1.34 (m, 2H) mide 4-(3-amino—6- 1H NMR (400MHz, CD30D) 6 ppm ((1s,4R)—4— 8.86(br.s.,1H),7.93 - 7.63 (m, hydroxycyclohexy 2H), 7.62 - 7.71 (m, 2H), 7.70 - 7.56 |)pyrazinyI) (m, 3H), 5.36 - 5.24 (m, 1H), 4.04 fluoro-N-((S)—2- (br. s., 2H), 3.96 - 3.61 (m, 1H), hydroxy—1-(3- 2.60 - 2.66 (m, 1H), 2.14 - 2.00 (m, (trifluoromethyl)p 2H), 1.90 (d, J=10.7 Hz, 2H), 1.77 - henyl)ethy|)benza 1.65 (m, 4H) mide 1H NMR (400MHz, CD30D) 5 ppm 7.95 - 7.64 (m, 2H), 7.71 (dd, J=1.6, N-((S)—2-amino—1 - 6.0 Hz, 1H), 7.63 (dd, J=1.5, 12.0 (3-bromo—5- Hz, 1H), 7.55 (s, 1H), 7.41 (td, fluorophenyl)ethy| J=2.1, 6.2 Hz, 1H), 7.33 - 7.23 (m, )(3-amino—6- 1H), 5.55 - 5.40 (m, 1H), 3.67 - 3.53 ((1r,4S)—4— (m, 1H), 3.52 - 3.39 (m, 2H), 2.72 - hydroxycyclohexy 2.54 (m, 2H), 2.06 (d, J=9.7 Hz, |)pyrazinyI) 2H), 1.99 - 1.67 (m, 2H), 1.76 - 1.56 fluorobenzamide (m, 2H), 1.49 - 1.31 (m, 2H) + Rt NMR Structure N-((S)—2-amino—1 - iodophenyl)ethyl) (3-amino—6- ((1r,4S)—4— hydroxycyclohexy |)pyrazinyI) fluorobenzamide576- 4-(3-amino—6- 1H NMR (400MHz, CD30D) 5 ppm ((1r,4S)—4— 8.76 (br. s., 1H), 7.92 - 7.80 (m, 2H), 7.73 - 7.55 (m, 3H), 7.45 (d, |)pyrazinyI) J=7.9 Hz, 1H), 7.22 (d, J=9.5 Hz, fluoro—N-((S)—1 - 1H), 5.49 (m, 1H), 5.23 - 5.11 (m, (3-fluoro—5- 1H), 3.94 - 3.76 (m, 2H), 3.69 - 3.53 enyl)—2— (m, 1H), 2.72 - 2.57 (m, 1H), 2.07 hydroxyethyl)ben (m, 2H), 1.97 (m, 2H), 1.97 (m, 2H), zamide 1.44 (m, 2H). 4-(3-amino—6- 1H NMR (400MHz, CD30D) 5 ppm ((1s,4R)—4— 8.75 (br. s., 1H), 7.95 - 7.79 (m, 2H), 7.77 - 7.58 (m, 3H), 7.44 (d, |)pyrazinyI) J=6.9 Hz, 1H), 7.22 (d, J=9.5 Hz, fluoro—N-((S)—1 - 1H), 5.49 (m, 1H), 5.15 (m, 1H), (3-fluoro—5- 4.02 (br. s., 1H), 3.85 (m, 2H), 2.71 enyl)—2— (m, 1H), 2.03 (m, 2H), 1.88 (m, 2H), hydroxyethyl)ben 1.77 - 1.59 (m, 4H) zamide 1H NMR (400MHz, CD30D) 5 ppm 4-(3-amino—6- 8.73 (br. s., 1H), 7.92 - 7.77 (m, ((1r,4S)—4— 3H), 7.71 - 7.56 (m, 3H), 7.44 (d, J=7.6 Hz, 1H), 7.15 (t, J=7.7 Hz, zinyI) 1H), 5.5 (m, 1H), 5.15 (m, 1H), 3.85 fluoro-N-((S)—2- (m, 2H), 3.61 (m, 1H), 2.65 (m, 1H), hydroxy—1-(3- 2.07 (m, 2H), 1.97 (m, 2H), 1.68 (m, iodophenyl)ethyl) 2H), 1.46 (m, 2H). benzamide Structure 4-(3-amino—6- 1H NMR (400MHz, CD30D) 5 ppm R)-4— 8.74 (br. s., 1H), 7.91 - 7.76 (m, hydroxycyclohexy 3H), 7.76 - 7.56 (m, 3H), 7.44 (d, |)pyrazinyI) 577.4 0.76 J=7.6 Hz, 1H), 7.15 (t, J=7.9 Hz, fluoro-N-((S)— 1H), 5.49 (m, 1H), 5.15 (m, 1H), hydroxy( 4.02 (br. s., 1H), 3.84 (m, 2H), 2.74 iodophenyl)ethyl) (m, 1H), 1.99 (m, 2H), 1.88 (m, 2H), benzamide 1.72 (m, 4H) 4-(3-amino—6- 1H NMR (500MHz, CD30D) 5 ppm ((1r,4S)—4— 7.93 - 7.79 (m, 2H), 7.73 - 7.57 (m, deuterido—4- 2H), 7.47 (s, 1H), 7.34 - 7.14 (m, ycyclohexy 548 1 0 71 2H), 5.18 (t, J = 5.7 Hz, 1H), 3.93 - |)pyrazin-2—yI)-N- ' 3.78 (m, 2H), 2.70 - 2.55 (m, 1H), ((S)(3-bromo— 2.06 (d, J = 12.3 Hz, 2H), 1.95 (d, J -fluorophenyI) =12.3 Hz, 2H), 1.76 - 1.58 (m, 2H), hydroxyethyI) 1.48 - 1.35 (m, 2H) fluorobenzamide 1H NMR (400MHz, CD30D) 5 ppm 4-(3-amino—6- 8.72 - 8.56 (m, 1H), 7.84 - 7.67 (m, ((1r,4S)-4— 2H), 7.67 - 7.45 (m, 2H), 7.37 (s, hydroxycyclohexy 549-1 1H), 7.23 - 7.03 (m, 2H), 5.07 (d, |)pyrazin-2—yI)-N- l551 J=5.1 Hz, 1H), 3.82 - 3.68 (m, ((S)(3-bromo— 0 0.15H), 3.59 - 3.41 (m, 1H), 2.67 - rophenyI) 2.44 (m, 1H), 2.05 - 1.79 (m, 2H), hydroxy, 2,2-di- 1.57 (dq, J=2.7, 13.0 Hz, 2H), 1.39 deuteridoethyI) - 1.24 (m, 2H) fluorobenzamide Structure 4-(3-amino—6— 1H NMR z, CD30D) 5 ppm ((1r,4S)—4— 8.64 (br. s., 1H), 7.82 - 7.68 (m, deuterido—4- 2H), 7.63 - 7.47 (m, 2H), 7.37 (s, hydroxycyclohexy 550.0 /552. 0.71 1H), 7.22 - 7.03 (m, 2H), 5.07 (d, |)pyrazin-2—yI)-N- J=7.4 Hz, 1H), 3.81 - 3.66 (m, ((S)—1-(3-bromo— 0.15H), 2.63 - 2.45 (m, 1H), 2.05 - -fluorophenyl)— 1.78 (m, 2H), 1.66 - 1.46 (m, 2H), oxy, 2,2—di- 1.39 - 1.20 (m, 2H) deuteridoethyl)—2- fluorobenzamide 1H NMR (400MHz, CD30D) 5 ppm 4-(3-amino—6— 7.87 (s, 1H), 7.84 (t, J=7.8 Hz, 1H), S)—4— 7.68 (d, J=8.2 Hz, 1H), 7.62 (d, hydroxycyclohexy 548.1 J=11.7 Hz, 1H), 7.46 (s, 1H), 7.27 |)pyrazin-2—yI)-N- (d, J=8.2 Hz, 1H), 7.20 (d, J=9.4 ((S)—1-(3-bromo— Hz, 1H), 3.85 (d, J=5.1 Hz, 2H), -fluorophenyl)—2— 3.60 (t, J=11.2 Hz, 1H), 2.63 (t, hydroxy, 1- J=11.9 Hz, 1H), 2.06 (d, J=12.1 Hz, deuteridoethyl)—2- 2H), 1.95 (d, J=12.9 Hz, 2H), 1.73 - fluorobenzamide 1.60 (m, 2H), 1.48 - 1.36 (m, 2H) 4-(3-amino—6— 1H NMR (400MHz, CD30D) 5 ppm ((1r,4S)—4— 8.76 (br. s., 1H), 7.92 - 7.80 (m, deuterido—4- 2H), 7.73 - 7.55 (m, 3H), 7.45 (d, ycyclohexy 549.1 J=7.9 Hz, 1H), 7.22 (d, J=9.5 Hz, |)pyrazin-2—yI)-N- /551. 1H), 5.49 (m, 1H), 5.23 - 5.11 (m, ((S)—1-(3-bromo— 1H), 3.94 - 3.76 (m, 2H), 3.69 - 3.53 -fluorophenyl)—2— (m, 1H), 2.72 - 2.57 (m, 1H), 2.07 hydroxy, 1- (m, 2H), 1.97 (m, 2H), 1.97 (m, 2H), deuteridoethyl)—2- 1.44 (m, 2H). fluorobenzamide N-((S)—2-amino—1 - 1H NMR (400MHz, CD30D) 5 ppm (3-bromo—5- 7.97 - 7.82 (m, 2H), 7.77 - 7.58 (m, fluorophenyl)ethy| 2H), 7.59 - 7.47 (m, 1H), 7.44 - 7.35 -amino—6— (m, 1H), 7.29 (d, J=9.4 Hz, 1H), .48 - 3.56 absolute stereochemistry ((1R,SS,4R) (t, J=7.2 Hz, 1H), 3.77 assigned aritrari/y fluoro (m, 1H), 3.53 - 3.38 (m, 3H), 3.10 - hydroxycyclohexy 2.94 (m, 1H), 2.31 -2.14 (m, 1H), |)pyrazinyI) 2.09 -1.78(m,4H), 1.77 - 1.60 (m, fluorobenzamide 1H) Structure 1H NMR (400MHz, CD30D) 6 ppm N-((S)—2-amino—1 - 7.65 - 7.74 (m, 2H), 7.62 (dd, J=1.4, (3-bromo—5- 6.0 Hz, 1H), 7.55 (dd, J=1.2, 11.7 fluorophenyl)ethy| Hz, 1H), 7.45 (s, 1H), 7.36 - 7.26 )(3-amino—6- (m, 1H), 7.20 (d, J=9.4 Hz, 1H), ((18,3R,4S)—3- absolute stereochemistry 5.39 (t, J=7.2 Hz, 1H), 3.66 - 3.46 assigned aritrarily fluoro (m, 1H), 3.44 - 3.32 (m, 2H), 2.96 - hydroxycyclohexy 2.62 (m, 1H), 2.21 - 2.05 (m, 1H), |)pyrazinyI) 1.97 - 1.70 (m, 4H), 1.69 - 1.49 (m, fluorobenzamide 4-(3-amino—6— 1H NMR (400MHz, CD30D) 6 ppm ((1R,38,4R)—3- 7.66 - 7.69 (m, 3H), 7.62 (dd, J=1.6, fluoro 6.2 Hz, 1H), 7.59 - 7.50 (m, 1H), hydroxycyclohexy 7.47 (s, 1H), 7.36 - 7.26 (m, 578/5 |)pyrazin-2—yI)-N- 1H),7.23 (dd, J=9.0, 14.9 Hz, 2H), 80'1 absolute stereochemistry ((S)—1-(3-bromo— 5.46 (t, J=7.2 Hz, 1H), 3.67 - 3.49 assigned ri/y -fluorophenyl)—2— (m, 1H), 3.49 - 3.39 (m, 2H), 3.00 - (methylamino)eth 2.65 (m, 1H), 2.72 (s, 3H), 2.14 (dt, y|) J=3.9, 10.6 Hz, 1H), 1.99 - 1.71 (m, fluorobenzamide 4H),1.70 - 1.49 (m, 1H) 4-(3-amino—6— 1H NMR (400MHz, CD30D) 6 ppm ((18,3R,4S)—3- 7.67 - 7.74 (m, 2H), 7.62 (dd, J=1.6, fluoro 6.2 Hz, 1H), 7.55 (dd, J=1.2, 12.1 hydroxycyclohexy Hz, 1H), 7.47 (s, 1H), 7.32 (td, 578/5 |)pyrazin-2—yI)-N- J=1.8, 6.2 Hz, 1H), 7.21 (d, J=9.4 80.2 absolute stereochemistry ((S)—1-(3-bromo— Hz, 1H), 5.55 - 5.40 (m, 1H), 3.67 - assigned aritrari/y rophenyl)—2— 3.50 (m, 1H), 3.46 - 3.37 (m, 2H), (methylamino)eth 2.99 - 2.64 (m, 1H), 2.72 (s, 3H), y|) 2.20 - 2.06 (m, 1H),1.97 - 1.69 (m, enzamide 66 - 1.50 (m, 1H) 4-(3-amino—6— 1H NMR (400MHz, CD30D) 6 ppm ((1S,38,4S)—3- 7.67 - 7.76 (m, 2H), 7.69 - 7.60 (m, fluoro 2H), 7.59 - 7.51 (m, 1H), 7.49 (d, hydroxycyclohexy J=7.4 Hz, 1H), 7.22 (d, J=9.4 Hz, 357 |)pyrazinyI) 626.1 0.68 1H), 5.45 (t, J=7.2 Hz, 1H), 4.43 - fluoro—N-((S)—1 - 4.14 (m, 1H), 3.62 - 3.49 (m, 1H), (3-fluoro—5- 3.45 (d, J=7.4 Hz, 2H), 2.61 - 2.66 enyl)-2— (m, 4H), 2.25 - 2.09 (m, 1H), 2.04 - lamino)eth 1.66 (m, 1H), 1.67 - 1.63 (m, 2H), y|)benzamide 1.64 - 1.30 (m, 2H) Structure 4-(3-amino 1H NMR (400MHz, CD30D) 5 ppm ((1R,3R,4R) 7.98 - 7.84 (m, 2H), 7.77 - 7.88 (m, fluoro 2H), 7.88 - 7.53 (m, 2H), 7.49 (d, hydroxycyclohexy J=8.2 Hz, 1H), 7.43 - 7.33 (m, 1H), zinyI) 626.1 0.67 5.58 (dd, J=5.5, 9.0 Hz, 1H), 4.50 - -N-((S) 4.25 (m, 1H), 3.72 - 3.59 (m, 1H), (3-fluoro 3.80 - 3.48 (m, 2H), 2.89 - 2.74 (m, iodophenyI) 4H), 2.33 - 2.19 (m, 1H), 2.05 (br. (methylamino)eth s., 1H), 1.98 - 1.73 (m, 2H), 1.73 - y|)benzamide 1.58 (m, 1H), 1.55 - 1.40 (m, 1H) 4-(3-amino 1H NMR (400MHz, CD30D) 5 ppm ((1R,3R,4R) 8.00 - 7.85 (m, 2H), 7.78 - 7.88 (m, fluoro 2H), 7.88 - 7.53 (m,2H), 7.49 (d, hydroxycyclohexy 560.2 J=8.2 Hz, 1H), 7.43 - 7.32 (m, 1H), |)pyrazinyI)-N- /562. 0.64 5.58 (dd, J=5.5, 9.0 Hz, 1H), 4.51 - ((S)(3- 2 4.24 (m, 1H), 3.74 - 3.80 (m, 1H), bromophenyI) 3.59 - 3.49 (m, 2H), 2.87 - 2.74 (m, (methylamino)eth 4H), 2.34 -2.19 (m, 1H), 2.14 - 1.97 y|) (m, 1H), 1.98 - 1.75 (m, 2H), 1.73 - fluorobenzamide 1.40 (m, 2H) 1H NMR z, CD30D) 5 ppm 4-(3-amino 7.87 (s, 1H), 7.81 (t, J=7.8 Hz, 1H), ((1r,4S) .71 (m, 3H), 7.42-7.49 (m, hydroxycyclohexy 1H), 7.21 (d, J=9.4 Hz, 1H), 5.25 |)pyrazinyI) 608.1 0.68 (dd, J=8.6, 5.1 Hz, 1H), 3.52-3.71 fluoro-N-((S) (m, 1H), 2.88-3.08 (m, 2H), 2.82 (tt, (3-fluoro J=12.1, 3.4 Hz, 1H), 2.44 (s, 3H), iodophenyI) 2.08 (d, J=9.8 Hz, 2H), 1.95 (d, (methylamino)eth J=12.9 Hz, 2H), 1.88 (qd, J=13.0, y|)benzamide 2.9 Hz, 2H), 1.32-1.50 (m, 2H) 1H NMR (400MHz, METHANOL- 4-(3-amino—6- d4) d = 7.88 - 7.75 (m, 2H), 7.69 - ((1R,3R,4R)—3- 7.51 (m, 2H), 7.47 (s, 1H), 7.37 - fluoro—4- 7.27 (m, 1H), 7.21 (d, J=9.0 Hz, hydroxycyclohexy 578.2 1H), 5.48 (t, J=7.2 Hz, 1H), 4.43 - |)pyrazinyI)-N- /580. 0.65 4.13 (m, 1H), 3.64 - 3.50 (m, 1H), ((S)—1-(3-bromo— 3.46 (d, J=7.4 Hz, 2H), 2.80 - 2.65 -fluorophenyI) (m, 4H), 2.17 (br. s., 1H), 2.05 - (methylamino)eth 1.89 (m, 1H), 1.86 - 1.64 (m, 2H), y|) 1.65 - 1.46 (m, 1H), 1.46 - 1.29 (m, enzamide 4-(3-amino—6- 1H NMR (500MHz, METHANOL- ((18,3R)—3- d4) 5 ppm 8.01 - 7.88 (m, 2H), 7.84 hydroxycyclohexy - 7.65 (m, 2H), 7.59 (s, 1H), 7.45 (d, |)pyrazinyI)-N- 560/5 J=8.2 Hz, 1H), 7.34 (d, J=9.1 Hz, -(3-bromo— 1H),5.73 - 5.49 (m, 1H), 3.81 - 3.64 -fluorophenyI) (m, 1H), 3.57 (s, 2H), 2.84 (s, 3H), (methylamino)eth 2.80 - 2.71 (m, 1H), 2.24 - 2.09 (m, single enantiomer,‘ cis on cyc/ohexyl group; y|) 1H), 2.08 - 1.76 (m, 3H), 1.63 - 1.39 absolute stereochemistry fluorobenzamide assigned arbitrarily (m,3H),1.39 - 1.16 (m, 1H) 4-(3-amino—6- ((1 R,38)—3- 1H NMR (500MHz, METHANOL- hydroxycyclohexy d4) 5 ppm 8.01 - 7.86 (m, 2H), 7.81 |)pyrazinyI)-N- 560/5 - 7.55 (m, 3H), 7.44 (d, J=8.2 Hz, ((S)—1-(3-bromo— 1H), 7.38 - 7.25 (m, 1H), 5.71 - 5.51 -fluorophenyI) (m, 1H), 3.80 - 3.46 (m, 3H), 2.84 (methylamino)eth (s, 4H), 1.91 ,4H),1.63 - 1.37 single enantiomer; cis on cyclohexyl group; y|) (m, 3H), 1.35- 1.13 (m, 1H) absolute stereochemislry fluorobenzamide assigned arbitrarily Structure 4-(3-amino( 1H NMR (500MHz, METHANOL- hydroxycyclohexy d4) 5 ppm 8.01 - 7.86 (m, 2H), 7.60 |)pyrazinyI)-N- (s, 3H), 7.48 (s, 3H), 5.72 - 5.46 (m ((S)(3- 1H), 3.79 - 3.64 (m, 1H), 3.65 - 3.49 chlorophenyl)—2- (m, 2H), 2.84 (s, 4H), 2.16 (d, (methylamino)eth J=12.0 Hz, 1H), 2.08 - 1.80 (m, 3H) y|) 1.63 - 1.39 (m, 3H), 1.33 - 1.19 (m single enantiomer; cis on cyclohexyl group; fluorobenzamide 1H) absolute stereochemistry unknown (S)(3-amino 1H NMR (500MHz, METHANOL- (tetrahydro-ZH- d4) 5 ppm 7.99 - 7.79 (m, 2H), 7.77 pyran - 7.57 (m, 2H), 7.50 (s, 1H), 7.37 - azinyI)-N- 546/5 7.07 (m, 2H), 5.41 - 5.21 (m, 1H), (1 omo 4.07 (dd, J=3.8, 11.0 Hz, 2H), 3.68 henyl)—2- - 3.54 (m, 2H), 2.98 (d, J=5.4 Hz, (methylamino)eth 3H), 2.48 (s, 3H), 1.99 - 1.66 (m y|) fluorobenzamide 1H NMR (500MHz, METHANOL- d4) 5 ppm 7.90 (s, 2H), 7.74 (dd, 4-(3-amino(3- J=1.4, 8.0 Hz, 1H), 7.67 (dd, J=1.4, hydroxycyclohexy 11.8 Hz, 1H), 7.60 (s, 1H), 7.50 - 366 23:28? y') N' - - - - /N 0| 7.41 (m, 3H), 5.69 - 5.47 (m, 1H), 498 2 0 67I 3.70 (tt, J=4.2, 11.0 HZ, 1H), 3.64 - ChIOFO hen |)_2_ 3.51 (m, 2H), 2.84 (s, 3H), 2.81 - 0H (meth fiamiri'omhV 2.72 (m, 1H), 2.20 -2.11 (m, 1H), yI)_2_ single enantlomer; 2.03 (d, J=12.6 HZ, 1H), 1.96 - 1.79 fluorObenzam'de, cis on cyclohexylgroup; 1 61 _ 1 42 (m absolute stereochemistry unknown (m’ 2H) ’ ' ' ’ 3H) 1 34 _ ’ ' 1.24 (m, 1H) F o {NHQ N/q/éj/KHHD= 1H NMR(500MHz L-d4) NH N 211(8) 2 ammo. ’ _ _ _ _ 1 _ ppm 8.01 - 7.82 (m, 2H), 7.78 - 7.64 (m, 2H), 7.61 - 7.56 (m, 1H), 367 /N 0' Shiogghrfimfiihum 3 0 61 7.52 - 7.35 (m, 3H), 5.65 - 5.42 (m ' 1H),3.77 - 3.66 (m, 1H), 3.55 - 3.42 (m, 2H), 2.84 - 2.73 (m, 1H), 2.16 hydroxycyclohexy (d, J=12.0 Hz, 1H), 2.03 (d, J=12.0 |)pyrazinyI) single omer; Hz, 1H), 1.97 - 1.83 (m, 2H), 1.62 - cis on cyclohexyl group; fluorobenzamide absolute stereochemistry unknown 1.41 (m, 3H), 1.34 - 1.22 (m, 1H) WO 66188 2014/062913 N-((S)amino 1H NMR (500MHz, METHANOL- (3- d4) 5 ppm 7.89 (s, 2H), 7.80 - 7.70 chlorophenyl)ethy (m, 1H), 7.58 (s, 2H), 7.47 (s, 3H), |)(3-amino 5.62 - 5.43 (m, 1H), 3.80 - 3.64 (m (3- 1H), 3.59 - 3.40 (m, 2H), 2.77 (br. hydroxycyclohexy s., 1H), 2.16 (d, J=12.0 Hz, 1H), |)pyrazinyI) 2.07 - 1.77 (m, 3H), 1.65 - 1.40 (m single enantiomer; cis on cyclohexyl group; fluorobenzamide 3H), 1.36 - 1.16 (m, 1H) absolute stereochemlstry unknown 4-(3-amino( hydroxycyclohexy 1H NMR (500MHz, METHANOL- |)pyrazin-2—yI)-N- d4) 5 ppm 7.89 (s, 2H), 7.80 - 7.71 ((S)(3- (m, 1H), 7.70 - 7.62 (m, 1H), 7.61 - chlorophenyl)—2- 7.54 (m, 1H), 7.48 (s, 3H), 5.67 - (methylamino)eth 5.50 (m, 1H), 4.18 (br. s, 1H), 3.65 - y|) 3.51 (m, 2H), 3.21 - 3.07 (m, 1H), fluorobenzamide 2.84 (s, 3H), 2.02 - 1.74 (m, 5H), single enantiomer; 1.70 - 1.46 (m, 3H) trans on cyclohexyl group; absolute stereochemistry unknown amino 1H NMR (500MHz, METHANOL- (3- d4) 5 ppm 7.97 - 7.84 (m, 2H), 7.74 chlorophenyl)ethy (d, J=0.9 Hz, 1H), 7.68 - 7.62 (m |)(3-amino 1H), 7.58 (s, 1H), 7.50 - 7.37 (m, (3- 3H), 5.62 - 5.44 (m, 1H), 4.27 - 4.13 hydroxycyclohexy (m, 1H), 3.57 - 3.42 (m, 2H), 3.17 single enantiomer; |)pyrazinyI) (br. s., 1H), 2.05 - 1.72 (m, 5H), trans on cyclohexyl group; fluorobenzamide 1.68 - 1.53 (m, 3H) absolute stereochemistry unknown (S)-4—(3-amino 1H NMR (400MHz, METHANOL- (tetrahydro-ZH- d4) 5 ppm 7.87 - 7.71 (m, 2H), 7.67 pyran - 7.53 (m, 1H), 7.46 (d, J=7.8 Hz, y|)pyrazinyI)-N- 560, 1H), 7.40 - 7.27 (m, 2H), 7.25 - 7.15 (1 -(3-bromo (m, 1H), 5.52 - 5.36 (m, 1H), 4.01 - fluorophenyl)—2- 3.82 (m, 2H), 3.54 - 3.36 (m, 4H), (ethylamino)ethyl 3.36 - 3.27 (m, 1H), 3.13 - 3.00 (m ) 2H), 2.84 (s, 1H), 1.73 (br. s., 3H), fluorobenzamide 1.31 - 1.18 (m, 3H) N-((S)amino—1 - (3- 1H NMR (500MHz, METHANOL- chlorophenyl)ethy d4) 6 ppm 7.88 (s, 2H), 7.74 (s, |)(3-amino—6- 1H), 7.66 (dd, J=1.3, 11.7 Hz, 1H), 7.58 (s, 1H), 7.49 - 7.40 (m, 3H), .59 - 5.43 (m, 1H), 4.18 (d, J=2.8 |)pyrazinyI) Hz, 1H), 3.56 - 3.42 (m, 2H), 3.22 - single enantiomer,’ fluorobenzamide 3.12 (m, 1H), 2.00 - 1.76 (m, 5H), trans on cyclohexyl group; absolute stereochemistry unknown 1.69 - 1.55 (m, 3H) amino—1 - (3-fluoro—5- 1H NMR (400MHz, METHANOL- iodophenyl)ethyl) d4) 5 ppm 7.92 - 7.81 (m, 2H), 7.78 (3-amino—6- - 7.67 (m, 2H), 7.66 - 7.47 (m, 2H), ((1r,4S)—4- 7.30 (d, J=9.4 Hz, 1H), 5.50 - 5.38 hydroxycyclohexy (m, 1H), 3.68 - 3.53 (m, 1H), 3.50 - |)pyrazinyI) 3.40 (m, 2H), 2.69 - 2.54 (m, 1H), fluorobenzamide 2.14 - 1.86 (m, 4H), 1.66 (dq, J=2.9, 13.0 Hz, 2H), 1.50 - 1.33 (m, 2H) 4-(3-amino—6- ((1r,4S) 1H NMR (500MHz, METHANOL- methoxycyclohex d4) 5 ppm 7.91 (s, 2H), 7.76 - 7.56 y|)pyrazinyI)-N- (m, 2H), 7.54 - 7.47 (m, 1H), 7.36 - ((S)(3-bromo— 7.27 (m, 1H), 7.27 - 7.13 (m, 1H), ropheny|) 5.36 - 5.25 (m, 1H), 3.41 (s, 3H), (methylamino)eth 3.12 - 2.89 (m, 2H), 2.76 - 2.59 (m, y|) 1H), 2.49 (s, 3H), 2.32 - 2.14 (m, fluorobenzamide 2H), 2.06 - 1.96 (m, 2H), 1.79 - 1.61 (m, 2H), 1.44 - 1.23 (m, 2H) Structure 4-(3-amino—6- 1H NMR (400MHz, METHANOL- ((1r,4S)—4- d4) 5 ppm 7.99 - 7.63 (m, 2H), 7.76 methoxycyclohex - 7.67 (m, 2H), 7.65 - 7.44 (m, 3H), aziny|)-N- 7.42 - 7.32 (m, 1H), 5.63 - 5.49 (m, ((S)(3- 1H), 3.64 - 3.46 (m, 2H), 3.37 (s, bromophenyl)—2- 3H), 3.26 (s, 1H), 2.61 (s, 3H), 2.71 (methylamino)eth - 2.57 (m, 1H), 2.20 (d, J=9.8 Hz, y|) 2H), 2.05 - 1.94 (m, 2H), 1.65 (dq, fluorobenzamide J=2.9, 13.0 Hz, 2H), 1.44 -1.25(m, mino—6- ((1r,4S)—4- 1H NMR (500MHz, METHANOL- hydroxycyclohexy d4) 5 ppm 7.97 - 7.63 (m, 2H), 7.79 |)pyraziny|)—N- - 7.57 (m, 2H), 7.50 (s, 1H), 7.36 - NHz fi/UF ((S)—1-(3-bromo- 560/5 7.29 (m, 1H), 7.27 - 7.16 (m, 1H), 0 64 ' NI \ 5-f|uoropheny|)—2- 62 5.39 - 5.28 (m, 1H), 3.63 (s, 1H), /N Br (methylamino)eth 3.13 - 2.91 (m, 2H), 2.66 (s, 1H), y|) 2.49 (s, 3H), 2.15 - 1.88 (m, 4H), fluorobenzamide 1.69 (d, J=12.6 Hz, 2H), 1.44 (d, 5H J=13.6 Hz, 2H) ’3‘ I g i 9. ‘r’ 5' ‘r’ H ,2: 3 $2 3 1H NMR (400MHz, METHANOL- F O _/N\ g g ‘5 5- d4) 6 ppm 7.93 - 7.90 (m, 1H), 7.88 3 5' 8 E g, (s, 1H), 7.71 (d, J=7.8 Hz, 1H), 7.63 ““2 fl ‘2’ g §é (d, J=12.1 Hz, 1H), 7.57(s, 1H), 377 N \ E 57—, g i 7.49 - 7.39 (m, 3H), 5.57 (dd, J=5.3, b” CI ‘5 'P ‘3’ 57/3 512.4 0.74 9.2 Hz, 1H), 3.61 - 3.50 (m, 2H), E é—h g 4P 3.37 (s, 3H), 3.28 - 3.22 (m, 1H), Q 3 3 2.81 (s, 3H), 2.70 - 2.60 (m, 1H), g f: 2.20 (d, J=10.2 Hz, 2H), 1.98 (d, O E} ‘17 J=12.9 Hz, 2H), 1.65 (d, J=14.9 Hz, \ 3 : 2H), 1.47 - 1.23 (m, 2H) % ‘4’ H (S)—4-(3-amino—6- 1H NMR z, METHANOL- F 0 g/ V (tetrahydro—2H- d4) 6 ppm 7.98 - 7.90 (m, 2H), 7.75 378 NH2 ” pyran (d, J=1.6 Hz, 2H), 7.71 - 7.65 (m, y|)pyrazinyI)-N-542/5 1H), 7.62 - 7.57 (m, 1H), 7.52 (s, N \ 0 69 ' /N Br (1-(3- 44 1H), 7.42(s, 1H), 5.65 - 5.45 (m, bromophenyl)—2- 1H), 4.11 - 3.99 (m, 2H), 3.69 - 3.50 (ethylamino)ethy| (m, 4H), 3.26 - 3.16 (m, 3H), 3.05 - o ) 2.87 (m, 1H), 1.85 (br. s., 4H), 1.38 fluorobenzamide (t, J=7.3 Hz,3H) Structure 4-(3-amino—6- 1H NMR (500MHz, METHANOL- ((1r,4S)—4- d4) 5 ppm 7.90 (s, 2H), 7.77 - 7.72 (m, 2H), 7.69 - 7.63 (m, 1H), 7.62 - |)pyrazin-2—yI)-N- 7.56 (m, 1H), 7.55 - 7.51 (m, 1H), ((S)(3- 7.42 (s,1 H), 5.67 - 5.49 (m, 1H), henyl)—2- 3.66 - 3.52 (m, 3H), 3.47 (t, J=1.6 (ethylamino)ethyl Hz, 1H), 3.23 - 3.16 (m, 3H), 2.71 - )—2— 2.62 (m, 1H), 2.09 (d, J=9.1 Hz, fluorobenzamide 2H), 1.97 (d, J=13.6 , 1.66 (d, J=15.4 Hz, 2H), 1.44 (d, J=12.6 Hz, 2H), 1.36 (t, J=7.4 Hz, 3H) (S)—4-(3-amino—6- (tetrahydro—ZH- pyran 1H NMR (400MHz, METHANOL- y|)pyrazinyI)-N- d4) 5 ppm 7.66 (s, 2H), 7.77 - 7.45 (1-(3- (m, 5H), 7.43 - 7.29 (m, 1H), 5.63 - bromophenyl)—2- 5.47 (m, 1H), 4.04 (dd, J=2.7, 11.3 (methylamino)eth Hz, 2H), 3.66 -3.46 (m, 4H), 3.04 - y|) 2.66 (m, 1H), 2.61 (s, 3H), 1.97 - fluorobenzamide 1.74 (m, 4H) 4-(3-amino—6- ((1r,4S)—4- 1H NMR (400MHz, METHANOL- hydroxycyclohexy d4) 5 ppm 7.69 - 7.74 (m, 2H), 7.64 |)pyrazin-2—yI)-N- (d, J=1.6 Hz, 2H), 7.56 - 7.45 (m, -(3- 542/5 2H), 7.40 (s, 1H), 7.31 (d, J=7.8 Hz, 381 0.65 bromophenyl)—2- 44 1H), 5.46 (dd,J=5.1, 9.4 Hz, 1H), (methylamino)eth 3.60 - 3.41 (m, 3H), 2.73 (s, 3H), y|) 2.61 - 2.43 (m, 1H), 2.05 - 1.76 (m, fluorobenzamide 4H), 1.57 (dq, J=2.9, 13.0 Hz, 2H), 1.33 (d, J=13.7 Hz, 2H) Structure N-((S)—2-amino—1 - 1H NMR (400MHz, METHANOL- Séiuirgfl'mh d4) 6 ppm 7.94 - 7.81 (m, 2H), 7.77 F o {NHz 4_(3Fjamir3:o_6_y - 7.51 (m, 4H), 7.37 - 7.21 (m, 1H), F 5.59-5.32 (m, 1H), 3.49 -3.40 (m, 382 NH2 N{U ((1r4s)_4_ 608 methox C clohex 2H), 3.37 (S, 3H),3.27 - 3.20 (m.
KIN/ 1 I) raz3i/nE12- 1H), 2.73 -2.55 (m, 1H), 2.20 (d, |) ; gugzobenzaéide J=9.4 Hz, 2H), 2.04 - 1.89 (m, 2H), 1.65 (dd, J=2.7, 12.5 , 1.33 (d, J=13.7 Hz, 2H) 0.77 N-((S)—2-amino—1- F O {NHZ (3- NH2 N bromophenyl)eth 383 y|)(3-am|no N \ 542/5 b,“ 0.73 B, ((1r,4S)—4- 44 NA g methoxycyclohex y|)pyrazinyI) enzamide F 0 {OH F 1H NMR (400MHz, DMSO d6) 5 NHZ N _ H 4_(3_amino_6_(3_ ppm 8.76 - 8.55 (m, 1H), 7.88 (s, N \ hydroxycyclohexy /N Br 1H), 7.77 - 7.53 (m, 3H), 7.47 (s, (g_1_(3_br:mo_I) razin_2_ I)_N_ 547/5 384 0.77 2H), 7.27 (d, J=9.8 Hz, 1H), 5.05 (q, J=6.5 , 3.58 - 3.37 (m, 3H), -fluoro'0henVI)_2_ OH 2.72 - 2.56 (m, 1H), 1.98 (d, J=11.7 hydroxyethyl)—2- single enantiomer; Hz, 1H), 1.90 - 1.64 (m, 3H), 1.49 - cis on cyclohexane ring; fluorobenzamide absolute stereochemistry unknown 1.24 (m, 3H), 1.17 - 0.97 (m, 1H) 1H NMR (400MHz, DMSO-d6) 5 4-(3-amino—6-( ppm 8.76 - 8.59 (m, 1H), 7.88 (s, ycyclohexy 1H), 7.76 - 7.53 (m, 4H), 7.50 - 7.21 |)pyraziny|)—N- 529/5 (m, 3H), 5.03 (q, J=6.7 Hz, 1H), ((S)(3- 3.80 - 3.68 (m, 4H), 2.75 - 2.57 (m bromophenyl)—2- 1H), 1.98 (d, J=11.7 Hz, 1H), 1.89 - hydroxyethyl)—2- sing/e enantiomer; 1.62 (m, 3H), 1.47 - 1.21 (m, 3H), fluorobenzamide cis on cyo/ohexane ring; 1.16 - 0.96 (m, 1H) absolute stereocnemistry unknown H NMR (400MHz, DMSO-d6) 5 ppm 8.76 - 8.55 (m, 1H), 7.83 (s, 1H), 7.73 - 7.50 (m, 3H), 7.45 - 7.32 |)pyraziny|)—N- (m, 2H), 7.22 (d, J=9.4 Hz, 1H), ((S)—1-(3-bromo— 5.00 (q, J=6.5 Hz, 1H), 3.48 - 3.35 -f|uoropheny|)—2- (m, 2H), 2.68 - 2.52 (m, 1H), 1.93 hydroxyethyl)—2- (d, J=11.7 Hz, 1H), 1.86 - 1.60 (m single enantiomer; cis on cyclohexane ring; fluorobenzamide 3H), 1.41 - 1.18 (m, 3H), 1.12 - 0.93 te stereochemistry unknown (m, 1H) (S)—4-(3-amino—6- (tetrahydro—2H- 1H NMR (400MHz, DMSO-d6) 5 pyran ppm 8.70 - 8.58 (m, 1H), 7.92 (s, y|)pyraziny|)—2- 1H), 7.76 - 7.52 (m, 3H), 7.37 - 7.21 fluoro—N-(2- (m, 2H), 7.18 - 7.04 (m, 2H), 5.09 - y—1-(3- 4.92 (m, 1H), 3.99 - 3.87 (m, 2H), (methylthio)phen 3.64 (d, J=6.7 Hz, 2H), 3.50 - 3.29 y|)ethy|)benzamid (m, 2H), 2.94 - 2.75 (m, 1H), 1.83 - 1.62 (m, 4H) 4-(3-amino—6- ((1r,4S)—4- 1H NMR (400MHz, DMSO-d6) 5 F 0 :/OH hydroxycyclohexy ppm 8.69 - 8.56 (m, 1H), 7.88 (s, |)pyraziny|) 388 NH2 N H 1H), 7.76 - 7.49 (m, 3H), 7.34 - 7.20 fluoro-N-((S)—2- N \ 497 0.69 (m, 2H), 7.18 - 7.02 (m, 2H), 5.02 I hydroxy—1-(3- /N s\ (q, J=6.7 Hz, 1H), 3.64 (d, J=6.3 (methylthio)phen Hz, 2H), 3.49 - 3.29 (m, 1H), 2.46 y|)ethy|)benzamid (s, 3H), 2.02 - 1.76 (m, 4H), 1.59 - 1.43 (m, 2H), 1.35 - 1.12 (m, 2H) Structure 1H NMR (400MHz, 6) 5 ppm 8.78 - 8.55 (m, 1H), 7.88 (s, 4-(3-amino—6-( 1H), 7.76 - 7.67 (m, 1H), 7.66 - 7.55 hydroxycyclohexy 529/5 (m, 3H), 7.48 - 7.35 (m, 2H), 7.34 - |)pyraziny|)-N- 7.24 (m, 1H), 5.03 (d, J=7.4 Hz, ((S)(3- 1H), 3.55 - 3.24 (m, 1H), 2.79 - 2.56 bromophenyI) (m, 1H), 1.98 (d, J=12.1 Hz, 1H), hydroxyethy|) 1.85 (d, J=12.1 Hz, 1H), 1.79 - 1.65 single enantiomer; fluorobenzamide cis on cyclohexane ring; (m,2H), 1.48 -1.22 (m, 3H), 1.09 absolute stereochemistry unknown (d, J=11.3 Hz, 1H) (S)(3-amino—6- 1H NMR (400MHz, DMSO-d6) 5 (tetrahydro—2H- ppm 8.79 - 8.55 (m, 1H), 7.92 (s, pyran 1H), 7.78 - 7.48 (m, 3H), 7.31 (s, aziny|)-N- 1H), 7.19 (t, J=10.0 Hz, 2H), 6.13 (1 -(3- (s, 1H), 5.13 - 4.95 (m, 1H), 4.82 - (chloromethyI) 4.66 (m, 1H), 3.92 (d, J=11.0 Hz, fluorophenyl)—2- 2H), 3.66 (t, J=5.9 Hz, 2H), 3.42 hydroxyethy|) (dd, J=2.7, 5.9 Hz, 2H), 2.84 (s, fluorobenzamide 1H), 1.78 - 1.64 (m, 4H) 1H NMR (500 MHz, METHANOL- 4-(3-amino—6-( d4) 5 ppm 8.06- 7.82 (m, 2 H) 7.77 hydroxycyclohexy -7.58 (m, 2 H) 7.49 (s,1 H) 7.46- |)pyraziny|)-N- 7.13 (m, 3 H) 5.30 -5.13 (m,1 H) ((S)(3- 4.19 (br. s., 1 H) 3.88 (dd, J=8.98, chlorophenyl)—2- 6.15 Hz, 2 H) 3.18 (d, J=4.41 Hz,1 hydroxyethy|) sing/e enantiomer; H) 2.08 -1.74 (m, 5 H) 1.71 -1.50 enzamide trans on cyclohexane ring; (m, 3 H) absolute stereochemistry unknown F 0 {NH2 1H NMR (500 MHz, METHANOL- N-((S)amino—1 - NH N d4) 5 ppm 7.90 (s, 2 H) 7.75- 7.71 H (3- (m, 1 H) 7.65 (dd, J=11.98, 1.26 392 N \ chlorophenyl)ethy I Hz,1 H) 7.58 (s,1 H) 7.47 (s, 3 H) /N CI |)(3-amino—6- .63 -5.42 (m, 1 H) 3.67 -3.58 (m, ((1r,4S) 1 H) 3.54 - 3.42 (m, 2 H) 2.70- 2.62 hydroxycyclohexy (m, 1 H) 2.09 (d, J=9.46 Hz, 2 H) |)pyrazinyI) 1.97 (d, 2 Hz, 2 H) 1.74- fluorobenzamide 1.63 (m, 2 H) 1.50 - 1.39 (m, 2 H) Structure 1H NMR (500 MHz, METHANOL- 4-(3-amino( d4) 5 ppm 8.00- 7.81 (m, 2 H) hydroxycyclohexy 7.75- 7.57 (m, 2 H) 7.57 -7.47 (m, zinyI)-N- 1 H) 7.42-7.13 (m, 3 H) 5.22 (s,1 ((S)(3- H) 4.19 (br.s.,1 H) 3.88 (dd, chlorophenyI) J=8.83, 5.99 Hz, 2 H) 3.23- 3.07 hydroxyethyI) sing/e enantiomer; (m,1 H) 2.12- 1.75 (m,5 H) 1.71- fluorobenzamide trans on cyclohexane ring; 1.49 (m, 3 H) absolute chemistry unknown (S)(2-amino (1 ,3-dimethyI-1 H- pyrazoI 1H NMR (500 MHz, DMSO-d6) 5 y|)pyridinyI) ppm 8.74 (d, J=7.88 Hz, 1 H) 8.16 fluoro-N-(1-(3- - 7.74 (m, 4 H) 7.61- 7.33 (m, 2 H) fluoro 7.19 -6.86 (m, 3 H) 5.19- 4.97 (m, (methylthio)phen 1 H) 3.79 (s, 3 H) 3.71 -3.64 (m, 2 y|) H) 2.29 (s, 3 H) hydroxyethyl)ben zamide (S)(3-amino (tetrahydro-ZH- 1H NMR (500 MHz, DMSO-d6) 5 pyran ppm 8.71 (d, J=7.88 Hz, 1 H) 7.95 y|)pyrazinyI) (s, 1 H) 7.79-7.44 (m, 3 H) 7.17- fluoro-N-(1-(3- 6.91 (m, 3 H) , J=6.83 Hz, 1 fluoro H) 3.97- 3.87 (m, 4 H) 3.67 (d, (methylthio)phen J=6.31 Hz, 3 H) 3.44 (br. s., 2 H) y|) .75 (m, 1 H) .68 (m, hydroxyethyl)ben 4 H) zamide 4-(3-amino 1H NMR (500 MHz, DMSO-d6) 5 ((1r,4S) ppm 8.70 (d, J=8.20 Hz, 1 H) 7.91 (s, 1 H) 7.77- 7.46 (m, 3 H) 7.14 (s, |)pyrazinyI) 1 H) 7.01 (t, J=10.25 Hz, 2 H) 5.05 fluoro-N-((S) (d, J=7.57 Hz,1 H) 3.50-3.33 (m, (3-fluoro 1 H) 2.60-2.53 (m,1 H) 2.47-2.42 (methylthio)phen (m, 1 H) 2.02 -1.80 (m, 4 H) 1.5 5 y|) (d, J=15.13 Hz, 2 H) 1.28 (d, hydroxyethyl)ben J=13.24 Hz, 2 H) zamide 2014/062913 Structure (S)(3-amino—6- 1H NMR (400 MHz, METHANOL- (4- d4) 5 ppm 7.83 - 7.70 (m, 2 H) oxocyclohexyl)py 7.65- 7.45 1 H) 545/5 (m, 2 H) 7.37 (s, razinyI)-N-(1- 7.22 - 7.00 (m, 2 H) 5.08 (t, J=5.67 (3-bromo—5- Hz, 1 H) 3.76 (t, J=5.67 Hz, 2 H) fluorophenyl)—2- 2.74- 2.58 (m, 1 H)2.04 (d, J=12.13 hydroxyethy|) Hz, 2 H) ) 1.80 -1.58 (m, 4 H) 1.41 fluorobenzamide (td, J=13.11,4.30 Hz, 2 H) 1H NMR (400 MHz, METHANOL- d4) 5 ppm 8.73 - 8.63 (m, 1 H) 7.88 4-(3-amino—6- -7.77 (m, 2 H) 7.70 -7.56 (m, 2 H) ((1r,4S) 7.47 (s,1 H) 7.40-7.23 (m, 3 H) hydroxycyclohexy .03-4.94 (m, 1 H) 4.13 (quin, ziny|)-N- 499.1 0.69 J=6.26 Hz, 1 H) 3.66 -3.54 (m, 1 R)(3- H) 2.74 -2.57 (m, 1 H) 2.06 (d, chlorophenyl)—2- J=9.78 Hz, 2 H) 1.96 (d, J=12.91 hydroxypropy|) Hz, 2 H) 1.74 - 1.58 (m, 2 H) 1.51- fluorobenzamide 1.35 (m, 2 H) 1.20 (d, J=6.26 Hz, 3 F 0 1H NMR (400MHz, CD30D) 6 7.94 NH2 N \ 4-(3-amino—6- (t, J=7.6 Hz, 1H), 7.85 - 7.76 (m, H I N / ((1r,4r) 2H), 7.69 (dd, J=1.6, 8.2 Hz, 1H), hydroxycyclohexy 7.62 (dd, J=1.2, 11.7 Hz, 1H), 7.42 399 N CI 4982 0'63 ;/ |)pyraziny|)-N- (s, 1H), 7.35 (d, J=8.2 Hz, 1H), 4.69 ((6-chloropyridin- (s, 2H), 3.67 - 3.54 (m, 1H), 2.72 - 2-y|)methy|) 2.58 (m, 1H), 2.07 (d, J=9.4 Hz, enzamide OH 2H), 1.96 (d, J=12.9 Hz, 2H), 1.74 - 1.56 (m, 2H), 1.50 - 1.35 (m, 2H) F 0 1H NMR (400MHz, CD30D) 6 7.93 NHZ N \ 4-(3-amino—6- (t, J=7.8 Hz, 1H), 7.85 (s, 1H), 7.80 H I N / ((1s,4s) (t, J=7.8 Hz, 1H), 7.71 (dd, J=1.6, 400 /N CI hydroxycyclohexy498-2 0.65 8.2 Hz, 1H), 7.65 (dd, J=1.4, 11.9 |)pyraziny|)-N- Hz, 1H), 7.41 (d, J=7.4 Hz, 1H), ((6-chloropyridin- 7.35 (d, J=8.2 Hz, 1H), 4.69 (s, 2H), 2-y|)methy|) 4.01 (br. s., 1H), 2.79 - 2.68 (m, fluorobenzamide 1H), 2.11 - 1.96 (m, 2H), 1.93 - 1.83 (m, 2H), 1.77 - 1.64 (m, 4H) Structure 1H NMR (500MHz, METHANOL- d4) 5 ppm 7.90 (s, 1H), 7.84 (t, 4-(3-amino—6— J=7.7 Hz, 1H), 7.70 (dd, J=1.4, 8.0 ((1r,4S)—4- Hz, 1H), 7.63 (dd, J=1.3, 11.7 Hz, hydroxycyclohexy 1H), 7.49 (s, 1H), 7.40 (d, J=5.0 Hz, |)pyrazin-2—yI)-N- 2H), 7.38 - 7.29 (m, 1H), 5.34 (dd, -(3- J=5.4, 8.8 Hz, 1H), 3.68 - 3.57 (m, chlorophenyl)—2- 1H), 3.07 (dd, J=9.0, 12.8 Hz, 1H), (methylamino)eth 2.97 (dd, J=5.4, 12.6 Hz, 1H), 2.71 y|) - 2.59 (m, 1H), 2.48 (s, 3H), 2.13 - fluorobenzamide 2.04 (m, 2H), 2.03 - 1.90 (m, 2H), 1.76 - 1.61 (m, 2H), 1.51 - 1.37 (m, 1H NMR (400MHz, CD30D) 5 ppm 4-(3-amino—6— 7.89 - 7.75 (m, 2H), 7.71 - 7.64 (m, ((1r,4S)—4— 1H), 7.61 (d, J=12.6 Hz, 1H), 7.53 - hydroxycyclohexy 7.45 (m, 1H), 7.46 - 7.27 (m, 3H), |)pyrazin-2—yI)-N- 510.2 0.83 5.43 - 5.28 (m, 1H), 3.74 (d, J=6.7 ((S)—2-azido—1-(3- Hz, 2H), 3.68 - 3.50 (m, 1H), 2.64 chlorophenyl)ethy (tt, J=3.6, 12.2 Hz, 1H), 2.14 - 1.99 |) (m, 2H), 1.96 (d, J=12.9 Hz, 2H), fluorobenzamide 1.77 - 1.56 (m, 2H), 1.51 - 1.31 (m, 4-(3-amino—6— 1H NMR (400MHz, CD30D) 5 ppm R)—4— 7.88 (s, 1H), 7.83 - 7.74 (m, 1H), hydroxycyclohexy 7.73 - 7.66 (m, 1H), 7.64 (d, J=11.4 |)pyrazin-2—yI)-N- 510.2 0.86 Hz, 1H), 7.50 (s, 1H), 7.43 - 7.27 ((S)—2-azido—1-(3- (m, 3H), 5.44 - 5.30 (m, 1H), 3.80 - chlorophenyl)ethy 3.67 (m, 4H), 2.79 - 2.64 (m, 1H), |) 2.11 - 1.93 (m, 2H), 1.76 -1.61 (m, fluorobenzamide 5H) Structure 1H NMR (400MHz, CD30D) 5 ppm (S)—4-(3-amino—6- 7.94 - 7.75 (m, 2H), 7.75 - 7.58 (m, (tetrahydro—ZH- 2H), 7.50 (s, 1H), 7.43 - 7.26 (m, pyran 3H), 5.35 (t, J=6.5 Hz, 1H), 4.13 - y|)pyrazinyI)-N-496.2 0.93 3.96 (m, 2H), 3.74 (d, J=6.7 Hz, (2-azido—1-(3- 2H), 3.57 (dt, J=2.3, 11.5 Hz, 2H), chlorophenyl)ethy 3.02 - 2.85 (m, 1H), 2.00 - 1.71 (m, |) fluorobenzamide 4H) —2- 1H NMR (400MHz, CD30D) 5 ppm acetamido—1-(3- 8.85 (br. s., 1H), 7.89 - 7.76 (m, chlorophenyl)ethy 2H), 7.71 - 7.55 (m, 2H), 7.45 (s, |)(3-amino—6- 1H), 7.40 - 7.24 (m, 3H), 5.26 (br. ((1r,4S)—4- s., 1H), 3.71 - 3.51 (m, 3H), 2.75 - hydroxycyclohexy 2.53 (m, 1H), 2.06 (d, J=9.8 Hz, |)pyrazinyI) 2H), 2.00 - 1.86 (m, 5H), 1.78 - 1.56 fluorobenzamide (m, 2H), 1.53 - 1.31 (m, 2H) N-((S)—2- 1H NMR (400MHz, CD30D) 5 ppm acetamido—1-(3- 7.93 - 7.79 (m, 2H), 7.73 - 7.57 (m, chlorophenyl)ethy 2H), 7.47 (s, 1H), 7.34 - 7.14 (m, |)(3-amino—6- 2H), 5.18 (t, J = 5.7 Hz, 1H), 3.93 - ((1r,4S)—4- 3.78 (m, 2H), 2.70 - 2.55 (m, 1H), methoxycyclohex 2.06 (d, J = 12.3 Hz, 2H), 1.95 (d, J azinyI) =12.3 Hz, 2H), 1.76 - 1.58 (m, 2H), fluorobenzamide 1.48 - 1.35 (m, 2H) 2014/062913 Structure (S)-methyl (2-(4- 1H NMR (500MHz, METHANOL- (3-amino—6- d4) 5 ppm 7.90 (s, 1H), 7.85 (t, (tetrahydro—ZH- J=7.7 Hz, 1H), 7.72 (d, J=7.9 Hz, pyran 1H), 7.66 (d, J=11.3 Hz, 1H), 7.48 y|)pyrazinyI) (s, 1H), 7.44 - 7.36 (m, 2H), 7.36 - enzamido) 7.22 (m, 1H), 5.28 (d, J=7.3 Hz, _2_(3_ 1H), 4.07 (dd, J=3.8, 11.0 Hz, 2H), chlorophenyl)ethy 3.67 (s, 3H), 3.60 (dt, J=2.0, 11.7 I)carbamate Hz, 2H), 3.54 (d, J=6.9 Hz, 2H), 2.97 (s, 1H), 2.02 - 1.81 (m, 4H) 1H NMR (500MHz, OL- (S)—N-(2- d4) 5 8.92 (br. s., 1H), 8.31 (br. s., acetamido—1-(3- 1H), 7.88 (s, 1H), 7.83 (t, J=7.7 Hz, bromo—5- 1H), 7.70 (d, J=7.9 Hz, 1H), 7.65 (d, fluorophenyl)ethy| J=12.9 Hz, 1H), 7.46 (s, 1H), 7.30 )(3-amino—6- (d, J=8.2 Hz, 1H), 7.20 (d, J=10.1 (tetrahydro—ZH- Hz, 1H), 5.26 (d, J=6.6 Hz, 1H), pyran 4.05 (dd, J=3.5, 11.0 Hz, 2H), 3.66 y|)pyrazinyI) - 3.53 (m, 4H), 3.01 - 2.88 (m, 1H), fluorobenzamide 1.95 (s, 3H), 1.94 - 1.80 (m, 4H) (S)-methyl (2-(4- 1H NMR (400MHz, CD30D) 5 ppm (3-amino—6- 7.89 (s, 1H), 7.86 - 7.78 (m, 1H), (tetrahydro—ZH- 7.74 - 7.67 (m, 1H), 7.67 - 7.57 (m, pyran 2H), 7.49 - 7.38 (m, 2H), 7.34 - 7.25 y|)pyrazinyI) (m, 1H), 5.25 (d, J=7.4 Hz, 1H), fluorobenzamido) 4.12 - 3.98 (m, 2H), 3.65 (s, 3H), _2_(3_ 3.62 - 3.49 (m, 4H), 2.99 - 2.89 (m, bromophenyl)eth 1H), 1.97 - 1.78 (m, 4H) yl)carbamate (S)-methyl (2-(4- 1H NMR (400MHz, CD30D) 5 ppm (3-amino—6- 7.89 (s, 1H), 7.88 - 7.80 (m, 1H), (tetrahydro—ZH- 7.76 - 7.68 (m, 1H), 7.64 (d, J=11.7 pyran Hz, 1H), 7.45 (s, 1H), 7.29 (d, J=8.2 y|)pyrazinyI) Hz, 1H), 7.19 (d, J=9.4 Hz, 1H), fluorobenzamido) 5.31 -5.19 (m, 1H),4.13 -4.01 (m, (3-bromo—5- 2H), 3.65 (s, 3H), 3.62 - 3.46 (m, fluorophenyl)ethy| 4H), 3.01 - 2.87 (m, 1H), 1.98 - 1.77 )carbamate (m, 4H) Structure (S)(3-amino 1H NMR (400MHz, CD30D) 5 ppm (tetrahydro-ZH- 7.99 - 7.88 (m, 2H), 7.75 (dd, J=1.4, pyran 8.0 Hz, 1H), 7.72 - 7.63 (m, 1H), azin-2—yI)-N- 578.2 7.58 (s, 1H), 7.43 (d, J=8.2 Hz, 1H), (1 -(3-bromo 7.32 (d, J=9.4 Hz, 1H), 5.61 (dd, fluorophenyI) J=5.5, 9.0 Hz, 1H), 4.74 (t, J=4.3 ((2- Hz, 1H), 4.05 (dd, J=3.1, 11.0 Hz, fluoroethy|)amino 2H), 3.72 - 3.53 (m, 5H), 3.53 - 3.45 )ethy|) (m, 1H), 3.04 - 2.86 (m, 1H), 2.01 - fluorobenzamide 1.72 (m, 4H) 4-(3-amino 1H NMR (400MHz, CD30D) 5 ppm ((1r,4S) 7.99 - 7.87 (m, 2H), 7.77 - 7.70 (m, hydroxycyclohexy 1H), 7.65 (d, J=12.1 Hz, 1H), 7.58 |)pyrazinyI)-N- (s, 1H), 7.43 (d, J=8.2 Hz, 1H), 7.32 ((S)(3-bromo- (d, J=9.4 Hz, 1H), 5.61 (dd, J=5.9, -fluorophenyI) 8.6 Hz, 1H), 4.74 (t, J=4.3 Hz, 1H), ((2- 3.73 - 3.49 (m, 6H), 2.70 - 2.53 (m, fluoroethy|)amino 1H), 2.07 (d, J=9.8 Hz, 2H), 1.95 (d, ) J=12.9 Hz, 2H), 1.76 - 1.58 (m, 2H), fluorobenzamide 1.52 - 1.34 (m, 2H) 1H NMR (400 MHz, DMSO-d6) 8 4-(3-amino 8.81-8.94 (m, 1H), 7.89 (s, 1H), (1 ,4- 7.69-7.80 (m, 1H), 7.52-7.67 (m, dioxaspiro[4.5]de 463.3 0.82 2H), 7.33 (d, J=4.3 Hz, 4H), 7.18- canyl)pyrazin- 7.27 (m, 1H), 6.09 (s, 2H), 4.49 (d, 2—yl)—N-benzyI J=5.9 Hz, 2H), 3.85 (s, 4H), 2.61- fluorobenzamide 2.70 (m, 1H), 1.67-1.84 (m, 6H), 1.48-1.65 (m, 2H) 1H NMR (400 MHz, CD30D ) 5 7.97 (2-amino - 7.85 (m, 2H), 7.75 - 7.69 (m, 2H), (3- 7.65 (dd, J=1.2, 11.7 Hz, 1H), 7.57 bromophenyl)eth (d, J=8.2 Hz, 1H), 7.48 (d, J=7.8 y|)(3-amino 5511:: 0.64 Hz, 1H), 7.38 (t, J=7.8 Hz, 1H), (tetrahydro-ZH- 5.48 (dd, J=5.9, 8.6 Hz, 1H), 4.04 pyran (dd, J=3.1, 11.3 Hz, 2H), 3.57 (dt, y|)pyrazinyI) J=2.2, 11.6 Hz, 2H), 3.52 - 3.39 (m, fluorobenzamide 3H), 2.99 - 2.87 (m, 1H), 1.97 -1.76 (m, 4H) WO 66188 Structure 1H NMR (400 MHz, CD30D) 6 7.61 (s, 1H), 7.71-7.79 (m, 1H), 7.65 (dd, 4-(3-amino J=8.0, 1.4 Hz, 1H), 7.59 (dd, ((1r,4R) J=11.3, 1.2 Hz, 1H), 7.45 (s, 1H), hydroxycyclohexy 7.31-7.36 (m, 2H), 7.23-7.29 (m, |)pyrazinyI)-N- 469.2 0.79 1H), 5.23 (q, J=6.8 Hz, 1H), 3.54- -(3- 3.67 (m, 1H), 2.65 (tt, J=12.1, 3.5 chlorophenyl)ethy Hz, 1H), 2.07 (d, J=9.4 Hz, 2H), |) 1.97 (d, J=12.9 Hz, 2H), 1.66 (qd, fluorobenzamide J=13.0, 2.9 Hz, 2H), 1.56 (d, J=7.0 Hz, 3H), 1.32-1.49 (m, 2H) 1H NMR (400 MHz, CD30D) 6 7.75 mino (s, 1H), 7.64-7.71 (m, 1H), 7.55- ((1s,4S) 7.60 (m, 1H), 7.47-7.54 (m, 1H), hydroxycyclohexy 7.35 (s, 1H), 7.21-7.26 (m, 2H), |)pyrazinyI)-N- 469.3 0.82 7.13-7.19 (m, 1H), .19 (m, ((R)(3- 1H), 3.92 (br. s., 1H), 2.59-2.70 (m, chlorophenyl)ethy 1H), 1.66-2.00 (m, 2H), 1.71-1.62 |) (m, 2H), 1.61 (d, J=12.1 Hz, 4H), fluorobenzamide 1.47 (d, J=7.0 Hz, 3H) 1H NMR (400 MHz, CD30D) 5 7.77 mino (t, J=7.8 Hz, 1H), 7.72 (s, 1H), 7.46- ((1r,4S) 7.61 (m, 2H), 7.37 (s, 1H), 7.23- hydroxycyclohexy 7.30 (m, 2H), 7.15-7.22 (m, 1H), |)pyrazinyI)-N- 485.3 0.66 5.10 (t, J=6.1 Hz, 1H), 3.69-3.85 ((S)(3- (m, 2H), 3.45-3.56 (m, 1H), 2.56 (tt, chlorophenyI) J=12.1, 3.4 Hz,1H),1.97(d,J=9.4 hydroxyethyI) Hz, 2H), 1.62-1.92 (m, 2H), 1.57 fluorobenzamide (qd, J=12.9, 2.7 Hz, 2H), 1.25-1.41 (m, 2H) mino 1H NMR (400 MHz, CD30D) 6 ((1s,4R) 7.70-7.65 (m, 2H), 7.50-7.64 (m, hydroxycyclohexy 2H), 7.37 (s, 1H), 7.22-7.30 (m, |)pyrazinyI)-N- 485.3 0.69 2H), 7.15-7.22 (m, 1H), 5.10 (t, ((S)(3- J=5.9 Hz, 1H), 3.92 (br. s., 1H), chlorophenyI) 3.65-3.63 (m, 2H), 2.59-2.75 (m, hydroxyethyI) 1H), 1.66-2.07 (m, 2H), 1.72-1.62 OH fluorobenzamide (m, 2H), 1.62 (d, J=12.1 Hz, 4H) Structure 4-(3-amino 1H NMR (400 MHz, CD30D) 8 7.88 ((1r,4R) (s, 1H), 7.83 (s, 1H), 7.74-7.81 (m, ycyclohexy 1H), 7.52-7.69 (m, 4H), 5.33 (q, |)pyrazinyI) J=7.0 Hz, 1H), 3.54-3.67 (m, 1H), fluoro-N-((R) 3.16 (s, 3H), 2.59-2.71 (m, 1H), (3-fluoro 2.07 (d, J=9.4 Hz, 2H), 1.91-2.01 (methylsulfonyl)p (m, 2H), 1.63-1.74 (m, 2H), 1.61 (d, ethyl)benza J=7.0 Hz, 3H), 1.33-1.50 (m, 2H) mide 4-(3-amino 1H NMR (400 MHz, CD30D) 8 ((1s,4S) 7.82-7.90 (m, 2H), 7.74-7.81 (m, hydroxycyclohexy 1H), 7.68 (dd, J=8.0, 1.4 Hz, 1H), |)pyrazinyI) 7.59-7.66 (m, 2H), 7.56 (d, J=9.4 -N-((R) Hz, 1H), 5.33 (t, J=7.0 Hz, 1H), (3-fluoro 4.01 (br. s., 1H), 3.16 (s, 3H), 2.73 (methylsulfonyl)p (tt, J=11.2, 3.3 Hz, 1H), 1.96-2.10 henyl)ethyl)benza (m, 2H), 1.81-1.93 (m, 2H), 1.64- mide 1.78 (m, 4H), 1.61 (d, J=7.0 Hz, 3H) 1H NMR (400 MHz, CD30D) 8 7.76 (t, J=7.6 Hz, 1H), 7.71 (s, 1H), 7.57 (dd, J=8.0, 1.4 Hz, 1H), 7.49 (dd, 4-(3-amino J=11.5, 1.4 Hz, 1H), 7.21-7.32 (m, cyclohexylpyrazin 405.3 0.97 4H), 7.12-7.20 (m, 1H), 4.52 (s, -N-benzy|—2- 2H), 2.50-2.67 (m, 1H), 1.73-1.89 fluorobenzamide (m, 4H), 1.66 (d, J=12.5 Hz, 1H), 1.27-1.55 (m, 4H), 1.12-1.27 (m, 1H NMR (400 MHz, CD30D) 8 7.77 (t, J=7.6 Hz, 1H), 7.72 (s, 1H), 7.58 (S)(3-amino (dd, J=8.0, 1.4 Hz, 1H), 7.47-7.55 cyclohexylpyrazin (m, 1H), 7.37 (s, 1H), 7.23-7.30 (m, y|)-N-(1-(3- 2H), 7.15-7.22 (m, 1H), 5.10 (t, chlorophenyI) J=5.9 Hz, 1H), 3.69-3.86 (m, 2H), hydroxyethyI) .65 (m, 1H), 1.73-1.93 (m, fluorobenzamide 4H), 1.67 (d, J=12.5 Hz, 1H), 1.28- 1.57 (m, 4H), 1.12-1.27 (m, 1H) Structure 1H NMR (400 MHz, CD30D) 5 7.87 (R)(3-amino (s, 1H), 7.63 (s, 1H), 7.74-7.60 (m, cyclohexylpyrazin 1H), 7.67 (dd, J=8.0, 1.4 Hz, 1H), y|)f|uoro-N- 7.50-7.65 (m, 3H), 5.27-5.36 (m, (1 -(3-f|uoro 1H), 3.16 (s, 3H), .71 (m, (methylsulfonyl)p 1H), 1.62-1.97 (m, 4H), 1.76 (d, henyl)ethyl)benza J=12.5 Hz, 1H), 1.61 (d, J=7.0 Hz, mide 3H), 1.37-1.56 (m, 4H), 1.23-1.37 (m, 1H) 1H NMR (400 MHz, CD30D) 6 7.96 (s, 1H), 7.70-7.79 (m, 1H), 7.61 (dd, 4-(3-amino J=8.2, 1.6 Hz, 1H), 7.53 (dd, (cyclohexen J=11.9, 1.4 Hz, 1H), 7.21-7.35 (m, y|)pyrazinyI)-N- 4H), 7.06-7.20 (m, 1H), 6.36-6.48 benzyI-Z- (m, 1H), 4.52 (s, 2H), 2.39 (d, J=2.0 enzamide Hz, 2H), 2.10-2.19 (m, 2H), 1.65- 1.74 (m, 2H), 1.54-1.63 (m, 2H) 1H NMR (400 MHz, CD30D) 6 7.96 (s, 1H), 7.71-7.60 (m, 1H), 7.62 (dd, (S)(3-amino J=8.0,1.4 Hz, 1H), 7.55 (d, J=11.7 (cyclohexen Hz, 1H), 7.37 (s, 1H), 7.26 (d, J=6.7 y|)pyrazinyI)-N- Hz, 2H), 7.14-7.21 (m, 1H), 6.44 (1 -(3- (br. s., 1H), 5.09 (t, J=6.1 Hz, 1H), chlorophenyI) 3.76 (t, J=5.9 Hz, 2H), 2.39 (d, hydroxyethyI) J=2.0 Hz, 2H), .21 (m, 2H), fluorobenzamide 1.65-1.76 (m, 3H), 1.54-1.64 (m, 1H NMR (400 MHz, CD30D) 6 7.96 (R)(3-amino (s, 1H), 7.76 (s, 1H), 7.64-7.70 (m, hexen 1H), 7.58-7.63 (m, 1H), 7.50-7.57 y|)pyrazinyI) (m, 2H), 7.46 (d, J=9.4 Hz, 1H), fluoro-N-(1-(3- 513.2 0.92 6.41-6.46 (m, 1H), 5.23 (q, J=7.0 fluoro Hz, 1H), 3.06 (s, 3H), 2.34-2.44 (m, (methylsulfonyl)p 2H), 2.15 (dd, J=6.3, 23 Hz, 2H), :Tenyl)ethyl)benza .75 (m, 2H), 1.54-1.64 (m, mide 426 3H), 1.51 (d, J=7.0 Hz, 3H) WO 66188 PCT/USZOl4/062913 Structure F 0 1H NMR (400 MHz, CD30D) 6 7.99 NHZ NAG 4-(3-amino—6- (s, 1H), 7.73-7.79 (m, 1H), 7.61 (dd, N/ (3,6-dihydro—2H- J=8.0, 1.4 Hz, 1H), 7.53 (dd, 427 \ 'N pyran 405.2 0.79 J=11.7, 1.2 Hz, 1H), 7.21-7.34 (m, y|)pyrazinyI)-N- 4H), 7.10-7.19 (m, 1H), 6.49 (br. s., \ benzyI 1H), 4.52 (s, 2H), 4.23 (d, J=2.7 Hz, fluorobenzamide 2H), 3.82 (t, J=5.5 Hz, 2H), 2.49 (d, J=1.6 Hz, 2H) 1H NMR (400 MHz, CD30D) 6 6.01 F 0 {OH (Sgtf'zm'nzolf' (s, 1H), 7.76 (t, J=7.6 Hz, 1H), 7.62 ' £1644? 428 . . . .
N\/ lN ”D m, , s, Edd’ffif'i’st‘?Hi’H‘fl’Sfi'SSf, m, 0'77 c1 {10fgiaz'n'2'yn'N'469'1 2H), 7.14-7.22 (m, 1H), 6.49 (br. s., 1H), 5.10 (t, J=5.9 Hz, 1H), 4.23 (d, chlorophenyl)_2_ \ J=2.7 Hz, 2H), 3.63 (t, J=5.5 Hz, hydroxyethyl)_2_ 2H), 3.76 (t, J=6.3 Hz, 2H), 2.50 (d, 0 fluorobenzamide J=2.0 Hz, 2H) (R)—4-(3-amino—6- 1H NMR (400 MHz, CD30D) 6 6.09 F O ihydro—2H- (s, 1H), 7.67 (s, 1H), 7.74-7.61 (m, F 1H), 7.66-7.73 (m, 1H), 7.59-7.67 NH2 N p);ran H y| pyrazinyI) 2- - (m, 2H), 7.56 (d,J=9.4 Hz, 1H), 429 Ag 515'1 0'75 1 fluoro—N-(1-(3- 6.59 (br. s., 1H), 5.33 (q,J=7.0 Hz, \ N O=f=o fluoro—5- 1H),4.32 (d, J=2.7 Hz, 2H), 3.92 (t, \ (methylsulfonyl)p J=5.5 Hz, 2H), 3.16 (s, 3H), 2.59 (d, henyl)ethyl)benza J=2.0 Hz, 2H), 1.61 (d, J=7.0 Hz, mide 3H) F 0 {OH ? 4-(3-amino—6- 1H NMR (400 MHz, CD30D) 6 NH2 ((1r,4S)—4-(2- 7.70-7.82 (m, 2H), 7.59 (dd, J=8.0, N/ methoxyacetamid 1.4 Hz, 1H), 7.53 (d, J=11.7 Hz, \ IN (:1 o)cyclohexyl)pyra 1H), 7.37 (s, 1H), 7.22-7.30 (m, 556 3 0 71 ziny|)-N-((S) ' ' 2H), .22 (m, 1H), 5.10 (t, (3-chlorophenyl)— J=5.9 Hz, 1H), .85 (m, 5H), 2-hydroxyethyl)— 3.32 (s, 3H), 2.52-2.65 (m, 1H), Hi 2- 1.91 , (d, J=11.3 Hz, 4H), 1.55-1.70 r0 fluorobenzamide (m, 2H), 1.33-1.48 (m, 2H) WO 66188 Structure 1H NMR (400 MHz, CD30D) 6 4-(3-amino 7.79-7.91 (m, 2H), 7.66 (dd, J=8.0, ((1r,4S)(3- 1.4 Hz, 1H), 7.62 (d, J=11.7 Hz, methoxypropana 1H), 7.46 (s, 1H), 7.33-7.40 (m, yclohexyl) 2H), 7.26-7.31 (m, 1H), 5.19 (t, pyrazin-Z-yI)-N- J=5.9 Hz, 1H), 3.60-3.92 (m, 2H), ((S)(3- 3.67-3.76 (m, 1H), 3.63 (t, J=6.1 chlorophenyI) Hz, 2H), 3.33 (s, 3H), 2.66 (t, hydroxyethyI) J=12.1 Hz, 1H), 2.41 (t, J=6.1 Hz, fluorobenzamide 2H), 2.01 (t, J=15.1 Hz, 4H), 1.62- 1.60 (m, 2H), 1.33-1.46 (m, 2H) 1H NMR (400 MHz, CD30D) 6 4-(6-((1s,4R) 7.75-7.63 (m, 2H), 7.56 (d, J=7.8 acetamidocycloh Hz, 1H), 7.54 (d, J=11.7 Hz, 1H), exyI) 7.37 (s, 1H), 7.23-7.31 (m, 2H), aminopyrazin-Z- 526.3 0.69 7.16-7.22 (m, 1H), 5.10 (t, J=5.9 y|)-N-((S)(3- Hz, 1H), 3.93 (d, J=3.5 Hz, 1H), chlorophenyI) 3.69-3.64 (m, 2H), 2.64-2.76 (m, hydroxyethyI) 1H), 1.66 (s, 3H), 1.76-1.65 (m, fluorobenzamide 2H), 1.66-1.77 (m, 4H), 1.55-1.67 (m, 2H) 4-(3-amino 1H NMR (400 MHz, CD30D) 6 ((1s,4R) 7.72-7.64 (m, 2H), 7.49-7.64 (m, (methylsulfonami 2H), 7.37 (s, 1H), 7.22-7.30 (m, do)cyclohexyl)pyr 562.3 0.72 2H), 7.15-7.22 (m, 1H), 5.04-5.15 -yI)-N-((S)- (m, 1H), 3.70-3.64 (m, 2H), 3.57 1-(3- (br. s., 1H), 2.66 (s, 3H), 2.62-2.76 chlorophenyI) (m, 1H), 1.76-1.96 (m, 4H), 1.55- yethyI) 1.75 (m, 4H) fluorobenzamide Structure methyl ((1R,4s)- 4-(5-amino(4- 1H NMR (400 MHz, CD30D) 5 7.81 (((S)(3- (s, 1H), 7.77 (t, J=7.6 Hz, 1H), 7.47- chlorophenyI) 7.63 (m, 2H), 7.37 (s, 1H), 7.22- yethyl)carb 542.3 0.76 7.31 (m, 2H), 7.12-7.22 (m, 1H), amoyI) 5.04-5.15 (m, 1H), 3.74-3.62 (m, fluorophenyl)pyra 2H), 3.71 (d, J=5.5 Hz, 1H), 3.53 (s, zin 3H), 2.62-2.74 (m, 1H), 1.53-1.92 y|)cyc|ohexyl)car (m, 8H) bamate (S)(3-amino-6— 1H NMR (400 MHz, CD30D) 6 (4,4- 7.79-7.92 (m, 2H), 7.66 (dd, J=8.0, difluorocyclohexyl 1.4 Hz, 1H), 7.56-7.65 (m, 1H), )pyrazin-Z-yI)-N- 505.2 0.87 7.46 (s, 1H), 7.32-7.40 (m, 2H), (1 -(3- .32 (m, 1H), 5.19 (t, J=5.9 chlorophenyI) Hz, 1H), 3.76-3.94 (m, 2H), 2.77- hydroxyethyI) 2.66 (m, 1H), 2.06-2.23 (m, 2H), fluorobenzamide 1.76-2.05 (m, 6H) 1H NMR (400 MHz, CD30D) 6 4-(3-amino 7.66-7.62 (m, 2H), 7.47-7.62 (m, S) 3H), 7.34 (dd, J=12.9, 7.6 Hz, 2H), hydroxycyclohexy 529.2 7.10-7.27 (m, 1H), 5.09 (t, J=5.7 |)pyrazinyI)-N- /531.
Hz, 1H), 3.69-3.60 (m, 2H), 3.44- ((S)(3- 3.57 (m, 1H), 2.50-2.62 (m, 1H), bromophenyI) 1.97 (d, J=9.8 Hz, 2H), 1.67 (d, hydroxyethyI) J=12.5 Hz, 2H), 1.46-1.66 (m, 2H), fluorobenzamide 1.21-1.41 (m, 2H) 4-(3-amino 1H NMR (400 MHz, CD30D) 6 ((1s,4R) 7.79-7.91 (m, 2H), 7.60-7.75 (m, hydroxycyclohexy 547.1 2H), 7.46 (s, 1H), 7.27 (d, J=8.2 Hz, 437 zinyI)-N- /549. 0.71 1H), 7.20 (d, J=9.4 Hz, 1H), 5.16 (d, ((S)(3-bromo- 1 J=5.1 Hz, 1H), 4.01 (br. s., 1H), -fluorophenyI) 3.66 (t, J=5.5 Hz, 2H), .60 hydroxyethyI) (m, 1H), 1.95-2.11 (m, 2H), 1.79- fluorobenzamide 1.92 (m, 2H), 1.61-1.76 (m, 4H) Structure (S)—4-(3-amino—6- (tetrahydro—ZH- 1H NMR (400MHz, DMSO-d6) 8 pyran 8.69 (m, 1 H), 7.92 (s,1 H), 7.78 - y|)pyrazin-2—yI)-N-471 .1 0.7 7.54 (m, 3 H), 7.45 (s,1 H), 7.44 - (1 -(3- 7.21 (m, 3 H), 6.13 (m, 1 H), 5.01 chlorophenyl)—2- (m, 1 H), 3.92 (m, 2 H), 3.65 (m, 2 hydroxyethyl)—2- H), 3.43 (m, 2 H), 1.74 (m, 4 H) fluorobenzamide 1H NMR (400 MHz, CD30D) 8 ppm 6-(2-amino—5- 1.59 - 1.80 (m, 4 H) 2.70 - 2.85 (m, (tetrahydro—ZH- 1 H) 2.98 (t, J=6.65 Hz, 2 H) 3.40 - pyran 3.54 (m, 4 H) 3.95 (dd, J=11.15, yl)pyridinyl)— 3.33 Hz, 2 H) 7.35 (s, 1 H) 7.36 - 3,4- 7.42 (m, 1 H) 7.68 (d, J=1.96 Hz, 1 dihydroisoquinoli H) 7.82 (d, J=2.35 Hz, 1 H) 7.99 (d, n-1(2H)—one J=7.83 Hz, 1 H) 4-(2—amino—5- ((1s,4R)—4- 1H NMR (400 MHz, CD30D) 8 ppm hydroxycyclohexy 7 7.75 - 7.86 (m, 2 H) 7.68 (d, dinyI)-N- 484.2 0.67 J=1.96 Hz, 1 H) 7.14 - 7.40 (m, 6 H) ((S)(3- 5.10 (t, J=5.87 Hz, 1 H) 3.95 (br. s., chlorophenyl)—2- 1 H)3.65 - 3.83 (m, 2 H) 2.34 - 2.65 hydroxyethyl)—2- (m, 1 H) 1.49-1.91 (m,8 H) fluorobenzamide Methyl ((1S,4r)—4- (5-amino—6-(4- 1H NMR (400 MHz, CD30D) 8 ppm (((S)—1-(3-bromo— 7.79 - 7.92 (m, 1 H) 7.57 - 7.71 (m, -fluorophenyl)—2— 1 H) 7.46 (s,1 H)7.14-7.31(m,2 441 hydroxyethyl)carb 606.1 0.83 H) 5.17 (t, J=5.87 Hz, 1 H) 3.83 - amoyl)—3- 3.98 (m, 2 H) 3.62 (s, 3 H) 3.39 - fluorophenyl)pyra 3.50 (m, 1 H) 2.65 (t, J=12.13 Hz, 1 zin H) .14 (m, 4 H) 1.61 - 1.79 y|)cyc|ohexyl)car (m, 2 H) 1.25 - 1.52 (m, 2 H). bamate WO 66188 Structure 1H NMR (400 MHz, CD30D) 8 ppm 4-(2-amino—5- 7.77 - 7.85 (m, 2 H) 7.69 (d, J=1.96 ((1r,4S)—4- Hz, 1 H) 7.18 - 7.38 (m, 6 H) 5.10 hydroxycyclohexy (t, J=5.87 Hz, 1 H) 3.70 - 3.86 (m, |)pyridinyI)-N- 484.2 0.63 2H) 3.45 - 3.60 (m, 1 H) 2.40 - 2.54 ((S)(3- (m, 1 H) 1.97 (d, J=9.78 Hz, 2 H) chlorophenyl)—2- 1.85 (d, J=12.52 Hz, 2 H) 1.40 - hydroxyethyl)—2- 1.57 (m, 2 H) 1.23 - 1.39 (m, 2 H) fluorobenzamide 1H NMR (400 MHz, CD30D) 8 ppm 4-(2-amino—5- 7.85 - 7.91 (m, 2 H) 7.81 (t, J=7.83 ((1r,4R)—4- Hz,1 H) 7.77 (d, J=1.96 Hz,1 H) hydroxycyclohexy 7.63 (d, J=7.83 Hz, 1 H) 7.55 |)pyridiny|)—2- (d,J=9.39 Hz, 1 H) 7.37 - 7.45 (m, 2 fluoro—N-((R)—1- H) 5.33 (q, J=7.04 Hz, 1 H) 3.54 - (3-fluoro—5- 3.74 (m, 1 H) 3.16 (s, 3 H) 2.48 - (methylsulfonyl)p 2.63 (m, 1 H) 2.06 (d, J=9.78 Hz, 2 henyl)ethy|)benza H) 1.94 (d, J=12.52 Hz, 2 H) 1.61 mide (d, J=7.43 Hz, 3 H) 1.49 - 1.58 (m, 2 H) 1.34- 1.48 (m, 2 H). 1H NMR (400 MHz, CD30D) 8 ppm (S)—4-(3-amino—6— 7.79 - 7.91 (m, 2 H) 7.58 - 7.71 (m, (4- 2 H) 7.46 (s,1 H) 7.24 - 7.40 (m, 3 (hydroxymethyl)c H) 5.19 (t, J=5.87 Hz, 1 H) 3.76 - yclohexyl)pyrazin 499.1 0.74 3.98 (m, 2 H) 3.41 (d, J=6.26 Hz, 2 -N-(1-(3- H) 2.56 -2.75 (m, 1 H) 1.88 - 2.14 single reomer; chlorophenyl)—2- (m, 4 H) 0.99 - 1.81 (m, 6 H) trans or cis hydroxyethyl)—2- fluorobenzamide (S)—4-(3-amino—6— 1H NMR (400 MHz, CD30D) 8 ppm 7.69 - 7.82 (m, 1 H) 7.50 - 7.62 (m, (hydroxymethyl)c 1 H) 7.37 (s,1 H)7.15-7.31 (m, 3 CI yclohexyl)pyrazin 499.1 0.75 H) 5.10 (t, J=5.87 Hz, 1 H) 3.68 - y|)-N-(1-(3- 3.86 (m, 2 H) 3.47 (d, J=7.04 Hz, 1 chlorophenyl)—2- 1 H) single diastereomer,‘ H) 2.74 (td, J=8.71,4.50 Hz, yethyl)—2- trans or cis 1.46- 1.97 (m, 11 H). fluorobenzamide Structure 1H NMR (400 MHz, CD30D) 8 ppm (S)—4-(3-amino—6— 7.79 - 7.91 (m, 2 H) 7.58 - 7.71 (m, 2 H) 7.46 (s,1 H) 7.24 - 7.40 (m, 3 (hydroxymethyl)c H) 5.19 (t, J=5.87 Hz, 1 H) 3.76 - yclohexyl)pyrazin 561/5 3.98 (m, 2 H) 3.41 (d, J=6.26 Hz, 2 y|)-N-(1-(3- H) 2.56 -2.75 (m, 1 H) 1.88 - 2.14 sing/e diastereomer; bromo—5- trans or ois (m, 4 H) 0.99 - 1.81 (m, 6 H) fluorophenyl)—2- hydroxyethyl)—2- fluorobenzamide (S)—4-(3-amino—6— (4- 1H NMR (400 MHz, CD30D) 8 ppm (hydroxymethyl)c 7.69 - 7.82 (m, 1 H) 7.50 - 7.62 (m, yclohexyl)pyrazin 561/5 1 H) 7.37 (s,1 H)7.15-7.31 (m, 3 -N-(1-(3- H) 5.10 (t, J=5.87 Hz, 1 H) 3.68 - sing/e diastereomer; bromo—5- 3.86 (m, 2 H) 3.47 (d, J=7.04 Hz, 1 trans or 01's fluorophenyl)—2- H) 2.74 (td, J=8.71,4.50 Hz, 1 H) hydroxyethyl)—2- 1.46- 1.97 (m, 11 H). fluorobenzamide 4-(3-amino—6— 1H NMR (400 MHz, CD30D) 8 ppm R)—4- 7.77 (t, J=7.63 Hz, 1 H) 7.72 (s, 1 fluorocyclohexyl) H) 7.50 - 7.63 (m, 2 H) 7.37 (s, 1 H) pyrazin-Z-yI)-N- 7.17 - 7.33 (m, 3 H) 5.10 (t, ((S)(3- J=5.87Hz,1 H) 3.65 - 3.85 (m, 2 H) phenyl)—2- 2.68 (t, J=11.74 Hz, 1 H) 1.96 - hydroxyethyl)—2- 2.13 (m, 2 H) 1.46 - 1.90 (m, 7 H). fluorobenzamide Structure F O :/OH 4-(3-amino—6- 1H NMR (400 MHz, CD30D) 5 ppm NH2 N H ((1r,4S) 7.80 - 7.90 (m, 2 H) 7.55 - 7.71 (m, N \ Dfluorocyclohexyl) 2 H) 7.46 (s, 1 H) 7.20 - 7.41 (m, 3 449 Kw CI pyrazinyI)-N- 487.2 0.88 H) 5.19 (t, J=5.87 Hz, 1 H) 4.42 - E ((S)(3- 4.71 (m, 1 H) 3.76 - 3.96 (m, 2 H) E? chlorophenyl)—2- 2.57 - 2.82 (m, 1 H) 2.19 (d, J=5.87 hydroxyethy|) Hz, 2 H) 2.00 (d, J=11.74 Hz, 2 H) fluorobenzamide 1.50 - 1.79 (m, 4 H) F 0 :/OH NHZ (0FN E:}'4'(3'am'"°'6'. 1H NMR (400 MHz, CD30D) 8 ppm 7.80 - 7.95 (m, 2 H) 7.59 - 7.72 (m, N) \ Cyan9°y°'°hexy') 556/5 2 H) 7.46 (s,1 H) 7.14 -7.30 (m, 2 450 ’N Br p1yraszg'2'yl)'5N' 0 85' 58.0 H) 5.17 (t, J=5.87 Hz, 1 H) 3.74 - 3.97 (m, 2 H) 3.14 (d, J=3.13 Hz, 1 trans/olsmlxture. . gu'érépLoemn:[)_é_ H) 2.67 - 2.85 (m, 1 H) 1.68 - 2.18 hydroxyethy|) (m, 9 H) CN fluorobenzamide F 0 :/OH .
NHZ N (3'am'"°'6' 1H NMR (400 MHz, CD30D) 8 ppm 7.80 — 7.95 (m, 2 H) 7.59 - 7.72 (m, I (U yclohexyl) 556/5 2 H) 7.46 (s,1 H) 7.14 -7.30 (m, 2 451 /N Br pyrazin_2_yl)_N_ 0.84 58.0 H) 5.17 (t, J=5.87 Hz, 1 H) 3.74 - (1_(3_br0m0_5_ 3.97 (m, 2 H) 3.14 (d, J=3.13 Hz, 1 trans/01s e. . fluorophenyl)_2_ H) 2.67 - 2.85 (m, 1 H) 1.68 - 2.18 hydroxyethy|) (m, 9 H) CN fluorobenzamide 1H NMR (400 MHz, CDch), 8 ppm 1.76 (s, 2 H) 2.15 (s, 3 H) 3.34 - 4-(3-amin0 3.57 (m, 3 H) 3.74 - 3.96 (m, 4 H) ((1S.SS) 4.39 (d, J=5.48 Hz, 2 H) 5.12 (d, F 0 (OH hydroxycycIOPent J=6.65Hz, 1 H) 7.22 (dd, J=9.78, F y|)pyraziny|) 1.96 Hz, 1 H) 7.48 (dd, J=8.22, 1.56 452 NH2 3 fluorO-N-((S) 581.0 0.73 Hz,1 H) 7.56- 7.72 (m, 4 H) 7.81 N’ (3-fluor0 (s, 1 H) 7.96 (t, J=7.82 Hz, 1 H) I RN | iodophenyI) 3 hydroxyethy|)ben ’0. zamide 2014/062913 Structure 1H NMR (400 MHz, CD3CN), 8 ppm mino—6- 1.56 - 1.82 (m, 2 H) 2.01 - 2.30 (m, ((1 R,3R)—3- 3 H) 3.47 (t, J=8.61 Hz, 1 H) 3.73- hydroxycyclopent 3.92 (m, 3 H) 4.32 - 4.45 (m, 2 H) y|)pyrazinyI) 5.05 - 5.19 (m, 1 H) 7.16 - 7.27 (m, fluoro—N-((S)—1 - 1 H) 7.48 (dt, J=8.12, 1.81 Hz, 1 H) (3-fluoro—5- 7.56 - 7.71 (m, 4 H) 7.74 - 7.81 (m, iodophenyl)—2- 1 H) 7.97 (t, J=7.83 Hz, 1 H hydroxyethyl)ben zamide 4-(3-amino—6- 1H NMR (400 MHz, CD3CN), 8 ppm ((1 R,38)—3- 1.65 - 1.91 (m, 4 H) 2.03 - 2.39 (m, hydroxycyclopent 3 H) 3.33 (t, J=7.24 Hz, 1 H) 3.70 - y|)pyrazinyI) 3.92 (m, 2 H) 4.30 (br. s.,1 H) 5.03 fluoro—N-((S)—1 - -5.19 (m, 2 H) 7.22 (d, J=9.78 Hz, 1 (3-fluoro—5- H) 7.40 - 7.71 (m, 5 H) 7.81 - 7.90 iodophenyl)—2- (m, 1 H) 7.97 (td, J=7.83, 1.96 Hz, hydroxyethyl)ben 1 H) zamide 4-(3-amino—6- 1H NMR (400 MHz, CD3CN) 8 ppm ((1S,3R)—3- 1.67 - 1.92 (m, 4 H) 2.02 - 2.17 (m, hydroxycyclopent 2 H) 2.22 - 2.43 (m, 1 H) 3.33 (t, y|)pyrazinyI) J=7.63 Hz, 1 H) 3.69 - 3.92 (m, 2 fluoro—N-((S)—1 - H)4.24 - 4.34 (m, 1 H) 5.03 - 5.18 (3-fluoro—5- (m, 3 H) 7.22 (dt, J=9.78, 1.96 Hz, iodophenyl)—2- 1 H) 7.44 - 7.53 (m, 1 H) 7.57 - 7.70 hydroxyethyl)ben (m, 4 H) 7.84 (s,1 H) 7.92 - 8.04 zamide (m, 1 H) mino—6- 1H NMR (400 MHz, DMSO), 8 ppm ((1S,4S)—3,3- 1.46 - 1.69 (m, 2 H) 1.71 - 2.26 (m, difluoro—4- 4 H) 2.79 - 3.02 (m, 1 H) 3.58 - 3.83 hydroxycyclohexy (m, 2 H) 4.94 - 5.15 (m, 2 H) 5.25 - |)pyrazinyI) 5.45 (m, 1 H) 6.11 - 6.26 (m, 1 H) fluoro—N-((S)—1 - 7.19 - 7.34 (m, 1 H) 7.46 - 7.56 (m, (3-fluoro—5- 1 H) 7.56 - 7.66 (m, 2 H) 7.66 - 7.77 iodophenyl)—2- (m,1 H) 7.95 (s,1 H) 8.66- 8.79 hydroxyethyl)ben (m, 1H) zamide 2014/062913 Structure 4-(3-amino—6- 1H NMR (400 MHz, DMSO), 6 ppm ((1R,4R)-3,3- 1.15- 1.30 (m, 1 H) 1.46- 1.69 (m, difluoro—4— 2 H) 1.72 - 2.25 (m, 5 H) 2.77 - 2.97 hydroxycyclohexy (m, 2 H) 3.57 - 3.64 (m, 3 H) 4.92 - |)pyrazinyI) 5.14 (m, 2 H) 5.27 - 5.42 (m, 1 H) fluoro—N-((S)—1 - 6.10 - 6.24 (m, 2 H) 7.16 - 7.34 (m, (3-fluoro—5- 1 H) 7.46 - 7.57 (m, 1 H) 7.57 - 7.67 iodophenyI) (m, 2 H) 7.67 - 7.77 (m, 1 H) 7.95 hydroxyethyl)ben (s,1H)8.63-8.80(m,1 H) zamide 4-(3-amino—6- 1H NMR (400 MHz, DMSO) 6 ppm S)-3,3- 1.56 (d, J=10.56 Hz, 2 H) 1.76 - difluoro—4— 1.94 (m, 2 H) 1.96 - 2.26 (m, 2 H) hydroxycyclohexy 2.63 (t, J=5.28 Hz, 3 H) 2.66 (br. s., |)pyrazinyI) 1 H)3.33 - 3.41 (m, 4 H) 3.66 (d, fluoro—N-((S)—1 - J=4.30 Hz, 3 H) 5.44 (d, J=7.82 Hz, (3-fluoro—5- 1 H) 6.07 - 6.30 (m, 2 H) 7.26 - 7.40 iodophenyI) (m, 1 H) 7.50 - 7.64 (m, 5 H) 7.97 aminoethyl (s, 1 H)6.45 - 6.70 (m, 2 H) 6.96 (d, )benzamide J=8.22 Hz, 1 H) 4-(3-amino—6- 1H NMR (400 MHz, CD3CN) 5 ppm F O {OH ((1R,4R)-3,3- 1.58 - 1.77 (m, 2 H) 1.85 - 2.12 (m, ? difluoro—4— 3 H) 2.27 - 2.37 (m, 1 H) 2.88 - 3.05 NH2 H/\©/N hydroxycyclohexy (m, 1 H) 3.40 (br. s., 2H) 3.70-3.94 459 I |)pyraziny|) (m, 3 H) 5.08 - 5.22 (m, 2 H) 7.21 585'0 0'73 \ N Br fluoro—N-((S)—1- (d, J=9.78 Hz, 1 H) 7.30 (d, J=8.61 (3-fluoro—5- Hz, 1 H) 7.46 (s, 1 H) 7.59 - 7.76 henyI) (m, 3 H) 7.86 - 8.00 (m, 2H). ; hydroxyethyl)ben 6H zamide 4-(3-amino—6- 1H NMR (400 MHz, CD3CN) 5 ppm F O {OH ((1S,4S)-3,3- 1.45 - 1.66 (m, 2 H) 1.71 - 1.87 (m, ? difluoro—4— 3 H) 1.87 - 1.97 (m, 2 H) 2.13 - 2.30 NH2 {UN hydroxycyclohexy (m, 2 H) 2.69 (t, J=11.35 Hz, 1 H) 460 I |)pyraziny|) 3.11 - 3.37 (m, 2 H) 3.61 - 3.83 (m, 585'0 0'73 \_ N Br fluoro—N-((S)—1- 3 H) 4.96 - 5.14 (m, 3 H) 7.10 (d, : (3-fluoro—5- J=9.78 Hz, 1 H) 7.20 (dt, J=8.31, bromophenyI) 1.71 Hz, 1 H) 7.36 (s, 1 H) 7.46 - hydroxyethyl)ben 7.64 (m, 3 H) 7.78 - 7.92 (m, 2 H) OH zamide Structure 4-(3-amino—6- ((1R,3R,4R)—3,4- oxycyclohe 1H NMR (400 MHz, CD30D) 8 ppm xyl)pyrazinyl)— 1.35- 1.55 (m, 1 H) 1.57 - 1.74 (m, 2-fluoro—N-((S)—1 - 2 H) 1.84 - 1.98 (m, 1 H) 1.98 - 2.23 (3-fluoro—5- (m, 2 H) 2.72-2.91 (m, 1 H) 3.34- iodophenyl)—2- 3.54 (m, 3 H) 3.74 - 3.93 (m, 2 H) hydroxyethyl)ben 5.06 - 5.23 (m, 1 H) 7.10 - 7.30 (m, zamide 1 H) 7.36- 7.52 (m,1 H) 7.64 (s, 3 H) 7.78 - 7.95 (m, 2 H) 4-(3-amino—6- ((1R,3R,4S)—3,4- dihydroxycyclohe 1H NMR (400 MHz, CD30D) 8 ppm xyl)pyrazinyl)— 1.53 - 1.75 (m, 2 H) 1.78 - 2.09 (m, 2-fluoro—N-((S)—1 - 5 H) 2.71 - 2.89 (m, 1 H) 3.64 - 3.77 (3-fluoro—5- (m, 1 H) 3.84 (s, 2 H) 3.91 - 4.04(m, iodophenyl)—2- 1 H) 5.06 - 5.23 (m, 1 H) 7.10 - 7.27 hydroxyethyl)ben (m,1 H) 7.36- 7.51 (m, 1 H) 7.57- zamide 7.74 (m, 3 H) 7.84 (s, 2 H) 4-(3-amino—6- ((1S,SS,4S)-3,4- dihydroxycyclohe 1H NMR (400 MHz, CD30D) 8 ppm razinyl)— 1.37 - 1.73 (m, 4 H) 1.83 - 1.96 (m, 2-fluoro—N-((S) 611.1 0.67 1 H) 1.98-2.21 (m, 2 H) 2.71 -2.91 (3-fluoro—5- (m, 1 H) 3.34 - 3.55 (m, 3 H) 3.85(s, iodophenyl)—2- 2 H) 5.05 - 5.26 (m, 1 H) 7.08 - 7.28 hydroxyethyl)ben (m,1 H) 7.34- 7.51 (m, 1 H) 7.64 zamide (s, 3 H) 7.84 (s, 2 H) 4-(3-amino—6- 1H NMR (400 MHz, DMSO) 8 ppm ((1S,38,4R)—3,4- 0.72 - 0.91 (m, 2 H) 0.96 - 1.25 (m, dihydroxycyclohe 5 H) 1.89 - 2.05 (m, 1 H) 2.81 - 2.95 xyl)pyrazinyl)— (m, 1 H) 3.03 (s, 2 H) 3.09 - 3.21 2-fluoro—N-((S)—1 - (m,1 H)4.25 -4.42 (m, 1 H) 6.30 - 464 (3-fluoro—5- 611.1 0.67 6.47 (m, 1 H) 6.55 - 6.69 (m, 1 H) enyl)—2- 6.77 - 6.94 (m, 3 H) 7.03 (s, 2 H) hydroxyethyl)ben zamide Structure 4-(3-amino—6- 1H NMR (400 MHz, CD3CN) 8 ppm ((1R,3R,4R)—3,4- 1.19 - 1.59 (m, 3 H) 1.68 - 2.07 (m, dihydroxycyclohe 4 H) 3.13 - 3.39 (m, 4 H) 3.62 - 3.88 xyl)pyrazinyl)— (m, 3 H)4.95-5.14(m,1 H) 7.10 2-fluoro—N-((S)—1 - (d, J=9.78 Hz, 1 H) 7.20 (dt, ro—5- J=8.31, 1.91 Hz, 1 H) 7.29- 7.74 henyl)—2- (m, 5 H) 7.86 (t, J=8.02 Hz, 1 H) hydroxyethyl)ben zamide 4-(3-amino—6- 1H NMR (400 MHz, CD3CN) 8 ppm ((1S,38,4R)—3,4- 1.42 - 1.95 (m, 7 H) 3.48 - 3.86 (m, dihydroxycyclohe 5 H)4.97-5.12 (m, 1 H) 7.10 (d, xyl)pyrazinyl)— J=9.78 Hz, 1 H) 7.20 (d,J=8.22 Hz, 2-fluoro—N-((S)—1 - 1 H) 7.36 (s,1 H) 7.44 -7.60 (m, 3 (3-fluoro—5- H) 7.68 (d, J=5.09 Hz, 1 H) 7.86 (t, bromophenyl)—2- J=7.83 Hz, 1 H) hydroxyethyl)ben zamide 4-(3-amino—6- 1H NMR (400 MHz, CD3CN) 8 ppm ((1S,SS,4S)-3,4- 1.19 - 1.58 (m, 4 H) 1.69 - 2.08 (m, dihydroxycyclohe 5 H) 2.65 - 2.79 (m, 5 H) 3.12 - 3.36 xyl)pyrazinyl)— (m, 5 H) 3.63 - 3.87 (m,3 H) 4.94 - 2-fluoro—N-((S)—1 - 5.14 (m, 1 H) 7.10 (d, J=9.39 Hz, 1 (3-fluoro—5- H) 7.15- 7.26 (m, 1 H) 7.36 (s, 1 H) bromophenyl)—2- 7.42 - 7.70 (m, 3 H) 7.79 - 7.95 (m, hydroxyethyl)ben 1 H) zamide mino—6- 1H NMR (400 MHz, CD3CN) 8 ppm ((1R,3R,4S)—3,4- 1.49 - 2.02 (m, 7 H) 3.55 - 3.94 (m, dihydroxycyclohe 4 H) 5.04 - 5.26 (m, 1 H) 7.21 (d, xyl)pyrazinyl)— J=9.00 Hz, 1 H) 7.30 (d,J=7.83 Hz, 2-fluoro—N-((S)—1 - 1 H) 7.46 (s,1 H) 7.54 -8.03 (m,4 (3-fluoro—5- H) bromophenyl)—2- hydroxyethyl)ben zamide Structure 4-(3-amino—6— 1H NMR (400 MHz, CD3CN) 8 ppm ((1S,38,4S)—3- 1.18- 1.35 (m, 2 H) 1.49 - 1.68 (m, hydroxy,4- 3 H) 1.86 - 2.00 (m, 5 H) 2.04 - 2.15 methoxylcyclohex (m, 3 H) 2.17 - 2.25 (m,3 H) 2.72 - y|)pyrazinyI) 2.89 (m, 2 H) 2.94 - 3.08 (m, 2 H) fluoro—N-((S)—1 - 3.41 (d, J=1.17 Hz, 3 H) 3.46 - 3.60 (3-fluoro—5- (m, 1 H) 3.72 - 3.91 (m, 2 H) 4.01 - bromophenyl)—2- 4.14 (m, 1 H) 4.70 (t, J=8.22Hz, 1 hydroxyethyl)ben H) 5.03 - 5.24 (m, 2 H) 7.14 - 7.26 zamide (m,1 H) 7.27- 7.35 (m, 1 H) 7.47 (s, 1 H) 7.56 - 7.74 (m, 2 H) 7.82 - 8.03 (m, 2 H) 4-(3-amino—6— 1H NMR (400 MHz, CD30D) 8 ppm R)—4,4- 1.16- 1.28 (m, 1 H) 1.75 - 1.98 (m, difluoro—S- 4 H) 2.07 - 2.28 (m, 2 H) 2.83 - 3.06 ycyclohexy (m, 2 H) 3.86 (s, 3 H) 4.03 - 4.19(m, |)pyrazinyI)-N- 521.1 0.76 1 H) 5.11 -5.27 (m, 1 H) 7.21 - 7.32 ((S)(3- (m, 1 H) 7.35 (d, J=6.26 Hz, 2 H) chlorophenyl)—2- 7.42 - 7.49 (m, 1 H) 7.57 - 7.65 (m, hydroxyethyl)—2- 1 H) 7.66 - 7.73 (m, 1 H) 7.79 - 7.88 enzamide (m,1 H) 7.90 (s,1 H) 4-(3-amino—6— 1H NMR (400 MHz, CD30D) 8 ppm ((1R,3R)-4,4- 1.07 - 1.37 (m, 3 H) 1.74 - 2.12 (m, difluoro—S- 6 H) 2.12 - 2.41 (m, 3 H) 3.04 - 3.24 hydroxycyclohexy (m, 3 H) 3.75 - 3.90 (m, 2 H) 3.92 - |)pyrazinyI)-N- 521.1 0.76 4.05 (m, 2 H) 5.10 - 5.27 (m, 2 H) ((S)(3- 7.35 (d, J=6.65 Hz, 3 H) 7.40 - 7.52 chlorophenyl)—2- (m, 1 H) 7.56 - 7.75 (m, 2 H) 7.78 - hydroxyethyl)—2- 7.99 (m, 2 H) fluorobenzamide 4-(3-amino—6— 1H NMR (400 MHz, CD30D) 8 ppm ((1R,38)—4,4- 1.23 (s, 2 H) 1.71 - 2.04 (m, 5 H) difluoro—S- 2.06 - 2.24 (m, 2 H) 2.26 - 2.46 (m, hydroxycyclohexy 1 H) 2.82 - 3.05 (m, 2 H) 3.86 (t, 472 zinyI)-N- 521.1 0.76 J=5.67Hz, 3 H) 4.01 - 4.18 (m, 1 H) ((S)(3- 5.19 (s, 2 H) 7.18 - 7.41 (m, 3 H) chlorophenyl)—2- 7.46 (s, 1 H) 7.70 (d, J=0.78 Hz, 2 hydroxyethyl)—2- H) 7.77 - 7.99 (m, 2 H) fluorobenzamide 1H NMR (500 MHz, (S)—4-(3-amino—6- (morpholine—4- ACETONITRILE-dS) 5 ppm 3.56 - carbonyl)pyrazin- 3.99 (m, 13 H) 5.06 - 5.23 (m, 1 H) .78 - 6.13 (m, 2 H) 7.22 (d, J=8.20 2-yl)—N-(1-(3- Hz, 1 H) 7.27 -7.36 (m, 1 H) 7.41 bromo—5- - fluorophenyl)—2- 7.79 (m, 5 H) 7.89 - 8.05 (m, 1 H) 8.25 - 8.43 (m, 1 H) hydroxyethyl)—2- fluorobenzamide 1H NMR (500 MHz, (S)—4-(2-amino—5- ACETONITRILE-dS) 5 ppm 3.49 - (morpholine—4- 3.74 (m, 7 H) 3.77 - 3.94 (m, 2 H) carbonyl)pyridin- 5.15 (br. s., 1 H) 7.15 -7.52 (m, 5 3-y|)-N-(1-(3- H) 7.62 - 7.83 (m, 2H) 7.92 - 8.07 - (m, 2 H) fluorophenyl)—2- hydroxyethyl)—2- fluorobenzamide 1H NMR (500 MHz, (S)—4-(3-amino—6- ACETONITRILE-dS) 5 ppm 1.12 - 1.36 (m, 2 H) 1.60 - 1.87 (m, 4 H) (hydroxymethy|)pi 2.71 - 2.92 (m, 2 H) 2.98 - 3.22 (m, peridine—1 - 1 H) 3.39 (d, J=5.99 Hz, 2 H) 3.85 carbonyl)pyrazin- (dd, J=18.29, 5.36 Hz, 2 H) 4.12 - 2-yl)—N-(1-(3- 4.36 (m, 1 H) 4.48 -4.68 (m, 1 H) bromo—5- .04 - 5.25 (m, 1 H) 5.58 - 5.82 (m, fluorophenyl)—2- 2 H) 7.15 - 7.26 (m, 1 H) 7.31 (s,1 hydroxyethyl)—2- fluorobenzamide H) 7.47 (s,1 H) 7.54 - 7.73 (m, 3 H) 7.97 (s, 1 H) 8.23- 8.38 (m, 1 H) 1H NMR (500 MHz, (S)—4-(3-amino—6- ITRILE-dS) 5 ppm 3.74 - (3- 3.99 (m, 3 H) 4.25 - 4.44 (m, 2 H) hydroxyazetidine— 4.58 (ddd, , 4.10, 2.52 Hz, 1 1- H) 4.81 (d, J=7.25Hz, 1 H) 5.16 (d, carbonyl)pyrazin- 476 549.9 0.66 J=5.04 Hz, 1 H) 5.89 (br. s., 2 H) 2-yl)—N-(1-(3- 7.22 (d, J=9.77 Hz, 1 H) 7.32 (dt, bromo—5- J=8.20, 2.05 Hz, 1 H) 7.48 (d, fluorophenyl)—2- J=1.26 Hz, 1 H) 7.58 - 7.77 (m, hydroxyethyl)—2- fluorobenzamide 3 H) 7.91 - 8.05 (m, 1 H) 8.49 - 8.74 (m.1 H) (S)—4-(2—amino—5- 1H NMR (500 MHZ. (4- ACETONITRILE-dS) 6 ppm 1.32 - hydroxypiperidine 1-57 (m, 2 H) 1-74 ' 1-39 (m, 3 H) 3.29 (ddd, J=13.16, 9.54, 3.15 HZ, carbonyl)pyridin- 2 H) 3.73 - 3.91 (m, 3H) 3.91 - 4.17 3-yl)—N-(1-(3- (m, 1 H) 5.15 (d, J=5.67 Hz, 1 H) bromo—5- 7.12 - 7.52 (m, 4 H) 7.68 (br. s., 1 heny|)_2_ H) 7.80 (d, J=1.89 Hz, 1 H) 7.91 - hydroxyethyl)—2— 8-08 (m, 2 H) fluorobenzamide Example 453 S nthesis of 4- 3-amino 1R 3R h drox 0 do ent | razin-2— Ifluoro-N- S 3-fluoroiodo hen Ih drox eth Ibenzamide F O F O NH2 0J< Pd (tri-t-butyl-Ph)2 TBAC N \ N \ —’ + | RFNI / N-cyclohexyl-N—methyl cyclohexanamine Br 40% F o J< F o F o J< J< m2 0 NH2 0 Step 3 NH2 0 NH2 H2 N \ NaBH4 NI \ NI \ | /N /N Pd/C, MeOH 100% 58.1 % OH "OH O (+/-) (+/.) F o 0 NH2 0 _eE_St 5 NH2 OH Ste § _l25te A N \ nane NI \ Amide coupling —.I —> /N ,N —. 100 A’D 45% Chiral separation -.,0H 6H F O {OH WN/OH: F :I /;N | Step 1. tert-butyl 4-(3-amino(3-oxocyclopentenyl)pyrazinyl)—2-fluorobenzoate: A mixture of tert—butyl minobromopyrazinyl)fluorobenzoate (1 g, 2.72 mmol), cyclopent—2-enone (0.892 g, 10.86 mmol), N-cyclohexyl-N- methylcyclohexanamine (1.061 g, 5.43 mmol), i-t—butylphosphine)palladium(0) (0.069 g, 0.136 mmol), TBAC (0.075 g, 0.272 mmol) in dioxane (7 mL) was microwaved at 1350C for 25 min. After cooling, the mixture was concentrated and the residue was diluted with 10 ml of DCM, sonicated for 5 min, ed and the solid was washed with 3ml of DCM. The combined DCM solution was directly applied for ISCO silica column separation. (40 gram column, 10 to 90% EtOAc in Heptane). 400 mg of the desired product was obtained as a light yellow solid. LCMS (m/z): (MH+) 370.0, 0.903 min. 1H NMR (400 MHz, DMSO) 6 ppm 1.12 - 1.26 (m, 5 H) 1.55 (s, 10 H) 1.59 - 1.72 (m, 5 H) 2.41 (dt, J=5.09, 2.15 Hz, 3 H) 2.48 (dt, J=3.62, 1.91Hz, 3 H) 3.00 (dd, J=5.09, 2.35 Hz, 2 H) 3.30 (s, 3 H)6.66 (t, J=1.76 Hz, 1 H)7.09 (s, H) 7.55-7.69 (m, H)7.83-7.95 (m, 1 H) 8.57 (s, 1 H).
Step 2: tert-butyl 4-(3-amino(3-oxocyclopentyl)pyrazinyl)fluorobenzoate: To tertbutyl mino(3-oxocyclopent—1-enyl)pyrazinyl)fluorobenzoate (650 mg, 1.760 mmol) in MeOH (15 ml) was added 15 ml of DCM under stirring until a clear solution was obtained. The solution was purged by nitrogen for 5 min, then Pd/C (300 mg, 10%, Degussa type) was added, and the resultant mixture was degassed by N2 stream for 15 min. After equipped with en gas balloon, the reaction mixture was stirred at room temperature for 16 h. The on mixture was filtered, and the ted solution was concentrated, and the crude material was purified by ISCO. (24 g silica gel, to 80% EtOAc in heptane) to afford 380 mg of the desired product as a light yellow solid. 58.1 % yield. LC-MS (m/z): (MH+) 372.1, 0.829 min.
Step 3: (+/-) tert-butyl 4-(3-amino((1R,3R)—3-hydroxycyclopentyl)pyrazinyl) fluorobenzoate and (+/-)tert-butyl 4-(3-amino((1R,3S)hydroxycyclopentyl)pyrazin f|uorobenzoate: To a on of tert-butyl 4-(3-amino(3-oxocyclopentyl)pyrazin- 2-yl)fluorobenzoate (200 mg, 0.538 mmol) in MeOH ( 4 mL) at -780C was added NaBH4 (61.1 mg, 1.615 mmol). The reaction mixture was stirred at -78 °C for 1 hr - . At 780C, the reaction mixture was quenched with sat NH4C| ( 4 ml), and the cooling bath was removed, and the mixture was gradually warmed to RT, then sat NaHC03 solution ( 4 ml) was added. The reaction mixture was extracted with EtOAc ( 30 ml x2). The c layer was washed with water and brine, dried over sodium sulfate, filtered off and concentrated in vacuo. About 210 mg of the crude product was obtained. The crude product was dissolved into 4 ml of DMSO, filtered and purified by prep HPLC. The more polar compound is trans ( desired, came out earlier), the less polar compound is cis, came out later. After netrilized with 1N NaOH, tran and cis compound were obtained as free base compounds. (+/-) tert-butyl 4-(3-amino((1R,3R)—3-hydroxycyclopentyl)pyraziny|)fluorobenzoate : 40 mg, 19.9 % , trans. LC-MS (m/z): (MH+) 374.1, 0.81 min, NMR (400 MHz, CD3CN) 6 ppm 1.61 (s, 9 H) 1.69 - 1.82 (m, 1 H) 1.88 - 2.25 (m, 6 H) 2.59 - 2.77 (m, 1 H) 3.32 - 3.56 (m, 1 H) 4.31 - 4.48(m, 1 H) 5.07 (br. s., 2 H) 7.59 (dd, J=12.13, 1.56 Hz, 1 H) 7.66 (dd, J=8.02, 1.76 Hz, 1 H) 7.88 - 8.03 (m, 2 H). (+/-) tert-butyl 4-(3-amino((1R,3R)—3-hydroxycyclopentyl)pyrazinyl)fluorobenzoate : 150 mg, 74.6 % yield, cis. LC-MS (m/z): (MH+) 374.1, 0.81 min. 1H NMR (400 MHz, CD3CN) 6 ppm: 1.55 - 1.67 (m, 9 H) 1.69 - 1.89 (m, 2 H) 1.91 - 2.03 (m, 4 H) 2.05 - 2.13 (m, 1 H) 2.21 -2.33 (m, 1 H) 3.21 -3.41 (m, 1 H) 3.99 (s, 1 H)4.20 -4.34 (m, 1 H) 5.04 - .23 (m, 2 H) 7.50 - 7.58 (m, 1 H) 7.58 - 7.67 (m, 1 H) 7.90 - 8.05 (m, 2 H). fluorobenzoate: The two trans isomers (160 mg total) were separated by chiral column: OJ column (21 X250 mm), SFC = 100 ml/min, CO2/EtOH = 85/15, loading: 70 mg/7ml EtOH, 274 bar. 80 mg of each enantiomer was ed. tert-butyl 4-(3-amino((1R,3R)—3-hydroxycyclopentyl)pyrazinyl)fluorobenzoate: NMR (400 MHz, DMSO) 6 ppm: 1.04 (t, J=6.85 Hz, 1 H) 1.47 - 1.73 (m, 11 H) 1.75 - 1.86 (m, 2 H) 1.89 - 2.18 (m, 2 H) 3.15 (s, 1 H) 3.30 (s, 4H) 3.97 - 4.16 (m, 1 H) 4.19 - 4.39 (m, 1 H) 4.44 - 4.59 (m, 1 H) 6.10 (s, 2 H) 7.57 (d, J=12.13 Hz, 1 H) 7.63 (dd, J=8.02, 1.76 Hz, 1 H) 7.77 - 8.01 (m, 2 H). tert-butyl 4-(3-amino((1S,3S)hydroxycyclopentyl)pyrazinyl)fluorobenzoate: NMR (400 MHz, DMSO) 6 ppm: 1.04 (t, J=6.85 Hz, 1 H) 1.14 - 1.28 (m, 1 H) 1.50 - 1.57 (m, 10 H) 1.59 - 1.71 (m, 1 H) 1.75 - 1.87 (m, 2 H)1.89 - 2.14 (m, 2 H) 3.15 (s, 1 H) 3.30 (s, 4 H) 4.18 - 4.37 (m, 1 H) 4.42 - 4.55 (m, 1 H) 6.10 (s, 2 H) 7.51 - 7.60 (m, 1 H) 7.63 (dd, J=8.02, 1.76 Hz,1 H) 7.81 - 7.95 (m, 2 H).
Step 5. mino((1R,3R)—3-hydroxycyclopentyl)pyrazinyl)fluorobenzoic acid Procedure: To a solution of tert-butyl 4-(3-amino((1R,3R)—3-hydroxycyclopentyl)- pyrazinyl)fluorobenzoate (7 mg, 0.019 mmol) in DCM (2 mL) at RT was added TFA (0.361 mL, 4.69 mmol). The resultant solution was stirred at RT for 2 h. The solution was concentrated, and further dried by high vacumm to afford the d product as a TFA slat, which was used at the next step directly. (6 mg, 100 % yield) LC-MS (m/z): 318.1 (MH+), 0.46 min.
Step 6: 4-(3-amino((1R,3R)—3-hydroxycyclopentyl)pyrazinyl)fluoro-N-((S)—1-(3- fluoroiodophenyl)hydroxyethyl)benzamide: To a mixture of (4-(3-amino((1R,3R)— 3-hydroxycyclopentyl)pyrazinyl)fluorobenzoic acid) ( 6 mg, 0.019 mmol), (S)—2- amino(3-fluoroiodophenyl)ethanol (8.96 mg, 0.028 mmol), HOAt (5.15 mg, 0.038 mmol) and EDC (7.25 mg, 0.038 mmol) in DMF (1ml) was added DIEA (0.036 ml, 0.208 mmol). The resultant e was stirred over night at RT. The mixture was diluted with EtOAc, washed with water three times and brine, dried with , filtered and concentrated to afford the crude product as a light yellow viscous liquid. This crude was purified by prep HPLC to afford desired product (6 mg, 45.2 % yield) as a light yellow solid, a TFA salt. LC-MS: (MH+) 581.0 at 0.726 min. 1H NMR (400 MHz, CD3CN) 6 ppm 1.56 - 1.82 (m, 2 H) 2.01 - 2.30 (m, 3 H) 3.47 (t, J=8.61 Hz, 1 H) 3.73 - 3.92 (m, 3 H) 4.32 -4.45 (m, 2 H) 5.05 - 5.19 (m, 1 H) 7.16 - 7.27 (m, 1 H) 7.48 (dt, J=8.12, 1.81 Hz, 1 H) 7.56 - 7.71 (m, 4 H) 7.74 - 7.81 (m, 1 H) 7.97 (t, J=7.83 Hz, 1 H).
Example 456 F O J< F O J< OTf N/ / O N tnfluoromethanesulfomc 013/0 \ lN step 2 anhydride \ N step4 —’ —’ Br O —> —>a77A) O step1 52% step3, 51% two steps F O F O Bno \ ,Bcc J< BeeNBocwk film1 Boo\ 800 N 0 0 N OOJ< N/ / N’ | XtalFlour-E step5 \ N —. \ N Pd-C, H2 : step7 87% 41% Gig—0 0 step 6,41% IN T, O ...\ I 2mg \i 2[\z N / TFA / DCM | I \z _Im 12 N r 2 \ N —’ _< step 8, 100% step 9, 89% F FF BZF OBZ step 10,100% NWNiEP/F —> K/N step 11 chiral separation Step 1: 3-oxocyclohexenyl trifluoromethanesulfonate: To a solution of cyclohexane- 1,3-dione (8 g, 71.3 mmol) in CH2C|2 ( 120 ml) at 00C ( ice water bath) under nitrogen was added sodium carbonate (8.32 g, 78 mmol). The resultant mixture was stirred at 00C for min. A on of trifluoromethanesulfonic anhydride (12.05 mi, 71.3 mmol) in 35 ml of DCM was added dropwise over 1h . The mixture was d at 00C for 1.5 h. The mixture was ed through fritted glass , and 60 ml of saturated NaHC03 was added . Organic layer was then separated and washed with 40ml of brine, dried over NazSO4, filtered and concentrated to e 9 g ( 52 % yield) ofdesired product as a light yellow liquid. LC-MS (m/z): (MH+) 244.9, 0.72 min.
Step 2: 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)cyclohexenone, (3-oxocyclohex— 1-enyl)boronic acid: A mixture of 3-oxocyclohexenyl trifluoromethanesulfonate (9 g, 36.9 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (14.04 g, 55.3 mmol), potassium acetate (10.85 g, 111 mmol) and Pd(dppf)Cl2.DCM (0.808 g, 1.106 mmol) in dioxane (80 mL) was flushed with nitrogen for 5 min and then heated at 90 °C overnight. After cooling, the mixture was filtered, and the solid was washed with 3x20mL warm dioxane. The combined solution was concentrated until about 70 ml of dioxan was left. This product ( in dioxane) was used directly at the next step. LCMS ( m/z): MH+=140.8 (Boronic acid), 0.284 min.
Step 3: Tert-butyl 4-(3-amino(3-oxocyclohexenyl)pyrazinyl)fluorobenzoate: A 250 ml RB was charged with 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)cyclohex enone (7.00 g, 31.5 mmol) ( in about 70 ml e), tert-butyl 4-(3-amino bromopyrazinyl)f|uorobenzoate (5.8 g, 15.75 mmol)), Pd(dppf)C|2.DCM (0.576 g, 0.788 mmol), and then Saturated Na2C03 (25 mL). The resultant e was flushed with nitrogen for 15min. DME (10 mL) was then added. The e was stirred at 1000C overnight. Ethyl acetate ( 150 ml) and water( 50 ml) were added, and the resultant mixture was stirred for 30 min. Organics was separated and the aqueous layer was extracted with ethyl acetate ( 30 ml x3). Organic layers were combined and dried over NazSO4, filtered and ated to provide crude desired material as a sticky dark color semi solid. This solid was taken to about 30 ml of ether, sonicated for 10 min, and the precipitaed yellow solid was filtered, and washed with cold ether( 5m| x3), dried under high vacumm to afford the desired product (3.1 g 51.3% , ) as a yellow solid. LC-MS (m/z): (MH+) 384.2, 0.92 min.
Step 4: tert-butyl 4-(3-(bis(tert-butoxycarbonyl)amino)(3-oxocyclohexen y|)pyrazinyl)fluorobenzoate: To a sion of tert-butyl 4-(3-amino(3- oxocyclohex—1-enyl)pyraziny|)fluorobenzoate (3 g, 7.82 mmol) in itrile ( 25 mL) at RT was added DMAP (0.048 g, 0.391 mmol) followed by Boc—anhydride (6.36 mL, 27.4 mmol). The resultant mixture was stirred at RT for 25 min. The solution was diluted with EtOAc, washed with sat NaHC03 and water, dried and concentrated. The crude product was purified by ISCO separation ( 80 g silica, 30 min, 5 to 60% EtOAc in Heptane). The desired product was obtained as a light yellow sticky liquid, which solidified upon standing over night. (3.5 g, 6.00 mmol, 77 % yield). LC-MS ( m/z): (MH+) 584.2, 1.286 min. 1H NMR (400 MHz, ACETONITRILE-d3) 5 ppm 0.91 (s, 1 H) 1.31 (s, 16 H) 1.61 (s, 7 H) 1.88 - 2.03 (m, 1 H) 2.16 (s, 2 H) 2.50 (d, J=7.04 Hz, 2H) 2.85 - 3.09 (m, 2 H) 6.90 (s, 1 H) 7.51 - 7.71 (m, 2 H) 7.91 - 8.11 (m, 1 H) 8.92 (s, 1 H).
Step 5: tert-butyl 4-(3-(bis—(tert-butoxycarbonyl)amino)(3-oxocyclohexyl)pyraziny|)- 2-fluorobenzoate: To a solution of tert-butyl 4-(3-(bis(tert-butoxycarbonyl)amino)(3- oxocyclohex—1-enyl)pyraziny|)fluorobenzoate (3g, 5.14 mmol) in MeOH (15 mL) and DCM (10 mL) at RT was added Pd-C (10%, degauss, 1.094 g, 1.028 mmol). The resultant mixture was d with hydrogen for 10 min, then stirred at RT for 5 hours under hydrogen atmosphere. The suspension was filtered and the solution was concentrated. ISCO silica column separation ( 80 g silica, 30 min, 5 to 60% EtOAc in Heptane) afforded the desired product as a light yellow sticky liquid, which solidified upon ng over night. (1.485 g, 2.54 mmol, 49.3 % yield). LC-MS (m/z): (MH+) 586.3, 1.17 min.
Step 6: tert-butyl (1S,4S)—4-(benzoyloxy)—3-oxocyclohexyl)(bis(tertbutoxycarbonyl )amino)pyrazinyl)fluorobenzoate and tert-butyl 4-(6-((1R,4R) (benzoyloxy)—3-oxocyclohexyl)(bis(tert-butoxycarbonyl)amino)pyrazinyl)—2- fluorobenzoate: A: Prep of the free base catalyst: 300 mg of -methoxyquinolin y|)((1S,2R,4S,5R)vinquuinuclidinyl)methanamine ( tri.HCl salt) was dissolved into ml of DCM, then neutrilzed with 1N NaOH (5 ml), the organic layer was ted, washed with brine ( 5ml x2) and water( 5ml x2), dried, filtered and concentrated to afford the product as a free base. (200 mg free base amine in 4 ml of dioxane).
B: A 10 mL microwave vial, equipped with a magnetic stirring bar, was charged with tert- butyl 4-(3-(bis-(tert-butoxycarbonyl)amino)(3-oxocyclohexy|)pyraziny|) fluorobenzoate (1.485 g, 2.54 mmol), BHT (Butylated hydroxyltoluene, 0.067 g, 0.304 mmol), (S)—(6-methoxyquinolinyl)((1S,2R,4S,5R)—5-vinquuinuclidinyl)methanamine (0.098 g, 0.304 mmol) ( in 2 ml of Dioxane) and trichloroacetic acid (0.050 g, 0.304 mmol). Dioxane ( 1ml) was then added, and the resultnat mixture was stirred for 5 min before benzoic peroxyanhydride (0.983 g, 4.06 mmol) was added. The reaction mixture was stirred at 30 °C for 16 h. The reaction mixture was diluted with dichloromethane, treated with a saturated aqueous on of , washed with brine, dried over Na2804, filtered, concentrated to approx. 3 ml of DCM. The crude ( in 3 ml of DCM) was purified by ISCO flash column chromatography eluting with a EtOAc in Heptane ( 10 to 45% EtOAc in Heptane, 120 g silica gel column, 35 min). The enantioselectivity could not be ined at this stage by chiral-phase HPLC analysis. No separations were observed by all the columns/methods available. This product was directly used in the next step reaction. (730 mg, 40.8 % yield) LC-MS (m/z): (MH+) 706.3 at 1.38 min. 1H NMR (400 MHz, CDCI3) 6 ppm 1.26 - 1.41 (m, 19 H) 1.46 - 1.67 (m, 11 H) 2.08 - 2.22 (m, 1 H) 2.26 - 2.42 (m, 2 H) 2.50 - 2.67 (m, 1 H) 2.70- 2.91 (m, 1 H) 3.08 (s, 1 H) 3.26 - 3.49 (m, 1 H) 4.03 - 4.19 (m, 1 H) 5.49 - 5.67 (m, 1 H) 7.26 (d, J=0.78 Hz, 2 H) 7.40 - 7.66 (m, 5 H) 7.97 (t,J=7.83 Hz, 1 H) 8.07 - 8.19 (m, 2 H) 8.41 (s, 1 H).
Step 7: tert-butyl 4-(6-(4-(benzoyloxy)-3,3-dif|uorocyc|ohexy|)(bis(tertbutoxycarbonyl )amino)pyrazinyl)fluorobenzoate: To a solution of utyl 4-(6- ((1S,4S)(benzoyloxy)oxocyc|ohexy|)(bis(tert-butoxycarbony|)amino)pyraziny|)- 2-fluorobenzoate (730 mg, 1.034 mmol) in DCM (7 mL) at RT was added XtalFlour-E (939 mg, 4.14 mmol) followed by triethylamine rofluoride (0.674 mL, 4.14 mmol).
The resultant mixture was stirred at RT for 5 hours. The mixture was filtered and the ed solution was directly applied for ISCO separation: 24 g silica gel, 0 to 70% EtOAc in Heptane, 30 min. A light yellow solid (670 mg, 0.902 mmol, 87 % yield) was obtained.
LC-MS (m/z): (MH+) 728.0 at 0.95 min ( lar MS method). 1H NMR (400 MHz, CDCI3) 6 ppm 0.88 (s, 2 H) 1.19 - 1.39 (m, 21 H) 1.48 - 1.68 (m, 11 H) 1.86 - 2.08 (m, 2 H) 2.08 - 2.21 (m, 1 H) 2.26 - 2.47(m, 2 H) 2.47 - 2.63 (m, 1 H) 3.21 - 3.44 (m, 1 H) 5.22 - .51 (m, 1 H) 7.41 - 7.55 (m, 4 H) 7.60 (s, 1 H) 7.96 (d, J=7.82 Hz, 1 H) 8.06 - 8.19 (m, 2H) 8.42 (s, 1 H).
Step 8: 4-(3-amino(4-(benzoyloxy)—3,3-difluorocyclohexyl)pyrazinyl)fluorobenzoic acid: To a solution of tert-butyl 4-(benzoyloxy)-3,3-difluorocyclohexyl)(bis(tert- butoxycarbonyl)amino)pyrazinyl)fluorobenzoate (670 mg, 0.921 mmol) in DCM (12 mL) at RT was added TFA (4.96 mL, 64.4 mmol). The resultant mixture was stirred at RT for 2 hours. The mixture was concentrated, diluted with EtOAc, neutrized with NaHC03 twice, then brine, the organic layer was separated, dried and concentrated to afford the crude product, which was used at the next step directly. (434 mg, 0.921 mmol, 100 % yield). LC-MS (m/z): (MH+) 472.1, at 0.942 min. 1H NMR (400 MHz, DMSO) 6 ppm: 1.07 (t, J=7.04 Hz, 2 H) 1.83 (t, J=10.17 Hz, 2 H) 2.16 (d, J=5.09 Hz, 1 H) 2.29 - 2.45 (m, 2 H) 3.02 (br. s., 1H) 3.16 - 3.44 (m, 9 H) 5.22 - 5.52 (m, 1 H) 5.73 (s, 1 H) 6.24 (s, 2 H) 7.44 - 7.75 (m, 5 H) 7.89 (t, J=7.83 Hz, 1 H) 7.94 - 8.07 (m, 3 H).
Step 9: 4-(5-amino(3-fluoro(((S)(3-fluoroiodophenyl) hydroxyethyl)carbamoyl)phenyl)pyrazinyl)-2,2-difluorocyclohexyl te, 4-(5-amino- 6-(3-fluoro(((S)(3-fluoroiodophenyl)hydroxyethyl)carbamoyl)phenyl)pyrazin y|)-2,2-difluorocyclohexyl benzoate: To a mixture of 4-(3-amino(4-(benzoyloxy)—3,3- difluorocyclohexyl)pyrazinyl)fluorobenzoic acid (434 mg, 0.92 mmol) (4-(3-amino ((4R)(benzoyloxy)-3,3-difluorocyclohexyl)pyrazinyl)fluorobenzoic acid), (S)—2- amino(3-fluoroiodophenyl)ethanol (320 mg, 1.012 mmol),HOAt (250 mg, 1.840 mmol) and EDC (353 mg, 1.840 mmol) in DMF (5 mL) was added DIEA (1.607 mL, 9.20 mmol) . The ant mixture was stirred over night at RT. The mixture was diluted with EtOAc, washed with water three times and brine, dried, concentrated to afford the crude product as a light yellow viscous liquid.
After ISCO cation (24 g silica, 10 to 80% EtOAc in heptane, 35 min), the d product was obtained as a light yellow liquid, which containes two possible isomers. (601 mg, 0.818 mmol, 89 % yield) LC-MS ( m/z): (MH+) 735.0 at 1.09 min. 1H NMR (400 MHz, CDCI3) 6 ppm 1.71 (br. s., 1 H) 1.80 - 2.00 (m, 2 H) 2.18 - 2.39 (m, 2 H) 2.39 - 2.52 (m, 1 H) 2.53 - 2.70 (m, 1 H) 3.13 (br. s.,1 H) 3.82 - 4.07 (m, 2 H) 4.78 (s, 2 H) 5.23 (d, J=5.09 Hz, 2 H) 7.02 - 7.16 (m, 1 H) 7.31 - 7.39 (m, 1 H) 7.41 - 7.50 (m, 2 H) 7.50 - 7.76 (m, 5 H) 7.87 - 8.03 (m, 2 H) 8.07 - 8.23 (m, 3 H).
Step 10: 4-(3-amino(3,3-difluorohydroxycyclohexyl)pyrazinyl)fluoro-N-((S) (3-fluoroiodophenyl)hydroxyethyl)benzamide: To 4-(5-amino(3-fluoro(((S)(3- fluoroiodophenyl)—2-hydroxyethyl)carbamoyl)phenyl)pyraziny|)-2,2-difluorocyclohexyl benzoate (600 mg, 0.817 mmol) in MeOH (8 ml), THF (8 ml) and Water ( 8 ml) at RT was added LiOH.H20 (206 mg, 4.90 mmol). The resultant e was stirred at 250C for 2 hours. The reaction e was concentrated and to the residue was added 30 ml of EtOAc, washed with water (10 ml x3), dried, filtered, and concentrated to afford the crude product as a light yellow sticky liquid, which became an off white solid after overnight standing. (515 mg, 100 % yield) . LC-MS (m/z): (MH+) 631.1 at 0.771 min.
Step 1 1: 4-(3-amino((1S,4S)—3,3-difluorohydroxycyclohexyl)pyrazinyl)—2-fluoro-N- ((S)—1-(3-fluoroiodophenyl)hydroxyethyl)benzamide: The compound obtained from step 10 was purified by chiral separation column (OJ column (21 X250 mm), SFC = 100 ml/min, CO2/EtOH = 85/15, g: 70 mg/7ml EtOH, 274 bar) to afford two chiral pure compounds: 4-(3-amino((1S,4S)—3,3-difluorohydroxycyclohexyl)pyrazinyl) fluoro-N-((S)(3-fluoroiodophenyl)hydroxyethyl)benzamide (255 mg, 27.8 % . 1H NMR (400 MHz, DMSO) 6 ppm 1.46 - 1.69 (m, 2 H) 1.71 - 2.26 (m, 4 H) 2.79 - 3.02 (m, 1 H) 3.58 - 3.83 (m, 2 H) 4.94 - 5.15 (m, 2 H) 5.25 -5.45 (m, 1 H) 6.11 - 6.26 (m, 1 H) 7.19 - 7.34 (m, 1 H) 7.46 - 7.56 (m, 1 H) 7.56 - 7.66 (m, 2 H) 7.66 - 7.77 (m, 1 H) 7.95 (s, 1 H) 8.66 - 8.79 (m, 1H). 4-(3-amino((1R,4R)—3,3-difluorohydroxycyclohexyl)pyrazinyl)f|uoro-N-((S)(3- fluoroiodophenyl)hydroxyethyl)benzamide (53 mg, 5.77 % yield). 1H NMR (400 MHz, DMSO) 6 ppm 1.15 - 1.30 (m, 1 H) 1.48 - 1.69 (m, 2 H) 1.72 - 2.25 (m, 5 H) 2.77 - 2.97 (m, 2 H) 3.57 - 3.84 (m, 3 H) 4.92 -5.14 (m, 2 H) 5.27 - 5.42 (m, 1 H) 6.10 - 6.24 (m, 2 H) 7.16 - 7.34 (m, 1 H) 7.46 - 7.57 (m, 1 H) 7.57 - 7.67 (m, 2 H) 7.67 - 7.77 (m, 1 H) 7.95 (s, 1H) 8.63 - 8.80 (m, 1 H).
Example 473 S nthesis of S 3-amino mor holinecarbon l razin l -N- 1- 3-bromo fluoro hen lh drox eth lfluorobenzamide WO 66188 Step1 N / N2\|r Step 2, 74% (:OA%\ 'N CH3CN i“ F o 78% 0 o/\ F O NH2 OH Step 4, 84% Step 3 N / N / | \N TFA in] {OH 100% ' F O O/\ H2N (S) oto“ /\©/ F 0 :/OH = N F (S) NH2 ” (S) Step5 100% I LiOH / MeOH \ N Br OOH 0 o/\ N(S) Step6 25% HN/W00 0 Step 1: Ethyl 5-aminobromopyrazinecarboxylate: To a solution of ethyl 5- yrazinecarboxylate (880 mg, 5.26 mmol) in acetonitrile ( 20 mL) at RT was added NBS (984 mg, 5.53 mmol), the resultant solution was stirred at RT for 1 hour. The reaction mixture was diluted with EtOAc, washed with sat NaHC03, brine and water, dried, filtered, and concentrated to afford the crude product, which was purified by ISCO ( 24 g silica gel column, 0 to 50% EtOAc in Heptane, 30 min). 1.01 g, 78 % yield. LC-MS (m/z): 247.9 ( MH+), 0.51 min.
Step 2: Ethyl 5-amino(4-(tert-butoxycarbonyl)fluorophenyl)pyrazinecarboxylate: A mixture of ethyl 5-aminobromopyrazinecarboxylate (210 mg, 0.853 mmol), tert-butyl 2-fluoro(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)benzoate (357 mg, 1.109 mmol), PdC|2(dppf).CH2C|2 adduct (69.7 mg, 0.085 mmol) and Na2C03 (362 mg, 3.41 mmol) (2M solution was used) in DME ( 5 mL) was placed into a 20 ml vial and sealed. The mixture was microwaved for 15 min at 1100C. The mixture was diluted with EtOAc, washed with water twice and brine, dried, filtered, and concentrated to afford the crude as a light yellow solid. The crude product was purified by ISCO ( 12 g, 10 -55 % EtOAc in e, min) to afford 228 mg (74 % yield) of light yellow solid. LC-MS (m/z): 362.1 ( MH+), 0.89 min.
Step 3: 4-(3-amino(ethoxycarbonyl)pyrazinyl)fluorobenzoic acid: To a solution of ethyl 5-amino(4-(tert-butoxycarbonyl)fluorophenyl)pyrazinecarboxylate (0.253 g, 0.7 mmol) in DCM (4 mL) at RT was added TFA (2.157 mL, 28.0 mmol). The resultant solution was stirred at RT for 2 hours. The reaction solution was concentrated and r dried to afford the crude desired product as a TFA salt. This product was ly used at the next step. 0.214 g (100 % yield) of light sticky liquid was obtained. LC-MS (m/z): 306.1 (MH+), 0.563 min.
Step 4: (S)-ethy| 5-amino(4-((1-(3-bromofluorophenyl)hydroxyethyl)carbamoyl) fluorophenyl)pyrazinecarboxylate: To a mixture of 4-(3-amino (ethoxycarbonyl)pyrazinyl)fluorobenzoic acid (0.214 g, 0.7 mmol) , (S)amino(3- bromofluorophenyl)ethanol (272 mg, 1.009 mmol),HOAt (187 mg, 1.376 mmol) and EDC (264 mg, 1.376 mmol) in DMF ( 2.5 mL) was added DIEA (0.961 mL, 5.50 mmol).
The resultant mixture was stirred over night at RT. The mixture was diluted with EtOAc, washed with water three times and brine, dried, concentrated to afford the crude product as a light yellow viscous liquid. ISCO purification ( 12 g silica, 10 to 90% EtOAc in heptane, 30 min) provided the desired product (200 mg, 84 % yield) as a light yellow liquid. LC-MS (m/z): 522.9 ( MH+), 0.787 min.
Step 5: amino(4-((1-(3-bromofluorophenyl)hydroxyethyl)carbamoyl) fluorophenyl)pyrazinecarboxylic acid: A mixture of (S)-ethy| 5-amino(4-((1-(3-bromo- -fluorophenyl)hydroxyethyl)carbamoyl)fluorophenyl)pyrazinecarboxylate (220 mg, 0.422 mmol) and 2O (142 mg, 3.38 mmol) in MeOH ( 2ml), THF (2mL) and Water ( 2mL) was stirred for 3 hours at RT. The mixture was trated, to the residue was added 2ml of water, 3N HCI was then added under stirring until the final pH was about 4. The resultant mixture was then concentrated and further dried to afford the crude product was a light yellow solid. (208 mg, 0.422 mmol, 100 % yield). LC-MS (m/z): 494.9 ( MH+), 0.653 min.
Step 6: (S)(3-amino(morpholinecarbonyl)pyrazinyl)—N-(1-(3-bromo fluorophenyl)hydroxyethyl)fluorobenzamide: To a mixture of (S)amino(4-((1- (3-bromofluorophenyl)hydroxyethyl)carbamoyl)fluorophenyl)pyrazinecarboxylic acid (40 mg, 0.081 mmol), morpholine (28.3 mg, 0.324 mmol),HOAt (33.1 mg, 0.243 mmol) and EDC (46.6 mg, 0.243 mmol) in DMF ( 0.5 mL) was added DIEA (0.170 mL, 0.973 mmol). The resultant mixture was stirred over night at RT. The mixture was d with EtOAc, washed with water three times and brine, dried, concentrated to afford the crude product as a light yellow viscous liquid. The crude product was dissolved into 1.5 ml of DMSO, filtered, and was purified by prep HPLC. (14 mg, 25.3 % yield). LC-MS (m/z): 563.9 ( MH+), 0.707 min. 1H NMR (500 MHz, ACETONITRILE-d3) 6 ppm 3.56 - 3.99 (m 13 H) 5.06 - 5.23 (m, 1 H) 5.78 - 6.13 (m, 2 H) 7.22 (d, J=8.20 Hz, 1 H) 7.27 -7.36 (m, 1 H) 7.41 - 7.79 (m, 5 H) 7.89 - 8.05 (m, 1 H) 8.25 - 8.43 (m, 1 H).
Example 478a and 478b 4- o R oxo i eridin l 2- lfluoro-N- S 3-fluoro iodo hen lh drox eth lbenzamide Exam le 478a and 4- 3-amino S oxo i eridin l razin lfluoro-N- S 3-fluoroiodo hen l h drox eth l benzamide Exam le 478b .
/O£10KZCO3,TBAII:LO 1. L-Selectride 1. ICI, MeOH 2. DMAP, TFAA, DIEA 2. cat. TFA acetone, rt, ON ¢fiwN99“—»PdClzdppf, NaZCO3 I N,\ Iw-OMSmay“ ”(gm TQM F o 0 NH 2 OH F O z/OH F 0 {OH N \ F : I OH NH N /N :/ 2 NH2 m + F m H2N ChiralSeparation NI \ H/\©/ + NI \ .HCI DMF /N | /N I HN E Example478a HN Example478b O o 1- 4-methox benz / i eridine-2 6-dione: Glutarimide (5 g, 44.2 mmol) was suspended in acetone (Volume: 100 mL) and then K2C03 (12.22 g, 88 mmol), Bu4Nl (3.27 g, 8.84 mmol) and 4-methoxybenzyl chloride (6.02 mL, 44.2 mmol) were added. The mixture was agitated at room temperature ght and filtered through celite and then trated in vacuo and the residue purified by flash tography (0-50% EtOAc/heptane) to afford 8.99 g of the desired product as a colorless solid. LCMS (m/z): (MH+), 234.2, 0.66 min. 1-(4-methoxybenzyl)—3,4-dihydropyridin-2( 1 H )—one: 1-(4-methoxybenzyl)piperidine-2,6- dione (8.99 g, 38.5 mmol) was dissolved in Toluene (Volume: 128 ml) and cooled to -78 °C. L-Selectride (42.4 mi, 42.4 mmol) was added dropwise and the mixture agitated for 1 h. After 1 h, thick slurry along with itate observed. Reaction mixture was briefly pulled outside cooling bath to nize the mixture. Then DMAP (0.047 g, 0.385 mmol) was added in one portion and then DIEA (38.4 ml, 220 mmol) was added and then TFAA (6.53 ml, 46.2 mmol) was added. Then the cooling flask was removed and the mixture agitated at room temperature for 2 h and then quenched with water and the product extracted with EtOAc. The combined organic layer was dried (MgSO4), filtered and concentrated in vacuo to afford crude residue which was purified by flash chromatography to afford 7.66g of the desired product as a yellow syrup. LCMS (m/z): (MH+), 234.2, 0.73 min. -iodo(4-methoxybenzyl)—3,4-dihydropyridin-2(1H)—one: ethoxybenzyl)—3,4- opyridin-2(1H)-one (2 g, 9.21 mmol) was dissolved in MeOH (90 mL) and cooled to -78 °C. lCl (13.81 mi, 13.81 mmol) was added slowly and the mixture ed for 1 h and then Sat'd Na28203 was added and the mixture was agitated until room temperature was observed. The solvent was evaporated in vacuo. The residue was dissolved in DCM and washed with Sat'd Na28203 and then with water and dried (MgSO4), filtered and concentrated in vacuo. The residue was dissolved in toluene (40 mL) and treated with Trifluoroacetic acid (100 uL) and heated immediately to 145 °C for 15 min and then cooled to 0 °C and ET3N (5 mL) was added. The mixture was agitated for 1 h and concentrated in vacuo and then the residue purified by flash chromatography (0-20% EtOAc/heptane) to afford the desired product as a gummy syrup. LCMS (m/z): (MH+), 344.1, 0.88 min.
Meth l4- 3-amino 1- 4-methox benz l oxo-1 4 5 6-tetrah dro ridin l razin yl)—2-fluorobenzoate: (4-methoxybenzyl)—3,4-dihydropyridin-2(1H)-one (630 mg, 1.836 mmol), PdC|2(dppf).CH2C|2 adduct (150 mg, 0.184 mmol), methyl 4-(3-amino bromopyrazinyl)fluorobenzoate (1028 mg, 2.75 mmol) and Na2C03 (2754 ul, 5.51 mmol) were combined in a flask and then DME (Volume: 6120 ul) was added. The mixture was degassed and purged with nitrogen and then finally heated at 90 °C for 2 h upon which complete consumption of starting al was observed. The reaction mixture was diluted with EtOAc and water and the organic layer was separated and dried (MgSO4), filtered and concentrated in vacuo and the residue purified by flash chromatography (0-60% EtOAc/DCM) to afford 361 mg of the d product as a yellow solid. LCMS (m/z): (MH+), 463.1, 0.88 min.
Meth l4- 3-amino 6-oxo i eridin | razin lfluorobenzoate: Methyl 4-(3- amino(1-(4-methoxybenzyl)oxo-1,4,5,6-tetrahydropyridinyl)pyrazinyl)—2- fluorobenzoate (361 mg, 0.781 mmol) was ved in MeOH (Volume: 7 mL) and then Pd-C (400 mg, 3.76 mmol) was added. The mixture was evacuated and purged with en thrice and finally, the mixture was agitated under 1 atm of hydrogen overnight.
The next g, desired product along with over-reduced amino-pyrazine was obtained.
The mixture was filter over celite and the filtrate trated in vacuo and the residue dissolved in DCM and agitated under airfor 1 day and then conentrated and purified by flash chromatography (0-50% DCM/EtOAc) to afford 144 mg the desired product as a yellow solid. LCMS (m/z): (MH+), 465.1, 0.81 min. 4- 3-Amino 6-oxo i eridin | razin lfluorobenzoic acid: Methyl 4-(3-amino- xopiperidinyl)pyrazinyl)—2-f|uorobenzoate (144 mg, 0.310 mmol) was dissolved in TFA (Volume: 3 mL) and heated at 150 °C for 30 min in microwave The solvent was evaporated in vacuo and the residue was azeotroped with toluene thrice to afford the crude debenzylated lactam. This crude product was dissolved in THF (Volume: 3 mL, Ratio: 3) and MeOH (Volume: 1.500 mL, Ratio: 1.5) and to the e was added LiOH (0.037 g, 1.550 mmol) dissolved in Water (Volume: 1.500 mL, Ratio: 1.5). The mixture was agitated at room temperature for 30 min and concentrated in vacuo and the residue neutralized with 2 mL (4.0 N HCI) and the solvent evaporated. The e was oped once with THF and once with toluene to afford the crude acid which was taken to the next step (assuming quantitative yield) without any further purification.
LCMS (m/z): (MH+), 331.2, 0.44 min. 4-(3-Amino(6-oxopiperidinyl)pyraziny|)f|uoro-N-((S)(3-f|uoroiodopheny|)- 2-hydroxyethyl)benzamide: 4-(3-Amino(6-oxopiperidinyl)pyrazinyl)—2- fluorobenzoic acid (41.0 mg, 0.124 mmol), DIEA (0.108 mL, 0.620 mmol) and HATU (94 mg, 0.248 mmol) were combined in DMF (1.0 mL) and then (S)amino(3-fluoro iodophenyl)ethanol (39.4 mg, 0.124 mmol) was added. The mixture was agitated at room temperature for 1 h and then subjected directly to purification by e-phase HPLC to afford the title compound as TFA adduct. The solid obtained upon llization was dissolved in MeOH and passed through basic carbonate containing silica catridge and the te was concentrated in vacuo to afford 28.5 mg of the mixture of diastereomer. The residue was purified by chiral SFC to provide the two diastereomers: Diasteromer1 (Example 478a): 4-(3-amino((R)—6-oxopiperidinyl)pyrazinyl)—2- fluoro-N-((S)(3-fluoroiodophenyl)hydroxyethyl)benzamide (8.8 mg). 1H NMR (CD3OD): 7.88 (s, 1H), 7.75 (t, J=7.8 Hz, 1H), 7.48-7.64 (m, 3H), 7.34 (d, J=7.4 Hz, 1H), 7.11 (d, J=9.8 Hz, 1H), 5.05 (t, J=5.7 , 3.67-3.83 (m, 2H), 3.43 (d, J=7.8 Hz, 2H), 3.00-3.15 (m, 1H), 2.28-2.46 (m, 2H), 1.88-2.16 (m, 2H); LCMS (m/z): (MH+), 594.1, 0.71 min.
Diasteromer 2 (Example 478b): 4-(3-amino((R)—6-oxopiperidinyl)pyrazinyl)—2- fluoro-N-((S)(3-fluoroiodophenyl)hydroxyethyl)benzamide (8.2 mg) 1H NMR (CD3OD): 7.89 (s, 1H), 7.75 (t, J=7.6 Hz, 1H), 7.50-7.65 (m, 3H), 7.35 (d, J=7.8 Hz, 1H), 7.12 (d, J=9.8 Hz, 1H), 5.06 (t, J=5.7 Hz,1H), 3.65-3.89 (m, 2H), 3.37-3.53 (m, 2H), 2.96- 3.16 (m, 1H), 2.31-2.59 (m, 2H), 1.88-2.20 (m, 2H); LCMS (m/z): (MH+), 594.1, 0.71 min. ical Activity Inhibition of ERK1 and ERK2 was measured using the following methods.
Activated ERK2 (20 pM) Kinase Assay: Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide peptide substrate ([Biotin] -AHA-K-R-E-L-V-E-P-L-T-P-S-G-E-A-P-N-Q-A—L-L-R- [NH2], the peptide ce derived from EGF receptor: SEQ ID NO:1). The assay was carried out in 20 mM HEPES [pH 7.5], 5 mM MgCl2, 1 mM DTT, 0.01% Tween-20, 0.05% BSA using 0.02 nM ERK2, 400 nM e peptide and 35 uM ATP (all concentrations are final in the reaction) in a total volume of 10.25 uL. A 16-point, half-log dilution series of compounds at 41x final concentration was used for ting |C50 curves. Compound on series were prepared in 100% DMSO. ERK2 was preincubated with compounds for 30 minutes at ambient temperature. Reaction was initiated by addition of a substrate cocktail of e peptide and ATP and was allowed to proceed for 4 hours at ambient temperature. on was terminated by addition of 10 uL of a 2x stop buffer consisting of 100 mM Tris-Cl [pH 7.5], 25 mM EDTA, 0.01 % Tween 20, 20 ug/mL of AlphaScreen Protein A or Beads, 20 ug/mL of Streptavidin Donor Beads (PerkinElmer, Waltham, MA), and 1:1000 dilution phospho-EGF Receptor (Thr669) antibody (Cat# 8808, Cell Signaling Technology, Danvers, MA). Terminated reactions were read, after overnight incubation in the dark, on an EnVision Multilabel Plate Reader (PerkinElmer, Waltham, MA), with excitation and emission wavelengths set to 680 nm and 570 nm, respectively. IC50 values were determined using a four-parameter fit.
The following assay conditions (ERK2 New) were used for some nds in the following Table, and provide substantially similar lC50s to the assay described above, for IC50 about 0.1 uM or above. When the limitation of this assay was reached, the assay described above was used.
Compound potency against activated ERK2 is determined using a kinase assay that measures ERK2-catalyzed phosphorylation of ylated ERKtide peptide ate ([Biotin] -AHA-K-R-E-L-V-E-P-L-T-P-S-G-E-A—P-N-Q-A—L-L-R- [NH2], the peptide sequence derived from EGF receptor: SEQ ID NO:1). The assay is carried out in 50 mM HEPES [pH 7.5], 5 mM MgCl2, 1 mM DTT, 0.01% 20, 0.05% BSA using 0.25 nM ERK2, 200 nM e e and 35 uM ATP (all concentrations are final in the reaction) in a total volume of 10.25 uL. A 16-point, half-log on series of compounds at 41x final concentration is used for generating IC50 curves. Compound dilution series are prepared in 100% DMSO. ERK2 is preincubated with compounds for 30 minutes at ambient temperature. Reaction is initiated by addition of a substrate cocktail of e peptide and ATP and is allowed to proceed for 2-3 hours at ambient temperature. Reaction is terminated by addition of 10 uL of a 2x stop buffer consisting of 100 mM Tris-Cl [pH 7.5], 25 mM EDTA, 0.01% Tween 20, 10 ug/mL of AlphaScreen Protein A Acceptor Beads, 10 ug/mL of Streptavidin Donor Beads (PerkinElmer, Waltham, MA), and 1.4 ug/mL phospho-EGF Receptor (Thr669) antibody (Cat # 3056, Cell Signaling Technology, Danvers, MA). Terminated reactions are read, after overnight incubation in the dark, on an EnVision Multilabel Plate Reader nElmer, Waltham, MA), with excitation and emission ngths set to 680 nm and 570 nm, respectively. |C50 values are determined using a four-parameter fit.
Activated ERK1 Kinase Assay: Compound potency against activated ERK1 was determined using a kinase assay that measures ERK1-catalyzed phosphorylation of biotinylated e peptide substrate ([Biotin] -AHA—K-R-E-L-V-E-P-L-T-P-S-G-E-A—P-N-Q-A—L-L-R- [NH2], the peptide sequence derived from EGF receptor: SEQ ID NO:1). The assay was d out in 20 mM HEPES [pH 7.5], 5 mM MgCl2, 1 mM DTT, 0.01% Tween-20, 0.05% BSA using 0.2 nM ERK1, 200 nM ERKtide peptide and 45 uM ATP (all concentrations are final in the reaction) in a total volume of 10.25 uL. A 16-point, half-log dilution series of compounds at 41x final concentration was used for generating |C50 . Compound dilution series were prepared in 100% DMSO. ERK1 was ubated with compounds for 30 minutes at ambient temperature. Reaction was ted by addition of a substrate cocktail of ERKtide peptide and ATP and was d to d for 4 hours at ambient temperature. Reaction was terminated by addition of 10 uL of a 2x stop buffer consisting of 100 mM Tris-Cl [pH 7.5], 25 mM EDTA, 0.01 % Tween 20, 10 ug/mL of AlphaScreen Protein A Acceptor Beads, 10 ug/mL of Streptavidin Donor Beads (PerkinElmer, Waltham, MA), and 1.4 ug/mL phospho-EGF Receptor (Thr669) antibody (Cat # 3056, Cell Signaling Technology, Danvers, MA). Terminated reactions were read, after overnight incubation in the dark, on an EnVision Multilabel Plate Reader (PerkinElmer, Waltham, MA), with excitation and emission wavelengths set to 680 nm and 570 nm, respectively. |C50 values were determined using a four-parameter fit.
All |C50s are presented in scientific notation where ‘E’ indicates the power of 10; for example, 1.63E-03 ents 1.63 x 103, or 0.00163.
ERK2 ERK2 (20pM) creen Example ERK2 New (pM) (pM) (pM) 1 1.63E-03 1.06E-03 2 1.92E-01 3 1.23E+01 4 3.15E-01 s ——— 6 ——— 7 ——— s ——— 9 ——— 1o ——— 11 ——— 12 ——— 1s ——— 14 ——— 1s ——— 16 2.06E-01 1.97E-01 17 --- 1s ——— 19 ——— 1.09E+00 21 2.67E+00 22 5.81E-01 23 3.93E-01 24 4.53E-01 04 26 3.27E-03 27 4.10E-03 1.87E-03 28 2.55E-03 1.20E-03 29 7.52E-02 6.95E-02 2.25E-02 31 7.40E-02 3.20E-02 32 2.43E-02 33 1.82E-02 02 34 03 3.98E-03 1.09E-03 36 1.60E-03 37 1.05E-03 38 8.09E-03 39 2.48E-03 1.30E-03 40 2.46E-03 1.26E-03 41 5.10E-02 42 5.44E-03 4s ——— 44 ——— 45 3.61E-03 46 4.79E+00 2014/062913 47 ——— 45 ——— 45 ——— 5o ——— 54 ——— 52 ——— 55 ——— 54 ——— 55 ——— 55 ——— 57 ——— 58 3.61E-03 59 --- 5o ——— 54 ——— 62 6.41 E-02 63 2.33E-02 64 03 3.64E-03 65 6.84E-04 1.84E-03 66 4.18E-02 5.53E-02 67 6.77E-02 8.55E-02 68 3.14E-01 2.14E-01 69 1.00E-02 1.60E-02 70 01 5.74E-01 71 8.78E-03 1.72E-02 72 1 .77E-01 73 1.29E-03 3.08E-03 74 2.03E-02 3.76E-02 75 00 00 76 3.04E-03 5.24E-03 77 5.08E-02 9.76E-02 78 1 .72E-01 79 3.24E-02 3.33E-02 80 5.10E-04 5.84E-04 81 4.87E-04 1.63E-04 1.66E-04 82 9.00E-04 2.13E-03 83 7.52E-04 5.74E-04 84 2.05E-03 9.64E-03 85 — 1.31E-03 2.06E-02 86 — 3.75E-03 4.78E-03 87 2.09E-01 2.66E-01 88 7.05E-02 8.14E-02 99 ——— 99 ——— 91 ——— 92 ——— 99 ——— 94 ——— 99 ——— 99 ——— 97 ——— 99 ——— 99 ——— 100 7.76E-03 192 ——— 199 ——— 104 1.91 E-01 105 2.56E-03 106 1.28E-03 107 1.16E-03 108 9.77E-03 109 5.81 E-03 1 10 1 .00E+00 11 1 3.08E-02 1 12 1 .41 E-01 113 7.80E-01 114 1.24E-01 115 2.74E-01 116 1.89E-02 9.42E-03 117 4.79E-03 118 1.76E-02 119 5.49E-04 120 1.35E-03 04 121 3.40E-04 2.17E-04 122 7.38E-03 1.10E-02 123 04 124 6.26E-02 125 2.23E+00 126 1.69E-01 127 ——— 129 ——— 129 2.02E-03 130 1 .66E-03 131 ——— 132 ——— 133 ——— 134 ——— 133 ——— 133 ——— 137 ——— 133 ——— 133 ——— 14o ——— 141 ——— 142 2.10E-04 2.01E-04 144 ——— 146 3—.39E-03_.33E-03 —— 147 02 148 1.90E-03 149 1.49E-04 150 9.37E-05 151 1.15E-04 2.33E-05 152 1.45E-04 4.10E-05 153 3.60E-04 154 2.88E-04 155 1.69E-03 156 3.32E-03 157 4.16E-04 158 634504 159 314503 160 6.53E-04 161 5.76E-03 162 4.87E-04 163 514503 164 1.40E-03 165 3.90E-01 166 -05 167 9.98E-04 168 5.13E-03 133 ——— 17o ——— 171 1.09E-03 172 1.58E-04 7.85E-05 178 ——— 174 ——— 178 ——— 178 ——— 177 ——— 178 ——— 178 ——— 18o ——— 181 ——— 182 ——— 188 ——— 184 2.61E-05 188 ——— 187 ——— 188 4.69E-05 189 1.39E-05 190 1.76E-05 191 4.53E-03 1.49E-03 192 8.04E-03 4.93E-03 193 1.19E-03 04 194 2.60E-04 9.55E-05 195 04 1.02E-04 196 04 3.63E-04 197 2.10E-03 7.51E-04 197 4.00E-05 198 2.23E-04 199 3.00E-04 200 2.07E-04 8.42E-05 1.83E-04 201 6.42E-02 202 1.52E-04 203 7.33E-03 204 5.46E-02 205 8.02E-02 206 1.04E-05 207 4.30E-01 208 7.44E+00 209 3.28E+00 21o ——— 211 ——— 212 3.97E-04 213 1.19E-02 214 ——— 21s ——— 216 ——— 217 ——— 218 ——— 219 ——— 22o ——— 221 ——— 222 ——— 22s ——— 224 ——— 225 9.01E-05 227 ——— 228 ——— 229 1.07E-03 230 8.99E-04 231 2.17E-04 232 2.57E-04 233 2.09E-05 234 1.47E-03 235 3.26E-04 236 5.66E-02 237 2.61E+00 238 3.52E-01 239 02 240 1.99E-05 241 9.44E-04 242 8.75E-06 243 1.21E-05 244 1.57E-01 245 2.67E-03 246 1.52E-03 247 7.30E-04 248 3.64E-05 249 3.71E-03 250 3.64E-05 251 7.04E-03 252 ——— 252 ——— 254 05 255 2.87E-05 255 ——— 257 ——— 255 ——— 255 ——— 255 ——— 251 ——— 252 ——— 255 ——— 254 ——— 255 ——— 255 ——— 267 05 255 ——— 275 ——— 271 3.08E-05 272 6.19E-05 273 4.82E-05 274 3.12E-05 275 7.45E-05 276 3.71E-05 277 05 278 1.46E-04 279 5.18E-04 4.29E-04 280 1.66E-03 281 1.79E-03 282 1.20E-03 283 1.69E-04 3.78E-05 284 2.96E-04 285 2.66E-02 286 3.90E-03 287 7.94E-04 288 2.03E-03 289 1.92E-04 8.14E-05 290 1.74E-03 291 1.48E-03 292 03 293 2.65E-02 254 ——— 255 ——— 296 1.08E-03 297 1.53E-04 7.15E-05 233 ——— 233 ——— 3oo ——— 331 ——— 332 ——— 3o3 ——— 334 ——— 333 ——— 333 ——— 337 ——— 333 ——— 309 1.04E-04 2.63E-05 311——— 312 ——— 313 6.17E-04 314 1.48E-03 315 5.00E-06 316 3.30E-01 317 1.34E+00 318 3.81E-01 3.11E-01 319 1.51E-01 320 3.54E-01 321 8.49E-02 322 02 323 3.29E-03 324 03 6.17E-03 325 5.93E-04 5.44E-04 326 2.53E-04 327 5.42E-02 328 8.29E-03 7.64E-03 329 05 330 2.22E-05 331 6.45E-05 332 8.15E-04 333 3.46E-02 3.38E-02 334 2.52E-02 1 .94E-02 335 2.08E-05 333 ——— 337 ——— 338 1.39E-05 339 1.05E-04 s40 ——— s41 ——— s42 ——— s43 ——— s44 ——— s45 ——— s46 ——— s47 ——— s48 ——— s49 ——— sso ——— 351 2.25E-05 353 ——— 354 ——— 355 2.30E-05 356 3.17E-05 357 1.43E-05 358 2.05E-05 359 7.60E-05 360 06 361 1.04E-04 362 2.91E-05 363 5.57E-05 364 2.05E-04 365 2.08E-05 366 1.27E-04 367 1.50E-04 368 8.95E-05 369 2.13E-04 370 1.38E-04 371 05 372 4.00E-05 373 8.37E-06 374 2.05E-05 375 4.01E-05 376 1.83E-05 377 7.00E-05 s78 ——— s79 ——— 380 9.70E-06 381 2.09E-05 332 ——— 333 ——— 334 ——— 333 ——— 333 ——— 337 ——— 333 ——— 333 ——— 33o ——— 331 ——— 332 ——— 393 7.52E-05 333 ——— 333 ——— 397 3.60E-05 398 2.81E-04 399 2.10E-02 400 1.59E-01 401 05 402 4.36E-04 403 5.81E-03 404 1.15E-04 405 2.38E-04 406 04 407 3.33E-04 408 2.01E-05 409 2.25E-04 410 9.43E-05 411 7.43E-05 412 3.74E-04 413 2.04E-01 414 2.00E-05 415 03 416 5.68E-03 417 6.90E-04 9.28E-05 418 1.28E-03 419 8.53E-04 423 ——— 421——— 422 1.87E-04 6.51 E-05 423 1.47E-04 6.14E-05 WO 66188 424 ——— 423 ——— 423 ——— 427 ——— 423 ——— 423 ——— 43o ——— 432 ——— 433 ——— 434 ——— 433 ——— 436 4.85E-05 433 ——— 440 7.01E-05 441 5.59E-05 442 3.39E-04 443 3.45E-04 444 2.15E-04 445 5.31E-04 446 4.64E-05 447 1.63E-04 448 3.71E-04 449 1.84E-04 450 1.50E-03 451 4.42E-05 452 0.00003 453 0.0000684 454 0.0000403 455 0.000144 456 872 457 0.0000581 458 0.0000823 459 0.0000261 460 0.0000397 461 0.00000431 462 0.000135 433 ——— 434 ——— 465 0.0000187 466 0.000218 2014/062913 467 ——— 468 ——— 469 ——— 470 ——— 471 ——— 472 ——— 473 ——— 474 ——— 475 ——— 476 ——— 477 ——— 478a 0.000009 478b 0.000039

Claims (12)

1. A compound of a (I): or a pharmaceutically acceptable salt f, wherein: R1 is an optionally substituted group selected from C3-8 cycloalkyl, 5-8 membered heterocyclyl containing 1-2 heteroatoms selected from N, O and S as ring s, phenyl, -SO2-phenyl, -C(O)-phenyl, -C(R8)2-phenyl, and 5-6 membered heteroaryl ring, n said heterocyclyl and heteroaryl contain 1-2 heteroatoms selected from N, O and S as ring members, and wherein the optional substituents for R1 are 1-3 groups independently selected from D, halo, hydroxy, amino, -N(R8)2, CN, C1-4 alkyl, C1-4 alkoxy, -S(C1-4 alkyl), C1-4 haloalkyl, C1-4 haloalkoxy, C3-6 cycloalkyl, 3-6 membered heterocyclyl containing 1-2 heteroatoms selected from N, O and S, oxo (except on aromatic rings), COOR8, CON(R8)2, (O)R8, -NR8-C(O)OR8 -SO2R8, -NR8SO2R8, and SO2N(R8)2, where each R8 is ndently H or C1-4 alkyl; L is wherein R” is methyl or ethyl, and is optionally substituted with fluoro, amino, hydroxy, methylamino, ethylamino, ylamino, -OP(O)(OH)2, methoxy or ethoxy; X and Y are independently selected from H, D, halo, CN, amino, hydroxy, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy; R2 is H, C1-4 alkyl, or aryl-C1alkyl-, wherein the aryl and C1-4 alkyl are ally substituted with halo, CN, C1-4 alkyl, C1-4 haloalkyl, C3-6 cycloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, or C1-4 alkylsulfonyl; or R2 and L are linked together to form a cyclic group selected from morpholine, piperidine, thiomorpholine, piperazine, and pyrrolidine that is attached to R1 and is also optionally substituted with one or two groups independently selected from C1-4 alkyl, C1-4 alkoxy, oxo, CN, COOR7, CON(R7)2, and -SO2R7, where each R7 is independently H or C1-4 alkyl; Z is N or CR4; R4 is H, D, halo, C1-4 alkyl, C1-4 haloalkyl, or C1-4 alkoxy; R5 is selected from R5a and R5a ; wherein R5a is an optionally substituted C3-8 cycloalkyl, C3-8 cycloalkenyl, saturated or unsaturated 3-8 ed heterocyclic ring containing 1-2 heteroatoms selected from N, O and S, phenyl, or 5-6 ed heteroaryl ring containing 1-3 heteroatoms selected from N, O and S, wherein the optional substituents for R5 are 1-4 groups independently ed from D, halo, hydroxy, amino, CN, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 haloalkoxy, C3-6 cycloalkyl, 3-6 membered heterocyclyl containing 1-2 heteroatoms selected from N, O and S, oxo (except on aromatic rings), -COOR9, -C(O)R9, )2, -NR9C(O)R 9, - NR 9CO 9, 2R -SO2R9, -NR9SO 9, 2R and -SO2N(R 9) 2, where each R9 is independently H or C1-4 alkyl optionally substituted with 1-3 groups independently selected from D, halo, OH, NH 5 2, NHMe and NMe2; and two substituents on the same or adjacent carbon atoms of R can optionally be taken together to form a 5-6 membered ring that can be saturated or aromatic and contains 1-2 heteroatoms selected from N, O and S and can optionally be substituted with 1-2 groups independently selected from D, Me, halo, OH, oxo, O(C1-4 alkyl), NH2, C1-4 mino, 4 alkyl)amino; and R6 is H, D, halo, C1-4 alkyl, or C1-4 haloalkyl.
2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Z is N.
3. The compound according to claim 1 or claim 2 or a ceutically acceptable salt thereof, wherein R2 is H or Me.
4. The compound according to any one of claims 1-3 or a pharmaceutically acceptable salt thereof, wherein R6 is H.
5. The compound according to any one of claims 1-4 or a pharmaceutically acceptable salt thereof, n R5 is ed from –C(O)-R5a and R5a ; wherein R5a is selected from C3-8 cycloalkyl, 5-8 membered heterocyclyl containing 1-2 heteroatoms selected from N, O and S, phenyl, and 5-6 membered heteroaryl, and is optionally substituted with 1-3 groups independently selected from D, halo, CN, hydroxy, C1-4 alkoxy, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 haloalkoxy, -SO2R’, -NR’-C(O)-R’, and – SO 2NR’ 2, where each R’ is independently H or C1-4 alkyl.
6. The nd according to any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein R5 is selected from –C(O)-R5a and R5a ; n R5a is selected from cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, ydropyran, dihydropyran, tetrahydrofuran, oxetane, azetidine, pyrrolidine, piperidine, piperazine, morpholine, tetrahydrothiopyran (thiacyclohexane), and tetrahydrothiofuran (thiacyclopentane), each of which is optionally substituted with 1-3 groups independently selected from halo, D, CN, hydroxy, C1-4 alkyl, C1-4 alkoxy, C1-4 kyl, C1-4 hydroxyalkyl, C1-4 haloalkoxy, oxo, COOR9, CON(R9)2, -NHC(O)R9, -NHCOOR9, -NHSO2R9, and -SO2R9, where each R9 is independently H or C1-4 alkyl.
7. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein R1 is phenyl and is ally substituted with one to three groups ndently selected from halo, D, CN, C1-4 alkoxy, C1-4 alkyl, C1-4 haloalkyl, C1-4 haloalkoxy, -SO2R’, -N(R’)2, -NR’-C(O)-R’, and –SO2NR’ 2, where each R’ is independently H or C1-4 alkyl.
8. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein Y is H, methyl, or halo.
9. The compound of claim 1, which is of the a IB: (IB) wherein R5 is a 4-7 membered cyclic ether or C5-6 cycloalkyl, and R5 can be substituted with up to four groups independently selected from D, F, Cl, CN, amino, -CH2OH, - NHC(O)Me, Me, -NHSO2Me, Me, OMe, OH, oxo, Et, iPr, OEt, and CF3; Y is H, F, Cl, or Me; R10 is –CH2-R*, where R* is H, -OH, F, -NH2, -NHMe, -OP(O)(OH)2, -NMe2, or – OMe; and R1 is phenyl, optionally substituted with 1-2 groups ndently selected from halo, CN, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, COOR8, CON(R8)2, and -SO2R8, where each R8 is independently H or C1-4 alkyl; or a pharmaceutically acceptable salt f.
10. The compound of any one of claims 1-4 or 9, wherein R5 is cyclohexyl substituted with 1-3 groups groups independently selected from D, F, Cl, CN, amino, Me, NHSO2Me, NHCOMe, OMe, OH, Et, CN, -CH2OH, and CF3.
11. The compound of claim 1, wherein R1 is phenyl substituted with 0, 1 or 2 groups independently selected from F, Cl, Br, I, SMe, SO2Me, and CH3.
12. The compound of claim 1, or a pharmaceutically able salt thereof selected from the group consisting of: F o 5 I NDH /N CI F 0 {OH F o {OH NH2 N NH2 N H H N \ N \ I ' / CI / Cl N o OH OH F o g F o 1 NH2 N NH2 N H H N \ N \ l I / CI / CI w 0 (N10 F o g F o 3 Z/:M IZ Z/IM IZ Z Z 471471 OH OH F O F O NH2 N NH2 N H H N N Cl Cl N N O O F O NH2 N NH2 N NH2 N H H N\ N\ l/ Cl l/ Cl 0 0 F o 3/ NH N 2 H/\© F o {0 NH2 N \ Cl o \ 473473 E F O Z/OH NH2 N NH2 H N/ ”w \ I o‘?°o NH2 N/\©H {OH N \ F o I f /N NH2 N N \ F /N CI :/ F O E NH2 N® NH2 N H H N/ N/ I w \ N \ N CI N N 0% o‘s\‘o F 0 {OH NH2 N 474474 F O :/ N/l N/\©H \ N CI 0%0/ F O {OH OH , F O / : NH2 N N CI N \ HQ \ 0 0% F O _/ O _/OH NH2 NH/\© N/ H \' NI \ / F 0:3\ /\0 O O _/OH 475475 0 / : CI 0 {OH N \ pg N \ “Q / ‘ O O F F /OH o KOH F O NH2 N NH2 N H H \ N \ / \\<0 0 (OH NHZO 0 ;/ N/ E/\© N \ N/\© CI \ o O o 0 g :/OH NHZ NH2 H N/\© N \ him N‘ \ | / //S\\ O O O 476476 F O {OH _/OH \ um N \ fig / I /S\ / O ;/ (OH m “Q N \ N \ / / / / l | \ \ N N F 0 {OH NH2 N F O ?/ _/OH N / HQ ‘U ‘ N \ \ / E J \ o N/ 477477 o Z/OH F O {OH NH2 N N I C' OH F O ,/ F o :/ : N NH2 N H NI \ CI {OH 0 0 r0“ N \ N/\© N \ F Em I/ ‘/ o \ 0 _/OH N \ N/\©H 0%0/ 478478 NH2 N N\ H/\© ‘/ CI F O 3 NH2 N '/ CI N o OH F 0 (OH NH2 RED NH2 N N \ N \ l/ ‘/ CI 0 N o 0 {0H N/ m© 479479 F o { /0H NH2 N I N/ N“ \ N—N N-N \ \ F o _/OH F o {OH NH2 N /N CI 0 (OH NH2 jH D D D D 480480 0 :/OH 0 {OH NH2 N NH2 H HN/\© N \ N \ ' ' /N /N 0 Q 0 /OH E/OH NH2 N H N / N/\© | \ IN O /N—N {OH F O F {OH N/ mg N/ m | \ IN Nfl /N
NZ717223A 2013-11-01 2014-10-29 Aminoheteroaryl benzamides as kinase inhibitors NZ717223B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361898761P 2013-11-01 2013-11-01
US61/898,761 2013-11-01
CN2014088409 2014-10-11
CNPCT/CN2014/088409 2014-10-11
PCT/US2014/062913 WO2015066188A1 (en) 2013-11-01 2014-10-29 Aminoheteroaryl benzamides as kinase inhibitors

Publications (2)

Publication Number Publication Date
NZ717223A NZ717223A (en) 2021-05-28
NZ717223B2 true NZ717223B2 (en) 2021-08-31

Family

ID=

Similar Documents

Publication Publication Date Title
US10660888B2 (en) Aminoheteroaryl benzamides as kinase inhibitors
TWI804003B (en) Tlr7/8 antagonists and uses thereof
EP3286172B1 (en) Lsd1 inhibitors and uses thereof
AU2011205302B2 (en) Voltage-gated sodium channel blockers
JP6577479B2 (en) Heterocyclic compounds and their use as NAV channel inhibitors
CA3165168A1 (en) Compounds and methods for the targeted degradation of androgen receptor
CA3199074A1 (en) Compounds and methods for the targeted degradation of androgen receptor protein
BR112020004800A2 (en) saramere-activating bisamide compounds and their uses
TW200838517A (en) Compounds useful as protein kinases inhibitors
BR112020014516A2 (en) Aminopyrrolotriazines as kinase inhibitors
ES2925473T3 (en) Pyridinyl pyrazoles as modulators of RORyt
AU2016366546A1 (en) Inhibitors of bruton&#39;s tyrosine kinase and methods of their use
KR20230035049A (en) Compounds, Compositions and Methods
NZ717223B2 (en) Aminoheteroaryl benzamides as kinase inhibitors
TWI810547B (en) Pd-l1 antagonist compound
JP2024526192A (en) Cereblon-binding compounds, compositions thereof and methods of treatment therewith